<SEC-DOCUMENT>0001779372-24-000002.txt : 20240320
<SEC-HEADER>0001779372-24-000002.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320160947
ACCESSION NUMBER:		0001779372-24-000002
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HeartBeam, Inc.
		CENTRAL INDEX KEY:			0001779372
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				474881450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41060
		FILM NUMBER:		24767861

	BUSINESS ADDRESS:	
		STREET 1:		2118 WALSH AVE., SUITE 210
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
		BUSINESS PHONE:		408-899-4443

	MAIL ADDRESS:	
		STREET 1:		2118 WALSH AVE., SUITE 210
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>beat-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2,d:572bc36408af457cba91ba941693f8aa-->
<html xmlns:beat="http://www.heartbeam.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>beat-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-38">0001779372</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-39">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-40">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-41">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="beat-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>beat:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:AGPAllianceGlobalPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:AGPAllianceGlobalPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-20</xbrli:startDate><xbrli:endDate>2023-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">beat:PennyWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beat:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beat:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:TripleRingTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:TripleRingTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">beat:TaxPeriodsPriorTo2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">beat:TaxPeriodsAfter2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:ClinicalResearchOrganizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>beat:site</xbrli:measure></xbrli:unit><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001779372</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:ClinicalResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i572bc36408af457cba91ba941693f8aa_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">001-41060</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-8">HEARTBEAM, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-10">47-4881450</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporation or Organization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I.R.S. Employer<br/>Identification No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">2118 Walsh Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-12">Suite 210</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">Santa Clara</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-14">CA</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-15">95050</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of Principal Executive Offices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zip Code</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-16">408</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-17">899-4443</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">BEAT</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" id="f-20">NASDAQ</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">Warrants</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">BEATW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" id="f-23">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-24">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-25">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-26">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-27">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer &#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer &#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-28">Non-accelerated filer</ix:nonNumeric> &#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company <ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-29">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-30">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="f-31">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-32">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-33">&#9744;</ix:nonNumeric></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-34">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, there were 25,990,516 shares of the registrant&#8217;s common stock, par value $0.0001 per share, issued and outstanding, of these, <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-35">21,352,087</ix:nonFraction> shares were held by non-affiliates of the registrant. The market value of securities held by non-affiliates was $51,458,385 as of June 30, 2023, based on the closing price of $2.41 for the registrant&#8217;s common stock on June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 19, 2024, there was <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-36">26,329,032</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-37" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div></ix:nonNumeric><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). In particular, statements contained in this Annual Report on Form 10-K, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future acquisitions, are forward looking statements. These forward looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;goals,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and &#8220;continue&#8221; or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part II, Item lA. &#8220;Risk Factors&#8221; and elsewhere in this. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward looking statements for any reason.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Forward-looking statements speak only as of the dates specified in such filings. Except as expressly required under federal securities laws and the rules and regulations of the SEC, we do not undertake any obligation to update any forward-looking statements to reflect events or circumstances arising after any such date, whether as a result of new information or future events or otherwise. You should not place undue reliance on the forward-looking statements included in this report or that may be made elsewhere from time to time by us, or on our behalf. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.</span></div><div id="i572bc36408af457cba91ba941693f8aa_10"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, &#8220;HeartBeam,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to HeartBeam, Inc.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:202%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:93.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.75pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_16">Part I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_19">Item 1. Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_22">Item 1A. Risk Factors&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_22">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_25">Item 1B. Unresolved Staff Comments&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_25">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.75pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1C. Cybersecurity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_25">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_28">Item 2. Properties&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_28">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_31">Item 3. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_31">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_34">Item 4. Mine Safety Disclosures</a></span><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_34">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_37">Part II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_40">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_40">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_43">Item 6. </a>RESERVED</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_43">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_46">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_46">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_73">Item 7A. Quantitative and Qualitative Disclosures About Market Risk&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_73">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_121">Item 8. Financial Statements and Supplementary Data </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_76">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_79">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_79">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_82">Item 9A. Controls and Procedures&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_82">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_85">Item 9B. Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_85">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_88">tem 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_88">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part </span><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_91">III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_94">Item 10. Directors, Executive Officers and Corporate Governance&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_94">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_97">Item 11. Executive Compensation&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_97">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_100">Item 12. Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_100">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_103">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_103">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_106">Item 14. Principal Accounting Fees and Services&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_106">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Part IV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_112">Item 15. Exhibits, Financial Statement Schedules&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_112">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_115">Item 16. Form 10-K Summary&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_115">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_118">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#1519fd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_118">68</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I</span></div><div id="i572bc36408af457cba91ba941693f8aa_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (&#8220;ECG&#8221;) solutions is achieved through the development of our proprietary and patented Vector Electrocardiography (&#8220;VECG&#8221;) technology platform. Our VECG technology is capable of capturing three-dimensional (&#8220;3D&#8221;) vector images of the heart&#8217;s electrical activity and synthesizing a 12-Lead (&#8220;12L&#8221;) ECG from these signals. In early studies, our approach demonstrated equal or superior diagnostic capability than traditional hospital-based 12L ECG systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="beat-20231231_g1.jpg" alt="3D vector image (002).jpg" style="height:288px;margin-bottom:5pt;vertical-align:text-bottom;width:297px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products (hereinafter &#8220;Product&#8221; or &#8220;Products&#8221;) require Food and Drug Administration (&#8220;FDA&#8221;) clearance and have not been cleared for marketing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our Products and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payors. We are developing our initial Product (&#8220;HeartBeam AIMIGo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; or &#8220;AIMIGo&#8482;&#8221;), to address the rapidly growing ambulatory cardiac monitoring market. HeartBeam AIMIGo is comprised of a credit-card sized electrocardiogram device, a patient application, a physician portal and powerful cloud-based algorithms. We intend to show that our easy-to-use device (without external electrodes) provides signals equivalent to a standard 12L device, and therefore will have a number of applications for ambulatory use. We believe that we are uniquely positioned to play a central role in ambulatory cardiac monitoring including high-risk coronary artery disease patients. Initial studies have shown that our ischemia detection system may be more accurate than existing ambulatory monitoring solutions. Coronary artery disease (&#8220;CAD&#8221;) patients are at increased risk for a heart attack or Myocardial Infarction (&#8220;MI&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><img src="beat-20231231_g2.jpg" alt="HBM_Device_Perspective_Open - updated.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:272px"/><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      </span><img src="beat-20231231_g3.jpg" alt="Screenshot 2024-03-06 095634 -1.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"/></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam AIMIGo device in ready position (left) and the front view(right)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have developed working prototypes for HeartBeam AIMIGo and we have submitted the Product for FDA 510(k) clearance. To date, we have developed working prototypes for HeartBeam AIMIGo and we have submitted the Product for FDA 510(k) clearance. As more fully discussed in the Products and Technology section below, we have received questions from the FDA and are working through the stages of the FDA clearance process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The custom software and hardware of our Products, we believe, are classified as Class II medical devices by the FDA, running on an FDA approved Class I registered software platform. Class II medical devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish special controls. Special controls can include performance standards, post-market surveillance, patient histories and FDA guidance documents. Premarket review and clearance by the FDA for these devices is generally accomplished through the 510(k) or 510(k) de-novo premarket notification process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam has 13 issued and allowed U.S. patents (U.S. 10,433,744, U.S. 10,117,592, U.S. 11,071,490, U.S. 11,419,538, U.S. 11,445,963, U.S. 11,701,049, U.S. 11,529,085, U.S. 10,980,433, U.S. 11,412,972, U.S. 11,234,658, U.S. 11,793,444, U.S. 11,877,853, and allowed U.S. patent application no. 18/068,481), and nine pending U.S applications. Outside of the U.S., HeartBeam has four issued patents in Germany, France, Netherlands and United Kingdom and fourteen pending applications in Canada, China, the European Union, Japan, South Korea and Australia. HeartBeam has two pending Patent Cooperation Treaty applications. The issued patents are predicted to expire between April 11, 2036 and April 21, 2042.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chronic diseases are the number one burden on the healthcare system, driving up costs each year, and cardiovascular illnesses are one of the top contributors. Regulators, payors, and providers are focused on earlier diagnosis and improved management of these conditions to drive better outcomes at lower cost. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One way to accomplish this is through the use of Connected Medical Devices &#8211; solutions that use technology to provide healthcare services remotely and aim to reduce healthcare expenditures while allowing patients to engage with clinicians and better self-manage their care. The Connected Medical Device Market size is estimated at $66 billion in 2024, and is expected to reach $133 billion by 2029, growing at a compounded annual growth (&#8220;CAGR&#8221;) of 15% during the forecast period (2024-2029)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular disease is the most expensive disease to manage and is estimated to be responsible for one in every eight healthcare dollars spent in the US, projected to cost the US healthcare system $1 trillion by 2035.  As cardiovascular </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease is the leading cause of death worldwide, early detection, diagnosis, and management of chronic cardiac conditions are necessary to relieve the increasing burden on the healthcare system. Diagnostic tests such as ECGs are used to detect, diagnose, and track numerous cardiovascular conditions. The market for cardiac monitoring technologies, such as Holter monitors, patch-based cardiac monitoring technologies, and any other ECG-based technology used for clinical diagnosis is projected to reach approximately $18 billion by 2030, a CAGR of approximately 8%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With advances in mobile communications, diagnostic monitoring of cardiac conditions is increasingly occurring outside the hospital. Global sales of Patient Monitoring Devices in 2021 were $42 billion. With a CAGR of approximately 11% from 2022 to 2032, the market is projected to reach a valuation of $125 billion by 2032. The adoption of such technology was greatly accelerated by the COVID-19 pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we will be able to show that our easy-to-use device (without external electrodes) provides signals that can provide a 12L ECG representation like the gold-standard and therefore will have a number of applications for ambulatory use. Our initial Product, HeartBeam AIMIGo, will allow physicians to evaluate the full range of cardiac conditions that they currently assess with a standard 12L ECG. Currently we believe there are no products on the market that are portable, easy to use, and always with the patient to provide physicians and patients with timely and highly accurate information about all heart conditions that could be detected with a 12L ECG, including</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential ischemic events. In the US, someone has a heart attack every 40 seconds. We believe a tool that is always with the patient and decreases time to intervention would have a significant effect on saving lives and healthcare dollars. We believe our technology will address this problem by providing a convenient, cost-effective cardiac monitoring solution, including software and hardware for physicians and their patients. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the US, mobile cardiac tests are primarily conducted through outsourced Independent Diagnostic Testing Facilities (&#8220;IDTFs&#8221;) or as part of an telehealth system. Reimbursement rates vary depending on the use case and generally are based on the value a technology offers to patients and healthcare providers. Actual reimbursed pricing is set by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). Reimbursement rates for private insurers typically provide for similar or higher reimbursement rates when compared to those set by the government for Medicare and Medicaid. Direct pay is an alternative for a product such as AIMIGo while data is being gathered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Products and Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation of our novel technology is the concept of VECG, a technology that has long been seen as superior to ECG in detecting MIs but is no longer used clinically because of the difficulty experienced by physicians interpreting the output. We solved the crucial problem of recording three orthogonal (x, y and z) projections of the heart vector with a device that is sized like a credit card. The thickness of our credit card-sized ECG signal collection device is about 1/8 inch (4 mm), and it weighs about 1 ounce (28 grams). The core technology consists of a series of patented inventions and associated algorithms. In addition to using VECG to get a more complete 3D characterization of cardiac activity, we use the concept of a baseline. We measure the change in cardiac parameters between an asymptomatic (baseline) recording and the symptomatic recording. It is personalized for every patient as every patient has a unique baseline. Our increase in diagnostic performance in detecting MIs, when compared to a panel of cardiologists, is attributed to a richer cardiac information set offered by VECG and the fact that our algorithms compare the patient&#8217;s personalized baseline and symptomatic recordings in the 3D space of VECG.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This novel technology has resulted in our initial Product, AIMIGo. Our AIMIGo ECG collection device is the size of a credit card and records cardiac signals with integrated electrodes rather than wires or self-adhesive electrodes. Unlike a standard 12L ECG machine that records signals in empirically determined locations on a human body, our approach is focused on recording three projections of the heart vector. The successful recording of the projections of the heart vector enables the synthesis, via a patented method, of a 12L signal set and internal algorithmic diagnostic work in the space of 3D heart vectors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are obvious ease-of-use advantages when comparing our credit card-sized device to the current 12L ECG machine. The small form factor of our device makes it portable and can be used by a patient at home or elsewhere. The device can be self-applied versus requiring a trained professional to apply. In addition, there are diagnostic performance advantages, including, based on our initial study, increased accuracy in diagnosing MIs. The collected data is sent to a physician to assess the patient&#8217;s ECG in the context of the patient&#8217;s baseline ECG, symptoms, and history.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HeartBeam AIMIGo system is initially expected to be a prescription-only cardiac monitoring system intended for individuals with known or suspected heart disease, including various arrhythmias and CAD. It helps physicians in choosing the best course of action for their patients who experience chest pain or other cardiac symptoms outside of a medical facility. HeartBeam AIMIGo will bring a medical grade ECG to patients and will enable them to receive a plan of action from a physician in a timely manner. At the time of onboarding, patients record a baseline 30-second ECG using our device. When a patient experiences symptoms, such as irregular heartbeats or chest pain, the patient simply opens the smartphone application and places the credit card sized device against the chest to collect signals. These signals are processed by cloud-based algorithms and converted to a synthesized 12L that is sent to the on-call physician, overlayed with the patient&#8217;s synthesized baseline ECG recording. In addition, the patient provides input on their symptoms that is sent, along with the ECG data, to the cloud for interpretation by a physician. From start to finish, the process takes just a few minutes.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HeartBeam AIMIGo system consists of a number of capabilities that will be introduced over time. These are:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:10.5pt">A credit card sized ECG collection device. The device captures cardiac signals that represent x, y and z projections of the heart vector and transmits them via Bluetooth connection to a smartphone. It is always with the patient given its small form factor. It is easy to use as all that is required of the patient is that the device be pressed against the chest.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:10.5pt">A smartphone application that receives the ECG signals from the HeartBeam signal collection device. The application has several functions: guiding the patient through the signal collection, asking about symptoms, displaying the status of the data collection including real time signal quality check, and notifying the patient of the plan of action as determined by a physician. In addition, the application will contain HIPAA-compliant video conferencing or text capabilities for the healthcare provider to communicate directly with the patient.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:10.5pt">A cloud-based software system that serves four basic functions: (1) Performing a final check of the ECG signal quality, (2) Synthesizing a 12L ECG from the three measured vector leads, (3) Creating a diagnostic suggestion based on 3D VECG interpretation, risk factors and symptoms and (4) Preparing a summary report for the physician. These software functions will be introduced to the HeartBeam AIMIGo product in a sequential manner. To facilitate a more accurate physician interpretation of the data, the software overlays the patient&#8217;s synthesized baseline 12L ECG waveform on the synthesized 12L ECG waveform from the current reading. To ensure high signal quality, the system checks for noise levels in the recorded signals. Those signals that can be effectively filtered are accepted and those that have a noise level above an empirically established threshold are rejected. If a recorded signal is rejected, the user is asked to repeat the recording.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:10.5pt">A web-based physician portal capable of displaying the following relevant information for the physician to analyze: diagnostic suggestion, patient history, symptoms, baseline and current, synthesized 12L ECG, and recorded 3 vector leads. Our physician portal assists physicians with their diagnostic interpretation by providing both the baseline 12L synthesized ECG and the 12L synthesized ECG that is under evaluation.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:10.5pt">A dedicated ECG monitoring and reading team of medical professionals to offer 24/7/365 services in order to provide a recommended course of action to patients based on the ECG signals, symptoms, and patient history. The patient will have the option of having a consult with a medical professional. This capability will be developed in-house or outsourced through a contracted third-party organization.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market release of our Product will be in multiple versions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Initial Product will include a 3D VECG credit card-sized device that records the &#8220;X, Y, Z&#8221; cardiac activity as 3 leads and displays the signals for clinician review. The system also includes a patient application, a physician portal, and wireless communications among the elements. We anticipate this to be the first patient-friendly, portable VECG device to be cleared by the FDA and this will be a major milestone for the company. In addition, this clearance will provide the regulatory foundation for subsequent products in our product portfolio. An FDA 510(k) application was submitted in the 2nd quarter of 2023. The review remains active with FDA, as we have successfully passed the acceptance of the filing and have completed the initial, substantive review phase with questions and requests from FDA.  As we continue to navigate the progress towards clearance, we have taken advantage of all available regulatory tools and opportunities to work interactively with FDA, gaining valuable official communication and feedback on our proposed response approach, including testing protocols. We have conducted this agreed upon testing to address FDA's open questions and are in the process of preparing our official responses. Once submitted, FDA will complete their review. We currently anticipate clearance by the end of Q2 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of the Initial Product, we will be working to obtain a second 510(k) clearance. This clearance will be focused on the ability to offer to the physician a pair of baseline and symptomatic 12L ECGs, both synthesized from 3D VECG signals (X, Y, Z) recorded by the HeartBeam AIMIGo device. This approach leverages recently issued patents for a personalized system for synthesizing 12L ECG waveforms. The 510(k) application is planned to be submitted to FDA by Q3 2024. A key part of this submission will be a pivotal study demonstrating the similarity between the synthesized 12L output from AIMIGo and a simultaneously recorded standard 12L ECG. We have held two Pre-submission meetings with FDA on the 12L synthesis submission. These meetings have been focused primarily on the performance goals of our clinical study.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on feedback from FDA and our clinical experts, we have designed our clinical study, &#8220;Clinical Validation of AIMIGo 12 Lead ECG Synthesis Software for Arrhythmia Detection: A Prospective Multicenter Pivotal Study,&#8221; (the &#8220;VALID-ECG Study&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 13, 2024, we enrolled the first patient in the VALID-ECG study. The VALID-ECG study is a prospective single-arm multicenter trial designed with the goal to validate the AIMIGo 12L ECG Synthesis Software by comparing its results with those of a standard FDA-cleared 12L ECG using both quantitative and qualitative assessment methodologies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We plan to enroll a total of approximately 198 patients presenting to an outpatient cardiology clinic or arrhythmia center for symptoms suggestive of cardiac arrhythmia or for routine checkup of previously diagnosed arrhythmia. The study is expected to include up to 5 sites. The primary objective is to demonstrate the equivalence of ECG waveforms between AIMIGo Synthesized 12L ECG and Standard 12L ECG, recorded simultaneously in each subject, by assessing intervals and amplitudes. In addition, we have completed an 70 patient pilot study, which mirrors the pivotal study. We anticipate to complete enrollment in the VALID-ECG study in Q2 2024 and submit the second 510(k) application by Q3 2024. We continue to anticipate that our limited launch of AIMIGo will occur by the end of 2024. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future versions of the Product may include AI algorithms that automatically classify the 3-lead VECG signals, and identify common arrhythmias as well as normal sinus rhythm. Other potential enhancements include our proprietary ECG interpretation MI algorithms and our overall MI diagnostic suggestion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ECGs are key diagnostic tests utilized in the diagnosis and monitoring of cardiovascular disease, the number one cause of death worldwide. According to the American Heart Association, there were approximately 130 million adults living with cardiovascular disease and approximately 20 million adults with diagnosed CAD in the US. The prevalence of these cardiac conditions and thus the market size is increasing, due to an aging population and lifestyle choices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Every 40 seconds someone in the US has a heart attack, or MI. Unfortunately, there is no way for patients at home to distinguish if the symptoms they are experiencing are due to an MI, or some other more benign condition such as indigestion. As a result, patients often ignore symptoms and delay seeking care, which leads to worse outcomes and increased mortality. Shortening that time from symptoms to the door of a medical facility would reduce complications and save lives. On the other hand, many patients who go to the ED with chest pain are not experiencing an MI. Chest pain is the second most common reason for an ED visit in patients over 45, yet fewer than 20% of chest pain ED visits result in a diagnosis of a life-threatening condition. These unnecessary ED visits lead to well over $10 billion in unnecessary healthcare expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><img src="beat-20231231_g4.jpg" alt="HB Image 2.jpg" style="height:354px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most ECGs are conducted in a healthcare facility setting using a 12L ECG machine, the gold standard. ECGs taken outside of healthcare facilities are expected to grow more quickly than in-hospital ECGs. Monitoring cardiac patients outside of a hospital is a fast-growing trend, as it is less expensive and provides a better patient experience. However, while ambulatory cardiac monitoring devices are often much easier for patients to use, they have fewer leads than the gold standard and therefore cannot offer as comprehensive a picture of cardiac health.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a standard 12L ECG readout is of great medical value, it is simply impractical to have a standard 12L machine next to patients when they experience symptoms outside the clinical setting, since recording the event requires attaching multiple electrodes to the patient&#8217;s body with professional assistance. While existing technologies use predominantly single lead ECG devices to monitor arrhythmias, these technologies do not provide information to the physician on the presence of life-threatening conditions such as acute coronary syndrome (ACS) including MIs, also known as heart attacks.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our technology addresses these market needs and has several key attributes that make it a good fit for these patients. Our Product can be used anywhere when symptoms occur and offers the potential for lifelong patient usage. The device is practically always near the patient and ready to be used for recording a cardiac event. It enables real-time transmission of the 3D VECG signals and a synthesized 12L ECG. We believe physicians will typically prescribe our solution to chronic cardiovascular patients for long term monitoring, thereby enabling prolonged data collection and delivering a more complete picture for diagnosis. This will also enable the use of artificial intelligence (AI) on our future database that will have a unique set of longitudinal VECG signals and synthesized 12L ECGs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">As we believe our VECG platform demonstrates 12L equivalence and clinical &amp; cost-effectiveness advantages, coupled with a patent protected technology, we believe this might open multiple licensing and/or partnering opportunities with players in the ECG, cardiac monitoring patch and smart watch verticals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to establish our Products as key solutions for cardiology practices. Our efforts to enter the market involve establishing clinical evidence and demonstrating the cost-effectiveness of adopting our Products. The initial geographic market for HeartBeam AIMIGo is the US.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that both HeartBeam AIMIGo Products will be subject to the US FDA&#8217;s 510(k) review process. An FDA 510(k) application for the initial Product was submitted in Q2 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary customers are cardiology practices and the cardiology departments of hospitals. Healthcare insurers are another important customer, as they will potentially benefit from the reduced costs to the healthcare system. We are working to develop new clinical studies and publish results of completed clinical studies and plan to demonstrate real world cost-effectiveness of the use of the solution. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial targets for HeartBeam AIMIGo are market segments that see value in an easy-to-use device that can generate synthesized 12L ECG recordings. These will be segments in which payment for the device will be outside of the established reimbursement system. These target segments may include concierge practices, hospital-at-home segment and  use in clinical trials. As we establish data on the clinical efficacy and cost-effectiveness of HeartBeam AIMIGo, we will target at-risk cardiology practices, including high-risk patients being discharged from hospitals after experiencing an MI.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term strategy is to generate sufficient evidence of clinical efficacy and cost-effectiveness to generate reimbursement coverage and payment specifically for the HeartBeam AIMIGo solution. We expect to be able to demonstrate significant clinical benefits for patients and savings to the healthcare system, justifying appropriate reimbursement levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary marketing strategy will focus on the medical community with continued validation of clinical efficacy and cost-effectiveness and the establishment of reference sites. We will also create educational materials and provide other support to help educate our customers&#8217; patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will explore other business models. For example, hospitals face CMS penalties if their 30-day readmission rates for patients who are discharged after an MI exceed certain thresholds. These CMS penalties are levied on all hospital CMS payments, so the impact can be significant. Our Product can be a tool to help hospitals manage these patients after discharge. We will explore models in which hospitals pay for the device and for the initial 30 days of service. In addition, we will explore models for value-based care, in which the use of Product reduces overall costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently speaking with hospitals in large healthcare systems to educate them about our first two Products. These are sophisticated customers, and we plan to use technical presentations, peer-reviewed clinical data, and demonstration projects to achieve penetration of this market. We plan to continue to utilize the expertise of our medical advisory board, conduct clinical trials with leading cardiologists to increase the body of evidence, and establish reference sites among these customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect our value proposition will be progressively increased as we gradually add additional functionality to our monitoring solutions and drive down the cost by increasing scale and automation. We expect our HeartBeam AIMIGo device to incorporate internally developed algorithms with the capabilities of detecting heart conditions that can be detected via a standard 12L ECG device. Additionally, as we collect rich longitudinal data sets from our patients, we expect to train AI and ML algorithms that could potentially have predictive capabilities regarding different heart conditions. Over time and with scale we expect our costs to decrease and provide more and better services to our patients by improving our capabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to establish a direct sales network with relationships and experience selling to our target markets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Data</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A landmark clinical study on the HeartBeam technology was published in the August 2023 issue of the journal JACC: Advances. The publication, &#8220;Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration&#8221; demonstrated that HeartBeam&#8217;s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12L ECG. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both 12L ECG and VECG signals were recorded in patients undergoing percutaneous coronary intervention. Readings were taken before and after a 90 second balloon inflation that occluded the artery, a surrogate for a heart attack. Automated computer analysis of the ST segment of the 12L ECG and VECG was performed. In addition, a panel of three cardiologists analyzed the 12L ECGs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study showed that the automated analysis of the VECG and 12L ECG signals had similar performance in determining whether the artery was occluded. Also in the study, the human interpretation of the 12L ECGs had significant intra- and inter-observer variability, which does not occur with automated readings.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the 12L ECGs and the VECG readings were analyzed in two ways: a &#8220;spot&#8221; reading, when only a single recording was considered, and a &#8220;comparative&#8221; reading when a separate &#8220;normal baseline&#8221; recording was available for comparison. The presence of the &#8220;normal baseline&#8221; recording, a novel feature that is integral to HeartBeam&#8217;s VECG technology, dramatically improved the accuracy of interpretation, increasing the Area Under the Curve (AUC), a standard measure of diagnostic performance, from 0.72 to 0.95. This is particularly important since physicians who are analyzing 12L ECGs often do not have access to a normal baseline, implying that the HeartBeam system could outperform this approach.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, HeartBeam has had data on its deep learning algorithm accepted for presentation at two prestigious Electrophysiology conferences: the European Heart Rhythm Society, to be held in Berlin, Germany in April 2024 and the Heart Rhythm Society, to be held in Boston MA in May 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cardiac monitoring and detection market is characterized by rapid technological change and strong competition. There are numerous companies developing technologies that are competitive, in a broad sense, to our products, and many of these companies have significantly greater resources than HeartBeam.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the category of ambulatory cardiac monitors &#8212; devices that are intended to be used outside of a health facility setting &#8212; there are two major segments: consumer devices and devices prescribed for ACS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Devices</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consumer device segment consists of devices that are FDA cleared but are sold directly to patients, without a prescription. Generally, these devices are single lead ECG devices intended to recognize heart rhythm abnormalities, such as atrial fibrillation, but are not intended for ischemia detection or for life threatening conditions such as heart attack. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Apple Inc, a public company located in Cupertino, CA, produces the Apple Watch, which includes ECG functionality. The Apple Watch is a single lead ECG with two electrodes that contact the wrist and the finger and is intended to detect some common cardiac arrhythmias, such as Atrial Fibrillation.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AliveCor Inc, a private company located in Mountain View, CA, produces the KardiaMobile, KardiaMobile Card and KardiaMobile 6L devices. These devices are intended to detect some common cardiac arrhythmias, such as Atrial Fibrillation. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Google Inc, a public company located in Mountain View, CA, produces the Pixel 2 smartwatch and ECG app. The Pixel 2 watch is a single lead ECG with two electrodes that contact the fingers and is intended to detect some common cardiac arrhythmias, such as Atrial Fibrillation.  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Samsung Electronics Co., Ltd, based in Seoul, South Korea, is publicly traded in Korea. It produces the Galaxy Watch3 and Galaxy Watch Active2 smartwatches with ECG functionality, intended to detect some common cardiac arrhythmias, such as Atrial Fibrillation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Devices prescribed for ischemia detection </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a small number of devices that have been cleared by FDA to be used outside of healthcare facilities that provide information for patients with potential ischemic events such as MIs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Angel Medical Systems, Inc. is a private company based in Eatontown, NJ. The AngelMed Guardian is an implantable cardiac monitor for patients who are deemed to be extremely high risk for an MI. Physicians implant the AngelMed Guardian in patients. We believe that the HeartBeam AIMIGo device will be a viable alternative to the AngelMed Guardian, as it does not require an implant and does not have a high up-front cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SHL Telemedicine Ltd., is based in Tel Aviv, Israel and is publicly traded. It produces Smartheart, a 12L ECG indicated for patient use at home. Smartheart Pro is larger and more complex than our telehealth solution, requiring the placement of an electrode belt, two underarm electrodes and a waist electrode, and moistening the areas before use. Most patients would find this technology impractical to be carried with them at all times because of the large size and complex lead attachment procedure. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our intellectual property (&#8220;IP&#8221;) protects our innovations, and our goal is to become a leader in the ambulatory VECG sector. For some aspects of our proprietary technology, we rely on trade secret protection. It is our view that the combination of these two methods of IP protection maximizes our chances for success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam has 13 issued and allowed U.S. patents (U.S. 10,433,744, U.S. 10,117,592, U.S. 11,071,490, U.S. 11,419,538, U.S. 11,445,963, U.S. 11,701,049, U.S. 11,529,085, U.S. 10,980,433, U.S. 11,412,972, U.S. 11,234,658, U.S. 11,793,444, U.S. 11,877,853, and allowed U.S. patent application no. 18/068,481), and nine pending U.S applications. Outside of the U.S., HeartBeam has four issued patents in Germany, France, Netherlands and United Kingdom and fourteen pending applications in Canada, China, the European Union, Japan, South Korea and Australia. HeartBeam has two pending Patent Cooperation Treaty applications. The issued patents are predicted to expire between April 11, 2036 and April 21, 2042.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our issued and pending U.S. patent applications cover compact VECG systems for remote detection and/or diagnosis of acute myocardial infarction (&#8220;AMI&#8221;). Outside of the U.S., the pending EU, Australian (&#8220;AU&#8221;), Japanese (&#8220;JP&#8221;) and Chinese (&#8220;CN&#8221;) patent applications correspond to the pending and issued US cases. The pending PCT applications cover methods and apparatuses for automatic cardiac diagnosis as well as compact systems including retractable electrodes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a brief description of issued and pending patents, including their respective titles:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Patent Type</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Application No. Pat. No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Status</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Predicted Expiration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title Summary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15/096,159<br/>US 10,433,744</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sep 15, 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15/632,155<br/>US 10,117,592</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/092,152<br/>US 11,877,853</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jun 2, 2037</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/202,299<br/>US 11,071,490</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(CN)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">201680030550.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Published</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(DE)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16777474.4<br/>DE 602016073016.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(FR)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16777474.4<br/>FR 3280326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(GB)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16777474.4<br/>GB 3280326</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(NL)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16777474.4<br/>NL 3280326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EU)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22174820.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS<br/>Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EU)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">198948150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nov 18, 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT<br/>Method and apparatus for performing automatic cardiac diagnosis.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/296,669<br/>US 11,701,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nov 18, 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT<br/>Method and apparatus for performing automatic cardiac diagnosis.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18,324,111</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nov 18, 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT<br/>Method and apparatus for performing automatic cardiac diagnosis.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/443,456<br/>US 11,793,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adhesive patch methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/570,368</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">US 11,419,538</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Adhesive patch methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18/363685</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 11, 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Adhesive patch methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17/609,014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 20, 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE <br/>Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(AU)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020275409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 20, 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE <br/>Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(CA)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3137669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 20, 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EU)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">208063123</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 20, 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(JP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021568329</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 20, 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EU)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2189294203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov 12, 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE WITH HYBRID ELECTRODE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EU)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18/252803</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov 12, 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE WITH HYBRID ELECTRODE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(CA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3204059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jan 4, 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS <br/>Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events (e.g., acute myocardial infarction).</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(CN)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022800141214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jan 4, 2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS <br/>Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events (e.g., acute myocardial infarction).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">227348299</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jan 4, 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events (e.g., acute myocardial infarction).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(JP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">202340687</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jan 4, 2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events (e.g., acute myocardial infarction).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18260318</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jan 4, 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS<br/>Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events (e.g., acute myocardial infarction).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/494,806</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">US 11,445,963 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oct 5, 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">METHOD AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Synthesizing (generating) 12L ECG dataset from 3-lead ECG data.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/948099</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oct 5, 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">METHOD AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <br/>Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(PCT)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PCTUS2022<br/>077601 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 5, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">METHOD AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <br/>Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/726,497</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">US 11,529,085 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 21, 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM<br/>Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a wrist-worn device to detect the three orthogonal cardiac leads.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18/068481 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 21, 2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM<br/>Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a wrist-worn device to detect the three orthogonal cardiac leads.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(PCT)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PCT/US2023<br/>065918</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Published</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oct 5, 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM<br/>Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a wrist-worn device to detect the three orthogonal cardiac leads.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16/362,527<br/>US 10,980,433</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oct 12, 2038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HEALTH MONITORING AND GUIDANCE<br/>Methods, systems and software for the determination of stress states utilizing PPG sensors.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16/368,568<br/>US 11,412,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 19, 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DETECTION OF ATRIAL FIBRILLATION<br/>Methods and software for determining atrial fibrillation utilizing PPG sensors.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16/368,571<br/>US 11,234,658</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apr 5, 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION<br/>Methods, systems and software for the creation of ECG-type waveforms from PPG sensor data.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17/887160</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Published</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mar 28, 2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DETECTION OF ATRIAL FIBRILLATION<br/>Methods and software for determining atrial fibrillation utilizing PPG sensors.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18/516,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mar 28, 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HEARTBEAT DETECTION<br/>Wearable devices to detect PPG data for detection of heartrate.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(EP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EP 19724961.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Published</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mar 28, 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION<br/>Methods, systems and software for the creation of ECG-type waveforms from PPG sensor data.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(KR)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KR 10-2020-7031103</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Published</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mar 28, 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION<br/>Methods, systems and software for the creation of ECG-type waveforms from PPG sensor data.<br/></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Utility<br/>(US)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18/595,410</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pending</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mar, 4, 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">METHODS AND APPARATUSES FOR ELECTROMYOGRAPHY NOISE ELIMINATION FROM ELECTROCARDIOGRAM SIGNALS BY ITERATIVE REGENERATION<br/>Methods and systems, including software, for reducing or eliminating noise from ECG signals.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered, and generally plan to continue to enter into, non-disclosure, confidentiality and intellectual property assignment agreements with all new employees as a condition of employment. In addition, we intend to generally enter into confidentiality and non-disclosure agreements with consultants, manufacturers&#8217; representatives, distributors, suppliers, and others to attempt to limit access to, use and disclosure of our proprietary information. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ownership of all filed patents is assigned to HeartBeam, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our quest to redefine the landscape of digital health through our innovative, user-friendly ambulatory VECG solutions, our primary objective remains steadfast: to deliver high medical value through products that are always with the patient, assisting physicians in monitoring and diagnosing cardiac disease in patients. We believe that our success in developing initial products, underscored by our emphasis on user-friendly solutions, will set a solid foundation for our future endeavors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our R&amp;D team, primarily based in the US and Belgrade, Serbia, is a testament to our commitment to excellence and innovation and is comprised of seven employees on December 31, 2023, plus consultants, with expertise in the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Healthcare IT platform development, biomedical engineering, electrical engineering with expertise in machine learning, signal processing and ECG analysis from the medical device industry, as well as specialties in wireless communication, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Of note, we have seven Physicists and Electrical Engineers (all Ph.D. E.E. or Ph.D. Physics) credited with our key inventions and patents. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, we plan to expand our team with several additional product development engineers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Looking ahead, we anticipate further enhancing our efforts in harnessing signal processing and artificial intelligence (AI) to broaden our diagnostic solutions across a spectrum of cardiac conditions. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our core technology, the heart vector VECG approach, is a platform technology that we believe is poised to revolutionize diagnostic solutions for cardiovascular patients. Potential applications include a VECG-based, synthesized 12L capable patch ECG monitor, offering significant diagnostic advantages through its 12L capability over existing single-lead ECG patch products. This innovation aims to provide standard of care 12L ECG capabilities in a form factor like current single-lead ECG patches, which we believe addresses a critical gap in the market.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A further potential application is a synthesized 12L ECG smartwatch-based monitor, designed for the detection of heart attacks and complex cardiac arrhythmias. The plan for this monitor is to eliminate the need for dedicated ECG devices, offering synthesized 12L ECG capabilities directly from a smartwatch, thereby enabling the detection of heart attacks and complex arrhythmias with unprecedented convenience and efficiency.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both the patch and smartwatch-based monitor technologies are covered by patents that we believe provide us a strong position to expand beyond the current AIMIGo platform.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our newly formed AI team, comprising industry leading experts, developed a roadmap for AI-based tool development. These tools will combine state of the art AI models and techniques applied to our unique and data rich set of VECG signals. Initial AI development results indicate potential to significantly enhance ambulatory diagnostic capabilities over what is currently available. It is expected that AI development efforts quickly become one of the major R&amp;D efforts. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As we continue to advance our synthesized 12L VECG technology, evidenced by our recently issued and allowed patents with potentially disruptive market impacts, our initial telehealth product will leverage rule-based algorithms, including signal processing and ECG synthesis. Concurrently, we are developing AI-based arrhythmia and ischemia detection algorithms to become the cornerstone of our commercialized systems.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To further amplify the impact of our R&amp;D efforts and ensure sustained leadership in digital health innovation, we are looking at several strategic enhancements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Expand Cross-Disciplinary Collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: Forge deeper partnerships with academia, technology leaders, and healthcare institutions to access new research, diversify our expertise, and explore novel applications of our technology.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Embrace Agile Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: Integrate agile methodologies into our R&amp;D processes, enhancing our adaptability and responsiveness to emerging technologies and market demands.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Strengthen Data Analytics and AI Integration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: We plan to invest in advanced data analytics and AI to refine our diagnostic algorithms and tailor our solutions to meet specific clinical needs, driving forward personalized medicine in cardiac care.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Foster Talent and Innovation Culture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: By continuing to attract and develop top-tier talent, nurturing a culture of innovation and continuous learning that aligns with the latest advancements in technology and healthcare.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Prioritize Intellectual Property and Regulatory Strategy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: We believe we are able to accelerate our efforts in expanding our intellectual property portfolio, engaging with regulatory bodies early in the development process to ensure our solutions meet the highest standards of safety and efficacy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By embracing these strategic enhancements, we are not only committed to advancing the full potential inherent in our VECG technology, but we believe we are also poised to make significant strides in transforming cardiovascular diagnostics and patient care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proposed products are subject to regulation by the FDA and various other federal and state agencies, as well as by foreign governmental agencies. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to those indicated below, the only other regulations we encounter are regulations that are common to all businesses, such as employment legislation, implied warranty laws, and environmental, health and safety standards, to the extent applicable. In the future we will be subject to industry-specific government regulations that govern our products when developed for commercial use. It is possible that other regulatory approvals will be required for the design and manufacture of our products and proposed products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA governs the following activities that HeartBeam performs, and will perform, upon the clearance or approval of its Product, or that are performed on its behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product design, and development</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product safety, testing, labeling and storage</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record keeping procedures; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product marketing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous FDA regulatory requirements governing the approval or clearance and subsequent commercial marketing of our products. These include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timely submission of product listing and establishment registration information, along with associated establishment user fees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued compliance with the Quality System Regulation, or QSR, which require specification developers and manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clearance or approval of product modifications that could significantly affect the safety or effectiveness of the device or that would constitute a major change in intended use;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical Device Reporting regulations (&#8220;MDR&#8221;), which require that manufacturers keep detailed records of investigations or complaints against their devices and to report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate use of the Corrective and Preventive Actions process to identify and correct or prevent significant systemic failures of products or processes or in trends which suggest same;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-approval restrictions or conditions, including post-approval study commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance regulations, which apply when necessary, to protect the public health or to provide additional safety and effectiveness data for the device; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">notices of correction or removal and recall regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending on the classification of the device, before HeartBeam can commercially distribute medical devices in the United States, it must obtain, either prior 510(k) Notification clearance, 510(k), De-Novo granting or premarket approval (&#8220;PMA&#8221;), from the FDA unless a respective exemption applies to the device under review by the FDA </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA classifies medical devices into one of three classes based on the degree of risk associated with each medical device and the extent of regulatory controls needed to ensure the device&#8217;s safety and effectiveness:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Class I medical devices, which are low risk and subject to only general controls (e.g., registration and listing, medical device labeling compliance, MDRs, Quality System Regulations, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Class II medical devices, which are moderate risk and generally require 510(k) Notification premarket clearance or De Novo granting before they may be commercially marketed in the United States as well as general controls and potentially special controls like performance standards or specific labeling requirements; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Class III medical devices, which are devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device. Class III medical devices generally require the submission and approval of a PMA supported by clinical trial data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The custom software and hardware of our products, we believe, are classified as Class II. Class II medical devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish special controls. Special controls can include performance standards, post-market surveillance, patient histories and FDA guidance documents. Premarket review and clearance by the FDA for these devices is generally accomplished through the 510(k). As part of the 510(k), the FDA may have required the following</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Development of comprehensive product description and indications for use;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of extensive preclinical tests and preclinical animal studies, performed in accordance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comprehensive review of predicate devices and development of data supporting the new product&#8217;s substantial equivalence to one or more predicate devices; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If appropriate and required, certain types of clinical trials (IDE submission and approval may be required for conducting a clinical trial in the US).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve use of the medical device on human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices (&#8220;GCPs&#8221;), including the requirement that all research subjects provide informed consent for their participation in the clinical study. A written protocol with predefined end points, an appropriate sample size and pre-determined patient inclusion and exclusion criteria, is required before initiating and conducting a clinical trial. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational Device Exemption, or IDE, regulations that among other things, govern investigational device labeling, prohibit promotion of the investigational device, and specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; as defined by the FDA, the agency requires the device sponsor to submit an IDE application, which must become effective prior to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA denies the application or notifies the Company that the investigation is on hold and may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE that requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but it must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given successful completion of all required testing, a detailed 510(k) premarket notification or De Novo request will be submitted to the FDA requesting clearance, or granted, to market the product. This notification will include all relevant data from pertinent preclinical and clinical trials, together with detailed information relating to the product&#8217;s manufacturing controls and proposed labeling, and other relevant documentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 510(k)-clearance letter from the FDA authorizes commercial marketing of the device for one or more specific indications of use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After 510(k) clearance, HeartBeam is required to comply with several post-clearance requirements, including, but not limited to, Medical Device Reporting and complaint handling, and, if applicable, reporting of corrective actions. Also, quality control and manufacturing procedures must continue to conform to Quality System Regulations (&#8220;QSR&#8221;). The FDA periodically inspects manufacturing facilities to assess compliance with FDA&#8217;s QSR, which impose extensive procedural, substantive, and record keeping requirements on medical device manufacturers. In addition, changes to the manufacturing process are strictly regulated, and, depending on the change, validation activities may need to be performed. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with QSR and other types of regulatory controls.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use or technological characteristics, requires a new 510(k) clearance or could require a PMA. The FDA requires each manufacturer to make the determination of whether a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modification requires a new 510(k) notification or PMA in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer&#8217;s decision not to seek a new 510(k) clearance or PMA for a particular change, the FDA may retroactively require the manufacturer to seek 510(k) clearance or PMA. The FDA can also require the manufacturer to cease U.S. marketing and/or recall the modified device until additional 510(k) clearance or PMA approval is obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the Federal Trade Commission (&#8220;FTC&#8221;), will also regulate the advertising claims of HeartBeam&#8217;s products to ensure that the claims it makes are consistent with its regulatory clearances, that there is scientific data to substantiate the claims and that product advertising is neither false nor misleading.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are applying for 510(k) clearance for the AIMIGo system. To obtain 510(k) clearance, a company must submit a notification to the FDA demonstrating that its proposed device is substantially equivalent to a predicate device (i.e., a device that was in commercial distribution before May 28, 1976, a device that has been reclassified from Class III to Class I or Class II, or a 510(k)-cleared device). The FDA&#8217;s 510(k) clearance process generally takes from three to 12 months from the date the application is submitted but also can take significantly longer. If the FDA determines that the device or its intended use is not substantially equivalent to a predicate device, the device is automatically placed into Class III, requiring the submission of a PMA. Once the information is submitted, there is no guarantee that the FDA will grant a company 510(k) clearance for its pipeline products, and failure to obtain the necessary clearances for its products would adversely affect its ability to grow its business. Delays in receipt or failure to receive the necessary clearances, or the failure to comply with existing or future regulatory requirements, could reduce its business prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Devices that cannot be cleared through the 510(k)-process due to lack of a predicate device but would be considered low or moderate risk may be eligible for the De Novo process. In 1997, the Food and Drug Administration Modernization Act (&#8220;FDAMA&#8221;) added the de novo classification pathway now codified in section 513(f)(2) of the FD&amp;C Act. This law established an alternate pathway to classify new devices into Class I or II that had automatically been placed in Class III after receiving a Not Substantially Equivalent (&#8220;NSE&#8221;), determination in response to a 510(k) submission. Through this regulatory process, a sponsor who receives an NSE determination may, within 30 days of receipt, request FDA to make a risk-based classification of the device through what is called a &#8220;de novo request.&#8221; In 2012, section 513(f)(2) of the FD&amp;C Act was amended by section 607 of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;), to provide a second option for de novo classification. Under this second pathway, a sponsor who determines that there is no legally marketed device upon which to base a determination of substantial equivalence can submit a de novo request to FDA without first submitting a 510(k).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company receives a Not Substantially Equivalent determination in response to a 510(k) submission, the device may still be eligible for the 510(k) de novo classification process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Devices that cannot be cleared through the 510(k) or De Novo classification process require the submission of a PMA. The PMA process is much more time consuming and demanding than the 510(k)-notification process. A PMA must be supported by extensive data, including but not limited to data obtained from preclinical and/or clinical studies and data relating to manufacturing and labeling, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. After a PMA application is submitted, the FDA&#8217;s in-depth review of the information generally takes between one and three years and may take significantly longer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also need to establish a suitable and effective quality management system, which establishes controlled processes for our product design, manufacturing, and distribution. We plan to do this in compliance with the internationally recognized standard ISO 13485:2013 Medical Devices &#8212; Quality Management Systems &#8212; Requirements for Regulatory Purposes. Following the introduction of a product, the FDA and foreign agencies engage in periodic reviews of our quality systems, as well as product performance and advertising and promotional materials. These regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction, and continued availability of new products. Where possible, we anticipate these factors in our product development processes. These agencies possess the authority to take various administrative and legal actions against us, such as product recalls, product seizures and other civil and criminal sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on all available data and opinions from our well qualified external consultants who specialize in FDA submissions, we believe that both our initial products and the follow-on products qualify for the 510(k)-clearance path or De Novo granting paths. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we plan to market our products in the EU and other foreign markets, in addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products in foreign countries. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preparations for Design for Manufacturing</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, our efforts have been primarily concentrated on the research and development of our initial HeartBeam AIMIGo device. We have successfully developed fully functional versions of the product which have passed design control processes, including all necessary verification and validation testing, to ensure compliance with safety standards such as IEC 60601. Documentation for these pre-production units has been submitted as part of our 510(k) regulatory filing with the FDA, seeking market clearance. In preparation for commercial production, we have proactively designed and procured the production tooling required to facilitate the future commercialization of our product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our manufacturing strategy is designed to be scalable. Initially, for the HeartBeam AIMIGo devices, we are collaborating with Evolve Manufacturing Technologies, a contract medical device manufacturing firm. Evolve offers comprehensive contract manufacturing services for the medical device and life sciences sectors. As we progress towards more automated manufacturing operations, we intend to implement specialized tooling (e.g., high-integrity molds, automated tools, and processes) and establish a formal manufacturing agreement with Evolve. This partnership will capitalize on Evolve's manufacturing and packaging expertise to support the commercial launch of the HeartBeam AIMIGo device. Evolve employs Design for Excellence (DFX) methodologies, and its quality management processes are closely integrated with those of Triple Ring Technologies, Inc. (TRT), a US-based medical device and design engineering firm with which we are currently collaborating. This collaboration between Evolve and TRT should facilitate a seamless design transfer process and provide comprehensive turnkey contract manufacturing solutions, including first article builds, prototypes, and low-to-medium volume commercial units.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance, we will explore partnerships with other manufacturers, both domestically and internationally, to accommodate our needs for high-volume and/or sub-assembly manufacturing.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had 15 full-time employees. We have budgeted to hire additional full-time employees (including additional consultants or independent contractors) in the near future to execute our growth plans. We consider our employee relations to be good.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050. Our telephone number is (408) 899-4443 and our web address is www.heartbeam.com. Financial and other information can be accessed on the &#8220;Investors&#8221; section of our website. We make available through our website, free of charge, copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the Securities and Exchange Commission (the &#8220;SEC&#8221;). Also posted on our website are certain corporate governance documents, including our Code of Business Conduct and Ethics. The reference to our website is textual in reference only, and the information included or referred to on, or accessible through, our website does not constitute part of, and is not incorporated by reference into, this report or any other filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also file periodic reports, proxy statements and other information with the SEC. Such reports may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at (800) SEC-0330. In addition, the SEC maintains an internet site at http://www.sec.gov that contains reports, proxy and information statements and other information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks, uncertainties and other factors described below, in addition to the other information set forth in this Form 10-K, before making an investment decision. Any of these risks, uncertainties and other factors could materially and adversely affect our business, financial condition, results of operations, cash flows or prospects. In that case, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. See also &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history upon which investors can evaluate our future prospects.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited operating history upon which an evaluation of our business plan or performance and prospects can be made. The business and prospects of the Company must be considered in the light of the potential problems, delays, uncertainties and complications encountered in connection with a newly established business and new industry. The risks include, but are not limited to, the possibility that we will not be able to develop functional and scalable products and services, or that although functional and scalable, our products and services will not be economical to market; that our competitors hold proprietary rights that preclude us from marketing such products; that our competitors market a superior or equivalent product; that we are not able to upgrade and enhance our technologies and products to accommodate new features and expanded service offerings; or the failure to receive necessary regulatory clearances for our products. To successfully introduce and market our products at a profit, we must establish brand name recognition and competitive advantages for our products. There are no assurances that we can successfully address these challenges and if unsuccessful, we and our business, financial condition and operating results could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and future expense levels of our business are based largely on estimates of planned operations and future revenues rather than experience. It is difficult to accurately forecast future revenues because our business is new and our market has not been developed. If our forecasts prove incorrect, the business, operating results and financial condition of the Company may be materially and adversely affected. Moreover, we may be unable to adjust our spending in a timely manner to compensate for any unanticipated reduction in revenues. As a result, any significant reduction in planned or actual revenues may immediately and adversely affect our business, financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 of our accompanying audited financial statements, our auditors have issued a going concern opinion on our December 31, 2023 financial statements, expressing substantial doubt that we can continue as an ongoing business for the next twelve months after issuance of their report based on our current development plans and our operating requirements and us having suffered recurring losses from operations and having a net capital deficiency. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we cannot raise the necessary capital to continue as a viable entity, we could experience a material adverse effect on our business and our stockholders may lose some or all of their investment in us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can provide no assurances that any additional sources of financing will be available to us on favorable terms, if at all. Our forecast of the period of time through which our current financial resources will be adequate to support our operations and the costs to support our general and administrative, selling and marketing and research and development activities are forward-looking statements and involve risks and uncertainties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no revenues and we cannot predict when we will achieve first revenues and sustained profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no revenues and cannot definitely predict when we will achieve revenues and profitability. We do not anticipate generating significant revenues until we successfully develop, achieve regulatory clearance, commercialize and sell our proposed products, of which we can give no assurance. We are unable to determine when we will generate significant revenues from the sale of any such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict when we will achieve profitability, if ever. Our inability to become profitable may force us to curtail or temporarily discontinue our research and development programs and our day-to-day operations. Furthermore, there can be no assurance that profitability, if achieved, can be sustained on an ongoing basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may never complete the development and commercialization of products that we are currently developing and future development of new generations of any of our other proposed products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurance of success as to the completion and of the commercial launch of our products or the completion and development of any new generations of products that are currently under development or other proposed or contemplated products, for any of our target markets. We continue to seek to improve our technologies while we are developing them so that they result in commercially viable products. Failure to improve on any of our technologies could delay or prevent their successful development for our target markets. Developing any technology into a marketable product is a risky, time consuming and expensive process. You should anticipate that we will encounter setbacks, discrepancies requiring time consuming and costly redesigns and changes, and that there is the possibility of outright failure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not meet our product development and commercialization milestones.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established milestones, based upon our expectations regarding our technologies, which we use to assess our progress toward developing our products. These milestones relate to technology development and design improvements as well as dates for achieving development goals. If our products exhibit technical defects or are unable to meet cost or performance goals, our commercialization schedule could be delayed and potential purchasers of our initial commercial products may decline to purchase such products or may opt to pursue alternative products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience shortages of the components used in our devices. The contract manufacturing operations that we will use could be disrupted by fire, earthquake or other natural disaster, a labor-related disruption, failure in supply or other logistical channels, electrical outages or other reasons. If there were a disruption to manufacturing facilities, we would be unable to manufacture devices until these manufacturing capabilities are restored or alternative manufacturing facilities are engaged.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we have met our milestone schedules when making technological advances in our product. We can give no assurance that our development and commercialization schedule will continue to be met as we further develop products currently under development or any of our other future products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent upon physicians utilizing and prescribing our solution; if we fail to engage physicians to utilize our solution, our revenues may never materialize or may not meet our projections.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our cardiac diagnosis and monitoring business is dependent upon physicians prescribing and utilizing our solution. The utilization of our solution by physicians for use in the prescription of cardiac monitoring is directly influenced by a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the physicians with whom we work to obtain sufficient reimbursement and be paid in a timely manner for the professional services they provide in connection with the use of our monitoring solutions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing ourselves as a cardiac monitoring technology company by publishing peer reviewed publications showing efficacy of our solutions,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to educate physicians regarding the benefits of our cardiac monitoring solutions over alternative diagnostic monitoring solutions,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our demonstrating that our proposed products are reliable and supported by us in the field;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplying and servicing sufficient quantities of products directly or through marketing alliances; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing our devices and technology service fees in a medical device industry that is becoming increasingly price sensitive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to drive physician utilization, our revenues may never materialize or may not meet our projections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive governmental regulations relating to the manufacturing, labeling, and marketing of our products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical technology products and operations are subject to regulation by the FDA, and other foreign and local governmental authorities. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and post market surveillance of our medical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the United States Federal Food, Drug, and Cosmetic Act, medical devices are classified into one of three classes &#8212; Class I, Class II or Class III &#8212; depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. We believe that our products currently under development and planned products will be Class II medical devices. Class II medical devices are subject to additional controls, including full applicability of the Quality System Regulations, and requirements for 510(k) pre-market notification.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may disagree with the classification of a new Class II medical device and require the manufacturer of that device to apply for approval as a Class III medical device. If the FDA determines that our Class II medical Products should be classified as Class III medical devices, we could be precluded from marketing the devices for clinical use within the United States for a period of time, the length of which depends on the specific change in the classification. Reclassification of our Class II medical Products as Class III medical devices could significantly increase our regulatory costs, including the timing and expense associated with required clinical trials and other costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products in foreign countries. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and foreign regulatory authorities may change, and additional government regulations may be enacted which could prevent or delay regulatory approval of our products and could also increase the cost of regulatory compliance. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and non-U.S. regulatory authorities require that our products be manufactured according to rigorous standards. These regulatory requirements may significantly increase our production costs and may even prevent us from making our products in quantities sufficient to meet market demand. If we change our approved manufacturing process, the FDA may need to review the process before it may be used. Failure to comply with applicable regulatory requirements discussed could subject us to enforcement actions, including warning letters, fines, injunctions, and civil penalties, product recall or seizure of our products, operating restrictions, partial suspension or total shutdown of our production, and even criminal prosecution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state, and non-U.S. regulations regarding the manufacture and sale of medical devices are subject to future changes. The complexity, timeframes and costs associated with obtaining marketing clearances are unknown. Although we cannot predict the impact, if any, these changes might have on our business, the impact could be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the introduction of a product, these agencies will also periodically review our design and manufacturing processes and product performance. The process of complying with the applicable good manufacturing practices, adverse event reporting, clinical trial and other requirements can be costly and time consuming, and could delay or prevent the production, manufacturing, or sale of our products. In addition, if we fail to comply with applicable regulatory requirements, it could result in fines, delays or suspensions of regulatory clearances, closure of manufacturing sites, seizures or recalls of products and damage to our reputation. Recent changes in enforcement practice by the FDA and other agencies have resulted in increased enforcement activity, which increases the compliance risk for the Company and other companies in our industry. In addition, governmental agencies may impose new requirements regarding registration, labeling or prohibited materials that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. Once clearance or approval has been obtained for a product, there is an obligation to ensure that all applicable FDA, and other regulatory requirements continue to be met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, injuries caused by the malfunction or misuse of cardiac devices, even where such malfunction or misuse occurs with respect to one of our competitor&#8217;s products, could cause regulatory agencies to implement more conservative regulations on the medical cardiac monitoring industry, which could significantly increase our operating costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insurance companies, and managed care organizations. The manner and level of reimbursement in any given case may depend on the site of care, the procedure(s) performed, the final patient diagnosis, the device(s) utilized, available budget, the efficacy, safety, performance and cost-effectiveness of our planned products and services, or a combination of these or other factors, and coverage and payment levels are determined at each payer&#8217;s discretion. The coverage policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities regarding which medical products they purchase and the prices they are willing to pay for those products. Thus, changes in reimbursement levels or methods may impact sales of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no direct control over payer decision-making with respect to coverage and payment levels for our medical device products and services. Additionally, we expect many payers to continue to explore cost-containment strategies (e.g., comparative, and cost- effectiveness studies, so-called &#8220;pay-for-performance&#8221; programs implemented by various public and private payers, and expansion of payment bundling schemes such as Accountable Care Organizations, and other such methods that shift medical cost risk to providers) that may potentially impact coverage and/or payment levels for our products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of physicians and other providers to successfully utilize our cardiac diagnostic and monitoring solutions and successfully allow payors to reimburse for the physicians&#8217; technical and professional fees is critical to our business because physicians and their patients will select solutions other than ours in the event that payors refuse to adequately reimburse our technical fees and physicians&#8217; professional fees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in reimbursement practices of third-party payers could affect the demand for our products and services and our revenue levels.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales of our proposed products and services could depend, in part, on the extent to which healthcare providers and facilities or individual users are reimbursed by government authorities, private insurers and other third-party payers for the costs of our products, or the services performed with our products. The coverage policies and reimbursement levels of third-party payers, which can vary among public and private sources and by country, may affect which products customers purchase and the prices they are willing to pay for those products and services in a particular jurisdiction. Reimbursement rates can also affect the acceptance rate of new technologies. Legislative or administrative reforms to reimbursement systems in the United States or abroad, or changes in reimbursement rates by private payers, could significantly reduce reimbursement for medical actions using the Company&#8217;s products or result in denial of reimbursement for those products, which would adversely affect customer demand, or the price customers may be willing to pay for such products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulty in obtaining reimbursement for our services from commercial payors that consider our technology to be experimental and investigational, which would adversely affect our revenue and operating results.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many commercial payors refuse to enter into contracts to reimburse the fees associated with medical devices or services that such payors determine to be &#8220;experimental and investigational.&#8221; Commercial payors typically label medical devices or services as &#8220;experimental and investigational&#8221; until such devices or services have demonstrated product superiority evidenced by a randomized clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, clinical trials have been performed on some mobile cardiac telemetry devices, proving higher diagnostic yield than monitoring devices and services that are already being reimbursed. Certain remaining commercial payors, however, have stated that they do not believe the data from the clinical trials justifies the removal of the experimental designation for mobile cardiac telemetry solutions. As a result, certain commercial payors may refuse to reimburse the technical and professional fees associated with cardiac monitoring solutions such as the one expected to be offered by the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If commercial payors decide not to reimburse physicians or providers for their services during the utilization of our cardiac monitoring solutions, our revenue could fail to materialize or meet our projections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement by Medicare is highly regulated and subject to change; our failure to comply with applicable regulations could decrease our expected revenue and may subject us to penalties or have an adverse impact on our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare program is administered by CMS, which imposes extensive and detailed requirements on medical services providers, including, but not limited to, rules that govern how we structure our relationships with physicians, and how and where we provide our cardiac solutions. Our failure to comply with applicable Medicare rules could result in the inability </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of physicians to receive reimbursement as they will likely utilize our cardiac monitoring solution under the Medicare payment program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation of commercial payors could result in payors eliminating coverage of mobile cardiac monitoring solutions or reducing reimbursement rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When payors combine their operations, the combined company may elect to reimburse physicians for cardiac monitoring services at the lowest rate paid by any of the participants in the consolidation. If one of the payors participating in the consolidation does not reimburse for these services at all, the combined company may elect not to reimburse at any rate. Reimbursement rates tend to be lower for larger payors. As a result, as payors consolidate, our expected average reimbursement rate may decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product defects could adversely affect the results of our operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, manufacture and marketing of our hardware and software products involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA, or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market. A recall could result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products. Personal injuries or deaths relating to the use of our products could also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions or delays in telecommunications systems or in the data services provided to us by cellular communication providers or the loss of our wireless or data services could impair the delivery of our cardiac monitoring services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our cardiac monitoring services will be dependent upon our ability to transmit, store, retrieve, process and manage data and to maintain and upgrade our data processing and communication capabilities. Our monitoring solution relies on a third-party wireless carrier to transmit data over its data network. All data sent by our monitors via this wireless data network is expected to be routed directly to healthcare providers and data centers or third-party ECG monitoring centers. We are therefore dependent upon a third party wireless carrier to provide data transmission services to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our commercial activities, an increased burden is expected to be placed upon our data processing systems and the equipment upon which they rely. Interruptions of our data networks, or the data networks of our wireless carrier, for any extended length of time, loss of stored data or other computer problems could have a material adverse effect on our business and operating results. Frequent or persistent interruptions in our cardiac monitoring services could cause permanent harm to our reputation and could cause current or potential users or prescribing physicians to believe that our systems are unreliable, leading them to switch to our competitors. Such interruptions could result in liability, claims and litigation against us for damages or injuries resulting from the disruption in service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems are also expected to be vulnerable to damage to or interruption of telecommunication services from earthquakes, floods, fires, power loss, telecommunication failures, terrorist attacks, computer viruses, break-ins, sabotage, and acts of vandalism. Despite any precautions that we may take, the occurrence of a natural disaster or other unanticipated problems could result in lengthy interruptions in these services. We do not carry business interruption insurance to protect against losses that may result from interruptions in service as a result of system failures. Moreover, the communications and information technology industries are subject to rapid and significant changes, and our ability to operate and compete is dependent on our ability to update and enhance the communication technologies used in our systems and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions in computing and data management cloud systems could impair the delivery of our cardiac monitoring services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our cardiac monitoring services will be dependent upon our ability to perform computing functions associated with our cardiac signal processing algorithms and data management. The diagnostic and monitoring functions rely on the uninterrupted availability of third-party cloud based computational and data management services. Availability of the cloud-based infrastructure is a critical link in our ability to deliver our services and could have a material adverse effect on our business and operating results. Furthermore, loss of data due to catastrophic events at the sites for these cloud based computer systems could cause permanent harm to our customers. These adverse events associated with unavailability of our cloud based computational infrastructure could result in liability, claims and litigation against us for damages or injuries resulting from the disruption in service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems are also expected to be vulnerable to damage or interruption in cloud computational services from earthquakes, floods, fires, power loss, technical failures, terrorist attacks, computer viruses, break-ins, sabotage, and acts of vandalism. Despite any precautions that we may take, the occurrence of a natural disaster or other unanticipated problems could result in lengthy interruptions in these services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacture, marketing and sale of medical devices entail the inherent risk of liability claims or product recalls. Product liability insurance is expensive and, if available, may not be available on acceptable terms at all periods of time. A successful product liability claim or product recall could inhibit or prevent the successful commercialization of our products, cause a significant financial burden on the Company, or both, which in either case could have a material adverse effect on our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We require additional capital to support our present business plan and our anticipated business growth, and such capital may not be available on acceptable terms, or at all, which would adversely affect our ability to operate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional funds to further develop our business plan. We may choose to raise additional capital in order to expedite and propel growth more rapidly. We can give no assurance that we will be successful in raising any additional funds. We may need to raise additional funds, doing so through debt and equity offerings, in order to meet our expected future liquidity and capital requirements, including capital required for the development completion and introduction of our future products and technologies. Any such financing that we undertake will likely be dilutive to current stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to make investments to support our business growth, including patent or other intellectual property asset creation. In addition, we may also need additional funds to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, satisfying debt payment obligations, developing new lines of business and enhancing our operating infrastructure. While we may need to seek additional funding for such purposes, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our Common Stock. We may also seek to raise additional funds through arrangements with collaborators or other third parties. We may not be able to negotiate any such arrangements on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all our business plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot predict our future capital needs and we may not be able to secure additional financing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise additional funds in the future to fund our working capital needs and to fund further expansion of our business. We may require additional equity or debt financings, collaborative arrangements with corporate partners or funds from other sources for these purposes. No assurance can be given that necessary funds will be available for us to finance our development on acceptable terms, if at all. Furthermore, such additional financings may involve substantial dilution of our stockholders or may require that we relinquish rights to certain of our technologies or products. In addition, we may experience operational difficulties and delays due to working capital restrictions. If adequate funds are not available from operations or additional sources of financing, we may have to delay or scale back our growth plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of our research and development efforts are uncertain and there can be no assurance of the commercial success of our products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we will need to incur additional research and development expenditures to continue development of our existing proposed products as well as research and development expenditures to develop new products and services. The products and services we are developing and may develop in the future may not be technologically successful. In addition, the length of our product and service development cycle may be greater than we originally expected, and we may experience delays in product development. If our resulting products and services are not technologically successful, they may not achieve market acceptance or compete effectively with our competitors&#8217; products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to pursue our growth strategy.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend upon the continued service of Dr. Branislav Vajdic and other members of our key management team and our technical contributors. Though no individual is indispensable, the loss of the services of these individuals could have a material adverse effect on our business, operations, revenues or prospects. We do not currently maintain key man life insurance on the lives of these individuals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not be profitable unless we can demonstrate that our products can be manufactured at low prices.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have focused primarily on research and development of the first versions of our software and hardware products, as well as other technologies we plan to introduce in our eco-system, and their proposed marketing and distribution. Consequently, we have little experience in manufacturing these products on a commercial basis. We plan to manufacture our products through third-party manufacturers. We can offer no assurance that either we or our manufacturing partners will develop efficient, automated, low-cost manufacturing capabilities and processes to meet the quality, price, engineering, design and production standards or production volumes required to successfully mass market our products, especially at the low-cost levels we require to absorb the cost of near free distribution of our products pursuant to our proposed business plan. Even if we or our manufacturing partners are successful in developing such manufacturing capability and processes, we do not know whether we or they will be timely in meeting our product commercialization schedule or the production and delivery requirements of potential customers. A failure to develop such manufacturing processes and capabilities could have a material adverse effect on our business and financial results. If we or our suppliers fail to achieve or maintain regulatory approval of manufacturing facilities, our growth could be limited and our business could be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to maintain compliance with FDA and other regulatory requirements, our development and manufacturing facilities must be periodically re-evaluated and qualified under a quality system to ensure they meet production and quality standards. Suppliers of components and products used to manufacture our devices must also comply with FDA regulatory requirements, which often require significant resources and subject us and our suppliers to potential regulatory inspections and stoppages. If we or our suppliers do not maintain regulatory approval for our manufacturing operations, our business could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a limited number of suppliers of components for our prototype devices. If these suppliers became unable to provide components in the volumes needed or at an acceptable price, we would have to identify and qualify acceptable replacements from alternative sources of supply. The process of qualifying suppliers is lengthy. Delays or interruptions in the supply of our requirements could limit or stop our ability to provide sufficient quantities of devices on a timely basis or meet demand for our devices or services, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that companies have been increasingly subject to a wide variety of security incidents, cyberattacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past few years, cyber-attacks have become more prevalent and much harder to detect and defend against. Several key areas of our business depend on the use of information technologies, including production, manufacturing, marketing, and logistics, as well as clinical and regulatory matters. We also utilize systems that allow for the secure storage and transmission of proprietary or confidential information regarding our customers, employees, and others, including personal information. Despite our efforts to prevent such behavior, third parties may nonetheless attempt to hack into our systems and obtain data relating to our pre-clinical studies, clinical trials, patients using our VCG technology and our telehealth ECG collection device or other information relating to us or our business. If we fail to maintain or protect our information systems and data integrity effectively, we could have problems in determining product cost estimates and establishing appropriate pricing, have difficulty preventing, detecting, and controlling fraud, have disputes with physicians, and other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences and reputational damages. While we have invested in the protection of data and information technology, there can be no assurance that our efforts or those of our third-party collaborators, if any, or manufacturers, to implement adequate security and quality measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being stolen or corrupted in the event of a security breach. Any such loss or breach could harm our business, operating results, and financial condition. For a discussion of our management of cybersecurity risks, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1C, "Cybersecurity-Risk Management" and "-Governance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">"</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will be effectively remediated or that additional material weaknesses will not occur in the future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, and the Sarbanes-Oxley Act. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time consuming and costly, and place significant strain on our personnel, systems and resources.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures, and internal controls over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have effective disclosure controls and procedures, or internal controls over all aspects of our financial reporting. We are continuing to develop and refine our internal controls over financial reporting. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. We will be required to expend time and resources to further improve our internal controls over financial reporting, including by expanding our staff. However, we cannot assure you that our internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. The material weaknesses identified to date include (i) lack of formal risk assessment under COSO framework (ii) policies and procedures which are not adequately documented, (iii) lack of proper approval processes, review processes and documentation for such reviews, (iv) insufficient GAAP experience regarding complex transactions and reporting and (v) insufficient number of staff to maintain optimal segregation of duties and levels of oversight.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Starting in third quarter of 2023, we have undertaken specific remediation actions to address the material weaknesses in our financial reporting. We are establishing more robust processes related to the review of complex accounting transactions, the preparation of account reconciliations and the review of journal entries. These remediation actions included hiring a Controller in July 2023, who we believe has extensive experience in developing and implementing internal controls and executing plans to remediate control deficiencies. We will be required to expend time and resources to further improve our internal controls over financial reporting. However, we cannot assure you that our internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls or our internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting could also adversely affect the results of management reports and independent registered public accounting firm audits of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures, and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is not required to audit the effectiveness of our internal control over financial reporting until after we are no longer an "emerging growth company&#8221; as defined in the JOBS Act and meet other requirements. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our internal control over financial reporting is documented, designed or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business and operating results, and cause a decline in the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Economic Conditions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We maintain our cash at financial institutions, often in balances that exceed federally insured limits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in tax laws or regulations may increase tax uncertainty and adversely affect results of our operations and our effective tax rate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to taxes in the United States and in the future expect to be subject to certain foreign jurisdictions. Due to economic and political conditions, tax rates in various jurisdictions, including the United States, may be subject to change. Our future effective tax rates could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws or their interpretation. In addition, we may be subject to income tax audits by various tax jurisdictions. Although we believe our income tax liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution by one or more taxing authorities could have a material impact on the results of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Escalating global trade tensions, the Russia and Ukraine war, the Israel-Hamas war, the adoption or expansion of tariffs and trade restrictions and economic disruption and uncertainty resulting therefrom could negatively impact us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Russia and Ukraine war and Israel-Hamas war could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations and could adversely affect our business and/or our supply chain, business partners or customers in other countries beyond Russia and Ukraine. The U.S. government and other governments in jurisdictions in which we operate have imposed severe sanctions and export controls against Russia and Russian interests and threatened additional sanctions and controls. It is not possible to predict the broader consequences of this conflict, which could include sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, currency exchange rates and financial markets. The impact of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, supply chain, partners or customers. More specifically, while it is difficult to anticipate the impact the sanctions announced to date may have on our Research and Development team is largely based in Belgrade, Serbia any further sanctions imposed or actions taken by the U.S. or other countries, and any retaliatory measures by Russia in response, such as restrictions on energy supplies from Russia to countries in the region, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters and other events beyond our control could materially adversely affect us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters or other catastrophic events may cause damage or disruption to our operations, international commerce and the global economy, and thus could have a strong negative effect on us. Our business operations are subject to interruption by natural disasters, fire, power shortages, pandemics and other events beyond our control. Such events could make it difficult or impossible for us to deliver our products and services to our customers and could decrease demand for our products and services. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business and operations, and the operations of our suppliers and customers, have been, and may in the future be adversely affected by epidemics, pandemics or other public health crises such as the COVID-19 pandemic outbreak.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may face risks related to health epidemics and pandemics or other outbreaks of communicable diseases. The COVID-19 pandemic and governments&#8217; measures taken in response had a significant adverse impact, both direct and indirect, on our business and on the broader economy. We may in the future experience, weakened demand from certain customers as a result of a public health crisis, which could adversely affect our revenues. For example, healthcare providers have, at times, deferred elective medical procedures in order to focus on combating the COVID-19 pandemic, which significantly reduced demand for certain of our medical products. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also faced difficulty sourcing some materials and components necessary to fulfill our developmental requirements due to suppliers&#8217; capacity constraints and shipping and transportation disruptions during the COVID-19 pandemic. These disruptions adversely affected our ability to meet our schedules. If we are not able to mitigate similar disruptions effectively in future epidemics, pandemics or other public health crisis, our ability to manufacture our products or meet our customers&#8217; schedules would be adversely affected, possibly materially, and our business could be harmed. In addition, efforts to find alternate sources of supply may increase our costs or lower the quality of our product, which could negatively affect our profitability, financial condition and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The industry in which we operate is highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical technology industry is characterized by intense competition and rapid technological change, and we will face competition on the basis of product features, clinical outcomes, price, services and other factors. Competitors may include large medical device and other companies, some of which have significantly greater financial and marketing resources than we do, and firms that are more specialized than we are with respect to particular markets. Our competition may respond more quickly to new or emerging technologies, undertake more extensive marketing campaigns, have greater financial, marketing and other resources than ours or may be more successful in attracting potential customers, employees and strategic partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will depend on multiple, complex factors, including our ability to achieve regulatory clearance and market acceptance for our products, develop new products, implement production and marketing plans, secure regulatory approvals for products under development and protect our intellectual property. In some instances, competitors may also offer, or may attempt to develop, alternative systems that may be delivered without a medical device or with a medical device superior to ours. The development of new or improved products, processes or technologies by other companies may render our products or proposed products obsolete or less competitive. The entry into the market of manufacturers located in low-cost manufacturing locations may also create pricing pressure, particularly in developing markets. Our future success depends, among other things, upon our ability to compete effectively against current technology, as well as to respond effectively to technological advances or changing regulatory requirements, and upon our ability to successfully implement our marketing strategies and execute our research and development plan. Our research and development efforts are aimed, in part, at solving increasingly complex problems, as well as creating new technologies, and we do not expect that all of our projects will be successful. If our research and development efforts are unsuccessful, our future results of operations could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from other medical device companies that focus on similar markets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from other companies that have longer operating histories and may have greater name recognition and substantially greater financial, technical and marketing resources than us. Many of these companies also have FDA or other applicable governmental approval to market and sell their products, and more extensive customer bases, broader customer relationships and broader industry alliances than us, including relationships with many of our potential customers. Increased competition from any of these sources could result in our failure to achieve and maintain an adequate level of customers and market share to support the cost of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unsuccessful clinical trials or procedures relating to products under development could have a material adverse effect on our prospects.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical experiences and regulatory studies. Unfavorable or inconsistent clinical data from current or future clinical trials or procedures conducted by us, our competitors, or third parties, or perceptions regarding this clinical data, could adversely affect our ability to obtain necessary approvals and the market&#8217;s view of our future prospects. Such clinical trials and procedures are inherently uncertain and there can be no assurance that these trials or procedures will be completed in a timely or cost- effective manner or result in a commercially viable product. Failure to successfully complete these trials or procedures in a timely and cost-effective manner could have a material adverse effect on our prospects. Clinical trials or procedures may experience significant setbacks even after earlier trials have shown promising results. Further, preliminary results from clinical trials or procedures may be contradicted by subsequent clinical analysis. In addition, results from our already completed clinical trials or procedures may not be supported by actual long-term studies or clinical experience. If preliminary clinical results are later contradicted, or if initial results cannot be supported by actual long-term studies or clinical experience, our business could be adversely affected. Clinical trials or procedures may be suspended or terminated by us, the FDA or other regulatory authorities at any time if it is believed that the trial participants face unacceptable health risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry in which we operate is characterized by extensive intellectual property litigation and, from time to time, we might be the subject of claims by third parties of potential infringement or misappropriation. Regardless of outcome, such claims are expensive to defend and divert the time and effort of our management and operating personnel from other business issues. A successful claim or claims of patent or other intellectual property infringement against us could result in our payment of significant monetary damages and/or royalty payments, or it could negatively impact our ability to sell current or future products in the affected category and could have a material adverse effect on business, cash flows, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining intellectual property protections we rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We will seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We will seek to protect our confidential proprietary information, in part, by entering into confidentiality and invention or intellectual property assignment agreements with our employees and consultants. Moreover, to the extent we enter into such agreements, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. In general, any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our proprietary rights, or if we infringe on the proprietary rights of others, our competitiveness and business prospects may be materially damaged.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for and were granted a number of utility patents in the U.S as well as through PCT covering international markets. We will continue to seek patent protection for our inventions and may seek patent protection for our proprietary designs if warranted. Seeking patent protection is a lengthy and costly process, and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our designs or our proprietary technology. There is also no guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the patent rights granted will provide competitive advantages to us. Our competitors have developed and may continue to develop and obtain patents for technologies that are similar or superior to our technologies. In addition, the laws of foreign jurisdictions in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent, as do the laws the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse outcomes in legal disputes regarding patent and other intellectual property rights could result in the loss of our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our products, or compel us to redesign our products to avoid infringing third parties&#8217; intellectual property. As a result, we may be required to incur substantial costs to prosecute, enforce or defend our intellectual property rights if they are challenged. Any of these circumstances could have a material adverse effect on our business, financial condition and resources or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dependence on our proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in our payment of significant monetary damages or impact offerings in our product portfolios.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success largely depends on our ability to market technologically competitive products. If we fail to obtain or maintain adequate intellectual property protection, we may not be able to prevent third parties from using our proprietary technologies or may lose access to technologies critical to our products. Also, our currently pending industrial design patent or any future patents applications may not result in issued patents, and issued patents are subject to claims concerning priority, scope and other issues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, to the extent we do not file applications for patents domestically or internationally, we may not be able to prevent third parties from using our proprietary technologies or may lose access to technologies critical to our products in other countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect our business, financial condition or operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use and disclosure of certain health care information by health care providers and their business associates have come under increasing public scrutiny. Recent federal standards under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish rules concerning how individually-identifiable health information may be used, disclosed and protected. Historically, state law has governed confidentiality issues, and HIPAA preserves these laws to the extent they are more protective of a patient&#8217;s privacy or provide the patient with more access to his or her health information. As a result </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the implementation of the HIPAA regulations, many states are considering revisions to their existing laws and regulations that may or may not be more stringent or burdensome than the federal HIPAA provisions. We must operate our business in a manner that complies with all applicable laws, both federal and state, and that does not jeopardize the ability of our customers to comply with all applicable laws. We believe that our operations are consistent with these legal standards. Nevertheless, these laws and regulations present risks for health care providers and their business associates that provide services to patients in multiple states. Because these laws and regulations are recent, and few have been interpreted by government regulators or courts, our interpretations of these laws and regulations may be incorrect. If a challenge to our activities is successful, it could have an adverse effect on our operations, may require us to forego relationships with customers in certain states and may restrict the territory available to us to expand our business. In addition, even if our interpretations of HIPAA and other federal and state laws and regulations are correct, we could be held liable for unauthorized uses or disclosures of patient information as a result of inadequate systems and controls to protect this information or as a result of the theft of information by unauthorized computer programmers who penetrate our network security. Enforcement of these laws against us could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject, directly or indirectly, to federal and state health care fraud and abuse laws and regulations and if we are unable to fully comply with such laws, the Company could face substantial penalties.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although not affected at this time, our operations may in the future become directly or indirectly affected by various broad state and federal health care fraud and abuse laws, including the Federal Healthcare Programs&#8217; Anti-Kickback Statute and the Stark law, which among other things, prohibits a physician from referring Medicare and Medicaid patients to an entity with which the physician has a financial relationship, subject to certain exceptions. If our future operations are found to be in violation of these laws, we or our officers may be subject to civil or criminal penalties, including large monetary penalties, damages, fines, imprisonment and exclusion from Medicare and Medicaid program participation. If enforcement action were to occur, our business and results of operations could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to federal and state false claims laws which impose substantial penalties.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the physicians and patients whom we expect to use our services will file claims for reimbursement with government programs such as Medicare and Medicaid. As a result, we may be subject to the federal False Claims Act if we knowingly &#8220;cause&#8221; the filing of false claims. Violations may result in substantial civil penalties, including treble damages. The federal False Claims Act also contains &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions that allow private individuals to bring actions on behalf of the government alleging that the defendant has defrauded the government. In recent years, the number of suits brought in the medical industry by private individuals has increased dramatically. Various states have enacted laws modeled after the federal False Claims Act, including &#8220;qui tam&#8221; provisions, and some of these laws apply to claims filed with commercial insurers. We are unable to predict whether we could be subject to actions under the federal False Claims Act, or the impact of such actions. However, the costs of defending claims under the False Claims Act, as well as sanctions imposed under the False Claims Act, could adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our Common Stock and Warrants may be subject to wide fluctuations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A consistently active trading market for our Common Stock and Warrants does not exist and may not develop or be maintained. You may not be able to sell your shares quickly or at the current market price if trading in our stock is not active. You may lose all or a part of your investment. The market price of our Common Stock and Warrants may be highly volatile and subject to wide fluctuations in response to a variety of factors and risks, many of which are beyond our control. In addition to the risks noted elsewhere in this prospectus, some of the other factors affecting our stock price may include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by third parties of significant claims or proceedings against us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our Common Stock or other equity securities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of our product;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish collaborations if needed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of our initial target markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully treat additional types of indications or at different stages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in annual and quarterly operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our Common Stock by our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our Common Stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our or our licensee&#8217;s technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions, including war and its unknown impact on our Serbia development team; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and any decision on our part to comply with certain reduced disclosure requirements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies including, but (i) not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) not being required to comply with any new requirements adopted by the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;), requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report in which the auditor would be required to provide additional information about the audit and the financial statements of the issuer, (iii) not being required to comply with any new audit rules adopted by the PCAOB after April 5, 2012 unless the SEC determines otherwise, (iv) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (v) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could remain an emerging growth company until the earlier of: (i) the last day of the fiscal year in which we have total annual gross revenues of $1.24 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration statement; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer. We cannot predict if investors will find our securities less attractive if we choose to rely on these exemptions. If some investors find our securities less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our securities and our stock price may be more volatile. Further, as a result of these scaled regulatory requirements, our disclosure may be more limited than that of other public companies and you may not have the same protections afforded to stockholders of such companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for complying with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new or revised accounting standards. We have opted for taking advantage of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jobs Act.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:90%">We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company under Rule 12b-2 of the Securities Exchange Act of 1934. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on smaller reporting company exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans and other equity securities could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell Common Stock or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Stock or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our Common Stock. Our Certificate of Incorporation authorizes the issuance of 100,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock. Initially, the aggregate number of shares of our Common Stock that may be issued pursuant to stock awards under our 2022 Equity Incentive Plan (&#8220;2022 Plan&#8221;) is 1,900,000 shares, increased to 5,900,000 shares at the last shareholders&#8217; meeting. As of December 31, 2023, there are 849,171 shares available for issuance under the 2022 Plan. The number of shares available for issuance under the 2022 Plan will be increased on the first day of each fiscal year beginning with the 2023 fiscal year by five percent (5%) of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year as defined in the Plan. Further increases in the number of shares available for future grant or purchase may result in additional dilution, which could cause our stock price to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Capital Market, may delist our Common Stock if we fail to comply with ongoing listing standards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market requires us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of our Common Stock and Warrants. If we fail to meet these continued listing requirements, our Common Stock or Warrants may be subject to delisting. If our Common Stock or Warrants are delisted and we are not able to list such Common Stock and Warrants on another national securities exchange, we expect our securities would be quoted on an over-the-counter market; However, if this were to occur, our stockholders could face significant material adverse consequences, including limited availability of market quotations for our Common Stock and Warrants and reduced liquidity for the trading of our securities. In addition, in the event of such delisting, we could experience a decreased ability to issue additional securities and obtain additional financing in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our Company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our need for future financing may result in the issuance of additional securities which will cause investors to experience dilution.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash requirements may vary from those now planned depending upon numerous factors, including the result of future research and development activities, our ability to estimate future expenses and acceptance of our products in the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no significant commitments for future financing of the commercial phase of our telehealth Product and other future products. In the future, our securities may be offered to other investors at a price lower than the price per share paid </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our investors, or upon terms which may be deemed more favorable than previously offered. In addition, the issuance of securities in any future financing using our securities may dilute an investor&#8217;s equity ownership. Moreover, we may issue other equity securities with derivative features to procure qualified personnel or for other business reasons. The issuance of any such derivative securities, which is at the discretion of our board of directors, may further dilute the equity ownership of our stockholders, including the investors in this offering. No assurance can be given as to our ability to procure additional financing, if required, and on terms deemed favorable to us. To the extent additional capital is required and cannot be raised successfully, we may then have to limit our then current operations and/or may have to curtail certain, if not all, of our business objectives and plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has adopted regulations, which generally define &#8220;penny stock&#8221; to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our Common Stock is less than $5.00 per share and therefore may be a &#8220;penny stock.&#8221; Brokers and dealers effecting transactions in &#8220;penny stock&#8221; must disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These rules may restrict the ability of brokers or dealers to sell our Common Stock and may affect your ability to sell shares of our Common Stock in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability of directors for breach of duty is limited under Delaware law.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for any:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breach of their duty of loyalty to us or our stockholders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transaction from which the directors derived an improper personal benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These limitations of liability do not apply to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies such as injunctive relief or rescission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our bylaws provide that we will indemnify for our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into separate indemnification agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors and officers for any and all expenses (including reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection with any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request provided that such person follows the procedures for determining entitlement to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation of liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In so far as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future and, as such, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. In addition, and any future loan arrangements we enter into may contain, terms prohibiting or limiting the amount of dividends that may be declared or paid on our Common Stock. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_25"></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_769"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cybersecurity Risk Management</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we use, store, and process data including data of our employees, partners, collaborators, and vendors. We also have implemented advanced data protection measures, including encryption, data masking, and secure data storage solutions, to protect patient data and other sensitive information from unauthorized access or disclosure. We are in the process of implementing a cybersecurity risk management program that is evolving to identify, assess, and manage cybersecurity risks associated with our digital healthcare technologies and operations. This encompasses continuously enhancing our safeguarding measures for proprietary ECG telemedicine technology, cloud-based software, and sensitive health data from cyber threats, ensuring compliance with relevant healthcare and data protection regulations, and actively maintaining the integrity, availability, and confidentiality of patient and company information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes a number of components, such as ongoing information security program assessments and continuous monitoring of critical risks from cybersecurity threats using automated tools. We leverage a combination of internal and external resources to continuously update our intelligence about emerging cybersecurity threats. This includes subscribing to threat intelligence feeds, participating in industry-specific security forums, and collaborating with cybersecurity organizations. We also employ state-of-the-art automated security systems that are regularly updated to recognize and respond to the latest cybersecurity threats. Automated alerts notify our security team of potential threats in real-time, enabling rapid assessment and response. Additionally, we have implemented an employee education program that is regularly updated to raise awareness of cybersecurity threats, including phishing awareness, secure password practices, and the proper handling of sensitive information. This training is included during the employee onboarding process and is revisited periodically. As part of our cybersecurity risk management program, we maintain processes to assess and review the cybersecurity practices of third-party vendors on an ongoing basis. Prior to engaging third-party vendors, all vendors are subjected to rigorous security assessments before engagement and are regularly re-assessed, and, as appropriate, include cybersecurity requirements in contracts. We, like other companies in our industry, face a number of cybersecurity risks in connection with our business. Although our business strategy, results of operations, and financial condition have not, to date, been materially affected by risks from cybersecurity threats, including as a result of previously identified cybersecurity incidents, we have, from time to time, experienced threats to and security incidents related to our data and systems, including phishing attacks. For more information on our cybersecurity related risks, see &#8220;Risk Factors-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm us.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Governance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the ultimate direction of our chief executive officer (CEO), our executive management team, including our President, Chief Technology Officer (CTO), Director of Platform IT and Chief Information Security Officer (CISO), and Vice President of Regulatory Affairs, along with oversight from our Audit Committee of the Board of Directors, is tasked </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with the continuous assessment, operation, and management of our cybersecurity threat management program. Our CTO leads the ongoing development of the Company's cybersecurity program, oversees the implementation of cybersecurity measures, and manages the response to cybersecurity incidents. The Director of Platform IT and CISO meets periodically with our Vice President of Regulatory Affairs to discuss the evolving cybersecurity landscape and our cybersecurity risk management program, including providing updates regarding the sources and nature of critical risks we face and how the IT department assesses those risks, including the likelihood of such risks, the severity of impact, and the progress on vulnerability remediation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Director of Platform IT and CISO regularly consults with other members of our information technology department, and with third parties with expertise in cybersecurity, to develop strategies to assess, address and align our continuous cybersecurity efforts with our business objectives and operational requirements. The Director of Platform IT and CISO role is currently held by an individual who has over 12 years of experience with information security and business systems, including digital infrastructure and cybersecurity.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our Board of Directors&#8217;, or Board&#8217;s, enterprise risk management program, our Board has responsibility for oversight of cybersecurity risk management. Our Board has delegated to our Audit Committee oversight of our cybersecurity risk management program, including oversight of information security and cybersecurity threats and related compliance and disclosure requirements. On a quarterly basis, our finance team provides an update to our Audit Committee regarding our cybersecurity risk management program, including as relates to critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards. The Audit Committee periodically reports on cybersecurity risk management to the full Board of Directors.</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our headquarters are located at 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050 which we lease pursuant to a monthly lease agreement entered into in May 2019 by our Chief Executive Officer Branislav Vajdic. The terms of the lease are month to month and either party can terminate with one months notice. We terminated this lease effective on January 11, 2024, and entered into a new lease in name of the Company with the same landlord. The new lease commenced on February 1, 2024, for initial period of 3 years</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the facilities described above are suitable and adequate for our present purposes and needs in the near future.</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no actions, suits, proceedings, inquiries or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our Common Stock, any of our officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II</span></div><div style="text-align:center"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock and warrants are traded on the NASDAQ Capital Market under the symbols &#8220;BEAT&#8221; and &#8220;BEATW&#8221;, respectively. The closing price of our common stock and warrants on the Nasdaq Capital Market on March 19, 2024 was $2.31 and $0.20 respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 19, 2024, there were approximately 84 holders of record of our common stock. As our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid any cash dividends on our common stock to date. The payment of dividends in the future will be contingent upon our revenues and earnings, if any, capital requirements and general financial condition, and will be within the discretion of our then-existing board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent, Warrant Agent and Registrar</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our transfer agent and registrar for our common stock and warrant agent for our warrants is VStock Transfer, LLC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph and Purchases of Equity Securities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following sets forth information regarding all unregistered securities sold by the registrant in the three years preceding the date of this Annual Report on Form 10-K;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On November 11, 2021, we issued 1,497,216 shares of Common Stock from the conversion of the 2015 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On November 15, 2021, in connection with the IPO, we issued 192,500 warrants (the &#8220;Underwriter Warrants&#8221;) to purchase Common Stock as compensation to the Underwriter, exercisable at a per share exercise price equal to $7.50 per share. The Underwriter Warrants will expire five years from the date of issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On January 14, 2022, we issued 78,025 shares of Common Stock to a consulting firm for services that were related to the IPO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On February 28, 2023 we entered into a securities purchase agreement and a note purchase agreement, each as amended March 7, 2023 (&#8220;SPA&#8221;, &#8220;NPA&#8221; or together &#8220;Agreements&#8221;) with Maverick Capital Partners, LLC (&#8220;Maverick&#8221; or &#8220;Investor&#8221;). Pursuant to the terms of the Agreements, as amended, we agreed to sell up to $4,000,000 of our common stock at 75% of the average calculated Volume Weighted Average Price (&#8220;VWAP&#8221;) per share during a Drawdown Pricing Period as defined in the Agreements. We issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023 the Convertible Note was settled upon the execution of a SPA and related issuance of 0.2&#160;million shares of common stock pursuant to the SPA drawdown notice dated </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 7, 2023. The 0.2&#160;million shares of common stock were registered under our registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On May 2, 2023, we issued 1,666,666 placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise price of $1.875 per share and are exercisable for five years from the date of issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These issuances were made in reliance on an exemption from registration set forth in Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving a public offering.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no issuer purchases of equity securities during the year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 12, 2015 we adopted the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), the 2015 Plan provided for the grant of stock options and RSUs to purchase common stock of which 1,636,362 were authorized by the board, of these 970,704 are outstanding as of December 31, 2023. At the Annual Stockholder meeting held on June 15, 2022 the 2015 Plan was terminated upon stockholder approval of the 2022 Equity Incentive Plan (&#8220;2022 Plan&#8221;) whereby no new awards can be issued under the 2015 Plan. Initially, the aggregate number of shares of our Common Stock that may be issued pursuant to stock awards under our 2022 Plan is 1,900,000 shares and increased to 5,900,000 at the 2023 annual shareholders&#8217; meeting. As of December 31, 2023, there are 849,171 shares available for issuance under the 2022 Plan. The number of shares available for issuance under the 2022 Plan will be increased on the first day of each fiscal year beginning with the 2023 fiscal year by five percent (5%) of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year as defined in the Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal provisions of our equity compensation plan is summarized below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan generally is administered by our Board of Directors. The Board of Directors will have authority to establish rules and regulations for the proper administration of our equity incentive plan, to select the employees, directors and consultants to whom awards are granted, and to set the date of grant, the type of award and the other terms and conditions of the awards, consistent with the terms of the 2022 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligibility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Persons eligible to participate in the 2022 Plan include all of our officers, employees, directors and consultants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Plan provides for the grant of: (i) incentive stock options; (ii) nonstatutory stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) other stock-based and cash-based awards to eligible individuals. The terms of the awards will be set forth in an award agreement, consistent with the terms of the 2022 Plan. No stock option will be exercisable later than ten years after the date it is granted. The 2022 Plan permits the grant of awards intended to qualify as "performance-based compensation&#8221; under Section 162(m) of the Internal Revenue Code of 1986, as amended.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant incentive stock options as defined in Section 422 of the Code, and nonstatutory stock options. Options shall be exercisable for such prices, shall expire at such times, and shall have such other terms and conditions as the Board of Directors may determine at the time of grant and as set forth in the award agreement; however, the exercise price must be at least equal to 100% of the fair market value at the date of grant. The option price is payable in cash or other consideration acceptable to us.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Appreciation Rights</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant stock appreciation rights with such terms and conditions as the Board of Directors may determine at the time of grant and as set forth in the award agreement. The grant price of a stock appreciation right shall be determined by the Board of Directors and shall be specified in the award agreement; however, the grant price must be at least equal to 100% of the fair market value of a share on the date of grant. Stock appreciation rights may be exercised upon such terms and conditions as are imposed by the Compensation Committee and as set forth in the stock appreciation right award agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may be granted in such amounts and subject to the terms and conditions as determined by the Board of Directors at the time of grant and as set forth in the award agreement. The Board of Directors may impose performance goals for restricted stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Awards</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant other types of equity-based or equity-related awards not otherwise described by the terms of the 2022 Plan, in such amounts and subject to such terms and conditions, as the Board of Directors shall determine. Such awards may be based upon attainment of performance goals established by the Board of Directors and may involve the transfer of actual shares to participants, or payment in cash or otherwise of amounts based on the value of shares.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_43"></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6. RESERVED</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to, those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. See Cautionary Statement Regarding Forward-Looking Statements.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a medical technology company focused on transforming cardiac care through the power of personalized insights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution ECG solutions is achieved through the development of our proprietary and patented VECG technology platform. Our VECG technology is capable of capturing 3D vector images of the heart&#8217;s electrical activity and synthesizing a 12L ECG from these signals. In early studies, our approach demonstrated equal or superior diagnostic capability than traditional hospital-based 12L ECG systems. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Products require FDA clearance and have not been cleared for marketing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our Products and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payors. We are developing our telehealth Product, HeartBeam AIMIGo, to address the rapidly growing field of ambulatory cardiac health monitoring. HeartBeam AIMIGo is comprised of a credit card sized electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. We believe that we are uniquely positioned to play a central role in ambulatory cardiac monitoring including high-risk coronary artery disease patients, because the initial studies have shown that our ischemia detection system may be more accurate than existing ambulatory monitoring solutions. CAD patients are at increased risk for a heart attack or MI.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have developed a working prototype for HeartBeam AIMIGo and have filed a 510(k) submission with the FDA. This submission is for the initial Product, a device which is a 3 lead X, Y, Z vector VECG. We expect this to be the first patient-held VECG device to be cleared by the FDA and this will be a major milestone for the company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA clearance of the AIMIGo device, we plan to file a submission for the software algorithms that synthesize a 12L ECG from the HeartBeam AIMIGo device. The result of these two 510(k) submissions, once cleared by the FDA, will be an ambulatory device, carried by patients, which can synthesize a 12L ECG for physician review.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have had productive discussions with the FDA on both products. On the first submission, we are in the substantive review phase of answering questions posed by the FDA. We have clarified the information requested in meetings with FDA representatives and are in the process of preparing our official responses. We currently anticipate clearance by the end of Q2 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have held two Pre-submission meetings with FDA on the 12L synthesis submission. These meetings have been focused primarily on the performance goals of our clinical study that is designed to demonstrate the similarity between our synthesized 12L signal and the output of a standard 12L ECG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on feedback from FDA and our clinical experts, we have designed our clinical study, &#8220;Clinical Validation of AIMIGo 12 Lead ECG Synthesis Software for Arrhythmia Detection: A Prospective Multicenter Pivotal Study,&#8221; (the &#8220;VALID-ECG Study&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2024, we enrolled the first patient in the VALID-ECG study. The VALID-ECG study is a prospective single-arm multicenter trial designed with the goal to validate the AIMIGo 12L ECG Synthesis Software by comparing its results with those of a standard FDA-cleared 12L ECG using both quantitative and qualitative assessment methodologies. We plan to enroll a total of approximately198 patients presenting to an outpatient cardiology clinic or arrhythmia center for symptoms suggestive of cardiac arrhythmia or for routine checkup of previously diagnosed arrhythmia. The study is expected to include up to 5 sites.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective is to demonstrate the equivalence of ECG waveforms between AIMIGo Synthesized 12L ECG and Standard 12L ECG, recorded simultaneously in each subject, by assessing intervals and amplitudes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to complete enrollment in the VALID-ECG study in Q2 2024 and submit the second 510(k) application by Q3 2024. We continue to anticipate that our limited launch of AIMIGo will occur by the end of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we withdrew the FDA application of our AIMI Product, which is a software-only product designed for use in hospitals. We are exclusively focusing on the large market of ambulatory cardiac monitoring,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have an active AI program underway. Our AI team includes 5 PhDs. The leadership has deep AI expertise, including prior positions at Apple, Microsoft and Google. We have acquired approximately one million 12L ECGs from various sources, a key element in our fast-paced AI development efforts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed initial deep learning algorithms, focused on the ability to detect various cardiac arrhythmias. HeartBeam has had data on its deep learning algorithm accepted for presentation at two prestigious Electrophysiology conferences: the European Heart Rhythm Association, to be held in Berlin, Germany in April 2024 and the Heart Rhythm Society, to be held in Boston MA in May 2024. We believe that, when combined with our Products, HeartBeam&#8217;s AI will provide additional value to patients and physicians in a number of ways, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Providing automated classification of cardiac conditions, including common arrhythmias;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The potential to further enhance user experience and simplify the onboarding process, and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">In the longer run, we believe that applying deep learning algorithms on top of the rich VECG data, especially with the longitudinal dataset from patients taking repeated readings, may result in unsurpassed predictive and diagnostic capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The custom software and hardware of our Products are classified as Class II medical devices by the FDA, running on an FDA registered Class I software platform. Premarket review and clearance by the FDA for Class II devices is generally accomplished through the 510(k) premarket notification process or De Novo process. Given the proposed intended use of our device, the 510(k) submission is expected to require clinical data to support FDA clearance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A landmark clinical study on the HeartBeam technology was published in the August 2023 issue of the journal JACC: Advances. The publication, &#8220;Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration&#8221; demonstrated that HeartBeam&#8217;s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12L ECG. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study showed that the automated analysis of the VECG and 12L ECG signals had similar performance in determining whether a coronary artery was occluded. Also in the study, the human interpretation of the 12L ECGs had significant intra- and inter-observer variability, which does not occur with automated readings. The study also showed that the presence of the &#8220;normal baseline&#8221; recording, a novel feature that is integral to HeartBeam&#8217;s VECG technology, dramatically improved the accuracy of interpretation, increasing the Area Under the Curve (&#8220;AUC&#8221;), a standard measure of diagnostic performance, from 0.72 to 0.95. This is particularly important since physicians who are analyzing 12L ECGs often do not have access to a normal baseline, implying that the HeartBeam system could outperform this approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study was a collaboration of Harvard Medical School Faculty at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and Clinical Center of Serbia in Belgrade.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">HeartBeam has 13 issued and allowed U.S. patents (U.S. 10,433,744, U.S. 10,117,592, U.S. 11,071,490, U.S. 11,419,538, U.S. 11,445,963, U.S. 11,701,049, U.S. 11,529,085, U.S. 10,980,433, U.S. 11,412,972, U.S. 11,234,658, U.S. 11,793,444, U.S. 11,877,853, and allowed U.S. patent application no. 18/068,481), and nine pending U.S applications. Outside of the U.S., HeartBeam has four issued patents in Germany, France, Netherlands and United Kingdom and fourteen pending applications in Canada, China, the European Union, Japan, South Korea and Australia. HeartBeam has two pending Patent Cooperation Treaty applications. The issued patents are predicted to expire between April 11, 2036 and April 21, 2042.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, we had 15 employees. We intend to hire or engage additional full-time professionals, employees, and / or consultants in alignment with our growth strategy. Although the market is highly competitive for attracting and retaining highly qualified professionals in our industry, we continue our endeavor to find such candidates for our Company. Our management team and additional personnel that we may hire in the future will be primarily responsible for executing and implementing growth opportunities, making tactical decisions related to our strategy and pursuing opportunities to invest in new technologies through strategic partnerships and acquisitions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Developments during 2023 and early 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Appointment of President</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, our Board of Directors appointed Robert P. Eno as President of the Company effective as of January 18, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Appointment of Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We increased the size of our Board of Directors (the &#8220;Board&#8221;) this year to eight, adding individuals that broadened the scope and experience of our then 5-person Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 5, 2023, the Board appointed Mark Strome and Ken Nelson as directors of the Company.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Mr. Strome combines over 40 years of experience in the investment management and securities industry. Mark is the Founder, Chief Investment Officer, and Chairman at Strome Investment Management, L.P. and Strome Group, Inc. Mark earned a Bachelor of Science in Engineering from Old Dominion University and Master of Science in Economics from the University of California at Berkeley.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Mr. Nelson is a 20-year digital health, medical device, and remote patient monitoring executive and innovator. Over the past 10 years, Ken has led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries for 3 of the top 4 market share players in cardiac digital health and remote patient monitoring. Ken earned a Bachelor of Arts in Economics from Vanderbilt University and is a graduate of Phillips Exeter Academy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 24, 2023, the Board appointed Dr. Michael R. Jaff as a director of the Company. Dr. Jaff is currently Chief Medical Officer and Vice President of Clinical Affairs, Technology, and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Dr. Jaff received a B.S. from Dickinson College, a D.O. from Kirksville College of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Osteopathic Medicine, a Business degree from Harvard Business School and an honorary Doctorate of Arts from Harvard Medical School.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Appointment of Additional Senior Management Team members</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">On August 8, 2023, we announced the appointment of Deborah Castillo, PhD, as Vice President of Regulatory Affairs. Ms. Castillo is an experienced biomedical engineer with extensive knowledge of and background at the FDA, EU, and Health Canada regulations. She has held various roles at the FDA, including overseeing 510(k) submissions encompassing a wide-range of cardiovascular devices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">On September 26, 2023, we announced the appointment of Richa Gujarati as Senior Vice President, Product, and Pooja Chatterjee as Vice President, Clinical. Ms. Gujarati has over 13 years of experience collecting market-level insights and translating them into business needs, driving overall product portfolio and go-to-market strategy. Previously at Apple, as Head of Health Products, Apple Watch, she built and launched applications in the wearable sensor space. Ms. Chatterjee brings over 15 years of extensive clinical leadership experience in the medical device industry and was responsible for multiple FDA approvals in medical technologies including heart failure and cardiac rhythm management. Additionally, while at Abbott Medical Devices her role included focus on obtaining peer reviewed publications in key journals. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Expanded the Scientific Advisory Board</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 9, 2023, we announced the expansion of our Scientific Advisory Board (SAB) to include several leading cardiologists. The SAB is led by Peter J. Fitzgerald, MD, PhD, the company&#8217;s Chief Medical Officer and C. Michael Gibson, MD. The newly announced members of the HeartBeam SAB are: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Tony Das, MD, a nationally recognized board-certified interventional cardiology specialist, leader, and educator in the field of cardiovascular diseases.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Robert Harrington, MD, Dean of Weill Cornell Medicine, and provost for medical affairs of Cornell University.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Campbell Rogers, MD, Executive Vice President and Chief Medical Officer at HeartFlow, Inc.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Niraj Varma, MD, Ph.D., Professor of Medicine, and consultant electrophysiologist at the Cleveland Clinic. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Retirement of Chief Financial Officer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 29, 2023, Richard Brounstein, informed the Company of his plans to retire from his position as Chief Financial Officer effective as of February 1, 2024. Mr. Brounstein has been an important member of the executive team at HeartBeam since 2015. Mr. Brounstein will provide CFO advisory services as a consultant to the Company to assist with a smooth transition of his former duties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Patent Assignments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2023, we were granted three U.S. patents:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We were granted two patents (US 11,877,853 and US 11,701,049) on mobile cardiac monitoring devices and methods for providing automated diagnosis of cardiac issues to patients, by the United States Patent and Trademark Office. These innovations build on our growing intellectual property portfolio enabling ECG diagnostics outside of a medical setting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We were also granted a patent (US 11,793,444) on electrocardiogram patch devices and methods by the United States Patent and Trademark Office. This patent further expands our coverage of wearable and patch-based patient monitoring.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We now have a total of eleven patents issued as of December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Subsequently in 2024 we received two additional patents on our core VECG technology. One patent covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks, The other covers methods and apparatuses around HeartBeam&#8217;s wrist-based ECG system. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">At-the-Market Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 1, 2023, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with AGP pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $13.0 million in at-the-market offerings (&#8220;ATM&#8221;) sales. At the same time, we filed a prospectus supplement under a shelf registration on Form S-3 relating to the Sales Agreement. The registration statement was declared effective on February 10, 2023. AGP will act as sales agent and will be paid a 3% commission on each sale under the Sales Agreement. Our common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary. There have been no sale of shares under the ATM since February 2023, nor under the Form S-3 since May 2023. As </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of December 31, 2023 there was approximately $11.0 million available for issuance under the ATM.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Note Purchase Agreement and Security Purchase Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2023, we entered into Agreements, each as amended on March 7, 2023, with Maverick. Pursuant to the terms of the Agreements, as amended, we agreed to sell up to $4,000,000 of our common stock at 75% of the average calculated Volume Weighted Average Price (&#8220;VWAP&#8221;) per share during a Drawdown Pricing Period as defined in the Agreements. We issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023, the Convertible Note was settled upon the execution of a SPA and related issuance of 0.2 million shares of common stock pursuant to the SPA drawdown notice dated March 7, 2023. These 0.2 million shares of common stock were registered under our registration statement on Form S-3 dated February 10, 2023, and the related prospectus supplement dated March 9, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Public Offerings under Forms S-1 and S-3</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2023, we entered into a Placement Agency Agreement with Public Ventures, LLC to consummate an offering of 16,666,666 shares of Common Stock at an offering price of $1.50 per share, which closed in accordance with the subscription agreement dated May 2, 2023. The Company received $23.2 million in net proceeds from the offering after deducting placement agent discounts and commission and other estimated offering expenses. In addition, the subscription agreement granted 1,666,666 placement agent warrants as part of this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2023, we completed a Registered Direct Offering of 1,000,000 shares of our common stock at an offering price of $1.50 per share. We received net proceeds of $1.1 million after deducting financial advisory and legal fees as well as other estimated offering expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_55"></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations for the years ended December 31, 2023 and 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods presented on our statement of operations data. The year over year comparison of results of operations is not necessarily indicative of results of operations for future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$ Change</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">% Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(In thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15,314&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13,031&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(15,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13,031)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2,283)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Income tax provision</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(14,639)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(12,962)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,677)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Statements of Operations for the year ended December 31, 2023 compared with the year ended December 31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses (&#8220;G&amp;A&#8221;) are largely related to personnel and professional services. G&amp;A expense increased $1.2 million or 16% when compared to the same period in 2022. The $1.2 million increase is primarily related to non-cash stock-based compensation expense amounting to $1.6 million associated with additional awards granted since December 31, 2022, primarily offset by costs associated with our commercial team during the year ended December 31, 2022, and lower investor relation costs, marketing costs and legal costs incurred in this year compared to the prior year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses (&#8220;R&amp;D&#8221;) are primarily from software development and hardware related to our credit-card sized collection device for HeartBeam AIMIGo. R&amp;D expense increased $1.1 million or 20% when compared with the same period in 2022. The $1.0 million increase is primarily due to non-cash stock-based compensation expense amounting to $0.5 million associated with additional awards granted since December 31, 2022 as well as the increase in headcount and professional services supporting the FDA clearance process, primarily offset by completion of the initial development costs of the AIMIGo platform when compared to December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily interest income. The increase is primarily related to our increased cash balance coupled with higher interest rates following the $26.5 million financing in May 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash requirements are and will continue to be, dependent upon a variety of factors. We expect to continue devoting significant capital resources to R&amp;D and following FDA clearance of our AIMIGo device, our commercialization go to market strategies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had approximately $16.2 million in cash and cash equivalents, an increase of $12.6 million from $3.6 million as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, we raised $24.8 million is primarily the issuance of common stock from the secondary financing in May 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our cash is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows for the year ended December 31, 2023 and 2022 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(12,093)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9,948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(256)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in our operating activities of $12.1 million during the year ended December 31, 2023, is primarily due to our net loss of $14.6 million less $3.2 million in stock-based compensation expense and $0.7 million of net changes from changes in operating assets and liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in our operating activities of $9.9 million during the year ended December 31, 2022, is primarily due to our net loss of $12.9 million less $1.1 million in stock-based compensation expense and $1.9 million from changes in operating assets and liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the year ended December 31, 2023, of $0.3 million, is primarily due to the purchase of property and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, net cash provided by financing activities of $24.9 million, is primarily the issuance of common stock from the secondary financing in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2022, net cash provided by financing activities of $0.3 million, is primarily from the issuance of common stock under the February Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The financial statements have been prepared in accordance with accounting principles generally accepted in the US, (&#8220;US GAAP&#8221;.) The preparation of these financial statements in accordance with US GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, assumptions and judgments. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions and the impact of such differences may be material to our financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, determined using a Black-Scholes option pricing model for stock options and fair value on the date of grant for non-vested restricted stock, and is recognized as an expense over the employee&#8217;s requisite service period (generally the vesting period of the equity award). Determining the fair value of stock-based awards at the grant date requires significant estimates and judgments. Management has determined the fair value and vesting period of stock-based compensation to be a critical accounting estimate due to certain options containing performance-based vesting condition.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_70"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div><span><br/></span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplementary data of the Company required by this Item are described in Item 15 of this Annual Report on Form 10-K and are presented beginning on page F-1.</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_79"></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We adopted and maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Annual Report on Form 10-K, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. Our disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, our management, including the Chief Executive Officer (our principal executive and accounting officer) after evaluating the effectiveness of disclosure controls and procedures, identified material weaknesses in our internal control over financial reporting. The material weaknesses identified include (i) lack of formal risk assessment under COSO framework (ii) policies and procedures which are not yet adequately documented, (iii) lack of proper approval processes and review processes and documentation for such reviews, (iv) insufficient GAAP experience regarding complex transactions and reporting, and (v) insufficient number of staff to maintain optimal segregation of duties and levels of oversight.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second half of 2023, we have undertaken specific remediation actions to address the material weaknesses in our financial reporting. We are establishing more robust processes related to the review of complex accounting transactions, the preparation of account reconciliations and the review of journal entries. These remediation actions included hiring a Controller in July 2023, who has extensive experience in developing and implementing internal controls and executing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">plans to remediate control deficiencies. We will continue to assess the weaknesses as this individual progress through our onboarding process and as we continue to implement and refine control policies and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an audit or attestation report from our registered public accounting firm regarding our internal control over financial reporting. Our management&#8217;s report was not subject to audit or attestation by our registered public accounting firm since we are not an accelerated filer or a large accelerated filer as defined in Rule 12b-2 under the Securities Exchange Act of 1934.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fourth quarter of the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_88"></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:center"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information About our Executive Officers and Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and affairs are organized under the direction of our board of directors, which currently consists of five members.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to the current directors of our Company:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NAME</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AGE </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">POSITION</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Richard Ferrari</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Chairman of the Board of Directors</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Branislav Vajdic, PhD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Executive Officer, Director</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">George A. de Urioste</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marga Ortigas-Wedekind</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Willem Elfrink</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Strome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kenneth Nelson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael Jaff</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Richard Ferrari - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Chairman of the Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Richard Ferrari, 70, joined our Board in 2019 and was appointed Executive Director of the Board of Directors in June 2021. Mr. Ferrari combines over 40 years of experience in Medical Device Start-ups as CEO, and entrepreneur. Also Mr. Ferrari is co-founder of De Novo Ventures which has $650M under management and has been Managing Director since 2000. Mr. Ferrari has also co-founded 6 more companies, two of which have been successful IPO&#8217;s and subsequent acquisitions, CTS one of the companies he co-founded was the fastest start-up to an IPO in the last 22 years in the medical device industry. Mr. Ferrari most recently from 2018 to 2021 was Chairman and CEO of PQ Bypass which was recently acquired by Endologix. Mr. Ferrari sits on the board of Pulmonx, a public company and is the Chairman of the Compensation Committee. Additionally, Mr. Ferrari is Executive Chairman of Tenon Medical, Vice-Chairman of ABS Interventional, Executive Chairman of Medlumics, and holds board positions with several other medical device start-ups. Mr. Ferrari has an undergraduate degree from Ashland University and an MBA from University of South Florida.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Mr. Ferrari is qualified to serve on our board of directors because of his experience in leadership and management roles in the field of medicine, as well as his experience as a member in the healthcare industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Branislav Vajdic, PhD - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Branislav Vajdic, 69, Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam&#8217;s technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices as well as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Dr. Vajdic is qualified to serve on our board of directors because of his experience in leadership and management roles in the field of medicine, as well as his experience as a member in the healthcare industry.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">George A. de Urioste - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. de Urioste, 68, combines over 40 years of experience in high technology industry senior management. Previously, Mr. de Urioste has been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. Mr. de Urioste was Chief Financial Officer of Remedy Corporation (software) from 1992 to 1998 and led the IPO, Chief Executive Officer of Aeroprise, Inc., from 2000 to 2003 (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software), interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc. (semiconductors) during 2008, Chief Financial Officer for Pluribus Networks, Inc. (software) 2014 to 2018, Chief Financial Officer for 4iQ, Inc. (software) 2019 to 2020 and interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste&#8217;s Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (business outsourcing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). Mr. de Urioste was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). Mr. de Urioste is currently a Board Director at Roambee Corporation (supply chain intelligence software) and Silicon Valley Directors Exchange, (a not-for-profit for Board education events). Mr. de Urioste has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California and is a member of the Latino Corporate Directors Association.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Mr. de Urioste is qualified to serve on our board of directors because of his experience in leadership and management roles in high technology industries, as well as his experience as a board member including Audit Committee Chairman roles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marga Ortigas-Wedekind -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Marga Ortigas-Wedekind, 62, Board member, has over 30 years of experience in health technology senior management. Ms. Ortigas-Wedekind has been Chief Commercial Strategy Officer of Fogarty Innovation, a non-profit educational incubator for early stage medtech companies since December 2019, Executive Vice President of Marketing and Payer Relations for iRhythm Technologies Inc., a publicly-traded digital healthcare company from July 2015 through July 2019, Executive Vice President, Global Marketing and Product Development of Omnicell Inc., a publicly-traded developer of automated medication dispensing and analytics systems where she led the Marketing, International and Engineering departments from 2009 to 2015, Senior Vice President, Marketing, Development, and Clinical Affairs at Xoft, Inc, a developer of disruptive technology to deliver radiation therapy with capital equipment and high-end disposables from 2002 to December 2008. She started her medtech career at Guidant Vascular, now Abbott Vascular.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Ortigas-Wedekind was on the board of Itamar Medical (NASDAQ: ITMR), which provides digitally-enabled systems for sleep apnea management until its sale to Zoll Medical in December 2021, Total Flow Cannula, an early stage company developing a mechanism to improve safety during on-pump open heart surgery and, the Bay Area Cancer Coalition, a non-profit organization that supports those affected by breast or ovarian cancer. Ms. Ortigas-Wedekind is a limited partner and advisory board member for Launchpad Digital Health, a venture fund focused on digital heath technologies and is also an angel investor with Health Tech Capital. Ms. Ortigas-Wedekind has an undergraduate degree from Wellesley College and an MBA from the Stanford Graduate School of Business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Ms. Ortigas-Wedekind is qualified to serve on our board of directors because of her experience in leadership and management roles in the field of medicine, as well as her experience as a member in the healthcare industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Willem Elfrink -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Willem Elfrink, 71, was Chairman of the Board since our founding and in June 2021 stepped down from this position but remains a Board member. Mr. Elfrink has over 40 years of experience in bringing new technologies to the market. Mr. Elfrink actively contributes to portfolio companies via board participation, strategic marketing, governance and capital structure. Mr. Elfrink is also the Founder and President of WPE Ventures Digitized Solutions, a security and digitization solutions investment firm. Mr. Elfrink joined Cisco in 1997 and was Cisco&#8217;s Executive Vice President of Industry Solutions and Chief Globalization Officer from 2000 to 2006 and 2007 to 2015 respectively, where Mr. Elfrink made and contributed to key strategic and operational decisions of the Company. Widely recognized as Cisco&#8217;s Corporate Entrepreneur in residence, his global charter was to identify significant technology opportunities. Mr. Elfrink also led an industry initiative &#8212; called the Internet of Things World Forum. Before joining Cisco, Mr. Elfrink held management and senior management positions at Olivetti, Xerox, HP, Digital Equipment Corporation and Philips. Mr. Elfrink earned a Bachelor of Engineering degree from the Institute of Technology in Rotterdam, the Netherlands.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Mr. Elfrink is qualified to serve on our board of directors because of his experience in leadership and management roles in bringing new technologies to the market, as well as his globalization experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mark Strome - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Strome, 66, combines over 40 years of experience in the investment management and securities industry. Mr. Strome is the Founder, Chief Investment Officer, and Chairman at Strome Investment Management, L.P. and Strome Group, Inc. Under his leadership, Mr. Strome&#8217;s investment management company has managed private placement hedge fund investments focusing on non-traditional investments including commodities, currencies, bankruptcy reorganizations, and numerous venture capital and private equity investments. Previously, he was a Portfolio Manager at Kayne Anderson. Mr. Strome has also been involved in the founding and incubation of numerous publicly traded companies and several successful private companies. These include Pulse Biosciences, and iWood Studios, a company that creates original content for film and TV. Mr. Strome has been a member of the Board of Directors of multiple companies over the last three decades. Mr. Strome has served as a Director at Endurance Ventures, National Water and Power, Eco-Duro Corporation, NWP Services Corporation and Mobil Satellite Ventures. Mr. Strome serves as Member of Advisory Board at Global Analytics, Inc. Mr. Strome is a Trustee for New Roads School and Big Bear Foundation and serves on the Board of Advisors of John Hopkins Medical Center. Mark earned a Bachelor of Science in Engineering from Old Dominion University and Master of Science in Economics from the University of California at Berkeley.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that Mr. Strome is qualified to serve on our board of directors because of his experience in leadership and management roles, as well as his experience as a member in the healthcare industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Kenneth Nelson </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">- Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Nelson, 48, is a 20 year digital health, medical device, and remote patient monitoring executive and innovator. Over the past 10 years, Mr. Nelson has led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries for 3 of the top 4 market share players in cardiac digital health and remote patient monitoring including BioTelemetry as VP of Sales, iRhythm as VP of Sales &amp; Marketing, and Bardy Diagnostics as Chief Commercial Officer. Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring for Biotronik, a leading cardiac digital health and medical device company. Mr. Nelson currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, the largest medtech and digital health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare, and is an active board member in a handful of other disruptive cardiac digital health and medtech startups. Mr. Nelson earned a Bachelor of Arts in Economics from Vanderbilt University and is a graduate of Phillips Exeter Academy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that Mr. Nelson is qualified to serve on our board of directors because of his experience in leadership and management roles in the field of medicine, as well as his experience as a member in the healthcare industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Michael Jaff, MD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> - Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Jaff, age 65, is currently Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Previously, Dr. Jaff was a professor of medicine at Harvard Medical School and served as President of Newton-Wellesley Hospital. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. Dr. is a recognized expert in all aspects of vascular medicine and is the founder of VasCore, the Vascular Ultrasound Core Laboratory. Dr. Jaff has published over 300 peer-reviewed publications and 10 textbooks and is the Past-President of the Society for Vascular Medicine. Dr. Jaff received a B.S. from Dickinson College, a D.O. from Kirksville College of Osteopathic Medicine, a Business degree from Harvard Business School and an honorary Doctorate of Arts from Harvard Medical School.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that Mr. Jaff is qualified to serve on our board of directors because of his experience in leadership and management roles in the field of medicine, as well as his experience as a member in the healthcare industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no agreements or understandings for any of our executive officers or directors to resign at the request of another person and no officer or director is acting on behalf of nor will any of them act at the direction of any other person.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors are elected to serve until their successors are duly qualified and elected.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Diversity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information relating to certain voluntary self-identified characteristics of our directors. Each of the categories listed in the table below has the meaning as set forth in NASDAQ Rule 5605(f).</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Board Diversity Matrix (As of December 31, 2023)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total Number of Directors</span></div></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Female</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Male</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Non-Binary</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Did Not Disclose Gender</span></div></td></tr><tr><td colspan="15" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Part I: Gender Identity</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Directors</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0</span></div></td></tr><tr><td colspan="15" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Part II: Demographic Background</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">African American or Black</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Alaskan Native or Native American</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Asian</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Hispanic or Latinx</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Native Hawaiian or Pacific Islander</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">White</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Two or More Races or Ethnicities</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LGBTQ</span></div></td><td colspan="12" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Did Not Disclose Demographic Background</span></div></td><td colspan="12" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has affirmatively determined that seven of the directors are &#8220;independent directors&#8221; under NASDAQ Listing Rule 5605(a)(2) and the related rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). In making this determination, our Board considered the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. The Company&#8217;s independent directors conduct executive sessions at regularly scheduled meetings as required by NASDAQ Listing Rule 5605(b)(2).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of our directors and executive officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership Structure</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board does not have an express policy regarding the separation of the roles of Chief Executive Officer (&#8220;CEO&#8221;) and Board Chairman, as the Board believes it is in the best interests of the Company to make that determination based on the position and direction of the Company and the membership of the Board. Currently, Dr. Branislav Vajdic serves as the Company&#8217;s CEO and Richard Ferrari serves as the Chairman of the Board. The Board believes that its current leadership structure best serves the objectives of the Board&#8217;s oversight of management; the ability of the Board to carry out its roles and responsibilities on behalf of the stockholders; and the Company&#8217;s overall corporate governance. The Board also believes that the current separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and managing the Company and leverages the experience and perspectives of the Chairman.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Oversight of Risk Management</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The full Board has responsibility for general oversight of risks facing the Company. The Board is informed by senior management on areas of risk facing the Company and periodically conducts discussions regarding risk assessment and risk management. The Board believes that evaluating how the executive team manages the various risks confronting the Company is one of its most important areas of oversight. While the Board has the ultimate oversight responsibility for the risk management process, various committees of the Board also have responsibility for risk management. For example, the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit Committee reviews and assesses the Company&#8217;s processes to manage financial reporting risk and to manage investment, tax, and other financial risks; the Compensation Committee oversees risks relating to the compensation and incentives provided to our executive officers; and the Nominating and Governance Committee oversees risks associated with our overall compliance and corporate governance practices, as well as the independence and composition of our Board. Finally, management periodically reports to the Board or relevant committee, which provides guidance on risk assessment and mitigation. In December 2023 the Board also formed a Commercialization Committee to support the strategy development and implementation of all defined areas of commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delinquent Section 16(a) Reports</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), as amended, requires the Company&#8217;s directors and executive officers, and persons who own more than 10% of a registered class of the Company&#8217;s equity securities, to file reports of securities ownership and changes in such ownership with the SEC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based solely upon a review of such forms filed electronically with the SEC or written representations that no Form 5s were required, the Company believes that all Section 16(a) filing requirements were timely met during the year ended December 31, 2023, except for Mr. George de Urioste submitted one late Form 4 filing in regards to disclosing initial securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a code of ethics policy during 2022 for its principal executive officer and senior financial officers and that is applicable to all directors, officers and employees, a copy of which is available online at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.Heartbeam.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Stockholders may also request a free copy of this document from: HeartBeam, Inc., 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050, Attn: Corporate Secretary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Meeting Attendance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Board held four meetings of the full Board, The Board also took action by written consent on eighteen occasions. During the year ended December 31, 2023, each member of the Board attended at least 75% of the aggregate of all meetings of the Board and the meetings of the committees on which he or she served (during the periods for which he or she served).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have a written policy requiring directors to attend the annual meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our board of directors has established an audit committee, a compensation committee, a nominating and governance committee, and a commercialization committee. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. The charter of each committee is available on our corporate website at https://ir.heartbeam.com/corporate-governance/governance-documents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee Composition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description below outlines our current membership for each committee of our board of directors:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee, among other things, will be responsible for:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">appointing; approving the compensation of; overseeing the work of; and assessing the independence, qualifications, and performance of the independent auditor;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing the internal audit function, including its independence, plans, and budget;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approving, in advance, audit and any permissible non-audit services performed by our independent auditor;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing our internal controls with the independent auditor, the internal auditor, and management;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing our financial compliance system; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing our major risk exposures regarding the Company&#8217;s accounting and financial reporting policies, the activities of our internal audit function, and information technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee will consist of Mr. de Urioste, Ms. Ortigas-Wedekind and Mr. Ferrari. Mr. de Urioste will chair the Audit Committee. We believe the Audit Committee will comply with the applicable requirements of the rules and regulations of the Nasdaq listing rules and the SEC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee will be responsible for:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing and making recommendations to the Board with respect to the compensation of our officers and directors, including the CEO;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing and administering the Company&#8217;s executive compensation plans, including equity-based awards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">negotiating and overseeing employment agreements with officers and directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing how the Company&#8217;s compensation policies and practices may affect the Company&#8217;s risk management practices and/or risk-taking incentives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee will consist of Mr. Ferrari, Mr. Elfrink, Mr. Strome and Mr. de Urioste, Mr. Ferrari will serve as chairman of the Compensation Committee. The board of directors has affirmatively determined that each member of the Compensation Committee meets the independence criteria applicable to compensation committee members under SEC rules and Nasdaq listing rules. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nominating and Governance Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Nominating and Corporate Governance Committee, among other things, will be responsible for:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing and assessing the development of the executive officers and considering and making recommendations to the Board regarding promotion and succession issues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">evaluating and reporting to the Board on the performance and effectiveness of the directors, committees and the Board as a whole;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">working with the Board to determine the appropriate and desirable mix of characteristics, skills, expertise and experience, including diversity considerations, for the full Board and each committee;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">annually presenting to the Board a list of individuals recommended to be nominated for election to the Board;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing, evaluating, and recommending changes to the Company&#8217;s Corporate Governance Principles and Committee Charters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">recommending to the Board individuals to be elected to fill vacancies and newly created directorships;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing the Company&#8217;s compliance program, including the Code of Conduct; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">overseeing and evaluating how the Company&#8217;s corporate governance and legal and regulatory compliance policies and practices, including leadership, structure, and succession planning, may affect the Company&#8217;s major risk exposures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Nominating and Corporate Governance Committee will consist of Ms. Ortigas-Wedekind, Mr. Elfrink and Mr. Nelson. Ms. Ortigas-Wedekind will serve as chairperson. The Company&#8217;s board of directors has determined that each member of the Nominating and Corporate Governance Committee is independent within the meaning of the independent director guidelines of Nasdaq listing rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercialization Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Commercialization Committee, among other things, will be responsible for:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advising on the Company&#8217;s overall business strategy of bringing products to markets and all aspects of the sales process;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advising on the Company&#8217;s product strategy and roadmap;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advising on the Company&#8217;s target markets and market segmentation;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advising on cross-functional elements of the Company&#8217;s go-to-market effort, including the commercial support functions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reviewing, evaluating, and recommending changes to the Company&#8217;s Commercialization Committee Charter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Commercialization Committee will consist of Mr. Elfrink, Dr; Jaff, Mr. Strome and Mr. Nelson. Mr. Elfrink will serve as chairperson. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stockholder Communications with the Board</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Stockholders who wish to communicate with the Board of Directors or with an individual director may do so by writing to the Corporate Secretary, HeartBeam, Inc., 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050. The letter should indicate that you are a stockholder and whether you own your shares in street name. Letters received will be reviewed by the Corporate Secretary and retained until the next Board meeting when they will be available to the addressed director. Such communications may receive an initial evaluation to determine, based on the substance and nature of the communication, a suitable process for internal distribution, review and response or other appropriate treatment. There is no assurance that all communications will receive a response.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging, Short Sales and Related Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s insider trading policy, the Company prohibits all directors, officers and employees of the Company (collectively, &#8220;Team Members&#8221;), as well as their spouses, minor children, other persons living in their household and entities over which they exercise control, from engaging in the following transactions involving Company&#8217;s securities without the advance unanimous written approval from members of the compliance committee designated by the Board:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Hedging.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Team Members may not enter into hedging or monetization transactions or similar arrangements with respect to the Company&#8217;s securities.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Short sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Team Members may not sell the Company&#8217;s securities short;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Options trading</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Team Members may not buy or sell puts or calls or other derivative securities on the Company&#8217;s securities; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Trading on margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Team Members may not hold the Company&#8217;s securities in a margin account or pledge the Company&#8217;s securities as collateral for a loan.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary Compensation Table</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our Named Executive Officers (&#8220;NEOs&#8221;) for services rendered in all capacities during the noted periods. The fiscal years ended December 31, 2023 and December 31, 2022 are indicated below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name and Principal<br/>Position</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Salary<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Bonus<br/>($)(1,2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Stock<br/>Awards<br/>($)(3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option<br/>Awards<br/>($)(3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">All Other<br/>Compensation<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Branislav Vajdic, PhD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,250,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,019,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Robert Eno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">345,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">102,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,534,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Business Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kenneth Persen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">78,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,412,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Technology Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">310,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Cash bonuses awarded to the Chief Executive Officer, President and Chief Business Officer, Chief Financial Officer and Chief Technology Officer in 2023 were paid early 2024.</span></div><div style="text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">In 2022 the Board of Directors ratified the Compensation Committee approval of cash bonuses to its Chief Executive Officer, Chief Financial Officer and Chief Technology Officer based on the Company&#8217;s achievements of the performance metrics as defined in the bonus plan. The Bonuses were paid in the second quarter of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Represents the full grant date fair value of the stock award or option grant, as applicable, calculated in accordance with FASB ASC Topic 718. Our policy and assumptions made in the valuation of share-based payments are contained in Note 5 to our December 31, 2023 financial statements. The value of stock awards presented in the Summary Compensation Table reflects the grant date fair value of the awards and does not correspond to the actual value that will be recognized by the named executive officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Employment Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into employment agreements, with Branislav Vajdic, the Company&#8217;s Chief Executive Officer, Robert Eno, the Company&#8217;s President and Kenneth Persen, the Company&#8217;s Chief Technology Officer .</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Branislav Vajdic Employment Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 10, 2021 we entered into an employment agreement with Dr. Vajdic as its Chief Executive Officer and a member of the board of directors (&#8220;2021 Vajdic Agreement&#8221;), Dr. Vajdic will receive an annual salary of $325,000, commencing on September 15, 2021. During 2022 the Board of Directors approved an amendment to the 2021 Vajdic Agreement, whereby effective January 1, 2022 Dr. Vajdic&#8217;s annual salary increased to $428,000 and he was awarded 359,000 stock options. The stock option will vest as to 25% on the 1-year anniversary of the vesting commencement date, and the remainder will vest monthly thereafter on the same day of the month as the vesting commencement date until fully vested. During 2023 Dr. Vajdic was awarded a total of 1,194,000 options, these stock options vest as follows: Sixty percent (60%) are milestone based vesting on FDA clearance for marketing of HeartBeam&#8217;s synthesized 12L product and the remaining forty percent (40%) are time based vesting monthly over 48 months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Pursuant to the amended 2021 Vajdic Agreement, Dr. Vajdic will be eligible to receive an annual bonus up to 60% of his annual compensation, subject to adjustment on an annual basis, based on his performance and overall progress of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Robert Eno Employment Agreement </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 18, 2023 we entered into an employment agreement with Mr. Eno as its President, Mr. Eno will receive an annual salary of $360,000, commencing on January 18, 2023 and was awarded 240,000 stock options. The stock option will vest as to 25% on the 1-year anniversary of the vesting commencement date, and the remainder will vest monthly thereafter on the same day of the month as the vesting commencement date until fully vested. Additionally, during 2023 Mr. Eno was awarded a total of 536,000 options, these stock options vest as follows: Sixty percent (60%) are milestone based vesting on FDA clearance for marketing of HeartBeam&#8217;s synthesized 12L product and the remaining forty percent (40%) are time based vesting monthly over 48 months. Mr. Eno will be eligible to receive an annual bonus up to 40% of his annual compensation, subject to adjustment on an annual basis, based upon his performance and overall progress of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Kenneth Persen Employment Agreement </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2022 we entered into an employment agreement with Mr. Persen as its Chief Technology Officer (&#8220;2022 Persen Agreement&#8221;), Mr. Persen will receive an annual salary of $300,000, commencing on August 2, 2022 and was awarded 80,000 stock options. The stock option will vest as to 25% on the 1-year anniversary of the vesting commencement date, and the remainder will vest monthly thereafter on the same day of the month as the vesting commencement date until fully vested. During 2023 Mr. Persen was awarded a total of 481,000 options, of these stock options, 421,000 will vest as follows: Sixty percent (60%) are milestone based vesting on FDA clearance for marketing of HeartBeam&#8217;s synthesized 12L product and the remaining forty percent (40%) are time based vesting monthly over 48 months, and the remaining 60,000 will vest as to 25% on the 1-year anniversary of the vesting commencement date, and the remainder will vest monthly thereafter on the same day of the month as the vesting commencement date until fully vested.  Mr. Persen will be eligible to receive an annual bonus up to 30% of his annual compensation, subject to adjustment on an annual basis, based upon his performance and overall progress of the Company. Pursuant to the 2022 Persen Agreement, at the Board of Directors meeting held on August 21, 2023, Mr. Persen&#8217;s annual eligible bonus was increased to 35% effective January 1, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Outstanding Equity Awards at Fiscal Year-End</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to the value of all equity awards that were outstanding at December 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.510%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Number of Securities Underlying Unexercised Options Exercisable (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Number of Securities Underlying Unexercised Options Unexercisable (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option Exercise Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option Expiration Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Equity: Unearned Shares, Units or Other Rights That Have Not Vested (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Branislav Vajdic, PhD(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">769,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">08/02/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">374,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">05/14/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">172,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">186,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">06/14/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Robert Eno(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">345,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">08/02/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">168,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">05/14/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">240,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">01/18/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11/12/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">36,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11/01/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Kenneth Persen(9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">243,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">08/02/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">159,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">05/14/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">03/21/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">(12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">53,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-1.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">09/17/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Dr. Vajdic was awarded 796,000 options on August 2, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Dr. Vajdic was awarded 398,000 options on May 14, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Dr. Vajdic was awarded 359,000 options on June 15, 2022, these options are scheduled to vest over 4 years with 25% vesting on January 1, 2023 and the remainder vesting and exercisable monthly thereafter.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Eno was awarded 357,000 options on August 2, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Eno was awarded 179,000 options on May 14, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Eno was awarded 240,000 options on January 18, 2023, these options are scheduled to vest over 4 years with 25% vesting on January 18, 2024 and the remainder vesting and exercisable monthly thereafter</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Eno was awarded 9,000 options on November 12, 2021, these options are scheduled to vest monthly over 4 years from the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9pt">Mr. Eno was awarded 36,363 options on November 1, 2020, these options are scheduled to vest monthly over 4 years from the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Mr. Persen was awarded 252,000 options on August 2, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Mr. Persen was awarded 169,000 options on May 14, 2023, these options are scheduled to vest sixty percent (60%) upon FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product and remainder forty percent (40%) one forty-eighth (1/48th) shall vest on each one-month anniversary of the vesting commencement date.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Mr. Persen was awarded 60,000 options on March 21, 2023, these options are scheduled to vest over 4 years with 25% vesting on January 18, 2024 and the remainder vesting and exercisable monthly thereafter.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Mr. Persen was awarded 80,000 options on September 17, 2022, these options are scheduled to vest over 4 years with 25% vesting on January 18, 2024 and the remainder vesting and exercisable monthly thereafter.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options Exercised and Stock Vested</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes, with respect to our named executive officers, all options that were exercised on stock that was vested during fiscal 2023:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.053%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option Awards</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Number of Shares Acquired on Vesting (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Value Realized on Exercise ($)(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Branislav Vajdic, PhD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Robert Eno</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kenneth Persen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6pt">Based on the closing market price of our Common Stock as reported on the NASDAQ Capital Market on December 31, 2023.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTOR COMPENSATION</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors who are also employees of the Company do not receive any separate compensation in connection with their Board service, and we pay cash fees to our non-employee directors. Prior to 2022, our non-employee directors received a non-qualified initial stock option award upon joining the Board, which vest monthly over a four-year period, beginning on the date of the director&#8217;s election to the Board. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Board of Directors approved a plan for the annual cash compensation of directors effective January 1, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Audit Committee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Committees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chair</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Member</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the total compensation for each person who served as a non-employee member of our board of directors and received compensation for such service during the fiscal year ended December 31, 2023. Other than as set forth in the table and described more fully below:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fees Earned or Paid in Cash ($)(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option Awards ($) </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Stock Awards($)(2)(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Non-Equity Incentive Plan Compensation ($)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">All Other Compensation</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total ($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Richard Ferrari</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">238,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">George de Urioste</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">152,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marga Ortigas-Wedekind</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">140,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Willem Elfrink</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">140,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Strome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kenneth Nelson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">102,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael Jaff(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">148,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Represents director fees paid for nine months period to each of Messrs Ferrari, de Urioste, Elfrink, Strome, Nelson, Jaff and Mmes Ortigas-Wedekind. Fees for three months ended December 31, 2023 is accrued and paid early 2024.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The annual RSU grants to Messrs Ferrari, de Urioste, Elfrink, Strome, Nelson and Mmes Ortigas-Wedekind occur at each Annual Stockholder Meeting, vesting in full at the following annual meeting. The dollars convert to shares based on the FMV at the date of grant. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The RSU awarded to Dr. Jaff will vest in equal annual installments over three years on the day following the annual shareholders&#8217; meeting in 2024, 2025 and 2026. The dollars convert to shares based on the FMV at the date of grant. </span></div><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding the Company&#8217;s Common Stock, beneficially owned as of December 31, 2023 by:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person known to the Company to beneficially own more than 5% of its Common Stock, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each executive officer, director and director nominee</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all officers, directors and director nominees as a group. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company calculated beneficial ownership according to Rule 13d-3 of the Securities Exchange Act of 1934, as amended as of that date. Shares of the Company&#8217;s Common Stock issuable upon exercise of options or warrants or conversion of notes that are exercisable or convertible within 60 days after December 31, 2023 are included as beneficially owned by the holder, but not deemed outstanding for computing the percentage of any other stockholder for Percentage of Common Stock Beneficially Owned. For each individual and group included in the table below, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of the 26,329,032 shares of Common Stock outstanding at December 31, 2023, plus the number of shares of Common Stock that such person or group had the right to acquire on or within 60 days after December 31, 2023. Beneficial ownership generally includes voting and dispositive power with respect to securities. Unless otherwise indicated below, the persons and entities named in the table have sole voting and sole dispositive power with respect to all shares beneficially owned. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Shares Beneficially Owned</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Richard Ferrari</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">291,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Branislav Vajdic. PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,203,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">George A. de Urioste</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marga Ortigas-Wedekind</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">119,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Willem Pieter Elfrink</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">457,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Strome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kenneth Nelson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">70,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael Jaff MD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Richard Brounstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">207,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Robert Eno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> (10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">137,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kenneth Persen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">55,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">All directors and executive officers as a group (11 persons)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,731,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Public Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9454 Wilshire Blvd., Suite 600 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beverly Hills, CA 90212</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,624,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Andrew Schwartzberg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1135 Rivas Canyon Road</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Palisades, CA 90272</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,899,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 1 percent ownership</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 65,653 shares acquired from the conversion of 2015 Convertible Notes. (ii) 73,529 shares acquired from the vesting of RSUs and (iii) 152,276 options exercisable within 60 days after December 31, 2023. Does not include 56,814 unvested stock options and 39,948 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 794,545 shares acquired as founders equity, (ii) 115,559 shares acquired from the conversion of 2015 Convertible Notes, (iii)  256,628 options exercisable within 60 days after December 31, 2023, (iv) 1,287 shares acquired from the exercise of warrants acquired from the short-term loan investment program and (v) 35,000 BEATW exercisable warrants. Does not include 1,296,373 unvested stock options.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 12,168 shares acquired from the vesting of RSUs and (ii)  27,503 options exercisable within 60 days after December 31, 2023. Does not include 16,497 unvested stock options and 23,961 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 9,000 shares and 9,000 BEATW warrants purchased November 11, 2021, (ii) 7,824 shares acquired from the conversion of 2015 Convertible Notes, (iii) 55,147 shares acquired from the vesting of RSUs and (iv) 38,525 options exercisable within 60 days after December 31, 2023. Does not include 5,110 unvested stock options and 23,961 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 101,818 shares acquired under the 2015 Incentive Plan (ii) 207,056 shares acquired from the conversion of 2015 Convertible Notes, (iii) 55,147 shares acquired from the vesting of RSUs (iv) 29,997 options exercisable within 60 days after December 31, 2023, (v) 60,000 BEATW exercisable warrants and (vi) 3,640 shares acquired from the exercise of warrants acquired from the short-term loan investment program. Does not include 13,639 unvested stock options and 23,961unvested RSUs. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes 3,150,000 shares purchased on May 2, 2023. Does not include 23,961 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes 70,001 shares purchased on May 2, 2023. Does not include 23,961 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">No securities held. Does not include 41,935 unvested RSUs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Includes (i) 72,725 shares acquired under the 2015 Incentive Plan, (ii) 5,000 shares and 5,000 BEATW warrants purchased November 11, 2021, (iii) 5,000 shares and 10,000 BEATW warrants acquired on the open market, (iv) 29,197 shares acquired from the conversion of 2015 Convertible Notes, (v) 184 shares acquired from the exercise of warrants acquired from the short-term loan investment program and (vi) 80,000 options which vest within 60 days after December 31, 2023. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Includes 55,274 options exercisable within 60 days after December 31, 2023. Does not include 505,726 unvested stock options.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Includes 137,714 options exercisable within 60 days after December 31, 2023. Does not include 683,649 unvested stock options.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Represents 1,058,633 shares issued pursuant to a subscription agreement of the Company dated May 2, 2023, 1,562,666 shares of Common Stock issuable under a warrant issued by the Issuer and 3,911 shares of Common Stock held by Christopher A. Marlett Living Trust.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Represents 1,833,334 shares issued pursuant to a subscription agreement of the Company dated May 2, 2023, 46,600 shares in open market purchases on May 4, 2023, and 19,602 shares in open market purchases on May 25, 2023.</span></div><div style="margin-top:2pt"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established policies and other procedures regarding approval of transactions between the Company and any employee, officer, director, and certain of their family members and other related persons. These policies and procedures are generally not in writing but are evidenced by long standing principles adhered to by our Board. The disinterested members of the Board review, approve and ratify transactions that involve &#8220;related persons&#8221; and potential conflicts of interest. Related persons must disclose to the disinterested members of the Board any potential related person transactions and must disclose all material facts with respect to such transaction. All such transactions will be reviewed by the disinterested members of the Board and, in their discretion, approved or ratified. In determining whether to approve or ratify a related person transaction the disinterested members of the Board will consider the relevant facts and circumstances of the transaction, which may include factors such as the relationship of the related person with the Company, the materiality or significance of the transaction to the Company and the related person, the business purpose and reasonableness of the transaction, whether the transaction is comparable to a transaction that could be available to the Company on an arms-length basis, and the impact of the transaction on the Company&#8217;s business and operations.</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of fiscal year 2023, the Company did not have any transactions to which it has been a participant that involved amounts that exceeded or will exceed the lesser of (i) $120,000 or (ii) one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years, and in which any of the Company&#8217;s directors, executive officers or any other &#8220;related person&#8221; as defined in Item 404(a) of Regulation S-K had or will have a direct or indirect material interest.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Audit Committee's evaluation and determination that Marcum LLP (&#8220;Marcum&#8221;) is independent, our Audit Committee has retained the firm of Marcum as our independent registered public accounting firm for fiscal year 2023. In making this determination, the Company is requesting its stockholders to ratify the appointment of Marcum at its next Annual Stockholder Meeting. In the event the stockholders fail to ratify the appointment, the Audit Committee will consider in its direction to select other auditors for the subsequent year. Even if the selection is ratified, the Audit Committee, in its discretion, may select a new independent registered public accounting firm at any time during the year if it feels that such a change would be in the best interest of the Company and its stockholders. Representatives of Marcum will be present at the 2024 Annual Stockholders' Meeting and will have the opportunity to make a statement and be available to answer questions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fees to Independent Registered Public Accounting Firm.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The merger of Marcum and Friedman LLP (&#8220;Friedman&#8221;) was effective as September 1, 2022. The following table sets forth the fees that the Company was billed by Friedman and Marcum in 2022 and Marcum in 2023, our independent registered public accountants for fiscal years 2023 and 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit Fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tax Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">187,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">138,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Audit fees relate to professional services rendered in connection with the audit of the Company's annual financial statements, quarterly review of financial statements and audit services provided in connection with other statutory and regulatory filings.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Fees related to services provided for registration statements during the first half of 2023 and the fourth quarter of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on Audit Committee Pre-Approval of Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee must pre-approve all services to be performed for us by our independent registered public accounting firm. Pre-approval is granted usually at regularly scheduled meetings of the Audit Committee. If unanticipated items arise between regularly scheduled meetings of the Audit Committee, the Audit Committee has delegated authority to the chairman of the Audit Committee to pre-approve services, in which case the chairman communicates such pre-approval to the full Audit Committee at its next meeting. The Audit Committee also may approve the additional unanticipated services by either convening a special meeting or acting by unanimous written consent. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_109"></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:202%">Part IV</span></div><div id="i572bc36408af457cba91ba941693f8aa_112"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed or Furnished Herewith</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000121390021046840/fs12021ex3-1_heartbeam.htm">Articles of Incorporation filed with the State of Delaware on June 11, 2015</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/07/2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000121390021046840/fs12021ex3-2_heartbeam.htm">Bylaws</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/07/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000121390021051350/fs12021a1ex3-3_heartbeam.htm">Amendment to Articles of Incorporation filed with the State of Delaware on September 27, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/07/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937222000048/exhibit31.htm">Second Amended and Restated Articles of Incorporation dated November 15, 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021057354/ea150126ex4-13_heartbeaminc.htm">Form of Representative&#8217;s Warrant</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021057354/ea150126ex4-14_heartbeaminc.htm">Form of Warrant Agency Agreement </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390023030048/fs12023a2ex4-13_heartbeam.htm">Form of Placement Agent&#8217;s Warrant</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/17/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-1_heartbeam.htm">Employment Agreement with Branislav Vajdic </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-2_heartbeam.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-2_heartbeam.htm">Employment Agreement with Richard Brounstein </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-2_heartbeam.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/12/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-3_heartbeam.htm">Employment Agreement with Jon Hunt </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390021051350/fs12021a1ex10-3_heartbeam.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937221000003/exhibit101.htm">Employment Agreement with Alan Baumel</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937221000003/exhibit101.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937221000003/exhibit101.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/12/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1779372/000177937222000033/exhibit102-08052022.htm">Employment Agreement with Ken Persen</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1779372/000177937222000033/exhibit102-08052022.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1779372/000177937222000033/exhibit102-08052022.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/08/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1779372/000177937223000001/exhibit102-robertpeno.htm">Employment Agreement with Robert Eno </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1779372/000177937223000001/exhibit102-robertpeno.htm">&#8224;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01/24/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937222000007/exhibit101-02222022.htm">Stock Purchase Agreement, dated February 18, 2022 by and between HeartBeam, Inc. and the Purchaser with the Form of Warrant</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937222000010/exhibit101-03102022.htm">Form of Professional Services Agreement between Triple Ring and HeartBeam, Inc. dated March 7, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/10/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937222000005/exhibit101-02022022.htm">Partnership Agreement between HeartBeam, Inc. and LIVMOR, Inc. dated January 31, 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/02/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937222000033/exhibit101-08052022.htm">Supplemental Agreement between HeartBeam, Inc. and LIVMOR, Inc. dated August 2, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/08/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390023006864/ea172486ex1-01_heartbeam.htm">Sales Agreement by and between HeartBeam, Inc. and A.G.P./Alliance Global Partners, dated February 1, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/02/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937223000004/exhibit101-02282023.htm">Securities Purchase Agreement dated February 28, 2023 between HeartBeam Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937223000004/exhibit101-02282023.htm"> and Investors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/03/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937223000004/exhibit102-02282023.htm">Note Purchase Agreement dated February 28, 2023 between HeartBeam Inc. and Investors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/03/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001779372/000121390023018655/ea174893-8k_heartbeam.htm">First Amendment to Securities Purchase Agreement dated March 7, 2023 to the Securities Purchase Agreement dated February 28, 2023 between HeartBeam, Inc. and Investors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/09/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001779372/000121390023018655/ea174893-8k_heartbeam.htm">First Amendment to Note Purchase Agreement dated March 7, 2023 to the Note Purchase Agreement dated February 28, 2023 between HeartBeam, Inc. and Investors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/09/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390023028604/fs12023a1ex10-16_heartbeam.htm">Form of Subscription Agreement</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/10/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000121390023028604/fs12023a1ex10-17_heartbeam.htm">Form of Escrow Agreement for the Offering</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/10/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001779372/000121390023036932/ea178097-8k_heartbeam.htm">Form of Securities Purchase Agreement dated as of May 2, 2023 between HeartBeam, Inc. and Investor</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/05/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1779372/000177937222000019/exhibit101-06162022.htm">2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/16/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001779372/000121390023056219/ea181573-8k_heartbeam.htm">First Amendment to the HeartBeam, Inc. 2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001779372/000177937223000006/exhibit141.htm">Code of Business and Ethics</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/16/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231.htm">Consent of Marcum LLP Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-12312023.htm">Certification Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-12312023.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="exhibit321-12312023.htm">#</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit971.htm">HeartBeam, Inc. Compensation Recovery Policy</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - The cover page iXBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management or compensatory plan or arrangement.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished and shall not be deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_115"></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 16. Form 10-K Summary&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_118"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HEARTBEAM, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Branislav Vajdic</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Branislav Vajdic</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March&#160;20, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive and Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">POWER OF ATTORNEY</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Branislav Vajdic his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact may do or cause to be done by virtue hereof.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Chairman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ George de Urioste </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">George de Urioste</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marga Ortigas-Wedekind</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marga Ortigas-Wedekind</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Willem Elfrink</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Willem Elfrink</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Strome</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark Strome</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth Nelson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Nelson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Jaff</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael Jaff</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Branislav Vajdic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Branislav Vajdic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contents</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firms (PCAOB ID No: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-42">688</ix:nonNumeric>) </span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_127">F-2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheets as of December 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_130">F-4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of Operations for the years ended December 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_133">F-5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_136">F-6</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_139">F-7</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i572bc36408af457cba91ba941693f8aa_142">F-8</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_127"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HeartBeam Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying balance sheets of HeartBeam, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related statements of operations, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Explanatory Paragraph &#8211; Going Concern</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-43">Marcum LLP</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2020 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-44">East Hanover, New Jersey</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 20, 2024</span></div><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-45">16,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-46">3,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-47">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-48">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:46.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">16,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">4,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-51">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-53">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">17,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">4,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses (includes related party $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="f-57">2</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="f-58">2</ix:nonFraction>, respectively)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:46.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-61">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right;text-indent:50pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-63"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-65"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-66">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-68">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-70">0</ix:nonFraction></ix:nonFraction> shares outstanding at  December&#160;31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-78">26,329,032</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80">8,009,743</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-81">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-82">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-83">52,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">24,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-85">36,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-86">22,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:46.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-87">15,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-88">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:46.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">17,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">4,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">8,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">7,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">6,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-94">5,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-95">15,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-96">13,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-97">15,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">13,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-99">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-100">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-102">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-103">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-104">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-105">14,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-106">12,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">14,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">12,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-111"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-112">0.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">1.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-116">20,333,280</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-117"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-118">8,168,516</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of Changes in Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity (Deficit)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">7,809,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-120">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">22,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">9,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">13,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-124">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-125">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issuance upon vesting and exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-126">38,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-127">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-128">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issuance upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-129">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Common Stock &amp; Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-130">136,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-131">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-132">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance &#8211; December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-135">8,009,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-136">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">24,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">22,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-140">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-141">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Common Stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-142">17,872,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-143">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-144">24,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-145">24,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issuance upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-146">180,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-147">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-148">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issuance upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-149">258,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Issuance upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-150">7,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-151">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-152">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">14,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">14,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">26,329,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">52,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">36,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">15,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">14,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">12,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right;text-indent:20pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-162">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-163">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right;text-indent:20pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-164">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-165">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accounts payable, accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-166">471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-168">12,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-169">9,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right;text-indent:50pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows From Investing  Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-170">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-172">256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-174">24,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-175">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-176">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-177">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-178">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-180">24,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-181">350</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right;text-indent:50pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-182">12,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-183">9,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash,  cash equivalents and restricted cash - beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-184">3,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-185">13,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash,  cash equivalents and restricted cash  - at end of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-186">16,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-187">3,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right;text-indent:20pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-cash Flow Information:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and warrants to settle accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="beat:StockAndClassOfWarrantOrRightIssued" format="ixt:fixed-zero" scale="3" id="f-192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="beat:StockAndClassOfWarrantOrRightIssued" scale="3" id="f-193">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-194">16,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-195">3,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-196">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-198">16,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-199">3,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_142"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEARTBEAM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-200" continuedAt="f-200-1" escape="true">ORGANIZATION AND OPERATIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-200-1"><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam, Inc. (&#8220;HeartBeam&#8221; or the &#8220;Company&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (&#8220;ECG&#8221;) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company&#8217;s ability to develop higher resolution ECG solutions is achieved through the development of the Company&#8217;s proprietary and patented Vector Electrocardiography (&#8220;VECG&#8221;) technology platform. HeartBeam&#8217;s VECG is capable of developing three-dimensional (3D) images of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver equal or superior diagnostic capability than traditional hospital-based ECG systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has validated this novel technology and is seeking U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance of its initial telehealth products during 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in 2015 as a Delaware corporation. The Company&#8217;s operations are based in Santa Clara, California and operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-201">one</ix:nonFraction> segment</span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_151"></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-202" continuedAt="f-202-1" escape="true">GOING CONCERN AND OTHER UNCERTAINTIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-202-1" continuedAt="f-202-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to those of early stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of December&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-203">36.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-204">22.2</ix:nonFraction> million, respectively. As of December&#160;31, 2023 the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-205">16.2</ix:nonFraction>&#160;million cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) pursuant to which the Company may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="beat:SaleOfStockMaximumAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-206">13.0</ix:nonFraction>&#160;million in at-the-market offerings (&#8220;ATM&#8221;) sales. At the same time, the Company filed a prospectus supplement under a shelf registration relating to the Sales Agreement. AGP will act as sales agent and will be paid a <ix:nonFraction unitRef="number" contextRef="c-27" decimals="INF" name="beat:SaleOfStockAgentCommissionPercentage" scale="-2" id="f-207">3</ix:nonFraction>% commission on each sale under the Sales Agreement. The Company&#8217;s common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary. As </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of December 31, 2023 there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="beat:SaleOfStockRemainingAmountAuthorizedForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-208">11.0</ix:nonFraction>&#160;million available for issuance under the ATM.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#8220;SPA&#8221;, NPA&#8221; or together &#8220;Agreements&#8221;) with Maverick Capital Partners, LLC (&#8220;Maverick&#8221; or &#8220;Investor&#8221;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="INF" name="beat:SaleOfStockMaximumAmountAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-209">4,000,000</ix:nonFraction> of the Company&#8217;s common stock at <ix:nonFraction unitRef="number" contextRef="c-29" decimals="2" name="beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" scale="-2" id="f-210">75</ix:nonFraction>% of the average calculated Volume Weighted Average Price (&#8220;VWAP&#8221;) per share during a Drawdown Pricing Period as defined in the Agreements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company issued a $<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-211">500,000</ix:nonFraction> Convertible Note to the Investor pursuant to the NPA. On March 9, 2023 the Convertible Note was settled upon the execution of a SPA and related issuance of <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-212">0.2</ix:nonFraction>&#160;million shares of common stock pursuant to the SPA drawdown notice dated March 7, 2023. These shares of common stock were registered under the Company&#8217;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships and revenue. Management can provide no assurance that such </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-202-2" continuedAt="f-202-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-202-3">The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.</ix:continuation> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i572bc36408af457cba91ba941693f8aa_154"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-213" continuedAt="f-213-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-213-1" continuedAt="f-213-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-214" continuedAt="f-214-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS&#160;OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRESENTATION</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-214-1">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-215" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with US GAAP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. On an ongoing basis, management evaluates its estimate related to probability and timing related to vesting of the stock-based compensation related to probability and timing related to vesting of milestone options</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-216" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2023 the Company has $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-217">15.9</ix:nonFraction>&#160;million held as cash equivalents and as of December 31, 2022 there were $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-218">2.6</ix:nonFraction>&#160;million held as cash equivalents. The Company maintains cash balances in accounts which exceed the federally insured limits during the year ended December 31, 2023 and 2022. The Company has made a deposit to the bank for their credit cards in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-219">50,000</ix:nonFraction> and is classified as restricted cash included in other non-current assets as of December 31, 2023.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-220" continuedAt="f-220-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">PROPERTY AND EQUIPMENT, NET</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-220-1">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company&#8217;s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred.</ix:continuation> As of December 31, 2023, property and equipment, net represents construction-in-progress of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="0" id="f-221">256,000</ix:nonFraction> related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-222" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">RESEARCH AND DEVELOPMENT EXPENSE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional services costs associated with the development of cardiovascular technologies and products.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-223" continuedAt="f-223-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash, accounts payable and accrued liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or is derived from such prices. The Company uses the market approach </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-213-2" continuedAt="f-213-3"><ix:continuation id="f-223-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation technique to value its investments.&#160;The market approach uses prices and other pertinent information generated from market transactions involving identical or comparable assets or liabilities.&#160;The types of factors that the Company may consider in fair value pricing the investments include available current market data, including relevant and applicable market quotes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Observable inputs such as quoted prices in active markets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.&#160;In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="beat:AccountingForWarrantsPolicyPolicyTextBlock" id="f-224" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACCOUNTING FOR WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company accounts for its currently issued warrant instruments in conjunction with the Company&#8217;s common stock in permanent equity. These warrants are indexed to the Company&#8217;s stock and meet the requirements of equity classification as prescribed under ASC 815. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-225" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK-BASED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically issues stock options and restricted stock awards (&#8220;RSUs&#8221;) to employees and non-employees for services. The Company accounts for such grants issued and vesting to employees and non-employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense over the vesting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of stock options on the date of grant is calculated using the Black-Scholes option pricing model, based on key assumptions such as the fair value of common stock, expected volatility and expected term. These estimates require the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. These assumptions are primarily based on historical data, peer company data and the judgment of management regarding future trends and other factors. The Company has estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by the actual awards forfeited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost for RSUs issued to employees and non-employees is measured using the grant date fair value of the award, and expense is recognized over the service period, adjusted to reflect actual forfeitures.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-226" continuedAt="f-226-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCOME TAXES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-213-3" continuedAt="f-213-4"><ix:continuation id="f-226-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition and measurement are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income tax expense.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-227" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOSS PER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SHARE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the years ended December&#160;31, 2023&#160;and&#160;2022&#160;as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, the penny warrants issued during 2019 have been excluded from the net loss per common share calculation following treatment of contingently issuable shares as there are circumstances under which these shares would not be issued and therefore not exercisable. These warrants expired as unissued in February 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of December 31, 2023, and 2022, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements" format="ixt:num-dot-decimal" scale="0" id="f-228">176,674</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements" format="ixt:num-dot-decimal" scale="0" id="f-229">175,958</ix:nonFraction> penny options have been included in the calculation of weighted average basic and diluted earnings per share. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-230" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of awards outstanding as of&#160;December&#160;31, 2023&#160;and&#160;2022, which are not included in the computation of basic and diluted weighted average shares: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options (excluding exercisable penny stock options)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-231">5,915,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-232">2,020,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-233">217,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-234">253,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-235">5,152,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-236">3,908,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-237">11,286,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-238">6,183,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-239" continuedAt="f-239-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We do not expect that the updated standard will have a rather significant impact on our financial statement disclosures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-239-1"><ix:continuation id="f-213-4"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13&#160;&#8220;Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05 &#8220;Financial Instruments-Credit Losses (Topic 326)&#8221; which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on an instrument by instrument basis. The guidance is effective for the fiscal year beginning January 1,&#160;2023, including interim periods within that year. The Company has adopted this guidance and it had an immaterial impact on Company&#8217;s accounting.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_160"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-240" continuedAt="f-240-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-240-1" continuedAt="f-240-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2022 the Company held a Special Meeting of Stockholders (&#8220;Special Meeting&#8221;), wherein the stockholders of the Company approved an amendment to the Company&#8217;s Certificate of Incorporation (&#8220;Certificate of Incorporation&#8221;) to increase the number of authorized shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-241">0.0001</ix:nonFraction> per share (&#8220;Common Stock&#8221;) to <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-242">100,000,000</ix:nonFraction>, and to authorize <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-243">10,000,000</ix:nonFraction> shares of the Company&#8217;s preferred stock. The amendment to the Certificate of Incorporation became effective upon filing with, and acceptance for record by, the Secretary of State of Delaware on November 16, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON STOCK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-244">78,025</ix:nonFraction> shares of Common Stock to a consulting firm for services provided that were related to the IPO. The Company calculated the value of the common stock using closing stock price on November 11, 2022, resulting in a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-245">365,000</ix:nonFraction>. Additionally, the Company was required to issue <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-246">72,727</ix:nonFraction> warrants based on performance metrics achieved in 2021, the warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-247">5.50</ix:nonFraction> with an expiration of <ix:nonNumeric contextRef="c-43" name="beat:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durwordsen" id="f-248">five years</ix:nonNumeric> from the date of issuance. The Company calculated the fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="beat:ClassOfWarrantOrRightFairValuePerWarrant" scale="0" id="f-249">1.25</ix:nonFraction> each for these warrants using the Black-Scholes option pricing model on the date the consulting firm achieved the milestone, using the following assumptions: (a) fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="2" name="beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" scale="0" id="f-250">2.28</ix:nonFraction> per share, (b) expected volatility of <ix:nonFraction unitRef="number" contextRef="c-39" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-251">90.81</ix:nonFraction>%, (c) dividend yield of <ix:nonFraction unitRef="number" contextRef="c-39" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-252">0</ix:nonFraction>%, (d) risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="c-39" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-253">0.87</ix:nonFraction>%, and (e) expected life of <ix:nonNumeric contextRef="c-39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-254">5</ix:nonNumeric> years, resulting in the fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="beat:ClassOfWarrantOrRightFairValueIssuedForService" format="ixt:num-dot-decimal" scale="0" id="f-255">91,000</ix:nonFraction>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, the Company entered into a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell (&#8220;Private Placement&#8221;) to OpenSky Opportunities Fund Ltd. <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-256">58,000</ix:nonFraction> shares of common stock par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-257">0.0001</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-258">58,000</ix:nonFraction> warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="beat:SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" format="ixt-sec:numwordsen" id="f-259">one</ix:nonFraction> share of common stock at a combined price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-260">6.00</ix:nonFraction> per share. The common stock and the warrants were immediately separable and issued separately but were purchased together in the Private Placement. These securities issued pursuant to the Stock Purchase Agreement. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="0" id="f-261">348,000</ix:nonFraction> in proceeds from the Private Placement. The Warrants will expire <ix:nonNumeric contextRef="c-47" name="beat:ClassOfWarrantOrRightTerminationPeriod" format="ixt-sec:durwordsen" id="f-262">five years</ix:nonNumeric> from the date of issuance. The Company paid no underwriting discounts or commissions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor, for the purchase and sale in a registered direct offering of <ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-263">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-50" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-264">1.50</ix:nonFraction> per share, generating net proceeds from the offering of approximately $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-265">1.1</ix:nonFraction>&#160;million after deducting financial advisory and legal fees as well as other estimated offering expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2023, the Company entered into a Placement Agency Agreement with Public Ventures, LLC to consummate an offering of <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-266">16,666,666</ix:nonFraction> shares of Common Stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-52" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-267">1.50</ix:nonFraction> per share, which closed in accordance with the subscription agreement dated May 2, 2023. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-268">23.2</ix:nonFraction>&#160;million in net proceeds from the offering after deducting placement agent discounts and commission and other estimated offering expenses payable by the Company. In</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">addition, the subscription agreement grants placement agent warrants as part of this transaction. See Warrants section below.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-240-2" continuedAt="f-240-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#8220;SPA&#8221;, NPA&#8221; or together &#8220;Agreements&#8221;) with Maverick Capital Partners, LLC (&#8220;Investor&#8221;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="INF" name="beat:SaleOfStockMaximumAmountAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-269">4,000,000</ix:nonFraction> of the Company&#8217;s common stock at <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" scale="-2" id="f-270">75</ix:nonFraction>% of the average calculated Volume Weighted Average Price per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2023, the Company issued a $<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-271">500,000</ix:nonFraction> Convertible Note to the Investor pursuant to the NPA. On March 9, 2023, the Convertible Note was settled upon the execution of the SPA and related issuance of <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-272">200,105</ix:nonFraction> shares of common stock pursuant to the SPA draw down notice dated March 9, 2023. These shares of common stock were registered under the Company&#8217;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023, whereby, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Company received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">total proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-273">500,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. These were the only transactions consummated under the SPA and NPA and the respective agreements expired on May 31 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 1, 2023, the Company entered into an At-the-Market Sales Agreement (&#8220;ATM&#8221; or &#8220;Sales Agreement&#8221;) with A.G.P./ Alliance Global Partners as placement agent, to issue and sell shares of the Company&#8217;s common stock. The issuance and sale of shares of Common Stock to or through the placement agent are effected pursuant to the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Registration Statement dated February 2, 2023. The Company shall pay to the sales agent in cash, upon each sale of placement shares through the placement agent pursuant to the Sales Agreement, an amount equal to <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="beat:SaleOfStockPlacementFeePercentage" scale="-2" id="f-274">3.00</ix:nonFraction>% of the aggregate gross proceeds from each sale of placement shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection to the Sales Agreement, on February 17, 2023 and February 22, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-275">6,184</ix:nonFraction> shares at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-276">3.76</ix:nonFraction> per</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> share for gross proceeds of approxi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mately $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="beat:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="0" id="f-277">23,000</ix:nonFraction>. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of December 31, 2023 there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="beat:SaleOfStockRemainingAmountAuthorizedForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-278">11.0</ix:nonFraction>&#160;million available for issuance under the ATM.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stock issuance costs, which consist primarily of legal, accounting and underwriting fees in connection with the above stated transactions related to the offerings and SPA was approximately $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-279">174,000</ix:nonFraction>, which as of December 31 2023, was recorded in additional paid in capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022 the Company issued <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-280">439,042</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-281">63,806</ix:nonFraction> shares of common stock upon exercise of vested stock options and vesting of restricted stock units. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, milestone warrants were issued to certain executives totaling <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-282">407,272</ix:nonFraction> warrants (&#8220;Penny Warrants&#8221;). These warrants were valued on the date of grant at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-58" decimals="4" name="beat:ClassOfWarrantOrRightGrantDateFairValue" scale="0" id="f-283">0.0003</ix:nonFraction> to vest upon meeting certain milestones. These warrants expired unissued in February 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-284">72,727</ix:nonFraction> warrants based on performance metrics achieved in 2021 to purchase <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" format="ixt:num-dot-decimal" scale="0" id="f-285">72,727</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-286">5.50</ix:nonFraction> per share, with an expiration of <ix:nonNumeric contextRef="c-39" name="beat:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durwordsen" id="f-287">five years</ix:nonNumeric> from the date of issuance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-288">58,000</ix:nonFraction> warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" format="ixt:num-dot-decimal" scale="0" id="f-289">58,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-290">6.00</ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2023 the Company issued <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">1,666,666</ix:nonFraction> placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-63" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-292">1.875</ix:nonFraction> per share and are exercisable for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-63" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-293">five years</ix:nonNumeric></span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> from the date of issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-294">11,638</ix:nonFraction> warrants were exercised, of which <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsCashlessExercise" format="ixt:num-dot-decimal" scale="0" id="f-295">5,817</ix:nonFraction> were exercised in the form of a cashless exercise utilizing <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" format="ixt:num-dot-decimal" scale="0" id="f-296">4,346</ix:nonFraction> warrants which resulted in the net issuance of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-297">1,471</ix:nonFraction> common shares. The remaining <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsExercisedForCash" format="ixt:num-dot-decimal" scale="0" id="f-298">5,821</ix:nonFraction> warrants were exercised for cash for approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-299">16,000</ix:nonFraction>. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-300" escape="true"><ix:continuation id="f-240-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the outstanding warrants as of December&#160;31, 2023 and 2022 is as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable -  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-301"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="beat:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="f-302">3,777,549</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="f-303"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-304">5.42</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-64" name="beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" format="ixt-sec:duryear" id="f-305"><ix:nonNumeric contextRef="c-64" name="beat:ClassOfWarrantOrRightWeightedAverageRemainingLife" format="ixt-sec:duryear" id="f-306">4.45</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-307"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-308">1,259</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" format="ixt:fixed-zero" scale="0" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="f-311">130,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" scale="0" id="f-312">5.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-313">3,908,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-314">5.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="beat:ClassOfWarrantOrRightWeightedAverageRemainingLife" format="ixt-sec:duryear" id="f-315">3.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-316">2,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="f-317">1,666,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" scale="0" id="f-318">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-319">11,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" scale="0" id="f-320">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="beat:ClassOfWarrantOrRightWarrantsExpired" format="ixt:num-dot-decimal" scale="0" id="f-321">410,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" format="ixt:fixed-zero" scale="0" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-323"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="beat:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="f-324">5,152,397</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-325"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="f-326">4.71</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" format="ixt-sec:duryear" id="f-327"><ix:nonNumeric contextRef="c-1" name="beat:ClassOfWarrantOrRightWeightedAverageRemainingLife" format="ixt-sec:duryear" id="f-328">3.35</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" scale="3" id="f-329"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" scale="3" id="f-330">792</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_166"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-331" continuedAt="f-331-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-331-1" continuedAt="f-331-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Company&#8217;s Board of Directors approved the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company&#8217;s business. The 2015 Plan provides for the grant of stock options and RSU&#8217;s to purchase common stock of which <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-332">1,636,362</ix:nonFraction> were authorized by the board of which <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-333">970,704</ix:nonFraction> are outstanding as of December&#160;31, 2023. The 2015 Plan was terminated upon shareholder approval of the 2022 Equity Incentive Plan (&#8220;2022 Equity Plan&#8221;) whereby no new awards can be issued under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s shareholders approved the 2022 Equity Plan at the annual meeting of stockholders held on June 15, 2022, pursuant to which <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-334">1,900,000</ix:nonFraction> shares of common stock were authorized for issuance. Under the 2022 Equity Plan, the number of shares available for issuance will be increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-335">3,800,000</ix:nonFraction> shares, five percent (<ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-336">5</ix:nonFraction>%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2023 <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-337">400,487</ix:nonFraction> shares, equivalent to five percent (<ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-338">5</ix:nonFraction>%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan. Also see Note 9- Subsequent event section below.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">At the July 7, 2023, Annual Shareholders&#8217; Meeting, the proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-339">1,900,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-340">5,900,000</ix:nonFraction> shares was approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Equity Plan includes a provision to add-back any cancelled options from the 2015 Plan up to <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-341">1,372,816</ix:nonFraction> shares. As of December&#160;31, 2023, there are <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-342">252,856</ix:nonFraction> shares from the 2015 Plan that are included in the <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-343">849,171</ix:nonFraction> shares available for issuance under the 2022 Equity Plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-344">2,208,000</ix:nonFraction> options to various executives and employees. Sixty percent (<ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-345">60</ix:nonFraction>%) of these options vest based on FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product  and the remaining forty percent (<ix:nonFraction unitRef="number" contextRef="c-77" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-346">40</ix:nonFraction>%) vest monthly over a period of <ix:nonNumeric contextRef="c-77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-347">48</ix:nonNumeric> months. The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and it is expensed based on management&#8217;s probability assessment of FDA clearance. The <ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-348">60</ix:nonFraction>% milestone options are issued and outstanding as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-349">0.2</ix:nonFraction>&#160;million from the exercise of stock options during the year ended December&#160;31, 2023 and a de minimis amount during the year ended December 31, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-331-2" continuedAt="f-331-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK OPTIONS</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-350" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity during the years ended December&#160;31, 2023 and 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>options<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)<br/>(*)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-351">1,105,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-352">2.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-64" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-353">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-354">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-355">1,251,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-356">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-357">121,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-358">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-359">38,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-361">2,196,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-362">1.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-363">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-364">6,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-365">4,363,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-366">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-367">288,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-368">2.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-369">180,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-370">1.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-371">6,092,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-372">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-373"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-374">8.7</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-375">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-376">1,212,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-377">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-378">7.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-379">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Intrinsic value is based on </span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of the Company's common stock.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-380" continuedAt="f-380-1" escape="true">For the years ended December&#160;31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-380-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Black-Scholes option pricing model assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-381">110.23</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-382">117.62</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-383">107.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-81" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-384">111.06</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-385">5.85</ix:nonNumeric> - <ix:nonNumeric contextRef="c-79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-386">6.07</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-80" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-387">5.62</ix:nonNumeric> -  <ix:nonNumeric contextRef="c-81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-388">5.94</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-389">3.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-390">4.77</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-391">1.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-81" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-392">3.17</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-395">1.75</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-396">3.38</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-397">1.08</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-398">3.34</ix:nonFraction></span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-331-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RESTRICTED STOCK UNITS</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-399" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSUs award activity:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-400">253,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-401">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-402">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-403">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-404">222,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-405">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-406">248,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-407">1.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-408">258,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-409">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-410">25,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-411">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-412">217,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-413">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-414">253,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-415">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK BASED COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-416" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock-based compensation expense:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-417">2,069,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-418">657,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-419">488,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-420">235,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administration</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-421">2,558,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-422">892,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-423">629,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-424">213,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-425">20,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-426">13,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-427">649,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-428">227,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-429">3,208,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-430">1,119,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-431">8.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-432">0.4</ix:nonFraction>&#160;million, respectively, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-82" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-433">2.66</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-86" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-434">1.2</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-435" continuedAt="f-435-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-435-1"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which the Company&#8217;s former Chief Financial Officer has significant influence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company incurred accounting fees from these firms of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="f-436">20,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="f-437">21,000</ix:nonFraction> during the years ended December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the Company had balances due to these firms amounting to approximately $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-439">2,000</ix:nonFraction></ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_172"></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-440" continuedAt="f-440-1" escape="true">COMMITMENTS </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-440-1" continuedAt="f-440-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a month to month lease agreement for our headquarters. The agreement is for an undefined term and can be cancelled at any time, given <ix:nonNumeric contextRef="c-101" name="beat:LesseeOperatingLeasePriorNoticeForCancellation" format="ixt-sec:durwordsen" id="f-441">one month</ix:nonNumeric>&#8217;s notice by either party. The Company&#8217;s monthly rent expense associated with this agreement is approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-1" name="beat:LesseeOperatingLeaseMonthlyRentExpense" format="ixt:num-dot-decimal" scale="0" id="f-442">1,440</ix:nonFraction>. The Company&#8217;s month to month headquarters lease is in the name of the Company&#8217;s Chief Executive Officer, and the cost is reimbursed monthly.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-440-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023 and 2022, rent expense was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-443"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-444">17,000</ix:nonFraction></ix:nonFraction>, for each year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnership Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a partnership agreement with LIVMOR Inc. (&#8220;LIVMOR&#8221;) to build a Company-branded version of the LIVMOR&#8217;s Halo+ FDA cleared turnkey solution for RPM to connect physicians and patients. As included in the agreement, the Company and LIVMOR have the right to enter into additional agreements as needed in order to further the Company&#8217;s development of its products. The agreement with LIVMOR included a commitment in 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-445">1.0</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a supplemental agreement with LIVMOR. The supplemental agreement stated the Company would pay an additional $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-446">0.2</ix:nonFraction>&#160;million for the source code access under the partnership agreement. Payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="beat:PaymentsForPurchaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-447">0.2</ix:nonFraction>&#160;million have been made by the Company and LIVMOR has delivered to the Company copies of source materials and codes. All licenses granted by LIVMOR will automatically be converted into a non-exclusive and perpetual license and become licenses granted on a royalty-free and fully paid-up basis, in which LIVMOR hereby expressly waives and relinquishes all HeartBeam payment obligations under the initial partnership agreement. Based on management&#8217;s review of Topic ASC 805 and 730, it was determined that only the source code and perpetual license were purchased and it was determined there was no alternative future uses, therefore management recorded the expense as research and development expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company expensed a total of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-448">1.2</ix:nonFraction>&#160;million associated with the LIVMOR agreements, which </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has been recognized as R&amp;D expense. In February 2023, the Company acquired LIVMOR&#8217;s Halo+&#8482; Atrial Fibrillation Detection System, the world&#8217;s first FDA-cleared (K201208) prescription wearable for continuous cardiac rhythm monitoring, comprising of intellectual property, including 3 issued United States patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Services Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (&#8220;TRT&#8221;), a co-development company, to assist in the design and development of the Company&#8217;s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with Triple Ring includes a commitment totaling $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-449">1.7</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 the Company has a remaining commitment of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="f-450">0.4</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i572bc36408af457cba91ba941693f8aa_175"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 - <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-451" continuedAt="f-451-1" escape="true">INCOME TAX </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-451-1" continuedAt="f-451-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-452" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed &#8220;expected&#8221; tax benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-453">3,074,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-454">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-455">2,722,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-456">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in income taxes resulting from):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="0" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-459">1,024,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-460">7.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="0" id="f-461">80,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-462">0.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="0" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-465">221,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-466">1.51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="0" id="f-467">241,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-468">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="0" id="f-469">224,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-470">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-471">130,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-472">0.89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-473">2,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-475">3,044,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-476">20.80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-477">3,973,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-478">30.65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-2" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-483" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below as of December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-484">5,799,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-485">4,115,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-486">619,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-487">377,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-488">647,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-489">349,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sec. 174</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="0" id="f-490">2,027,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="0" id="f-491">1,032,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsOther" format="ixt:fixed-zero" scale="0" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-493">172,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-494">9,092,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-495">6,047,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Valuation Allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-496">9,092,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-497">6,047,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net Deferred Tax Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-2" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="0" id="f-500">3,044,500</ix:nonFraction> for the period ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-501">21,496,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-502">18,394,200</ix:nonFraction>, respectively. The federal NOL carryforwards consist of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-503">2,405,400</ix:nonFraction> generated prior to 2018 which will begin to expire in 2035, however, are able to offset 100% of taxable income and $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-504">19,091,000</ix:nonFraction> generated after December 31, 2017 that will carryforward indefinitely but will be subject to 80% taxable income limitation beginning tax years after December 31, 2021 as provided by the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act (PL 116-136).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company has federal R&amp;D credit carryforwards of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="f-505">617,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which will begin to expire in 2041 and state R&amp;D credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-2" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="f-506">338,400</ix:nonFraction> which do not expire.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;) a corporation that undergoes an ownership change may be subject to limitations on its </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-451-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company&#8217;s ability to use its NOLs or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (&#8220;R&amp;E&#8221;) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the years ended December 31, 2023 and December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits as of December&#160;31, 2023 is approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-2" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-507">286,600</ix:nonFraction>, which relates to federal and state R&amp;D credits. If recognized <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt-sec:numwordsen" id="f-508">no</ix:nonFraction>ne of the unrecognized tax benefits would affect the effective tax rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to account for interest and penalties as income tax expense. As of the December&#160;31, 2023 the Company had <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt-sec:numwordsen" id="f-509">no</ix:nonFraction> interest related to unrecognized tax benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt-sec:numwordsen" id="f-510">No</ix:nonFraction> amounts of penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within twelve months of this reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, with varying statutes of limitations. The tax years from inception through 2023 remain open to examination due to the carryover of unused net operating losses that are being carried forward for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the U.S. Inflation Reduction Act of 2022 and the CHIPS and Science Act of 2022 were signed into law. These acts include, among other provisions, a corporate alternative minimum tax of 15%, an excise tax on the repurchase of corporate stock, various climate and energy provisions, and incentives for investment in semiconductor manufacturing. These provisions are not expected to have a material impact on the Company&#8217;s results of operations or financial position.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i572bc36408af457cba91ba941693f8aa_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 - <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-511" continuedAt="f-511-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-511-1"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Under the 2022 Equity Plan, the number of shares available for issuance are increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-512">3,800,000</ix:nonFraction> shares, five percent (<ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-513">5</ix:nonFraction>%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2024, <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-514">1,316,452</ix:nonFraction> shares, equivalent to five percent (<ix:nonFraction unitRef="number" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-515">5</ix:nonFraction>%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="f-516">0.5</ix:nonFraction>&#160;million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of <ix:nonFraction unitRef="site" contextRef="c-115" decimals="INF" name="beat:ResearchAndDevelopmentNumberOfClinicalStudySites" format="ixt-sec:numwordsen" id="f-517">five</ix:nonFraction> planned sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-518">0.7</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i769bcef6d5d9424b8db6acf6286f9e37_35"></div><div style="min-height:72pt;width:100%"><div style="padding-left:396pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Independent Registered Public Accounting Firm&#8217;s Consent</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements of HeartBeam, Inc. on Form S-8 (File No.&#8217;s 333-261430, 333-266114 and 333-273230) and Form S-3 (File No. 333-269520) of our report dated March 20, 2024,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to our audits of the financial statements of HeartBeam, Inc. as of and for the years ended December 31, 2023 and 2022, which report is included in this Annual Report on Form 10-K of HeartBeam, Inc. for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Marcum LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marcum LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">East Hanover, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 20, 2024 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311-12312023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i74d0c0f44a9149f6bbc011766786bb98_1"></div><div style="min-height:49.5pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Branislav Vajdic, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of HeartBeam, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.376%"><tr><td style="width:1.0%"></td><td style="width:36.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.177%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 20, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Branislav Vajdic</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Branislav Vajdic</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-12312023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id34ad277400f47e39c4f4c4627dcd0c1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Branislav Vajdic, Chief Executive Officer of HeartBeam, Inc. (the &#8220;Company&#8221;), hereby certify that, to the best of his knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.260%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 20, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Branislav Vajdic</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Branislav Vajdic</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>5
<FILENAME>exhibit971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic26d7ed85aa34ab4a0f1d17dc8f71b40_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HeartBeam, Inc. Compensation Recovery Policy</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purpose.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The purpose of this Compensation Recovery Policy of the Company (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), dated as of November 30, 2023 to describe the circumstances in which current and former Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, Exchange Act Rule 10D-1 promulgated thereunder, and the rules and requirements of Nasdaq (including Nasdaq Listing Rule 5608) (such legal requirements, and rules and requirements of Nasdaq, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SEC&#47;Nasdaq Clawback Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Each Executive Officer shall be required to sign and return to the Company the form of acknowledgment to this Policy in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Administration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Policy shall be administered by the Committee. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy, and any such determinations made by the Committee shall be in the Committee&#8217;s sole discretion and shall be final and binding on all affected individuals. Except as otherwise required by applicable legal requirements or the rules and requirements of Nasdaq, any determinations of the Committee hereunder need not be uniform with respect to one or more Executive Officers (whether current and&#47;or former).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For purposes of this Policy, the following capitalized terms shall have the meanings set forth below&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement (i) to correct an error in previously issued financial statements (a &#8220;Big R&#8221; restatement) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;little r&#34; restatement).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Board of Directors of the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Clawback Eligible Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean all Incentive-Based Compensation Received by any current or former Executive Officer on or after the Nasdaq Effective Date, provided that&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) such Incentive-Based Compensation is Received after such individual began serving as an Executive Officer&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) such individual served as an Executive Officer at any time during the performance period for such Incentive-Based Compensation&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) such Incentive-Based Compensation is Received while the Company has a class of securities listed on Nasdaq&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) such Incentive-Based Compensation is Received during the applicable Clawback Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Clawback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Compensation Committee of the Board.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the common stock, par value $0.001 per share, of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean HeartBeam, Inc., a Delaware corporation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Company, together with each of its direct and indirect subsidiaries.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any current or former Executive Officer in connection with any Accounting Restatement, the amount of Clawback Eligible Incentive Compensation Received by such current or former Executive Officer that exceeds the amount of Clawback Eligible Incentive Compensation that otherwise would have been Received by such current or former Executive Officer had such Clawback Eligible Incentive Compensation been determined based on the restated amounts as reflected in connection with such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting Restatement, taking into account any discretion that the Committee had applied to determine the amount of Clawback Eligible Incentive Compensation originally Received and computed without regard to any taxes paid.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean any officer as defined in Rule 10D-1(d) (or any successor provision thereof) under the Exchange Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any other measures that are derived wholly or in part from such measures. For purposes of this Policy, stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented within the Company&#8217;s financial statements or included in a filing with the SEC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Nasdaq Stock Market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Nasdaq Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean October 2, 2023 (which is the effective date of the final Nasdaq listing standards).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean when Incentive-Based Compensation is received, and Incentive-Based Compensation shall be deemed received in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if payment or grant of the Incentive-Based Compensation occurs after the end of that period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(q) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(r) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the U.S. Securities and Exchange Commission.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recovery of Erroneously Awarded Compensation.</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) In the event that the Company is required to prepare an Accounting Restatement, (i) the Committee shall determine the amount of any Erroneously Awarded Compensation for each applicable current or former Executive Officer (whether or not such individual is serving as an Executive Officer at such time) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in connection with such Accounting Restatement, and (ii) the Company will reasonably promptly require the recovery of such Erroneously Awarded Compensation from any such Applicable Executive, and any such Applicable Executive shall surrender such Erroneously Awarded Compensation to the Company, at such time(s), and via such method(s), as determined by the Committee in accordance with the terms of this Policy.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) For Incentive-Based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, (i) such amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received, and (ii) the Company will maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The Committee shall determine, in its sole discretion, the method(s) for recovering any Erroneously Awarded Compensation from any Applicable Executive, which may include one or more of the following&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) requiring one or more cash payments to the Company Group from such Applicable Executive, including, but not limited to, the repayment of cash Incentive-Based Compensation previously paid by the Company Group to such Applicable Executive&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards previously made by the Company to such Applicable Executive and&#47;or, subject to applicable legal requirements, otherwise requiring the delivery to the Company of shares of Common Stock held by such Applicable Executive&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) withholding, reducing or eliminating future cash compensation (including cash incentive payments), future equity awards and&#47;or other benefits or amounts otherwise to be paid or awarded by the Company Group to such Applicable Executive&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) offsetting amounts against compensation or other amounts otherwise payable by the Company Group to any Applicable Executive&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) cancelling, adjusting or offsetting against some or all outstanding vested or unvested equity awards of the Company held by such Applicable Executive&#59; and&#47;or</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) taking any other remedial and recovery actions with respect to such Applicable Executive permitted by applicable legal requirements and the rules and regulations of Nasdaq, as determined by the Committee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Notwithstanding anything herein to the contrary, the Company shall not be required to recover Erroneously Awarded Compensation from any Applicable Executive pursuant to the terms of this Policy if both (1) the Committee determines that such recovery would be impracticable, and (2) any of the following conditions is met&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered, provided that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement pursuant to this clause (i), the Company has (x) made a reasonable attempt to recover such Erroneously Awarded Compensation, (y) documented such reasonable attempt(s) to recover, and (z) provided such documentation to Nasdaq&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation, has provided copy of the opinion is provided to Nasdaq&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Indemnification, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company Group shall not (x) indemnify any current or former Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company Group&#8217;s enforcement of its rights under this Policy, or (y) pay or reimburse any current or former Executive Officers for insurance premiums to recover losses incurred under this Policy.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supersedure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Policy will supersede any provisions in (x) any agreement, plan or other arrangement applicable to any member of the Company Group, and (y) any organizational documents of any entity that is part of Company Group that, in any such case, (a) exempt any Incentive-Based Compensation from the application of this Policy, (b) waive or otherwise prohibit or restricts the Company Group&#8217;s right to recover any Erroneously Awarded Compensation, including, without limitation, in connection with exercising any right of setoff as provided herein, and&#47;or (c) require or provide for indemnification to the extent that such indemnification is prohibited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> above.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment&#59; Termination&#59; Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Committee may amend or terminate this Policy at any time, subject to compliance with all applicable legal requirements and the rules and requirements of Nasdaq. It is intended that this Policy be interpreted in a manner that is consistent with the SEC&#47;Nasdaq Clawback Rules. This Policy is separate from, and in addition to, any other compensation recovery or recoupment policy of the Company or any applicable provisions of plans, agreements, awards or other arrangements of the Company that provide for the recoupment or recovery of compensation from Executive Officers that is voluntarily adopted by the Company and intended to provide for discretionary recoupment beyond the scope of this Policy and the SEC&#47;Nasdaq Clawback Rules.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Recoupment Rights&#59; No Additional Payments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Policy below, any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company Group pursuant to (i) the terms of any recoupment provisions in any employment agreement, incentive or equity compensation plan or award or other agreement, (ii) any other legal requirements, including, but not limited to, Section 304 of Sarbanes-Oxley Act of 2002, and (iii) any other legal rights or remedies available to the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Notwithstanding anything herein to the contrary, to prevent duplicative recovery&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) to the extent that the amount of any Erroneously Awarded Compensation is recovered from any current or former Executive Officers under this Policy, the Company will not be entitled to recover any such amounts under any other compensation recovery or recoupment policy of the Company or any applicable provisions of plans, agreements, awards or other arrangements of the Company that provide for the recoupment or recovery of compensation from Executive Officers&#59; and</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) to the extent that any Erroneously Awarded Compensation includes any amounts that have been actually reimbursed to the Company Group from any Applicable Executive pursuant to Section 304 of the Sarbanes-Oxley Act (any such amounts that have been reimbursed to the Company Group, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable SOX Recoupment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the amount of any Erroneously Awarded Compensation to be recovered from any such Applicable Executive shall be reduced by the Applicable SOX Recoupment Amount.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Successors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Policy shall be binding and enforceable against all current and former Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Form of Acknowledgement</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the HeartBeam, Inc. Compensation Recovery Policy (such policy, as amended from time to time, the &#8220;Policy&#8221;). Capitalized terms used but not otherwise defined in this acknowledgement shall have the meanings ascribed to such terms in the Policy.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By signing this acknowledgement, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment with the Company Group. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation to the Company group to the extent required by the Policy.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.180%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"><div style="text-indent:18pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>beat-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:beat="http://www.heartbeam.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.heartbeam.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beat-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beat-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beat-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="beat-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.heartbeam.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.heartbeam.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.heartbeam.com/role/BalanceSheets">
        <link:definition>0000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.heartbeam.com/role/BalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.heartbeam.com/role/StatementsofOperations">
        <link:definition>0000005 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofChangesinStockholdersEquity" roleURI="http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity">
        <link:definition>0000006 - Statement - Statement of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.heartbeam.com/role/StatementsofCashFlows">
        <link:definition>0000007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONS" roleURI="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS">
        <link:definition>0000008 - Disclosure - ORGANIZATION AND OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOINGCONCERNANDOTHERUNCERTAINTIES" roleURI="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES">
        <link:definition>0000009 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000012 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000013 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTS" roleURI="http://www.heartbeam.com/role/COMMITMENTS">
        <link:definition>0000014 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAX" roleURI="http://www.heartbeam.com/role/INCOMETAX">
        <link:definition>0000015 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.heartbeam.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954473 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXTables" roleURI="http://www.heartbeam.com/role/INCOMETAXTables">
        <link:definition>9954475 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONSDetails" roleURI="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails">
        <link:definition>9954476 - Disclosure - ORGANIZATION AND OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOINGCONCERNANDOTHERUNCERTAINTIESDetails" roleURI="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails">
        <link:definition>9954477 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails" roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails">
        <link:definition>9954479 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>9954480 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYCommonStockDetails" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails">
        <link:definition>9954481 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYWarrantsDetails" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails">
        <link:definition>9954482 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYWarrantsOutstandingDetails" roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails">
        <link:definition>9954483 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954484 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockOptionsActivityDetails" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails">
        <link:definition>9954485 - Disclosure - STOCK-BASED COMPENSATION - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsDetails" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails">
        <link:definition>9954486 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails">
        <link:definition>9954487 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails">
        <link:definition>9954488 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>9954489 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSDetails" roleURI="http://www.heartbeam.com/role/COMMITMENTSDetails">
        <link:definition>9954490 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9954491 - Disclosure - INCOME TAX - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXDeferredTaxAssetsDetails" roleURI="http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails">
        <link:definition>9954492 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXAdditionalInformationDetails" roleURI="http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - INCOME TAX - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9954494 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="beat_SubstantialDoubtAboutGoingConcernLineItems" abstract="true" name="SubstantialDoubtAboutGoingConcernLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_CertainInvestorsMember" abstract="true" name="CertainInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_LesseeOperatingLeaseMonthlyRentExpense" abstract="false" name="LesseeOperatingLeaseMonthlyRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_TripleRingTechnologiesMember" abstract="true" name="TripleRingTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightRollForward" abstract="true" name="ClassOfWarrantOrRightRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" abstract="true" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" abstract="false" name="SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="beat_AGPAllianceGlobalPartnersMember" abstract="true" name="AGPAllianceGlobalPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightTerminationPeriod" abstract="false" name="ClassOfWarrantOrRightTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ResearchAndDevelopmentNumberOfClinicalStudySites" abstract="false" name="ResearchAndDevelopmentNumberOfClinicalStudySites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" abstract="true" name="ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_ClinicalResearchOrganizationMember" abstract="true" name="ClinicalResearchOrganizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightWarrantsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ExecutivesAndEmployeesMember" abstract="true" name="ExecutivesAndEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_TaxPeriodsPriorTo2018Member" abstract="true" name="TaxPeriodsPriorTo2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="beat_SaleOfStockAgentCommissionPercentage" abstract="false" name="SaleOfStockAgentCommissionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_AccountingForWarrantsPolicyPolicyTextBlock" abstract="false" name="AccountingForWarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="beat_TaxPeriodsAfter2017Member" abstract="true" name="TaxPeriodsAfter2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" abstract="false" name="ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsExercisedForCash" abstract="false" name="ClassOfWarrantOrRightWarrantsExercisedForCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_LIVMORMember" abstract="true" name="LIVMORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_A2022EquityPlanMember" abstract="true" name="A2022EquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_LesseeOperatingLeasePriorNoticeForCancellation" abstract="false" name="LesseeOperatingLeasePriorNoticeForCancellation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightFairValuePerWarrant" abstract="false" name="ClassOfWarrantOrRightFairValuePerWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsCashlessExercise" abstract="false" name="ClassOfWarrantOrRightWarrantsCashlessExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_MaverickCapitalPartnersLLCMember" abstract="true" name="MaverickCapitalPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_SaleOfStockPlacementFeePercentage" abstract="false" name="SaleOfStockPlacementFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="beat_PaymentsForPurchaseObligations" abstract="false" name="PaymentsForPurchaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_SaleOfStockRemainingAmountAuthorizedForIssuance" abstract="false" name="SaleOfStockRemainingAmountAuthorizedForIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_SubstantialDoubtAboutGoingConcernTable" abstract="true" name="SubstantialDoubtAboutGoingConcernTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="beat_A2015EquityIncentivePlanMember" abstract="true" name="A2015EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" abstract="false" name="ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_OpenSkyOpportunitiesFundLtdMember" abstract="true" name="OpenSkyOpportunitiesFundLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_StockAndClassOfWarrantOrRightIssued" abstract="false" name="StockAndClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_PennyWarrantMember" abstract="true" name="PennyWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" abstract="false" name="ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightFairValueIssuedForService" abstract="false" name="ClassOfWarrantOrRightFairValueIssuedForService" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_SaleOfStockMaximumAmountAuthorized" abstract="false" name="SaleOfStockMaximumAmountAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightGrantDateFairValue" abstract="false" name="ClassOfWarrantOrRightGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWarrantsExpired" abstract="false" name="ClassOfWarrantOrRightWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="beat_ConsultantsMember" abstract="true" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>beat-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.heartbeam.com/role/BalanceSheets" xlink:type="simple" xlink:href="beat-20231231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.heartbeam.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_48f3bb02-5249-4f6b-8a91-5b1f57e876c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_63ff3d04-daec-4883-a8e9-25de55cffeed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_48f3bb02-5249-4f6b-8a91-5b1f57e876c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_63ff3d04-daec-4883-a8e9-25de55cffeed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41b95c4d-0291-4a94-a063-e3b4c4328e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_48f3bb02-5249-4f6b-8a91-5b1f57e876c1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41b95c4d-0291-4a94-a063-e3b4c4328e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5274154-7082-4256-b075-8e6661982305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7b6086fc-0651-4268-a15c-0696978f19da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a5274154-7082-4256-b075-8e6661982305" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7b6086fc-0651-4268-a15c-0696978f19da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5130c520-0248-4232-96b2-12c8a76830e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a5274154-7082-4256-b075-8e6661982305" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5130c520-0248-4232-96b2-12c8a76830e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d1e51272-7350-421a-a907-ea9156d2d9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a5274154-7082-4256-b075-8e6661982305" xlink:to="loc_us-gaap_CommonStockValue_d1e51272-7350-421a-a907-ea9156d2d9e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_02866bb1-0d6f-434d-9810-c855b4792b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a5274154-7082-4256-b075-8e6661982305" xlink:to="loc_us-gaap_PreferredStockValue_02866bb1-0d6f-434d-9810-c855b4792b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_755bcb2e-446a-4c7b-aa82-c1770ef24a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fce35162-e01b-40ed-8013-3e88f3106347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_755bcb2e-446a-4c7b-aa82-c1770ef24a22" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fce35162-e01b-40ed-8013-3e88f3106347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c28e0eab-b074-48d3-9f22-56096c5231c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7880e3fc-8903-4a1e-8717-7ca1846709a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c28e0eab-b074-48d3-9f22-56096c5231c1" xlink:to="loc_us-gaap_AssetsCurrent_7880e3fc-8903-4a1e-8717-7ca1846709a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de7cd3bd-24cd-4917-a97c-2a99f2963454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c28e0eab-b074-48d3-9f22-56096c5231c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de7cd3bd-24cd-4917-a97c-2a99f2963454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f8f320c8-390c-4c88-bf6e-0307863491bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c28e0eab-b074-48d3-9f22-56096c5231c1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f8f320c8-390c-4c88-bf6e-0307863491bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af14943-e8d3-4ad9-ae0c-ed029ce12113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fd556e89-9d55-4cf8-b6fa-9ed0e8a163c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af14943-e8d3-4ad9-ae0c-ed029ce12113" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fd556e89-9d55-4cf8-b6fa-9ed0e8a163c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f6764d0-51a7-4bbf-aecd-6d6273f5be51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af14943-e8d3-4ad9-ae0c-ed029ce12113" xlink:to="loc_us-gaap_StockholdersEquity_5f6764d0-51a7-4bbf-aecd-6d6273f5be51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_152d72d5-936d-4072-8d6b-156606ae35e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af14943-e8d3-4ad9-ae0c-ed029ce12113" xlink:to="loc_us-gaap_Liabilities_152d72d5-936d-4072-8d6b-156606ae35e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementsofOperations" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.heartbeam.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a783c7e-cc31-4f40-9311-28880ece9680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc93e9bd-a7ff-4ad4-8da5-d9cf50f6e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a783c7e-cc31-4f40-9311-28880ece9680" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc93e9bd-a7ff-4ad4-8da5-d9cf50f6e5a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58770472-f3e0-4e01-8d31-5974e7493dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a783c7e-cc31-4f40-9311-28880ece9680" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58770472-f3e0-4e01-8d31-5974e7493dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45612904-f11f-49a1-b611-891860f3f8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_04ef75bd-3289-4fdd-95b5-5ebeff4d9a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45612904-f11f-49a1-b611-891860f3f8a3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_04ef75bd-3289-4fdd-95b5-5ebeff4d9a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_09452997-ec4a-45c5-a44e-6e2fc57096f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45612904-f11f-49a1-b611-891860f3f8a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_09452997-ec4a-45c5-a44e-6e2fc57096f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_122f2931-b463-4abe-b06b-28bbd73f28de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f38ff6ad-3ce6-4fc7-854e-d6825eb737a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_122f2931-b463-4abe-b06b-28bbd73f28de" xlink:to="loc_us-gaap_OperatingExpenses_f38ff6ad-3ce6-4fc7-854e-d6825eb737a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39625eeb-6f59-405b-a345-c63aee1123d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e9e8949c-ee5a-4101-ae18-fd86f9379d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39625eeb-6f59-405b-a345-c63aee1123d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_e9e8949c-ee5a-4101-ae18-fd86f9379d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_794cdb6d-7573-4d2c-9b38-5ffc16f0d29a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39625eeb-6f59-405b-a345-c63aee1123d2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_794cdb6d-7573-4d2c-9b38-5ffc16f0d29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_679539ef-eb1d-4092-9548-b914e2a7d995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_83ba9f26-71c0-41af-96dc-11682f1c1e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_679539ef-eb1d-4092-9548-b914e2a7d995" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_83ba9f26-71c0-41af-96dc-11682f1c1e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7d956439-0eb7-4525-a9e6-0cae053d2465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_679539ef-eb1d-4092-9548-b914e2a7d995" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7d956439-0eb7-4525-a9e6-0cae053d2465" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.heartbeam.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4827592-d4a1-45c8-bc69-8302d9c7058a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbda7334-cefb-4d26-9fe6-103e848c827c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4827592-d4a1-45c8-bc69-8302d9c7058a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbda7334-cefb-4d26-9fe6-103e848c827c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f8684ce-f26e-475d-a9d5-48ec7f327635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4827592-d4a1-45c8-bc69-8302d9c7058a" xlink:to="loc_us-gaap_NetIncomeLoss_0f8684ce-f26e-475d-a9d5-48ec7f327635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bd0c853c-8a76-4525-9578-bf16091535d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4827592-d4a1-45c8-bc69-8302d9c7058a" xlink:to="loc_us-gaap_ShareBasedCompensation_bd0c853c-8a76-4525-9578-bf16091535d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_713cb1f7-0af4-4623-9dd5-6506b5f35bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4827592-d4a1-45c8-bc69-8302d9c7058a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_713cb1f7-0af4-4623-9dd5-6506b5f35bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2a77011-54c9-48c9-86fc-2f21d3ad2c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fc7c50f5-e50b-41da-ae2f-44ac87fe40f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2a77011-54c9-48c9-86fc-2f21d3ad2c08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fc7c50f5-e50b-41da-ae2f-44ac87fe40f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f781e70-2562-45db-ae7b-328610c80f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2a77011-54c9-48c9-86fc-2f21d3ad2c08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f781e70-2562-45db-ae7b-328610c80f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1248bbe4-49e3-4260-a777-86fc57310ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2a77011-54c9-48c9-86fc-2f21d3ad2c08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1248bbe4-49e3-4260-a777-86fc57310ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_789d162f-9d6b-4c1b-a269-288d0db0cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87488260-6a4b-443f-8b58-5bf157324746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_789d162f-9d6b-4c1b-a269-288d0db0cc75" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87488260-6a4b-443f-8b58-5bf157324746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eef647c-68c6-40d0-846e-5c14628a032d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4ebc2d1b-c848-4849-9e9f-135bc0f700fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eef647c-68c6-40d0-846e-5c14628a032d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4ebc2d1b-c848-4849-9e9f-135bc0f700fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_09b072d4-494b-4a12-a5f5-60d4f5d9d714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eef647c-68c6-40d0-846e-5c14628a032d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_09b072d4-494b-4a12-a5f5-60d4f5d9d714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98d8d133-c1d0-478f-a97f-fc475dab49bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eef647c-68c6-40d0-846e-5c14628a032d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98d8d133-c1d0-478f-a97f-fc475dab49bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c94630fb-6209-4805-a663-6bb77a74dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c94630fb-6209-4805-a663-6bb77a74dcce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f4dec1c6-df69-4c30-af92-582dcf22c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f4dec1c6-df69-4c30-af92-582dcf22c54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_10fc2d6e-82cd-4c1c-b3a1-c7cbf4929d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_10fc2d6e-82cd-4c1c-b3a1-c7cbf4929d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f27b8f33-e790-44dc-b7fc-972d3bd01f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_f27b8f33-e790-44dc-b7fc-972d3bd01f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7149cd42-d1b0-4be1-a116-1f5f9a17ee42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7149cd42-d1b0-4be1-a116-1f5f9a17ee42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2e3eba67-7fa6-4258-8773-86155ca780a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2e3eba67-7fa6-4258-8773-86155ca780a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_77749280-ad0b-4e45-bcf3-6981b17fadcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7f0ecc00-2c89-46f5-a844-ddf36b167ca7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_77749280-ad0b-4e45-bcf3-6981b17fadcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_55db6bc9-1b69-4486-bfde-1341ee1a4a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_55db6bc9-1b69-4486-bfde-1341ee1a4a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fec69f12-a487-4ada-b2b7-597461cdf765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fec69f12-a487-4ada-b2b7-597461cdf765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ec574141-d42e-42f4-9a4b-a94264bf44e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ec574141-d42e-42f4-9a4b-a94264bf44e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_69784f92-a512-4074-8928-ae5d0f4e4701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_69784f92-a512-4074-8928-ae5d0f4e4701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_85819069-7c40-460e-988b-11735260966c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_85819069-7c40-460e-988b-11735260966c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7cac89fe-cdbb-45d4-ba2e-6c44f67370fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7cac89fe-cdbb-45d4-ba2e-6c44f67370fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fa96e59e-9756-4236-b373-39c86f3db307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_60414f18-3308-4011-8c80-a56f8ea6c735" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fa96e59e-9756-4236-b373-39c86f3db307" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cd744b88-e2e8-45d8-a702-321726b333c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cd744b88-e2e8-45d8-a702-321726b333c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4c6c581e-7aff-409c-971e-1189ee869ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4c6c581e-7aff-409c-971e-1189ee869ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a1d912d4-3111-4b0b-82ec-fa0586fd4c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a1d912d4-3111-4b0b-82ec-fa0586fd4c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_488cee63-9c9a-4b58-b80e-a8a6c4a14635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_488cee63-9c9a-4b58-b80e-a8a6c4a14635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_7aaff94e-2544-4619-bae5-4c7b07385246" xlink:href="beat-20231231.xsd#beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_59f38d7d-323d-458b-bdbd-70e9992b98b6" xlink:to="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_7aaff94e-2544-4619-bae5-4c7b07385246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da257eaa-0d29-4efa-ad41-aca5448a5f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ef708f20-f017-4b4c-9b49-a5aed9cad919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da257eaa-0d29-4efa-ad41-aca5448a5f2c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ef708f20-f017-4b4c-9b49-a5aed9cad919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ba2757be-a93d-475b-b59e-df268a275e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_da257eaa-0d29-4efa-ad41-aca5448a5f2c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ba2757be-a93d-475b-b59e-df268a275e6f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>beat-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.heartbeam.com/role/CoverPage" xlink:type="simple" xlink:href="beat-20231231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e82b251-a281-468b-a7c4-6a5d7177b044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:to="loc_us-gaap_ClassOfStockDomain_0e82b251-a281-468b-a7c4-6a5d7177b044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:to="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c3f38af4-2482-4bfc-bdb7-47e4024b9d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:to="loc_us-gaap_CommonClassAMember_c3f38af4-2482-4bfc-bdb7-47e4024b9d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f5799b8-aac5-4aa8-9f4a-78aa42818ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:to="loc_us-gaap_WarrantMember_6f5799b8-aac5-4aa8-9f4a-78aa42818ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fc57b327-1d8c-432a-9830-7cba03d1e97d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentType_fc57b327-1d8c-432a-9830-7cba03d1e97d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cb31021c-86fe-4188-816d-609ed05c2758" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentAnnualReport_cb31021c-86fe-4188-816d-609ed05c2758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_48b3436e-2bc1-4855-accb-f41ab7dc1894" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentPeriodEndDate_48b3436e-2bc1-4855-accb-f41ab7dc1894" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b24ceb5f-8f5f-419c-820d-5ba8c98ec75f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_CurrentFiscalYearEndDate_b24ceb5f-8f5f-419c-820d-5ba8c98ec75f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9a94263b-818e-4dd2-b10b-7724e32745c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentTransitionReport_9a94263b-818e-4dd2-b10b-7724e32745c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_128f1143-f1ce-4c12-9549-b3df422540eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityFileNumber_128f1143-f1ce-4c12-9549-b3df422540eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_972a52e4-df2f-451b-b78b-f22f85c5c817" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityRegistrantName_972a52e4-df2f-451b-b78b-f22f85c5c817" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_66e20192-59b8-48fe-98db-465e5439e67d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityIncorporationStateCountryCode_66e20192-59b8-48fe-98db-465e5439e67d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1ba0f41-cea1-4d2a-b1fc-68a633e6f5cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1ba0f41-cea1-4d2a-b1fc-68a633e6f5cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7dc712a6-41a0-4717-adc6-d7ecbb1d179d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressAddressLine1_7dc712a6-41a0-4717-adc6-d7ecbb1d179d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a767b19c-2f4e-48a0-a55b-e992ca129cec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressAddressLine2_a767b19c-2f4e-48a0-a55b-e992ca129cec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_10c4d424-1132-4892-ac9c-761bcb08253a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressCityOrTown_10c4d424-1132-4892-ac9c-761bcb08253a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_af439686-8c61-42d7-833c-bee95ab9b240" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressStateOrProvince_af439686-8c61-42d7-833c-bee95ab9b240" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7ee4c08f-ea16-4880-8f05-fd9ce56a47b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressPostalZipCode_7ee4c08f-ea16-4880-8f05-fd9ce56a47b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82b35327-c62d-4bdf-be80-97bbfefec3a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_CityAreaCode_82b35327-c62d-4bdf-be80-97bbfefec3a5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b20c802a-a135-487c-9b2a-e2a79ae83d57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_LocalPhoneNumber_b20c802a-a135-487c-9b2a-e2a79ae83d57" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_542bd0e6-9eaa-463f-b693-a0b83e6374ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_Security12bTitle_542bd0e6-9eaa-463f-b693-a0b83e6374ec" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d7726d51-265a-4ed4-a9ca-832a51d1ec90" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_TradingSymbol_d7726d51-265a-4ed4-a9ca-832a51d1ec90" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4ac1e581-e334-4f94-8b04-18d5790e5cde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_SecurityExchangeName_4ac1e581-e334-4f94-8b04-18d5790e5cde" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_913a5b5a-8102-466a-8dac-35e83b7c1491" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_913a5b5a-8102-466a-8dac-35e83b7c1491" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_009b3882-ea78-44a3-b9b0-ee0698eb1c67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityVoluntaryFilers_009b3882-ea78-44a3-b9b0-ee0698eb1c67" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d2eaa6a9-8bc0-4c2d-98eb-a3f2e1547996" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCurrentReportingStatus_d2eaa6a9-8bc0-4c2d-98eb-a3f2e1547996" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ec6dfff4-afa8-429c-83c5-d5b512a5096e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityInteractiveDataCurrent_ec6dfff4-afa8-429c-83c5-d5b512a5096e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ca7be70d-5985-46fd-84b7-8f59073a169e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityFilerCategory_ca7be70d-5985-46fd-84b7-8f59073a169e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_603592e4-cca6-4625-8fc0-f354327ab0ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntitySmallBusiness_603592e4-cca6-4625-8fc0-f354327ab0ad" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_57182f6b-30e0-4a50-80d9-6d28985633d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityEmergingGrowthCompany_57182f6b-30e0-4a50-80d9-6d28985633d7" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6f221535-d4a5-4db8-a66d-240f640ca4df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityExTransitionPeriod_6f221535-d4a5-4db8-a66d-240f640ca4df" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5b77a84d-bd57-49eb-81f5-a9ff6a8b1b6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5b77a84d-bd57-49eb-81f5-a9ff6a8b1b6d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_7441e558-0f3d-4977-842f-fa83dc6ed99e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_7441e558-0f3d-4977-842f-fa83dc6ed99e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3fb38846-cd2f-40c7-9b92-5441da7efcc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityShellCompany_3fb38846-cd2f-40c7-9b92-5441da7efcc3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c4faa55f-20d6-422e-87ec-bf786b519c33" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityPublicFloat_c4faa55f-20d6-422e-87ec-bf786b519c33" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b04e7510-8551-4697-9d18-901b408ded45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b04e7510-8551-4697-9d18-901b408ded45" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a1373304-0b69-4b90-b03d-21bec89160bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCentralIndexKey_a1373304-0b69-4b90-b03d-21bec89160bf" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_28d8f225-1f73-4a87-9539-4cd323c39dd3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFiscalYearFocus_28d8f225-1f73-4a87-9539-4cd323c39dd3" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_28762aa3-bf28-45a8-83b7-69d97f836986" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFiscalPeriodFocus_28762aa3-bf28-45a8-83b7-69d97f836986" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_55747a8b-2c7d-4a7a-b4bc-fe32035ba477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_AmendmentFlag_55747a8b-2c7d-4a7a-b4bc-fe32035ba477" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e9cbcf4e-bd22-44a3-a782-0989d9bf8230" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e9cbcf4e-bd22-44a3-a782-0989d9bf8230" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="beat-20231231.xsd#BalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:to="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:to="loc_us-gaap_RelatedPartyDomain_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:to="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_417008c3-c35e-4a03-a17d-95639866a7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:to="loc_us-gaap_RelatedPartyMember_417008c3-c35e-4a03-a17d-95639866a7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_251e86f0-9b3b-4479-8b8e-b7df1af9c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_251e86f0-9b3b-4479-8b8e-b7df1af9c8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:to="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e474461b-6e41-4286-b92a-b5bcecf3fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e474461b-6e41-4286-b92a-b5bcecf3fdcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dd226ff8-6e8e-4c2c-821a-232eda4b409c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dd226ff8-6e8e-4c2c-821a-232eda4b409c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_587807f0-38c9-4534-80a9-59d13af28d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_587807f0-38c9-4534-80a9-59d13af28d6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0bd9c321-512c-4199-b547-e57a5fca5599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0bd9c321-512c-4199-b547-e57a5fca5599" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3025e665-cc9b-4a13-9ed0-bf1f914a4527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3025e665-cc9b-4a13-9ed0-bf1f914a4527" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c5bba167-f296-4f8f-a15f-67c827257c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesIssued_c5bba167-f296-4f8f-a15f-67c827257c6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56839d65-c98a-4017-ab31-cfc4ac4fb782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56839d65-c98a-4017-ab31-cfc4ac4fb782" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:to="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dc4829cc-88d0-4c7c-9944-d2fd33358900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:to="loc_us-gaap_EquityComponentDomain_dc4829cc-88d0-4c7c-9944-d2fd33358900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:to="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b67b39e0-f16c-4006-9114-122914b70784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_CommonStockMember_b67b39e0-f16c-4006-9114-122914b70784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fa3765f0-07d0-461d-9d7c-3357c01d3687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fa3765f0-07d0-461d-9d7c-3357c01d3687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0426d59a-7817-42d2-8031-b9180be23464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_RetainedEarningsMember_0426d59a-7817-42d2-8031-b9180be23464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f39f212f-5b05-4d0e-8814-ee3c4be8a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f39f212f-5b05-4d0e-8814-ee3c4be8a94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_079b0e36-2989-4ef0-bed3-d28e21f3be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockholdersEquity_079b0e36-2989-4ef0-bed3-d28e21f3be2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d5967a9-aeac-4562-bb56-458c9608366b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d5967a9-aeac-4562-bb56-458c9608366b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75c3e1f2-b0ad-4128-8f46-3d304abbf82e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75c3e1f2-b0ad-4128-8f46-3d304abbf82e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03e090d7-761c-48e6-8d2c-c6dbf6ce5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03e090d7-761c-48e6-8d2c-c6dbf6ce5b43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06c4dcb5-df43-46fa-8a91-2d067a65adb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06c4dcb5-df43-46fa-8a91-2d067a65adb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9330e342-8b26-41b2-9f91-87e70fa4ac58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9330e342-8b26-41b2-9f91-87e70fa4ac58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_880b3ce8-b5d7-4a8e-ae9c-8f5c1da19ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_880b3ce8-b5d7-4a8e-ae9c-8f5c1da19ec4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1c68503f-8fdd-4156-9445-fd1ad6a0358b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1c68503f-8fdd-4156-9445-fd1ad6a0358b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_eb12c030-d629-4ffe-8e0d-0af2adaa6ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_eb12c030-d629-4ffe-8e0d-0af2adaa6ea5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f0f3e7d-ec0a-42e2-82ce-d67c7cfb9ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_NetIncomeLoss_0f0f3e7d-ec0a-42e2-82ce-d67c7cfb9ad1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_09e08442-9ec2-40c3-bf61-544aa877f848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ed04f1eb-b325-4e4f-9646-4304ca20da31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#GOINGCONCERNANDOTHERUNCERTAINTIESDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AGPAllianceGlobalPartnersMember_cfc8f848-2eb1-435c-8750-c474106a39ac" xlink:href="beat-20231231.xsd#beat_AGPAllianceGlobalPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:to="loc_beat_AGPAllianceGlobalPartnersMember_cfc8f848-2eb1-435c-8750-c474106a39ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_MaverickCapitalPartnersLLCMember_124388e8-bf43-4c24-8ddb-a9bdf29b8a38" xlink:href="beat-20231231.xsd#beat_MaverickCapitalPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:to="loc_beat_MaverickCapitalPartnersLLCMember_124388e8-bf43-4c24-8ddb-a9bdf29b8a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_378a096c-bd88-4525-8010-1982662cc508_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_378a096c-bd88-4525-8010-1982662cc508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_37e3addc-c5c1-4e92-a5f0-c1701817d284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:to="loc_us-gaap_PrivatePlacementMember_37e3addc-c5c1-4e92-a5f0-c1701817d284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cd31f1cb-4182-4312-8e9f-7332da02a67d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cd31f1cb-4182-4312-8e9f-7332da02a67d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_210bc8be-dbf5-4a4a-928f-8ccbdb3e4403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:to="loc_us-gaap_ConvertibleDebtMember_210bc8be-dbf5-4a4a-928f-8ccbdb3e4403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a38e1f8-67bd-4b4b-a407-c91a17a04666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a38e1f8-67bd-4b4b-a407-c91a17a04666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f3f0329-27b9-46bc-900b-98c9f7bc99f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f3f0329-27b9-46bc-900b-98c9f7bc99f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockMaximumAmountAuthorized_d79572e4-fde2-44ab-bc57-975437ff2551" xlink:href="beat-20231231.xsd#beat_SaleOfStockMaximumAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockMaximumAmountAuthorized_d79572e4-fde2-44ab-bc57-975437ff2551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockAgentCommissionPercentage_41db07dd-c045-491f-82a2-2f21d4415680" xlink:href="beat-20231231.xsd#beat_SaleOfStockAgentCommissionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockAgentCommissionPercentage_41db07dd-c045-491f-82a2-2f21d4415680" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_ddaf57f3-76dc-49e4-baf1-39c7683d98ff" xlink:href="beat-20231231.xsd#beat_SaleOfStockRemainingAmountAuthorizedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_ddaf57f3-76dc-49e4-baf1-39c7683d98ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_ccd1983d-b7b5-48ca-b79b-c143e8599359" xlink:href="beat-20231231.xsd#beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_ccd1983d-b7b5-48ca-b79b-c143e8599359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31b51672-7b1c-4196-add9-9f760bcb04e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31b51672-7b1c-4196-add9-9f760bcb04e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0ddaa0d-a89c-4c66-9033-ce980c4b7c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0ddaa0d-a89c-4c66-9033-ce980c4b7c9e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b497936e-ff25-4b10-8838-1e6e9e6f61c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_StockOptionMember_b497936e-ff25-4b10-8838-1e6e9e6f61c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_069cfccb-ccb8-4e2a-aed1-d8522cee8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_RestrictedStockMember_069cfccb-ccb8-4e2a-aed1-d8522cee8cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ad755766-c235-430a-ae63-48128af37c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_WarrantMember_ad755766-c235-430a-ae63-48128af37c98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51e78d8c-ab0a-4f7a-a13d-8ba6839ef9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51e78d8c-ab0a-4f7a-a13d-8ba6839ef9dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8bc2a9a-46d8-413a-bb79-76077c592790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8bc2a9a-46d8-413a-bb79-76077c592790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7d3a24de-a009-417e-a5df-b1b699459318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:to="loc_us-gaap_IPOMember_7d3a24de-a009-417e-a5df-b1b699459318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_958bf942-e6d4-46c1-a437-5969209f09ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:to="loc_us-gaap_PrivatePlacementMember_958bf942-e6d4-46c1-a437-5969209f09ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:to="loc_us-gaap_EquityComponentDomain_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:to="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ec5ef7d-6dfe-4b79-87e2-ed9c268ce89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:to="loc_us-gaap_CommonStockMember_0ec5ef7d-6dfe-4b79-87e2-ed9c268ce89b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a9f3e81e-053e-4ddb-9f88-f914d95d8485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:to="loc_us-gaap_WarrantMember_a9f3e81e-053e-4ddb-9f88-f914d95d8485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cec5da8d-aa82-4768-855e-29552639a07c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:to="loc_us-gaap_RelatedPartyDomain_cec5da8d-aa82-4768-855e-29552639a07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:to="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ConsultantsMember_d8c1580b-e092-434a-9dd4-467725a48827" xlink:href="beat-20231231.xsd#beat_ConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:to="loc_beat_ConsultantsMember_d8c1580b-e092-434a-9dd4-467725a48827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584e8110-46fd-4107-aec8-d9015c15fa1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584e8110-46fd-4107-aec8-d9015c15fa1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_75d63a8a-03aa-4abf-9023-d4c60a86767f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:to="loc_us-gaap_ConvertibleDebtMember_75d63a8a-03aa-4abf-9023-d4c60a86767f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58fa1f69-c999-4a7d-8d14-4c7d017c3fba_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58fa1f69-c999-4a7d-8d14-4c7d017c3fba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_OpenSkyOpportunitiesFundLtdMember_e48797b9-92b2-4760-a5fb-6f162ee2510e" xlink:href="beat-20231231.xsd#beat_OpenSkyOpportunitiesFundLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_OpenSkyOpportunitiesFundLtdMember_e48797b9-92b2-4760-a5fb-6f162ee2510e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_MaverickCapitalPartnersLLCMember_e3e8bcda-08e1-4eff-b174-df11f16b6ab6" xlink:href="beat-20231231.xsd#beat_MaverickCapitalPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_MaverickCapitalPartnersLLCMember_e3e8bcda-08e1-4eff-b174-df11f16b6ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_CertainInvestorsMember_c517ca2e-13a2-4474-a188-b7b3d4867ab6" xlink:href="beat-20231231.xsd#beat_CertainInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_CertainInvestorsMember_c517ca2e-13a2-4474-a188-b7b3d4867ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AGPAllianceGlobalPartnersMember_e2fa1d03-7f8c-4e60-8e0a-aa262f30f3c4" xlink:href="beat-20231231.xsd#beat_AGPAllianceGlobalPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_AGPAllianceGlobalPartnersMember_e2fa1d03-7f8c-4e60-8e0a-aa262f30f3c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e2f0bd91-5e19-4507-a5fa-e6a72486c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e2f0bd91-5e19-4507-a5fa-e6a72486c1a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_561213f0-c70f-48e9-a92c-9118bad2346d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_561213f0-c70f-48e9-a92c-9118bad2346d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ae598281-bf83-4c99-8fe1-995c8071747c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ae598281-bf83-4c99-8fe1-995c8071747c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExpirationPeriod_38167ddb-59ec-4272-a227-d9194e250fa6" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightExpirationPeriod_38167ddb-59ec-4272-a227-d9194e250fa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant_7b10d64a-3ab4-4c13-b729-b5beeb1b55b3" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValuePerWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant_7b10d64a-3ab4-4c13-b729-b5beeb1b55b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_14880131-83e0-47ce-8b4e-604d14e0b294" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_14880131-83e0-47ce-8b4e-604d14e0b294" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19e919e2-86d6-4bdd-8100-f81ece5c052a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19e919e2-86d6-4bdd-8100-f81ece5c052a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4dee9a1-10c5-4b6b-b34f-e87102d18a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4dee9a1-10c5-4b6b-b34f-e87102d18a40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7169edb-39cb-4a43-8306-55153b604b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7169edb-39cb-4a43-8306-55153b604b1c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ecb1b610-f858-445c-be7b-b79cc8100e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ecb1b610-f858-445c-be7b-b79cc8100e95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService_bee077db-831d-40d2-b6d6-5c469ac2e9b5" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValueIssuedForService"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService_bee077db-831d-40d2-b6d6-5c469ac2e9b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15a9a67e-aef2-45f8-896e-f01752291f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15a9a67e-aef2-45f8-896e-f01752291f4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8ec9e15-9eae-47d6-896f-d65e0067d2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8ec9e15-9eae-47d6-896f-d65e0067d2de" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_a178d1d4-17ac-4798-9123-4d221eac7c14" xlink:href="beat-20231231.xsd#beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_a178d1d4-17ac-4798-9123-4d221eac7c14" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_abdf27f0-2179-4cf4-a985-9442e41d92e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_abdf27f0-2179-4cf4-a985-9442e41d92e9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_929dd59a-a1b2-4e47-8e4f-53c3cbe8b5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_929dd59a-a1b2-4e47-8e4f-53c3cbe8b5e4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightTerminationPeriod_34a11eca-ddc5-4474-be60-7286b89d8bd1" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightTerminationPeriod_34a11eca-ddc5-4474-be60-7286b89d8bd1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c0c342-c906-44d7-bf17-b5f56870352f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c0c342-c906-44d7-bf17-b5f56870352f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockMaximumAmountAuthorized_8ba01ffc-28f7-49f3-8c0c-7d43ba471d62" xlink:href="beat-20231231.xsd#beat_SaleOfStockMaximumAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockMaximumAmountAuthorized_8ba01ffc-28f7-49f3-8c0c-7d43ba471d62" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_e6cbdfcd-90ff-4dd9-a190-a4ea53290cf0" xlink:href="beat-20231231.xsd#beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_e6cbdfcd-90ff-4dd9-a190-a4ea53290cf0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_754c70af-103e-46ef-80c7-14dcff3502ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_754c70af-103e-46ef-80c7-14dcff3502ee" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockPlacementFeePercentage_2139354e-9290-4f18-b1b6-77e07bd3f9c6" xlink:href="beat-20231231.xsd#beat_SaleOfStockPlacementFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockPlacementFeePercentage_2139354e-9290-4f18-b1b6-77e07bd3f9c6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross_e1bb1427-9ce5-46e6-93a9-fb2a39a46172" xlink:href="beat-20231231.xsd#beat_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross_e1bb1427-9ce5-46e6-93a9-fb2a39a46172" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_e4c9f607-6a5f-45af-b17e-23e4562c9eb2" xlink:href="beat-20231231.xsd#beat_SaleOfStockRemainingAmountAuthorizedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_e4c9f607-6a5f-45af-b17e-23e4562c9eb2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e89f764-3e67-456c-b96c-4f66f7151491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e89f764-3e67-456c-b96c-4f66f7151491" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_56f739bf-d6f6-49d6-a424-a9c42b57744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_56f739bf-d6f6-49d6-a424-a9c42b57744d" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_af9fa22b-230a-40d5-95b1-bd49b9f11dc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_af9fa22b-230a-40d5-95b1-bd49b9f11dc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PennyWarrantMember_e6ee9838-c564-4e92-ac69-7115130d5de5" xlink:href="beat-20231231.xsd#beat_PennyWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:to="loc_beat_PennyWarrantMember_e6ee9838-c564-4e92-ac69-7115130d5de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3592c933-c7d7-40f4-b047-e017ab35ec19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3592c933-c7d7-40f4-b047-e017ab35ec19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b3da8cba-43b0-4e0d-bcab-1cd882ac22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:to="loc_us-gaap_IPOMember_b3da8cba-43b0-4e0d-bcab-1cd882ac22fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3dcf4bab-6673-4b87-a653-ab10a0dd08be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:to="loc_us-gaap_RelatedPartyDomain_3dcf4bab-6673-4b87-a653-ab10a0dd08be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:to="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ConsultantsMember_9cbca28a-8c27-4b62-aa16-3df25d9c8fd8" xlink:href="beat-20231231.xsd#beat_ConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:to="loc_beat_ConsultantsMember_9cbca28a-8c27-4b62-aa16-3df25d9c8fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e54e124c-5a9f-465f-9df9-d0cc013004be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:to="loc_us-gaap_EquityComponentDomain_e54e124c-5a9f-465f-9df9-d0cc013004be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:to="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0655f411-cb83-41b1-849d-15edad61e3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:to="loc_us-gaap_WarrantMember_0655f411-cb83-41b1-849d-15edad61e3f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8506b516-46a1-433a-898d-3f6c1b298b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:to="loc_us-gaap_CommonStockMember_8506b516-46a1-433a-898d-3f6c1b298b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0272a909-02cf-4793-98a3-5247c7da847e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0272a909-02cf-4793-98a3-5247c7da847e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightGrantDateFairValue_14858ad2-1d73-4103-b77a-8ecb53931587" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightGrantDateFairValue_14858ad2-1d73-4103-b77a-8ecb53931587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_aa40cec3-4a82-42d0-95c4-84f91b9f79c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_aa40cec3-4a82-42d0-95c4-84f91b9f79c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_20838771-2c8d-47d7-a606-6c7cd3bc92a2" xlink:href="beat-20231231.xsd#beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_20838771-2c8d-47d7-a606-6c7cd3bc92a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_364ba976-03f0-4e90-9517-b288059c039a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_364ba976-03f0-4e90-9517-b288059c039a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExpirationPeriod_9d18d5f8-a526-41d4-831c-a010708855be" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightExpirationPeriod_9d18d5f8-a526-41d4-831c-a010708855be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_fb48686e-e0ad-4dd6-bb2a-3e70037d0c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_fb48686e-e0ad-4dd6-bb2a-3e70037d0c88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercised_a8ce6e43-b68c-4ea2-b86d-dba79b38d698" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExercised_a8ce6e43-b68c-4ea2-b86d-dba79b38d698" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_551bf5f7-9f4b-4b1b-b0c6-9676a546f866" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_551bf5f7-9f4b-4b1b-b0c6-9676a546f866" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_505e05b8-6997-461d-963e-85d6c6220d9e" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_505e05b8-6997-461d-963e-85d6c6220d9e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_dd973b7c-0fd0-487c-85b9-2a06a4270dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_dd973b7c-0fd0-487c-85b9-2a06a4270dde" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_8d2592f1-2bae-4f52-8f67-2562453e8d53" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercisedForCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_8d2592f1-2bae-4f52-8f67-2562453e8d53" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_3b7785b8-975a-4ce5-a719-e27d6441d118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_3b7785b8-975a-4ce5-a719-e27d6441d118" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5baa449f-093c-4fdf-bb67-793f4b544ce1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:to="loc_us-gaap_PlanNameDomain_5baa449f-093c-4fdf-bb67-793f4b544ce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:to="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2015EquityIncentivePlanMember_99134c31-0f32-4a54-8df5-0d192bf03eea" xlink:href="beat-20231231.xsd#beat_A2015EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:to="loc_beat_A2015EquityIncentivePlanMember_99134c31-0f32-4a54-8df5-0d192bf03eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2022EquityPlanMember_e0364cf5-6997-4865-86e2-f8223409ed49" xlink:href="beat-20231231.xsd#beat_A2022EquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:to="loc_beat_A2022EquityPlanMember_e0364cf5-6997-4865-86e2-f8223409ed49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4db25176-39d9-4851-8218-06834805b595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4db25176-39d9-4851-8218-06834805b595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2b910ab7-89a3-44da-8ce9-8fbf0249db1b" xlink:href="beat-20231231.xsd#beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2b910ab7-89a3-44da-8ce9-8fbf0249db1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f10f81dc-69b4-4c49-917b-fefc27a8e39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f10f81dc-69b4-4c49-917b-fefc27a8e39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_97cfddb7-523f-408d-8e1a-b548f16c8cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_97cfddb7-523f-408d-8e1a-b548f16c8cdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6bf79d03-ec65-4ed0-ada5-5e8967ca9016_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6bf79d03-ec65-4ed0-ada5-5e8967ca9016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ExecutivesAndEmployeesMember_b55289c9-253e-4faa-bfba-3f09d46aa466" xlink:href="beat-20231231.xsd#beat_ExecutivesAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:to="loc_beat_ExecutivesAndEmployeesMember_b55289c9-253e-4faa-bfba-3f09d46aa466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:to="loc_us-gaap_VestingDomain_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:to="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6fe3eb81-1ac7-4971-8bb7-5cb6df1eebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6fe3eb81-1ac7-4971-8bb7-5cb6df1eebdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7f6c40a3-376b-4011-b6d6-5a9bc21a10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7f6c40a3-376b-4011-b6d6-5a9bc21a10c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c5e82589-fdeb-4248-a3e4-d06e2b01bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c5e82589-fdeb-4248-a3e4-d06e2b01bfd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_ad7bd6ae-c6cb-4e29-8365-738c64c549ad" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_ad7bd6ae-c6cb-4e29-8365-738c64c549ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_f5be4865-4203-4ae1-8ab3-7ae1302458fa" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_f5be4865-4203-4ae1-8ab3-7ae1302458fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_47bdb958-a92e-4c56-a61d-cccaf62acc11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_47bdb958-a92e-4c56-a61d-cccaf62acc11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f97e3b95-355c-4a1b-887c-ed48e1e24733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f97e3b95-355c-4a1b-887c-ed48e1e24733" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_733895e7-d222-4d17-a11c-33bce5e44bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_733895e7-d222-4d17-a11c-33bce5e44bd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280dd7fa-252a-43f7-95aa-fb44922c00e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280dd7fa-252a-43f7-95aa-fb44922c00e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91bbad73-e943-4aa3-aeac-96fbaa9236e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91bbad73-e943-4aa3-aeac-96fbaa9236e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_759aed5c-20e5-4ea8-858c-bded315c1eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_759aed5c-20e5-4ea8-858c-bded315c1eab" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:to="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd59fa66-025f-4d06-b34c-2ebc15802bdf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:to="loc_srt_RangeMember_fd59fa66-025f-4d06-b34c-2ebc15802bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:to="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92829fc2-1457-4f27-bbfc-2b30a5975b22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:to="loc_srt_MinimumMember_92829fc2-1457-4f27-bbfc-2b30a5975b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7e7cf02-ffa2-45c3-a853-ad7ed757092b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:to="loc_srt_MaximumMember_b7e7cf02-ffa2-45c3-a853-ad7ed757092b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:to="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c92ebd2-521f-4aef-aac2-43499be5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c92ebd2-521f-4aef-aac2-43499be5e392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_542512fd-4c52-4f6e-a8b4-7b4b14fc5ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_542512fd-4c52-4f6e-a8b4-7b4b14fc5ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd2fde82-8db6-4e5d-a286-5273ee54e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd2fde82-8db6-4e5d-a286-5273ee54e4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c9d1ec5-93ba-4302-bc74-e3597b72922e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c9d1ec5-93ba-4302-bc74-e3597b72922e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2b7cbf24-ce89-4e84-b430-3a50ae3b70dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2b7cbf24-ce89-4e84-b430-3a50ae3b70dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_064cb814-4c80-4de7-b6dd-f4c591090e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_064cb814-4c80-4de7-b6dd-f4c591090e52" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:to="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc37c4df-2c13-4e11-9250-2debcdda0457_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc37c4df-2c13-4e11-9250-2debcdda0457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_72e3c24d-f990-4c8d-9189-d221cc9eb7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_72e3c24d-f990-4c8d-9189-d221cc9eb7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73c5edd7-2720-48cc-9497-db8897ea155b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73c5edd7-2720-48cc-9497-db8897ea155b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97c985c0-c7b1-4265-ba58-066084c0f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97c985c0-c7b1-4265-ba58-066084c0f6bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7df1b704-e168-4dd9-b076-8d352cff15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7df1b704-e168-4dd9-b076-8d352cff15cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72a6de4f-ccdc-4181-ad5f-04e61186d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a9aff7-7908-4213-b722-97bf80ab84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a9aff7-7908-4213-b722-97bf80ab84d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d5050a1-887c-41c1-80ea-5410a569706d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d5050a1-887c-41c1-80ea-5410a569706d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_65a8eb4a-862e-456f-99fb-633c675289d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_65a8eb4a-862e-456f-99fb-633c675289d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8950fc3-cc29-4ce5-a5ec-6c12fe268697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4313ecdb-b691-4564-9d0f-b3f098f3aba3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4313ecdb-b691-4564-9d0f-b3f098f3aba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3a024efe-0a6c-4714-b08c-1fa7ec99a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3a024efe-0a6c-4714-b08c-1fa7ec99a3f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_133928be-ca0a-446b-b578-da1f37ffa324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_133928be-ca0a-446b-b578-da1f37ffa324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:to="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12998b65-d426-436b-9e1b-d0cbca8129e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12998b65-d426-436b-9e1b-d0cbca8129e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_73e05187-e267-43f1-a373-4fdd97f79646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_73e05187-e267-43f1-a373-4fdd97f79646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd8e84c8-a506-43a6-8306-aa14139ab9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd8e84c8-a506-43a6-8306-aa14139ab9e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e59d0f79-e9b6-47f0-a0ff-16ce62585e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e59d0f79-e9b6-47f0-a0ff-16ce62585e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ac5abeb-b062-4c16-b944-fd0f77bdd2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ac5abeb-b062-4c16-b944-fd0f77bdd2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e39de886-202e-425f-80a0-629dbacfa136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e39de886-202e-425f-80a0-629dbacfa136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_febe2a08-d09f-4810-9c7e-223ba4b8ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_febe2a08-d09f-4810-9c7e-223ba4b8ee5d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b95e67c-9da9-4016-9369-88cb76fe199d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:to="loc_us-gaap_RelatedPartyDomain_5b95e67c-9da9-4016-9369-88cb76fe199d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:to="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_cc89377f-3ffc-48a4-a80c-c356738d791b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:to="loc_us-gaap_RelatedPartyMember_cc89377f-3ffc-48a4-a80c-c356738d791b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1470867e-8fa4-4f99-aaff-c7d447dfef48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1470867e-8fa4-4f99-aaff-c7d447dfef48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b36bd78-e9c6-44bb-a6a9-04bc0e0cdc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b36bd78-e9c6-44bb-a6a9-04bc0e0cdc20" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/COMMITMENTSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#COMMITMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/COMMITMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:to="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c29bd75-c273-4d12-8493-e91f81b6be67_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c29bd75-c273-4d12-8493-e91f81b6be67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LIVMORMember_04ff45a7-c3a6-48ce-938a-8d628477ca45" xlink:href="beat-20231231.xsd#beat_LIVMORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:to="loc_beat_LIVMORMember_04ff45a7-c3a6-48ce-938a-8d628477ca45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TripleRingTechnologiesMember_b79821db-a081-4a83-a9c6-5454556cf89e" xlink:href="beat-20231231.xsd#beat_TripleRingTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:to="loc_beat_TripleRingTechnologiesMember_b79821db-a081-4a83-a9c6-5454556cf89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation_aa8f3566-e887-43aa-b82b-e955211ff591" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeasePriorNoticeForCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation_aa8f3566-e887-43aa-b82b-e955211ff591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeaseMonthlyRentExpense_13fddad4-75c7-459b-83fa-fa66d555285a" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_LesseeOperatingLeaseMonthlyRentExpense_13fddad4-75c7-459b-83fa-fa66d555285a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_926ace16-5246-4a1c-a460-c893311a4cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_OperatingLeaseCost_926ace16-5246-4a1c-a460-c893311a4cd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6e0914c8-2bbb-46f0-a568-77f34e562b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_PurchaseObligation_6e0914c8-2bbb-46f0-a568-77f34e562b21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PaymentsForPurchaseObligations_fe3dd1d9-7c0a-4e3c-a4a8-be3ca42814e9" xlink:href="beat-20231231.xsd#beat_PaymentsForPurchaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_PaymentsForPurchaseObligations_fe3dd1d9-7c0a-4e3c-a4a8-be3ca42814e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_688afbe5-36e2-47bf-aa39-63fa21b97730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_688afbe5-36e2-47bf-aa39-63fa21b97730" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_80f58307-bb9c-4259-90f2-592e6a0d1b07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_80f58307-bb9c-4259-90f2-592e6a0d1b07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_594c5327-2299-469e-ba1a-13f59443f9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:to="loc_us-gaap_DomesticCountryMember_594c5327-2299-469e-ba1a-13f59443f9a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_33e76233-ce24-4a4a-976f-5899a9d363cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_33e76233-ce24-4a4a-976f-5899a9d363cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b6052df2-8de8-4b7a-9f12-be31017dbb68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:to="loc_us-gaap_TaxPeriodDomain_b6052df2-8de8-4b7a-9f12-be31017dbb68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:to="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsPriorTo2018Member_c2e09345-cc9f-4b2b-b69d-a5bdbe4552be" xlink:href="beat-20231231.xsd#beat_TaxPeriodsPriorTo2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:to="loc_beat_TaxPeriodsPriorTo2018Member_c2e09345-cc9f-4b2b-b69d-a5bdbe4552be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsAfter2017Member_b6f3333a-8fac-4fc6-8278-89d4f1f7ddf1" xlink:href="beat-20231231.xsd#beat_TaxPeriodsAfter2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:to="loc_beat_TaxPeriodsAfter2017Member_b6f3333a-8fac-4fc6-8278-89d4f1f7ddf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce857fdb-564e-4f66-8d61-d93037f5fdc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce857fdb-564e-4f66-8d61-d93037f5fdc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_57450454-6ad2-4e37-9204-3d9b25c8241e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:to="loc_us-gaap_ResearchMember_57450454-6ad2-4e37-9204-3d9b25c8241e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_aac2f56d-92aa-456c-8a49-256abb80e657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_aac2f56d-92aa-456c-8a49-256abb80e657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8a4d921b-9c74-4101-8fce-8cfa287ff4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8a4d921b-9c74-4101-8fce-8cfa287ff4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d82d193a-7a8f-4788-86b6-16a299bd3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d82d193a-7a8f-4788-86b6-16a299bd3cb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a12e0dc3-3ed4-4fe3-be2f-cb47e04c4e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a12e0dc3-3ed4-4fe3-be2f-cb47e04c4e0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2b77d1ba-2826-4a45-93d9-60bd7440eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2b77d1ba-2826-4a45-93d9-60bd7440eb31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_b57a6c1d-d199-47da-9a11-5ebe133aa5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_b57a6c1d-d199-47da-9a11-5ebe133aa5bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_573c22b9-5f6f-4994-ac35-45521885374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_573c22b9-5f6f-4994-ac35-45521885374e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3303369a-a18f-4814-9f5c-652bc52d1107_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:to="loc_us-gaap_PlanNameDomain_3303369a-a18f-4814-9f5c-652bc52d1107_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:to="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2022EquityPlanMember_180ae276-c82d-4083-8792-86f9487b882a" xlink:href="beat-20231231.xsd#beat_A2022EquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:to="loc_beat_A2022EquityPlanMember_180ae276-c82d-4083-8792-86f9487b882a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e96b8682-c4db-439e-af95-14e03283cd66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e96b8682-c4db-439e-af95-14e03283cd66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3619113a-a255-40c9-b233-a9a8042b7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:to="loc_us-gaap_SubsequentEventMember_3619113a-a255-40c9-b233-a9a8042b7ce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_caed7f25-ebb6-4518-8597-6c39f81a4a24_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:to="loc_srt_ScenarioUnspecifiedDomain_caed7f25-ebb6-4518-8597-6c39f81a4a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:to="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bde29748-80c4-4dc1-9734-5b36945aa552" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:to="loc_srt_ScenarioForecastMember_bde29748-80c4-4dc1-9734-5b36945aa552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f748ac61-6f2f-4543-9fea-b67ac605046a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f748ac61-6f2f-4543-9fea-b67ac605046a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClinicalResearchOrganizationMember_3b411395-0498-40bf-ab4f-b864f4662232" xlink:href="beat-20231231.xsd#beat_ClinicalResearchOrganizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:to="loc_beat_ClinicalResearchOrganizationMember_3b411395-0498-40bf-ab4f-b864f4662232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_385bfc1f-0b48-4c7d-aee9-40c7df68bd61" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_385bfc1f-0b48-4c7d-aee9-40c7df68bd61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b6a4b3e-1290-41f9-aa35-ab3f51734d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b6a4b3e-1290-41f9-aa35-ab3f51734d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91903527-05aa-4f5b-8efa-07e2a809026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91903527-05aa-4f5b-8efa-07e2a809026f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_81509ba8-ec36-4d33-a30a-a992f9e8473d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ContractualObligation_81509ba8-ec36-4d33-a30a-a992f9e8473d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_7c18beae-0df4-42ab-a8df-286774d9f65b" xlink:href="beat-20231231.xsd#beat_ResearchAndDevelopmentNumberOfClinicalStudySites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_7c18beae-0df4-42ab-a8df-286774d9f65b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53f1ac50-480d-4057-a929-7954023ad808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53f1ac50-480d-4057-a929-7954023ad808" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>beat-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityVoluntaryFilers_72d5bc95-e6b9-4754-9529-8be9a9c33da4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3d938772-f962-43b5-acc4-a873a2ead212_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7f90cb82-1b4a-4884-b416-a102f5840a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_06690aae-f524-46d9-ba2f-42f3248b7c0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_e6d7a8a3-9582-4e6a-ac97-19346ac52180_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_f5002cfa-e27b-40bc-95de-1b0027e0bbd5_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:to="lab_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5b766a1-db9c-4ac7-906c-dc8ac608212d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f4545a2-c33a-4307-a192-4299def9dd75_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_db02c9dd-f048-4947-b024-baa431bd7f9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_f47dbf29-bfa3-484f-a386-e93186f6a616_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental common shares attributable to dilutive effect of equity forward agreements (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_bbc07db7-992b-4087-ba78-e1668048ee25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSE</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ExecutivesAndEmployeesMember_f5a65b70-7027-4dfa-9779-6246df4b654a_verboseLabel_en-US" xlink:label="lab_beat_ExecutivesAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Executives and Employees</link:label>
    <link:label id="lab_beat_ExecutivesAndEmployeesMember_label_en-US" xlink:label="lab_beat_ExecutivesAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executives And Employees [Member]</link:label>
    <link:label id="lab_beat_ExecutivesAndEmployeesMember_documentation_en-US" xlink:label="lab_beat_ExecutivesAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executives And Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ExecutivesAndEmployeesMember" xlink:href="beat-20231231.xsd#beat_ExecutivesAndEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ExecutivesAndEmployeesMember" xlink:to="lab_beat_ExecutivesAndEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife_43334270-f50f-4c08-b880-02e73648b801_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Life</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWeightedAverageRemainingLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:to="lab_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_PennyWarrantMember_a76e5d34-4624-46bc-8146-ca9a583e7b3f_terseLabel_en-US" xlink:label="lab_beat_PennyWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penny Warrant</link:label>
    <link:label id="lab_beat_PennyWarrantMember_label_en-US" xlink:label="lab_beat_PennyWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penny Warrant [Member]</link:label>
    <link:label id="lab_beat_PennyWarrantMember_documentation_en-US" xlink:label="lab_beat_PennyWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penny Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PennyWarrantMember" xlink:href="beat-20231231.xsd#beat_PennyWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_PennyWarrantMember" xlink:to="lab_beat_PennyWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_6d3e8adc-3f1f-41d6-acb7-0391e7a733a6_terseLabel_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual increase of shares authorized (in shares)</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_076847de-0cea-4a89-8f93-92a56000bb85_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0c5092da-daf0-4193-89b2-9476163876f9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_79cf0917-fa0a-4a09-94a6-48656d4a8e0b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_PaymentsForPurchaseObligations_b4e90c27-eedf-4558-8b0f-10d9f1fd9a10_terseLabel_en-US" xlink:label="lab_beat_PaymentsForPurchaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for purchase obligations</link:label>
    <link:label id="lab_beat_PaymentsForPurchaseObligations_label_en-US" xlink:label="lab_beat_PaymentsForPurchaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Purchase Obligations</link:label>
    <link:label id="lab_beat_PaymentsForPurchaseObligations_documentation_en-US" xlink:label="lab_beat_PaymentsForPurchaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Purchase Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PaymentsForPurchaseObligations" xlink:href="beat-20231231.xsd#beat_PaymentsForPurchaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_PaymentsForPurchaseObligations" xlink:to="lab_beat_PaymentsForPurchaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_43d7a08f-e536-4d6b-83a9-b5bd95dc00ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7c85e913-35bd-43e1-9a2d-40eea0eec835_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_068f8864-0c4f-4012-99b5-daeff69cfb94_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d093d229-bb05-4081-8d30-5526c7a85bac_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_226f10fb-df89-441d-803b-8014df0f2b78_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_937d9ccc-6b09-406c-87a8-599bb077cd1a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_94341bae-bee8-434e-9a6b-aa441f4abe5c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ba128882-f05d-4d73-8f6a-ac96f0845325_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35963fdb-dc2e-42b4-82e7-8221dd389702_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate (as the percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_61b70fb3-106b-4c41-93a6-f93764b77f29_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c035678d-7784-40a0-82f8-1ed4aa63453b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_531a1cf2-a3ec-4bf8-91d6-58e6002ba827_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c2e1bab4-8b1f-47b9-9da2-b51de82dc704_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4663fcfa-2473-4d71-b089-5e897fc5fd71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at December&#160;31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_55bc62a3-b1a8-469f-abab-90d7c5c41332_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eec4d11e-fcf4-4f2b-bc63-a0107a1aa0f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_0a949814-d190-446b-b8bd-774b6e89319a_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, warrants, cashless exercise, warrants utilized</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants, Cashless Exercise, Warrants Utilized</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants, Cashless Exercise, Warrants Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_77007c4b-0732-4345-907a-b02d47d7a8d2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_f60ca3cb-5777-4155-89d5-1d357061e710_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8367bedb-181d-497c-9666-c96a872dcf6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5c33b53-281f-425d-9a77-d4986e6cd157_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f032ff98-daad-49c1-ada5-44a85d0d5558_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance upon vesting and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cd353488-96b7-4e3d-afe4-5c8424ea2dcc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ae46d9ac-123b-4499-a15b-5e2bd114ff1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_51296ce3-5730-4ba4-8855-51038771aa68_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8930fad8-ad29-4081-a28e-b9714e1b2d28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d5630215-8cc0-4029-876b-2b9997503b30_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ff12da4e-545c-4497-8497-84169593556a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_026b6ca3-d568-4514-8cd2-b898e411011d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_894084e9-adef-44c1-83f5-42c7596a22d7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_77f326b5-3251-4d8d-85f4-fde75ad847f8_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_10ead0cf-1124-44ac-8db1-83db711d763d_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, warrants exercised for cash</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised For Cash</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised For Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercisedForCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsExercisedForCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6d13a198-aa9a-4c1b-b569-72e3e07cbcce_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd9cbdbc-cba5-4a58-8ffe-2c76f784d636_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1aef784-5910-4b0b-a0ee-a2594c3b8b14_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c3a6b9a6-4ba0-4b95-bd13-c56befb16789_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments from related parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7d6828b5-db9c-4b8c-b454-3ad1cdaa1bd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c89e8e7-13fd-433e-bbf3-1bb6125d6882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9269155a-468b-4283-a613-f9197bdc6be1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_8fc004e1-1d3e-4837-8437-f83fef7118de_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:to="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c349e418-d345-4739-b251-c24fc9b822f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2ec93de4-1395-4e91-9fdf-fe33807821db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_0b9dd256-54cf-40ab-9196-352adcb92830_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7dddb90-c532-420c-89d6-84aaaf21d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0abf8760-174e-4b71-9ac4-6473960c23d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_de6038c9-031a-4e78-864c-899a08ca70e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_1b2aa0a0-39c0-43f9-9b58-9c696c4d7d3f_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, warrants, cashless exercise</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants, Cashless Exercise</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants, Cashless Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsCashlessExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7ad23b39-46a7-4a10-861b-0dd407c1a40a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_0a36d484-9795-4b3b-83e6-18be4ff5611c_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining life (years)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life [Abstract]</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:to="lab_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockMaximumAmountAuthorized_e014852d-8983-4760-bc76-03690ece8f35_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum amount authorized</link:label>
    <link:label id="lab_beat_SaleOfStockMaximumAmountAuthorized_label_en-US" xlink:label="lab_beat_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Amount Authorized</link:label>
    <link:label id="lab_beat_SaleOfStockMaximumAmountAuthorized_documentation_en-US" xlink:label="lab_beat_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockMaximumAmountAuthorized" xlink:href="beat-20231231.xsd#beat_SaleOfStockMaximumAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockMaximumAmountAuthorized" xlink:to="lab_beat_SaleOfStockMaximumAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cac39f95-5e2a-429d-9252-898ec15d0195_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_40055304-5094-4162-a189-7b6689714ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernLineItems_3a47d66c-b647-4e06-963b-97665c8675a4_terseLabel_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Line Items]</link:label>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernLineItems_label_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Line Items]</link:label>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernLineItems_documentation_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:to="lab_beat_SubstantialDoubtAboutGoingConcernLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1b047d48-00c6-442c-aa32-5e7cfadf0940_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c811a183-11ef-4c6f-a008-595a322144ef_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_02a121d5-b175-4ca0-8a87-a284a6bbf9cd_terseLabel_en-US" xlink:label="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock purchased</link:label>
    <link:label id="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_label_en-US" xlink:label="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Purchased With Warrants</link:label>
    <link:label id="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_documentation_en-US" xlink:label="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Purchased With Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:href="beat-20231231.xsd#beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:to="lab_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightTerminationPeriod_ce55d506-0070-443e-843b-e20077c8ab49_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period which warrants are exercisable (in years)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightTerminationPeriod_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Termination Period</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightTerminationPeriod_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:to="lab_beat_ClassOfWarrantOrRightTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8e1d99d9-40ec-4d9c-bff7-c1eeea9623f9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_646322d0-65d9-4c53-ba9f-643d393a89f3_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_b235dd2e-e8fe-497a-bb6b-79a99e751d11_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3e459799-52d8-4d7a-96e5-b096c4e453fe_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8bcdf9b1-db43-4aa9-898d-05482cc07c2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_b10f35cc-0e59-41c2-9782-011ac9b155c0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_658cfdcb-d4b0-481a-b049-01bf179c82f9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_56fb2e46-961d-42a1-a328-cc3750a68c68_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c5a74359-cee5-4bdd-864c-fd7f388d49c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsIssued_76bf5f45-6236-44d9-bef0-e2b76ddf805f_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsIssued_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Issued</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsIssued_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_05acfbcc-700b-49c3-8f7a-6f12b20a3e27_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_5baa2e3b-c8d8-49a1-990b-bb5bbe85b7c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercised_80c6fb42-8456-4803-ace8-c2a4ba09b03c_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercised_c9112635-dc07-4d0f-903a-393f1c1c4862_negatedLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercised_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExercised_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_9457a269-df0b-45c9-a71a-41a51f36fa16_verboseLabel_en-US" xlink:label="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount available for issuance</link:label>
    <link:label id="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_f2087d88-208d-41e0-83b2-cd7db6e3f29b_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, remaining amount authorized for issuance</link:label>
    <link:label id="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_label_en-US" xlink:label="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Amount Authorized For Issuance</link:label>
    <link:label id="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_documentation_en-US" xlink:label="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Amount Authorized For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:href="beat-20231231.xsd#beat_SaleOfStockRemainingAmountAuthorizedForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:to="lab_beat_SaleOfStockRemainingAmountAuthorizedForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock_75ebc396-b9b1-45d4-ba4b-46e7a1c56508_terseLabel_en-US" xlink:label="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCOUNTING FOR WARRANTS</link:label>
    <link:label id="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting For Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting For Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:href="beat-20231231.xsd#beat_AccountingForWarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:to="lab_beat_AccountingForWarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b8e4b6e6-b17d-4e1c-9442-bfb4c4d82e4d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d0a9ee08-1dce-47e7-bb26-307797aad8d3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_b80bdb6b-8d12-4a43-ab0d-2af85144d4cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOING CONCERN AND OTHER UNCERTAINTIES</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_728e742a-3c00-4339-85df-0f627bf26e63_terseLabel_en-US" xlink:label="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec. 174</link:label>
    <link:label id="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label id="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="beat-20231231.xsd#beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExpired_cd254ece-004c-45c9-8926-5d56fcd3dc8d_negatedTerseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExpired_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Expired</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightWarrantsExpired_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:to="lab_beat_ClassOfWarrantOrRightWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0251d773-fb3a-4409-9d3a-437a249d90c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3b1ceeb4-5b43-4a18-bd82-e66b677b3ace_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f3ee8d1-3538-4806-800f-395c9afc6255_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b2e0df3c-1939-4ca5-b144-a7c1b845fccc_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3471f67d-e72c-4450-87b9-5fb522e62da8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f1675e1-aa27-4e99-99c5-d3a8cf2df91b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_db8e968a-eee1-4c38-9c2e-3eb65cc1abb8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fe696775-5710-4862-b71e-d741079eb49a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_3cf72409-ffad-489f-bf8a-fb64e79c8644_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_12eda342-fbed-44b8-89e6-ff1513c3c6f6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administration</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_33ba6dd3-8094-4f95-9a98-4dd515dc65af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4fd2a6b7-e9a2-4a60-ae8b-8b170e97a8e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6d4cc3c0-eb0a-4d86-81c5-9d98e0156f96_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fe946ad3-d72c-47dc-a960-33cfed8e3b1e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USE OF ESTIMATES</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_26503052-4e6f-47d3-920d-00770198e5b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_31489c9a-d52c-4e7c-b9c7-4e2fe37b04cd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08ed5ed6-50e2-4f65-9576-9fad9e0cf316_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_04558966-c9c8-425c-a251-2b48996aa78b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_06a69700-165b-4ec6-9392-a2bd7bb89c27_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_233359ee-6986-4eed-a960-db8d6bfedd5c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RECENTLY ISSUED ACCOUNTING STANDARDS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a6a214ba-c406-4878-8882-698559c2ad22_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_859f1195-b568-4c7e-9b20-6e795c12a800_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_030f0037-82a8-4a2e-9bb9-ba504c08b999_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash - at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73edad08-26bf-43f8-9416-888830ca957a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d42ea794-c085-457a-9bce-b7b8f41823ff_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in IPO, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_76dde6bf-0462-43d3-aafe-d89e469b120f_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4e75d32b-60ef-4168-8592-dc68c299b6fa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_536eb997-11d6-49f1-b63a-babccbc48227_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9bd0446f-20bd-48e8-8eeb-39866304ba05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b4c4b861-4705-46d3-af9e-f053cb7ef418_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_4e20c096-3f0f-4557-80a4-6ce62b27448b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0b679592-6562-419f-9c92-ac8eb0322f76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_67bac5b5-78b4-4fa0-b2ed-99c4288ab97b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_678f7708-6d1f-4671-9534-87368ef47040_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_188e8e26-646d-47f0-9eaa-5a9bf5918ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation_362b5af7-dd92-44af-8c28-62e04458ea77_terseLabel_en-US" xlink:label="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, prior notice for cancellation</link:label>
    <link:label id="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation_label_en-US" xlink:label="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Prior Notice For Cancellation</link:label>
    <link:label id="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation_documentation_en-US" xlink:label="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Prior Notice For Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeasePriorNoticeForCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:to="lab_beat_LesseeOperatingLeasePriorNoticeForCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bd807071-27cd-45e3-ad43-d4b4a32b3952_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2aab752f-5469-4154-ad6a-5a63fa07995e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share-based compensation arrangement vesting (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_147b9ae8-4cf0-4887-a356-2590e17e3fc1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_4e05031b-2c71-4e5b-a4c5-b1916c7071bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_a7509813-db22-408e-9274-f838b136e4fb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be5ee331-1cc0-42e0-a497-ef7c4ccef02d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_04452647-ea31-4c1c-81c3-2eabaeac4b36_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_CertainInvestorsMember_27da65d9-db09-43a1-8834-1c4797c46eb1_terseLabel_en-US" xlink:label="lab_beat_CertainInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Investors</link:label>
    <link:label id="lab_beat_CertainInvestorsMember_label_en-US" xlink:label="lab_beat_CertainInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Investors [Member]</link:label>
    <link:label id="lab_beat_CertainInvestorsMember_documentation_en-US" xlink:label="lab_beat_CertainInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_CertainInvestorsMember" xlink:href="beat-20231231.xsd#beat_CertainInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_CertainInvestorsMember" xlink:to="lab_beat_CertainInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_efe49bb1-4fbf-4cf4-941e-c4c06051f4bc_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f01b70c7-848d-43be-acb7-36d10439f686_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_OpenSkyOpportunitiesFundLtdMember_a3b45953-7c9b-4998-92ab-65af06c1bd5d_terseLabel_en-US" xlink:label="lab_beat_OpenSkyOpportunitiesFundLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OpenSky Opportunities Fund Ltd.</link:label>
    <link:label id="lab_beat_OpenSkyOpportunitiesFundLtdMember_label_en-US" xlink:label="lab_beat_OpenSkyOpportunitiesFundLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OpenSky Opportunities Fund Ltd. [Member]</link:label>
    <link:label id="lab_beat_OpenSkyOpportunitiesFundLtdMember_documentation_en-US" xlink:label="lab_beat_OpenSkyOpportunitiesFundLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OpenSky Opportunities Fund Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_OpenSkyOpportunitiesFundLtdMember" xlink:href="beat-20231231.xsd#beat_OpenSkyOpportunitiesFundLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_OpenSkyOpportunitiesFundLtdMember" xlink:to="lab_beat_OpenSkyOpportunitiesFundLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_33badfe7-741d-4fac-99d2-1b0bc1e3b201_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ec5bd7e4-0cf5-4671-80db-5ccc885ee390_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_25e2856d-65cf-4e81-ace7-690e36bfc993_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ab975465-6053-4c56-ac06-877650bb7b89_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3f4fda5c-7c80-489b-a040-fac9a592e74f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_58ec6fe6-e9b8-43a6-a001-01e5b691385c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90e2260f-028b-4832-acb7-706ae53bae6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_64ddb85d-23ea-4204-a818-e0647cc3e16f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS&#160;OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e9bd2b3-5174-46a9-accc-5490f54bf1e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisable_7c566751-4d46-491a-a379-fe37a6997f4a_periodStartLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercisable, beginning balance (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisable_580b0c43-61b8-4c14-99f2-d21f73876f79_periodEndLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisable" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisable" xlink:to="lab_beat_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_54604ff1-8193-447d-8f29-0a801b9bc092_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4e2bdff2-c2e1-4ccf-8a94-1f236343aeb3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_a34b5541-8c5f-400c-b013-16db55afb25a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash (included in other assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6412fc5c-897a-419d-97ab-96bb4fd054ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_186039b4-fc7c-4ec5-a2c5-7044135a4456_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e0f566b3-ebf3-43d7-8b9a-bb4c49b1f62b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Common Stock &amp; warrants, net of fees and issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_305bf2a2-4d90-4e9d-b57d-d30da786d7d7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock &amp; warrants, net of fees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3df7c938-9336-4811-bc0b-56f749de810e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9159997-0bdd-44b2-ab5c-35572b061455_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e82f9ea0-7282-49df-bc48-6e5ac41c5a6f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b5eaad17-8958-4c04-bd6c-e0da40dc37ea_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_ba6f305e-2497-4938-bdf9-53ebccfa93e1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1c3a9e25-3100-4231-8210-3331b8b0aec2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-Vested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5775ddeb-0c44-45d1-96a3-506b8067f7aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_40556c32-14d7-4640-8659-fd421ef5f21a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf1ab225-a21f-4f29-b477-f095d812a268_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a2d24467-57cd-4e62-a7b6-921880a0fecb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_afb6bed2-9359-4b16-aabd-9c881fa2b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c10b18f4-3a4a-41e4-ac93-1e8bfc4acca6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExpirationPeriod_2766d9b4-55cc-4591-be7c-5c35413062f4_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration period (in years)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExpirationPeriod_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_beat_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e5b5accd-fa87-4675-a3cf-af51a5d3febb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef07e1a9-6907-44e6-9ca3-eeb1a8ad81c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_276f26f7-af8f-46ee-9c06-ceedadc99f75_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3fb1085c-c50e-458b-833d-ba95098b3120_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_193a75bb-d5b3-4796-97aa-8db9cb6ae8a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Non-cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5c0e1aa-f5a4-4069-b4cd-04dab19415df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0b51c99c-bae3-4f49-84d5-950e4580dfda_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_53316f1b-c973-4695-b006-4e09c236c9fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4d5041a8-d616-45a5-b70a-4529775ba489_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_42d07c84-fa54-4f61-be17-8dc1c7e2c313_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bcd33cfe-5cf4-4b21-839a-db1497f728f9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bfab5d34-c389-4a20-b21b-d38deadaa347_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7c42c673-bf1f-4236-8484-38a014429e7c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_66566770-81f6-44e3-84cd-d7404f63cc40_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant_b93ed102-ade3-4bfd-913e-1814442f224d_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant fair value (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Per Warrant</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Per Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValuePerWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:to="lab_beat_ClassOfWarrantOrRightFairValuePerWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768e0abd-d63f-4cf2-a742-9940f6524964_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_a88f5fe7-0551-4fe8-b17b-2d2dbaccade4_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d5a2666-63de-46a0-bcfc-849e3239f7d7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6b2e4ed7-691c-4799-9f7f-e734bd4947de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_b60cee85-8707-4ef4-a599-233d5c952bc8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_StockAndClassOfWarrantOrRightIssued_f1e9ba5b-e3d2-4cd6-8dde-58eff947a2c0_terseLabel_en-US" xlink:label="lab_beat_StockAndClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and warrants to settle accrued expenses</link:label>
    <link:label id="lab_beat_StockAndClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_beat_StockAndClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock And Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_beat_StockAndClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_beat_StockAndClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock And Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_StockAndClassOfWarrantOrRightIssued" xlink:href="beat-20231231.xsd#beat_StockAndClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_StockAndClassOfWarrantOrRightIssued" xlink:to="lab_beat_StockAndClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_edb2434c-db40-4ef2-9bf0-34ea8c0571f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f56cdb07-dc64-414e-8c6e-2eb20bb717b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_21867a5b-87ae-41e0-a3c3-80053e71967c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_85f7a400-27d2-473a-b464-9da52e69e607_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Remaining Life</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Remaining Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:to="lab_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9d2cead8-1d3a-4566-886a-ae3ad7d312bd_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ca57a4ea-0e1b-46e5-a0d1-8c871582304d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_A2015EquityIncentivePlanMember_b2c870bd-6ace-4013-817c-f578f6c986b0_terseLabel_en-US" xlink:label="lab_beat_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:label id="lab_beat_A2015EquityIncentivePlanMember_label_en-US" xlink:label="lab_beat_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_beat_A2015EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_beat_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2015EquityIncentivePlanMember" xlink:href="beat-20231231.xsd#beat_A2015EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_A2015EquityIncentivePlanMember" xlink:to="lab_beat_A2015EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6aa9d1e1-c5f4-4053-ab1b-2ab1248a6aef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_64f85e32-dfdc-47c0-88ce-a6c93c38d30c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d3a04bf3-efcc-4bce-a71b-ca9937480b05_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcf7434e-f04c-4643-92d0-11025ef9731c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1ad2abdd-f3ee-4c5b-98af-8b9e166f449d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fd58275d-70d3-4c6c-b842-229060e061e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33460c5e-5db5-40be-977d-2ec4d7f5d801_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4665f5a8-b881-4fd1-85f9-6af20004963b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d6dea9ff-27a8-41e4-a578-134f7d2f6665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate (as the percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_48d28d45-7991-4eb0-9b01-b77233156711_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a0d5a328-eb71-4f73-801f-e799a72d8e90_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_d1257d5a-b6f7-40d7-a03e-07603df23faf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_d1b156c4-862d-4bb6-9804-7f9d40c26efa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a64319e8-e8ac-42b7-9731-ed197b2ad427_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_a321451e-35fa-4401-90e8-0eeae643da08_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:to="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c176dd0c-e31f-478a-ad60-2875b4cc94fb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_943f6a9b-4545-4656-bdbb-269822b4de36_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_388b3da2-684e-4f38-a071-5558b1bec7ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - $0.0001 par value; 100,000,000 shares authorized; 26,329,032 and 8,009,743 shares issued and outstanding at December&#160;31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_10f38926-5f67-4ddf-9afa-73c85051a525_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_TripleRingTechnologiesMember_f3bb1f2b-740e-473e-8e2e-3959aa88e724_terseLabel_en-US" xlink:label="lab_beat_TripleRingTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Triple Ring Technologies</link:label>
    <link:label id="lab_beat_TripleRingTechnologiesMember_label_en-US" xlink:label="lab_beat_TripleRingTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triple Ring Technologies [Member]</link:label>
    <link:label id="lab_beat_TripleRingTechnologiesMember_documentation_en-US" xlink:label="lab_beat_TripleRingTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Triple Ring Technologies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TripleRingTechnologiesMember" xlink:href="beat-20231231.xsd#beat_TripleRingTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_TripleRingTechnologiesMember" xlink:to="lab_beat_TripleRingTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding_518b233b-3d04-4e38-9dc3-307025d56381_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercisable, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercisable, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:to="lab_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_93375c79-c9b0-4bc2-952a-d09cb23da9c2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8dc019d4-8090-4267-916e-1d2decbe9c62_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_783c361c-72a0-4211-8dcd-9ff81b2f1ce0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_810f0b03-6a28-4c32-8be0-9b18e62786e3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_7c825aaa-fe15-49cd-ae2b-2ae7c5c87935_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f34297c4-64b0-445b-82a0-8a2b8b54497e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_05a46042-b7a7-4fbd-95d6-555074c80d94_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3b755c66-a048-4e6f-b595-e88b5f9763d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ec138e67-4de6-459b-ae1e-52f974386702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1b8e852b-d3c0-4463-bc42-7690fe5857f7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f9ee59d2-16fa-4d61-a46f-441420eb5c8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ec895cf8-d375-43ca-bae6-6c0c616f031d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_35a598d4-305a-4462-9faa-b2a1b569f920_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d087eb17-037a-4c99-9bc9-30e727165d45_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_abdfc163-6a03-48fc-8096-79724b3d9bc2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_89eeb9d0-cb35-4b96-92eb-89a7918d6bad_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aeda1b73-eb0e-4914-92e7-87625de40dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockPlacementFeePercentage_4ccd40aa-babd-41fa-99ca-46b9572c96cc_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockPlacementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, placement fee, percentage</link:label>
    <link:label id="lab_beat_SaleOfStockPlacementFeePercentage_label_en-US" xlink:label="lab_beat_SaleOfStockPlacementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage</link:label>
    <link:label id="lab_beat_SaleOfStockPlacementFeePercentage_documentation_en-US" xlink:label="lab_beat_SaleOfStockPlacementFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockPlacementFeePercentage" xlink:href="beat-20231231.xsd#beat_SaleOfStockPlacementFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockPlacementFeePercentage" xlink:to="lab_beat_SaleOfStockPlacementFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c9f58cfb-bb95-4932-8513-565ef3d70cc7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_24007cd4-528f-47d9-ac38-084fbe16ec3d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightRollForward_800f1857-8fad-42a3-8501-b073a0c78ff7_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightRollForward_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Roll Forward]</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightRollForward_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightRollForward" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward" xlink:to="lab_beat_ClassOfWarrantOrRightRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_57cdff8e-cc0f-4a3a-9a90-c85261b4a5db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_67719bd7-a841-4154-a82b-e17cd67d5e13_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e40bac52-f1c7-4302-aba1-b1c25980b873_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_9413c3f3-12e6-4936-8393-baee67aff2f8_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND OPERATIONS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_29408e8a-34d5-48ec-bd5f-c514ca45459a_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued per each unit (in shares)</link:label>
    <link:label id="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_label_en-US" xlink:label="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction Per Each Unit</link:label>
    <link:label id="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_documentation_en-US" xlink:label="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction Per Each Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:href="beat-20231231.xsd#beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:to="lab_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_LesseeOperatingLeaseMonthlyRentExpense_2256321e-cc6a-48c8-9729-6a3e427f23df_terseLabel_en-US" xlink:label="lab_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly rent expense</link:label>
    <link:label id="lab_beat_LesseeOperatingLeaseMonthlyRentExpense_label_en-US" xlink:label="lab_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Expense</link:label>
    <link:label id="lab_beat_LesseeOperatingLeaseMonthlyRentExpense_documentation_en-US" xlink:label="lab_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:to="lab_beat_LesseeOperatingLeaseMonthlyRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_65bfc483-e0ac-47c0-8e53-3d3eadf45f3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses (includes related party $2 and $2, respectively)</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeacc5f3-4da6-4ee4-bc58-3a7b4d4ac119_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due to related party</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_3328ae36-f8a1-4062-87dd-1c214f6b9dda_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_4eda320c-2ed2-454c-ba60-50dd489b4641_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d388d087-8c61-4536-887f-9e8d740bc2f9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0ff5d8a5-8f66-41da-b4b8-d00d82ea2b48_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a390cf82-7f18-4c80-9cfc-edcb9fbf7651_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1d01a8cc-c038-46f9-80cd-182cc4b721e3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_b906967c-6210-419e-a888-5f3ae61784ed_terseLabel_en-US" xlink:label="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value (in thousands)</link:label>
    <link:label id="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class OF Warrant Or Right, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class OF Warrant Or Right, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:href="beat-20231231.xsd#beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:to="lab_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b4f5fec3-f9c9-4874-863e-65c6ea26522f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_6db12ae8-075a-4053-83b4-069786afbce1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec03394-6696-4e7b-9dda-8e811c21b59f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_TaxPeriodsPriorTo2018Member_68d48833-3448-4169-82a9-86ea34cd9765_terseLabel_en-US" xlink:label="lab_beat_TaxPeriodsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Periods Prior To 2018</link:label>
    <link:label id="lab_beat_TaxPeriodsPriorTo2018Member_label_en-US" xlink:label="lab_beat_TaxPeriodsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Periods Prior To 2018 [Member]</link:label>
    <link:label id="lab_beat_TaxPeriodsPriorTo2018Member_documentation_en-US" xlink:label="lab_beat_TaxPeriodsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Periods Prior To 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsPriorTo2018Member" xlink:href="beat-20231231.xsd#beat_TaxPeriodsPriorTo2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_TaxPeriodsPriorTo2018Member" xlink:to="lab_beat_TaxPeriodsPriorTo2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86b624e6-138e-4608-bc96-f8c2b157633f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65529735-325f-416c-8533-d96e084e84d6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_817c05c8-31dc-484e-b230-c3be0bfadcb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b9829dd-fb15-4c7d-8c85-d973cc2f0d0a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issuance upon exercise of warrants(in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ed79a3e2-b9e7-48cd-9623-041e63361a5b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_3acd903b-1e50-4695-9827-853d488ac339_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService_5b4b4d3f-ef2e-4941-9350-38bb5d34eb1e_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued for service</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Fair Value, Issued For Service</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Fair Value, Issued For Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValueIssuedForService"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:to="lab_beat_ClassOfWarrantOrRightFairValueIssuedForService" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b65cff2-cb16-4f3f-ab19-5ee071dc4ffb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9af34bd4-6bb0-49b2-ad78-8f378b8947da_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7454b675-f4db-4470-8797-66ccad51141c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_b68dfe2c-6f60-4260-a763-6aa72a3941e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClinicalResearchOrganizationMember_d28bc68f-ec04-40d9-a217-16e034b2fdec_terseLabel_en-US" xlink:label="lab_beat_ClinicalResearchOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Research Organization</link:label>
    <link:label id="lab_beat_ClinicalResearchOrganizationMember_label_en-US" xlink:label="lab_beat_ClinicalResearchOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Research Organization [Member]</link:label>
    <link:label id="lab_beat_ClinicalResearchOrganizationMember_documentation_en-US" xlink:label="lab_beat_ClinicalResearchOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Research Organization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClinicalResearchOrganizationMember" xlink:href="beat-20231231.xsd#beat_ClinicalResearchOrganizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClinicalResearchOrganizationMember" xlink:to="lab_beat_ClinicalResearchOrganizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_67446725-fb4a-4ff8-8a05-ded26e5793b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2a89b185-5207-49fc-984e-ff0971c8e242_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_820ab529-720b-4e36-9358-75a69b747d13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_8ec95761-812f-4fe3-99c2-487e16dd0bd9_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:to="lab_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8f358bc9-0238-4926-9841-0a9dfb3ec775_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_04b0dd1f-b7a2-4fc4-b2ac-79feb884b340_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4a19af6e-7aee-4ddc-a895-d77cbf79b22c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_96239b20-008a-4176-ae2d-23993584ead8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4a8e0ce4-02b9-4f7d-b8e4-9fdf0bc4723b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_970f5baa-bbb8-4286-8760-d4e91e2e48f1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a5284462-b86e-4afe-815b-65c2501ec6a3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2cb8a1af-dc4f-4d98-bdeb-99a1e4071c4e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_4b7d533f-94a3-4bb6-8547-d4cec55bfe52_periodStartLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercisable, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_62997803-9db2-434a-a96d-9dc34fff9d4f_periodEndLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:to="lab_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a39f6489-d2e1-4412-9b06-6c7207e43ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ConsultantsMember_bf7805a7-99cb-4b75-9464-23ee801599b7_terseLabel_en-US" xlink:label="lab_beat_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consultants</link:label>
    <link:label id="lab_beat_ConsultantsMember_label_en-US" xlink:label="lab_beat_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultants [Member]</link:label>
    <link:label id="lab_beat_ConsultantsMember_documentation_en-US" xlink:label="lab_beat_ConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consultants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ConsultantsMember" xlink:href="beat-20231231.xsd#beat_ConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ConsultantsMember" xlink:to="lab_beat_ConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_02d0cd20-37c3-4a1f-9027-6fc96ccdc8fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_99c61826-5d1a-4fe4-b701-233f39001dab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_618d4084-5898-4ec7-a793-40811fec82f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_bfed0988-5a91-4736-bb37-a692dbb057ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f8c9805c-b24f-4996-8de1-ac2245fbc029_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08d0dab4-7cc4-43b3-8e2f-0bed231e5064_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65a080af-a9a5-4642-b6e9-eb949ded0c25_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dbbaad7f-12aa-4fe7-b54f-f021a5be74bf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4d1ed332-fd67-4430-bd7f-d6ab19732d22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_90c2a8ce-253c-4f33-8459-5d1143ab76a1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_51dcaf76-60c7-4e0e-880d-88cb9d7fbadd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c0115a4b-b928-4d6b-baa1-a5fb410f5a97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50a26862-d29c-4463-b2fa-846dd52a0958_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f7d5da15-9d73-4a9a-a23b-943889df7339_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_da955c3e-88c9-48d6-8250-428b3a99fbdc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost not yet recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e76dff9e-fa4a-4408-b2d6-d07cfafccf23_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options (excluding exercisable penny stock options)</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_811a508d-3048-4c54-8446-b0107f4154c2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e4165c8d-7069-4b36-b24d-2ce1c5f27f16_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_704f469e-c9cd-4699-bd32-f696813c69d3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernTable_d20b8c58-c0a9-44d8-8d72-01bf66e9e5b9_terseLabel_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Table]</link:label>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernTable_label_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Table]</link:label>
    <link:label id="lab_beat_SubstantialDoubtAboutGoingConcernTable_documentation_en-US" xlink:label="lab_beat_SubstantialDoubtAboutGoingConcernTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernTable" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable" xlink:to="lab_beat_SubstantialDoubtAboutGoingConcernTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_74cac9a6-c2d6-41f1-a361-8419f5f980e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_b51e54fe-4e02-4d4a-8f71-ea1fd4e12489_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_A2022EquityPlanMember_4b5d8eca-8533-47b4-b8e3-8281b8458cdc_terseLabel_en-US" xlink:label="lab_beat_A2022EquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Equity Plan</link:label>
    <link:label id="lab_beat_A2022EquityPlanMember_label_en-US" xlink:label="lab_beat_A2022EquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Equity Plan [Member]</link:label>
    <link:label id="lab_beat_A2022EquityPlanMember_documentation_en-US" xlink:label="lab_beat_A2022EquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2022EquityPlanMember" xlink:href="beat-20231231.xsd#beat_A2022EquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_A2022EquityPlanMember" xlink:to="lab_beat_A2022EquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7fcb3bef-b65b-4890-b6e3-388d064ec0c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for service</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockAgentCommissionPercentage_83eeb6ac-39f4-48c3-8cb8-ee14fa2d249b_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission fee percentage on each sale (as a percent)</link:label>
    <link:label id="lab_beat_SaleOfStockAgentCommissionPercentage_label_en-US" xlink:label="lab_beat_SaleOfStockAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent, Commission Percentage</link:label>
    <link:label id="lab_beat_SaleOfStockAgentCommissionPercentage_documentation_en-US" xlink:label="lab_beat_SaleOfStockAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent, Commission Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockAgentCommissionPercentage" xlink:href="beat-20231231.xsd#beat_SaleOfStockAgentCommissionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockAgentCommissionPercentage" xlink:to="lab_beat_SaleOfStockAgentCommissionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b5a7c86e-489d-420e-88c7-9f3bd9976074_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e0a5ec0e-8767-459e-b836-a07ce9e47f34_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_77e45263-d6dd-48fe-ba10-634701ef4e1e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6a419466-0c52-4efb-aef4-980115ba2a09_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_dcf88478-bc01-48c8-bbe1-6111a5a56b12_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c58b18a-3f8d-4d50-b8ba-c2edddd8e1d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_50385689-25de-4e6f-8a9e-a5b3ac16ba64_terseLabel_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_label_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares, Nonvested, Number</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_documentation_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:to="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_425ca072-c278-4a8e-909a-8d8db1de5f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total number of outstanding shares of all classes of common stock (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9c2cb08b-51be-4993-80ee-f74f0edfd175_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0bf9267a-4ad6-49bb-864c-91e42dd28178_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_AuditInformationAbstract_label_en-US" xlink:label="lab_beat_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_beat_AuditInformationAbstract_documentation_en-US" xlink:label="lab_beat_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AuditInformationAbstract" xlink:href="beat-20231231.xsd#beat_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_AuditInformationAbstract" xlink:to="lab_beat_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0e5e5713-8a56-474f-a1db-d899f49af4a7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5f274cd3-8f0f-4867-a98e-584f0b536d02_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_41d6e6db-62d3-4d8b-9428-8569c21ccb93_terseLabel_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_label_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value Per Share</link:label>
    <link:label id="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_documentation_en-US" xlink:label="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:to="lab_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_d7429c2a-b3c2-4310-bbdc-e945d820cbc9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38a6a348-e9ef-4776-b589-91947d89b703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0336d480-c124-4a00-b7e3-07e52615c16d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c878c32b-51ce-443a-a9b2-e1d8f3aa9436_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_8d665f31-af28-4d2e-9208-9c7ebabf8489_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction Flag</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cd95835f-f5a3-471d-98ae-06ed2a0738d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c1718524-97a5-4b78-962e-1ac76f23061a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bbf9857e-d142-489b-b31e-2f535f672c6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share based payment awards, exercised in period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4ef716d0-d8cc-49b7-82ed-46b6d9b4564b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_839966cb-9afe-40aa-bef3-d3d8fe44a251_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_225814c9-9e78-4930-aa32-19ec2496cfde_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_7f295c2d-d4e7-4d38-9b0b-64a43e8082b5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f5b04a98-9f9b-4e98-8534-4015498315c3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c40e8840-8657-4ed4-81d2-f4fab03b8fcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_96242f93-c562-445f-9e74-0ab42b046c65_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_TaxPeriodsAfter2017Member_1a565c55-48db-44f6-9ea3-7974f2564317_terseLabel_en-US" xlink:label="lab_beat_TaxPeriodsAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Tax Year 2017</link:label>
    <link:label id="lab_beat_TaxPeriodsAfter2017Member_label_en-US" xlink:label="lab_beat_TaxPeriodsAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Periods After 2017 [Member]</link:label>
    <link:label id="lab_beat_TaxPeriodsAfter2017Member_documentation_en-US" xlink:label="lab_beat_TaxPeriodsAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Periods After 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsAfter2017Member" xlink:href="beat-20231231.xsd#beat_TaxPeriodsAfter2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_TaxPeriodsAfter2017Member" xlink:to="lab_beat_TaxPeriodsAfter2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_275f6747-d1f6-4db3-9a4a-1300085b43d5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_45789633-ef87-4422-81fa-7a669a4632cd_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8431b234-d341-4b8c-b5d7-dba2d95dcdfb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3b343bc2-4e0b-4b1e-a6fc-078319d0e43f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_25bbe232-05a1-4b47-b059-f480530fd665_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e4b1088a-6e8a-4f53-975f-9935d3a02104_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_379009c8-fcf8-4fad-b6c5-a997b8f62cd0_terseLabel_en-US" xlink:label="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of planned sites to carrying out the clinical study</link:label>
    <link:label id="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_label_en-US" xlink:label="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Number Of Clinical Study Sites</link:label>
    <link:label id="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_documentation_en-US" xlink:label="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Number Of Clinical Study Sites</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:href="beat-20231231.xsd#beat_ResearchAndDevelopmentNumberOfClinicalStudySites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:to="lab_beat_ResearchAndDevelopmentNumberOfClinicalStudySites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_eced6153-51da-4142-b519-12db6fe81b95_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_c97482ec-8ba6-4b2c-aa81-84ce500d4217_terseLabel_en-US" xlink:label="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:href="beat-20231231.xsd#beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:to="lab_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f47baf82-19a7-4b6c-a254-5b635ba64eaa_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_AGPAllianceGlobalPartnersMember_cb5a5781-1aa8-436e-99cc-73bf643d9773_terseLabel_en-US" xlink:label="lab_beat_AGPAllianceGlobalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A.G.P./Alliance Global Partners</link:label>
    <link:label id="lab_beat_AGPAllianceGlobalPartnersMember_label_en-US" xlink:label="lab_beat_AGPAllianceGlobalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A.G.P./Alliance Global Partners [Member]</link:label>
    <link:label id="lab_beat_AGPAllianceGlobalPartnersMember_documentation_en-US" xlink:label="lab_beat_AGPAllianceGlobalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A.G.P./Alliance Global Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AGPAllianceGlobalPartnersMember" xlink:href="beat-20231231.xsd#beat_AGPAllianceGlobalPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_AGPAllianceGlobalPartnersMember" xlink:to="lab_beat_AGPAllianceGlobalPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e9990de-99d3-40ab-812b-561865ea9b70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Common Stock &amp; warrants, net of fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_ClassOfWarrantOrRightGrantDateFairValue_47676828-2e96-4c9f-a02c-5a426431e145_terseLabel_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightGrantDateFairValue_label_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</link:label>
    <link:label id="lab_beat_ClassOfWarrantOrRightGrantDateFairValue_documentation_en-US" xlink:label="lab_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:to="lab_beat_ClassOfWarrantOrRightGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_238e3fb0-96d4-4d16-9d2d-8f8ae236e5a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a8de7fff-ae1a-421e-84db-80d867b6e4e6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f653c4b7-eaa0-4339-b60a-3b365b30e41e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0f6f5542-e5f2-461d-8dca-e27903464f25_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_160516c4-d2a8-470f-bfd9-7cb0166f3124_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_4afcfa5a-5523-485f-b48b-3b1396bc02d4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a8205c80-2a21-45a9-9444-2104fd4b7596_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_2c97470e-886d-41b5-858f-6f88e71ae76b_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, percentage of the average calculated volume weighted average price per share (as a percent)</link:label>
    <link:label id="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_label_en-US" xlink:label="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage</link:label>
    <link:label id="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_documentation_en-US" xlink:label="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:href="beat-20231231.xsd#beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:to="lab_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2b84084e-a4f0-4c08-addd-540bd997a425_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for service (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4076f8ce-eba2-49f5-9a75-f727b53596b2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c3a7dfd-d136-48a9-8560-77a28120d4e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_3aae472e-03d2-4aea-9f8d-f75d93e4941b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_77d23a8c-ba1d-4481-b2dc-5bee9acabf4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8504323-24dd-4e1f-a236-43734abfdba1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_MaverickCapitalPartnersLLCMember_fd971443-a0e5-4104-be02-7e5f513e7d20_terseLabel_en-US" xlink:label="lab_beat_MaverickCapitalPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maverick Capital Partners, LLC</link:label>
    <link:label id="lab_beat_MaverickCapitalPartnersLLCMember_label_en-US" xlink:label="lab_beat_MaverickCapitalPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maverick Capital Partners, LLC [Member]</link:label>
    <link:label id="lab_beat_MaverickCapitalPartnersLLCMember_documentation_en-US" xlink:label="lab_beat_MaverickCapitalPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maverick Capital Partners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_MaverickCapitalPartnersLLCMember" xlink:href="beat-20231231.xsd#beat_MaverickCapitalPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_MaverickCapitalPartnersLLCMember" xlink:to="lab_beat_MaverickCapitalPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_02e64c29-637e-4a1e-91db-ebc41da75b83_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2450f6bf-a7dc-4c39-8a3a-cc8c5e37b526_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross_528a239c-587d-4ae0-8b5a-19f0139f81f9_terseLabel_en-US" xlink:label="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross consideration received on transaction</link:label>
    <link:label id="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:label id="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="beat-20231231.xsd#beat_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_beat_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_91629e33-ac91-4687-b122-9959e62b7b64_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_d8302fa6-6359-4923-b65b-d634daf6bbfb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a6ace2bd-29b1-4315-b37b-ab0e3303cab2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_5cb0401c-97e0-4e8c-8b81-4c22949064e0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_73d3f278-ebc9-4404-b356-263eb92e84ef_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92e93a52-401c-42e7-8aba-99034d901fb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_94d2c567-5013-473d-8cbb-f52d931b0334_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2505ce1f-16c9-422d-b138-33976f859a10_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5804df96-63b5-4cbd-9519-94db1d0a16fc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c351bf4-4a38-42bb-bfff-8187f8dcfb2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_437b77e6-c655-4cc0-9a5c-14ca4ecbfe5b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_f06b9f6f-0268-4c31-ba73-051b3a1e9232_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_68682562-6793-453a-b93c-19a62799dad0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount to be paid to Clinical Research Organization</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f7868c56-ff77-48e9-9b5c-8363b48a7c3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_800dfee6-3644-4437-850c-04ad81a6123e_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f9564226-8f3a-457c-838b-0e21374b854c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d25866e4-6486-42d7-adc0-739ffaaf070b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e58378c2-6d68-4219-9b9c-25ecae73160b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0d7d1852-7302-4136-9969-32e54ca3704e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c659f6d4-f556-463b-a18d-109013a72c4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c76ed1a4-051a-4a0a-b4fe-0d2b5a9582de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issuance upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f58d7bdc-ac54-4acb-bb0a-c1ef835e5e38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_145da044-823f-420e-9ee4-6190875e2108_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_58e60bb6-7bf1-4e51-916d-ff3c14853925_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_beat_LIVMORMember_100246de-7bd0-4298-839c-3922a738dd1c_terseLabel_en-US" xlink:label="lab_beat_LIVMORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIVMOR</link:label>
    <link:label id="lab_beat_LIVMORMember_label_en-US" xlink:label="lab_beat_LIVMORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIVMOR [Member]</link:label>
    <link:label id="lab_beat_LIVMORMember_documentation_en-US" xlink:label="lab_beat_LIVMORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LIVMOR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LIVMORMember" xlink:href="beat-20231231.xsd#beat_LIVMORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_beat_LIVMORMember" xlink:to="lab_beat_LIVMORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_df0b6094-0c9d-435a-923d-e2a652657473_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_f64996ff-5f17-4107-8667-091869fbfdec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>beat-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a2bf7ab4-21e9-48ac-8911-0bfc02240706,g:d1579df9-2e16-4140-a8a0-7b6bad73fdc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.heartbeam.com/role/CoverPage" xlink:type="simple" xlink:href="beat-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aea90e4f-5276-45f3-a6cb-b3cae9da0a77" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aea90e4f-5276-45f3-a6cb-b3cae9da0a77" xlink:to="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e82b251-a281-468b-a7c4-6a5d7177b044" xlink:to="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c3f38af4-2482-4bfc-bdb7-47e4024b9d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:to="loc_us-gaap_CommonClassAMember_c3f38af4-2482-4bfc-bdb7-47e4024b9d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f5799b8-aac5-4aa8-9f4a-78aa42818ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41162959-da9f-4d35-b4cb-c663fa1bd93f" xlink:to="loc_us-gaap_WarrantMember_6f5799b8-aac5-4aa8-9f4a-78aa42818ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_73f30a0c-a6f1-4465-a641-f3dc3dc5f660" xlink:to="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fc57b327-1d8c-432a-9830-7cba03d1e97d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentType_fc57b327-1d8c-432a-9830-7cba03d1e97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cb31021c-86fe-4188-816d-609ed05c2758" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentAnnualReport_cb31021c-86fe-4188-816d-609ed05c2758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_48b3436e-2bc1-4855-accb-f41ab7dc1894" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentPeriodEndDate_48b3436e-2bc1-4855-accb-f41ab7dc1894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b24ceb5f-8f5f-419c-820d-5ba8c98ec75f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_CurrentFiscalYearEndDate_b24ceb5f-8f5f-419c-820d-5ba8c98ec75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9a94263b-818e-4dd2-b10b-7724e32745c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentTransitionReport_9a94263b-818e-4dd2-b10b-7724e32745c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_128f1143-f1ce-4c12-9549-b3df422540eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityFileNumber_128f1143-f1ce-4c12-9549-b3df422540eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_972a52e4-df2f-451b-b78b-f22f85c5c817" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityRegistrantName_972a52e4-df2f-451b-b78b-f22f85c5c817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_66e20192-59b8-48fe-98db-465e5439e67d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityIncorporationStateCountryCode_66e20192-59b8-48fe-98db-465e5439e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1ba0f41-cea1-4d2a-b1fc-68a633e6f5cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1ba0f41-cea1-4d2a-b1fc-68a633e6f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7dc712a6-41a0-4717-adc6-d7ecbb1d179d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressAddressLine1_7dc712a6-41a0-4717-adc6-d7ecbb1d179d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a767b19c-2f4e-48a0-a55b-e992ca129cec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressAddressLine2_a767b19c-2f4e-48a0-a55b-e992ca129cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_10c4d424-1132-4892-ac9c-761bcb08253a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressCityOrTown_10c4d424-1132-4892-ac9c-761bcb08253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_af439686-8c61-42d7-833c-bee95ab9b240" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressStateOrProvince_af439686-8c61-42d7-833c-bee95ab9b240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7ee4c08f-ea16-4880-8f05-fd9ce56a47b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityAddressPostalZipCode_7ee4c08f-ea16-4880-8f05-fd9ce56a47b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82b35327-c62d-4bdf-be80-97bbfefec3a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_CityAreaCode_82b35327-c62d-4bdf-be80-97bbfefec3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b20c802a-a135-487c-9b2a-e2a79ae83d57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_LocalPhoneNumber_b20c802a-a135-487c-9b2a-e2a79ae83d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_542bd0e6-9eaa-463f-b693-a0b83e6374ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_Security12bTitle_542bd0e6-9eaa-463f-b693-a0b83e6374ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d7726d51-265a-4ed4-a9ca-832a51d1ec90" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_TradingSymbol_d7726d51-265a-4ed4-a9ca-832a51d1ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4ac1e581-e334-4f94-8b04-18d5790e5cde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_SecurityExchangeName_4ac1e581-e334-4f94-8b04-18d5790e5cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_913a5b5a-8102-466a-8dac-35e83b7c1491" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_913a5b5a-8102-466a-8dac-35e83b7c1491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_009b3882-ea78-44a3-b9b0-ee0698eb1c67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityVoluntaryFilers_009b3882-ea78-44a3-b9b0-ee0698eb1c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d2eaa6a9-8bc0-4c2d-98eb-a3f2e1547996" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCurrentReportingStatus_d2eaa6a9-8bc0-4c2d-98eb-a3f2e1547996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ec6dfff4-afa8-429c-83c5-d5b512a5096e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityInteractiveDataCurrent_ec6dfff4-afa8-429c-83c5-d5b512a5096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ca7be70d-5985-46fd-84b7-8f59073a169e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityFilerCategory_ca7be70d-5985-46fd-84b7-8f59073a169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_603592e4-cca6-4625-8fc0-f354327ab0ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntitySmallBusiness_603592e4-cca6-4625-8fc0-f354327ab0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_57182f6b-30e0-4a50-80d9-6d28985633d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityEmergingGrowthCompany_57182f6b-30e0-4a50-80d9-6d28985633d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6f221535-d4a5-4db8-a66d-240f640ca4df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityExTransitionPeriod_6f221535-d4a5-4db8-a66d-240f640ca4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5b77a84d-bd57-49eb-81f5-a9ff6a8b1b6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5b77a84d-bd57-49eb-81f5-a9ff6a8b1b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_7441e558-0f3d-4977-842f-fa83dc6ed99e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_7441e558-0f3d-4977-842f-fa83dc6ed99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3fb38846-cd2f-40c7-9b92-5441da7efcc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityShellCompany_3fb38846-cd2f-40c7-9b92-5441da7efcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c4faa55f-20d6-422e-87ec-bf786b519c33" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityPublicFloat_c4faa55f-20d6-422e-87ec-bf786b519c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b04e7510-8551-4697-9d18-901b408ded45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b04e7510-8551-4697-9d18-901b408ded45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a1373304-0b69-4b90-b03d-21bec89160bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_EntityCentralIndexKey_a1373304-0b69-4b90-b03d-21bec89160bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_28d8f225-1f73-4a87-9539-4cd323c39dd3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFiscalYearFocus_28d8f225-1f73-4a87-9539-4cd323c39dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_28762aa3-bf28-45a8-83b7-69d97f836986" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentFiscalPeriodFocus_28762aa3-bf28-45a8-83b7-69d97f836986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_55747a8b-2c7d-4a7a-b4bc-fe32035ba477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_AmendmentFlag_55747a8b-2c7d-4a7a-b4bc-fe32035ba477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e9cbcf4e-bd22-44a3-a782-0989d9bf8230" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_01512558-516d-45d9-8df8-da53c323f522" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e9cbcf4e-bd22-44a3-a782-0989d9bf8230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/AuditInformation" xlink:type="simple" xlink:href="beat-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_beat_AuditInformationAbstract_4bbfc2a5-1b9c-466b-9bdb-de025d1808f5" xlink:href="beat-20231231.xsd#beat_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ba9e09d7-7efe-4f7d-9ddb-eafa820fc4ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_AuditInformationAbstract_4bbfc2a5-1b9c-466b-9bdb-de025d1808f5" xlink:to="loc_dei_AuditorFirmId_ba9e09d7-7efe-4f7d-9ddb-eafa820fc4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_07e9e411-3f68-4890-a02f-a2c2ee4d3bcf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_AuditInformationAbstract_4bbfc2a5-1b9c-466b-9bdb-de025d1808f5" xlink:to="loc_dei_AuditorName_07e9e411-3f68-4890-a02f-a2c2ee4d3bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_80125d85-1718-4bf2-9913-30116029b3ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_AuditInformationAbstract_4bbfc2a5-1b9c-466b-9bdb-de025d1808f5" xlink:to="loc_dei_AuditorLocation_80125d85-1718-4bf2-9913-30116029b3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/BalanceSheets" xlink:type="simple" xlink:href="beat-20231231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6a9cfda2-b759-48cb-839c-3077bd897383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6a9cfda2-b759-48cb-839c-3077bd897383" xlink:to="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_03edc8f6-c0cb-4aac-a474-1d6b10023b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_03edc8f6-c0cb-4aac-a474-1d6b10023b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16fd932a-f392-449c-8d2c-558cd6106540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03edc8f6-c0cb-4aac-a474-1d6b10023b62" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16fd932a-f392-449c-8d2c-558cd6106540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6e6fae6f-1b94-419b-bf8d-458f2217a1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03edc8f6-c0cb-4aac-a474-1d6b10023b62" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6e6fae6f-1b94-419b-bf8d-458f2217a1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9ab1dc1-cec7-4c39-9c07-490f820b4e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03edc8f6-c0cb-4aac-a474-1d6b10023b62" xlink:to="loc_us-gaap_AssetsCurrent_d9ab1dc1-cec7-4c39-9c07-490f820b4e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44c3ca40-713b-4eee-acc1-f9fb15b6fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44c3ca40-713b-4eee-acc1-f9fb15b6fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d8c84cd8-7059-4ee4-b8f1-d32b6feabdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d8c84cd8-7059-4ee4-b8f1-d32b6feabdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ba8cfc3c-58da-48da-8d66-a11c4e645017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c36be73f-6ae4-4f82-88f6-a6346dbc426e" xlink:to="loc_us-gaap_Assets_ba8cfc3c-58da-48da-8d66-a11c4e645017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6a9cfda2-b759-48cb-839c-3077bd897383" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_aebb7648-28e6-4e47-ac0a-a8d5d8e242a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_aebb7648-28e6-4e47-ac0a-a8d5d8e242a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1c28fce1-3485-4908-9bfe-ecf3eed4915d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aebb7648-28e6-4e47-ac0a-a8d5d8e242a0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1c28fce1-3485-4908-9bfe-ecf3eed4915d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99e7c560-0b8c-4d45-b3fd-89521111b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:to="loc_us-gaap_Liabilities_99e7c560-0b8c-4d45-b3fd-89521111b5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cb8a67d7-73f4-4622-bfcd-28313ce14e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cb8a67d7-73f4-4622-bfcd-28313ce14e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:to="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ee7c5bc1-f8d3-4476-9448-c7da41b45b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:to="loc_us-gaap_PreferredStockValue_ee7c5bc1-f8d3-4476-9448-c7da41b45b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b80a2ba-98ed-4484-ae80-7dcebf5966c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:to="loc_us-gaap_CommonStockValue_0b80a2ba-98ed-4484-ae80-7dcebf5966c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6384c7be-490b-4ebf-a14d-e8d88d2921d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6384c7be-490b-4ebf-a14d-e8d88d2921d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8ebffe4-337c-43bd-bcf5-4ab7945741a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8ebffe4-337c-43bd-bcf5-4ab7945741a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f3bd992-6528-4d85-a975-9e894f602a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_caf7fd6b-5971-4fa0-936e-777c4a7bd63f" xlink:to="loc_us-gaap_StockholdersEquity_6f3bd992-6528-4d85-a975-9e894f602a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_94930385-0116-4194-8776-94fdf549fc54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b79e9a6-9a2c-497a-a90e-7a355921c517" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_94930385-0116-4194-8776-94fdf549fc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="beat-20231231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fdfa4450-d5af-4d0a-8844-d57f07b45dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fdfa4450-d5af-4d0a-8844-d57f07b45dad" xlink:to="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b31ea3ce-c45d-4f29-8e3a-9f85c91b5a59" xlink:to="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_417008c3-c35e-4a03-a17d-95639866a7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7a71d4a2-4372-4bba-b4cb-30f47d203f9e" xlink:to="loc_us-gaap_RelatedPartyMember_417008c3-c35e-4a03-a17d-95639866a7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1b45906-dff4-4588-b75d-846560ffab12" xlink:to="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0db835b-7a0a-4ed8-97bc-107fc634e3f4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_251e86f0-9b3b-4479-8b8e-b7df1af9c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbe86c43-82cc-452a-8e54-8f9a1aa31740" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_251e86f0-9b3b-4479-8b8e-b7df1af9c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb87c36-e165-462b-a1d8-6be7ca4e61df" xlink:to="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e474461b-6e41-4286-b92a-b5bcecf3fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e474461b-6e41-4286-b92a-b5bcecf3fdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dd226ff8-6e8e-4c2c-821a-232eda4b409c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dd226ff8-6e8e-4c2c-821a-232eda4b409c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_587807f0-38c9-4534-80a9-59d13af28d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_587807f0-38c9-4534-80a9-59d13af28d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0bd9c321-512c-4199-b547-e57a5fca5599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0bd9c321-512c-4199-b547-e57a5fca5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3025e665-cc9b-4a13-9ed0-bf1f914a4527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3025e665-cc9b-4a13-9ed0-bf1f914a4527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c5bba167-f296-4f8f-a15f-67c827257c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesIssued_c5bba167-f296-4f8f-a15f-67c827257c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56839d65-c98a-4017-ab31-cfc4ac4fb782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_343adbb4-9693-482a-b6d1-8beed167a2f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56839d65-c98a-4017-ab31-cfc4ac4fb782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementsofOperations" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_29c436e4-bb3f-45fb-87bf-7106975f92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_29c436e4-bb3f-45fb-87bf-7106975f92f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8a125bf3-3144-4fcf-83e9-a95cf950ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29c436e4-bb3f-45fb-87bf-7106975f92f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8a125bf3-3144-4fcf-83e9-a95cf950ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e423f6a-5ba6-4733-b703-7e3aa706ebcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29c436e4-bb3f-45fb-87bf-7106975f92f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e423f6a-5ba6-4733-b703-7e3aa706ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a3079fe-2109-43dd-8d52-57277c4db085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29c436e4-bb3f-45fb-87bf-7106975f92f3" xlink:to="loc_us-gaap_OperatingExpenses_1a3079fe-2109-43dd-8d52-57277c4db085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21a21e70-e28c-4361-bc64-7b4b574a50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_OperatingIncomeLoss_21a21e70-e28c-4361-bc64-7b4b574a50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b3480932-687c-4135-ad5e-bd31bf39f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b3480932-687c-4135-ad5e-bd31bf39f8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5d3a0523-ede6-4ae3-a511-9c8873bbbdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b3480932-687c-4135-ad5e-bd31bf39f8db" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5d3a0523-ede6-4ae3-a511-9c8873bbbdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61a4bdc3-1df5-4c8a-9062-c31a1308b238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b3480932-687c-4135-ad5e-bd31bf39f8db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61a4bdc3-1df5-4c8a-9062-c31a1308b238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d83355b3-f5de-4b0c-b224-2c72e4a29408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b3480932-687c-4135-ad5e-bd31bf39f8db" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d83355b3-f5de-4b0c-b224-2c72e4a29408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9f0b7c-e635-4221-b149-a5edef4812b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9f0b7c-e635-4221-b149-a5edef4812b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70f602cc-8020-4a4a-b91c-8e6be7dad9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70f602cc-8020-4a4a-b91c-8e6be7dad9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_627a3ca9-9d6f-4922-8069-96e1ae9e7c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_NetIncomeLoss_627a3ca9-9d6f-4922-8069-96e1ae9e7c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5ab83867-09f8-416c-93db-79b42e6d5e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_EarningsPerShareBasic_5ab83867-09f8-416c-93db-79b42e6d5e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ed08ccfc-800e-4dfa-9884-6ae2a8ff0322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ed08ccfc-800e-4dfa-9884-6ae2a8ff0322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5b0f72a-b4b8-431e-aebe-b961264bb34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5b0f72a-b4b8-431e-aebe-b961264bb34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_38380a05-4865-4254-85ed-19c4f4d64a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f3cb25f-394c-4f05-9a8f-7dddd9f61088" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_38380a05-4865-4254-85ed-19c4f4d64a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_799b83f3-8927-4d5f-9569-dcfa220e7940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_799b83f3-8927-4d5f-9569-dcfa220e7940" xlink:to="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dc4829cc-88d0-4c7c-9944-d2fd33358900" xlink:to="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b67b39e0-f16c-4006-9114-122914b70784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_CommonStockMember_b67b39e0-f16c-4006-9114-122914b70784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fa3765f0-07d0-461d-9d7c-3357c01d3687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fa3765f0-07d0-461d-9d7c-3357c01d3687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0426d59a-7817-42d2-8031-b9180be23464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e2760f9-2884-4433-a4d7-8215586afad7" xlink:to="loc_us-gaap_RetainedEarningsMember_0426d59a-7817-42d2-8031-b9180be23464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_11717bc6-8326-4356-adab-dd0c50dd8e4f" xlink:to="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_451b2704-34d8-41d8-a00a-fa5518fb4026" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f39f212f-5b05-4d0e-8814-ee3c4be8a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f39f212f-5b05-4d0e-8814-ee3c4be8a94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_079b0e36-2989-4ef0-bed3-d28e21f3be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockholdersEquity_079b0e36-2989-4ef0-bed3-d28e21f3be2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d5967a9-aeac-4562-bb56-458c9608366b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d5967a9-aeac-4562-bb56-458c9608366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75c3e1f2-b0ad-4128-8f46-3d304abbf82e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75c3e1f2-b0ad-4128-8f46-3d304abbf82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03e090d7-761c-48e6-8d2c-c6dbf6ce5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03e090d7-761c-48e6-8d2c-c6dbf6ce5b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06c4dcb5-df43-46fa-8a91-2d067a65adb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06c4dcb5-df43-46fa-8a91-2d067a65adb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9330e342-8b26-41b2-9f91-87e70fa4ac58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9330e342-8b26-41b2-9f91-87e70fa4ac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_880b3ce8-b5d7-4a8e-ae9c-8f5c1da19ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_880b3ce8-b5d7-4a8e-ae9c-8f5c1da19ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1c68503f-8fdd-4156-9445-fd1ad6a0358b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1c68503f-8fdd-4156-9445-fd1ad6a0358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_eb12c030-d629-4ffe-8e0d-0af2adaa6ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_eb12c030-d629-4ffe-8e0d-0af2adaa6ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f0f3e7d-ec0a-42e2-82ce-d67c7cfb9ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_NetIncomeLoss_0f0f3e7d-ec0a-42e2-82ce-d67c7cfb9ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_09e08442-9ec2-40c3-bf61-544aa877f848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_09e08442-9ec2-40c3-bf61-544aa877f848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ed04f1eb-b325-4e4f-9646-4304ca20da31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ab08932-15e3-4563-8d5e-221ffbaf7a3c" xlink:to="loc_us-gaap_StockholdersEquity_ed04f1eb-b325-4e4f-9646-4304ca20da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="beat-20231231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b974842-dd36-4e29-9f84-354308a5056a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:to="loc_us-gaap_NetIncomeLoss_4b974842-dd36-4e29-9f84-354308a5056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4f295c85-b2a7-47dc-a014-8be0fb246c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4f295c85-b2a7-47dc-a014-8be0fb246c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5d1be118-0161-4769-8184-27bc8bd7fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4f295c85-b2a7-47dc-a014-8be0fb246c4a" xlink:to="loc_us-gaap_ShareBasedCompensation_5d1be118-0161-4769-8184-27bc8bd7fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_955ecce3-fabd-44cd-be79-ff7c12f73dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_955ecce3-fabd-44cd-be79-ff7c12f73dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6bba8ca1-d9fc-4da7-b597-4ecf82a847ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_955ecce3-fabd-44cd-be79-ff7c12f73dc6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6bba8ca1-d9fc-4da7-b597-4ecf82a847ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16efde99-71c0-44bd-b4b8-fe4d8e254b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_955ecce3-fabd-44cd-be79-ff7c12f73dc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16efde99-71c0-44bd-b4b8-fe4d8e254b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a0c46a5-b41c-466c-ab90-611449e4cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7f1a395d-033f-4cfd-b70f-7b302caf64d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a0c46a5-b41c-466c-ab90-611449e4cc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08662d89-f93d-4d9b-9c39-3a9387506e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08662d89-f93d-4d9b-9c39-3a9387506e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb151a7f-5e5d-4490-8175-e30479be644f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08662d89-f93d-4d9b-9c39-3a9387506e29" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb151a7f-5e5d-4490-8175-e30479be644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b38342d5-7dc1-4b58-9457-2814f85a3a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08662d89-f93d-4d9b-9c39-3a9387506e29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b38342d5-7dc1-4b58-9457-2814f85a3a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e0da0b3f-c141-49dc-9d88-30368cdb29cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e0da0b3f-c141-49dc-9d88-30368cdb29cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d54a09ae-b523-4964-90fd-534819a88aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d54a09ae-b523-4964-90fd-534819a88aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1f150036-34e6-40b5-b264-36bed3a268f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1f150036-34e6-40b5-b264-36bed3a268f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2118ca9-96a1-45cb-ba0c-4e4e424a3573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_193008f3-c67c-44d5-8bbe-2b7aed165130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2118ca9-96a1-45cb-ba0c-4e4e424a3573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_143a89d5-6cb7-48d7-8a40-66d0d37e9032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_143a89d5-6cb7-48d7-8a40-66d0d37e9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b92f4c61-d6ad-43e1-a94e-1c3a04a16e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b92f4c61-d6ad-43e1-a94e-1c3a04a16e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79675c77-9129-44f3-b63e-83576c7f0216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79675c77-9129-44f3-b63e-83576c7f0216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9edc44ba-131c-413a-a6a3-fe0e44e39b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9edc44ba-131c-413a-a6a3-fe0e44e39b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_8a371c82-e789-42b5-99ca-7d2873598541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9edc44ba-131c-413a-a6a3-fe0e44e39b29" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_8a371c82-e789-42b5-99ca-7d2873598541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7f768593-d9fa-4d1f-9169-6b05f465a965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9edc44ba-131c-413a-a6a3-fe0e44e39b29" xlink:to="loc_us-gaap_InterestPaidNet_7f768593-d9fa-4d1f-9169-6b05f465a965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_58b238f5-f82c-4a16-9d65-8b38506964ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_58b238f5-f82c-4a16-9d65-8b38506964ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_StockAndClassOfWarrantOrRightIssued_10ea7891-a251-48ea-873d-0d5b94f09cb1" xlink:href="beat-20231231.xsd#beat_StockAndClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_58b238f5-f82c-4a16-9d65-8b38506964ea" xlink:to="loc_beat_StockAndClassOfWarrantOrRightIssued_10ea7891-a251-48ea-873d-0d5b94f09cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8c1d504c-ee79-495f-85ac-56ea40390540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_528a7649-61b7-40d1-9684-2726deb0cadf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8c1d504c-ee79-495f-85ac-56ea40390540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbd9d021-3637-4660-8b04-ef8c4b832ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8c1d504c-ee79-495f-85ac-56ea40390540" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbd9d021-3637-4660-8b04-ef8c4b832ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f44d4869-9f2d-4e4b-bcf9-7c6cbd59923b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8c1d504c-ee79-495f-85ac-56ea40390540" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f44d4869-9f2d-4e4b-bcf9-7c6cbd59923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f931f74b-c7fc-437c-88c0-b1ed870185b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8c1d504c-ee79-495f-85ac-56ea40390540" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f931f74b-c7fc-437c-88c0-b1ed870185b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="beat-20231231.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c0d0e59-b489-4c88-b672-10b9039abfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_8191b1bd-09a0-4d66-adb8-08c8c2502763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c0d0e59-b489-4c88-b672-10b9039abfef" xlink:to="loc_us-gaap_NatureOfOperations_8191b1bd-09a0-4d66-adb8-08c8c2502763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES" xlink:type="simple" xlink:href="beat-20231231.xsd#GOINGCONCERNANDOTHERUNCERTAINTIES"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ea2990-feef-49da-a95c-c1d1be39560a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_159d81e4-b14c-4334-a96b-4199b5c738cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ea2990-feef-49da-a95c-c1d1be39560a" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_159d81e4-b14c-4334-a96b-4199b5c738cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b29e86cd-043c-45ca-8f89-1660c011a363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_37849e0f-c2a6-439e-849f-98b593547f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29e86cd-043c-45ca-8f89-1660c011a363" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_37849e0f-c2a6-439e-849f-98b593547f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ddc86b08-2dcb-4afb-afef-6c3953b7a4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7369afc8-b0cf-4fc1-b1c0-6812b6fc58a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ddc86b08-2dcb-4afb-afef-6c3953b7a4e6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7369afc8-b0cf-4fc1-b1c0-6812b6fc58a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78f6296c-ee49-49e7-b99e-9e2ee64193f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ce527b6-4aad-4577-b001-b2544b357374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78f6296c-ee49-49e7-b99e-9e2ee64193f1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ce527b6-4aad-4577-b001-b2544b357374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="beat-20231231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ac0192bf-40c0-4e58-90e3-11bb31291a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6d15b3d6-6e0d-4711-9478-4fcd2f8885ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ac0192bf-40c0-4e58-90e3-11bb31291a8b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6d15b3d6-6e0d-4711-9478-4fcd2f8885ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/COMMITMENTS" xlink:type="simple" xlink:href="beat-20231231.xsd#COMMITMENTS"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/COMMITMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f422801-49fe-467d-bf89-063f3a8cae17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85e91582-c252-4b9e-9225-50206f676594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f422801-49fe-467d-bf89-063f3a8cae17" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85e91582-c252-4b9e-9225-50206f676594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAX" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAX"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/INCOMETAX" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3fedab6a-1bbf-4aa3-8c25-f94f8cafa064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7b1a8282-d8e6-42c0-9cfc-e58f1c3b1f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3fedab6a-1bbf-4aa3-8c25-f94f8cafa064" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7b1a8282-d8e6-42c0-9cfc-e58f1c3b1f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="beat-20231231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_61eb1af0-76fa-407f-8030-259efd0585c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4bdd16e1-5c4e-491a-a7a2-a5677641638d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_61eb1af0-76fa-407f-8030-259efd0585c9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4bdd16e1-5c4e-491a-a7a2-a5677641638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a2029770-a779-4232-b4f8-de8af0212318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a2029770-a779-4232-b4f8-de8af0212318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5a527c5d-0f0c-480d-899d-88121bd7ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_UseOfEstimates_5a527c5d-0f0c-480d-899d-88121bd7ec47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_085f6b1f-bea5-4eb6-80a7-eebcde64826f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_085f6b1f-bea5-4eb6-80a7-eebcde64826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8018e00f-652e-4534-8fb1-ab2f38f153ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8018e00f-652e-4534-8fb1-ab2f38f153ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b3ec2ea1-8fd4-4ed7-a258-06dc5d10ee71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b3ec2ea1-8fd4-4ed7-a258-06dc5d10ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_51ae63f6-063c-45bd-b270-3f93352583e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_51ae63f6-063c-45bd-b270-3f93352583e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AccountingForWarrantsPolicyPolicyTextBlock_a17ddebe-6a42-4a8f-90e7-7af987a97fd0" xlink:href="beat-20231231.xsd#beat_AccountingForWarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_beat_AccountingForWarrantsPolicyPolicyTextBlock_a17ddebe-6a42-4a8f-90e7-7af987a97fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_78c1f094-575d-44e1-9686-06ed5fae6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_78c1f094-575d-44e1-9686-06ed5fae6e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5598401e-3271-425a-83c6-651e82e79408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5598401e-3271-425a-83c6-651e82e79408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6dc5857b-28d1-488b-93be-081565270063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6dc5857b-28d1-488b-93be-081565270063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13c13683-7132-43d6-a8d8-de4f268cfd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f429146-47e1-4fdd-994c-095e9b5bedb6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13c13683-7132-43d6-a8d8-de4f268cfd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c847ec3c-82e1-4e7e-957b-f790697adcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b07c840e-c8ad-41ac-8907-47a5058534a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c847ec3c-82e1-4e7e-957b-f790697adcc0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b07c840e-c8ad-41ac-8907-47a5058534a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_66a6e5e8-18ae-48b8-948e-1d2290d010c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ecd9c72d-898f-416c-9935-20844a5152fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66a6e5e8-18ae-48b8-948e-1d2290d010c3" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ecd9c72d-898f-416c-9935-20844a5152fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7377dc68-92ff-4ab0-b0bb-7ff1db9b2434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c86fb44-365d-49c7-8860-5893ac4ade7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7377dc68-92ff-4ab0-b0bb-7ff1db9b2434" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c86fb44-365d-49c7-8860-5893ac4ade7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0cb41b2e-d51c-42bc-b395-8ed804580af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7377dc68-92ff-4ab0-b0bb-7ff1db9b2434" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0cb41b2e-d51c-42bc-b395-8ed804580af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5bba0699-f838-4687-b4f3-50bea79df213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7377dc68-92ff-4ab0-b0bb-7ff1db9b2434" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5bba0699-f838-4687-b4f3-50bea79df213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7d6cea33-221d-4d37-b4ba-fc81a6274460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7377dc68-92ff-4ab0-b0bb-7ff1db9b2434" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7d6cea33-221d-4d37-b4ba-fc81a6274460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXTables" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXTables"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3a545232-2cfb-460d-b42d-ff9c5f46d526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_77600642-96f9-4ada-85c6-f65c2eca8495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a545232-2cfb-460d-b42d-ff9c5f46d526" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_77600642-96f9-4ada-85c6-f65c2eca8495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_05a8da96-899e-4651-9660-b3b45efc2c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a545232-2cfb-460d-b42d-ff9c5f46d526" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_05a8da96-899e-4651-9660-b3b45efc2c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#ORGANIZATIONANDOPERATIONSDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ddc4716-5571-44ef-a281-70960006cf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6e802ee1-1fd8-41b7-827c-a034de99f594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ddc4716-5571-44ef-a281-70960006cf9e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6e802ee1-1fd8-41b7-827c-a034de99f594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#GOINGCONCERNANDOTHERUNCERTAINTIESDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d309dfa8-efb8-4e2e-90e1-250cd787cd54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d309dfa8-efb8-4e2e-90e1-250cd787cd54" xlink:to="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2c9ab1ad-6a6b-4490-997d-8ae80ce30bbf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AGPAllianceGlobalPartnersMember_cfc8f848-2eb1-435c-8750-c474106a39ac" xlink:href="beat-20231231.xsd#beat_AGPAllianceGlobalPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:to="loc_beat_AGPAllianceGlobalPartnersMember_cfc8f848-2eb1-435c-8750-c474106a39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_MaverickCapitalPartnersLLCMember_124388e8-bf43-4c24-8ddb-a9bdf29b8a38" xlink:href="beat-20231231.xsd#beat_MaverickCapitalPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b62c4409-29e8-43ff-8db1-e0efbd0a5885" xlink:to="loc_beat_MaverickCapitalPartnersLLCMember_124388e8-bf43-4c24-8ddb-a9bdf29b8a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_378a096c-bd88-4525-8010-1982662cc508" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_37e3addc-c5c1-4e92-a5f0-c1701817d284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b929a1ed-ea6b-4292-8efd-6582b339ac6e" xlink:to="loc_us-gaap_PrivatePlacementMember_37e3addc-c5c1-4e92-a5f0-c1701817d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cd31f1cb-4182-4312-8e9f-7332da02a67d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_210bc8be-dbf5-4a4a-928f-8ccbdb3e4403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f876c1f-8b4b-452a-b25f-af905815bf2e" xlink:to="loc_us-gaap_ConvertibleDebtMember_210bc8be-dbf5-4a4a-928f-8ccbdb3e4403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:href="beat-20231231.xsd#beat_SubstantialDoubtAboutGoingConcernLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernTable_3ef4a60c-04eb-42c9-a4c5-0a0b54eb5355" xlink:to="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a38e1f8-67bd-4b4b-a407-c91a17a04666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a38e1f8-67bd-4b4b-a407-c91a17a04666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f3f0329-27b9-46bc-900b-98c9f7bc99f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f3f0329-27b9-46bc-900b-98c9f7bc99f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockMaximumAmountAuthorized_d79572e4-fde2-44ab-bc57-975437ff2551" xlink:href="beat-20231231.xsd#beat_SaleOfStockMaximumAmountAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockMaximumAmountAuthorized_d79572e4-fde2-44ab-bc57-975437ff2551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockAgentCommissionPercentage_41db07dd-c045-491f-82a2-2f21d4415680" xlink:href="beat-20231231.xsd#beat_SaleOfStockAgentCommissionPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockAgentCommissionPercentage_41db07dd-c045-491f-82a2-2f21d4415680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_ddaf57f3-76dc-49e4-baf1-39c7683d98ff" xlink:href="beat-20231231.xsd#beat_SaleOfStockRemainingAmountAuthorizedForIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_ddaf57f3-76dc-49e4-baf1-39c7683d98ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_ccd1983d-b7b5-48ca-b79b-c143e8599359" xlink:href="beat-20231231.xsd#beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_ccd1983d-b7b5-48ca-b79b-c143e8599359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31b51672-7b1c-4196-add9-9f760bcb04e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31b51672-7b1c-4196-add9-9f760bcb04e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0ddaa0d-a89c-4c66-9033-ce980c4b7c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_SubstantialDoubtAboutGoingConcernLineItems_15b51863-b0a6-4660-a726-e973b7b0141e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0ddaa0d-a89c-4c66-9033-ce980c4b7c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14b0e594-8a68-4c22-8500-5aec2e19b883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_da881200-e890-4dac-9c58-a0fee9969745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14b0e594-8a68-4c22-8500-5aec2e19b883" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_da881200-e890-4dac-9c58-a0fee9969745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fefa9498-88c7-4f13-8325-79eb87efac9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14b0e594-8a68-4c22-8500-5aec2e19b883" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fefa9498-88c7-4f13-8325-79eb87efac9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_75227495-70a4-4542-9a23-542688fe34b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14b0e594-8a68-4c22-8500-5aec2e19b883" xlink:to="loc_us-gaap_ConstructionInProgressGross_75227495-70a4-4542-9a23-542688fe34b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_8a935b76-df68-40ae-82ba-cb65a0a5f733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14b0e594-8a68-4c22-8500-5aec2e19b883" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements_8a935b76-df68-40ae-82ba-cb65a0a5f733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9fd39d92-76fd-49d4-8a6e-ead692f4917c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9fd39d92-76fd-49d4-8a6e-ead692f4917c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_016f2cb7-ddf5-4fd6-88fc-15228ccb9b77" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b497936e-ff25-4b10-8838-1e6e9e6f61c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_StockOptionMember_b497936e-ff25-4b10-8838-1e6e9e6f61c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_069cfccb-ccb8-4e2a-aed1-d8522cee8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_RestrictedStockMember_069cfccb-ccb8-4e2a-aed1-d8522cee8cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ad755766-c235-430a-ae63-48128af37c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_acad119f-c30f-4030-9ca1-e9930679f36e" xlink:to="loc_us-gaap_WarrantMember_ad755766-c235-430a-ae63-48128af37c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1a5a4d92-f213-44cb-8004-9dc43c2afdf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51e78d8c-ab0a-4f7a-a13d-8ba6839ef9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1727e380-c10d-431e-b528-7101e860c0c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51e78d8c-ab0a-4f7a-a13d-8ba6839ef9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2277f1b2-30a4-4614-a6dd-292b7ef4c21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_db63bf2d-f81d-48be-85fe-d5fb15d58f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2277f1b2-30a4-4614-a6dd-292b7ef4c21b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_db63bf2d-f81d-48be-85fe-d5fb15d58f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4f192596-106b-46c5-bb0c-5d5fa3c4e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2277f1b2-30a4-4614-a6dd-292b7ef4c21b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4f192596-106b-46c5-bb0c-5d5fa3c4e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0b759f5b-d73a-4465-af74-876c56892c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2277f1b2-30a4-4614-a6dd-292b7ef4c21b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0b759f5b-d73a-4465-af74-876c56892c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_211e6020-a115-4d4c-8024-073de061f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_211e6020-a115-4d4c-8024-073de061f51c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8bc2a9a-46d8-413a-bb79-76077c592790" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7d3a24de-a009-417e-a5df-b1b699459318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:to="loc_us-gaap_IPOMember_7d3a24de-a009-417e-a5df-b1b699459318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_958bf942-e6d4-46c1-a437-5969209f09ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e124c1da-dcca-44a1-988e-43e8379f622f" xlink:to="loc_us-gaap_PrivatePlacementMember_958bf942-e6d4-46c1-a437-5969209f09ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c1c3dd5-ad69-4a1e-8c66-d1c3539fdd98" xlink:to="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ec5ef7d-6dfe-4b79-87e2-ed9c268ce89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:to="loc_us-gaap_CommonStockMember_0ec5ef7d-6dfe-4b79-87e2-ed9c268ce89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a9f3e81e-053e-4ddb-9f88-f914d95d8485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_be028fba-abb1-47a1-9366-919b0a0d3157" xlink:to="loc_us-gaap_WarrantMember_a9f3e81e-053e-4ddb-9f88-f914d95d8485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cec5da8d-aa82-4768-855e-29552639a07c" xlink:to="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ConsultantsMember_d8c1580b-e092-434a-9dd4-467725a48827" xlink:href="beat-20231231.xsd#beat_ConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cbc25f11-ba08-499c-9a60-6f5f5c8c39c4" xlink:to="loc_beat_ConsultantsMember_d8c1580b-e092-434a-9dd4-467725a48827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_584e8110-46fd-4107-aec8-d9015c15fa1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_75d63a8a-03aa-4abf-9023-d4c60a86767f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a328033b-1a06-417d-9dab-01629ebe6bc4" xlink:to="loc_us-gaap_ConvertibleDebtMember_75d63a8a-03aa-4abf-9023-d4c60a86767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_58fa1f69-c999-4a7d-8d14-4c7d017c3fba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_OpenSkyOpportunitiesFundLtdMember_e48797b9-92b2-4760-a5fb-6f162ee2510e" xlink:href="beat-20231231.xsd#beat_OpenSkyOpportunitiesFundLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_OpenSkyOpportunitiesFundLtdMember_e48797b9-92b2-4760-a5fb-6f162ee2510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_MaverickCapitalPartnersLLCMember_e3e8bcda-08e1-4eff-b174-df11f16b6ab6" xlink:href="beat-20231231.xsd#beat_MaverickCapitalPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_MaverickCapitalPartnersLLCMember_e3e8bcda-08e1-4eff-b174-df11f16b6ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_CertainInvestorsMember_c517ca2e-13a2-4474-a188-b7b3d4867ab6" xlink:href="beat-20231231.xsd#beat_CertainInvestorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_CertainInvestorsMember_c517ca2e-13a2-4474-a188-b7b3d4867ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_AGPAllianceGlobalPartnersMember_e2fa1d03-7f8c-4e60-8e0a-aa262f30f3c4" xlink:href="beat-20231231.xsd#beat_AGPAllianceGlobalPartnersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d6b512-a889-4c72-829a-c6b8fd18e2f6" xlink:to="loc_beat_AGPAllianceGlobalPartnersMember_e2fa1d03-7f8c-4e60-8e0a-aa262f30f3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7b7240b-2295-469e-8233-2f4fcedab237" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e2f0bd91-5e19-4507-a5fa-e6a72486c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e2f0bd91-5e19-4507-a5fa-e6a72486c1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_561213f0-c70f-48e9-a92c-9118bad2346d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_561213f0-c70f-48e9-a92c-9118bad2346d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ae598281-bf83-4c99-8fe1-995c8071747c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ae598281-bf83-4c99-8fe1-995c8071747c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExpirationPeriod_38167ddb-59ec-4272-a227-d9194e250fa6" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightExpirationPeriod_38167ddb-59ec-4272-a227-d9194e250fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant_7b10d64a-3ab4-4c13-b729-b5beeb1b55b3" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValuePerWarrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightFairValuePerWarrant_7b10d64a-3ab4-4c13-b729-b5beeb1b55b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_14880131-83e0-47ce-8b4e-604d14e0b294" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare_14880131-83e0-47ce-8b4e-604d14e0b294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19e919e2-86d6-4bdd-8100-f81ece5c052a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_19e919e2-86d6-4bdd-8100-f81ece5c052a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4dee9a1-10c5-4b6b-b34f-e87102d18a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c4dee9a1-10c5-4b6b-b34f-e87102d18a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7169edb-39cb-4a43-8306-55153b604b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7169edb-39cb-4a43-8306-55153b604b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ecb1b610-f858-445c-be7b-b79cc8100e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ecb1b610-f858-445c-be7b-b79cc8100e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService_bee077db-831d-40d2-b6d6-5c469ac2e9b5" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightFairValueIssuedForService"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightFairValueIssuedForService_bee077db-831d-40d2-b6d6-5c469ac2e9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15a9a67e-aef2-45f8-896e-f01752291f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_15a9a67e-aef2-45f8-896e-f01752291f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8ec9e15-9eae-47d6-896f-d65e0067d2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8ec9e15-9eae-47d6-896f-d65e0067d2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_a178d1d4-17ac-4798-9123-4d221eac7c14" xlink:href="beat-20231231.xsd#beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit_a178d1d4-17ac-4798-9123-4d221eac7c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_abdf27f0-2179-4cf4-a985-9442e41d92e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_abdf27f0-2179-4cf4-a985-9442e41d92e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_929dd59a-a1b2-4e47-8e4f-53c3cbe8b5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_929dd59a-a1b2-4e47-8e4f-53c3cbe8b5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightTerminationPeriod_34a11eca-ddc5-4474-be60-7286b89d8bd1" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightTerminationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_ClassOfWarrantOrRightTerminationPeriod_34a11eca-ddc5-4474-be60-7286b89d8bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c0c342-c906-44d7-bf17-b5f56870352f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c0c342-c906-44d7-bf17-b5f56870352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockMaximumAmountAuthorized_8ba01ffc-28f7-49f3-8c0c-7d43ba471d62" xlink:href="beat-20231231.xsd#beat_SaleOfStockMaximumAmountAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockMaximumAmountAuthorized_8ba01ffc-28f7-49f3-8c0c-7d43ba471d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_e6cbdfcd-90ff-4dd9-a190-a4ea53290cf0" xlink:href="beat-20231231.xsd#beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage_e6cbdfcd-90ff-4dd9-a190-a4ea53290cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_754c70af-103e-46ef-80c7-14dcff3502ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_754c70af-103e-46ef-80c7-14dcff3502ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockPlacementFeePercentage_2139354e-9290-4f18-b1b6-77e07bd3f9c6" xlink:href="beat-20231231.xsd#beat_SaleOfStockPlacementFeePercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockPlacementFeePercentage_2139354e-9290-4f18-b1b6-77e07bd3f9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross_e1bb1427-9ce5-46e6-93a9-fb2a39a46172" xlink:href="beat-20231231.xsd#beat_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockConsiderationReceivedOnTransactionGross_e1bb1427-9ce5-46e6-93a9-fb2a39a46172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_e4c9f607-6a5f-45af-b17e-23e4562c9eb2" xlink:href="beat-20231231.xsd#beat_SaleOfStockRemainingAmountAuthorizedForIssuance"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_beat_SaleOfStockRemainingAmountAuthorizedForIssuance_e4c9f607-6a5f-45af-b17e-23e4562c9eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e89f764-3e67-456c-b96c-4f66f7151491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e89f764-3e67-456c-b96c-4f66f7151491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_56f739bf-d6f6-49d6-a424-a9c42b57744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b9e51d77-3215-4f4c-819d-19cd23d1edc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_56f739bf-d6f6-49d6-a424-a9c42b57744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_07177dce-7d12-4551-9127-44158c6c6907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_07177dce-7d12-4551-9127-44158c6c6907" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af9fa22b-230a-40d5-95b1-bd49b9f11dc9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PennyWarrantMember_e6ee9838-c564-4e92-ac69-7115130d5de5" xlink:href="beat-20231231.xsd#beat_PennyWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_74bcb24f-e147-4123-aa4a-9fd63bf59232" xlink:to="loc_beat_PennyWarrantMember_e6ee9838-c564-4e92-ac69-7115130d5de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3592c933-c7d7-40f4-b047-e017ab35ec19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b3da8cba-43b0-4e0d-bcab-1cd882ac22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1874a53e-e908-418f-97d1-cf44e756e121" xlink:to="loc_us-gaap_IPOMember_b3da8cba-43b0-4e0d-bcab-1cd882ac22fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3dcf4bab-6673-4b87-a653-ab10a0dd08be" xlink:to="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ConsultantsMember_9cbca28a-8c27-4b62-aa16-3df25d9c8fd8" xlink:href="beat-20231231.xsd#beat_ConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c9b6f1e4-a448-40ff-bae7-40fe6e1af77b" xlink:to="loc_beat_ConsultantsMember_9cbca28a-8c27-4b62-aa16-3df25d9c8fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e124c-5a9f-465f-9df9-d0cc013004be" xlink:to="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0655f411-cb83-41b1-849d-15edad61e3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:to="loc_us-gaap_WarrantMember_0655f411-cb83-41b1-849d-15edad61e3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8506b516-46a1-433a-898d-3f6c1b298b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aad101e0-b307-4ee1-8c4b-6e8c5c1b022f" xlink:to="loc_us-gaap_CommonStockMember_8506b516-46a1-433a-898d-3f6c1b298b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bba97e9b-32d4-4737-96b1-c9c365a887ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0272a909-02cf-4793-98a3-5247c7da847e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0272a909-02cf-4793-98a3-5247c7da847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightGrantDateFairValue_14858ad2-1d73-4103-b77a-8ecb53931587" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightGrantDateFairValue_14858ad2-1d73-4103-b77a-8ecb53931587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_aa40cec3-4a82-42d0-95c4-84f91b9f79c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_aa40cec3-4a82-42d0-95c4-84f91b9f79c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_20838771-2c8d-47d7-a606-6c7cd3bc92a2" xlink:href="beat-20231231.xsd#beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants_20838771-2c8d-47d7-a606-6c7cd3bc92a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_364ba976-03f0-4e90-9517-b288059c039a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_364ba976-03f0-4e90-9517-b288059c039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExpirationPeriod_9d18d5f8-a526-41d4-831c-a010708855be" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightExpirationPeriod_9d18d5f8-a526-41d4-831c-a010708855be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_fb48686e-e0ad-4dd6-bb2a-3e70037d0c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_fb48686e-e0ad-4dd6-bb2a-3e70037d0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercised_a8ce6e43-b68c-4ea2-b86d-dba79b38d698" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExercised_a8ce6e43-b68c-4ea2-b86d-dba79b38d698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_551bf5f7-9f4b-4b1b-b0c6-9676a546f866" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExercise"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExercise_551bf5f7-9f4b-4b1b-b0c6-9676a546f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_505e05b8-6997-461d-963e-85d6c6220d9e" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized_505e05b8-6997-461d-963e-85d6c6220d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_dd973b7c-0fd0-487c-85b9-2a06a4270dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_dd973b7c-0fd0-487c-85b9-2a06a4270dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_8d2592f1-2bae-4f52-8f67-2562453e8d53" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercisedForCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExercisedForCash_8d2592f1-2bae-4f52-8f67-2562453e8d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_3b7785b8-975a-4ce5-a719-e27d6441d118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c5e3fa1f-f04a-485e-8b9c-9dc1158efd2c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_3b7785b8-975a-4ce5-a719-e27d6441d118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKHOLDERSEQUITYWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_eeb73c04-7c49-4cf3-8c93-1eff165552a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeb73c04-7c49-4cf3-8c93-1eff165552a6" xlink:to="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_43db4df9-9018-4fac-9d91-a8f0c1c88930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_43db4df9-9018-4fac-9d91-a8f0c1c88930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisable_dca04065-9c31-4d21-9f08-2e1e7afd19f9" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_beat_ClassOfWarrantOrRightExercisable_dca04065-9c31-4d21-9f08-2e1e7afd19f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsIssued_09c142d9-d013-4f3f-b79c-ae90193f493d" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsIssued_09c142d9-d013-4f3f-b79c-ae90193f493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExercised_f6dc27f9-3e59-4313-b171-59224a8efdf9" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExercised_f6dc27f9-3e59-4313-b171-59224a8efdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWarrantsExpired_9944e264-3164-4657-952f-dc1a2858fb94" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_beat_ClassOfWarrantOrRightWarrantsExpired_9944e264-3164-4657-952f-dc1a2858fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3731f17d-9dc5-4cee-9017-ee53c0b5afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3731f17d-9dc5-4cee-9017-ee53c0b5afb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisable_7ad77c59-7dad-4fec-8135-3e028605f683" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightRollForward_cfa12070-300f-4e2f-82c6-1104ca53a0bb" xlink:to="loc_beat_ClassOfWarrantOrRightExercisable_7ad77c59-7dad-4fec-8135-3e028605f683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeb73c04-7c49-4cf3-8c93-1eff165552a6" xlink:to="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5753b974-3bb0-4e94-a16b-c8e962b3328e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5753b974-3bb0-4e94-a16b-c8e962b3328e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_e2438969-da54-419f-8849-c09196a65c25" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_e2438969-da54-419f-8849-c09196a65c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_c09dcee7-8d31-4554-b70a-16e63c1d790c" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_c09dcee7-8d31-4554-b70a-16e63c1d790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_220f494d-db71-48b5-a991-afd2a91f61be" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_220f494d-db71-48b5-a991-afd2a91f61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_9f14f218-872e-4ac4-bcd4-755fe42384b8" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_9f14f218-872e-4ac4-bcd4-755fe42384b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_62cf1765-7ae5-4e20-9737-f5f73b630485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_62cf1765-7ae5-4e20-9737-f5f73b630485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_e82ce84a-0b27-45f3-a3c1-82fbd0caf38c" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_b84ad40c-ed15-45ad-b087-082638dc5689" xlink:to="loc_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_e82ce84a-0b27-45f3-a3c1-82fbd0caf38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_edb103a4-733e-42a8-8666-5551edca837c" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeb73c04-7c49-4cf3-8c93-1eff165552a6" xlink:to="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_edb103a4-733e-42a8-8666-5551edca837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife_4a3a307d-698e-4073-b60a-1dde0b154e0f" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightWeightedAverageRemainingLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_edb103a4-733e-42a8-8666-5551edca837c" xlink:to="loc_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife_4a3a307d-698e-4073-b60a-1dde0b154e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_3e2922d6-891b-4b6e-b748-cdd6392fd965" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract_edb103a4-733e-42a8-8666-5551edca837c" xlink:to="loc_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_3e2922d6-891b-4b6e-b748-cdd6392fd965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_d31c67e1-8c62-4147-b4e2-a0863434c556" xlink:href="beat-20231231.xsd#beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeb73c04-7c49-4cf3-8c93-1eff165552a6" xlink:to="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_d31c67e1-8c62-4147-b4e2-a0863434c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_56f80f7a-9a4e-48b9-8bbc-aadc12127dba" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_d31c67e1-8c62-4147-b4e2-a0863434c556" xlink:to="loc_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_56f80f7a-9a4e-48b9-8bbc-aadc12127dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding_61db063c-5891-4cf3-850e-347eb7933833" xlink:href="beat-20231231.xsd#beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract_d31c67e1-8c62-4147-b4e2-a0863434c556" xlink:to="loc_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding_61db063c-5891-4cf3-850e-347eb7933833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90e651d8-532e-496e-bc37-0726ce6c0da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90e651d8-532e-496e-bc37-0726ce6c0da9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5baa449f-093c-4fdf-bb67-793f4b544ce1" xlink:to="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2015EquityIncentivePlanMember_99134c31-0f32-4a54-8df5-0d192bf03eea" xlink:href="beat-20231231.xsd#beat_A2015EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:to="loc_beat_A2015EquityIncentivePlanMember_99134c31-0f32-4a54-8df5-0d192bf03eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2022EquityPlanMember_e0364cf5-6997-4865-86e2-f8223409ed49" xlink:href="beat-20231231.xsd#beat_A2022EquityPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9c023c12-537e-4113-a335-d80e29edcdd7" xlink:to="loc_beat_A2022EquityPlanMember_e0364cf5-6997-4865-86e2-f8223409ed49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4db25176-39d9-4851-8218-06834805b595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2b910ab7-89a3-44da-8ce9-8fbf0249db1b" xlink:href="beat-20231231.xsd#beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2b910ab7-89a3-44da-8ce9-8fbf0249db1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f10f81dc-69b4-4c49-917b-fefc27a8e39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f10f81dc-69b4-4c49-917b-fefc27a8e39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_97cfddb7-523f-408d-8e1a-b548f16c8cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d65340-0f55-4782-8f73-047b9ccf8dea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_97cfddb7-523f-408d-8e1a-b548f16c8cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6bf79d03-ec65-4ed0-ada5-5e8967ca9016" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ExecutivesAndEmployeesMember_b55289c9-253e-4faa-bfba-3f09d46aa466" xlink:href="beat-20231231.xsd#beat_ExecutivesAndEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1e00772-f279-4fe1-ac4d-0f6d27ae47a1" xlink:to="loc_beat_ExecutivesAndEmployeesMember_b55289c9-253e-4faa-bfba-3f09d46aa466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_54ec31c4-2bbe-4f0d-946b-0f09e4b50a0c" xlink:to="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6fe3eb81-1ac7-4971-8bb7-5cb6df1eebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6fe3eb81-1ac7-4971-8bb7-5cb6df1eebdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7f6c40a3-376b-4011-b6d6-5a9bc21a10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_de3d4eca-8ddf-4d27-925b-52c9dbfa5021" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7f6c40a3-376b-4011-b6d6-5a9bc21a10c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7256346e-a3c4-4191-86c4-dcec6905e895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c5e82589-fdeb-4248-a3e4-d06e2b01bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c5e82589-fdeb-4248-a3e4-d06e2b01bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_ad7bd6ae-c6cb-4e29-8365-738c64c549ad" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber_ad7bd6ae-c6cb-4e29-8365-738c64c549ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_f5be4865-4203-4ae1-8ab3-7ae1302458fa" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_f5be4865-4203-4ae1-8ab3-7ae1302458fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_47bdb958-a92e-4c56-a61d-cccaf62acc11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_47bdb958-a92e-4c56-a61d-cccaf62acc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f97e3b95-355c-4a1b-887c-ed48e1e24733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f97e3b95-355c-4a1b-887c-ed48e1e24733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_733895e7-d222-4d17-a11c-33bce5e44bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_733895e7-d222-4d17-a11c-33bce5e44bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280dd7fa-252a-43f7-95aa-fb44922c00e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280dd7fa-252a-43f7-95aa-fb44922c00e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91bbad73-e943-4aa3-aeac-96fbaa9236e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91bbad73-e943-4aa3-aeac-96fbaa9236e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_759aed5c-20e5-4ea8-858c-bded315c1eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2475fb95-2038-4cdc-8725-ad8f527dcdd5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_759aed5c-20e5-4ea8-858c-bded315c1eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93534eb2-d89c-4c3a-94e9-1b7cdfb80dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93534eb2-d89c-4c3a-94e9-1b7cdfb80dda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d1522ac-c417-41fe-a122-3b06778261dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d1522ac-c417-41fe-a122-3b06778261dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18c4d60d-c829-4bdc-9c4d-dd9bce36c0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18c4d60d-c829-4bdc-9c4d-dd9bce36c0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d18fb368-c104-4fa1-8ad3-0bfdd444614c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d18fb368-c104-4fa1-8ad3-0bfdd444614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93c01b32-67fa-4143-a365-477428ffbf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93c01b32-67fa-4143-a365-477428ffbf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f707aac4-bf10-4a4b-91aa-9d13d98c4bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e78e233d-0d74-42ce-8eb3-6315e87849fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f707aac4-bf10-4a4b-91aa-9d13d98c4bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93534eb2-d89c-4c3a-94e9-1b7cdfb80dda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be7b6100-44e6-4308-a0e0-f5fac7fb2ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be7b6100-44e6-4308-a0e0-f5fac7fb2ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d9af8389-b296-459e-b7b6-ecc6217db328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d9af8389-b296-459e-b7b6-ecc6217db328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_df9ee735-957f-4a47-b07d-5c0a9c1b1884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_df9ee735-957f-4a47-b07d-5c0a9c1b1884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73d90ff3-7a38-4974-9adf-1dc2956c3617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73d90ff3-7a38-4974-9adf-1dc2956c3617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3dc2eaad-5867-4a5d-8707-ba45d22be069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24207b9-a394-4b57-85ae-ae7c11317cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3dc2eaad-5867-4a5d-8707-ba45d22be069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93534eb2-d89c-4c3a-94e9-1b7cdfb80dda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fbbed4ca-a55b-4669-9a24-d741d1669132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fbbed4ca-a55b-4669-9a24-d741d1669132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c543da69-3d88-4474-b76b-8a15f94cb74c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c543da69-3d88-4474-b76b-8a15f94cb74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0f1d8702-016d-4d56-9dee-632f3d7fe1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0f1d8702-016d-4d56-9dee-632f3d7fe1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fb8ae7fb-6341-43d5-bc1f-f15e73ec75a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fb8ae7fb-6341-43d5-bc1f-f15e73ec75a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ac837ab2-3596-4cac-b45a-43556c8c0138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ac837ab2-3596-4cac-b45a-43556c8c0138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fb797784-f814-4578-b972-7c41ba1f94a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92c25204-497d-45e3-b7f4-efc60e6ede34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fb797784-f814-4578-b972-7c41ba1f94a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b1560c7-41f6-4bfa-bf8e-e49fd8fea1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b1560c7-41f6-4bfa-bf8e-e49fd8fea1ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:to="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd59fa66-025f-4d06-b34c-2ebc15802bdf" xlink:to="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92829fc2-1457-4f27-bbfc-2b30a5975b22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:to="loc_srt_MinimumMember_92829fc2-1457-4f27-bbfc-2b30a5975b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7e7cf02-ffa2-45c3-a853-ad7ed757092b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9555eb7-5a6e-413a-a815-b7c0529eec6f" xlink:to="loc_srt_MaximumMember_b7e7cf02-ffa2-45c3-a853-ad7ed757092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:to="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad94dcbc-c09d-419b-8e8a-d7c3b9128a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c92ebd2-521f-4aef-aac2-43499be5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f3b9c8e-acf5-4c06-9c16-310425ef2886" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c92ebd2-521f-4aef-aac2-43499be5e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1785d607-908d-4977-be8e-0966c96bd444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_542512fd-4c52-4f6e-a8b4-7b4b14fc5ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_542512fd-4c52-4f6e-a8b4-7b4b14fc5ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd2fde82-8db6-4e5d-a286-5273ee54e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd2fde82-8db6-4e5d-a286-5273ee54e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c9d1ec5-93ba-4302-bc74-e3597b72922e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c9d1ec5-93ba-4302-bc74-e3597b72922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2b7cbf24-ce89-4e84-b430-3a50ae3b70dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2b7cbf24-ce89-4e84-b430-3a50ae3b70dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_064cb814-4c80-4de7-b6dd-f4c591090e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_411eee9b-b1d9-4a45-a0c0-fd716d84c0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_064cb814-4c80-4de7-b6dd-f4c591090e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a0ccb6f-7761-417f-9785-44cc8cf3f195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a0ccb6f-7761-417f-9785-44cc8cf3f195" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:to="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc37c4df-2c13-4e11-9250-2debcdda0457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_72e3c24d-f990-4c8d-9189-d221cc9eb7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25cf3236-e91f-4cf0-b25f-418b25a6b615" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_72e3c24d-f990-4c8d-9189-d221cc9eb7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63adda79-1a46-486f-a350-db82dc2d410c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73c5edd7-2720-48cc-9497-db8897ea155b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_73c5edd7-2720-48cc-9497-db8897ea155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97c985c0-c7b1-4265-ba58-066084c0f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_97c985c0-c7b1-4265-ba58-066084c0f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7df1b704-e168-4dd9-b076-8d352cff15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7df1b704-e168-4dd9-b076-8d352cff15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72a6de4f-ccdc-4181-ad5f-04e61186d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0e59bda-cee9-404b-b02b-bf45f765e043" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72a6de4f-ccdc-4181-ad5f-04e61186d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac494221-25af-47c2-906e-c9d2feb9bd2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a9aff7-7908-4213-b722-97bf80ab84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a9aff7-7908-4213-b722-97bf80ab84d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d5050a1-887c-41c1-80ea-5410a569706d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d5050a1-887c-41c1-80ea-5410a569706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_65a8eb4a-862e-456f-99fb-633c675289d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_65a8eb4a-862e-456f-99fb-633c675289d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8950fc3-cc29-4ce5-a5ec-6c12fe268697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_526ca3d8-177a-4ccf-b14f-45c476b8c7bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8950fc3-cc29-4ce5-a5ec-6c12fe268697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af705d8b-b493-475c-bb4e-bbf16457ceec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af705d8b-b493-475c-bb4e-bbf16457ceec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4313ecdb-b691-4564-9d0f-b3f098f3aba3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3a024efe-0a6c-4714-b08c-1fa7ec99a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3a024efe-0a6c-4714-b08c-1fa7ec99a3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_133928be-ca0a-446b-b578-da1f37ffa324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac9c9093-e3e9-4175-a69b-77d26200ba1d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_133928be-ca0a-446b-b578-da1f37ffa324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:to="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12998b65-d426-436b-9e1b-d0cbca8129e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_73e05187-e267-43f1-a373-4fdd97f79646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_73e05187-e267-43f1-a373-4fdd97f79646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd8e84c8-a506-43a6-8306-aa14139ab9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ccdcaad-527c-4deb-8b50-27641826ac31" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd8e84c8-a506-43a6-8306-aa14139ab9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_51b09a7a-c1c6-4843-a639-c88e84c6fbc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e59d0f79-e9b6-47f0-a0ff-16ce62585e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e59d0f79-e9b6-47f0-a0ff-16ce62585e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ac5abeb-b062-4c16-b944-fd0f77bdd2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ac5abeb-b062-4c16-b944-fd0f77bdd2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e39de886-202e-425f-80a0-629dbacfa136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e39de886-202e-425f-80a0-629dbacfa136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_febe2a08-d09f-4810-9c7e-223ba4b8ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66b8e996-3f4b-4ab2-822e-30cf2ce8e455" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_febe2a08-d09f-4810-9c7e-223ba4b8ee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_47719918-102d-458f-bdc6-a3dfb2bb9143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_47719918-102d-458f-bdc6-a3dfb2bb9143" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b95e67c-9da9-4016-9369-88cb76fe199d" xlink:to="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_cc89377f-3ffc-48a4-a80c-c356738d791b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_175e842f-656a-4792-b457-857c9403bf79" xlink:to="loc_us-gaap_RelatedPartyMember_cc89377f-3ffc-48a4-a80c-c356738d791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2c59aa10-9653-4bc6-a220-926fdeb68e52" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1470867e-8fa4-4f99-aaff-c7d447dfef48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1470867e-8fa4-4f99-aaff-c7d447dfef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b36bd78-e9c6-44bb-a6a9-04bc0e0cdc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bd03668d-7e4e-499c-b1d5-9bb3e4e40ed9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b36bd78-e9c6-44bb-a6a9-04bc0e0cdc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/COMMITMENTSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#COMMITMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/COMMITMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_12592866-07d8-4800-8a54-e7178e14d304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_12592866-07d8-4800-8a54-e7178e14d304" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:to="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2c29bd75-c273-4d12-8493-e91f81b6be67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LIVMORMember_04ff45a7-c3a6-48ce-938a-8d628477ca45" xlink:href="beat-20231231.xsd#beat_LIVMORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:to="loc_beat_LIVMORMember_04ff45a7-c3a6-48ce-938a-8d628477ca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TripleRingTechnologiesMember_b79821db-a081-4a83-a9c6-5454556cf89e" xlink:href="beat-20231231.xsd#beat_TripleRingTechnologiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21f22d2b-cc5a-4faa-b2c4-02925e6ea76f" xlink:to="loc_beat_TripleRingTechnologiesMember_b79821db-a081-4a83-a9c6-5454556cf89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_e2b24e01-4217-4e4d-a6ea-55d35ce16d23" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation_aa8f3566-e887-43aa-b82b-e955211ff591" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeasePriorNoticeForCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_LesseeOperatingLeasePriorNoticeForCancellation_aa8f3566-e887-43aa-b82b-e955211ff591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_LesseeOperatingLeaseMonthlyRentExpense_13fddad4-75c7-459b-83fa-fa66d555285a" xlink:href="beat-20231231.xsd#beat_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_LesseeOperatingLeaseMonthlyRentExpense_13fddad4-75c7-459b-83fa-fa66d555285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_926ace16-5246-4a1c-a460-c893311a4cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_OperatingLeaseCost_926ace16-5246-4a1c-a460-c893311a4cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6e0914c8-2bbb-46f0-a568-77f34e562b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_PurchaseObligation_6e0914c8-2bbb-46f0-a568-77f34e562b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_PaymentsForPurchaseObligations_fe3dd1d9-7c0a-4e3c-a4a8-be3ca42814e9" xlink:href="beat-20231231.xsd#beat_PaymentsForPurchaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_beat_PaymentsForPurchaseObligations_fe3dd1d9-7c0a-4e3c-a4a8-be3ca42814e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_688afbe5-36e2-47bf-aa39-63fa21b97730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_2d89fb34-b45e-43de-89a3-00de2284be9d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_688afbe5-36e2-47bf-aa39-63fa21b97730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38a6822f-bf3d-4596-9eb6-92dd941b4e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38a6822f-bf3d-4596-9eb6-92dd941b4e13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c1744146-bd42-454d-a135-18e288f9320b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c1744146-bd42-454d-a135-18e288f9320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_4f6c9605-fd04-4db0-bb13-d71a3e2ff404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_4f6c9605-fd04-4db0-bb13-d71a3e2ff404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_5b2d6c01-4bc0-425d-aca4-a4852a01a35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_5b2d6c01-4bc0-425d-aca4-a4852a01a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_428517c2-cdae-487e-a948-7daa6a640b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_428517c2-cdae-487e-a948-7daa6a640b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_84418754-f18e-4c45-b96b-12666c5c1a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_84418754-f18e-4c45-b96b-12666c5c1a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c6feac1e-4d11-4e4d-b08c-f77c89550546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c6feac1e-4d11-4e4d-b08c-f77c89550546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f616c039-8054-4945-be11-8cab9a570e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f616c039-8054-4945-be11-8cab9a570e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_126d1074-bede-403d-9d02-198996c6abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f7ca128e-5e2d-4505-ab8a-aeaece155ddd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_126d1074-bede-403d-9d02-198996c6abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38a6822f-bf3d-4596-9eb6-92dd941b4e13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31e7fdb2-1da6-43ab-8509-b057f188b54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31e7fdb2-1da6-43ab-8509-b057f188b54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_103c088e-9b67-4c07-a963-4552c6330044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_103c088e-9b67-4c07-a963-4552c6330044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_3b7926f5-2a5e-4ad0-b59e-cb67fbf7e3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_3b7926f5-2a5e-4ad0-b59e-cb67fbf7e3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e2f28fe5-23ed-4d5a-93ba-9537ba7b30f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e2f28fe5-23ed-4d5a-93ba-9537ba7b30f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3e9cf863-9d2f-48c4-b5d2-3567b38f922f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3e9cf863-9d2f-48c4-b5d2-3567b38f922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7e2009bb-1656-400d-8771-8ff4e71bf676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7e2009bb-1656-400d-8771-8ff4e71bf676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c87a7e2b-6c7a-4932-8975-8836678dbcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c87a7e2b-6c7a-4932-8975-8836678dbcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_317c1102-cff1-4c07-b7ce-c24f56981524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eceb5d1e-041d-4675-814f-0d70b746a1a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_317c1102-cff1-4c07-b7ce-c24f56981524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b83df02-6b3e-42e1-b09e-1b921d295f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b83df02-6b3e-42e1-b09e-1b921d295f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a02af2cf-c0b1-4b1b-a3de-94940a33e526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a02af2cf-c0b1-4b1b-a3de-94940a33e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_21529e4c-89a0-4830-894d-b79ecc26b185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_21529e4c-89a0-4830-894d-b79ecc26b185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b1c89cae-b885-49e5-b43d-95e673b5ff66" xlink:href="beat-20231231.xsd#beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b1c89cae-b885-49e5-b43d-95e673b5ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8974b581-8a46-47ec-af97-60f37c542bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8974b581-8a46-47ec-af97-60f37c542bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_07dabd29-5a23-4b21-8242-2d8d696ca24f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_07dabd29-5a23-4b21-8242-2d8d696ca24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b68b6b8-ed5b-4152-92f2-4163c8f04153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b68b6b8-ed5b-4152-92f2-4163c8f04153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b593243-59de-4a50-9e3c-ef4397d73dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28d1cf39-b704-4210-8ad5-7234b8344fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b593243-59de-4a50-9e3c-ef4397d73dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#INCOMETAXAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f202a03b-db19-4043-9fff-e72a21dc4393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f202a03b-db19-4043-9fff-e72a21dc4393" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80f58307-bb9c-4259-90f2-592e6a0d1b07" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_594c5327-2299-469e-ba1a-13f59443f9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:to="loc_us-gaap_DomesticCountryMember_594c5327-2299-469e-ba1a-13f59443f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_33e76233-ce24-4a4a-976f-5899a9d363cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49e435a4-c8b6-4642-a7d3-d70c3a21112e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_33e76233-ce24-4a4a-976f-5899a9d363cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_b6052df2-8de8-4b7a-9f12-be31017dbb68" xlink:to="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsPriorTo2018Member_c2e09345-cc9f-4b2b-b69d-a5bdbe4552be" xlink:href="beat-20231231.xsd#beat_TaxPeriodsPriorTo2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:to="loc_beat_TaxPeriodsPriorTo2018Member_c2e09345-cc9f-4b2b-b69d-a5bdbe4552be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_TaxPeriodsAfter2017Member_b6f3333a-8fac-4fc6-8278-89d4f1f7ddf1" xlink:href="beat-20231231.xsd#beat_TaxPeriodsAfter2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c52ac248-26f6-4ff4-852d-f5c34f8959f2" xlink:to="loc_beat_TaxPeriodsAfter2017Member_b6f3333a-8fac-4fc6-8278-89d4f1f7ddf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ce857fdb-564e-4f66-8d61-d93037f5fdc3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_57450454-6ad2-4e37-9204-3d9b25c8241e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7eb9e8f2-6a49-4102-bf1c-db16078e6882" xlink:to="loc_us-gaap_ResearchMember_57450454-6ad2-4e37-9204-3d9b25c8241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2cb6a816-9239-4845-aec7-3b2c6a224c51" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_aac2f56d-92aa-456c-8a49-256abb80e657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_aac2f56d-92aa-456c-8a49-256abb80e657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8a4d921b-9c74-4101-8fce-8cfa287ff4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8a4d921b-9c74-4101-8fce-8cfa287ff4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d82d193a-7a8f-4788-86b6-16a299bd3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d82d193a-7a8f-4788-86b6-16a299bd3cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a12e0dc3-3ed4-4fe3-be2f-cb47e04c4e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a12e0dc3-3ed4-4fe3-be2f-cb47e04c4e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2b77d1ba-2826-4a45-93d9-60bd7440eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2b77d1ba-2826-4a45-93d9-60bd7440eb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_b57a6c1d-d199-47da-9a11-5ebe133aa5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_b57a6c1d-d199-47da-9a11-5ebe133aa5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_573c22b9-5f6f-4994-ac35-45521885374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fc4b9df3-96ae-4c76-adff-42c603eb9b70" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_573c22b9-5f6f-4994-ac35-45521885374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="beat-20231231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_50e8a6e3-6dfc-4787-bcaa-29767a19367a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_50e8a6e3-6dfc-4787-bcaa-29767a19367a" xlink:to="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3303369a-a18f-4814-9f5c-652bc52d1107" xlink:to="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_A2022EquityPlanMember_180ae276-c82d-4083-8792-86f9487b882a" xlink:href="beat-20231231.xsd#beat_A2022EquityPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_85993ece-3f98-4faf-b39e-afd471d7f7dc" xlink:to="loc_beat_A2022EquityPlanMember_180ae276-c82d-4083-8792-86f9487b882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e96b8682-c4db-439e-af95-14e03283cd66" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3619113a-a255-40c9-b233-a9a8042b7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_896bed7e-7769-463a-b9e1-277ee849f2ea" xlink:to="loc_us-gaap_SubsequentEventMember_3619113a-a255-40c9-b233-a9a8042b7ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_caed7f25-ebb6-4518-8597-6c39f81a4a24" xlink:to="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bde29748-80c4-4dc1-9734-5b36945aa552" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_74703333-c66c-4d3c-a899-927886664493" xlink:to="loc_srt_ScenarioForecastMember_bde29748-80c4-4dc1-9734-5b36945aa552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f748ac61-6f2f-4543-9fea-b67ac605046a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ClinicalResearchOrganizationMember_3b411395-0498-40bf-ab4f-b864f4662232" xlink:href="beat-20231231.xsd#beat_ClinicalResearchOrganizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_125cab18-5b72-4851-add1-d9a23d4f9b36" xlink:to="loc_beat_ClinicalResearchOrganizationMember_3b411395-0498-40bf-ab4f-b864f4662232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c489e17d-c9bf-4986-ad0c-0e5ec6404980" xlink:to="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_385bfc1f-0b48-4c7d-aee9-40c7df68bd61" xlink:href="beat-20231231.xsd#beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_385bfc1f-0b48-4c7d-aee9-40c7df68bd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b6a4b3e-1290-41f9-aa35-ab3f51734d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b6a4b3e-1290-41f9-aa35-ab3f51734d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91903527-05aa-4f5b-8efa-07e2a809026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91903527-05aa-4f5b-8efa-07e2a809026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_81509ba8-ec36-4d33-a30a-a992f9e8473d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ContractualObligation_81509ba8-ec36-4d33-a30a-a992f9e8473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_7c18beae-0df4-42ab-a8df-286774d9f65b" xlink:href="beat-20231231.xsd#beat_ResearchAndDevelopmentNumberOfClinicalStudySites"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_beat_ResearchAndDevelopmentNumberOfClinicalStudySites_7c18beae-0df4-42ab-a8df-286774d9f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53f1ac50-480d-4057-a929-7954023ad808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_49fba7f5-3f28-441c-83c8-b1914cb863d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53f1ac50-480d-4057-a929-7954023ad808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>beat-20231231_g1.jpg
<TEXT>
begin 644 beat-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0"&17AI9@  34T *@    @  P$2  ,
M   !  $   $Q  (    A    ,H=I  0    !    5     !!9&]B92!0:&]T
M;W-H;W @,C4N," H36%C:6YT;W-H*0    .@ 0 #     0 !  "@ @ $
M 0   NB@ P $     0   M      _^$)?6AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB6$U0($-O<F4@-BXP+C B/B \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<#I#<F5A
M=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P(#(U+C @*$UA8VEN=&]S:"DB+SX@
M/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" \/WAP86-K970@96YD/2)W(C\^ /_  !$( M "Z ,!(@ "$0$#$0'_Q  ?
M   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$
M!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6
M%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V
M=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$!
M 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#
M$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G
M*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%
MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35
MUM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_VP!#  $! 0$! 0(! 0(# @(" P0#
M P,#! 8$! 0$! 8'!@8&!@8&!P<'!P<'!P<(" @(" @)"0D)"0L+"PL+"PL+
M"PO_VP!# 0(" @,# P4# P4+" 8("PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+
M"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PO_W0 $ "__V@ , P$  A$#$0 _
M /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#_T/[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM&Y?6@!:*** &.NY<5$8F'W:FW+ZBG4 0%&S2/$/+*U8I-R],T 1QQ;*8P<
MKZU/N7UIDOW1]: /Y'_^#K9FC^"7PEF/4>.+3'_@+<5_2=^R ^_]ESP"_4G0
M['_T2M?S9_\ !U[@? _X2?\ 8[VG_I+<5_23^QZ__&+7@%C_ - *Q_\ 1*4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P _C_@XZMCH/_!:'X4:Y)PDNCZ6?RO;FO[]?@K<K>_";P[<C^.P@/\ XX*
M/4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH __U_[^**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY=O&J!V'5FP!U)S7T!!9P6L0@M$$2C@!%  _"K)C4]10 NU?04ZBB@ HHHH
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M?)*JEGIEXBJP]#/;*K?A0!_5MYBUQWBCXA^!O!=E)J/B[6+/38(EW,]S,D8
M]]Q%?YZ'B3_@MC_P6W_;$UI]-_9L\!:[:6<IVPLNGQ6JD=/];*D:]_6M#1/^
M"5'_  <5_MAW<5Q^T)J%YH&A:J09OM.N63!8S_TSM[EW[#^&@#^WWQ7_ ,%%
M?V&_ ^FSZKXE^*?AN"&W($G^GQ,PR0/NJ2>IK\Q/VCO^#EW_ ();?!*UET_P
MOXW/C#6-K;+72K.YF7=R #)Y7E\D?WJ^3_V-_P#@UC_9=^'5DWB#]JZXG\:Z
MQ.,M$+J;R4;N>6PWY5^F&B_\$%?^"7^@RPW&G?#2Q\V%MP>3+G.<\\T ?S?_
M !,_X.AOVR/B5J4^F?LL_!K5-1LY_DM[A[1V8LW /RCC\Z^6=7^)_P#P<F_M
ML.UKX)\!:WHUM='DKJ$5BH5^_P"]FCZ#VK^^[X8?LK_ +X-:3%I/P\\*Z=IT
M,'W/*@3@^O(KW>TL+2U_X]8HX_\ <4#^5 '^>O\ #?\ X-N_^"I?[4-VLW[7
M_C1_#MN#G$^HF\?GD\1,X_6OT[^"/_!H[^S3X"9+OXC^*IO$5QP7#P!E)'^\
M:_KX3[U3T ?EQ\ ?^"0O[%O[/5Q;WOA#PEIQN+;!61K2,-Q[U^D^F^'-%T2(
M0:7:0P*.@10/Y"N@HH K[&QT_6K%%% !1110 4444 %%%% !1110 4444 12
MMM7.,U_!K_P=2WO]J_M4?!+PPG+-?RL%^LD K^\F7G[O)K^ W_@Y N(O$W_!
M37X'>$+8^;*EWN9/]^: 4 ?VD_L6:<^D?LL>";%AAH],B7;Z<5]6INQ\W6O%
M/V>=,&C_  6\-:7LV&*R1<?05[1'WH _S@?^#H:-D_;S^'TO][5+D@_\"AK^
M][]C# _96\ /UQH=C_Z)6OX,?^#I-67]NCX=-CC^T[K_ -"AK^\S]BOYOV4_
MA\W_ % ['_T2E 'U/1110 C?=-?D/_P6%O\ XAVO[.NE'X=M9I>'6(@WVVYC
MMD*[6SAI649K]>#T-?C'_P %IH/";_LY:)%XRTF_UF ZW#MBT^&2:0-M;#$1
M D"@#]-/@*^I-\$?"+ZN$^UG2;/S?+8.F_REW89201GN*_BF_P"#I;X"ZM\,
M?C/X _;,T&!]FF:I;/=31C&U8VC7)(YQDU_:I^S^MM#\#/""Z?;R6]N-'L?+
MBE!615\I<!@W(([YK\Z_^"V_[)Z?M6_\$^O'7A+3;(7NJZ?8-?V@SAMULRRG
M!)'.U* /7_\ @F5\>M _:P_82\(?$33+E+M-1M+BWN",G;)'*\94YQS@*:_A
MD_X**^ ?'O\ P2*_X+4^'_VFTLY[;P;JNLZ9JQNXQ^Z>V295F4[<]-C?*17Z
M:_\ !IO^V#)X9T;QI^P;\4;[[%JFCZI+?6%I< @A)TB78K8QRP8XS7]*_P#P
M4I_X)N_"+_@HS\%KOX=?$"TA;48[6=-/NGR&BF=?D.Y2",-@T ?6?[.W[0'P
MT_:1^&&E?$[X7ZO;ZM9:C;1S;X&W;"Z@D$<$5[XKJW2O\S?PMXL_X*Q_\&^_
MQ>CM_&^BZI>?"]+HJ7@>'4+5K56P3\C3&,[3GY@M?VD_\$X_^"R7[&__  4&
M\+0P^ ?%UM!XK@3-WI%XLEK<*?5!*D8D'^X6H _8*BHXC&R!X^0>14E !111
M0 4444 %%%% !1110 W>OK3JJ?3BK*MNH =1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?_2_OXHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **A>1E!]>U,25V'3F@"S6=/<PVL+W-S($C0$LS$ */<F
MOAK]KO\ X*2_L@_L2:++?_'SQOI>CWB(7CL7N%-U(!Z0J2Y_ 5_%9^T__P %
MHO\ @I#_ ,%.?$MY\%/^"=OAC79-$FF=7OK*Q#(]NYVH6E>(!,YR,LM ']6?
M[>O_  6Z_89_89TB2Q\6^-+#4O$9;RX]-TZ47LRN!G]XL&_9_P #VU_*+\0/
M^"N?_!9K_@I-XLO/#G[$W@S5K3PU>S/':7@L%MX3#N)1C<2A5&5P<[J^R_\
M@G%_P;$W?B345^.7_!0]#J>L7R^<VFS3OYBRN<DN8GQ^%?V2?"#X&?"[X#^!
MK#X<?"W1X-*TG384@@BB7&U(U"@$]3P* /X>_@%_P:Y_M#_M ZS#\3?V[O$K
M1WU\3<WML+PROYK')&8MR]^QK^@7]EG_ (-\/^"?W[,M[;Z[IOAX:IJL SYU
MU(\HSCKAB:_=ORDS[>E&SY>1S0!QOA3P+X1\%:1%HWA?3X+*VA&Q8XE  'X5
MVNQ?2F;.GZU+0 5%+*D2;FZ=*-FSF.G,J.FQAP: (G=ROW:_-#XV_P#!7#]A
M+]GKX\:9^SM\5/'=CI?B+4Y##Y<CGRXGR !-)C9%G/\ $5K]+6B*#Y#7\Z?_
M  5F_P""!?P/_;QTS4?B;X%M8M*^()CDECN_-D FEQE5QOV]1W% '] ?A;QA
MX6\:Z3'K_A#4;74[*?E)[299HCW^\A([UTK;G'7(/-?YLOP0_:K_ ."LG_!#
M/QS%X1_:-\-Z[>?#F:88F:U6>U49VL?.5),': =I:O[2OV#_ /@KC^Q?^W5X
M5LY?ASXVTO\ MZ50LVDSW ANED.>!%)M=O\ @(H _5ZBH3*,_+R*>C[^U #Z
M*** "BBB@ HHHH **** "BBB@ HHHH A8#?\W2O\^7_@L+<CQO\ \%XOA-X4
MC_>_9'MW8#L#.G^%?Z#4G3=V'>O\['XBZD_QT_X.,O#ILS]J&G16[''(7;.?
M3Z4 ?Z$'@2U33_!NG6B+M$<( %=84\M15'38&MK**$_P@#'I6BOSYW<XH _S
MF_\ @Z;5O^&W/AM)W.IW61^,-?W@?L2Y/[*'P_\ ^P'8_P#HE:_A(_X.H8]O
M[:OPU/\ U$KK^<5?W;_L2_\ )J'P_P#^P'8_^B5H ^J:*** "OR5_P""N7BW
MQ9X0^"&A7_A#7K'P]<2:S$C3WTL<:,I#94&3C-?K.^[8=O6OQF_X+1Z!!X@^
M 7AFWN?"-YXN4:_ 3;6:2.\?RM\Y$?.!0!^I'P7N;O4?A'X9O+^>.ZFETNT=
MYHB"LC&-264CC!KNM:TJRUW1KK1KY=\%W"\,B^J2#!'Y&O/?@9;+9?!KPM;1
MVKV0CTJT46[@AX@(E^0@\Y'2O6G^Z: /\VS_ (*;_"7QI_P2 _X+!:'^TQX&
MMI;3P;XK-E>/=(IDA$BN8Y(SUPP$8;'O7^@K^SI\;O"G[07P>T#XK>"[V&^L
M=8M4F62)@06'#=/0@U^;'_!;W]@.#]N[]D>_\.:5I_V[7]#BFNM.VY$GF;>B
MX(R>*_G(_P"#?3_@J=:?LA^(;C_@GY^V]J+>$KNQU,VFE_VNOV94\\C8I9E&
M 7.?F- ']N_QG^"/P[^/_P .]3^%_P 3].BU+2=6A>":*49^1P5)'X&OY#OV
MR/\ @V0UWX:>(9?V@_\ @G1KKZ#XDL0TD=D;AEW8YPI;(YQCK7]G^DZG8:Q8
M0ZII<R7,%PH>.6-@RNIY!!'!K9H _AX_9G_X+S_MD_\ !/I=.^!__!5/X=ZS
M#:(0L'B%+5V1H5)1B74%6*XR0/FK^G_]F/\ X*B_L)_M=V%M=?!;XD:->7-R
M0%LIKI+:[W$9QY,I20]?[M>W_M+?LH_ []J_P-+\/_C7H5OK-A*CQJ)5PRB0
M8;# @C/M7\5G[;'_  ;%?&GX&>(IOC3_ ,$\[]A>VKF:VL+:=EG0@D@ SO@T
M ?WQ&7*=1ST.:GC^Z*_SS_V=_P#@MW_P4\_X)_\ B>V\)?\ !1CPAXA70KAT
MC%_>Z<(XT\LY;;)'#AN&!X:OZR/V0O\ @M)_P3__ &O=$MSX(^(NC6NKM&K2
MV%]<K:SJQXP$F$9;!_NB@#]:Z*H6EY#?01W5LX>*50ZL.58'D$&KF]"M #Z*
M** &.7"'8,FHO,;UJ27[M0G-  /UI >*.G2@4 3+)V8U+57KTZU85MU #J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T_[^****
M "BBB@ HHHH **** "BBB@ HHHH **** ,^638"6X0<LU?R]_P#!9S_@O9X>
M_8VN(?@I^S)=6GB/Q[<+*LL-JXNGMBNP*"L>[#$ENO\ =KOO^#A?_@J[>?L,
M?L^K\./@IJ4'_"P?%LLME;K&5EN($VX9Q'G(;+KCBORW_P"#?W_@C6_Q=M;K
M]OC]M_3+O5?$.M7B7&G1:DKQ$J-S/+LPF0Q(]N* /D+]B7_@B=^V)_P5>^(K
M_M-?\%'+S6=/LKZ07"PWL9MVECD^? C(#*#GLM?W._LK?L3?L\_L:^!XO OP
M+\/6VDVT<21,ZKF601C RQR3UKZDLK"UL85L;2,1)&,!4&!C\*UT0*FV@"*"
M+R_I5BBB@ HHHH **** &?-N]J5>%]:=3&W_ ,- #ZHNKHWR#(ZC_"KB[<?+
MTIU '@WQW_9U^$G[2WP_NOAO\8]&@U?2[Q2KQRKD@D$9!ZCK7\2?_!0[_@W&
M^+7[+_C5?V@O^"9MQJ<-R'>9=.LWWO R$%<9^8YR:_O?=<M]:5URNS;Q0!_
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M5]B],U^"G_!Q5^TG-^SO_P $U/&DNE7"0W^O0-IL09B&)G4KD8(.>: /Y/\
M]BOP1KG_  6@_P""R5UXW^+:2ZQX2\(N;\&W^6!660%%8G< &*'O7^D)X5\-
M:)X,T*U\+^'K=+6SLU$4,2# 51T K^5'_@U/_9=M/AE^S)K?QJU"W>+4?$TD
M"%W4 E8MYX.,_P =?UI1;M^#S[T 2^6OI3Z** "BBB@ HHHH **** "BBB@
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M^'/_  43\.#P7X@\T0/=R6\MI$X_O,)20/SK^QDPQW"%)U#IZ,N:^ _VW/\
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MC'+ 5]TIO[]*YSP?I:Z-X9LM+0;1;Q*@'T%=10 4444 %%%% !1110 4444
M%%%% !30@&<=Z=10 4QGVD#UI]1N<,M $E%%% !1110 4444 %%%% !1110
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M]17\7W[0O_!J?HGPV%U\3_\ @G[XXU'PUXJAD,EK#*^V, ]5WJP/2O@/3?\
M@LS_ ,%9/^"1/CFQ^ O[9^CP>)=$L284NKABLLD6"582E7SR1VH _P!#:15=
MR*\Y^(WPH^'OQ9\.7GA+Q_ID&I6=["T,T<B@Y5A@CI7Y5_\ !/W_ (+8?LG_
M +=WABR.@7_]F>(7RMQ82$,$<-MX;"]>#TK]E+:XBN@)87WJXRI'IB@#^7[]
MJW_@UG_85^-"W7B#X;6][X9UF8NX>UF54WDY'#(>]?@7\1_V*/\ @M%_P1YU
MN34/V2KO6]?\*9\Z1H+>6YB5NA#%5V_=45_I#52QN' [T ?P8_L9?\'4_P 6
M/#?B^Q^&O[=>D6VG^5<+%=7WEFWD1#@%FWDCCZ5_:)^S[^U5\"?VGO!UMXZ^
M#7B"UUJPNU!5H)%;DC/."?6OG[]MS_@F7^RU^WCX8ET3XU:,LUS)$T27<6!,
MG7D$CM7\?W[1'_!O=^UM_P $[?%C_'C_ ()T^*;Z]N+)C/';>5M=<'H660YX
M_P!F@#_065PWX4,ZIUK_ #I?@]_P<U?M\_LI^+4^'O[8_AB'5%R-TC/Y,J '
M!_Y9M7]=/["G_!8_]D7]NO2$'@+5C:ZN@036DN/D9]V!N&,_=/:@#]</-3)!
M[4@E1NG-44N;>X07$;;T/=>E/N)4@B$KGA>2: +?FH?EI?-3?Y?>OYZ_^"K'
M_!;'PI^QY<Q_!+X'0)XA^(]\RK':[MB1(RYW9"N<\CM7IW_!'FP_;X\9^%M1
M^.W[9VML7\4M]KL]&\LA+2&7YU 8N>BL!C:* /W*HHHH **** "BBB@ HHHH
M **** "BBB@#_];^_BBBB@ HHHH **** "BBB@ J&3EL5-2;5]* %ICIO'TI
M]% %9HG>,ACSVK_/P_9(^'4GBO\ X.?M<L?%$?F'1=1O[U>. T0#(?UK_08K
M^'3]@BUT2Y_X.??BI<V6K"X6.#460L WF,57* YXQ0!_<712$X&:6@ HHHH
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M?PKV$S\WE%IV:):*:=_\.* 6Z8H$.HIA9L]*?0 4444 %%%% !1110 4444
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M>Q,[L<UR?@AYY/"&F27+B20VL19@,9;:,G%==0 4@4+]VEHH **** "BBB@
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MU_FM?\%KO$VI_MM_\%L?"7[.]O(9M.@N-*T@HI)4"2Y;<<=.C4 ?V._\$/\
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M'2'\NZ4?VAXBN=H,"N2H58P).O)SD=*^]/\ @GA_P0G^$OP"U!_CK^U!=_\
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M1DX7 .XG=7^A%\(/'5E\2OACX<\?615X]:TNTO0P[^?$LG'_ 'U0!ZC1110
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M+3Y&)R=UK D9Y^HKS+_@X8^%%I\4?^"=/B&*YC$LFG7<-Q'D9QA7']:^!?\
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MQ/\ P4'_ .#;7]J_]B;P;)\2M$GMO$^B6R[KB:WG5&B7!))641DXQV%>%?\
M!#[_ (*2?&?]B/\ ;)\):%I]_)<^']7U./3;ZRF8R)LNB8CM'.,,^>*]D_;D
M_P"#D3]LG]M3X?3_  HEM[+1M'N@5F2VA4R2*<@@DJ3SGM7Y.?LQ>#_B3\._
MC#X6^.OBGP7KFH:#I.I6^HR2V]E*4D6"3?PP3&"PH _V\_"6OV_B7PS8>(;?
M[E["LRCV89KI-ZU_)_\ LX?\'2'[$,FB6/A7XPVNI>"UM8D@#7=I<MMV<<[(
M6K]2OAM_P76_X)5?$^%?^$?^,&EQRL<;+J"ZMCGW,L"+0!^N^]:-ZGH:^9/!
MW[8/[)WCZ".[\&?$CPWJ/G'Y1#JEN6)_W=^?TKW[2M9T;7(/.TB\BO8CR'AD
M60?FI- &YO1>":7>OK51\ >OI6/KFOZ)X:T^35M<N8K.WB&9)IG$<:CU); H
M U[Z_LM,M6NK^588HQEG=@ !ZDFO*?A-\>_A#\==-N=9^$>NP:[:69599;=7
M"J7SCEE&<X/2OXI?^"ZO_!QU8Z/:Z]^S%^Q??Q:MYD;VU[K=HC.B')5EC9DP
M3QG<.*_47_@UDTR]L_\ @GS+K6K2R3SWUW$6>5RY;8K=R3ZT ?TXM<0QQ[W;
M ]32)=6[H'C<,#T(Y_E7\WO_  75_P""R_@_]@CP=H_PS^%VIVNH>/-<G.^S
M0^:UO;(!EGP"H+%QMR?6OUO_ ."?OB_Q1\0/V/? 7C?QE<?:=2U?1;&\N),
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M](?'#_@E?^P9^T/J(UOXD_#ZS>^[W-C+-82M_O-;O'N_X%FOS[\>_P#!M_\
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M+1ELAAP?F0D'UK]D/V8?^"S?[</[*W@VP^''@[5M.UCPYID @L]/U6Q21(4
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M O\ @[&^!$_PY^+/AK]JOPW&T5T;FWC:1#T<;VR:_M!_8=^,<7Q]_9>\'_%
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MNYWD2PMI6VM<3K&6 4=32?\ !V3<6'A?]B:P\,Z4JPP"542->@0#  K^5?\
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M=D,D\K2E(0BJ JEL#.3BOTQ5U;A>U1-;]U/-/2'9P">* &3(KKAAGUK\I_\
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MK_\ !.S_ (+Q_P#!/Z^_MWX5Y\=PVOS*L0EG+!> -D<^XYH UO\ @ZINFO\
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M@6DN+N9(44 9.6<@5_*W^UU_P65_:1_:P^*]W^RK_P $NO!G_"4V]NS+?^*
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MKN7% 'SM\$/V<_AW\!Y=8N/!-L(9M<O9;ZZ? R\DC%B<_C7T3M3EO6H?*?\
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ME<Z[;Z)\;=$O_"3E@DS7<6P(W?/-?I[\+_\ @MW_ ,$T_BJ%ATCXGZ5;W#'
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M/Z0WB5D^2Y/'PNX3IQ^KTE%5I_%9IN3IJZUGS6E4FG?F;CH^:WC%[_P;S_L
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MPO\ -&WS-'AD /H5'^%?SL_\'EMQ;R?L_?"*%&!8>)6;CG ,$F#^E9W[6/\
MP4QO/A)_P3^^$W[&W[.6L&UUFX\,V+>(K^U<I-:P-"C);HP PTH;+D$%5&/X
MN/N\VS6CE^&EB:VRV75OHE_6VI_)'AUX?YGQEG='),L5I2UE)I\M."^*<O);
M)=6U%:L]-_X+C_\ !5JU^(MYJ_[%'P%EWZ1IUUY'B+5D;_CXN+=COM8AC[D;
MC]X^?F8;0-H);Y!_X(W_ /!,'Q%^U]\4+/XU_$ZS\CX:>'+GS)?-'_(4NHON
MP1CC]VK8,K],#8.22O@/_!+G_@G)XQ_;U^,L"ZI!-:_#_1)@VNZBA"$C&Y;>
M(]3))P"0/D4[CS@'_0J\%>#?"OP[\(Z;X$\#V,.FZ/H]M'9V=K NV.&&%0J(
MH'8  5^?Y)E=?/,6\US#^&G[L>CMT_PKKW?S/[(\4N/<J\*N'8^'W!K3QDXW
MK5;^]!R24I.U_P![-?"K_NXV:^R;<,-II=E'9V:+%%$H2.-1@  <  >E?A%_
MP54\$>"_&/[1OP4O_$.N3:;>P:Q L$$62)661FPV&'!S7[HWDZF3DX K\(_^
M"K?PI/C[XX?"&XM8%'D:O#)/<95)(8PYY4G!_*OU,_S^/W;@N8DA15_N_>KY
MV_:7_:O^#?[*GPZO_B!\5]6BL;>RA:18V/[R1EZ*H[DGI7P%^V!_P5I_9X_9
M)\.S^!O#VH)XM\<1+':6.DV1+RS7#[50,1D#[V3S7Y=? 7_@D]^T)^W;\?[3
M]LS_ (*,W#2Z=.Z7FF^&#,QMX5QE%>(EEX&,C'6@#Y@^./[7/[:/_!=+QU<?
M ']D/2[WPK\,+5UAOM9N9#!YS/CS,>6I+ *PX+&O9/VA?^#>K^P_V</ G[+7
MP@A@O[B_U:&?Q%K<D6R39/-$LO.69@L:D\FOZR?AQ\-O WPE\+6_@WX>:7;:
M3IMM_JX+:)8T!/4X4 5Z*DRL.1R* /!_V:?@-X1_9L^#FA?"'P?"D5MI%I'
M2B[0S*H#' ]<5_+K_P '6OPL\5?&_P "?#/X8>"+9[F_U+5)8455/ 8Q+D^P
MS7]@_##/6N(\2?#/P1XMU:TUWQ'I\%[=6!8P231J[H3C.TD$CIVH _+O_@BW
M_P $\M,_X)X?L::+\--0B@D\0W[M?ZE,B8)ED 7;GDG:%K^)3_@Z*^&?B3XP
M_P#!5O2_AWX0MWN=0U+3H+>)%[L\SC%?Z=2VX1 B]%Z"OREUG_@EE\-O%_\
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MM'X.ZL."UBJY'!PMS(?ZU_<#^QU=?;/V7?!%UG[^E0DG\Z_BA_X.^H!_PO\
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MJ=0!%'@?B,U+110!4^]N(.[':L^_TZRU2W:PU"!9XGX9' *G\#6W3&&&W^E
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M_DS'7<?\&O=[Y_\ P37TB#IY<KC_ ,B24 ?TF)]T4ZD7[HI: "BBB@ HHHH
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M=(CCJ:_A*T[]G3_@XV_8;L9_'&E^(+/XA6=HF]K=AYK-M[!%D5CG%==\ _\
M@Z@^-W@'5F\%?MQ_"2;2[NV<QR3Z=!/"V5X.4F9_T- ']OC73<D]ZKU_,'IW
M_!U9_P $^9KKRM9M-7TX?]-8,G]*]'MO^#GW_@F?=0/*FJWS..BM P_]EH _
MHU%78HMI^<5_+]XH_P"#K3_@G[X=4BRL=1O^N,%EZ?\ ;(U\C_$/_@\F_9YT
M@R6OP]^%FIZM(.$>2]V*3]/(!_\ 'J /[049U0@# %<AXC^(7A#P;9F_\4:G
M:V,"?>>:55Q^9K^ ;QG_ ,'6/_!0#X\7#^#/V=_A)I6GR7I*0RR174TRH>!S
MYRKG)'\-6?A[_P $T_\ @MI_P4Z4^-_C5\3)?!&A7?[TVL8"]> % 8D?\"-
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M/$%C<*?NE9T/]:]"MM<T:X.Z"ZB=3T(8'^M '\O7_!UZ%7]B+PC@?\SC9?\
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MQG&2#:*0!]:_UH/$6A:3XFT:XT+7H1=6=TIBFB;HZ,,$'%?B=^TM_P &^O\
MP3D_:)TV<6OA(^&=1E!(NM.E96R1UQ)O% '\IGPU_P""/\OC31UUS]DK]K6U
M6W;[L-_JEJ9@>P*_*?6O>5_X)P?\'!/PBMOMGPX^,%OXDLX>5\L1R;@.G3%>
MR_$S_@T7\0^&=6DU[]FOXL:CII))6.X5&*D=.04]Z^==7_8Q_P"#@3]@;=KG
MA?QA_P )GI%E\RP.JR!E7@#:LF[D4 ?FS_P4[_:0_P""MX^".F_##]L_0UFT
M'3]8AN(;W[%+%ONH8Y55=^_;\RLYP!VK[\_9B_X.@OVM/V>_A-X=^&WC#X,1
MW.DZ38PVUO<165[&TD<:!0V]I&0Y SPM?!G_  4L_P""P'[:O[17P!TWX!_M
M5?#-- 33=9M[[^T8[:6+S)+>*6,IE]R_,),]>U?L'^QG_P %]_\ @F1XE^#O
MA3X'?M%_#=(;K2+&"U>[G;<CM&BH3A8UZX]: /H#P)_P>)_ B5H;3XH?#'5=
M-GZ2M'<;5![_ "M&37Z@? /_ (./_P#@GE\<9(X;O6O^$<>4#Y;^5% )[$G;
M7GWAKX'_ /!O[^V3ID>K:7IWAF&XOE#$&^^S3 MST:3K_P !KQ?XJ_\ !KW_
M ,$Z?C3#)>_"+6+[1Q*2Z-97<4RC/3'R'B@#]_/ '[<?[('Q*M%NO"?Q'\-W
M!< B,ZI:A_R\S-? /[46HQ>-_P!M;X>^(O!<?AO6M,BM$W7[W0EG0B4\1>7.
MJG_OAJ_ KQ5_P:#:YX9F.I?!SXO:E:S!OD62-20/P*U^8_QX_P""1W_!2S]E
M[]I7PO\ "7P1\4;O5=8U"V$^GSE,)$AD*@??P>1GK0!_IHVUU:R?(LJ,WLP-
M:&5K_/?OK3_@XI_8]E;5M3NH_%D&FG)#1^9Y@/\ N2^]6]._X.+/^"M?P77[
M'\4O@LFH)$?G=+6Z7.._#-0!_H*[E]:6OX/?#O\ P=\?%70T$/Q2^"L]O*#\
MWEO-%@?\"B-?0'AS_@\>_9M9$7Q9\-]3M'R-Q6[Z>O6WH _M"HK^2K1O^#O+
M]@O4T#77A[4[8]P92W_M$5W=I_P=A?\ !/JZ@R]EJ$?L6_\ M5 ']2LL0D'O
M68\#(:_EUO?^#LG_ ()]6GW=/U"0@=F/_P :KS'7?^#P3]AS3@5TSPGJMV0<
M8$^W_P!H&@#^M"M.T\H+E37\==]_P>!?LESV$4OAWX>>(+V[9L/"A#!0>^[8
M,_E7S_\ %3_@Z*_:Y\>F-_V6_@%?G3Y!Q<WD4\VX_P#;-%6@#^Y&]O+&T7==
MRI&.Y=@O\Z^7?C-^VC^R[\ ] NO$'Q0\<:)IZV@.Z*2_MQ*S#)P$+@Y_"OX>
M%\6_\'"/_!1>[+:'&/ EE=@9V1&'8IY_Y:R9_2O;/AO_ ,&J/[2'QEU6#Q)^
MV1\7+V\9\2S0P*NXN>HSN?W[4 ?9_P"U3_P=H_LW_#"_N?!OP"\)W7C#4D8J
ML_F[H#@?W8U!/X-7X]:Q\7_^"RW_  7K\9GPUX5LY/AWX)E;,GD64]O$T2\<
MO,S%L@]C7]57[)__  ;Y?\$\?V9]+@DNO"Q\4:K$ #>:E*6.1SD+'L%?M)X-
M\!^#/A_I,.A^#-,@TVT@4)''"@4 #@"@#\;/^"4G_!%KX$?\$XO#MIXC2)];
M\<-;,EWJMRXD/F2$E]H"J!R2OTK]OFXZ+CVJU10!YC\4_&FD_#?X=ZSXTULH
M(=-M)KAS(P PBD]3]*_SB/\ @GW\/=8_X*S?\%P;SX\^.K87?A[1M=,TL?EY
MAV:;!NC3H5()C%?U-_\ !QG^V</V9/V-K[PQIKA=0\4136<8W8.V5&7('UKP
MG_@UG_8T@^"W[%L/QV\20;M<\;7=U?;V&&C0.\0'_ E44 ?M[XW_ ."<W[$?
MQ+M&L_&_PVTB]0KM($;0\?6-EKX#^+'_  ;J?\$N_B1$[6'@:31)W& ]A>RI
MCW_>&3UK]WZ* /XU?B5_P:)_ +4+Z74?A5\0/$VB,W,:"[B9%/;'[C-?*VL_
M\&U__!2/X1S-/^SM\<[U%@),*W1$AR.F?D%?WIT4 ?Y[?B?X#_\ !Q]^QU N
MNGQ-_P )?:(>%%KYI./92K5GZ7_P<:_\%A?V?7&D?&/X/0:D%ZR-H]^I(7KR
MLV.]?Z%4MK;W"[9XUD'HP!KB/$'PV\ >)5,&OZ19749ZK)$I_I0!_EF?\%@?
M^"V7B7_@I?\ "G2O _BWX?S^&M6L+F.9G1)55BH8;0DFXCKZUL^%_P#@O3^W
MGXM^$OA']CCX5Q:=X"M+6*.R75)+66.7:H"@N\TNP>OW:_T1/'O_  2J_P""
M?WQ)U:/6_%WPTTR>YB?S ZF1,M[@-7,?$'_@C[_P3F^)-D+3Q!\,=/C89Q+;
MO+'(,]<'?_[+0!_&O\$O^"/'B[]M'48?%G[8O[5.E:B+A5E-G8:O9PR+N_A*
MDOC'TK^N+_@G9_P2_P#V#OV&/#5G/\"X[75M<6-?-UF6]6ZGF<* S H0F#UX
M2OASXQ?\&R_[('C#4'U3X1:SKG@R;^$VMP'4#TPZ-7RU=?\ !O9^VI\+IVN/
M@+^T=K<,41S#;W,43J!V!(*YXH _K]$MO(FZ%@Y'H:O Y&17\F/@_P#9X_X+
MW?LW;KO1_%6B>-K: 8V7EN5=@.G2Y'/X5S_C#_@LI_P52_9OO/L'QJ^!MOJ\
M,7RM+IIE!)'&< S=: /Z[Z3<OK7\B?A/_@ZN\ Z;(FE_&KX->(=!N$)65P9-
M@/K\UMG]:_37X"_\%[O^"?'QNAM4E\3)X?N;SY?(OV$?ED$C#,P3'2@#]M]R
M^M12S11(9)6"J.Y.!7SWX,_:K_9N^(<22>"O&^BZCO\ NB"]A=LGV5C4WQU\
M$ZO\:O@SK/@KP!KC:3>:G;M'!J%N59HF(X89R* />K:ZM;I!):RK*IZ%2"/T
MJSN7UK^+GX6?\%&_VO?^"0OQQLOV:/VZ+67Q=X-OM07RO$ZAHVAM[I]H9V&]
M#L8\CCBOZ^?AA\4O OQ@\&6/CKP!J,&HZ=J$*RQR0.'7##(Y4T >G45%"<K^
M)J6@ HHHH __U/[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,O6-,M]9TBZT>Y&8[N&2)@?1P0?YU_G:?LYZ=-_P3\_X.)_$O@E
M@8M.\2W5VL /R*8Y%#C'KR*_T77^[7^?K_P<)Z$_[.'_  5H^$_[1%D"%U1F
M65P-OS?,O)^E ']^^GW27EE!>1<B50__ 'V,UILN['M7B7[/'C*/X@?!7PQX
MPMW&R]TZ!QWYV#/->WT -"JOW12>6OI3Z* "BBB@ HHHH **** "BBB@ HJ%
MY=O8TJS*T>_TH D;H:H33A8C+N"J,EF/0 =:X/XF?%GX??"'PG=>,_B%J=OI
M>GV:%Y);B147 &<98BOY2?CY_P %IOCI^WM\0-4_8T_X)P>$[J.;5)'LG\63
MN3;6\* ^;*BHA&<@J#Y@YH _33_@HE_P6X^ O[&MNO@/X>@>/_'U[+]GM=&T
MR7>ZR _-OV*S *H)/':OR6\$_P#!/K]MG_@LQ\0;#]I+]MC5;WP)\/Y'!M/"
M< )+1P90%S*01O(+9\L<&OT,_P"";/\ P0E^'O[,NMS?'3]J'5?^%D_$"]!F
M%U>1[$LY90?,*8=LGDCD]*_H.T^PLM,LDL+",06\0PB < >U 'BW[/O[+_P0
M_9A\!6/P\^#'A^UT6PL8PBB! &9NK,2>['DU] B)!_6F),&48''2I/,3=M]:
M #REJ2HO-0?+4M "8&<TSREJ2B@"/RH_2J5S86=R@BGB60=PXW#]:T:CE^[0
M!_)]_P '6'@GP99?L1^&+ZUTNV263Q=9QNR1!696M[G() [UUOP3_P""#'_!
M//\ :Z_8S\">)M8\*KH&NWVD6LLU[IQ"NSM&N20P;J:C_P"#KG'_  PIX57)
MY\860'_@+=5^UO\ P374?\,0?#=]W_,%L_\ T4E '\K_ ,4/^#06'2-1F\0_
ML_?%_4]*<,6AAFME8H2<@;UECZ?[M?/%W_P1J_X+P_LQ7#:K\%_BY?:O;69^
M6 S;5=%Z#:)2:_T#/*#\TC1<'=S^% '\"FD?\%)O^"_?['3KIGQ+^%TGC2WM
M?E:18;DLV.,Y1G%>(_$?_@X[_:'_ .&@?#/CKXY_ UM#NM)MQ'+#+YXG<>86
MRA>,;1^#5_H>7_A;0-539J-G'*.X89S7\]'[<'[./[-'C7_@HGX%\-^-_ <V
MK)<Z6&:6),6G^N(Q)QU_&@#XC\(?\'=/[&^MS16'Q$\$7VF3.V)=TF]4//7,
M(K[C^''_  7U_P""3/QIMQ;>(K^PTTRCE;Y(^_J<"OK/XE?\$)/^"7_Q-ANE
MO_AA86$]P.9K0LK@^HRQK\S_ (M?\&EW["OCA'E\$:WJOAN1N1L"2A?PP* /
MMY_CA_P0G^-X^V:UJO@2\DD^4K<S1(Q[8QO%9=U^Q'_P09^* \ZWT'P1<"?C
M-O= 9S_P,U^+/BK_ (,T=#AN#=?#SXX7EF.H2;2MY! _O"X7^5>1WW_!J7^V
MIX3?9X%^/$AC3[G^A-'SV_Y;F@#]VKS_ ((5?\$8_'*DZ#X:LHO,Y!L[E,<^
MF5-8*_\ !M9_P2UU*0RV>BW(4= LZ8_]%U^&DG_!O7_P6:\'+N\'_':9\?=&
M63_V<UD2?\$</^#A712(])^,]Q(HZ$3N* /WN_XAOO\ @E3HJB75=!FVIU\V
M=%Z?]LZY[7O^"8'_  0!^#$;3>.]/\-6GV?[QOK] >/7&VOPVC_X(Q_\'!/B
MQOLWB#XT3Q1-P3Y[G@]?2N@TG_@U8_;D^*UTI^.OQUD$<A'G9M&G//7&9EH
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M)=8E)*].$E'>O[S?V6/A1I7P.^ 7A/X6Z)&L$6DZ=!#M4;1NV9/'U-?P:?\
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M=?J=^R=_P;O_ +"O[-7ABSTW7;%_&&IVV7>^O88X_,<DG[A\S'7^_7W/KO\
MP2[_ &(_$.C2:)J/@:Q,,BE"%BCS@_\  * /F/\ 86_X+N_L+?MVW#Z+X'UE
M]#U4-L%GJ>V.1C@'Y<'GK7[36]Q!=0K<6[!XW&58="*_B&_X*??\&S-_H<A_
M:&_X)^^))-'U>P7=-HLD7E(^PE@Z31N""<XV^7VJ]_P1C_X+V:AX.\0Z=^P5
M^W)ITVD>)[.]%A;ZK+*61Q(0%$@901AL\\T ?VZ45F:9J5GJMC'?V,BRQ2@,
MK+T(;H:TZ "HY/NU)5<N$EQZT ?RV?\ !US_ ,F,^%,=O&5EG_P&NJ_:_P#X
M)K[#^P[\.?\ L"VG_HI*_%K_ (.NL']A#PLX_P"APLO_ $GNJ_:?_@FG_P F
M/_#?_L"6G_HI* /NJBBB@!C?=SUK\0OVJM \5ZC_ ,%)? NHZ9XHL-/L8]*
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MTH NS;_,&RODS]JO]M#X!?L<?#ZX^(7QLUN&PM802L*,KW#X&3MCR":_*O\
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MK7XQ_P#!UHH;]@OPXZ_]#?9?^DUU7[0_\$Q1C]A3X;?]@6U_]%K0!]ZT444
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M/_@W,_:G\2?M;VOQ9_:B^(L'BKPAI>LMJ,-A=WMW=DQJY>)!'*FWAL$\X&*
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M'4=:Q)_$>BVNH1Z1=744=S,"4C+ .P&,X&<]Z .@IK-M4MZ5'YR; _6O@O\
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M5_3'&CQY]*^&/^"D_P +[/XM?L.?$[P1=1^;]J\/7VT8S\Z1%E_4"@#\E/\
M@V*^-MS\2OV"-/\ #M[<>:^BYA"]U4-CFOZ55=NW>OX2_P#@TK^*-]X=^)7Q
M!_9^U&7_ (\/-*QG@C9(<\?A7]V\;YX?[U $M%%1>9QG% $M%1>:/2F&X44
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M_M'&)GUL6/V#S/-;9Y>1QLSM[=<5_#OJG_!O3_P5A^#;>=\&_B1K%SY9PO\
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M+P>#0!WOA7P7X5\#:/!H'A&P@TRRM(Q%%!;QK%&BJ,  * .!77(^Y>>M244
M%<-\0M$C\2>"M7T&=?,CO+.:%AZAD(_K7;2?=-591YJE#R",;: /\YW_ ()+
M:G=?LQ_\' _B#X3L_P!CLM<NM4B$;?*& @GE7T'45_HRQ2*R+]*_SC_^"F]C
M=?LE?\%Z? OQ?T;_ $6*_P!:MU8XV@_:$\I@2?9Z_P!$/P)K4'B;P7IFOP<B
MYMUD&#GMB@#MLK5)FCCC+;P% .<USOB3Q;H'@_3WU;Q)=Q6<,8):25@H '7D
MU_+'_P %Z?VJO^"CL5WX=^ O[%=O>6FE^,W-HVK:;:R322+*R)M5URO(8]J
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M'V= P8."-F.A -?:-% '\97[4G_!IY\$M7OCKG[*.M:UX7;;Q!%>($WC/]Y
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M'!]5K^\SX.?%S0/C)\,M&^(^@LL5OK%NEQ$GF!N'&1@]Z /9MR^M+6>'W/\
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M=3OKJ0OW/[YO\* /ZN(CEC5BH5;)Z"IJ "BBB@ HHHH **** "BBB@ HHHH
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M([_@Z[_Y1Y:+C_H;K+_TFN:_7/\ X)3HO_# ?PT&/^8/;?\ HM: /T0HHHH
M**** "BBB@ HHHH **** "BBB@!#TZ9K\FO^"F__  2>^ G_  4F^'"^'?'<
M$>G:]:N9+355B$DD>1@J1N7.<#OVK]9JH2A-O[WI0!_*W^RO^T)^RS_P0OM_
M#7[ WQD\9:KXL\27K1PBZ6WCM[:$NH"_(T\A4<=,FOZF-'O['5+"/4;!@\4J
M!U8=P><U_*]_P<7_ /!*.Q_:(^$]]^U9\(HDL_&WAJ-;EI8UQ),J=.001M!-
M;7_!M=_P5"\8_M>_!0_ +XN+=W?BCPGIT;-?S/Y@GBA986))P<Y93WH H?\
M!V-XU&A?L*Z!H$+$2ZEXA@3@]A;W!KZW_P"#<#P,W@S_ ()F^#%90'NXY)S@
M8_UC$_UK\B?^#PGQS/;>!/A-\.K=CNU#6#<L < A(I%_]FK^C?\ X(^>"(?
MO_!/;X::5$NW?HMK*P]Y(PQ_G0!^FBY5]M2T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_];^_BBBB@ HHHH
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MY&>!CJ*_U:OA;I?]B?#7P_HX&T6FG6L.!_TSC4?TH ] HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __7_OXH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"NW+%J_FM_X.3/V"M?_:R_927Q_P""(D?6?!ZS78#$AVC4%L*0#WK^EJL'
MQ#H6D^)M&N="UR!;FTNXVBEC<9#*PP00: /Y+?\ @V@_X*F^&/BE^SYIG[''
MQ=O)8/&7A2[FL+<SA566$MYB?-G).79>1VK^NU/NBOX$_P#@KI_P1/\ VC_V
M3/V@I_V]/^";073]-TZ--8O;"VG9)HKFS8R.41AM92J@XSR<U^N/_!([_@X3
M^ G[6=MI/[/?QSGN_#7Q*@2.VD&H0B."YE48.V1&(!R/X@M ']/U%4+.YM;V
M(7=DXDB?E60Y!_*K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %0Q=ZFHH _GR_X.-OV=OBO^TM^P_I_@3X0:<=2U2+Q+:W31 A3Y*0SJQR?=
MA7Z2_P#!.KP%XE^&7[&O@/P-XPM_LNI:?I=O#/'G)5@B@CCZ5]NW%E9WL7DW
MD2RK_=<;A^M210PPJ%B0*!T % $R_=%+110 4444 %%%% !1110 4444 %%%
M% !1110!6EX;DXKXP_X*!_$KQ?\ !C]C_P =_%#P$T::QHFFM<VSS*KH'# 9
M*L"#U]*^S)]^X>G:O@W_ (*<>&]<\6_L(_$SP[X8C6:]N-'DV([!00I4GDG'
M04 ?YMO_  3:^*7Q5_;[_P""O47Q,^-%TNI:QB2>2146-0(WCC&U8U4< CM7
M^K_IL"VEA#;ITCC51^ K_,0_X-=O@?K7BC_@I)XLU.XA4MH6E3F7+#"EKF <
M'IVK_3^7;_#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#_T/[^**** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHICLJCYJ 'T4FY?6F[U]: (+@\A/6OQO\
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MCI1O;&T<M7^>MHO_  4\_P"#C;]GB=+/XO?#?5-2LK(@RN-"NN8QU^85]/\
MA/\ X.N/'OP]5;'X^?"S5;>ZC \TBSGCQCJ<,M ']Q19U'(I=S;<U_'MH'_!
MX'^QG<E1XF\.ZK8R?Q P/Q^=>S:3_P '9W_!.[4PIGGNH >JO&0?Z4 ?U1^;
MZC]:9YC=<U_,Q;_\'3__  36F8>=K+IGU'3]:W(_^#H__@F>ZX?Q#CZD?XT
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>beat-20231231_g2.jpg
<TEXT>
begin 644 beat-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /  T8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 0UY9\<M&\W3[#5%7+0.89,?W6Y!_ @C_@5>IUD^*M&'B#P[?V&
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M#]#6I5 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6Y/TK0-<MX@N]NH2+G[H _0&FA/89)<[:HS7F.]4KB^]ZS+C4!ZU1F=;X7O
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M[SCT'/\ GZU3KH/!\.ZXN)3_  J%''J?_K4@.II:**DL**** "BBB@ HHHH
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M],5URJ=O%4(1?SQ4B_,/:D'M2CMDFF!(,TY:C6GCZ4"'<]Z :/QI:!A1110
M5T_@U@5NOJO]:YCTK;\)W(BU!HB>)%P/J.?\:0'84445)84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=,PP7;ITPN    * T-4\'%%2W*[9#45:&+W"BBBF(**** "DHI: "D_2BC-
MT'XT44E RWI5U]CU"&4GY0<-_NG@UWU>;?I7=Z)=?;--AD)RP&UOJ./\_6I8
MT7Z***104444 (>E? GQ.\.2>%/B1KNF,BK"ETTD:D\%'.]!_P!\D?C7WV:^
M:/VM?"K1WVB^(X5P)%-C<-[C+Q_B09!_P$4F-'@MBI^<,-[>ON/P_P \5WOA
M:8S:>D>X_(V-R^G7_P"M7$6K?,'PQ']W;G_)_P#KUT?A:8P:@$S@-A?GZ9^F
M/\YJ2['=VK#<.0?0 'CVKL?!]V8[B2W?I(-P^H_^MG\JX^W&Q0H!)Z$?Y_&M
M;3;K['=02+U5AG^OU[]/6K(:/1\&C&.G/UI%.]0RG*D9S3L_6K,Q,4OJ:2E[
M>E "YHI!VI: %Q2]:3VIW2@044E+0 6.AZ5J'B;1M2U"-3<Z5)+/9S,VT1.\
M31L3Z@J[#GO@]J](1@P!!R#R"#Q7G4,AAE21>J$,/PK/_P"$^2W^..D^#=!T
MMI8YM.;5-8N(6Q#:1L'$6Y>@=W"^Y!)Z9J66CU>EHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "LKQ/IO]JZ#=VZC+E-T>.NX<C^6/QK5I* /
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'!AU*TY']TL,'\F_E6/\(=5EO/"8L;GB\TN5K*4$\_*<+^F!^% SMZ2E^E%
M!2&BB@""^5O+$D9VR1D.K>A'->EZ=>KJ5C!<I]V9 V/3V_"O.V4,I!Z'BNC\
M WI:SN;%S\UN^Y<_W6Y_GG\Z3&CJA2T45)04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !24&B@#S[XHZ;_QYWZCUA<_JO\ [-7 U[3XITW^UM!NX NY]F]!
MCG<O('X]/QKQ;_"J1$@HHHIDG7>!;S=]ILV/WAYB?4=:WKN/S(B.]<#H=\=/
MU6WGS@!@&^AKT>=1O;'W3R/I0!@&DJ6X3RY2*BH*"BBB@ HHHH$%>,_%7PKI
M\GQ$T"\U&-FT[4B+6<HVTB0<*<_B/RKV:N*^+^@MKG@>\,.?M-GBZB('(*\G
M'_ <T 10?!/PA!C_ (EK.?5YY#_6O*]1TF>V\,^)?#JDBYT"^%_;<\^2<@D?
M0$-^->Y^"]=7Q)X6TW4007FB&_V<<,/S!KB/&T*>&_B=H6L,H^PZFC:?=@CY
M3G@9_,?]\T".;T7P-XV\6:5;:@/%S"VN4#KMN),@=P0  "#D5,?A*WA^\-QK
M?BA';4$>Q'F(Q,K.A"J6)[$ _A5^2]U'X):C-$;674O"5Q(9(BGWK8GJO_Z^
MOL<BN?\ $WC>3XM>)M#TK2K2>&UAN%E8R8W'GEC@X "@_G0!Z'\'=:^U>&SH
MUR/+U+2&-M-$WW@H)VG'IVS[4[XU68E\#7%VIV7-C-'<0OCE6# <'Z']*K^.
MO ^I1ZLOB;PM((=9C&)[?HMRH['MGC\<"N%\0:]XV^)"Q>'I-#?3D>1?M$@B
M=0<'J2W0=\=\4 =#XTU99+7P;X[MAQ"Z)<;?^>;C!!^AW#\:];1A(BNARK#(
M/MVKR_PSX(U%O GB#PIJ4+!(Y76RN'^[(#AE8'TW#]:[/P+!J-KX2TRWU6+R
M;Z&/RG7<&X4X4Y'J /SH Y3P?CPK\3?$&A$;+:_ U"U';G[P'Z_]\UZ57)^*
MO"-QJWB;0-:L)8X+G3Y2)1)GYX6ZCCOC/YUUE %'7+.XU#1;ZUM+@VEU-"\<
M5P.L;D$!OP-?-NC?LH[M-FO_ !?XB-E>.YR865E!)P"SO]XD_P Z^H*X#XX^
M";SQ[\/+[3=/.;Y&2>&/./,*\[<^XSU[XKBQ-&%1<\E>W0^GR7,J^$J+#TJG
M)&;5Y6U2)OA+X'U7P#HUUIE_K']LV8FWV4C9W1QD#*G)/?T)%=S7G?P$@UZS
M^&]E:^(;>:WO;>1X46X&)/*!^3/YD#V KT2MJ%O9QLK'G9IS?7*O/)2=]UL_
M,\I^)-\? 7CC2/%:0M+:SPM9W4<?!;C*_C_\37%^*OB)+\4]<T+3M,T^2W$5
MTLBEV#.3D<\= !DU] ZAIMIJUOY%[;1W<!(8QS('7(Z'!J*QT/3M+.;.PMK5
MNF8854_H*W/+.+\;^$-5L]87Q/X695U55V7-HV MT@]O[P__ %<UP'B+5O%_
MQ2NK+1)M"ETNV28/,WEN%R,_,S$8  )X'6OH#'^310!RWC3P#:^+M+@A\UK2
M^M<-:W<?WHV'3\*\WU/P/\1O$S1:-JU]')I2N-]PLB8< ]3@!B?J*]P]:7Z<
M4"/.-/\ A?/;^$_$'AN6=#83S>;I\A)+1< C([88#]:[C2;.>/0[6TOV2>X6
M!8IF7)5R!@GGM5[FB@#!\%^%_P#A#]%_LU+IKJ%97>$L,%%8Y"^^,GGW-2:3
MX5M=&US5=3MY) ^HE'EA)&P,H(W#CJ<UM=J"*!A244M A**** "I]"O/[-\2
M6TF<17'[E\>_3]<5!5>^C+VY*\.OS CUI#/5:6J6CZ@-4TRVNAC,B MCLPX8
M?GFKM26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4-W#YUNR=\4AGJ0IU9/AC4?[4T6VF)S*%\N3_>7@_P"/XUK5)84444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #Q2-EL#DAON_2@!#D=LG'(_SUIJY9L]1R...F:7;QM.?K]?PI%.V09SG^E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIS]?_P!= ";>OIDDK3MV>.@[\9IF[W)&<[B?RXI,\ G//MS0 F[Y5]*9N 4
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M?%,;.[D GL,=: %P!@= O3^E,DQNVYP/IFAC\O+<=!Q_6D7C#')],T !;<V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!*\2\2:;_9.N7=L!A%?*?[IY'Z&O;J\[^*.F[9;._4<,#"Y^G*_S/Y"
MFB6<'1115$!^E>C:)=_;]&MY?XT&Q\^U><UU7@>\^:XLV/#KO4>XZT :^I1]
M&JA6S=1^9":Q^G'>@8E%%% PKRSQ99_V;XEO%(/DW(6YC].>& ^C#/\ P*O4
MZXWXE:>TFGVFH(/GMI/+D;_IF^ ?_'MA_.I>PX[G%9&TX/?TR.M!PQ(//TXI
MNWC([]?Y4+SCL/3I69J-;OC@'@''?M2.[*/;&!Q1][=P!^O%(K!?<9&/?WH
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MG+.@W?[PX/ZYJ64C0HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]XBVR+Y<R$I(OHZ\-^H/Y4]L,V?NL?>M7QA8C3/%%R,!8[H"YC],]''_ 'T
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M<?+TH &8D 9QSP:;Q\Q!V\?6GM\K-@ $\?4"FR'KT(QZ4 #,'Y Q^)/M3#M
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M7KEG=DXC+>7)V&UN,_AU_"D,]-I:04M24%%%% !1110 4444 %%%% !1110
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M;8!4CL,@TK=\ @=.U-9OEYVG)Z \>M "-AE W?,H[]_>D^ZQ/KWQTXI"S#@
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M8((H1Z1H%'Z"CE#F/#OAC\)M6DUPW7BS4?[;M5B.VW:R,-LK9&"-QRQZ]1C
MKVK3]%T_24"6-C;V:C^&")4'Z"KM)5$ZL*.:7BCGM3$)1110,**!10 4444"
M"BBB@+A1110 4444 -M[K^R]6LKWHB/MD_W3PWZ&O417E=S'YT++W/3ZUWGA
M'4/[2T&V<G,D:^4_U7C]1@_C292-FBBBI*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX;/MT_3%;M<%X)O/L>N3VIX2Z3>G^\O_ -;/Y5WF:@U%HHHH **** "BBB@
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MD4,I]B,U+4F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSSQNZK^/!'XUZ'4%H6BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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M[E(/0BNI^']Z9-.FLG/SVLF!G^Z>1^N[]*3&CJJ***DH**** "BBB@ HHHH
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M6H4444""BBB@ HHHH&%(:6DH&%%%% "T4E% A:*2EH **2EH$%%%% !1110
ME%%% T'<4M)1^- PH':C_&@T %%':DH /XJ.*!0* "K7AR\_LWQ) 2<1W0,+
M?4_=/UR!^=5:@O%8P[TXD0AE(]12%U/6*6JFDWRZGIUM=)TE0-CT/<?G5NI-
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "D/2EI* /.OBAINRXM;]1PX\I
M_3(Y'Z9_*N%KV3QEIO\ :GAV[C S)&OFI]5Y_ED?C7C=4C-A1113$=3X'O/W
MT]HQX==R_45T-U'YD3"N TF\-AJ$$X.-K<_2O1IE#,2/NMR* .?/R]:2IKJ/
MRYC4- PHHHH&%)2T4 %%%%!(4444#"BBDH$+24M)0,***.*!!0:** %HI**
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MS\TB#=_O#AA^>:\[^O2NA^'][L^V6#GE&\Y,^AX/ZX_.DQH[$4M%%24%%%%
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MCWQD=ZX'2;PV&H03 XVMS]*]&E4$Y'*L,C\: .>(VDBBIKJ/RYC4- !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ",-RD$9!KP[7-..E:Q=6I&!&Y"_[IY4_D17N)KSCXH:;Y=Y:WRCB5?+<
MX[CD'\1_*FB9'#T4451 E>@Z#=_;]&@<G+Q_(U>?5T_@F\VW$UJQXD7<H]Z
M-G4HLJ&K.K:NH]\;#O6*P*DB@:$HHHH&+VH%)10 M)110 4444 %%%% !]:?
MO!0JPX(P13*0Y]:!'E?B*_A\/>"]>L9SAK&4Q1J.\;8,>/P/->#77BB9LB%
M@]:]<_:.MVL[6TNH7_=73B&?' W)DJ?J03^0KP7<,\5!:+-Q?3W!)DE8_P J
M@YP*;NI>*!A1110 4444 '7BF1G=O?U./RX_QITC;4)]J1?EC48Z"@!&:OJ#
M]BOPS^[\1>(Y$'S,EC _T&^0?K'^5?+K'_&OO[]G_P *GP?\)]!M9$V7-Q$;
MR88P=TAW#/N%*C\* /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%86L>*-,T6,R7]_# ,9PSC/Y5UFD_L]^)-<Q)XH\4+I\+?>L=!3YO;]](/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 C#<I&,UY;XR_9A^&7CJ\>[
MU3PI:K=N27FLG>U9B>26\ME#$^I%>IT4 >2^$?V4_A7X*NQ=6'A"SGN001+J
M#/=E2.A42LP4^X&:]7CC6)%1%"(HP%48 %/HH **** "BBB@ HHHH YSXCZY
M)X:^'_B/583B>ST^>:(_[80[?UQ7Y8>*,G36B7*>80"R\^Y/^?7\OU4\>:$_
MB?P3KVDQX\V]L9H(]W3<R$+^N*_-.33XQ(R7<.3'T7;AD(SG'IT/'M0!Y VG
M2;AL!<=#R.YZGCZ#'O6IH>DQ,I5YOW[$ML;"@C=G@9)( Q_^KFO3F\-V*H2@
MC$0.6+ *47'4\]<YZ>IK$632;>\*P[9[GD @ A0"N?FQZB@#+M],^W:C# _S
M;7VMMS@@'G],_E7:S6:QP*Q50V1@KT]?2L[PW:">^>;:H2-<8Q@?-QGWZ5MZ
MM)\Z1@\#+?B>U %$=OU-.'\Z;3AQ]* '$A1[5652S%SU;FIY.8SZ4Q5^7'44
M &!_]>IO+,6%)); )J>QMPY>:3_51@$^A/85"[&1V8]2: $KWW]D7P'IWB+7
M-;O]3T^WU."QCB$1NHMRI*[$Y522,X4\GIQC%> U]O?LJ>&3H/PIM[IU*S:I
M<271W#D*,(H^F$W?\"H ]A11&JJJA548  P *=110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>beat-20231231_g3.jpg
<TEXT>
begin 644 beat-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $X ,D# 2(  A$! Q$!_\0
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M)*MLI1QRRJV\85_E R-Q.!UIH9]3?#2WLK7P)HT6GNLEJD. Z2^:"V3O^?\
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MK6/"684G58K@[70, <ISS7U/7BGQO\+)XF\9: MQ)LLXK=RZK]YLN.!Z=.M
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M/^&E?A<?^9UTX_A)_P#$TO\ PTI\+QP?&FG?E)_\30!Z5S1V]Z\V'[27PO\
M^AUT['TD_P#B:3_AI3X7_P#0Z:=^4G_Q- 'I=)7FO_#2GPO7_F=-/_[YD_\
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MO)YH&.7##UIP4\9/-$8^8?H*E5>1^8H&)&NW [4[;D9XS3@O)QS3U0_CZT@
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M@!4)'&0 ,X[FO1MQZ9-)0)NX4^#_ %R?6H_2I(?]<GUIDGH_A_\ Y!<7U/\
M.M&L[P__ ,@N+ZM_,UHT%A7F/Q*_Y&S2_P#KW/\ Z$:].KS+XE?\C9I?_7N?
M_0C0(H4444$A11_*B@ H]**.:8!24?K2T@"C^=)^-+0 ?C11T%% !]:6DI:
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MGCDN9DN["?3WAFFW+MEV_O!SPZE?E/;<>*+"/LO(S]Y<_44<>H_.OCSP_P#
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M?K@B3&.F3ZU^A=02)2T4E A>U)2T"@ I]O\ ZY/K3*M:?;M/<*0,J#F@#O\
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M #]?^0Q_C112 /\ A"%_Y^__ "&/\:/^$)7_ )^O_(8_QHHH$'_"$+_S]?\
MD/\ ^O1_PA*_\_7_ )#'^-%% Q1X)4'/VK_R&/\ &M73M"M]/(8$RR#HS=OH
**** -*BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>beat-20231231_g4.jpg
<TEXT>
begin 644 beat-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +H!6@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0!0UW7M.
M\,Z7-J.JWL.GV,(W27%PX1%'N37RWXM_X*=? WPIJC6)UZ>_D23RWDM8/,08
M[@@\U\B_\%0OCOX@^(GQDTCX,^%;R6& /$DZPN5$TTA "DCL"#^=>_?"?_@E
M#\)]/\!:>GBJRGU?7KB!9+BY,SIM=AD@ ,!QG]* /IKX-_M.?#KX\0EO"/B*
M"]N%&6M'8+,/?9G->J"OR'\0?\$_?BG\#?VE;#4?A#'>3^'(YH[A;G>51$W8
M:-L=>!WSUK]7XM:&C^%XM2U^:*P,-N)+R1VPD9 RW/IUH VZ*^,_&'_!5;X,
M^%]8ET^VGOM:,,AC>:QC5D!!P3DL*]D^ O[7'PY_:*BE7PIK"27T0S)8S$+*
MH]<4 >T45XW\9OVK? ?P)\2:/HGBJ^>UOM4;;;JH&#TZY/N*\R^*O_!2KX0_
M"[5#ISWUQK5TJJT@TY XCW*" 22.QH ^L:*\D^ ?[3G@7]I#1I[_ ,(:D+A[
M<XGM9,"6/IU ^M<C\=OVZ?A?\ =:;1M<U)[S6E7<UA9 /(OID$B@#Z)HKX[\
M _\ !4CX.^-M:M],N+B]T&>X<)&^HQJB9/T)KZOO/$NF:;H,FM7%[#%I<<7G
MM<LWR;,9SF@#5HKXQ\3?\%6/@UX?UZ3389=0U6.-RCWEG$K1#!QG)85]"_!3
M]H#P9\?_  \VK^#]6CU"&,[98@?GB/HPH ])HKRSX[?M(^"/V==!CU/QAJ:V
M@F)6&W4@R2GT KR/X6_\%)_A!\3[RXLXK^XT>XCB>94U!0GFJHR=N">: /J^
MBO&/@C^UAX#_ &@-1U>S\)7LEU-I9/V@,  ,=<8-9WA3]M#X;^,OBU/\.M.U
M"1_$D,K0M$5&-RC)[^@H ]XHKB?B[\7/#_P3\%W/BCQ-.UOI4#JCNHR<GI_*
ML[X,?'KPI\>/!\GB7PO=F72XW*/))@8(S[^U 'H]%?(WQ0_X*;?!_P"&GB2X
MT/[9=:Y>6TGES-IJ*ZH>_)(KT_X!_M<?#O\ :-6>/PGJP>_MQNEL9L+,HYYP
M/I0![517B'Q4_; ^'GP=\?:=X0\2Z@]KJ]\,Q+@;<>I.:\S^)W_!3KX/?#?7
MI=*^UW>M30.$EET]%>-#]210!]=T5YK\#?V@?!W[0OA<Z[X/U%;VW5MDL1^_
M$WHP_/\ *N0^/7[:7PS_ &>;Z+3_ !)J_F:K(NX6-KAI0/<$B@#WFBODGX9_
M\%-/@]\2/$%KHPOKG1;VZ?RXAJ**BLQZ#@GK7TYXD\8:1X2\.W.NZK?PV>E6
M\1EDN9&P@4#.<_2@#:HKXKU3_@K!\&M/UUK&-M2O+9&*M>P1*8N#CKNKZ:^$
M?QG\)_'#PK%K_A+5(M2L'X;8?FC;T8>O- '=45X3\>_VS/AM^SK>16'B?5"V
MK2+O73[4!I<=C@D5Y)X3_P""K7P<\1:K'97C:CH@D?8LU]$J)SWR&- 'VC15
M'1=9LO$&EVVHZ=<QWEE<H)(IHSE74]Q5UCB@!:*\0^/7[87PW_9U:*#Q3K"C
M4)1N2QM\-*1ZX)KR;P-_P5/^#7C#6H=-N+F]T-YI!''+J$:HA).!R&- 'V+(
MVT$DX4=37S!\2O\ @HS\&?ACXJDT#4-<FNKZ&3RYC9Q>8D9[@D&N_P#V@_V@
M_"7PB^$]QXDU;4L:=?0^5:W-N00[./E(_,5^,?[)OCCX46OQX\2ZY\6(#J.C
MW1G>S$G.9&F!4GG^[F@#]VOAU\0=&^*7@_3O$WA^=KG2;^/S8)67:67Z5'\2
M?B/H7PI\*W/B/Q)=_8=)MB!)-C.">G\J;\+8?#\/@'1?^$5MDM/#[VX:SB08
M"IVKP;_@I4,_LD^*<_WX_P#V:@!W_#R7X#_]#6W_ 'Z'_P 57=?#W]L+X2?$
MZ=(-$\9:>US(=J07$R1R,?0*3FOS$_X)T?L/^!?VH/A[XDUGQ3+=1W6GWT=O
M$(#QM*$GN.]=E^V%_P $S[#X%_#R?QW\.M9OQ+I;+)/;L2I"[@ RD'/?]* /
MUOC<2*&4AE/((IU?$W_!+C]H[4OC9\'KC2-=NC=:SH+K$TSG+/$<A,^IPM>J
M_'[]N+X9?L[ZBNE^(-3:[UDIO_L^R >4?4$B@#Z$KCOBI\5_#?P;\*R^(O%-
M]_9^E1NL;38S\QZ#K7B'P7_X*(?"?XU>(+?0K'49M)U>XXBMM14(7/H,$\US
M'_!53#?LGZKQD?;(/YF@#Z4^%?Q:\-_&?PO%XA\*7IO]*D8JLI7'()![^H-=
MG7Q9_P $HYDM_P!DK3)9&6-$FE9F;H!YC\UK_$S_ (*=?![X<^(+S1EN[O7;
MRUD\N4Z:BNH(Z\DB@#Z\HKYK^!O[?OPK^/'B*'0-'U*2QUF5<QVE\ C/[#!/
M-;/Q6_;4^&WP8\>P>$?$]_+9:K-MV94;3G&#G/O0![W15)=4MVTO^T%E!M/*
M\_S,\;<9S^5>*?#;]LWX=?%;XE77@;P[>S7FMVQD$BJHVC8<,<YH ]XHKQ#X
M_P#[8'PZ_9Q$,7BG5/\ B8S+NCL+?#2L/7!->=?"O_@I=\(/BAX@M=%6^N=#
MO[IMD*ZD@0.QZ 8)H ^M*1NE9VL>(-/\/Z/<:MJ%W%:Z=;QF62XD;"JH&2<_
M2OD34/\ @JM\&;/Q0VDQS7]U$DAC>^AC4P@@XSG=T_"@#VGQE^UE\-O ?Q#M
M_!.LZV;;Q#.ZQI;;,@LS8 SGUKV')!YK\3_VF/&FB?$/]OGPAKN@7T.I:7>7
M%K)'/"<@_O3^M?ME0!S7Q"^(&B_##PG?^)/$-U]BTBQ3S)YL9VK7,_!G]HCP
M/\?+>\N/!FJ'4HK,[9B5V[>GO[UYS_P40 _X9%^(''_+BW\Q7RE_P1?NH['P
M3X\N93B.&0R.?]D!2: /T_HKYQT7]OKX0:Q<^(8/[?6T;0PWVHW& ,KG(7GD
M_*:\]TW_ (*M?!F^\41Z2\NH6D,C[%OIXE6+KUSNSC\* /L^J-CK5AJ=Q<0V
ME[#<RV[;9DC<,8SZ$=NE?+'[=G[5FB_"OX$SR:5K+0:QK\ &DW5O@A@3DD$_
M[.:^5/\ @EW^UEX>\-)J?AWQ?K-U<^)_$&H((&F<N79F/<GCEA0!^L-%>1?'
M;]J/P!^SKI=O=^+]62VEN1F&TC(,LGN!7C7P_P#^"HGP<\<:]!I4ES>:)+<2
M".*74(U1&)Z<AC0!]A45@>(_&FE^&/"-YXEN[@-I%K;M=/-&<@QA=V1^%?.>
MH?\ !2?X,V/@N?Q&-8DEACG^SBV0+YKM@G@9Z<&@#ZKHKY"TS_@J#\&KZRL;
MF:[O;);QQ''Y\:CDG_>KZKT#7+3Q+HMEJMA*)K*\B6>&0=&5AD'\J -*BO ]
M._;6^&NK?%P?#FROY;GQ'Y_V?RHU!7=^=:/Q^_:Z^'?[.,,"^*]6"WUP,Q6$
M&&F8>N"10![717R1\+O^"FGP?^)GB"TT;[9=:'?74@BA&I($5V)P!P3UKWOX
MM_&;PW\%O!$GBOQ'=&+1TQ^]CP<Y&1C\* .\HKYA\0_\%$O@[H'@;3_$S:TU
MU%?Y\BS@ :=L#.<9_K3O@+_P4&^%OQ^\2)X?TB\GT[69,^5:WZJC28],$T ?
M2=]?V^FVLES=SI;6\8R\LC!54>I-4-0\4:;IWAZ?6Y+M&TN&%IVN(R&78!DD
M'OTK\J?^"IW[6PUCQ%I_@?PEKMW:)8'9JT,+;-S;LCD'.,&OJK]F7]HKX>_&
MC]GFX\+0ZA-*VC:&5U8L 61"&#$'//% 'M/P=_:B^'GQWU*^L?!VLG4KFS :
M9=F, Y]_8UZTO2O@_P#X)[Z#\"])\8^)7^%6KWNHZ@R*+I;I0 J_-C&&/O7U
M)\;/VAO!'[/^AIJGC#5XK!)#B*#(\R0^P_"@#TVBOB?2?^"LOP:U+5Q:3_VE
M8P,P5;N>)1&<GKG=7UOX3\>:'XX\,0>(=#U&'4M*FC\Q+B%L@C&: .AHKYUT
M?]O/X1:M?^([4Z^MFV@J[7;7& !M8*0.>3DUYS9_\%6O@S=>*$TEYM0MH'<(
MM]-$HB))QG.[./PH ^T*9)((E9VX51N/T%4?#^OV'BC1[35=+N8[RPNHUEAG
MC.5=2,@BK=WM-M,'/R;&W?3'- 'D?@G]J_X;_$+XA7'@K1-;-UXAA9E>V*8P
M5!)YS[5["M?GY^S;X>^ =E^UEJUSX0UF^NO')EE,MO,H$8;:=V/F],]J^F?B
MY^UQ\/\ X)^-M+\+>)[][75-1*B%0!M^;&,\^] 'M=%?(_Q0_P""FGP?^&NL
M-IQO+K6IH]OF/IZ!T3(SR217M'P)_:+\%_M$>''U?P?J2W<<3;9H&P)(CQPP
M'UH ]/->)?%C]L3X7?!3Q-_8/BS7CI^IA-YA" \<>_O7MHK\3/\ @JGHDGB+
M]K>STV'B6ZMU1?KM6@#]>_A+\9?"GQN\-MKOA'4AJ6G+(8FDZ$, #@C/N*S/
MC1^T3X&^ %MIL_C35O[,343(+8;02^S9NXR.GF+^=?GW_P $>?'%SX;\3>-_
MAMJ1,;PD74<3GGS"0",?1:XC_@J/?7OQH_:<\/\ @+2YBXTJSDD*@Y"F01;C
MC_MG0!^D_P '_P!JSX<?'?4[O3O!VM'4;NTB,\J%-N$! )Z^XK/T[]LKX6:K
M\1V\"VVOE_$@G-O]F\L?? R1G-?G;_P1VL?[-^,'CVT;E[?3YH2?=70'^5>8
M?#<#_AYA<<?\QN;_ -%T ?N@M<M\2OB5H/PF\*7?B/Q+=_8=)M1F6;&<?A75
M5\J?\%,_^31_&'_7*@"S_P /)?@/_P!#6W_?H?\ Q5=Q\/?VQ/A)\3KR*TT3
MQE8/=RG"6\\R1NQ] ":_,?\ X)V?L/\ @7]I[X<ZWK7BB6Z2[L[]K>/R#QM"
MH?4?WC5#]OS]B/1_V2]/T3Q5X*UR[CBFE\MH7?9(C9&"I!SWH _:Y'$F&4Y4
MC((Z$4^OFG]AWXU2_$#]EG0?$WB.Y\A[.!H[FZG. 51BH8GZ**X7QA_P58^#
MGAG5IK&U?4-:\F0QO-8Q*R<=\EAQ0!]GFJU]J%OI=I)=7=Q';6T8R\LK!54>
MI)KQ#X _MH?#7]HV^FT_PQJA75(EWM8W.%E([D $U\$?\%3/VM(];\2:;X)\
M)Z]=VJ:>^W5H(6V;FW9 R#GH: /U8U'Q1INE^'9]=FND.E0PM.UQ&=R[ "21
MZ]*\]^#O[4/P]^/&H7UEX-UDZE<60#3+LV[0<X[GT->-?LZ_M&?#KXW?L_WO
MAF#4)I5T;1"-5) RB$$,1SS7'_\ !/;0?@9I'B[Q0WPIU:]U&_9$^UK=* %'
MS8QAC[T ?=U+7CWQZ_:J\ ?LY6,,OB_5E@N9_P#4V46#,X]0*\A^''_!3[X.
M_$#7[?2'NKO0[BXD$<+ZBBHC$].03UH ^OZ*XSXD_%?0/A7X$N?%VMW6W18%
M#--'@Y!&01^5>,:I_P %#/@_I?P^L_%K:VTMK>,RV]I& 9WP2"0,^H/>@#Z:
MJO=WD-C;R7%S,L$$8+/)(V%4#J2:^8O@C_P45^%'QP\3Q>'M/O+C2M6F)6&'
M4%5#(<9P,$U\K_\ !6#]JR-(;3X>^%=<NK'4K=V_M2*!MFY21M&X'/9J /U"
MT_4;;5+5+FSN([JW?[LL;!E/T-6Z^1/V"/VGO!GQ-^'FB>#-)OI;C7]+L ]V
MDG;! )SGU(K=^-'_  4+^$_P4\07.@W^H3:KK%N<36NG*':-O0Y(H ^GJ*^3
M/A3_ ,%+?A#\4?$%IHBWESHFHW3B.)-214#,3@#@GK7U='*LT:R(X9& 96'0
M@]Z ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *FJNT>EWCHQ5EA<AE."#M/-%)K'_((OO\ K@__ *":
M* +E%%% !1110 4E+36H _#GXE.5_P""F49N^%_X2"+&_P!/.XK]P+0@VD&.
MGEKC\J_*C_@J!^SAXC\)_%+3/C1X-L)9XXS&]V;="QADC(*N0.Q.23[5Z=\(
M_P#@KQ\.7^']M'XS@O\ 3_$5G"L3Q6]N9$E91C.>,9Q0!^@<^K6-K=+;37MM
M#<L,K#)*JN1[ G-? /\ P6$^+FH^#?A/H7AG3+R2T.N3,9FB.-Z)MRN?0AJ^
M3]0^+WQ*_;F_:PL-0\#2:GH^E02QQK]EE=4AMU<L2Y&.2"1S7V'_ ,%0/V=]
M;^('[/NA7FD02:SJOAE1YI4%I7C(&]NY/"4 :'["/[%'PZTOX#Z5K'B+0+/Q
M!K.MQ>=/<72[BJDG 'X8KXQ_:,\&Q?L1_MIZ%>^"9GL=+O)XK@6J'"I&\A1D
MQZ8S^=?0_P"Q7_P4B\!^$/@[:^%?B!<3Z1K&AHT*[8=PE4$\=L$<#%?/GB;6
M=5_X*(?MD:7J'AW2YU\,Z=/&//=#A88W+Y8XX)Y% '5?\%?-;'B#Q+\.=6MR
M8Q=V1GC;H1N6,BOLWX2_L;_#-?V:;&UN_#5G>W^HZ2MQ/J$ZEI6=TW9S[9KX
MX_X+%:?!HOC#X?V$ "06UHT:+Z*H0"OTZ^%YS\!?#I_Z@4/_ *)% 'Y<?\$I
MX[GPO^U!XS\/P3G[.+=HN.G#-@X_*O/_ (S:GK/[-O[:'B;Q3XY\)-XNTVXN
MYI84O(V,;0NY*[6R!D"O0_\ @FP[K^V1X[:$!Y1%(44]"V6P*]6^(G[;FC7'
MQZOOA_\ '7X>65KX<@>2%+VX@65^N$=<J/E/7K0!Q?\ PN#]DK]J.]T.+Q'H
ML_P_U6%Q\UN!ASZ$A2,9KTO_ (*7_$&V^$?[*O@[P=X1U*:;2]6;[-%=K(&,
MD*@./F'7H:^5_P!MK2/V;;K1].N/@_)/)XIN)PIM[4YAV'/8< YQ7LWQJ_9O
M\;^+/^"=O@675+2>\U_PZ/M:6Y4F5(6 7:1UX&XT 8W[)?Q$_99\!_!6VT[Q
MK:1:EXCOU)OI+FTE=ER/N@A<<9-<I^PK\3+'P#^VU<Z/X.NISX)UZX:"*-D9
M4(8AAP0,8QBNM_9$_:#_ &<-/^#L>E_$OPKIMMXGTE2CR36"2-< # .2.O'Z
MUZS^Q=\:/#GQT^,EQ#X9^#6DZ5HNF2LT>OPP(C1 '"GB,?,0<XS0!\Y_M>:I
M-\?_ -OZV\&ZI=22:)9WR62V^?E" [C^8)%?;O[5'[#?PUF_9YUA?#OA^VT/
M5="L6N+6^M1MD)C0G!/O@9KXI_;C\+ZM^SK^VM9_$B;3Y)-"O+U+U)U4[3SA
MESZX%?3?[17_  4D\ >,/@-JFF^"GNM6\3:W8-#]A2$Y@#H0[-C/W<^E 'C_
M /P1GB:#Q'\0HW.72-E8^X S7$_LT_\ *3C6O^PC<?\ HHUV_P#P1C\RX\2?
M$#S!B5XSN!_O';FO(X_&T/[+_P#P44UK7O%]M/;::NI2LT@0DF-T*AQZC)_2
M@#]#O^"H@_XQ+U[_ *^8?_9J^._@7\2+[X9?\$R_%^H:;,UO?7$[6T4J=5)W
MG/Z5V'_!0O\ ;6\*_&KX,W/A'X>"ZUQ7DCN;Z^6$B.W1><$C(R1G\JPOV:?A
M3>_&'_@FWXPT338C<:BLK36\:C)9P6X'X$T >9?L#_$#X > _#&M:K\5($U'
MQ->7#(BW-M)*JQ84Y!5>N2W>L6U^)WA+P#^W-H?B3X1326WA;4+R&.:&.%T0
M"1QYBX(''-=!^PG\6/@O\/=+UWP?\9_#-G'J=M<M)#>7UDLCC@#RSN'&,$_C
M7L_PI_:%\ ?%3]HR'PC\._@MH^J:'%<J4UA;5$:)0W,IQ&<<<CF@#R/_ (*I
M0_\ "0?M.>#T5S&+RRC^9>" Q3_&OO.Z_8N^%=G^S9>:3_PB]F]RND23F_92
M9FE$98.3ZY KX;_X*A*L/[6W@M H14@C7:.@P5XK]6M8/_%EM0]/[$E_]$M0
M!^6__!)OQ1=>!_%7Q/L_/9[&QM&G*=LQK(<XKF_V+? 6G_M8?MF>*]7\;+_;
M%M8//>"WN"65]DH15(],&NC_ ."5&E1Z]\8/B;ITN#'=V\D+?1@XKBO@OXZN
M/V!_VS->3QC8W%IHM_+-"\PC/^I>0.'7UP,4 ?>'[17_  35\"_&;5-&U'P^
ML/@N[L7!EDL%*F51T['D&OGO_@J=XAU/X0_ _P !?#.UUFZNXG39<7$C?/,L
M00#<<#U/YUK?M3_\%07O-6\.:%\"[DZEJD\P\^6>VWJV[@(!GGG^=4?^"BGP
MH\>_%+]F?P-XXUW3/-\4:;%YFIPVD>/+$BH3\HZ8VG- '+_L_P#Q*_90\+_
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MV9=AA*@J5],58I: / O%'[#'P6\7:L=2O_!EJ;IG\QC"S1@G.>BD"O4?A_\
M"_PO\+-)&F^%]&MM(M.I6% "WU/4UUE)0!R?Q$^%OA;XK:.=+\5:-;ZM9]0L
MR<K]#U%>%^-/V4?A;\'_ (3>.=3\,^%+6SO_ .R;K$[@R,N8VZ;B<?A7U#5?
M4-/M]4LYK2[A6>VF0I)$XR&4C!!H _*K_@C=&\?CKXA;T9-S,1N4C/S+7Z%?
M%;]F?X<?&BX2Y\6^&K;4KI1@7'*/C.>2N":ZOPC\,?"O@.:>;P]H5GI,L_\
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MPCAFP!G]!76T44 5-4TNTUJQGLKZWCN[29=DD,RAE8>A!KQ*W_8?^"]KK_\
M;*>"K,7@?S!DL5W9S]W./TKWBDH \XF_9V^'=QXGM?$)\+6,6KVNWR;B&,(4
MV_=P!Z5K?$SX0^$_B]H/]D>+-'AU:Q!RJ2CE3TX(Y'6NRHH \E^&G[+?PU^$
M=K?V_ACPY#8I?Q&"Y^=F\Q#_  G)-;WP_P#@?X)^%EW=77A;0;?29[H 3/".
M6QG_ !-=W2T <;\1?A#X0^*^GK9>*M#M=7@7[OG(-R_1NHKSCP?^Q!\&? VK
MKJ>F>#;5;M'WHTQ:0*?4!B17O-)@4 8OBCP7HOC3P_+H>L6$5YI4H :U883
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M>S1FO(?^$LU7_GZ:C_A+-5_Y^FHY0N>O9HS7D/\ PEFJ_P#/TU'_  EFJ_\
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M>S1FO(?^$LU7_GZ:C_A+-5_Y^FHY0N>O9HS7D/\ PEFJ_P#/TU'_  EFJ_\
M/TU'*%SU[-&:\A_X2S5?^?IJ/^$LU7_GZ:CE"YZ]FC->0_\ "6:K_P _34?\
M)9JO_/TU'*%SU[-&:\A_X2S5?^?IJ/\ A+-5_P"?IJ.4+GKV:,UY#_PEFJ_\
M_34?\)9JO_/TU'*%SU[-&:\A_P"$LU7_ )^FH_X2S5?^?IJ.4+GKV:,UY#_P
MEFJ_\_34?\)9JO\ S]-1RA<]>S1FO(?^$LU7_GZ:C_A+-5_Y^FHY0N>O9HS7
MD/\ PEFJ_P#/TU'_  EFJ_\ /TU'*%SU[-&:\A_X2S5?^?IJ/^$LU7_GZ:CE
M"YZ]FC->0_\ "6:K_P _34?\)9JO_/TU'*%SU[-&:\A_X2S5?^?IJ/\ A+-5
M_P"?IJ.4+GKV:,UY#_PEFJ_\_34?\)9JO_/TU'*%SU[-&:\A_P"$LU7_ )^F
MH_X2S5?^?IJ.4+GKV:,UY#_PEFJ_\_34?\)9JO\ S]-1RA<]>S1FO(?^$LU7
M_GZ:C_A+-5_Y^FHY0N>O9HS7D/\ PEFJ_P#/TU'_  EFJ_\ /TU'*%SU[-&:
M\A_X2S5?^?IJ/^$LU7_GZ:CE"YZ]FC->0_\ "6:K_P _34?\)9JO_/TU'*%S
MU[-&ZO)(?%6J--&#=-@L!7K,/,:$]<4FK#'T444@"BBB@"GK'_((OO\ K@__
M *":*-8_Y!%]_P!<'_\ 0310!<HHHH **** "BBB@#RWQ_\ \C W^XO\JYNN
MD\?_ /(P-_N+_*N;K5;$A1110(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "E S24J]10!\F^-/BC\4M>_:(UGP%X.O;6WAM4\R,3H#@<]\^U=[X
M)T'XYV?BBSE\3:GI\VB*?](2)0&(R.G/UKPSQ7X2UWQG^V;XEL/#^O?\([?"
M+=]KXZ<\<@U[U\-?@]X]\(^++?4==^()U[3T!#V1"_-GZ"O/I\TI.]]S[+%1
MIT:$%'E5XKIK]YZQH_BS1O$5Q=0:9J5O>S6K;9HX9 S1GT('2ET_Q5H^K:I=
M:=9ZC;W-]:_Z^".0%H_J.U?*GB+7%_9M_:#UR]GS#HGB"S::$D_+YORC'\ZG
M^#FFZCX=^ ?CGXA,))=>UI9)T<]50X''ZUJJSORVU/-EED5!5%+25K>K_P C
MZ5E^)'A6#5O[+D\0:>FH9V_9S<+OSZ8S5S6O&&A^';BT@U/5+6QEN_\ 4+-*
M%\SZ9/-?!?@WPQ=>+/@?/>0>"[^_UVZ9I4\0^>1MDZCG?TR?2M/XSV.MZ];?
M!/3?$PDM=3D)@FVL=Q4.P!R/8"L_K+M>QV_V-3]IR\^U[_)=#[/A^*G@^XNH
MK>+Q'I\DTK^6B+<*2S>@YZUJZWXHTCPVUN-4U"WL3<.$A$T@4NWH,]3S7SK^
MT=\!]&\-_"R'5?#%FUGJ&CW$=YYB.Q9N5SU/H#7)6?B@?M(?%[X?VMLYGL-'
ML8[V^(/R^;M5L'WRIK1UIQ?*UJ<=/+Z-6G[>G)\BO>_EM]Y]6^-O$4_AGPCJ
M&K6-G)J-S##YD-O""S2'L !7S%??&[XN?#]= \2^*[:S70]9N1"-."!9H@3@
M<=<\^E?5NL:QI_AO39+W4;B.TL(5 :67[J@>M?*/[4N@Q6T.D_%2SUT:SID-
MU'Y.E,1Y!!8#*CUY_2G7O%73V%E:ISG[*I"ZEU?Y>1Z=\?OC=J/@>S\.:5X9
MBCD\1>(75+99AD1JV!D_]]"L;X4_&#QCIWQ1?X?>/X[>749H1/;7=N %(.W@
M_P#?7Z5Y]\;M6;6/C-\%M=DA^S6MX(90#PJ9\LX_6M_QOG4/VV/"_P!D</Y-
MKNEVGHOR]:Q]I+GO?JCT8X6C'#J#CJXR=_-'U'?7D&FVLMS=2K!;Q#<\CG 4
M>I-<Z/BEX/\ ]%_XJ/3O]*_U/^D)\_TY]ZK?&C_DE/BG'_/D_P#*OBG1?AWI
M#?L73>*I(Y'UU+AA%=&5LQA>@'/%;U*KA*R72YY6!P-+$4^>I)J\E'3S/N>?
MXB>%[74X].EU^P2_DQLMS<+N.?;-<+\1/$WB33/BCX8LM,UG3K+1IP6NK6XD
M432\-R@)R>U?-OQ8^'.D>'_V6/#GBNU$P\1-+$QOVE8N<@\9S6Q\3KJ:]^+?
MP;GFD9I9-.)=L]3LDY-8RK2V:['HT<MIQ?-"5U[RU75'UA<_$[PC;QW,S^(=
M/BA@D,4C/.HVL#C:>>M7)/&6A1:&VM-JMK_9*C)O/-'EC\<XKX__ &>_AOHO
MC[Q%\6YM;BDO$M;R<10M(P526DYP#UXKE_#,\X_91^)MB9I)(+74&2%68DJH
M9N!36(=KM::D/**7,XJ;NG&_S/NR7Q3I$&AC69-0@72F7<+LN/+P>^>E>1_'
M#]IC2_AG;^'4TRXM;^35IT'FB4%8H21ES[8.?PKB_%-Q'_PP[9GSEYL(P#NY
MSO%>0?%#P[IUU\+_ ('W,UN'GNGB@F=B?FC_ '8P?P-%2M*WN]KCP66T95.:
MJVU=JWHC[E@\;Z$?#=MK<NK6BZ=)&K?:FE41DXY .<=<U/X?\7Z)XLA:71M4
MM=21?O&WE#X^N*^/OV@H1IWQ4^'WA"QTN:[\/);K*-*MI"HN&(!(ZC/4]ZW/
M _A_Q#X=^/6F:AH7A*Z\,Z+<1>7?6,DN5Z-A@"Q[X_*J]N^:S1A+*Z?L?:J6
MK3:].S/KS->>?$+XL:)H_A7Q%_9FO6#:[96K2QVXF4L&!'\.?>M7XP:E=:-\
M,?$]Y8;OM4-E*T97KG:>E?*G@GX6^%M<_97USQ/J#LVO21RS/>-.V\.'(V]:
MJK4<?=B<^ PE.HE6JOJE9>9[]^SC\2K[QU\&['Q-XENX4N'+>;.V$0 5Z!X=
M\>>&_%=X;?2=;LM0F4X:."968?@#7P-?>)-2T_\ 9?\ A]I-HLQLM1U'9<F%
MBI8#!VY'KC]:[Z;PAK^E^._ NI>$O!%WX:>VFC2Z:28[;F(E<MC<<\ _G6,<
M0TDK=CTZV4TY3G.]KMV[:=SUKX7_ !<\0>)OV@?&/A6_FC;1],0- NW!7A>I
M_$UZI-\4_!UMJ7]GR^)--2]SM\DW*;L^F,U\O_#W4K/3?VA/BK>:I*UM9I8A
MKB13AE&V/./QKA_&6FZ5JGP?U+6/"W@Z=-+63S$\17T[B5CN'*_,?\FB-:48
M_>%3+:5:LELK1VVNS[HO/&.AZ=J-I87.J6T-Y=C-O"T@#2Y_NC//44_6/%>C
M^'KJTMM2U&WLKB[.V".:0*TA] #UKX]\=:3>W7[//PV\?QM)/J.AR0M+-D[C
M'\A.?7A:Z#POJL/[07[1^CZM'(;K1?#]A'+M!^3S2J$Y]^36OMW>UNQQO*X*
M#J.7NJ]_5?YGT-\7-4U71O .HW>BWMKIVHHJF*XO&"Q+DCJ35?P7X\M(/"N@
MQ^)-=T\ZW=6RR,R3*$E.T$LO/(YKE_VN3_Q87Q'@X^5.G'\:U\PZEHL7B37/
M@9IES+(EO<6$2R>6Y!*[8LC(-*I5=.;LBL'@88K#)R=M7T[(^X]#\=>'?$MY
M+:Z5K5G?W,1P\4$RLP_ &MS^=?('BKPAIWPT_:U\%VWAV-["VO(OW\2R,5<@
M@9.37U%\0-2N='\%:Y?6:E[J&TD>,#UVGFMJ=1R3YEL>?B<)&G*G[.5U-=2'
M5_B5X4\/WPL]2\0:?9W9.!#+<*K?D36C?^)M)TO2/[5NM0MX=-QG[4T@$?Y]
M*^5OV;?A'X4^*?PUU/Q)XI=M2UF]FF\^>:9@8.>PSQC/Z5YHFO:A)^SI\3M"
M:>6[TC2;\QV5V[$DKD_*#_GI6'UB25VM]CTEE5*<_9QF[II/3OV/N/\ X65X
M4%[!9GQ!IXNIQF*+[0NYL],#-:NL:YIWA^Q-YJ5[!8VH_P"6T[A5_,U\9>)/
MA+X9T[]DO3_%L,LC>(HX(KE+WSVW[]X&T<_YS7/>+O&&M>.-7^%FEZM876J6
M;V$<SZ?$Y4W3;4/)R,__ %Z3Q#CNBHY/"H[TY.R;3OY=C[FT'Q=HGBBWDGTC
M5+7488^7:WE5]OUP:S9?BEX0AMWN)/$>GQPH_ELS7"C#>G7KS7S/X/\ #?B+
MP_\ &Z&^T7PK=>%] FM6BO;&64LO0?-@L?3]:P?V<_ACH?CK1?B?=ZU"]XUM
M).8%:1@(R$!! !ZT_;RT5B?[+H14IRF^56]=3Z=^+7BJ]B^%][J_A/6+"VNL
MKY-_<2KY '.<L3CTJ_X:\;V5CX9T%?$6M6*ZM>PAMXE4+,>Y7GD5\6Z#?W-Q
M^Q'XSMYKB25+;5#'%O8DJH9AC/X5J_$[3EUB/X$6,LDBQ7$*I(48@D9/<5'M
MW\270Z?[*A;V4I;2>MM=%<^T]&\=>'?$5[+9Z7K5G?W<?#PPS*S#\ :-<\=>
M'?#5U':ZKK5E87$APD4\RJQ_ FOE/QYX5L/A;^U;X+A\-H]C#=6;/-$LC$2-
MM?KD^PJU\#O!^D?&#XO?$'4?&(:[O;2[>""TFE91$FYQD#/L*T]M*_);4XWE
MM)059R?):^VN]CZMTWQ)I.L7$EO8ZC;W<\8W/'#(&*@]SCZUROQH^*EE\(O!
M-UK=RT;7 &VW@D<*9&]!Z]:^>?V3]/AT7]HCXC:=:7,EQ96\96+?(7P,IQR>
MU>J?M@:#8:M\%M4N+N!9IK3#P,3]QBP!/Y5?M'*DY(Q^ITZ.-IT)-N+M^)P7
MQ%_:?U-?@OX9\2^']0M!K%Y>10WL,9#^2&(!4CL>OY5[YH?Q.\-WD.G6DVOV
M']K301N]OYZ[]Q4$\9]Z^,/BIX2TK2?V4? D]A;K;7&HWD!N)$/+$E>?U-=7
M^T?\,=#^'_PF\&ZYH\,EOK"S6^Z[\UM[[D).>:YHU:D;M^1Z]; 86HH4H)IN
M4DOD?8&N>)=*\,V@NM6U"WT^W/22XD" _G1H7B;2?%%J;G2-1M]2@'62WD#@
M?E^-?&/Q,UJ_\6?M!:'I.H:7=>(M/M=/22/2H9"HE;#<GD9_^M79_!CP]XB\
M-_'F]GL?#ESX<\,WMN!/832[E1P&P0"QQ]XUNJ[<K6T/-J95&G1YW+WK7\O0
M^J;BZALX7FGE6&%!EI'. ![FN<TWXH>$=8U V%EXCTZYO,X\F.X4MGTQFN?_
M &@M4T#2?ACJ;^))KB'3'^1A:L5D<]@#D?SKXU^+VGMHNA>"-6T?PG)X4LY+
M^)8;]IF\^Y7<OWAN/K55:KIO0QP&7QQ<;R;5]NQ]Z:QXZ\/>']1%AJ>L6=C>
M&/S?)GF56VXSG!/2O'_BK^U9H?@_Q#X=TO1=0L-1CU";;=7:SJRVZ<Y)].U>
M7?%;PY;>-OVL/ VG:F7>VN-)B>55<C?\BY!QZU#^TE\)_"OAGXK?#G3M/TN.
MWM+VXVW";B=XR>N36$JTVFXZ69Z.&R_"PG"-5MN46['UU=^-_#^GZ+;ZM<ZQ
M9P:;.H:*YDE4(_T.>:FT?Q5HWB&P>]TS4[:_M$&7E@D#*H]3@U\;?%%3<_M(
M:=X4&AW&LZ!I=H/LNBV\A56^]SU&?S[5O?#SP]XB\._%3Q%/9^';GPYX9N]-
ME\VPFEW"-PIP0"QQUK3V[O:QS/*J:I\W,[M7\K?YGTJ_Q6\'1HKMXDTY59B@
MS<)R0<$=?8UKZ+XHTCQ)I[WVEZA!?V:9W30N&48&3R/:ODS]D+X2^'O&VB^)
M-4UFV:]N8]2E2'S)&Q'\S=!G%<WIOC2;X!P_%'P1/*T,LK9TW)ZB0JGR_K0J
M[24I+1CEE=*52="E)N4;;^?^1]KZ#XHTCQ1'-)I.H0:A'"_ER-;N'"L.H..]
M>;P>+/$%O\;M1L;O6]-7PQ!;>9]B\Q?M"'"Y8C.<<G\ZF_9@\"KX#^$6CP2(
M1?7JB[N6;DLS@'G\<UX1XER/VJO'?S-C^Q#QGCI%3G4<8QD]S'"X6G.O5I1=
MTEO\SZDD^*G@Z*QCO'\2:<EK(VU)&N% 8^@YK?L]3L]0L5O;6ZBGM&7<)T<%
M,>N:^+_V<OA'X>\4_ /Q'K&KPR7MW^^\G?*V(L+D;1GUK-\.^,-:T/\ 8PUE
M[*XF,BW[VOG;B6CC)(//TI*O)*\ETN;SRJFVX4IW:DD[^9]BVOQ.\)7VJ'38
M/$6GRW^=OV=;A2V?3&:L:IX^\-Z'?O9:AK5G9W:)YC0S3*K!?7!-> Z+^S[\
M-Y?A?X9U6]U)])N66.X;5EG;>\A&2#SZD_E7&^+O!VF>,_VNM'TF]FDO=,_L
MX9*N1YH&_K@^U#JS25UN94\!AZDY)2=HIWT['UC+X\\.V^BIK$NLV<>F2?<N
MFF4(WT.>:LZ#XIT?Q3;-<:/J5MJ4*]7MY X'Y5\;?&BT2Q_:&\.^#K31)]2\
M.6=OYD.BP2$"5B%SW&>@[UT/P]TO6O!GQFN]0M?#EWX7\(SVC"^M99=PA^[\
MX&XXX'ZT>W?-9K38IY5#V*G&6K5U_EZGTKJ'Q1\(:3J L+SQ'IUO>$[?)DN%
M#9],9K8O/$&F:=IHU"ZU"W@L2,BXDD 0CV-?#^N6&A>)_ /BG5?"?@ZXU&Q#
MN[>(;^=PRL,?<PQJ_'X4\1?$C]F7P6VG:BLM[9W!;[)<3%?M*@KA<]^GZTO;
MR[&G]DTN6,G)K6SN?7^@?$3POXJN#!I&O6.H3CCRX)U9OR!J7Q!XZ\/>%)$C
MUC6;/39)/NI<3*A/YFOCKP?XKTWPC\1O#T?C/P)<>$-64^7;W5I*WDRMC@L-
MW.<>E9O@^\NOB)\6O'M[K7A6[\92P2M##!'(56V7 P<;AZT?6'HK:E/)XJ3;
M;Y4K]/P/NFSU6RU"Q6]MKJ&>T(W">-P4QZYKR/XY?'"P\-_#77;_ ,+:]87.
MN6(XCCE5RI_W0:^?86\9> ?@?\0K>6TNM-TY[C_0U>0LT,;%]RYR2,#'>KGQ
M*^$WA+2?V3[/7K7Y-7:)96N/.8M,YY((SS_]:IE7E*+Y59VN.CEE*E5BZDKK
MF27_  3Z=\"_$:V;X6^'_$7B?4;>Q>]A4O/,P1"Y.,#/X5WEO<1W5O'/"XDA
MD4.CJ<AE/0BO&_ GP_T+XD? 'PAIGB&/S+)($F5=Y7Y@V1R".X%>OZ;9PZ=I
M]M:6XQ;V\:Q1C.?E P*ZZ<I-*YXF+A3A.2AO=^EBQ1116AYX4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $D'^OC_P!X5[?#_J4^@KQ"#_7Q
M_P"\*]OA_P!2GT%3(I#Z***@84444 4]8_Y!%]_UP?\ ]!-%&L?\@B^_ZX/_
M .@FB@"Y1110 4444 %%%% 'EOC_ /Y&!O\ <7^5<W72>/\ _D8&_P!Q?Y5S
M=:K8EA1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C..:**
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M^&HU28V;.S_;/XN?P_I7LE%.4(R=VB:>)JT8J$'9)W^9Y/XR^ -EXR^$&G^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** )(/]?'_O"O;X?]2GT%>(0?Z^/_ 'A7M\/^I3Z"ID4A]%%%0,**
M** *>L?\@B^_ZX/_ .@FBC6/^01??]<'_P#0310!<HHHH **** "BBB@#RWQ
M_P#\C W^XO\ *N;KI/'_ /R,#?[B_P JYNM5L2PHHHH$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9WB*.^FT.]CTMUCU%HR(';H&[&OA_7/AWJ_@
M/]I3P%-X@UF36M9U"0RSRM]U.&^5?;CTK[QQ7S#\=O#^IZA^TO\ #N^MK&:>
MS@SYLR*2J</U-<N(C=)^9[^4UG"I.GI9I_D?26K>(M*TN\>*]U&WM9<YV2O@
MX]:\5^*WQJUWX<_%3PE;Y@G\%:TWE-.HR5?ZX]CWK8^,'[+_ (7^,GBDZUK%
MYJ$%R(Q$%M90J[1QZ&L#]H?X36T?P#-GITN)?#JBXM99V&[Y<CK^-.I*=F[;
M$X2&%YX)RNY:--;7*WQ,_:$U7PS\7AH&FM"=$L+(W>HR, 3T; ''<@?G7(+^
MT?\ $F[\*W'CZ"PTQ/"44IQ8R2'SVB!^]T]/>L']G_X;W_QB^&/C;Q)JS&35
M]<C,%O*_8)A@![9KC/#_ (7C\/>%!X5U?X<ZIJGB2*0P[U8?9Y5Z9/\ ^NN-
MSJ-*71GOQPV#IMTK)RA9/S[GT[XL^+7BK5_"/AS4_ NE0W"ZL@:6\N6Q%:]<
MYZ]QZ5ROPP_:!\43?%V3P#XK-A?W#6[317VGME,@,<'@?W?2N/\ C%X8\0>&
M[/P':QZ+>?\ "&01[M0TC3F!(8DG:>OK6-\/_#<UO^TOI&N:;X2N_#WAV:SD
MCB60;CG8_+'L3FKE.?,CGI87#.A*Z5K-KON==X'^.7Q6^(_CKQ/H6BVMBT&D
M:@T1GDXQ$'88X7J0*^F=8OKG2_"MU>G;]M@M?,/IO &?UKYZ_9/T#4M'^(/Q
M/FOK&:TCN-2=H7D4@.N]^1^=?0GBZ-YO">KQQJ7D:V8*HZFNFES<CDSR<P]E
M]9C3IQ2BK;'RMX3_ &@OB[XT^'^K^)-/L=/%OI,K&::3@RJ,9"C;Z58;]I3X
ME>(?A>WQ T;1[*UT*RXN4F8[Y2/O;>#QQZ]ZL? CP[JNG_LT^,[&YL)X+R4S
M>7 Z$,V5&,"LWP5X9U>W_88U72Y-.N$U-C-BU9#O.1QQ7+[]EKNCV7'"J4ER
M1TDE\F=OXM_:=OX_"O@]?#>EI?>)_$D>Z*W8_+'R02?Q%5(_C;\1?A?XLT33
MOB3IMG)IFKRB**\LR?W;GHIX'M^=>>M\//%'AWPG\+_'6F:1+?76BPLEWI^,
M2;2Q/0_A6WXRU;Q'^U)XM\*Z;:^&+S0](TN[6ZNKF^&.5YP.GH*?-/YZ$_5\
M-'W5%<GO7?5=C>\0?'?XB77QOU?P+X5LK2[\N(2V[S<!!SDG ^E>6:1+\49_
MVJHUNY[-?$JP#S5W$PK%\O &WKT[5ZM\/?#NHV/[87B.^DLIDT[["(X[IE.Q
ML!NAK(\<?VQ\/OVLH/%!T.[U32[N 0K);+D*?EZ_E2E&37,V]S2E*C3DZ=**
MUA^)V_Q"^('Q1M_$E[9:+:Z=HNEV47F'4-1? N",Y"C!KAK[XTWOQD_9C^(3
MZI;Q0ZCIJO!*T!RCX#C(_*N:\06NL-\7_$TGCKPUJGB:QNE/]CQ6Y_<Q9'&:
MS_ASX1UK3O@7\7-+FT2YLKRXD9H+3822#YF /6B4IMOYA3P]"%.,FE=.+NO7
M4G\/^,[CP[X?^#&GV^GV=T;P.!-<*"T9WM]WBH_ANWQ'F_:@\;#3;JU_M5(_
M]*\XDH(^=H4;3WJ./PCK@C^!X.EW(^R,WVC]V?W7SM][TKM- DUKX8_M8^(]
M1NO#]Y>Z=K@2*&YA&449ZDUG%.\;[7.NK4IQC4Y+-N+_ #.U^$/Q]U;6--\=
M6_B\0QZOX<:5OW8P'1=V#T']VNG_ &;_ (@>)OB=X3O->\0K%'%+=.EE'$,?
MNPQ&3Q[5\Z?M4>'=4\&_%ORM D6.+QI&MI.BGD$\,<?\#K[#^'/A.#P/X(T;
M1H!A;:W3<?5B,G]2:ZJ3DYV?0\''4Z%/#JK!:U+?*V_XGRI\4-2US2_VQX'\
M.6*7^JRVNR-)#A5^_P#,<>G]*]"\-_&KQWH7Q2_X0/QQ9VB7]_"TEA>6Q.TM
MC@=!ZCM7&?%!?$_AW]JY/$ND:#<:K:6UKF78N R_-D ],\U<T$Z_\>/VBM$\
M6R^'KK0M%T.,X:[&&9^/_B:R3DI-+>YZ-2-.I2@YI.*AOUOT.U^#OQ\U/7K/
MQU;^+C#!J?AR5SA!C,8Z'H/45O?LV_$3Q-\5/"U]K^O1QPV<MPR6*(,$Q\<G
MCZU\Z?M;>']1\(_%]%\/-Y0\80BWN88^K<J.G_ :^QOASX5B\$>!M%T6)0HM
M;=5./7J?YUM2E.4W%OX3SL=3H4\/&M!:U+6\K;_B>,_M#?#/X:^#O"NL>*]2
MT&.ZUBX)6$-*X,LS9V\9]:W/V5?@Y!\,? JW\L)BU75_])F4D_NU/*K^6*Y[
M]IK2=1\7?$CX?:+'937.E+>+/<.BDHN&0C/ZU[GXNUQ_!_A&[U&VLWOGL8 4
MM8OO/@ 8%4HQ]HY-;&-6M5^ITZ/,VY^?3HCSS]J[4KRQ^"NKPZ?#-/=796$+
M",MC<N?TS7SA\*X_ GA&Z\)67C'X>7>CW$YC%OK%PS 23#;R?F]2O;O7T9KG
MQ \9^)_@[!XG\,:(MMK)8/)IEZF6V C( R.<9KQKQUXD\4?M+R>$O#<'A*[T
M633[E9]0O+E0J(04)V_]\M^E95;.?,MSNP#E"@Z,M%=W:=FM"_\ '#PAK*^/
M?%%Q#HEQK=KKVE+::=-$@80M^[P>>G"GI6S':W'B*^\'^ ]0N533O#ELMYK,
MKM\H<%MJ,?8A3^->]^*->A^'O@.:^F5KC[!:JBJB%V=@H'  KYQ\2> -;L?@
M/>ZVT<TVMZ[?Q7NHJ@)D\CS$RF.O1352AR-V,Z&(]M!1EHD[+UVO]Q]0:%K^
MDZ]9^;H]Y!>6J'8#;G(7':M*OFG]F&SV_$+Q7=Z/:3V7A62&%8(Y$9!Y@#[B
M W/I7TL*Z:<N>-SP\906'K.FG<****T.$****8PHHHI""BBB@ HHHH ****
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MY75_-49(Q^-=?LY>R<7N>!+&4I8^%?[*L?*GQ@^%&@^#_P!G#PSXJTV*2#Q
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MKJO_ #Z/^5>OT4<P6/(/^$5U7_GT?\J/^$5U7_GT?\J]?HHY@L>0?\(KJO\
MSZ/^5'_"*ZK_ ,^C_E7K]%',%CR#_A%=5_Y]'_*C_A%=5_Y]'_*O7Z*.8+'D
M'_"*ZK_SZ/\ E1_PBNJ_\^C_ )5Z_11S!8\@_P"$5U3_ )]7_*C_ (175/\
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M1S!8\@_X175?^?1_RH_X175?^?1_RKU^BCF"QY!_PBNJ_P#/H_Y4?\(KJO\
MSZ/^5>OT4<P6/(/^$5U7_GT?\J/^$5U7_GT?\J]?HHY@L>0?\(KJO_/H_P"5
M'_"*ZK_SZ/\ E7K]%',%CR#_ (175?\ GT?\J/\ A%=5_P"?1_RKU^BCF"QY
M!_PBNJ_\^C_E1_PBNJ_\^C_E7K]%',%CR#_A%=5_Y]'_ "H_X175?^?1_P J
M]?HHY@L>0?\ "*ZK_P ^C_E1_P (KJO_ #Z/^5>OT4<P6/(/^$5U7_GT?\J/
M^$5U7_GT?\J]?HHY@L>0?\(KJO\ SZ/^5'_"*ZK_ ,^C_E7K]%',%CR#_A%=
M5_Y]'_*C_A%=5_Y]'_*O7Z*.8+'D'_"*ZK_SZ/\ E1_PBNJ_\^C_ )5Z_11S
M!8\@_P"$5U7_ )]'_*C_ (175?\ GT?\J]?HHY@L>0?\(KJO_/H_Y4?\(KJO
M_/H_Y5Z_11S!8\@_X175?^?1_P J/^$5U7_GT?\ *O7Z*.8+'D</A;5%F0FU
M8 ,#7K4/$:COBG44F[C%HHHI %%%% %/6/\ D$7W_7!__0311K'_ ""+[_K@
M_P#Z":* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)G'6EIK+NR.QH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HI-U+0 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I,UG>(/$6F^%M)N-2U:\AL+&W4O)/.X55&/4UY
MW\)?CM!\8M<U1=%T>\3P[:?+#K-PA1+EAC.P$8(SGD'M0!-\4OC0? &O:+H&
MGZ#?:_K.J2 1Q6RX2),\NSD;1@ ]^U>F6[O)!&TB;'*@LOH?2FFUC:83&-3*
M!@/CFIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *>L?\@B^_P"N#_\ H)HHUC_D$7W_ %P?_P!!-% %RBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **3-&: %HI,T4 +1110 4444 ?-_[*O\
MR/7Q9_[#DO\ Z,>OH^OG#]E7_D>OBS_V')?_ $8]?1] "T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F
M:6@!-PK(D\7:-'KT6B-J,']K2IYB6>[+E>><?@:Y_P"+=MXQO/"<MIX(FM;7
M6;AO+^U7:EEA4CE@ 1S7*_!C]G33/AC</K>I7<WB/QE=#-UK5XV7)/55X&%_
MQH Z?XG_  ?T3XN1Z;!KQGDLK*83?9HY61)2"#A\$9''0^M=;I.C66A6$-CI
M]K#9VD*A4AA0*H ]A5VEH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *>L?\@B^_ZX/_ .@FBC6/^01?
M?]<'_P#0310!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,GQ-XBL/">BW>JZE.
M+>SMDWNY]*^+_B#^U=\=O&E],OPD^&<Z:/&VU-3U>)E\_P!U1DZ?C7VAK_AZ
MP\1PQ0:C$L\"2!Q$WW6(]1WINLZK8>#?#UW?SJEM8V4+2LL:@# &< >M 'PA
MX9_:&_:X\-WRW?BCX:VVLZ4IS+!8ILEV]R,(<U]B_!WXQ:;\7?#_ -L@MKC2
M]1A^6ZTV]C,<T#>A4\X]\5\Y:#_P4>L-4\91:?=^ ]>L- FG\E-8E@ CP3@.
M?FZ=Z^L-)T'2);Y-?L((XYKJ$'S(AM$BM@@D#J>E &]2T@I: "BBB@#YO_95
M_P"1Z^+/_8<E_P#1CU]'U\X?LJ_\CU\6?^PY+_Z,>OH^@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6DR/6J^
MH:A;:79RW5W,EO;1*6>60X50.YKQ31_VED\>_$B#PYX&T2;Q#I4,FS4=< Q;
M0>RG.2?P]: /2_B-XZM?ASX4O=<N[:YO4@7Y;>SB,DDC$X50!ZDBO(_A4WQ4
M^*'BVU\8^(Y!X3\+(C?9/#Z@F:4'&&E/!!Z<$=S7O\UO'<ILFB25.NV101^M
M2*NW  P!Z4 +2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9X]\/W.B:S!]ITZY&)8<XW#T_6IO"_A'2/!>D0:9HNGPZ?90J%2*%<"M@4M
M!1110 4444 %%)FJ^I:E:Z/8S7E[<1VMK"N^2:5@JJ/4DT 6-PJG::Q97]Q/
M!;7<%Q- <2I%(&*'T(!XZ5\U>)OC=XJ^.FK2^&/A%"T.E*YBO_%<ZD0HO<0]
MG/N&[UZY\&O@MIGP=T2>VM+JYU+4;QO-O=1O)"\MQ)U))/.,D\9[T >C44E+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %/6/^01??]<'_P#0311K'_((OO\ K@__ *":* +E%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!YM\>/!_ASQYX#N-#\3W,UC8WC>6E[!(T;P/@X8,""*\/\
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M2_\ HQZ^CZ %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %/6/^01??\ 7!__ $$T4:Q_R"+[_K@__H)HH N4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ''?$KXH:)\*M-LM1UZ8V]E=72VHEQD*Q!.3[<5TNDZM9:Y8
MQ7EA<QW=M(,K+$P93^(JAXFT/1M<AM8];M[>YABF$D272@KOP1T/'0FOD?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=2G\-?!O2_[<OPWESZ].,65MSR0^"KG';(H ]<^)WQB\,?"71Y+_ %[4$CD
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M"\O+?3X6GNIX[:%?O23.$4?B: )Z*K6.I6NI0":SNH;N$_\ +2"0.OY@U9H
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M!'X5!\.?@SX3^%VGI;Z'I44<H'S74P\R=SZEVRWZUW"]Z=0 U:=110 4444
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MDT^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"GK'_((OO^N#_^@FBC6/\ D$7W_7!__0310!<HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY!%]_P!<'_\ 0311K'_((OO^N#_^@FB@"Y1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444WO0 ZBO/\ XB_'
M3P5\+[=GU_7+>"XZ+9Q.'N'/HJ9R:Z?PGXDM_%_A^QUBS2:.UO(Q)&EQ&4<
M^JGI0 GB7QAHOA"S>ZUG5+73H5&<SRJI/T!.3^%0^#?'&D>/M'75-$N&NK%F
M*K*8V3)!(. 0/2O-M8_9;\,^+_'EQXF\4W-]XA8ON@TZ\G9[2'G.!&<CT_*O
M7-(T>QT&QCL].M(;*TC&$A@0*H'L!0!Y-\2?V=(?BWXH-UXE\0ZE<>'E VZ%
M%(%@+ YRPQD]N_:O2/!G@?0O &BQ:5X?TV'3+",86&$8%;U% !1110 4444
M%%%% !112-0 M(W2O/\ XH?'+PA\([%IM?U5([C_ )9V,)#W$I/0+'G)KQQ_
M$/Q@_:%NHX]#MC\//!4G$E]=H?MTZ'NJ':R<=\F@#T_XJ_M&>$OA7#Y5Q<MJ
MVKN=L.EZ:#-,[$X .T';^->8+X:^+7[15P)]=O9?AYX)F'_(,M6'VV=#V=P6
M4 CM@=:]/^%?[.7@_P"%S&\M;1M4UR3YIM6U%O.N';N=[<@?C7JE '$?#/X.
M>%/A-I8L?#VE16NX[I+@C,DK?WF/K7<444 %%%% !1110 4E-FF2WB>21UCC
M499F. !7+>$?B;X;\=:EJ5CH.J0ZG-IS;+AK=PRJWID'WH =X]^)7AWX9Z++
MJ?B#4H;*",9"%LR/[*@Y8_05S/P7^+FI?%R&_P!3/AN[T30U?;93WA >Y7^]
MMZ@=>HK6\6_!?PIX[\4Z=K^NZ=_:-[IXQ;QSG=$IXYV$8SP.:[>&%((DCC01
MQH-JJHP !VH 0P1M()#&ID'1B.1^-2444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]
M8_Y!%]_UP?\ ]!-%&L?\@B^_ZX/_ .@FB@"Y1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 <_XV\&:3X_\.W>B:W"9].NE*2(LC1DCZ@@U\H>&_\ @GIX-^#?BR;Q
M1X6T:V\3%WWFQU9F<1C_ &.NX_6O5_VO-9N='\"Z,(?$TGA."YU6.&ZU.-MI
MCB*,3S@^@JUX;_:/^$WA_1[:Q7Q[I]R8T :::X4NQQU- '!> ?BMHGP+T_7X
MO%^GGPQ-J&K2/9Z?)$%$@=SM"@<=Q7U%IMVE_I]K<QC$<T2RJ/9@"/YUX+\0
MOCQ\#O&FCK9:QKVE:PC3(8H%<,YDS\NW'?->[Z.8&TBQ-L,6Q@C\H>B[1C],
M4 7**** "BBB@#YO_95_Y'KXL_\ 8<E_]&/7T?7SA^RK_P CU\6?^PY+_P"C
M'KZ/H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTD)\WR\#!<=CUZ&@#G_C/\=KKX?WT'A_P]X=OO$OBJ\7,%M#&PA0'^)Y "%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G/]N#5/#NC_#'2IO%[[?#!U2,:@N"0\6QR00.O(%?)7[3G[1G
M[,WQ0^#5QX=T6>VL]4C,2V=Q!:NCPC>H8@[?[N:^]_CO\$=#^/GA.W\.>(@[
M:2MRL\Z1MM+ *1C/;K7Q'\0/@K^Q+\,=<?2-<O-M_&<2107JR%#Z-Z&@#'_9
MI^,7[,?[.FBV,7AF[_M_QM>&.![VX@<R/(W! )4 #)K],])O!J.EV=V!M$\*
M2@>FY0?ZU\)_#?\ 8W_9B^+FGQ:K\-[D7&H6DRS1O'>AWC93D;E';BONW2K/
M^SM+L[0'<+>%(L^NU0/Z4 6JY#XG?$W2?A7X=;5M4+N&=8H+:(9DGD;A44#N
M377U\E?MO0ZQ<>,?A+%IMTMC!)K"I+=2KE(V,D>TX]>N* /7?A?\?(/B)X@N
M-#O/#^H^'-6CB\](;U<B6/CY@P&.XXSFO5Q7S9X-O?$7P_\ V@+/PIJ>M1>*
M++4].>[CGDC_ -(M2'4;=V2=IR3V[5V/Q)A^,[^(R?!5SH\6C;.%O(U+[LGU
M/TH Y+]E;_D>OBS_ -AR;_T8]?1]?+'[$JZTFJ?$L>(VA?6_[9E^T-;@",MY
MC],?C7U/0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1244 +16%XR\8:=X$\.W>MZJ\B6-JI>0Q)O;&,\#
MN>*\6T/]I?Q#\1M4M8O!?@+4I]*DEP^IZJC6J!.Y4,IW?G0!]!LP522<*.23
M7G_C;X]^!_ *M_:FOV[3#_EWM#Y\F?3:F37=7%N+RQD@E! FC*/M.",C!P?Q
MKS;PC^S7\/?!NH3ZA:>'X+O49G,C7=\HFER3GAB,B@#OO#^OV_B71[74[0.+
M:Y3?'YBE6P?4$9%>.^,/V>_$/Q'\5:A/XC\=ZBOAB5OW&C:>PC4+Z/E3G\#7
MN<420QJB($11@*HP!3L"@#EOAS\.-"^%OAN+0_#]I]EL8R6VY))8]23ZUU-+
M10 E+110 4444 %%%% !1110 4452U75[+0[-[N_NX;*U09::=PJCZDT 7:C
MFE6%&>1UCC49+,< ?4UX#XH_:[T>356T7P'I5YXZUC)4G3XRUJA]6E4,!6';
M_"7XM_&21YOB#XF'AC1)#\NC:&Y60H>S3*1_*@#NOB5^U+X-^'K-:03R>(]8
MSMCT_25,[,WH64$+^-<)Y/QN^.TD;M.OPQ\+R#.R,AK^1#VW E1QZBO8/AO\
M#/!?PLM@F@:+!#<=7O95#W$A]6?&37?4 >3_  U_9G\$_#>Y;4(; ZKKDAW2
MZKJ!\R=V[G/3]*]75%50% 51T &!3J* "BBB@ HHHH ***0G% "TC5B^+/&6
MB^!]+EU+7=3M],LHU),EQ($''IGO4?@WQEIGC[08=9T>9KC3YR?+D9<;L$C(
M]N* ,_Q]\5/#/PSTN2]U_5H;0*"5AW;I7/HJ#YC^ J+X5_$RW^*WAA=<M--O
M-.M7D9(EO$*.ZCHV" 0#[U@77[.?@_6/B)-XRUFUDUO4V_U,5^_FP0?[B-PI
MY[5Z?#$D$:QQJ$C4855& !Z4 <Z?ASX;D\6/XEDTBWDUQDV?;77+A>./T%=*
M %X P*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*>L?\@B^_P"N#_\ H)HHUC_D$7W_ %P?_P!!-% %RBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \B_:8F\2W7P_&@>$Y_L>M:].-/BO/^?<,"2__ ([^M?-FB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S/X]?'+1?V?_"=MXE\0>8NE-=+!-)&NXH"I.<?A7R_XJ_;D_9/\;7O
MVW7+2#5+OO-<Z4KN?Q-?47Q\^!NA?M"> YO"OB!I$LWD$JO%U5@" >OO7S8_
M[#GP[\ V*'6_ %KK]A$/GO+69Q*%'\3+D+0!+H?_  40^ 'AFP@TCP0OD7-Q
M,D,%G;6(A1F8X&<5]FZ3>_VEI=G=[=OVB%)=OIN4'^M?&GAG]EW]F7XF!8_!
MT>GQZW9SK*OD7+F6&1#G!!..M?9FEV8T[3;2T4[E@A2('UVJ!_2@"U1110 4
M444 ?-_[*O\ R/7Q9_[#DO\ Z,>OH^OG#]E7_D>OBS_V')?_ $8]?1] "T44
M4 %%%% !1110 4444 %%%% !1110 44C'%9NK>)-+T&UDN-0U"WM(8QEFED
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M2R.-VAZ&S6\7T9E;#?E7K_@'X+^#/AFN?#V@VEE<'[UT(E\Y_=GQDUW&!2T
M)1@4M% !1110 4444 %%%(30 M(34;7$:R!&D57/12PR?PK%\:S:Y%X;O&\.
M16\VL[<0+=,5CSGJ2 : -F>ZBM0K32+&K':"QQD^E5-::^_LFZ.F"-K[RSY
MD.%+=L^U>"^"?V<?$VL^)X/%7Q,\776L:E"XE@TNR<Q6L!!R!\NTMCC[P[5]
M$1J%4*.@&!0!\[:3^SAXC\=:ZNN?%+Q1<:H4D\R'1=/<PVL1!R-P#$/^5?0E
MG:165K%;PKLBB4(BCL!T%3X%% !M%&*6B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>L?\@B^_ZX/_Z":*-8
M_P"01??]<'_]!-% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS,?4OC)- 'C[?%+XS_%ZU(\&^%(O!FFS?*NI:X0[X/\ $$1@1^(J]IO[(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU%-W4;O:@!U%-W&C=0 ZBFEL4A?'/;UH ?13%D#+E2"/44Z@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZQ_P @B^_ZX/\ ^@FB
MC6/^01??]<'_ /0310!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q5X1T?QM
MHESI&N6,6HZ=<+MEMYA\K"OG70?V'/!_PG\8/XI\ :/I\%TQR]E?1EX_^ 8Q
M@_4UZO\ ';XR)\$_"EMJYTJ?6IKJZ6TAM+?.YG8$CH#Z5T>@^,HKS2[>?5_L
M^D7DBAS:O."R9'0]* /G[P[\5)/V?['Q$WC/1KBQNM0U5Y;86\9>)_-<E0"H
M(7\37T_I=X-2TRTNU&U;B%)0/3<H/]:^>OVF/B-K7@[3;'5$T/3O&'@N6\AM
M[J$LIDA9VP''!SCDU] :#/'=:'ITT,?E126\;I'_ '5*@@?@* +]%%% !111
M0!\W_LJ_\CU\6?\ L.2_^C'KZ/KYP_95_P"1Z^+/_8<E_P#1CU]'T +1110
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M/U,^'AJ3P06LSQ;_ #8HBX.5R."&% '8?#3XM>)O&/QW\6:'=(+;1K6U$EC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %/6/^01??]<'_P#0311K'_((OO\
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M5%/Y@5L*@50 , = !3J* $HI:* "BBB@ HHHH **** "BBB@ HHHH ***89
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MLV,@[1Z^M?J7X=N'O/#^F3R',DMK$['W* FL:\\%>%_$FE&T_LS39;4$#]S
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MB^'&N:?]G7PIIEHZNLB36]LB.C#H00*].T^S33[&VM8_N01K$OT4 #^56**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/6/\ D$7W
M_7!__0311K'_ ""+[_K@_P#Z":* +E%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?-_[*O_ "/7Q9_[#DO_ *,>OH^OG#]E7_D>OBS_
M -AR7_T8]?1] "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]8_Y
M!%]_UP?_ -!-%&L?\@B^_P"N#_\ H)HH N4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%9?B3Q-IGA'29M3U>\BL;*(?-+,P4?3GO0!J45R7@7X
MJ^&/B0EP= U2&]>W.)8E8;U]R,UUE 'SA^RK_P CU\6?^PY+_P"C'KZ/KYP_
M95_Y'KXL_P#8<E_]&/7T?0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !136
MD5!ECM'J:7<* %HIOF+N*A@6'44Z@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH IZQ_R"+[_ *X/_P"@FBC6/^01??\ 7!__
M $$T4 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>'M'N=0\*/<:U*\,3+;R@(50L<_O/04 ?:.:,U\N_P!D?M1_]!KPC_X"3?\
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MEIY&HZU+Y][+G_6/QS^@KJ:* $%<_P")/ FC^+-2TF^U*V\^XTN<7%JV?N.
M1G]370T4 (.*J:MI=OK6FW5A=IYEM<QM%*GJI&"*N44 9?AOP[8^%-'@TS3H
MO(LX<B./TR<UIUD^+&U./P[J!T58WU7RC]F64X7?VS7R9XNTGQE\$YO"WB*]
M\=W6J>+-6OD@N=$9%,,P9@&"#' 523G Z4 >L_M'?"/6_B=KO@"ZT@Q"+1=7
MAO;GS&P?+616./? ->W1_*JKW KYE_:T^,?B31_#]QX?\".L6N0HMUJ%YU%I
M"!DCH>6&<?2K7Q,\4>(_$4GPV\"Z;J\FDR^(;**?4-1A4&41[ &*@C&2Q!H
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M/\:3_AJWX4?]#QI'_@5'_C0!YQ\<M'N]'^-7ASQ/KV@3^*/!\=BUM]GA7?\
M99RP(<J.3P&Z#O7DC_"?7]<N-8\=Z-X=N--T+3]86^TS1'X=U)0.ZKV^7/!]
M*^HO^&K/A/T_X3?2,?\ 7U'_ (T?\-6_"?MXXTC_ ,"H_P#&@#B/"FJ:A\:O
MCII/B>/1+S2M!T.SD3S+U"C22R < '!X*^G>OI$=*\E_X:L^$_\ T/&D?^!<
M?^-+_P -7?"?_H=](_\  I/\: /6J*\E_P"&KOA/_P!#OI'_ (%)_C1_PU=\
M)_\ H=](_P# I/\ &@#UJBO)?^&KOA/_ -#OI'_@4G^-'_#5WPG_ .AWTC_P
M*3_&@#UJBO)?^&KOA/\ ]#OI'_@4G^-'_#5WPG_Z'?2/_ I/\: /6J*\E_X:
MN^$__0[Z1_X%)_C1_P -7?"?_H=](_\  I/\: .V^(GB>?P;X+U?6K6PFU2Y
MLX&DCLX/ORMV KXO^$7Q3DUGQU#XG\=^#?$5_P"+KR7RK430DV^F*QP GR\=
M3SD]:^F?^&K/A/\ ]#QI'_@5'_C1_P -6_"C_H>-(_\  J/_ !H \#^,G[+G
MCVS\.^-M5\/>-KB4ZU(T\ECM)=@=Q"=.@W$5T&O^%_%/PW3X4^*]0\[Q3=Z+
M;+;:@L>!,L+#=D+U.WY5X!KUS_AJSX3]O'&D?^!4?^-?!_\ P4C_ &O'\.^*
MO FM_"WQI')<VL;F=+&X#QM\YX=5//XT ?7_ ,%=)U3QQ\;O%'Q(N]/FTO29
MK1-.L8;E2LCA7+ER#R!\Q'3M7T4M?G1^RW_P5F\/^./L6@?$F :+J[XC&HQ_
MZF1O<8 7\Z_0W2=4M=:T^WOK*9+FTN$$D4L9RK*1D$&@"Y1110 4444 %%%%
M "5Q?Q;U[Q)X7\&W&I>&-,35]0@96:S?J\>X;\<CG;FNUHH ^-Y+&;XV?&#P
MOJ7AOPK=^%TMH)3K5]<)L\P.%_='.-W1AD52AU37_"_PK\0?"*/PM?MK%U<S
M0V=RBY@9))3)O+=  #CK7VGM]!BEQS0!\D6OAN^_9J^)UIXA_L>ZU?2-0T6.
MQGDLEW,DR,[\@9.#D#I7I?[-/A_58[?Q+XGU:R?39=?OY+F&TE^^D.XE-WOA
MJ]KQD=.*.] #J*** "BBB@ HHHH **** "O-/C5XQ\2^!]+T_4M%T0:]IPN
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MCCL7A=0-SJ6 /X UV_Q%^) ^'/@*Z\4WFFS7%O:1>=/#&X#*M $'_"B/A_\
M]"II?_@,G^%'_"B/A_\ ]"II?_@,G^%8?ASX^0>)/@VWQ&@T2ZCTG[(;T0,Z
M^88@N[/Y57^%?[01^,'@FW\4^'_#=X^FW!D5/,E0,2C%3U]U- '2?\*(^'__
M $*FE_\ @,G^%'_"B/ '_0J:7_X#)_A6/>?'06'PSU/QC<>';Z&/32PN;%V
ME4* 21Z]:N_ 7XZ>'_VA/ -OXL\.ETM)7:)X)C^\C9>H(H N?\*'\ ?]"II?
M_@,G^%)_PHCX?_\ 0J:7_P" R?X5A?M"?M'>'/V=/#]CJ6NQ37DE[<+;P6MM
M]]F.>>G3BJ_Q4_:(M?A'\/K#Q=K&AW3V-T\4?EQR+O1I&55S^+"@#I?^%$?#
M_P#Z%32__ 9/\*/^%$_#_P#Z%32__ 9/\*EU+XK:5X=^'R^+M?;^R+!H1,(Y
M6!<Y&0H ZD^@K&T7XKZYX@T^/5K/PA>#1Y$\Q)))4#LO8[2<\CVH U/^%$?#
M_P#Z%32__ 9/\*/^%$?#_P#Z%32__ 9/\*G^%?Q1L?BKHMUJ-C:SV0MK@VTD
M-RI5U8 $\$#UJ#Q%\2KS2O%QT+3_  Y=ZJZP^;)<QNJQKD9 Y[T '_"B/ '_
M $*FE_\ @,G^%'_"B/ '_0J:7_X#)_A7GG@+]K"/XE6OB2?0/".H7?\ 8%P;
M6[3SD!\P9X&?I4OQ$_:TTKX:Z#X0U74] OO)\37(M+6(, Z2D]&X^E '??\
M"B?A_P#]"II?_@,G^%+_ ,*'\ ?]"II?_@,G^%<_\<?V@[3X"> X_%NNZ+=3
MZ9O2.;[.P+1%NF>N:[WP'XVTSXB>$=-\0Z1*)M/OHEEC;/3/8^XZ4 87_"A_
M '_0J:7_ . R?X4G_"B?A_\ ]"II?_@,G^%<O\7/VGO#WPG\>^&_!]Q:7&I:
MWKDFR&&W( C'/+$CV-'Q4_:0L_A)XJ\*:!J>B74UYXDF^SV9A=<;\J,'\6%
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M129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10
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M#_OPO^%'_"F_!?\ T+MA_P!^%_PH_>^06RWO/\"3_A:_A/\ Z#=K_P!]T?\
M"V/"?_0;M?\ ONH_^%-^"_\ H7;#_OPO^%'_  IOP7_T+MA_WX7_  H_>^0?
M\)O>?X$G_"V/"?\ T&[7_ONC_A;'A/\ Z#=K_P!]U'_PIOP7_P!"[8?]^%_P
MH_X4WX+_ .A=L/\ OPO^%'[WR#_A-[S_  )/^%L>$_\ H-VO_?='_"V/"?\
MT&[7_ONH_P#A3?@O_H7;#_OPO^%'_"F_!?\ T+MA_P!^%_PH_>^0?\)O>?X$
MG_"V/"?_ $&[7_ONC_A;'A/_ *#=K_WW4?\ PIOP7_T+MA_WX7_"C_A3?@O_
M *%VP_[\+_A1^]\@_P"$WO/\"3_A;'A/_H-VO_?='_"V/"?_ $&[7_ONH_\
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M_P#0NV'_ 'X7_"D_X4WX+_Z%VP_[\+_A1^]\@_X3>\_P)?\ A;'A/_H-VO\
MWW1_PMCPG_T&[7_ONH_^%-^"_P#H7;#_ +\+_A1_PIOP7_T+MA_WX7_"C][Y
M!_PF]Y_@2?\ "V/"?_0;M?\ ONC_ (6QX3_Z#=K_ -]U'_PIOP7_ -"[8?\
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M9'T.!6Y'\5_"BHH.N6Q(')+]:9_PIOP7_P!"[8?]^%_PH_X4WX+_ .A=L/\
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MG^!EZ%XN\#:%/<W,>LVTEY<MNEN'8%F]!6S_ ,+8\)_]!NU_[[J+_A3?@O\
MZ%VP_P"_"_X4?\*;\%_]"[8?]^%_PH_>^0?\)O>?X$G_  MCPG_T&[7_ +[H
M_P"%L>$_^@W:_P#?=1_\*;\%_P#0NV'_ 'X7_"C_ (4WX+_Z%VP_[\+_ (4?
MO?(/^$WO/\"3_A;'A/\ Z#=K_P!]T?\ "V/"?_0;M?\ ONH_^%-^"_\ H7;#
M_OPO^%'_  IOP7_T+MA_WX7_  H_>^06RWO/\"3_ (6QX3_Z#=K_ -]T?\+8
M\)_]!NU_[[J/_A3?@O\ Z%VP_P"_"_X4?\*;\%_]"[8?]^%_PH_>^06RWO/\
M"3_A;'A/_H-VO_?='_"V/"?_ $&[7_ONH_\ A3?@O_H7;#_OPO\ A1_PIOP7
M_P!"[8?]^%_PH_>^0?\ ";WG^!)_PMCPG_T&[7_ONC_A;'A/_H-VO_?=1_\
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M/"?_ $&[7_ONH_\ A3?@O_H7;#_OPO\ A1_PIOP7_P!"[8?]^%_PH_>^0?\
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M *#=K_WW1_PMCPG_ -!NU_[[J/\ X4WX+_Z%VP_[\+_A1_PIOP7_ -"[8?\
M?A?\*/WOD'_";WG^!)_PMCPG_P!!NU_[[H'Q6\*,RK_;5MEC@?/41^#?@O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\!9?_B:/[4A_N7/_ ("R_P#Q-%% !_:D/]RY_P# 67_XFC^U(?[ES_X"R_\
MQ-%% !_:D/\ <N?_  %E_P#B:/[4A_N7/_@++_\ $T44 ']J0_W+G_P%E_\
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M (FC^U(?[ES_ . LO_Q-%% !_:D/]RY_\!9?_B:/[4A_N7/_ ("R_P#Q-%%
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-46LO)*GC[M%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243304112320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEARTBEAM, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4881450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2118 Walsh Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Santa Clara<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">95050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">899-4443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,352,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,329,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001779372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BEAT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BEATW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243305022592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Hanover, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297763552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,189<span></span>
</td>
<td class="nump">$ 3,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">16,825<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">17,131<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses (includes related party $2 and $2, respectively)</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at December&#160;31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value; 100,000,000 shares authorized; 26,329,032 and 8,009,743 shares issued and outstanding at December&#160;31, 2023 and 2022</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">52,759<span></span>
</td>
<td class="nump">24,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(36,825)<span></span>
</td>
<td class="num">(22,186)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">15,937<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 17,131<span></span>
</td>
<td class="nump">$ 4,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243304803872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,329,032<span></span>
</td>
<td class="nump">8,009,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,329,032<span></span>
</td>
<td class="nump">8,009,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243304932848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 8,516,000<span></span>
</td>
<td class="nump">$ 7,354,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,798,000<span></span>
</td>
<td class="nump">5,677,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,314,000<span></span>
</td>
<td class="nump">13,031,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,314,000)<span></span>
</td>
<td class="num">(13,031,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(14,639,000)<span></span>
</td>
<td class="num">(12,962,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (14,639,000)<span></span>
</td>
<td class="num">$ (12,962,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">20,333,280<span></span>
</td>
<td class="nump">8,168,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">20,333,280<span></span>
</td>
<td class="nump">8,168,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297495840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,809,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 13,410<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 22,633<span></span>
</td>
<td class="num">$ (9,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issuance upon exercise of stock options (in shares)</a></td>
<td class="nump">38,806<span></span>
</td>
<td class="nump">38,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issuance upon vesting and exercise of stock options</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of Common Stock &amp; warrants, net of fees and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of Common Stock &amp; warrants, net of fees and issuance costs</a></td>
<td class="nump">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issuance upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">8,009,743<span></span>
</td>
<td class="nump">8,009,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,374<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">24,559<span></span>
</td>
<td class="num">(22,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issuance upon exercise of stock options (in shares)</a></td>
<td class="nump">180,072<span></span>
</td>
<td class="nump">180,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issuance upon vesting and exercise of stock options</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of Common Stock &amp; warrants, net of fees and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,872,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of Common Stock &amp; warrants, net of fees and issuance costs</a></td>
<td class="nump">$ 24,764<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">24,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issuance upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issuance upon exercise of warrants(in shares)</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">7,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issuance upon exercise of warrants</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,639)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">26,329,032<span></span>
</td>
<td class="nump">26,329,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 15,937<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 52,759<span></span>
</td>
<td class="num">$ (36,825)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297649040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,639)<span></span>
</td>
<td class="num">$ (12,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,208<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(191)<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other current liabilities</a></td>
<td class="num">(471)<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,093)<span></span>
</td>
<td class="num">(9,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(256)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(256)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of equity, net of issuance costs</a></td>
<td class="nump">24,764<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,994<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and restricted cash</a></td>
<td class="nump">12,645<span></span>
</td>
<td class="num">(9,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of the year</a></td>
<td class="nump">3,594<span></span>
</td>
<td class="nump">13,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - at end of the year</a></td>
<td class="nump">16,239<span></span>
</td>
<td class="nump">3,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Non-cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_StockAndClassOfWarrantOrRightIssued', window );">Issuance of common stock and warrants to settle accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">16,189<span></span>
</td>
<td class="nump">3,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in other assets)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 16,239<span></span>
</td>
<td class="nump">$ 3,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_StockAndClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock And Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_StockAndClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211789008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND OPERATIONS</a></td>
<td class="text">ORGANIZATION AND OPERATIONS<div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam, Inc. (&#8220;HeartBeam&#8221; or the &#8220;Company&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (&#8220;ECG&#8221;) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company&#8217;s ability to develop higher resolution ECG solutions is achieved through the development of the Company&#8217;s proprietary and patented Vector Electrocardiography (&#8220;VECG&#8221;) technology platform. HeartBeam&#8217;s VECG is capable of developing three-dimensional (3D) images of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver equal or superior diagnostic capability than traditional hospital-based ECG systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has validated this novel technology and is seeking U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance of its initial telehealth products during 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in 2015 as a Delaware corporation. The Company&#8217;s operations are based in Santa Clara, California and operates as one segment</span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211736304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN AND OTHER UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN AND OTHER UNCERTAINTIES</a></td>
<td class="text">GOING CONCERN AND OTHER UNCERTAINTIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to those of early stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of December&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of&#160;approximately $36.8 million and $22.2 million, respectively. As of December&#160;31, 2023 the Company had approximately $16.2&#160;million cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) pursuant to which the Company may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $13.0&#160;million in at-the-market offerings (&#8220;ATM&#8221;) sales. At the same time, the Company filed a prospectus supplement under a shelf registration relating to the Sales Agreement. AGP will act as sales agent and will be paid a 3% commission on each sale under the Sales Agreement. The Company&#8217;s common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary. As </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of December 31, 2023 there was approximately $11.0&#160;million available for issuance under the ATM.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#8220;SPA&#8221;, NPA&#8221; or together &#8220;Agreements&#8221;) with Maverick Capital Partners, LLC (&#8220;Maverick&#8221; or &#8220;Investor&#8221;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $4,000,000 of the Company&#8217;s common stock at 75% of the average calculated Volume Weighted Average Price (&#8220;VWAP&#8221;) per share during a Drawdown Pricing Period as defined in the Agreements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, the Company issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023 the Convertible Note was settled upon the execution of a SPA and related issuance of 0.2&#160;million shares of common stock pursuant to the SPA drawdown notice dated March 7, 2023. These shares of common stock were registered under the Company&#8217;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships and revenue. Management can provide no assurance that such </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.</span></div>The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243305125136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS&#160;OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRESENTATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with US GAAP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. On an ongoing basis, management evaluates its estimate related to probability and timing related to vesting of the stock-based compensation related to probability and timing related to vesting of milestone options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2023 the Company has $15.9&#160;million held as cash equivalents and as of December 31, 2022 there were $2.6&#160;million held as cash equivalents. The Company maintains cash balances in accounts which exceed the federally insured limits during the year ended December 31, 2023 and 2022. The Company has made a deposit to the bank for their credit cards in the amount of $50,000 and is classified as restricted cash included in other non-current assets as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">PROPERTY AND EQUIPMENT, NET</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company&#8217;s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. As of December 31, 2023, property and equipment, net represents construction-in-progress of $256,000 related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">RESEARCH AND DEVELOPMENT EXPENSE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional services costs associated with the development of cardiovascular technologies and products.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash, accounts payable and accrued liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or is derived from such prices. The Company uses the market approach </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation technique to value its investments.&#160;The market approach uses prices and other pertinent information generated from market transactions involving identical or comparable assets or liabilities.&#160;The types of factors that the Company may consider in fair value pricing the investments include available current market data, including relevant and applicable market quotes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Observable inputs such as quoted prices in active markets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.&#160;In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACCOUNTING FOR WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company accounts for its currently issued warrant instruments in conjunction with the Company&#8217;s common stock in permanent equity. These warrants are indexed to the Company&#8217;s stock and meet the requirements of equity classification as prescribed under ASC 815. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK-BASED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically issues stock options and restricted stock awards (&#8220;RSUs&#8221;) to employees and non-employees for services. The Company accounts for such grants issued and vesting to employees and non-employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense over the vesting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of stock options on the date of grant is calculated using the Black-Scholes option pricing model, based on key assumptions such as the fair value of common stock, expected volatility and expected term. These estimates require the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. These assumptions are primarily based on historical data, peer company data and the judgment of management regarding future trends and other factors. The Company has estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by the actual awards forfeited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost for RSUs issued to employees and non-employees is measured using the grant date fair value of the award, and expense is recognized over the service period, adjusted to reflect actual forfeitures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCOME TAXES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition and measurement are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income tax expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOSS PER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SHARE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the years ended December&#160;31, 2023&#160;and&#160;2022&#160;as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, the penny warrants issued during 2019 have been excluded from the net loss per common share calculation following treatment of contingently issuable shares as there are circumstances under which these shares would not be issued and therefore not exercisable. These warrants expired as unissued in February 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of December 31, 2023, and 2022, 176,674 and 175,958 penny options have been included in the calculation of weighted average basic and diluted earnings per share. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of awards outstanding as of&#160;December&#160;31, 2023&#160;and&#160;2022, which are not included in the computation of basic and diluted weighted average shares: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options (excluding exercisable penny stock options)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,286,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,183,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We do not expect that the updated standard will have a rather significant impact on our financial statement disclosures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13&#160;&#8220;Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05 &#8220;Financial Instruments-Credit Losses (Topic 326)&#8221; which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on an instrument by instrument basis. The guidance is effective for the fiscal year beginning January 1,&#160;2023, including interim periods within that year. The Company has adopted this guidance and it had an immaterial impact on Company&#8217;s accounting.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211704928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2022 the Company held a Special Meeting of Stockholders (&#8220;Special Meeting&#8221;), wherein the stockholders of the Company approved an amendment to the Company&#8217;s Certificate of Incorporation (&#8220;Certificate of Incorporation&#8221;) to increase the number of authorized shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;) to 100,000,000, and to authorize 10,000,000 shares of the Company&#8217;s preferred stock. The amendment to the Certificate of Incorporation became effective upon filing with, and acceptance for record by, the Secretary of State of Delaware on November 16, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON STOCK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company issued 78,025 shares of Common Stock to a consulting firm for services provided that were related to the IPO. The Company calculated the value of the common stock using closing stock price on November 11, 2022, resulting in a fair value of approximately $365,000. Additionally, the Company was required to issue 72,727 warrants based on performance metrics achieved in 2021, the warrants have an exercise price of $5.50 with an expiration of five years from the date of issuance. The Company calculated the fair value of $1.25 each for these warrants using the Black-Scholes option pricing model on the date the consulting firm achieved the milestone, using the following assumptions: (a) fair value of $2.28 per share, (b) expected volatility of 90.81%, (c) dividend yield of 0%, (d) risk-free interest rate of 0.87%, and (e) expected life of 5 years, resulting in the fair value of approximately $91,000. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, the Company entered into a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell (&#8220;Private Placement&#8221;) to OpenSky Opportunities Fund Ltd. 58,000 shares of common stock par value $0.0001 and 58,000 warrants to purchase one share of common stock at a combined price of $6.00 per share. The common stock and the warrants were immediately separable and issued separately but were purchased together in the Private Placement. These securities issued pursuant to the Stock Purchase Agreement. The Company received $348,000 in proceeds from the Private Placement. The Warrants will expire five years from the date of issuance. The Company paid no underwriting discounts or commissions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor, for the purchase and sale in a registered direct offering of 1,000,000 shares of the Company&#8217;s common stock at a price of $1.50 per share, generating net proceeds from the offering of approximately $1.1&#160;million after deducting financial advisory and legal fees as well as other estimated offering expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2023, the Company entered into a Placement Agency Agreement with Public Ventures, LLC to consummate an offering of 16,666,666 shares of Common Stock at an offering price of $1.50 per share, which closed in accordance with the subscription agreement dated May 2, 2023. The Company received $23.2&#160;million in net proceeds from the offering after deducting placement agent discounts and commission and other estimated offering expenses payable by the Company. In</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">addition, the subscription agreement grants placement agent warrants as part of this transaction. See Warrants section below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#8220;SPA&#8221;, NPA&#8221; or together &#8220;Agreements&#8221;) with Maverick Capital Partners, LLC (&#8220;Investor&#8221;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $4,000,000 of the Company&#8217;s common stock at 75% of the average calculated Volume Weighted Average Price per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2023, the Company issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023, the Convertible Note was settled upon the execution of the SPA and related issuance of 200,105 shares of common stock pursuant to the SPA draw down notice dated March 9, 2023. These shares of common stock were registered under the Company&#8217;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023, whereby, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Company received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">total proceeds of $500,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. These were the only transactions consummated under the SPA and NPA and the respective agreements expired on May 31 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 1, 2023, the Company entered into an At-the-Market Sales Agreement (&#8220;ATM&#8221; or &#8220;Sales Agreement&#8221;) with A.G.P./ Alliance Global Partners as placement agent, to issue and sell shares of the Company&#8217;s common stock. The issuance and sale of shares of Common Stock to or through the placement agent are effected pursuant to the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Registration Statement dated February 2, 2023. The Company shall pay to the sales agent in cash, upon each sale of placement shares through the placement agent pursuant to the Sales Agreement, an amount equal to 3.00% of the aggregate gross proceeds from each sale of placement shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection to the Sales Agreement, on February 17, 2023 and February 22, 2023, the Company sold 6,184 shares at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3.76 per</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> share for gross proceeds of approxi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mately $23,000. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of December 31, 2023 there was approximately $11.0&#160;million available for issuance under the ATM.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stock issuance costs, which consist primarily of legal, accounting and underwriting fees in connection with the above stated transactions related to the offerings and SPA was approximately $174,000, which as of December 31 2023, was recorded in additional paid in capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022 the Company issued 439,042 and 63,806 shares of common stock upon exercise of vested stock options and vesting of restricted stock units. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, milestone warrants were issued to certain executives totaling 407,272 warrants (&#8220;Penny Warrants&#8221;). These warrants were valued on the date of grant at $0.0003 to vest upon meeting certain milestones. These warrants expired unissued in February 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company issued 72,727 warrants based on performance metrics achieved in 2021 to purchase 72,727 shares of common stock at an exercise price of $5.50 per share, with an expiration of five years from the date of issuance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, the Company issued 58,000 warrants to purchase 58,000 shares of common stock at an exercise price of $6.00 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2023 the Company issued 1,666,666 placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise price of $1.875 per share and are exercisable for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">five years</span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> from the date of issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, 11,638 warrants were exercised, of which 5,817 were exercised in the form of a cashless exercise utilizing 4,346 warrants which resulted in the net issuance of 1,471 common shares. The remaining 5,821 warrants were exercised for cash for approximately $16,000. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the outstanding warrants as of December&#160;31, 2023 and 2022 is as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable -  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243213286736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Company&#8217;s Board of Directors approved the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company&#8217;s business. The 2015 Plan provides for the grant of stock options and RSU&#8217;s to purchase common stock of which 1,636,362 were authorized by the board of which 970,704 are outstanding as of December&#160;31, 2023. The 2015 Plan was terminated upon shareholder approval of the 2022 Equity Incentive Plan (&#8220;2022 Equity Plan&#8221;) whereby no new awards can be issued under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s shareholders approved the 2022 Equity Plan at the annual meeting of stockholders held on June 15, 2022, pursuant to which 1,900,000 shares of common stock were authorized for issuance. Under the 2022 Equity Plan, the number of shares available for issuance will be increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2023 400,487 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan. Also see Note 9- Subsequent event section below.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">At the July 7, 2023, Annual Shareholders&#8217; Meeting, the proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from 1,900,000 shares to 5,900,000 shares was approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Equity Plan includes a provision to add-back any cancelled options from the 2015 Plan up to 1,372,816 shares. As of December&#160;31, 2023, there are 252,856 shares from the 2015 Plan that are included in the 849,171 shares available for issuance under the 2022 Equity Plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company granted 2,208,000 options to various executives and employees. Sixty percent (60%) of these options vest based on FDA Clearance for marketing of HeartBeam&#8217;s synthesized 12L product  and the remaining forty percent (40%) vest monthly over a period of 48 months. The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and it is expensed based on management&#8217;s probability assessment of FDA clearance. The 60% milestone options are issued and outstanding as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received proceeds of $0.2&#160;million from the exercise of stock options during the year ended December&#160;31, 2023 and a de minimis amount during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK OPTIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity during the years ended December&#160;31, 2023 and 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>options<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)<br/>(*)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,196,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,363,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Intrinsic value is based on </span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of the Company's common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the years ended December&#160;31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Black-Scholes option pricing model assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.23% - 117.62%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.25% - 111.06%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85 - 6.07</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62 -  5.94</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54% - 4.77%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47% - 3.17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.75 - 3.38</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.08 - 3.34</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RESTRICTED STOCK UNITS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSUs award activity:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK BASED COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock-based compensation expense:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administration</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $8.1&#160;million and $0.4&#160;million, respectively, which is expected to be recognized over a weighted-average period of 2.66 years and 1.2 years, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211755008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which the Company&#8217;s former Chief Financial Officer has significant influence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company incurred accounting fees from these firms of approximately $20,000 and $21,000 during the years ended December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the Company had balances due to these firms amounting to approximately $2,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211723840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text">COMMITMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a month to month lease agreement for our headquarters. The agreement is for an undefined term and can be cancelled at any time, given one month&#8217;s notice by either party. The Company&#8217;s monthly rent expense associated with this agreement is approximately $1,440. The Company&#8217;s month to month headquarters lease is in the name of the Company&#8217;s Chief Executive Officer, and the cost is reimbursed monthly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023 and 2022, rent expense was approximately $17,000, for each year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnership Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a partnership agreement with LIVMOR Inc. (&#8220;LIVMOR&#8221;) to build a Company-branded version of the LIVMOR&#8217;s Halo+ FDA cleared turnkey solution for RPM to connect physicians and patients. As included in the agreement, the Company and LIVMOR have the right to enter into additional agreements as needed in order to further the Company&#8217;s development of its products. The agreement with LIVMOR included a commitment in 2022 of $1.0&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a supplemental agreement with LIVMOR. The supplemental agreement stated the Company would pay an additional $0.2&#160;million for the source code access under the partnership agreement. Payments totaling $0.2&#160;million have been made by the Company and LIVMOR has delivered to the Company copies of source materials and codes. All licenses granted by LIVMOR will automatically be converted into a non-exclusive and perpetual license and become licenses granted on a royalty-free and fully paid-up basis, in which LIVMOR hereby expressly waives and relinquishes all HeartBeam payment obligations under the initial partnership agreement. Based on management&#8217;s review of Topic ASC 805 and 730, it was determined that only the source code and perpetual license were purchased and it was determined there was no alternative future uses, therefore management recorded the expense as research and development expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company expensed a total of $1.2&#160;million associated with the LIVMOR agreements, which </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has been recognized as R&amp;D expense. In February 2023, the Company acquired LIVMOR&#8217;s Halo+&#8482; Atrial Fibrillation Detection System, the world&#8217;s first FDA-cleared (K201208) prescription wearable for continuous cardiac rhythm monitoring, comprising of intellectual property, including 3 issued United States patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Services Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (&#8220;TRT&#8221;), a co-development company, to assist in the design and development of the Company&#8217;s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with Triple Ring includes a commitment totaling $1.7&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 the Company has a remaining commitment of $0.4&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211667392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text">INCOME TAX <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed &#8220;expected&#8221; tax benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,074,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,722,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in income taxes resulting from):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,973,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below as of December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,799,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,115,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">619,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">377,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">647,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">349,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sec. 174</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,027,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,032,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">172,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,092,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,047,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Valuation Allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9,092,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6,047,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net Deferred Tax Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,044,500 for the period ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $21,496,500 and $18,394,200, respectively. The federal NOL carryforwards consist of $2,405,400 generated prior to 2018 which will begin to expire in 2035, however, are able to offset 100% of taxable income and $19,091,000 generated after December 31, 2017 that will carryforward indefinitely but will be subject to 80% taxable income limitation beginning tax years after December 31, 2021 as provided by the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act (PL 116-136).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company has federal R&amp;D credit carryforwards of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $617,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which will begin to expire in 2041 and state R&amp;D credit carryforwards of approximately $338,400 which do not expire.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;) a corporation that undergoes an ownership change may be subject to limitations on its </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company&#8217;s ability to use its NOLs or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (&#8220;R&amp;E&#8221;) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the years ended December 31, 2023 and December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits as of December&#160;31, 2023 is approximately $286,600, which relates to federal and state R&amp;D credits. If recognized none of the unrecognized tax benefits would affect the effective tax rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to account for interest and penalties as income tax expense. As of the December&#160;31, 2023 the Company had no interest related to unrecognized tax benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amounts of penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within twelve months of this reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, with varying statutes of limitations. The tax years from inception through 2023 remain open to examination due to the carryover of unused net operating losses that are being carried forward for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the U.S. Inflation Reduction Act of 2022 and the CHIPS and Science Act of 2022 were signed into law. These acts include, among other provisions, a corporate alternative minimum tax of 15%, an excise tax on the repurchase of corporate stock, various climate and energy provisions, and incentives for investment in semiconductor manufacturing. These provisions are not expected to have a material impact on the Company&#8217;s results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243213333312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Under the 2022 Equity Plan, the number of shares available for issuance are increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2024, 1,316,452 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $0.5&#160;million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of five planned sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $0.7&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243212128768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS&#160;OF PRESENTATION</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS&#160;OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRESENTATION</span></div>The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with US GAAP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. On an ongoing basis, management evaluates its estimate related to probability and timing related to vesting of the stock-based compensation related to probability and timing related to vesting of milestone options</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2023 the Company has $15.9&#160;million held as cash equivalents and as of December 31, 2022 there were $2.6&#160;million held as cash equivalents. The Company maintains cash balances in accounts which exceed the federally insured limits during the year ended December 31, 2023 and 2022. The Company has made a deposit to the bank for their credit cards in the amount of $50,000 and is classified as restricted cash included in other non-current assets as of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">PROPERTY AND EQUIPMENT, NET</span></div>Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company&#8217;s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">RESEARCH AND DEVELOPMENT EXPENSE</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">RESEARCH AND DEVELOPMENT EXPENSE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional services costs associated with the development of cardiovascular technologies and products.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash, accounts payable and accrued liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or is derived from such prices. The Company uses the market approach </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation technique to value its investments.&#160;The market approach uses prices and other pertinent information generated from market transactions involving identical or comparable assets or liabilities.&#160;The types of factors that the Company may consider in fair value pricing the investments include available current market data, including relevant and applicable market quotes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Observable inputs such as quoted prices in active markets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.&#160;In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_AccountingForWarrantsPolicyPolicyTextBlock', window );">ACCOUNTING FOR WARRANTS</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACCOUNTING FOR WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company accounts for its currently issued warrant instruments in conjunction with the Company&#8217;s common stock in permanent equity. These warrants are indexed to the Company&#8217;s stock and meet the requirements of equity classification as prescribed under ASC 815. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK-BASED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically issues stock options and restricted stock awards (&#8220;RSUs&#8221;) to employees and non-employees for services. The Company accounts for such grants issued and vesting to employees and non-employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense over the vesting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of stock options on the date of grant is calculated using the Black-Scholes option pricing model, based on key assumptions such as the fair value of common stock, expected volatility and expected term. These estimates require the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. These assumptions are primarily based on historical data, peer company data and the judgment of management regarding future trends and other factors. The Company has estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by the actual awards forfeited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost for RSUs issued to employees and non-employees is measured using the grant date fair value of the award, and expense is recognized over the service period, adjusted to reflect actual forfeitures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCOME TAXES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition and measurement are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOSS PER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SHARE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">RECENTLY ISSUED ACCOUNTING STANDARDS</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We do not expect that the updated standard will have a rather significant impact on our financial statement disclosures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted as of December&#160;31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued&#160;ASU 2016-13&#160;&#8220;Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the FASB issued ASU 2019-05 &#8220;Financial Instruments-Credit Losses (Topic 326)&#8221; which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on an instrument by instrument basis. The guidance is effective for the fiscal year beginning January 1,&#160;2023, including interim periods within that year. The Company has adopted this guidance and it had an immaterial impact on Company&#8217;s accounting.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_AccountingForWarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting For Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_AccountingForWarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211784144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of awards outstanding as of&#160;December&#160;31, 2023&#160;and&#160;2022, which are not included in the computation of basic and diluted weighted average shares: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options (excluding exercisable penny stock options)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,286,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,183,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243211642144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the outstanding warrants as of December&#160;31, 2023 and 2022 is as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable -  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297597296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity during the years ended December&#160;31, 2023 and 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>options<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)<br/>(*)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,196,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,363,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable &#8211; December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Intrinsic value is based on </span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of the Company's common stock.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">For the years ended December&#160;31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Black-Scholes option pricing model assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.23% - 117.62%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.25% - 111.06%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85 - 6.07</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62 -  5.94</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54% - 4.77%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47% - 3.17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.75 - 3.38</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.08 - 3.34</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSUs award activity:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock-based compensation expense:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administration</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217330016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed &#8220;expected&#8221; tax benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,074,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,722,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in income taxes resulting from):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,973,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below as of December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred tax assets (liabilities):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net operating loss carryforwards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,799,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,115,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">619,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">377,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">647,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">349,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sec. 174</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,027,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,032,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">172,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,092,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,047,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Valuation Allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9,092,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6,047,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net Deferred Tax Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243213317680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297496128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOING CONCERN AND OTHER UNCERTAINTIES (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SubstantialDoubtAboutGoingConcernLineItems', window );"><strong>Substantial Doubt About Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,186,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,594,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=beat_AGPAllianceGlobalPartnersMember', window );">A.G.P./Alliance Global Partners | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SubstantialDoubtAboutGoingConcernLineItems', window );"><strong>Substantial Doubt About Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockMaximumAmountAuthorized', window );">Sale of stock, maximum amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockAgentCommissionPercentage', window );">Commission fee percentage on each sale (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockRemainingAmountAuthorizedForIssuance', window );">Amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember', window );">Maverick Capital Partners, LLC | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SubstantialDoubtAboutGoingConcernLineItems', window );"><strong>Substantial Doubt About Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember', window );">Maverick Capital Partners, LLC | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SubstantialDoubtAboutGoingConcernLineItems', window );"><strong>Substantial Doubt About Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockMaximumAmountAuthorized', window );">Sale of stock, maximum amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage', window );">Sale of stock, percentage of the average calculated volume weighted average price per share (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock &amp; warrants, net of fees (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockAgentCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent, Commission Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockAgentCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockMaximumAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockMaximumAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockRemainingAmountAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Amount Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockRemainingAmountAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SubstantialDoubtAboutGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Substantial Doubt About Going Concern [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SubstantialDoubtAboutGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_AGPAllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_AGPAllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217449888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in other assets)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements', window );">Incremental common shares attributable to dilutive effect of equity forward agreements (in shares)</a></td>
<td class="nump">176,674<span></span>
</td>
<td class="nump">175,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shared included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity forward arrangements using the reverse treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 35<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-35<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297916128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">11,286,129<span></span>
</td>
<td class="nump">6,183,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options (excluding exercisable penny stock options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,915,851<span></span>
</td>
<td class="nump">2,020,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">217,881<span></span>
</td>
<td class="nump">253,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,152,397<span></span>
</td>
<td class="nump">3,908,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217430016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243205306560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 02, 2023</div></th>
<th class="th"><div>Apr. 20, 2023</div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Number of share based payment awards, exercised in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,042<span></span>
</td>
<td class="nump">63,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Maverick Capital Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExpirationPeriod', window );">Warrant expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightFairValuePerWarrant', window );">Warrant fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare', window );">Fair value assumptions, fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate (as the percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (as the percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightFairValueIssuedForService', window );">Fair value of warrants issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Warrants | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in IPO (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">16,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in IPO, price per share (in dollars per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | OpenSky Opportunities Fund Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in IPO, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Maverick Capital Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockMaximumAmountAuthorized', window );">Sale of stock, maximum amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage', window );">Sale of stock, percentage of the average calculated volume weighted average price per share (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Certain Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in IPO, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockPlacementFeePercentage', window );">Sale of stock, placement fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | A.G.P./Alliance Global Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockMaximumAmountAuthorized', window );">Sale of stock, maximum amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockRemainingAmountAuthorizedForIssuance', window );">Sale of stock, remaining amount authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock | OpenSky Opportunities Fund Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit', window );">Shares issued per each unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightTerminationPeriod', window );">Period which warrants are exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightFairValueIssuedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value, Issued For Service</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightFairValueIssuedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightFairValuePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value Per Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightFairValuePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockMaximumAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockMaximumAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Issued In Transaction Per Each Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockPlacementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Placement Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockPlacementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockRemainingAmountAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Amount Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockRemainingAmountAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_MaverickCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beat_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beat_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_OpenSkyOpportunitiesFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_OpenSkyOpportunitiesFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_CertainInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_CertainInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_AGPAllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_AGPAllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243303647952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,152,397<span></span>
</td>
<td class="nump">3,908,276<span></span>
</td>
<td class="nump">3,777,549<span></span>
</td>
<td class="nump">1,666,666<span></span>
</td>
<td class="nump">407,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsCashlessExercise', window );">Class of warrant or right, warrants, cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized', window );">Class of warrant or right, warrants, cashless exercise, warrants utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issuance upon exercise of warrants(in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsExercisedForCash', window );">Class of warrant or right, warrants exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants', window );">Number of shares of common stock purchased</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issuance upon exercise of warrants(in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Consultants | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Consultants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants', window );">Number of shares of common stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExpirationPeriod', window );">Warrant expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=beat_PennyWarrantMember', window );">Penny Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants, Cashless Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants, Cashless Exercise, Warrants Utilized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants Exercised For Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues, Purchased With Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beat_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beat_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=beat_PennyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=beat_PennyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217432560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Warrants Outstanding (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,908,276<span></span>
</td>
<td class="nump">3,777,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisable', window );">Exercisable, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,777,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsIssued', window );">Issued (in shares)</a></td>
<td class="nump">1,666,666<span></span>
</td>
<td class="nump">130,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(11,638)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWarrantsExpired', window );">Expired (in shares)</a></td>
<td class="num">(410,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">5,152,397<span></span>
</td>
<td class="nump">3,908,276<span></span>
</td>
<td class="nump">3,777,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisable', window );">Exercisable, ending balance (in shares)</a></td>
<td class="nump">5,152,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,777,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Exercisable, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued', window );">Issued (in dollars per share)</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="nump">5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.75<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired', window );">Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">4.71<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Exercisable, ending balance (in dollars per share)</a></td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract', window );"><strong>Weighted average remaining life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife', window );">Outstanding</a></td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
<td class="text">3 years 5 months 19 days<span></span>
</td>
<td class="text">4 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Exercisable</a></td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding', window );">Outstanding</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding', window );">Exercisable</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class OF Warrant Or Right, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercisable, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable, Weighted Average Remaining Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ClassOfWarrantOrRightWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Remaining Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ClassOfWarrantOrRightWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297994304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jul. 06, 2023</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=beat_ExecutivesAndEmployeesMember', window );">Executives and Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=beat_ExecutivesAndEmployeesMember', window );">Executives and Employees | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of share-based compensation arrangement vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Executives and Employees | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of share-based compensation arrangement vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beat_A2015EquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beat_A2015EquityIncentivePlanMember', window );">2015 Equity Incentive Plan | Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,636,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beat_A2022EquityPlanMember', window );">2022 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">849,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of annual increase of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of outstanding shares of all classes of common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">400,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares, Nonvested, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=beat_ExecutivesAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=beat_ExecutivesAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beat_A2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beat_A2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beat_A2022EquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beat_A2022EquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217235888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,196,798<span></span>
</td>
<td class="nump">1,105,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">4,363,800<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="num">(288,001)<span></span>
</td>
<td class="num">(121,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(180,072)<span></span>
</td>
<td class="num">(38,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">6,092,525<span></span>
</td>
<td class="nump">2,196,798<span></span>
</td>
<td class="nump">1,105,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">2.42<span></span>
</td>
<td class="nump">1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">2.48<span></span>
</td>
<td class="nump">2.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">1.19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average remaining contractual life</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 2,945<span></span>
</td>
<td class="nump">$ 6,770<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,212,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Average remaining contractual life</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate intrinsic value</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243298065424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions (Details) - Stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">110.23%<span></span>
</td>
<td class="nump">107.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.54%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">117.62%<span></span>
</td>
<td class="nump">111.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.77%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243304230720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Units (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted (in dollars per share)</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="nump">253,970<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">222,881<span></span>
</td>
<td class="nump">248,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested (in shares)</a></td>
<td class="num">(258,970)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (in shares)</a></td>
<td class="nump">217,881<span></span>
</td>
<td class="nump">253,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-Vested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Shares vested (in dollars per share)</a></td>
<td class="nump">1.48<span></span>
</td>
<td class="nump">2.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217101632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">$ 3,208,076<span></span>
</td>
<td class="nump">$ 1,119,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Cost not yet recognized, options</a></td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Cost not yet recognized</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period of recognition (in years)</a></td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period of recognition (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">$ 2,558,527<span></span>
</td>
<td class="nump">892,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administration | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">2,069,556<span></span>
</td>
<td class="nump">657,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administration | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">488,971<span></span>
</td>
<td class="nump">235,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">649,549<span></span>
</td>
<td class="nump">227,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">629,092<span></span>
</td>
<td class="nump">213,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation</a></td>
<td class="nump">$ 20,457<span></span>
</td>
<td class="nump">$ 13,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297518352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Investments from related parties</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243217190640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_LesseeOperatingLeasePriorNoticeForCancellation', window );">Operating lease, prior notice for cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_LesseeOperatingLeaseMonthlyRentExpense', window );">Monthly rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=beat_LIVMORMember', window );">LIVMOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_PaymentsForPurchaseObligations', window );">Payments for purchase obligations</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=beat_TripleRingTechnologiesMember', window );">Triple Ring Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_LesseeOperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_LesseeOperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_LesseeOperatingLeasePriorNoticeForCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Prior Notice For Cancellation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_LesseeOperatingLeasePriorNoticeForCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_PaymentsForPurchaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Purchase Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_PaymentsForPurchaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_LIVMORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_LIVMORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_TripleRingTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_TripleRingTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243305001696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; tax benefit</a></td>
<td class="num">$ (3,074,000)<span></span>
</td>
<td class="num">$ (2,722,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,024,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="num">(80,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">221,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(241,800)<span></span>
</td>
<td class="num">(224,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">130,600<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">3,044,500<span></span>
</td>
<td class="nump">3,973,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; tax benefit</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">7.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(1.51%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.89%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.80%)<span></span>
</td>
<td class="num">(30.65%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243304223408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX - Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 5,799,000<span></span>
</td>
<td class="nump">$ 4,115,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">619,000<span></span>
</td>
<td class="nump">377,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">647,000<span></span>
</td>
<td class="nump">349,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Sec. 174</a></td>
<td class="nump">2,027,200<span></span>
</td>
<td class="nump">1,032,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">172,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">9,092,200<span></span>
</td>
<td class="nump">6,047,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(9,092,200)<span></span>
</td>
<td class="num">(6,047,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Tax Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297756080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 3,044,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">286,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income taxes expense</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, income tax penalties expense</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">21,496,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">617,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Tax Periods Prior To 2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,405,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | After Tax Year 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">19,091,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">18,394,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 338,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=beat_TaxPeriodsPriorTo2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=beat_TaxPeriodsPriorTo2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=beat_TaxPeriodsAfter2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=beat_TaxPeriodsAfter2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140243297835584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>site</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,798<span></span>
</td>
<td class="nump">$ 5,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Clinical Research Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Clinical Research Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amount to be paid to Clinical Research Organization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ResearchAndDevelopmentNumberOfClinicalStudySites', window );">Number of planned sites to carrying out the clinical study | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beat_A2022EquityPlanMember', window );">2022 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of annual increase of shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of outstanding shares of all classes of common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=beat_A2022EquityPlanMember', window );">2022 Equity Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of outstanding shares of all classes of common stock (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares) | shares</a></td>
<td class="nump">1,316,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ResearchAndDevelopmentNumberOfClinicalStudySites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Number Of Clinical Study Sites</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ResearchAndDevelopmentNumberOfClinicalStudySites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>beat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=beat_ClinicalResearchOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=beat_ClinicalResearchOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=beat_A2022EquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=beat_A2022EquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-\VW 5S4%9LM-1V;"@VX56CX@R4R'1!>9U2>&V'!2@VPK 8$6VHZ+!40<*N
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MO$%A$(YZ_$9=DB/K-[HV2?1[OI5*Z%_BS[E\G=OXO)LIDYFL< :)I^M @CB
MEW[^-(R";SVLXXYUW.?N6+E ]T10M%J>P^LWB*;3'HQ)AS&Y"N,)4SC'T*]^
MQ"*K*5JO-STH48<2786RYMG%/[3?X0Y+A1XPXP<0-^A)MXKO("2\GX/S3VJ)
M@MC;CB%1QFNF7%EUJUU3FKM:_!?N.IJ^A3UA$I6PT])@\$5?FG!=PDT4KVQE
M;KG2=6Z'A6ZL($R WM]QKHX3<T#7JM,/4$L#!!0    ( #&!=%C9U#'$D00
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MLH8<KTZSV?CH["#:)X-[Q6N_\TTQDJ6U#W%P)4^S423$FO,0$03^'OF<M8Y
MH/&MP\SZ+:/C[O<6_3+%CEB6PO.YU;\K&<K3[$-&DE>BT>'.KC]Q%\]AQ,NM
M]NF7UIWM**.\\<%6G3,85,JT_^)[EX=_XS#I'":)=[M18CD704Q/G%V3B]9
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M2<AZ7^+.A];P+CGPXI&R5] &:T_9D5\A6UL@E@/"P++->^1$X TZ[XIA5M5
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MA9*D#?"Y"E(@8HT$ABQ:U#G[GD950BPN.Y"/3!R9]ENS"QG_]FXTF?U. $1
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M>> *JMJX%()<\4$X/48>D33P3HCY?L%WL"#+E!T15G&$:'Q3T]2%FG1X[*8
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MY!KZC^G/P\E(O <'S@@?A;86^>:F%6?R$?R"F7-5U$$-BLOONN*D05G.1\1
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M,/P+0?Y0Z0W]*F^NJTJOZ<^5Q""&+\#SA88DY#[@!N%GFN_^!5!+ P04
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MN2&UD!UQHJ.B)N) '+(\SE*F<R[<R$<1FE[V9!;,MF;:MX3#3A1:G$DJ/O=
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M+FW(B=N\X<?O>@^I^,B(-7]L.ZV'!A;18;H@[Y3:2X,'NU(YD)3$HJQ,/B0
M:;S6DL<*/61K"U*T'3;,:=K1+8!/R?P60!XH@MQ> W(J=;)$WDUMT?+$)_>=
M\,CAM-WI@E:[*L<!<H/N#=%U+Z[E.JF03W=0'FELX[AA],&B3G.X1VC507/H
MECD4V7+SR*!\^5"Q=Z0^<U6NU_3U?.!PZ8F -![^V&PE5>#-=J?X>Y'6N,A\
MY8$-GJ=VRQUG5*MZ=KPW.>0^6\4DVEHKX74!J^ 61>'XB3S57!:LL?8J'EQD
MBP,\*JZZ7'9H4>.N556EX,FW+]J%'CNJFQ:::^C=E$.EN:XTY8O60X@9^,.C
M/<IN.0:IN)0;$1>;G"*/+-2 1$M>5^ /D[6W)U=[N&0>]*399*\$FNZ''-MX
MH!F<F#WO6_;;OM+BM6MM&K4!1YK:V1HVJ]?KM(MP'6/S0&*^<TMR8%<5E ,.
MW?@28[W=Z,T*,N+E*%PM>- MR&_KW?CHD_TT@K.\U(BXK-:V/^&+&.%R/[ &
M[_36WX<6E+?J.9:?0_5[@/5,TF5GNH<>TR\W+<1H(*6[N8L6T]XOO;O>I9BB
M&'"8_9(6\Q9H,'IVD=4[T($_O>4P-<E%M>MP</3X;9_[HK*HEZ;^[4(]-=EF
MLG&@*?W<#LJ9"\J=0#Q8,2$0=$-]:FAI-J5ABKH92;WR3"[S1;519"N?5>F4
M\'M9VW679^9G5%\%;OUP#?;U<5/8@N02>Y?4E2R1-'JGDI\4C(LL8CRWA>^8
M"$4[7,>ME-W:[V"!U 4NLR,OF P:2P#?S_N]\:@U1*.N=T?R;3<IFG82I,U@
M1)N94V3&+,UXF=B6!F-W^]"@YV\;T0>9I-QM$%<7A=O41@8A!A@S#/JY/5&A
MJ?C9_@RX@*BB/BZ3:#SY0L_MJ\<=&[S%G5,>=V\8W-LF'9N[KD[.BP=E8#/N
MHM#.Z*IIH4R_16!T2.VQ*;Q68+EKM@8\>9I$+:9M-]W<R5R1.,JYC^B)=W79
M#$3,78M[@ .^(+'VYL^VV@[Z5YX_"'G/J.]-_-&QNF/RJIE!895J<#,#M9,>
M8P):L)TX#4C0"6SWT44?<?YU^OGS]-.76:-$Z <H(&[8LWNE-K)2SX\2+I.\
MJ=,/E,P4'41CX(^]<!QNS[HYA,JA<--6;CNL+]TA%K/BH4+<F5%!#>YI.5EX
MVM G44A+8Y3,SNX;X9P:>H]'4X!@!J-3TFZ+FEKTM)GLWQDQ=D8CEM(1OYNK
MTK'A8_NJ]#?FD >ZP\-:GQKQG!X9'=5C=\[3'2X<$B)PU\NCMYRV7$<**:.Q
MG?(T&-*VXIZ@06\R'K:0FJ\PI6JV.AQ]FLEWX.,8>G@T.A_U)SMYTHB'.P>H
M&E ;>I-@O+/L1IS4<5(=X2J-_-!;#6L:PO[)*>SU!Z,6)R9KQJ5;4G0];K?A
M@3<8!\[7MI!^X1Z0_I!.="$98OZ(!FPSDHJ_[.+VR-:YYB_M39DOZ@JU(8_Y
M#S:MN^W!:N@0..$]9GZM7XA/[J]A[@*UO4FY/@)-)URED\B./)^Q(8I:@ZR^
M$+<M28A1.QR>[PD3B+XW'H^]X>!*G(MA#]@_Z V&^!YXX?!*O'=FX7XQ?'GT
M\X--AK[/\$'$@+Z[N]K2[4L30IHK?P+<'C72]'L#(A9Z?N@['B[AD .3/1Y;
MF9^98+T0O@A[2);]G09_GPUPU;GRQQ='M?MK5NTCQ()AZ/6O2/9!#P'9[_7)
MJN.K4!SZ6_9EZV<&F2J7_&,*ZLW1JYA?'+BW[O<:4_,SA>UV\V,/W$*6B \T
M/ L<]:'WF2C-#RC,0U6L^4<+\Z*JBHR_KI1$'T0;L+XH<"&V#\3 _8KES?\
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MES>?;J\_3\[O/]Y\/CUJ()W6'*6=I LCR7M!DNNQ3[)J%HI=5YG(M@4< =:
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MRF2+MHB-G6ALA1B'T37"&!TB,=D2).02N,V',]#L[O4Y<OZR9! ]O!AZ,4M
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MK0J8+.=?)K>/+6"0<5T E[#)>9(?HIR>7,:=BVOJH->%&B8YQPQNN60RX4S
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M.)L.A/7OW?R/VJSY7=?"U+4I^>M*48-!$_ \-Z9N?] &W<O/R_\#4$L#!!0
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M2V1Y ]97QOAVP@ZZ[Z_9OU!+ P04    "  Q@7182<+!]=01  !4-   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM6VESVSBV_2LH3\^4727O<?:D
M2K;E;LV+EY'LSG2]>A\@$K(04X2:(.UH?OT[]V(A:,M*.ID/G38EXN*NYRZ
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M@  36=X) "T]Z$IDV!)?9K+*F5-ZQ<4MJ>B7H[W>WMX>;Z(A5P'TTU.M6!M
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MHOY1]JV@<#YX^4Y\(E03^V);7+:.ILM% X;8G1!]S'$>C*S#&,0+!%&ZQ Y
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MUJOKQ]V@>=,\;F]>AI^$QF0S4,H)'@VP1G9 -Z^M9F+5W+UP1LKB>\D-9_A
ME9HVX/>)4G8U(07K)V__;U!+ P04    "  Q@718)6Z=]J\$  "B"@  &0
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M90%!VM+./&UTA;8?H2?!=:'0 \\@^Y\@,!H[H=%)Z"RZR;B M(<&_3L4A=$
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MJ2X_4TS5 PBX!JC^&6/RJ:)OP/I)%?P#4$L#!!0    ( #&!=%BX^6/']A$
M +$C 0 9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;+7=_6^;6H+&\7\%
M95:C.U(G,7Y+TFDCM>']?6_G[FBUVA^(?9*@VL8#.&E7]X]?L$DP#CDQU3<=
M:>JXG,_!L?U<##SFTV.:?<_OA2B4'\O%*O]\<E\4ZX]G9_GL7BSC_#1=BU7Y
M+[=IMHR+\L?L[BQ?9R*>;P<M%V?#P6!ZMHR3U<G5I^U]47;U*=T4BV0EHDS)
M-\MEG/W\*A;IX^<3]>3ICM^3N_NBNN/LZM,ZOA/?1/''.LK*G\Z>E7FR%*L\
M25=*)FX_GWQ1/T;3035@N\1_)>(QW[NM5 _E)DV_5S_8\\\G@VJ-Q$+,BHJ(
MR[\>Q+58+"JI7(]_U^C)\YS5P/W;3[JQ??#E@[F)<W&=+OZ5S(O[SR<7)\I<
MW,:;1?%[^FB)^@%-*F^6+O+M_RN/];*#$V6VR8MT60\NUV"9K'9_QS_J7\3>
M '7TRH!A/6!X.&#\RH!1/6!T[(!Q/6!\[(!)/6!R[(!I/6!Z[(#S>L#YL0,N
MZ@$7QPZXK =<'@Z8OO;$#9Z>N<&Q<ZC/3_:+9_O5(4]/MWKT\ZT^/>'JT<^X
M^O24JT<_Y^K3DZX>_:RK3T^[NGW>SW9ODNT[3(N+^.I3ECXJ6;5\Z54WMF_3
M[?CRC96LJD3Y5F3EOR;EN.+JVS_#:]<*/4W__=M?_W(Q5,__H>C_^8?]S_]6
M_JY<I\ME^:[_5J2S[\IOFBCB9)'_K?R'/[YIRF__\;=/9T6Y"A5T-JNG<W;3
M#5^93ATJ?KHJ[G-%7\W%O V<E>O^_ "&3P_@ZU J^O%/93#\H P'PU''^ES+
M1W]99Z?ET%>':V]-7@X?7+XZ7)</-\1-.?OK*V_(AP?IPZFBJMOAPX[AYC&S
M7[PZW#IBN/KZ<%L^W(E7Y?#QJ\,=^7!-S$Z5D?KJK\X]?GC7[-[QP]6.X?[Q
MO_FNE0^.&"YYS8?'#'_]5Q<=\ZKK?.):;^#1<P*-MM[HM03:W.3)/"DW9SXH
MW^*%4-+;.G'^QRL75>Q"+//_[5C/KSMWW.U6FV(?\W4\$Y]/RFVM7&0/XN3J
MKW]1IX-_=.4$B6DDII.806(FB5DD9I.80V(NB7DDYI-80&(AB440ULJZ\7/6
MC67ZE?Y#9+,D%\HZ2V;;I'N,LRQ>%;GR6[)2YNEB$6>YLA;E9[[[.!-=6UA?
M=U.HNRVZZA/CPY5Z>G$^^73VL!]HTC7I&V@DII.806(FB5DD9I.8L\,N]EY
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M#%4^=C.F:5MLT#( E&9#:0Z4YD)I'HHFBZTI$.CJ"L%I$D5)3(IQK5-'T,H
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M!NK]G#&Y&^@%RO\&#/X#4$L#!!0    ( #&!=%BD*2 MI@,  + -   9
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M_OOY 1EA 6T2^T+\N.?XG(MO;KH;QI]$"B#1<YY1T7-2*8MKUQ5Q"CD65ZP
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M0C1)G'5,:?_]VDD(!(Q;I'=N( D^C^V<(]O8PPUE/XH5(1R]IDE6C(P5Y_G
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MP0O"9 'Q^S.E?'LC*VA.L\?_ U!+ P04    "  Q@718MT1#Z50$  !]$0
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M G!^SIA\'JB6W'R")7\ 4$L#!!0    ( #&!=%C 2\9H-P0  "03   9
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MC9%%>;M&EJ%R%>S_2RG-<\%U4!^,S?\!4$L#!!0    ( #&!=%AN'6-*Z04
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MA3Y [;_G7#ZOZ ;:5V7F?P-02P,$%     @ ,8%T6+9MZ'], P  T!0   T
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M<',O87!P+GAM;%!+ 0(4 Q0    ( #&!=%@:I0_<[0   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  Q@718V=0QQ)$$  !C$0  &
M    @(&Z$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M,8%T6/[P 1UC P  KPT  !@              ("!@1<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #&!=%A5[I?,!00  )0/   8
M          " @1H;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  Q@718^^@-&-<%  !<)0  &               @(%5'P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ,8%T6 1ILE(&!@  TQH
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #&!=%C,K"=9%@H  (89   9
M      " @4Q9  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ ,8%T6$91]7[N @  @P8  !D              ("!F6,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  Q@718W02/=AX'  "?$
M&0              @(&^9@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( #&!=%@79W36@0L   @=   9              " @1-N  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ,8%T6#&^"!Q$
M!   BPD  !D              ("!RWD  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  Q@7182<+!]=01  !4-   &0
M@(%&?@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #&!
M=%CNNI'9+@,  ((&   9              " @5&0  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ ,8%T6#/\SG$G P  #@<  !D
M         ("!MI,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  Q@718Q_N<..L%  #^#@  &0              @($4EP  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #&!=%@E;IWVKP0  *(*
M   9              " @3:=  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ ,8%T6*VSNH)+ @  UP0  !D              ("!'*(
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  Q@718H.V?
M;T %   V(@  &0              @(&>I   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( #&!=%B,##'I)0,  "D(   9
M  " @16J  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M,8%T6+J>&AND P  A0\  !D              ("!<:T  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  Q@718\N\<;,("  !>"0  &0
M            @(%,L0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( #&!=%BX^6/']A$  +$C 0 9              " @46T  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ,8%T6(AF.''@!P
M14X  !D              ("!<L8  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  Q@718>< "^QL%  !U'   &0              @(&)
MS@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #&!=%@5
M]9275@<  #1(   9              " @=O3  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ ,8%T6+-1&C(9!0  ^!D  !D
M     ("!:-L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #&!=%CXG>AF;P0  -D>   9              "
M@?[P  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ,8%T
M6+=$0^E4!   ?1$  !D              ("!I/4  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  Q@7185@I01R,#  "."0  &0
M        @($O^@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( #&!=%C 2\9H-P0  "03   9              " @8G]  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ,8%T6&X=8TKI!0  -C,
M !D              ("!]P$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  Q@718MFWH?TP#  #0%   #0              @ $7" $
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #&!=%B7BKL<P    !,"   +
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4!08     ,  P  <-   @% $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>116</ContextCount>
  <ElementCount>252</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity</Role>
      <ShortName>Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - ORGANIZATION AND OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS</Role>
      <ShortName>ORGANIZATION AND OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES</Role>
      <ShortName>GOING CONCERN AND OTHER UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/COMMITMENTS</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/INCOMETAX</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/INCOMETAXTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/INCOMETAX</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - ORGANIZATION AND OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails</Role>
      <ShortName>ORGANIZATION AND OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails</Role>
      <ShortName>GOING CONCERN AND OTHER UNCERTAINTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - STOCKHOLDERS??? EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - STOCKHOLDERS??? EQUITY - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - STOCKHOLDERS??? EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - STOCKHOLDERS??? EQUITY - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - STOCK-BASED COMPENSATION - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/COMMITMENTSDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/COMMITMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - INCOME TAX - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAX - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAX - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - INCOME TAX - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails</Role>
      <ShortName>INCOME TAX - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="beat-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.heartbeam.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="beat-20231231.htm">beat-20231231.htm</File>
    <File>beat-20231231.xsd</File>
    <File>beat-20231231_cal.xml</File>
    <File>beat-20231231_def.xml</File>
    <File>beat-20231231_lab.xml</File>
    <File>beat-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>beat-20231231_g1.jpg</File>
    <File>beat-20231231_g2.jpg</File>
    <File>beat-20231231_g3.jpg</File>
    <File>beat-20231231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="414">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "beat-20231231.htm": {
   "nsprefix": "beat",
   "nsuri": "http://www.heartbeam.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "beat-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "beat-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "beat-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "beat-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "beat-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "beat-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 214,
   "keyCustom": 38,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 15,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 116,
   "entityCount": 1,
   "segmentCount": 41,
   "elementCount": 392,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 414,
    "http://xbrl.sec.gov/dei/2023": 44
   },
   "report": {
    "R1": {
     "role": "http://www.heartbeam.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.heartbeam.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.heartbeam.com/role/BalanceSheets",
     "longName": "0000003 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.heartbeam.com/role/StatementsofOperations",
     "longName": "0000005 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity",
     "longName": "0000006 - Statement - Statement of Changes in Stockholders' Equity",
     "shortName": "Statement of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.heartbeam.com/role/StatementsofCashFlows",
     "longName": "0000007 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS",
     "longName": "0000008 - Disclosure - ORGANIZATION AND OPERATIONS",
     "shortName": "ORGANIZATION AND OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES",
     "longName": "0000009 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES",
     "shortName": "GOING CONCERN AND OTHER UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION",
     "longName": "0000012 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "0000013 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.heartbeam.com/role/COMMITMENTS",
     "longName": "0000014 - Disclosure - COMMITMENTS",
     "shortName": "COMMITMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.heartbeam.com/role/INCOMETAX",
     "longName": "0000015 - Disclosure - INCOME TAX",
     "shortName": "INCOME TAX",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.heartbeam.com/role/SUBSEQUENTEVENTS",
     "longName": "0000016 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954473 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.heartbeam.com/role/INCOMETAXTables",
     "longName": "9954475 - Disclosure - INCOME TAX (Tables)",
     "shortName": "INCOME TAX (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails",
     "longName": "9954476 - Disclosure - ORGANIZATION AND OPERATIONS (Details)",
     "shortName": "ORGANIZATION AND OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
     "longName": "9954477 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details)",
     "shortName": "GOING CONCERN AND OTHER UNCERTAINTIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "beat:SaleOfStockAgentCommissionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "longName": "9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails",
     "longName": "9954479 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "longName": "9954480 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
     "longName": "9954481 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
     "longName": "9954482 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Warrants (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails",
     "longName": "9954483 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Warrants Outstanding (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "beat:ClassOfWarrantOrRightWarrantsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954484 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails",
     "longName": "9954485 - Disclosure - STOCK-BASED COMPENSATION - Stock Options Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
     "longName": "9954486 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
     "longName": "9954487 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails",
     "longName": "9954488 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "9954489 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.heartbeam.com/role/COMMITMENTSDetails",
     "longName": "9954490 - Disclosure - COMMITMENTS (Details)",
     "shortName": "COMMITMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "beat:LesseeOperatingLeasePriorNoticeForCancellation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "beat:LesseeOperatingLeasePriorNoticeForCancellation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9954491 - Disclosure - INCOME TAX - Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "INCOME TAX - Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails",
     "longName": "9954492 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)",
     "shortName": "INCOME TAX - Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - INCOME TAX - Additional Information (Details)",
     "shortName": "INCOME TAX - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9954494 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "beat-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "beat_A2015EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "A2015EquityIncentivePlanMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Equity Incentive Plan",
        "label": "2015 Equity Incentive Plan [Member]",
        "documentation": "2015 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "beat_A2022EquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "A2022EquityPlanMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Equity Plan",
        "label": "2022 Equity Plan [Member]",
        "documentation": "2022 Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "beat_AGPAllianceGlobalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "AGPAllianceGlobalPartnersMember",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A.G.P./Alliance Global Partners",
        "label": "A.G.P./Alliance Global Partners [Member]",
        "documentation": "A.G.P./Alliance Global Partners"
       }
      }
     },
     "auth_ref": []
    },
    "beat_AccountingForWarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "AccountingForWarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTING FOR WARRANTS",
        "label": "Accounting For Warrants, Policy [Policy Text Block]",
        "documentation": "Accounting For Warrants, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses (includes related party $2 and $2, respectively)",
        "verboseLabel": "Due to related party",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r474",
      "r572"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r368",
      "r511",
      "r512",
      "r513",
      "r556",
      "r573"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r213"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r257"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r100",
      "r118",
      "r151",
      "r154",
      "r156",
      "r158",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r285",
      "r287",
      "r299",
      "r339",
      "r402",
      "r474",
      "r486",
      "r521",
      "r522",
      "r561"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r104",
      "r118",
      "r158",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r285",
      "r287",
      "r299",
      "r474",
      "r521",
      "r522",
      "r561"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "beat_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.heartbeam.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.heartbeam.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.heartbeam.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS\u00a0OF PRESENTATION",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r98",
      "r455"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - at end of the year",
        "terseLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r62",
      "r116"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r62"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r570"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosures of Non-cash Flow Information:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "beat_CertainInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "CertainInvestorsMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Investors",
        "label": "Certain Investors [Member]",
        "documentation": "Certain Investors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOFWarrantOrRightAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value (in thousands)",
        "label": "Class OF Warrant Or Right, Aggregate Intrinsic Value [Abstract]",
        "documentation": "Class OF Warrant Or Right, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r101",
      "r102",
      "r103",
      "r118",
      "r140",
      "r141",
      "r143",
      "r145",
      "r149",
      "r150",
      "r158",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r191",
      "r192",
      "r195",
      "r198",
      "r204",
      "r299",
      "r359",
      "r360",
      "r361",
      "r362",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r390",
      "r411",
      "r433",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r499",
      "r508",
      "r515"
     ]
    },
    "beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisable",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Exercisable, beginning balance (in shares)",
        "periodEndLabel": "Exercisable, ending balance (in shares)",
        "label": "Class of Warrant or Right, Exercisable",
        "documentation": "Class of Warrant or Right, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Class Of Warrant Or Right, Exercisable, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Class Of Warrant Or Right, Exercisable, Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Exercisable, beginning balance (in dollars per share)",
        "periodEndLabel": "Exercisable, ending balance (in dollars per share)",
        "label": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights",
        "documentation": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life",
        "documentation": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised",
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired",
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued",
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration period (in years)",
        "label": "Class Of Warrant Or Right, Expiration Period",
        "documentation": "Class Of Warrant Or Right, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightFairValueIssuedForService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightFairValueIssuedForService",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants issued for service",
        "label": "Class Of Warrant Or Right, Fair Value, Issued For Service",
        "documentation": "Class Of Warrant Or Right, Fair Value, Issued For Service"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightFairValuePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightFairValuePerWarrant",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant fair value (in dollars per share)",
        "label": "Class Of Warrant Or Right, Fair Value Per Warrant",
        "documentation": "Class Of Warrant Or Right, Fair Value Per Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightGrantDateFairValue",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value (in dollars per share)",
        "label": "Class Of Warrant Or Right, Grant Date Fair Value",
        "documentation": "Class Of Warrant Or Right, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life (years)",
        "label": "Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life [Abstract]",
        "documentation": "Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Class of Warrant or Right [Roll Forward]",
        "documentation": "Class of Warrant or Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "beat_ClassOfWarrantOrRightTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightTerminationPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period which warrants are exercisable (in years)",
        "label": "Class Of Warrant Or Right, Termination Period",
        "documentation": "Class Of Warrant Or Right, Termination Period"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsCashlessExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsCashlessExercise",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, warrants, cashless exercise",
        "label": "Class Of Warrant Or Right, Warrants, Cashless Exercise",
        "documentation": "Class Of Warrant Or Right, Warrants, Cashless Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, warrants, cashless exercise, warrants utilized",
        "label": "Class Of Warrant Or Right, Warrants, Cashless Exercise, Warrants Utilized",
        "documentation": "Class Of Warrant Or Right, Warrants, Cashless Exercise, Warrants Utilized"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Class Of Warrant Or Right, Warrants Exercised",
        "documentation": "Class Of Warrant Or Right, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsExercisedForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsExercisedForCash",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, warrants exercised for cash",
        "label": "Class Of Warrant Or Right, Warrants Exercised For Cash",
        "documentation": "Class Of Warrant Or Right, Warrants Exercised For Cash"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsExpired",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Class Of Warrant Or Right, Warrants Expired",
        "documentation": "Class Of Warrant Or Right, Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsIssued",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued (in shares)",
        "label": "Class of Warrant or Right, Warrants Issued",
        "documentation": "Class of Warrant or Right, Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClassOfWarrantOrRightWeightedAverageRemainingLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingLife",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Class Of Warrant Or Right, Weighted Average Remaining Life",
        "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Life"
       }
      }
     },
     "auth_ref": []
    },
    "beat_ClinicalResearchOrganizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ClinicalResearchOrganizationMember",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Research Organization",
        "label": "Clinical Research Organization [Member]",
        "documentation": "Clinical Research Organization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43",
      "r340",
      "r389"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r163",
      "r164",
      "r452",
      "r520"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Common Stock",
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r511",
      "r512",
      "r556",
      "r571",
      "r573"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r390"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r390",
      "r408",
      "r573",
      "r574"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - $0.0001 par value; 100,000,000 shares authorized; 26,329,032 and 8,009,743 shares issued and outstanding at December\u00a031, 2023 and 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r342",
      "r474"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "beat_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultants",
        "label": "Consultants [Member]",
        "documentation": "Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount to be paid to Clinical Research Organization",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails",
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r180",
      "r193",
      "r316",
      "r456",
      "r458"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r178",
      "r307",
      "r465",
      "r466"
     ]
    },
    "beat_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec. 174",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Deferred Tax Assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r554"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r554"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r554"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r554"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r215",
      "r246",
      "r247",
      "r249",
      "r471"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction Flag",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r495"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r138",
      "r140",
      "r143",
      "r144",
      "r145",
      "r147",
      "r297",
      "r298",
      "r336",
      "r349",
      "r460"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r140",
      "r143",
      "r144",
      "r145",
      "r147",
      "r297",
      "r298",
      "r336",
      "r349",
      "r460"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER COMMON SHARE",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computed \u201cexpected\u201d tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r265",
      "r281"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r551"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost not yet recognized, period of recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost not yet recognized, options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r95",
      "r108",
      "r109",
      "r110",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r148",
      "r159",
      "r160",
      "r206",
      "r250",
      "r251",
      "r252",
      "r277",
      "r278",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r309",
      "r352",
      "r353",
      "r354",
      "r368",
      "r433"
     ]
    },
    "beat_ExecutivesAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ExecutivesAndEmployeesMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Executives and Employees",
        "label": "Executives And Employees [Member]",
        "documentation": "Executives And Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r413"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administration",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r55",
      "r81",
      "r151",
      "r153",
      "r155",
      "r157",
      "r337",
      "r347",
      "r462"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r418"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r418"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAX"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r260",
      "r266",
      "r269",
      "r275",
      "r279",
      "r282",
      "r283",
      "r284",
      "r364"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r92",
      "r135",
      "r136",
      "r152",
      "r264",
      "r280",
      "r350"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r262",
      "r263",
      "r269",
      "r270",
      "r274",
      "r276",
      "r358"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computed \u201cexpected\u201d tax benefit",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToEquityForwardAgreements",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental common shares attributable to dilutive effect of equity forward agreements (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements",
        "documentation": "Additional shared included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity forward arrangements using the reverse treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r459"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r115"
     ]
    },
    "beat_LIVMORMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "LIVMORMember",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIVMOR",
        "label": "LIVMOR [Member]",
        "documentation": "LIVMOR"
       }
      }
     },
     "auth_ref": []
    },
    "beat_LesseeOperatingLeaseMonthlyRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "LesseeOperatingLeaseMonthlyRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly rent expense",
        "label": "Lessee, Operating Lease, Monthly Rent Expense",
        "documentation": "Lessee, Operating Lease, Monthly Rent Expense"
       }
      }
     },
     "auth_ref": []
    },
    "beat_LesseeOperatingLeasePriorNoticeForCancellation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "LesseeOperatingLeasePriorNoticeForCancellation",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, prior notice for cancellation",
        "label": "Lessee, Operating Lease, Prior Notice For Cancellation",
        "documentation": "Lessee, Operating Lease, Prior Notice For Cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r118",
      "r158",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r286",
      "r287",
      "r288",
      "r299",
      "r388",
      "r461",
      "r486",
      "r521",
      "r561",
      "r562"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r80",
      "r344",
      "r474",
      "r509",
      "r518",
      "r558"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Purchase Commitment [Line Items]",
        "label": "Long-Term Purchase Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Purchase Commitment [Table]",
        "label": "Long-Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r27"
     ]
    },
    "beat_MaverickCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "MaverickCapitalPartnersLLCMember",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maverick Capital Partners, LLC",
        "label": "Maverick Capital Partners, LLC [Member]",
        "documentation": "Maverick Capital Partners, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r209",
      "r322",
      "r351",
      "r380",
      "r381",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r463",
      "r469",
      "r470",
      "r475",
      "r523",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r209",
      "r322",
      "r351",
      "r380",
      "r381",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r463",
      "r469",
      "r470",
      "r475",
      "r523",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r93"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity",
      "http://www.heartbeam.com/role/StatementsofCashFlows",
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r64",
      "r82",
      "r96",
      "r105",
      "r106",
      "r110",
      "r118",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r142",
      "r151",
      "r153",
      "r155",
      "r157",
      "r158",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r298",
      "r299",
      "r348",
      "r410",
      "r431",
      "r432",
      "r462",
      "r484",
      "r521"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RECENTLY ISSUED ACCOUNTING STANDARDS",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "beat_OpenSkyOpportunitiesFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "OpenSkyOpportunitiesFundLtdMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OpenSky Opportunities Fund Ltd.",
        "label": "OpenSky Opportunities Fund Ltd. [Member]",
        "documentation": "OpenSky Opportunities Fund Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r155",
      "r157",
      "r462"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r473"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r65",
      "r66",
      "r77"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "beat_PaymentsForPurchaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "PaymentsForPurchaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for purchase obligations",
        "label": "Payments For Purchase Obligations",
        "documentation": "Payments For Purchase Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for repurchase of warrants",
        "label": "Payments for Repurchase of Warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "beat_PennyWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "PennyWarrantMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penny Warrant",
        "label": "Penny Warrant [Member]",
        "documentation": "Penny Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r191"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r390"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r390",
      "r408",
      "r573",
      "r574"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at December\u00a031, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r341",
      "r474"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r338",
      "r346",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r88",
      "r91",
      "r345"
     ]
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining commitment",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r79"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitments",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r207",
      "r209",
      "r241",
      "r242",
      "r243",
      "r321",
      "r322",
      "r351",
      "r380",
      "r381",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r463",
      "r469",
      "r470",
      "r475",
      "r478",
      "r519",
      "r523",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r207",
      "r209",
      "r241",
      "r242",
      "r243",
      "r321",
      "r322",
      "r351",
      "r380",
      "r381",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r463",
      "r469",
      "r470",
      "r475",
      "r478",
      "r519",
      "r523",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r313",
      "r314",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r407",
      "r409",
      "r440"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r313",
      "r314",
      "r315",
      "r316",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r407",
      "r409",
      "r440"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments from related parties",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r313"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r418"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r313",
      "r314",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r407",
      "r409",
      "r440",
      "r560"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r317",
      "r365",
      "r366",
      "r367",
      "r416",
      "r417",
      "r418",
      "r437",
      "r439"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails",
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r180",
      "r193",
      "r316",
      "r457",
      "r458"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r259",
      "r569"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSE",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "beat_ResearchAndDevelopmentNumberOfClinicalStudySites": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ResearchAndDevelopmentNumberOfClinicalStudySites",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of planned sites to carrying out the clinical study",
        "label": "Research And Development, Number Of Clinical Study Sites",
        "documentation": "Research And Development, Number Of Clinical Study Sites"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash (included in other assets)",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r504",
      "r507"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r72",
      "r343",
      "r355",
      "r356",
      "r363",
      "r391",
      "r474"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r159",
      "r160",
      "r250",
      "r251",
      "r252",
      "r277",
      "r278",
      "r289",
      "r291",
      "r292",
      "r294",
      "r296",
      "r352",
      "r354",
      "r368",
      "r573"
     ]
    },
    "beat_SaleOfStockAgentCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockAgentCommissionPercentage",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission fee percentage on each sale (as a percent)",
        "label": "Sale Of Stock, Agent, Commission Percentage",
        "documentation": "Sale Of Stock, Agent, Commission Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross consideration received on transaction",
        "label": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockMaximumAmountAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockMaximumAmountAuthorized",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum amount authorized",
        "label": "Sale Of Stock, Maximum Amount Authorized",
        "documentation": "Sale Of Stock, Maximum Amount Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in IPO (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued per each unit (in shares)",
        "label": "Sale Of Stock, Number Of Shares Issued In Transaction Per Each Unit",
        "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction Per Each Unit"
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockPlacementFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockPlacementFeePercentage",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, placement fee, percentage",
        "label": "Sale Of Stock, Placement Fee, Percentage",
        "documentation": "Sale Of Stock, Placement Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in IPO, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockRemainingAmountAuthorizedForIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockRemainingAmountAuthorizedForIssuance",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount available for issuance",
        "terseLabel": "Sale of stock, remaining amount authorized for issuance",
        "label": "Sale Of Stock, Remaining Amount Authorized For Issuance",
        "documentation": "Sale Of Stock, Remaining Amount Authorized For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "beat_SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, percentage of the average calculated volume weighted average price per share (as a percent)",
        "label": "Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage",
        "documentation": "Sale Of Stock, Volume Weighted Average Price Per Common Share, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r514"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r210",
      "r500",
      "r514"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r414",
      "r415",
      "r418"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.heartbeam.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Non-vested, beginning balance (in shares)",
        "periodEndLabel": "Non-vested, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Non-Vested at beginning of period (in dollars per share)",
        "periodEndLabel": "Non-vested, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate (as the percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility rate (as the percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value assumptions, fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value Per Share",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of annual increase of shares authorized (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "beat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares, Nonvested, Number",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares, Nonvested, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, additional disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeitures (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, Weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Ending balance, Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total number of outstanding shares of all classes of common stock (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised, Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures, Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r219",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256"
     ]
    },
    "beat_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs)",
        "label": "Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share-Based Payment Arrangement, Option And Restricted Stock Units (RSUs)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of share-based compensation arrangement vesting (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r101",
      "r102",
      "r103",
      "r118",
      "r140",
      "r141",
      "r143",
      "r145",
      "r149",
      "r150",
      "r158",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r191",
      "r192",
      "r195",
      "r198",
      "r204",
      "r299",
      "r359",
      "r360",
      "r361",
      "r362",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r390",
      "r411",
      "r433",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r499",
      "r508",
      "r515"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16",
      "r95",
      "r108",
      "r109",
      "r110",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r148",
      "r159",
      "r160",
      "r206",
      "r250",
      "r251",
      "r252",
      "r277",
      "r278",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r309",
      "r352",
      "r353",
      "r354",
      "r368",
      "r433"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r148",
      "r323",
      "r357",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r479"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r210",
      "r500",
      "r501",
      "r514"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r148",
      "r323",
      "r357",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r479"
     ]
    },
    "beat_StockAndClassOfWarrantOrRightIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "StockAndClassOfWarrantOrRightIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants to settle accrued expenses",
        "label": "Stock And Class Of Warrant Or Right, Issued",
        "documentation": "Stock And Class Of Warrant Or Right, Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issuance upon exercise of warrants(in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r15",
      "r28",
      "r72",
      "r184"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued for service (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of Common Stock &amp; warrants, net of fees and issuance costs (in shares)",
        "terseLabel": "Sale of common stock &amp; warrants, net of fees (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r72",
      "r359",
      "r433",
      "r447"
     ]
    },
    "beat_StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock purchased",
        "label": "Stock Issued During Period, Shares, New Issues, Purchased With Warrants",
        "documentation": "Stock Issued During Period, Shares, New Issues, Purchased With Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance upon vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share based payment awards, exercised in period (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockOptionsActivityDetails",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance upon exercise of stock options (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r72",
      "r225"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issuance upon exercise of warrants",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued for service",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Common Stock &amp; warrants, net of fees and issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r72",
      "r368",
      "r433",
      "r447",
      "r485"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance upon vesting and exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16",
      "r72"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options (excluding exercisable penny stock options)",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.heartbeam.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/StatementofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r67",
      "r392",
      "r408",
      "r434",
      "r435",
      "r474",
      "r486",
      "r509",
      "r518",
      "r558",
      "r573"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/BalanceSheets",
      "http://www.heartbeam.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r117",
      "r190",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r295",
      "r436",
      "r438",
      "r451"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r319"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r319"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r319"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r319"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r319"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r320"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "beat_SubstantialDoubtAboutGoingConcernLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SubstantialDoubtAboutGoingConcernLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Substantial Doubt About Going Concern [Line Items]",
        "label": "Substantial Doubt About Going Concern [Line Items]",
        "documentation": "Substantial Doubt About Going Concern [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "beat_SubstantialDoubtAboutGoingConcernTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "SubstantialDoubtAboutGoingConcernTable",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Substantial Doubt About Going Concern [Table]",
        "label": "Substantial Doubt About Going Concern [Table]",
        "documentation": "Substantial Doubt About Going Concern [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOING CONCERN AND OTHER UNCERTAINTIES",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "beat_TaxPeriodsAfter2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "TaxPeriodsAfter2017Member",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Tax Year 2017",
        "label": "Tax Periods After 2017 [Member]",
        "documentation": "Tax Periods After 2017"
       }
      }
     },
     "auth_ref": []
    },
    "beat_TaxPeriodsPriorTo2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "TaxPeriodsPriorTo2018Member",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Periods Prior To 2018",
        "label": "Tax Periods Prior To 2018 [Member]",
        "documentation": "Tax Periods Prior To 2018"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r517",
      "r559"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "beat_TripleRingTechnologiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.heartbeam.com/20231231",
     "localname": "TripleRingTechnologiesMember",
     "presentation": [
      "http://www.heartbeam.com/role/COMMITMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Triple Ring Technologies",
        "label": "Triple Ring Technologies [Member]",
        "documentation": "Triple Ring Technologies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r267"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, income tax penalties expense",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest on income taxes expense",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "documentation": "Amount of interest expense for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USE OF ESTIMATES",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r86",
      "r87",
      "r89",
      "r90"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.heartbeam.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.heartbeam.com/role/CoverPage",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
      "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding (in years)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.heartbeam.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "35",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-35"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001779372-24-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001779372-24-000002-xbrl.zip
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M\N'13@>?3@:>YV*"Y2<O&",!A;$OPYN.\/88E(PCUW'M<#FR/;DQW^8D="\
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M(FW%N0"(2_A$S5&5?_)J@8T[I%,1"N]4< 403;5;1#_7]:=1$W](WEAL?Y?
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M8.\X7]T/+HC55\0,KH2O:-A(PFUEYF,<1QZ$R_2]\\!WX0N:@ZTNBSC;>@*
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MF*+G@S87QBAU48U Q6Z:>$#:0>(H469[Y[#$>#9GW'-QCKV#FXUFP27K8XB
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M!ZGN<N9.9N)<^A)-P$F@V]%Y8"32I:X?)5@@[RKS55FWR-<Q1()^<WA1PG0
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M \]+^XE2==)\R4SN(PV!X "E!$.JQ.MUV%GJ<"DNY09-"#ORI5EHL41-*$I
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MZ#)4H?%PAU@R.R5*II/5N,/M$[!!,74H24M.5$TAZC$\XR[!ML7N5#D0TLH
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MN)3T0G@O+#7;2+;HC6O,[V-M17!+E'BQ#5]4!, \F=JPG5"&T=_^TFM8W7>
M.8M0@L(24VXS7 5/BT-WG,1!B/I0LEAXK@Q566@ :E!('EH[!HQ<4%DIXAL
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MY_9DAJS6 YGCTZVL["-_0.ZA&1$R3AN^7R)7(,, D4._6S7V@!.$ PV7R-Y
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MQ$377Q !*647?[P.<0FB0+BB*"(^%A)(E*&@**NKSFCM1B?DG#):T<#V5-6
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MX6;*:2/YT7B1^PG_F/;H4(;!O+!V:09&DAB+=E<O!ZC^$L$_5H,DBMLN900
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M/F\%E,P?9;OD>/8J@P:*'B05Y&0O>/@,,A>R,2A U168XB6.;,"*8'F#WM]
M'@C<Q&0*B=>)QMVS*VIN128:_*ZIPY'KE)#$7*\#,ZZPK1@87*94IVNCQ;/<
MQ:.PU-;*T66?/HI']CZ^.&7DP+@;??7LS:14J:';DMC+>^TB,1KY^&P-TLWR
M-W(BRF9O I;YQ,]8GNVTK9>"&]\CC3,/\?BVR>';R<;H[5*=LN@*<WK%L"5>
MJ7%W+- 5RZT(/,CXI4V+QY?F(>F&;K4=GSJ<,E@0]SS;8R=PRG3Z.,T&ZJ8P
MVEA[NG4-CCS?%]YZV'7!T !FSGB*Q.4,R_8J$7K&F_W"_MCW+;'*J>5^]<OW
MYCF3I44],]G4:,XN6/&DISI<[EH,2II_MH3YR#X9&FX>*5Y&7&+'CM6#7E$G
M_#4B>'9>7GQ\GK!V1P2[\82 GV&_=95SI@S26GX<&)+CY/:!<CXG9Q5579IU
M7QY(B4=G/T;+LN BKO&CY5\@>\)O-CK>>#:SMDHV8D?:X.<?Y@[G G^BTTK5
M&TF2=I'%FNPT:,I'FSO*!,L=%1\;7\-R]2JZ"F65'<U'XJ32/2U?0E4U@3GB
M55#M(N\5[%*XD705T'84H9+LUKB/B:[@->IP!LT4@*IHB8)$MV&V,1\S+X<F
MFNY[$F"O8*;L]7T>D<M33 ;H'LZ.]KQU):^R*2&((].Q3IGTX+Z5YFZN2;CA
MSV55':5,9UR19*<R2(Z)'O<'.Q^=_81(J#-A5IWT^2T24^[O!M78@:&%N9=-
MZ[98PFUY#YJ=%^ <O>0;LMO3( ,7A;#A)R<!VMNX7#$[V"]@DBP$XY^=QG_:
M/B@(_)ZX@[R#Z4!Y!,)>B,;9\[J/]](6,]EJ@X:WO(N;CR<OA4!*YM"-:B_
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M56XY 2Y30\]=K:G:S7/XVP*1Z:U\N_?G-;W3U[N\(,BRJW!31#2=#J0=]U0
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M#KV?_O6'KIPY/85Z/6AFJ+1F[-P>S#U[<7(&BP_&5P.=H+J03H6I,FMPA\W
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M.S\"$7=^"=^VI54IT5'3D@Y-//P6"!:0F2MFT:V.2RRPXIC39'-BF::_Z?(
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MZ#,9$!L\CLS'XZ>#H20P+)]-&RGN9;3CLI\V'D:ZH'.\E3;9G #V(YP#$-?
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MH75 =56$D=I9)OMC*-SJ7&7E^';,7(LZE Q*<R>OTTT:IKU,H353O2I<P\6
M&#JM%[1Y%<J4-T& K(T=2@V-7M(AUW7.OS8A- OON^>VGQXOT1>9]V&2J- <
M*'2E.FH[N6>1<\AZ\C]MVN$,HT"THQ$CL$)N?^+5&2@Q_$/T^,&+)4E(2;,,
M)"=D1TM#SM(->&HY; =R$@2NR V>& V,YS!$&DNAM>1RD/=#40>[5K8<^2&I
MRW#/W'\.8YTQPU,JHVX7I7!R'=!>P#<,_\5='S Y2F8'#?@>+*G).'($Z3H.
M,V,YD%SB'7. 3P,:3(--,N7[:?%7.]$\AYLK4SJ99?]K&J;L](R1)@.**;MR
M*O2A!_G,@:F8>-!,,B+M/V8;TTVGME-+8&BZ#!>+$[*PP^N+ON+U"\MH_I;H
MBZ<I0NXJ+J S!M4Z'E>U4\IYF'-Q0MI:5)_S<TM\#"'L\,1(@.):%/POU*?'
MLO!>;NXJ:HQ>7:Y-"VJ2Z#B%_J[J=1?T#*Y/3#9R_YR6[,#T)<.$:;2,I>:-
M=#]_%B-Q&5G%1>\]>%$6X.&6I01W)\;@MM,=:I5_];T:8E>G#O"3)OGD3LEV
MRELMG.K;A8XKE?Q^IC*^X2_2(\,<XU%(;L&2<@[QE[+_=!^E8T!.COT(E,CB
M?C35(M5#4N<U.:'J_0'!$+]BL!?]G(/GN.=.JPT/E7[%HIHX&)5U:M#+>5\H
M_SW.Y+6\.0S(E(3+*TG%+<<3G V:CBE;@]32"O.1FJG4_\IZ4@$]D.YD[N^B
M0DQ6D93A[$_+SM+&W$B69'V^8+#"/YW)'E()BXNCA1+/^WN!HWD=BOPD4OA9
MC-VE:8$IY1$50B#_>Z1F2Q]0'4Y=-7!(.25=_J82E_DM/9B*86=PVIL!3IU]
M/Y7J,G)#, DS9?3Q[)_-JCQK.]BAEL'-\:[]%M.G%TJ,L>JYM4G'_L*%0AGQ
MG5:@=U)U<%&$\+ [KNR"N8T["ITP3HDTAJ%Z_J$4NS19+G0^GE!IIQ)3BI6T
M!L_&0>H:_4P909SGXF0T :>X>%[@!54-P74%1W<U>6I'(3HYHNJ8L1LH<8&Q
M$K5<ZCARR/^XVALZ*#MG4+T07?S5626B(5B$Q[,?DZW-O&.]YT7/YY]&V2N/
M1D_SVRS#[,6%BVT@GIRQ9(;M'(3\5$*6]F?:+<AQ\[4X?75*6,=XS775N]Y8
M1U^Q(?7Z=?00NKWYLKPU+GVVN73ZE@1*Y2U!#@B+"WH:_;+>@UPJJW]E-\/Z
MKN.ANMR[E7#Y(PB]E9Q\_ PE!_[D4!T1=;H:!RRFL2U!'.!'P;ZC3T@KOX8G
MY5^7V?Y(DJ!2""J^+6PPO_.IKB'J=(55A(?IT9W._+Q@E"^='4,CI??G_'G@
M&C"@S+-G4AUZ>2!;I9UDF7AI\202FU?Q1*-Y)H=XUSAQ'BG@ J/R17DFKZ82
M5"3!*30H@G%943*$H_=%'<-I70:>5H7)[[UI\$3X0STK\KJ1T,VQ&X;9^"P&
M\\H5# D;+ZM3CBH:R169S!0.)J+@H<.*IY0-"!],F7P>1.>)BY[DH_-4 2CM
M-3,R/<AL<BG36/5)LP$-8+_ 3:B-% .%$,%*RRU*@2_QNR!!R2(KE,>@!*3L
M127 XGS&!/5\SI^09-M=R&J6"*05D+',O.OX0&S)\&3TKN56WDWY5J:&.AL'
M3:?MIB.F3;G7_*=?[VO2(2&[+5H,VGG2M?L2,A?\,V%GO;C/Q:?1*$ =NX?F
MV J*S. QE-,\@;4TK.CE[D!J,$#C_:INSP]H:IF[<^.26O<EZILM43_YXDO4
MUSTM#566B0ENE6G+*R8Y !2W)_:$UU:!U PE.EU-^]WBLQ][/3F?.D6&2J\X
M-KA)B48TH5F3;C!8*03?-6S(HX6COJFC&$\4([TE1N4Y':N,7"OC-#U0QDPD
MCGT([P<SC-!L\'Q25*#3G#:SO' +8A''1"1===GZ*$^Z8!2Y)&,D!S316K+)
MYA*1=)*E_B20!R2QK86PB] *S(1VXF'=0[81'*\@'QU\@^.(Q3:OC.%SLO$E
M%WB69U7?9CTVF4=Q>,RD52+IB!V<F\,#.1HUN*00C!(VP,GU%0/_N"?D.,_'
M.1L^G1E]7>Z>:T&I*?5#N&G@E<&3\6/Q7-B5BSSAZO7)1+X'AW1Z$O:-L#X,
M%WIH:'RY?+  I?CD0E"U3)*:L=PMDY>*8!)3R^#!:/Y^H/LMF&V572@A>V;]
MICBU),I!I,?RQ,N1KTCMI-G#99V&A?,/2^%"/3(U#M>PP>XE_39N>.XRI1<:
MA.PHGT??IH/_@S7.H%=>[Q-$%!0YTUZB98JA[.(-]!]^E_OA143N<O#9'XV$
M9PYJ 4[D\*#S\#@>-AHY3M]*#.Y2=4,QV::-@2AY]$Y9BK>_26S%OT0;L=:V
M4>F)H"!C*T$"R](-=#GYH9S25RHF8U_LKO[":1W02KO&NQZRNZ,#CR8<FI(0
M@XF/Q&I8JWR->3TS=?#=2>'W% 8U]9J-5+2FZZ=Y9W 2TOJBL@07^#U#R\6C
MK"FI\V"!E:+M)J:$1GS+6I&#Y6$^4NK5UYREH;=279OCKMO@*ZF& /.7KMI.
M['A'9=6R86.:*-EWPI_ ZSIQ[1R_S= =IQUH5=Z\>#<#5:_CMC;Y*P&BZ('M
M59AP>$NT[/:5(JSLS$UUX$M^X:>:V1Q[+(JRXW<D\=4 <K/Q-2!$(.+6ENZN
M]UH)*JZ2[-?ATLP^,@;+5!XE@R4BE;56CXJD&D;*Q9+?("E5_:65EE@J<IF>
MWX,[E%B?6MZI#,S*VNAL'>P>'9F)04NF&[@FT6>@LG=\V9-=B6$,Z7'M,>+R
M:NME)KRP.(UO$<>3H3!G<1<L521M476+W?I,>#?U_;%9>5YDG^K2Q&6]BKJA
M[@DWA#Y:QK?GZ-!6NL?<\: +R2]#C[07'T;?:S6$DB7DO2 SX-IDN+7L!P,W
M I2E8#]:31-/99D\0]UE'3T=)V@RV)IZ8Y=B 75DQ='L"4K!WB8KUK3I$4<^
MS>T^@BZ6M)/\E**N@= C#S3IOJ;BI:Q13ZA\P4@/\WD8WS8G_#WTX\*RJYSR
M]LD_SUB%V<PJKU)\UM^1V8P6A[/CG-3-,[0-"B,.RRF;V"FS4";0"LS8;<4H
MRSX0G:8F]$Y-EV;@<_!L*]NUED>-'CC,4[Z^"2H"YG\YW*6&G-Y N]@. &"?
MI[Y5W]\RH %'M[;!B*33C(UG#Y1@#"H0MS S :><+]UJU8K=9HA;F4UD7N$$
M,H)%%'3NM6JJR9\\U+V6$$X?+Y7Z&3N7+R5N6 17EAYZB/#"RVH8K+%,CCB1
MG9$*>B2_*Z&XYG/_PYSD_SKY?08^,SL0<_:9\H*VDM"&6[5UU=Z&DA8=UJXL
M+ !E9>X1H/)L#/05^%>&(1[TXZ5F[%RY7 YXKQ61*;Q=E#<L#B0^4M#L;:H+
MBP^Z65(%IVLRE6[*O_FO+#JAH3+->'VYY]$WDR#&>)[41U2:,]0+85-398JY
MC[BN([Z.=TKM+=,Z%5]6OBTJ!MEG0TH4J]P27D9$W"NJIN_CN;:(H^N/4*ZM
MW6H[=.%2%]0)83PGTGP"Y:;H+)\']'_(\"[),]G*6D]ZBQQIU?O/;G5.$-K=
M[@F^YD'#.4X3;Q%^=&G@ KB5W&SG5W;56;G8"TA8I-"YG@S%-)])0W?(Q<1M
M!VJIO^O4_Q28!Z@8I-SUCAG6%<>A5 B,T4L#--]G?TIT(A+&5[XFUO?MHD+:
M%CX7$L*,@4W]&LJ]T"\Z$NG:$TZ!RJDVK^2\+>-4]D[=\V_\"(F7_0UQ5#BN
MRN=,)ZL?/6<@Q>-OO_T:KO'?7KUY_KQ(,FNB;^U,ZFG+6-3X=E"W.5*Y0H\S
M&JZ<.4:5)"\LJ^HZR<@Y_1M#\(7+SY8K%,\8Y![&Y24VXGPTX,G1K!2Z,P3.
MY.9R8)E9/_.- 7_7P_8L"+\,KWT#<^H>8:#7F>;>=8LPB!T-[6:K"&H:OTYV
M:#P<66APF+/J'AEPL\B IU\\,N#"\>$P<:1+QI_R3G/4\06W<?2I$ 4D^)+S
MLR21V*L$)!M"2S :8;4GHK>4@+@"XEYP$_,6J7;V*>>[+AH#5,K0;0*J*3&.
M:@Y:N3E34I%2I,+5,I0"H,<",!:*WC4S87+K:%T/>;:%*6MTR&K>-EYCV08F
MEOU7:#=TYOZ'C8<:7Q7#L4X3*5<IU<7$7?$:2BENTH<#ED"'PU?=(C*%2"_9
MH7$<UPKAUDY#C=/;V<OAA,"H(DE*E"VKMOM-)QTGK,6&>OX_L:68!.VIEL5T
M//M>U (O>#RF3U]P2I'"Z'">N.X2VSO7ZAQYL<%N&1B,6FMAZ97$$-^GK,GD
M_>6 H_Z'CIC2N,284B_JIH+NA/-G53_S/8Y5WN]R.1-J(3&]S[E1>O>DG6JR
MRAB?U8_IDWZ!Y = ",LPQM!U%>.1SV(8FQ)PHO4YI%\:TBT14+Y:'1I*WIJ.
M56+:3YV:9AEA)PA#Y=10LP* 4D\V@J(F#.I.X+G)F>L/N;@#KCDG6:F-YYXX
M.@?.5'UV*0IX\ZMA6$_#2BZ=^8W9 Y,!V&T9Y'/2E6O,&^%E8I0=MF:YXG]#
MV5G]=D4XF/?O%^P0[/D')OJ^\-S>KYK:A0LON8A"^!,U:M9_(0X?KW9O3%==
MN1/=A_GNH,&C3,A$Q=IUVL@)@BP@GU;@HV-!/ED%Z!+P^>>XPDJHE-Z"0,TD
M-D!_I\C@4O9BD@IT1^,4X2FF;7JV,@94%?O@2B?/&Y\U/)N7S>%0D46%M/Z6
M""C?\'ZWRL+S."E'_ZM:O*?N(U3$=MO$-$P*W>_ITLHZ-T6N$$W(:34GO9(8
MV)SN^VI!9/G(Q'0@M:3'^1D0?P'P\3^J93J40:!.L##R6+"H^'Z(@NR:IS!W
M7FDPG4+%;$(%AY2Y-B*7\BKKE1LX,ZL8KBXE\4UZ-U5;>V_4QO<\:'VYI<IT
MZ%P[3KI[/("A';;HT(+DUKR?(:$QTFRX^XXDQF$2 Y.N1*^H36H(\;WJ76\]
MR@<&EZ<Z->V($,U*RSU\.<8)*":I741+/P&NO8058:*+Z8LTT'X9C&WPJJRI
M*,8)9!A=7N5,SG]KK:0C%DB;58F(98,#9W?N=:MV@M<T)YW)Q2A7+".T0F&O
M6L<(K.?%"LO@G&M9XHD(>G(G'"R4>O$M%]7]B&EZP0]!N2L^!@DNS0PGHCR(
MF$%U9W$!KJQ15M3-]/'L?]2<#*MD65T65F/24FR[ *)F-@O,S7/P89E=IT41
MJ-='/2?RB3I>A=A%]9'C\,J?HX<_VY9K_4,*:(U_I3WG)!7J29J7@]V>L]1C
M4GF8AQB3K'1!>!T7@K\F/"58D*C83$7!4];MI4--5"#3#^'X<^PUVX>R$S\C
MX;KZ'=2R -LR-((VE5DWV7P_^0ITY\KX'Y9Q.952C8@3)P>RA#'P:.,$X;S&
M_EVWRT#0,V[8O6@1^?F\;-0YPE3R.N]C@SPV%:&<;G?JEYZQ4&G'8?P0;LB"
M,^>G 6>XCW#<;M#93"G?PZ_%BF=.WX7WHJJ4_2VN. :!"XE%KQ)K7,Z3-TEW
M&M_!8?/&@B87_?!"JNX[%U1<@PCW74M>.HDCOR5QY%O]VK^!"#=3B?8#@7WW
M*^,JISR[<\HJK>H=U=)O2['IN<O4U7O.#W'_3:)4,ZCIX<&P-"/2JI;1H4\4
M:4C)TJ2]3/66_]WNIFJW0/KM<?@3U4UOW):4T9 >,&G4S'2]JY4]M^!#H.VM
MREK\:NFN QG?DEME]PK"[;=\N+P[(!]^Z<(0OF019AN1)8\62Z:10%86 5_@
M'*VP.K*S39NU,-HB";T02HZ54P;]8C1XG$*-0P(Y@3Z<,^:UX;!5H=\[1Y"*
MGA'/OBJV4@OI/,X\/(Z*]:]_N.78T+LT)T=U6&W_^O3KN,+'5^*/*G1)_/7H
M\3>;[2?:6CBYO_Y.7^;C/\)WV7 ]_NKX&8T%K:JTXEQ^(O&%?'<_ 3<X :KS
MQAUJ(.30M($'<0]P<=I#2.[?(EK$7M7VQKRXE'4O9O]JHZ6=$0J&$\XD/[6A
M@Q#.8 7S=C_3'W>F1Q01V0P+F8+0N80EH(XI<7X_5S<Y5TH8"YW J3/>.M^H
MXD6Z,%SUB!-Y/S$WNXD(%5MSXIR#,Z,JXI1*/^2GYL1W8VBQG$]9^-FJL["<
M_,*0CQWE\E0"GV!*VAM4AX &S+R&.%>>ST?W2A%-_%.":1 R)KL(08H G (:
M2-(!75CM>L8;4ERO:8&:!33@PU(M-OJMW.F61&==I>]^I=[H2DT2YYP]Z'CA
M<LT[9^VZGXF;G GN^%L@7\9]+D3:1J6KP3P4" TO^H:T/!B%&BI1BAW*OWH_
MIQ]G=YG]U2G.#*QCVJ6L<'4V37::<Z$=GKI[%.3-HB"_^BQ1D/<;]O=O6%8'
MXK92M/]V.8(DN52#'@J_F^?152(3#7>)V\H&]CE35(3KH^2X]_;X8]ACYSIG
M('TA'4Q\1_?3<=,N3W101J31!B#4V$@T)E?2$,>[)2F_, #)76?9SOH61+")
MRA6IWOL)_;@3FAIB$KT8IW%)(2@LP_)^0F[6X'%(+8$=9?$4ROL^[#W]6YO1
MK1K!ZOWTW.3T5%3Q4LTQ$<WR$E>&)$(;N5)A3V3>[Z?IX^7$!RGP/["R<3^]
MG^S4\F>6$T!CDXCI..G:\^WI_4S<Y$R ZHC:O2@9S@.>Z'=8PV!+&&-%4=QO
MC(^Y,3)ADBTI=_F4_7:_8<?"*^XP_(7(/B'*0K##DWLG_(9/*^9%0:PD,/GH
M.>00BGBB[03('2.M;AM(Q>@>4_'1=Q<X]37?>C_<-SW<+L^^#H%Q>435LK:>
M3E'C=.VK#EFGC+K;O7$A"O0>5?;SJ@^)[8"+L$Q&<3^S-SFS/,;6W61BJ5W8
ML#CJG(K7R;%6_#SKGF'SG:$+2A4W(%JY7A.0WXXQJH$ON_*<RS!V#]"IDHLX
M]^@*$92ZMZ ?+5OOU)S/REKAJ0C5F/_3U$'OI^1&K2QM!R*!#1T0' ()@:%E
M#-*]Y_X1IN$P)(PTUA7^3%3 0F^0NGOO)^9&(UQ!^Y^U]6X]"<R_'_^/=&24
M3.G%C&[4:7%?'KKQ=+?EUIJ0,RMW#;-D@"/D?A9N<A:,*=O0P5DY?" T/=)O
M2#@'HQAU5+HQDMHJI]&T(O!A50#Y'^&_#H8M]226]TOC1MT&SUM>GJ,+>3SC
MK%A@_H.;_OO9N<G9$=&;&++60N0*YHQH-=LU!+R$8RC';I<L(5)!+IXZ_AOK
M;&9L^MO0S:LR@Y-O0[G^CGYV/Y\W&2MQ:\895Q6M4?&*;9)?4HNS=/W'1Y'.
M@K .'8@7I$C$T?V^T!8#;:8P0+4RR%/+[( N4*EUNK#<+4+&7^MQ>I_%N%VF
M'72E4;)! D$%1,DD OROU]^_%88"J HS'QLQOS-E02;',F=<^8&9T,SHXK05
M8;)M^=X)P=#Z#A_">B/\V<3ZHVQ1G+CC0H0#2@[0ERSIR&2_EMU)EJ\ #O-!
M]7" Q2RD=]M=?CE<$FB?B5?9HGZU)123" 6XQXDO\%8\F*\>?:59CK=E-R^C
M=WOT^D,=]CR8#RIYBHOO2@N6$"#Y2R_;C9!IT>7?\/LJ(]GS%,.\)F@CK8;9
M]VW9+6</Z.NR$-Z\>/[Z>YGVARHZPLWRE./DOJ#XNK-5U:UGT3-+='R,O6-4
MD#86\<BX!B*:KJ2(XT?/Q-O\2VN.?+KA1_*U=A7C[DHT66 OL5E DIXHC3L,
M];7&FN_ ;,W#H:9!$QZ4Y]$-KF?/BMF31X^?Q',4BH&8[A]>Q$W$G1;D4FL=
M@)[D[.&436GC!)Y(?C)QBL>ML-@A]PS81]/S4*AH!.D6+>.\6TJ;2Q4?]FXH
MF&/E0;SK<%^A@WZP=,EW \T-Z9'.*]&[8CU/8@#80G7CP&,Q 53R 'V' HWL
M"7T,W<YR<4KT:ZIP+>)'X8SV>9V0G,>'*9UOPW%VF5E6;:$UT*T'C>:,MG+-
MR=*RJRMP ?T5-HS5GOKM;%D:,]4J+JHXYD0@E,E1@=1GVV[A(*+.&V_3H]$O
M1-N-Z?\_'A\_^6HV)YE+WNA$$_P=6ZKAO5 Y<_=:M<2>I)1\JVJ%_=20G'M/
MD:(\WA*<F_KS+EZ/LI+@A.=TUZ@I-5KSCMH(M\J>I]D"VB@5H%7TM+;DOY/M
MGNXV' 41O@ ',KB.XWL_LM>.@Q87?SS3B-"W B%5F,?7ABJ2:!+R4B4)O1"8
MJPDT4]C=D_>E(WA)6J[*OE<*+QYAD6MP*"_1#MF!S6A!X+*MT1A5*ZDW4CN]
M\(>)X^?&">8G'DR=<)\PG5<Z:DTS&41+R1R *P\,&>DF5[G^@)057)BGK1(1
MLY%3'L)DZ@J1X1-RD5(N>R%=2U9#6TXR=2BGM;*4',]$LZ.8((\E$KJX<,/2
M-U1Y6\C,@,X^^UN8U\ TV>76%"G'C@<][MZQP_ N5.TV+VI=KN+;+D5OR.?A
MM077+GJ[G?P+K:*Z3H\?_44-AGJ?3/@F3H(2MATVFJ3R./8M3;D  ]W%)V5"
M&3Y*]>KP?/51_O*@?/C@R<,'WS\T9RZM1E-\>/J4U]F:+^W=K/SKR=]:B7A:
MO==NZGL%@T_5N_?LL^S=^VRV)?G$:'J+CB!Q#:3XPC'@JT@MN\O0WBS?B_]X
MY1TXL2FN<//,17 VY,'<-NU_M7/LOS_.>'[Z-,BW/KZ?]6LBGNQ<G&Q1MZB^
MBU=!ZJZ2W6!U0PM(KA1B'[I/I=RF:S*[@E5?PS.CHWKH/:!57=R-\:3<KF/K
M\CD0_L9?8D@Y>_QD?O1DXC#YX0/7(=VI\E5T8RY-MUPT\Y)O^=U9%E/.O5*Z
MQ;Y-R^V"]>)3TA\S*+ZFCWWA.IZ+IH:,M#K9AU?"%1WO"V]:>J+?Z_O3_MK%
M-5SJ6^UX7C.[_*.G45*Y1!9X/4"JE,29XW$4MW(?LJ]D)3-W7M&E).B-7Z#.
M.Q+ K)5:^@!5TTB9>%E%Q\X)"X$:2+;[N;0<Z9-G\07K<-#%>"$/EP+Q],2U
M? LH0']-O-MD@+)^K)14U!8K6>+<<#K0,MBVR<K"JM2D9K3,1&/2;%*-;;>8
MX%'I"\=77/V'#56@0(]"3-9^P;$KN%$(Y;F*FQ.Y44U[IP(DC,@)H%_FEIA4
MX&,<7A( 65[:#@10DUZ1%0RFM0F:#V*O3:F32V$3E3WBE)\@@2XY4,DX5FO.
M^<?_5677ZSQ(X>RD&BA172'!6=H G*@EOG&BD&HXNQ0-[5N*H'DO0WR18LFT
M=TR[Q3:1[DOEQ_$[ABTFN:7I<7@#G:!B))"(#50A0J-C0Z3<T8H2SJ@/C2C.
MTYIS@?[0K!S/2&3W!26B:"%SZNP5:2-MI&EZ9FHWO:6\%5\9@X[B$?^_,M#&
M3T=\KX^GOO6&-2T@'X\'><6M5A!>H23\R0D=R=N,G]Q^/3*/)D,VM_2;MX%L
M;\IS)\!(EWCRZ,F3V0^\#%Z9;7P3-^/L@437^ I]HH$UL>0^+K[-7JAPS.?Q
M;L\&?U8R7J0W\9%,B:J'4%M 7 4@V(]O]S(L M[YZ6/*_3]YJF<PN3S??/5M
M\?@OC^W2IOE$AZ_-3J+SMA=@AM[1:%[] NRUL'B6O*QPLG&B51*WH02?6\K<
MSHFMOK%X2Z[Y-/\.4=2=V:DR>_#L_[30BI/*4\L@\V':W18!&R@UFLG<=;4F
M-ONXJ$@'F3B/F ?)/<>X.LE#)\D^>W6#KUXRGF+O3XCP&,!_/;ES 0-W?*B)
M4*F82X[.9: CX0OSG?Y1]LORW[,7<M+^#.^39=:6H29>[9&!J#*=;U^4BX%/
M2\N@-E.L*8?/8F@N]$@F!T(CJUXTX-!TI!&YE3,+/<Q7=5O&P9M#ZH96%=GL
MNHJ76.)XM"0(2G V7/.RK_CH[F IG$>#K2>C>1D)^%"!73ND^A2'+NUBXQ3Z
M\&2_@'2>5P;,[*MI!]M^S-44^KIHWTJ%!>SH$IIBF2%Q?IC@'"/&SH8J<7N_
M)TA 7CA%ET$YPBK9_]Z!AESFX"QT1_&R1TA5A4[BK^^22@02+U4_I4>4.>=>
M7,RYLR.Q.>*^A\>S&(@O2:U"K)Y)94I 2$_MM,HOIH-G?22.TM/Z6XDPAH::
M&F+8& WT#,4NLZJYUC9L[IT8(0UX5]$;S0B'ID>:PX["D?"V>5@G4N(@^X+L
M+B;63_[^EV6=*>F0!JI-K6_6H*:*]K! _6D*4-K./HLC26L6/BG)1*[*L^B2
M,J^LAC. ;.3JA\,C$C".O/V!IU\/SL]BA"^5.;^*S@3<LV78! Z46*BAD02L
MBP U<\5!["4SI=,Q;&=T:J*K+'H35\LN0&J8Z%?$<;1LSYOH#%&%+<U4FG7X
M57_(O+,O(+[1Y"/V[B$7[--97V4ZM9!2:[F)5W(ONF9Y%.,((ZU)==Z.HI=E
M6$-L4&O+>"A;<[ RZMNM@9R:]NTF%JYS][XD>_(:"JI2\Q&'.AG:W)$>AJC3
MQEM@$[1?>/!3H,V:N7HPJ#-^"ZS$:VWLS_+J-#IG!(\12!9!-1H2(9.$$YL+
M&L?=)J[D&,V$CM+TA@K.E3 3RD'FX0JII6+8DJ&][WH-&N^FES-5N/.:I!]C
MU%19P^WMW@&7V?M._<V!LD4B;9K<"V)[G8;9!L&FC&2,>X-HG[YQ_.\B6,,7
MT]&&5Y4\F&+HF(I_K11A5JM).XE*-&++()<W,]EW_C!N,HZ9XTD58X][;,(G
MPB9\?8]-N&A\I'79UC7X&V L*?>L9XEL!X'@P<M(C@L6OL.?RJ89!"[#HRM/
MD),;,MKOY/V<3.U,SE53J*C/;;AIR7I;S>9X]G-\VA91HR3O.>XYE*U'TB0&
MCR0!22F[52B97HXQU@MZQ'_OXM2M*LK"*J<CG"C+O9LH+OE#*%6^&Y[<S5YC
M-[N53]6+Y*LE5ZFNVP6M4,$Y!"*=5!(A$BU-+C2,G,N307(L 1<6LH9G8;)T
MJ@B&>46"X1\ME5&B%TLO0U"QN#9.J &5$HR2^W<GH@[;5"2)6%X!Y5),U;4G
MR\VM--*#15G&<#"3M:FJ3QAU5'X,N8%RSC)CW4I5_M/0*,Z7(W\^5NAC%9KS
M@M#-\L\@^-S;C^*WMI3HD6P4W@U)E;HN;-IT:;1(W<11D_H&E2QO][%__4#:
MB?OELO5&]1,:VB@('-!0$,=T:VDC_ +6B-C0J@4Y;_1#BL#<M6^!>_M.VAZ@
M72XM$XXD7>V!="M2N0YI? 5)NF$RI6%K)LI,W)[C8M9('^H92@<&0;J?'3]Z
ME'R83#:=!'% ;^NA&%>21ZSZP[?0CI0NK%J/QQB_X;&^XO==^UY+\,OH^-%_
M!Q,DS.JL57/!4*UW5$=AX(P#=[GN&4=G+LDZO71A:;+9>1S>+=G DRYP;X\U
MBFA=I)-GU;JN21RG+U1Z:$2+MX=FL:GR:G$% &B7('R':)_[;21>W';50MI]
M4M9R+N,%VF(>+I79G$Q=HM3+8KC[(6TA_>B"@F6>'_R2K-K?*S?B=C3#-R '
M<P'RS>6.X"J]Y9>Y'/DR>OWGM!7B_]P"FX60/*^M5UEM'6_72[UD<E3$RJ_+
M#]5ZM]83?4.[8RM@A&Q0LG\-T.SIJI#+\@^"5(AX .RQP8;20TDA,ZY<9F00
M]?3!?,6'K*CA)L:.%;ZUXRQY[YVO\(%B>_PRO:[0Z]]+H'Z.S>+#"<:VI'.P
MW9<U&[J4$O;.\CTGPPV3K6+0US%@HNU+.S<>*"<M(=Q+%+6%*3(&*6U]AA"2
M+ =' ?%G BGC9EOB9T":N6IK(S2,]N-^$F]R$G=-'.(88*4V55A^,MC-LN?B
MAWQ#W/N@#HY(!"T-8EWVD[U%C_]B'>)V+OPD?!XOG/G_>YSK>,G[Z;Y9#C9U
MB=GM36WKZ6!&K@,Q.=&E=!1,VWD<S^8FQC1W///=!R?XB2V17 6I&I>0Y4$*
M@O\"3Z.KD Q+N+55W!\=4U(#F9^UFI+,%B(-N20[\0@'!D@&1(=2?R3T&,$K
M*2U5DDW]UZ[15N&Z"BO>EOV"S?(=GBCR;.=[C*)1#PLQ,5Q),@/K)CZ?E4'3
M&D<&BY(1(?FWE&<B0=8I_S;>I;!H*UTXVK[HA83@4>S1,06DR#V>[^JT9RQ3
M\P?7+M"ZLG"EJ.BG[SK1/BGMX7'H\J,S:N_,4XU2RH[P>[V6'#2-*;L^TZN^
MPXN#8/)4T,!9A%"8*!FVP29/:9,M#R!)Y</K1$/X](NX)-;4LL03OSVMH!XL
M24T!OJ7%<L$*-'DO*C[&I6M+X('O'9)\0Z FF;9KPMZPNZL0<&/*<2!+O(@W
MVS*6ON!$R**K-O8)?9\;I.(JIP_BJR/=R1>*/S@+Z2F*Z')OF&<:C0 ]([\K
M;E"D9U86#;UAJ,/FE- .T5/H3N@*<3E2FT8!%-19Z/:J\(-;/IS]:[<\D3%=
M@4\$0[$F:%G/M;FXUONPW0HA"U/]UWL!DU@JQN\9SMRG@+-+ T[_W<R0+^]F
MJ 6$T[)>0?J7*@4+B4B%+V5J\YBU!PY$@Q/3+2I[AGNL!O/NGJ*8R;1KHG\W
M[ZME#%T%"(,_86DM$@8$JSH./M,=I/.;3^@4;:<'V8H.-\M-FXO&R!L:(ODI
MDUOT4AV-K[E$166%1!3GPM":%J=]FVAQ1ONI6:I-6@OZS59SSZBA[:FA) YM
M1C2OS>D\.TOYMSZP0>5WZ#6_?]&61@$[4!6!$@)D9+F_3)8-<H+#.E&>,<A-
MP-TUF.].O=.3^SQ3@_S_L_?ES6TC69Y?!5%3/6M'0"R1$G78.Q-!2[)+W65+
M;;G*L_O/1A),DBB# !N'9/6GWW?E 1#484L6J>+NUK9%$HD\7K[[_9YW!E*5
M>*.7B;@$2T..#1;(HC#-J98*2DKI$.-77.LC4(QPI'!21;G45=?N^B&.?>T7
MPQ!<![NZO@!U3=%818O'A?<\1,_%E_JT$%)Z)Z:S5!/D$H%Q-<=C+W(52GZ5
M!7XR&K2X+6IUB;(+K#O8ON3C1CS+0X.RP(?&$P_L5N!7O-C;%:$0259&(7V\
M/%:**B@YU$QQRLT+KQ6U\+5<3AS/^,:<IMAJ<\P%&\T=\/V+[:9! V%##M!I
MG9AHY]R6ON0R;$KP$!..PH<6^F>HM0F,")^W&<G9')BXJY^\.#D*608TYQ\[
M*I 4?<3>C*YQK<#/@3@+5Y[26 H7DGIAHBK5.)M(H_;R\!2Q2<YYW.2<_4UR
MSDW[,Z#Z^@*.R)3(Q8CV%IBD1D^BU!5(]HNR#GU]HZ8H&1N2;K)X56T>!7,'
MYB 6$L-6C9#O3>Q!A/5"3&.J<U@R05O0Z!6)!5&BXAG7Z=4GLMZL_OZXK,9M
M8UN-H90UITE9L)XC-5T>?<V0>#0'N3BYBB!(%?MX0ILO@XB!.N)69J1E$/A%
M6US7U$A2/!AX&BA9\"]V$E#YKJEG67SW&D0T'W/K&32#TXC(FD00'T9ZX_P!
MV%BON++"%QC$79-)K"@%@2XL_H"]JWY6\D*'1Z^.P4_&:PR<9*AD8IW2Q#@L
MQ,G!+@["G(7=HYPFSLV"NSR-AS$7P>6LWYOT"#:NZ_Y^OX(9L_R5X2EH@+=L
M)!4+.Y".5:?49>PF'OW73W%_OS>,=O9VMP_4>+>_'PW581?^V^WN'>Z,#Y3Z
M?[W^3RTOFRF$9MLJL_FKW@\(-RQ)TBKU+.B^Z02_I[!-&&S#DG8UYD)XI)7_
M_(_NWO9B+.UIP)]N+B?-4GU/J*2[G=_^WN%/J[+TFX[QJ!,<70^QXE%RP1;3
MTE<<LZO;[<%JZHOX&!=?@O>VS_KZ@F%U^VS[D3F%:$WH;T!GAJMQ<!5A5^@&
MQL0\T.AT:'":T#> \*G*R^:E/^5Y&U8(;2]M=.DF('70GY(9>(Y+8-J(+(9"
MBQP<C/PZ$]1J;3UQ(Q[>ZSPRTPKAIVH)Q3J-\NLY,VWZ_4P57RC[EU"/-:4'
MTQ>X'/+=9%R:A#[?S R/O3)B%'3T4Q<8 0U9&@[Z27OD\:E2B_#!U3<%Y[]9
MF"Q>(JK6J?-/<A\=NUSV&$4UJLN1ZF:6ZO"Y2:YFDI< IJS1P-&3B5%C("E4
MO0HZ/0[X4!_LQ6%;0&I(?9^0".02EPBG[#=QX>VP[AQT4.$L4G+P%ES^1P7G
MG*2OTZFIJD'YJ,9Z4@E"F#E DI!^MYJ3HW?D@,<X843IB^;]L#+8SFJT-:0B
MXR(;EU?*D*4[':G.H=.CTZ&UB\& ;J^T8)A@ C"(*?I$ZP>36R/ZFK]X=B[5
M::^6,LOU5K;I>$SZBTMO+_4$=SRLA41#00I*QWQFRL1)#>7QU^PS]XAMW2'X
M*)?O3O3-EQKIS0,'P1T!X4I!%A,^-D@*_I6THYO1^#Z(1YUW7F@44_(0[5X*
MOZ)<VK/P!7'4X^4U$Q5)U0C<^FPF\<\L84:6:*E_Q>S V3!.K4/:=LNBYB]?
MY0]4>%!E+#SX![X]U9PAJJ715@(GR)7V5+IK075;)R@WT^XCQF9@=4/A%?RK
M^K!CL)J%8[-5(B7XIIYYRZ9DVY?!GE>SPI"SX>\6I:8^LRR?J%0 MCR>S\*"
MTPNVLC%!,F#5M=M;.T)Q78"&X4$7VHIAV2LQ=:)LDII>]+"]\RRU+N4$^P67
MR_9L8-^)B<L,>F]"G^[7&D@*+VM6\N6U1$&M2%2RA=A9R&= VZ?()Y@5(X\(
MO7D5(!D&MK1$RD06I6!J16J (0#KI*[)@O;-(&0Q\IR8QFVM:Z\!WP'E3(F\
MS6.AD9[(Y*] :W!]]T+;Y$%2;8#CCQ*Y3ZTB4TBSS(51.C(=^0#N=L592D5(
M-#,1F^*A);A92FTVB)*XAV34<>$^JR-W8CE2H,/\V[R(+R6?G)S:90R\D$(1
MM5'M?K!K.LY'6SB%:Z/CM &_=(+S7"#&=#I1$U[YPJ,A6>UF'"1[*9.0$XXG
M&94;V[GX[&[('FP:WX5+ZG<GAPM'CXC/C5&RYRR4@9 ,;2QH$7Z1-$>>*3A)
MESND$%4M_FM@ZFJ-G DVI<;E6S25EK!VW>\P2"2.52M^HKX#&O6&UF!4N#0:
M13<0[CZIA2/: @I*>$AVG.W$@?K;I(5_N1I ]UY%H^AO&,BMCP(/TW<N1!(N
M8O6%7LG]R'(DZL;@<5 [%#<+E*)CU/N,KBL\MIT?E*6*OA2,=TL54;[8%?]*
MDT;X-;1%R$9L-1$95&^Y1'[KD1,-EUI^2SUT!!'KU8TS8*R_7*>6.D<7-ZG'
MO5,CN!PJXD[E=C<2-2\DU0E3 CS%UB,0= $N.W^&P, H*=8H2FG17\1O38;K
M.RRRQ0M[7Q_+"NG"M)#?;2 5. %#.7#HQ"N^C::8#^FPE$W:W(NCD[.7H8!?
MFB\]D88:BD]2^,-SX#E$16%P1,-^<O1[9L?]A.,>VTR],2+WE4CSP>DG(G-^
M]M2[!Q>&3-THIQ<X#/[\#\R0LJ_& 3^Z9AZ#,5P8EF^941DSVPN+.!S.?$"-
MGHX(MZ'4-E/PC:E,/G919E0KP.;7&R2$)PNV'FR"K3==>XO>Z=F@3E\+G7;B
M>V],(MJB>!4[;E&=%5#:3V=@CZH1)\49Y=,/YLAE$I"F_U4LJ+6B'-.]U :_
MUM@FUK2M/^6<<VX-A<&^(:N';-UV(<=5OC?R(. OA'%8U/1^IQ?>A>MP?DH1
M5=(.SGK2ZM-*X(5%I.;:9CK=T9KPU"=*G6)X(-0E?9Q\*K(5\Y\ BPD&HL45
M0>B.@F@US=@"@>T885IPR7H]J_"% !2)PE6'6ZAGC9$/17['U;YPR.*)XD:S
M->-NDI,!F0:758+E+Y)<QQG]Z^Z?HLN)5^96PG-V$^(YDE7!A$>6SHQ A[T&
MZ:T*HSLV27)@KA"C88WN%X,0POG-,66HU0F/+1.^R,;.B7US-<1 ;&[L5MI=
MVX16^$Z=D@7R?-&Z:F)(6!9%SBMG M[QXN88)05![:+44YUPC0#YFC"8BYWO
M$/,. 020\P3='G=PLTG?#"U&<VUU_5&^IK4#%VT:X^>&AW,%^U=%)G.AOBWK
M3M(-5\BBTB0I^&2GT+<&Y";T4[67LCDW*)Z5L/?8*TMV"EVK;>\-RB++#3;2
MB9[X-NJ"(N@/_4VLN3;"4CIJ]P"S.XBM6R^20 &#]C[$L$!,0 *[,(>-!<(G
M+U H;1;)J&'GHDV"!WH1)_"2+7"2Y)O6KXP?@)W/1N2TN&!"JSTTQ38BSCOF
MX%B1A$9<*YHE;?Q,=C9C9GJ]JI";--=;D_<>>N3-*_<*I%INP'VO^!VS+0X6
M@_5/$H_OH9LQ(SFBORF-8J5X6D_$]!2T6KE([!--LH@=]V70ZW8/@L\J*:;!
M@/JFAL%%%<,EZG6WX9_87RDX A&NP!0>!(?][?ZV:P*:(+9HO9TI!HG**4(Y
MT'<.>:56H042^KVZQC;#AX'@G;&Q?&)-=&,AO\E5&A>)N@S^4'\"-3.M<\J3
M*.3R*L2HP9<3JC?]@V)',>D:["6F)HI4W8)\0M#8Y3$.8$0<?K8_&C'2%K_"
M=6J%:_1WE588@^URSX1=OL.U92IJJL'/8A=6;)%9-R)<AP+JGXD:--#%2%HG
MV(<)8)&<E?#BMWJ8\YO-BSE!D]I9F+YS\)H=5@/6VN-UF^NQ63:$BK])PP>A
M@%$\@MC.+K5$ Z2VEDN7T.]8:ELS*JF]2-'SS "$(A*LZ[Y G8&7Y*0]!"O<
MZ;8EGCW!EM_ )7<ZP6\@2Q/DE9(^_)QK/VKPJ )?%1(E46FDW0)4%JCCO(&V
M1K@^DVPML:4L9^6=LXA*VQ.!HG9A,"&/+9NH&&B^QBA ,M[RU $_,DS#9:-K
MFWZ>Y:$1X(BQD>B1WZ2RX1JUAI=7<;BD0C'T4\A-K0C^W&)[>>,L-DH(_7']
MZA:7 ,_W*T9(83"F8P/FPUG1MNVW2FV#@)&.J.K(NOGQAB_V$6"6_</S1W=V
M5T2CV>T$[S$QZ$*--0C 8ZMM+\J%E<P/+3VM^-M4L8T3^W&=V(?+G=CWN"_[
M]KZLAN?[D?:T=Z>;>XY>B-/3!R.9NYW![O;JJQ[]CNDYA#K;1S">T8A.R_]5
M&('#W=5"^([=#1>NV!8>+4L#3WF*F,-Y<.X0CL:F,YLK<5QB JZA:M.^I[*7
M7HCR.:SUAH1*OW\;.9/]#DR$4FM[S'T87!P/_MEL=>5J>HOKV3!+"I.B\>9D
M\,G E^+(WL>?Y7-*K9EK28!E&P^E,0<^/(C6Y=,T<VMMPY6A58V]$;J';!G"
M<T7P<Z^STZ51?M[N]+;K<W@.Q]U.VK]S\HB8*,_8"D8=:;!<1UK#=;8?Z*^N
MJ^A''67Y:'T]<UQ*3$NI7UA35$Q=U"BK\"NENR37P<&NWU<UIQUHXQ?<T].A
M>#>[5B*C,T&DH0?7;+IIP):4E6"AI08J!P.@-61ZJ32N4@.%;'NLE&T--'W8
MCUR+FX7S 1E40M9C03'6YFS;:?58JBR#<P)2> Z7<JD+SN1_<N'H\J+<&A5*
MJBC+0,&CK)>GUOM7F]I1CL@BZAJWQ&"T(W)<,QF;BEQ7BFH*51?B* +=WI;4
M:B+-_%+TT<IT%IL^8#."+=M6>;$%Q#,6L9\0:VP,5WPPH>B\-%;D/VD'C8*^
MB/2YJBM=KCN69K7*+B\WR[,>Y&6:FSQD?F;UN;@(_N#J:+.98?#;;T?/F&C.
M=4[&!@9PW^5JSE&:F\VP-:<>*6=403%32:)S"<::LCH"G7-MH$$F?JQ J'9[
MPZV><=Z>2.=6B[EC<#XL&DCIHT[6D\WM;XSQ@E4D8$T_8RH##1'OVX5*F*2P
M5A[O*L7F;B"L-=R ]KCO)\)10) _:C&MN8-;(P/(941@U4SE[Y&'75MDB='4
M+,=+;?-## QH23AR+<Y)5@HX'-';($TQ4>DC43Y%,3'7J;N]]8^'=Z^L"WHT
M'=33HD?#%-K1H\_2X$-V20EZ)L+=);6?>G6-@FZX>[@?]KI[GIU10_NPG59
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MYZ(8K/$04D(T]L""W[R/(]!,X-SINK[+,M!,G/VJ(FF%4&^N1$W !>M/6*M
MD5V"NI$A]![0&=6NJ>"+OL:(DV$:E/6EBG)KKK!!-\S8CYGK,>8:/== ;ZT'
MD(LG&-<^'6$B+7D\SUE8RV;!%'4_80%5?KOOBWI-X0<)D5#0?0)JI,+!4"U<
M\E:ICY-K[[P1E$=,=C)^5L83>N\)AQ3)%V82<=*QSE%\%Z]HTB<5HB_ ?M-T
M@H\TOV!0%)G4:X02:B!#'"CEC<YA]\+@G<XIB L?#8"0$R==K,O0C'8!8VEL
M9]D8*<-P1/!^@'\0YI^1-7YT$EDAQM2SV3"V"K@?9?;"N3:Q NB7Q(YI)F+\
M"G"<G+%,"= VHV7DW(74LTEY"#'H9_8N[:MO[.KUV-"0 S13OB]NN&J D#L=
MVH%S.D.Z!178#)3)$B6@!L9C3X+:##(O1=]Q6@'W\>[?\OS$S4E]ZTF1(9%A
M'E7,MO&XRJF60Z=3!H(J\ \4A;$VJ3.@\L^INI_<72GAEDD0%YVIG-*P.:P'
M/ZQ340*S=((I=17[7&MY(:BD7E,.^A(12)(OFYN05(XJ*P>I09*% ?5HY71I
MZS;!]Z&9%B,OQI]1)C,J*98?EXJB^+D&N827'5/5N1L>9G5(O FX=)4653Y'
M>Q!=MYAT:GT@;7EM\7.U#*T1#]H(,$@ORD>)#OF(_A KP^5FY=JR44TU=T?X
M5W!Z:A-X.097U*)U0"BIV!"P2 Z*6.AH&<'-P"5/GN=:+ V)W5 ]53/6@>.A
M8F.G8J: ("(6L0IT(#1]N23*S_,4*W9NWX5H[E9*V/!,'APCY/QE9C[J!.^
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M!QU?7PS<K=PJ[T?,;4;OW=D5TN5V9\?04SLE4W%NE0.9<=4':.A 9E(5A2E
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M8\?#8'\[#/[,J([! :S':=#;[AY2LA96_:CY/(L)A]+MB%GX\AUA()I48]E
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MRUTU*/-\G<@PED4MH4/U[*A!& /:.SRKF%F-#($Z\-7=;=]K@N*)T+&LU>M
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MNNVCWS%3.-2\5?6[)&JJ5.E+)CPG-XW'Q$U;AEBLZS$/PC"_B#:]53+C=I4
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M!+:<&]*$>.\\V$X#><V#.;XPDPU[0)>&I@BYW)^P5Q#"BODH@L0GVT]M'5A
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M-#K\*Z&RA)*.U5GZ(P&W5Q:$B#D84V_\+;$9M?,Q>"BX %BJ'\1PY-H7GD<
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M=%FDD]S1O]GW=H?.5B8UW<> OQ$@ : C@)Y"S_Q!?@>0,6MA#V7=8';.Q/,
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M:7+TX[GGR4J(E:RT1AY\V_/Q(7%JN?S19)T6H?R)?T< \[X-O]NN'=I K>*
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M3CQ85MXC9N7Y5A+PWHDSU$3'YEWD?!)*V7,O?8R5@7;^A  ^-VH9"@Q#DSC
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MPS/ _?"8%_GDLP= X2O ]LLV6D7"5$R6'0L#_ARL_-5F;TH,0<97ZE,DAUE
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MV32G5. ;%NB#MSEG^$UP'7HA[)+"J,B_(=_O.1@5I.\)@G4H",KPS>.D"AX
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M$=*7@%"?$3;L,<MB%GFSPX'M\A02<5>"\ >M6&#4RH"10[]?88&1+")YL@&
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MM+@ >""<5GXS+;Y,,KG:SZ_< !S<^*8*?Q)?3NUNV9V5:V\XM(. ;S6&*-[
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M3?C*G#%\UV<^'I)B+4->UC !0']"(M/-)-"H$0 8\2(?ML;I2NP^ZQ4R\EF
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M'9D4YUQW/M(#J.(>D_.;4>2/$(DP2"R(;%Y]?%X6L7Y?N!$NRJH%29=GPYS
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MWG,\:-W<FO6#7HWR!;U*G$!4AO2O6S>ICIXS_VLC$7J(]\OB5Q\P8OX0^>:
MBDJI(Q]ML7#,?6ALU#O"$W/I,V\9W02')FF5; )0??80P_G!H6X(?LY- NH,
MS=52L9[]8LTTZ1Z7CF:*=(_ST$S:%.K;/YEU_K_,][)H29L4=Y+^\/X#FVOZ
MP_9$[4I_N 3^\,0*2GL?BZRE;RNFI;];8H(K4K3GH;/U1;NQ7+0G)'BX8YOR
M,,$2'[M>9A^[8.-+.L;;.L9?Q>WXW/>B3LTO%K*]4QKL+DOS\0 ,5D#ZB-L
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MM4-@#N!3F\L8APEF1**W(A.^LR+.P+JJUVOD-!#Q1A$DIN>/O F]PP(:A*)
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M)K92C/H@\5%N?"9:X.$X[_B31!/!V>$]:K<(<X)J\[^IM9L?Z/02JJRS J'
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M U],QA)K.V_,DGV*7QEH]-K= )9B)K,CUP)/&1T=-X[VS7P#YFUTD\R;>CB
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MQ<7+&?>SS^%Z]]4/-@Q1AY%ZMT[HQJT!GZ#I,6LR0,-@),]CJQ)0W">HL-D
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M>WGW[4I[[/WW^V9@\+5DK+!VMOKPGO&89X=%$'H 31*SEYVA95OT_D?4:#/
M5=N+^3Q\8UI@_HBMY0#L@$'(A^F !@,J/'X->"&2(@6,22?GX2?T0(PL !:J
M6S)Q4N2^^:2[A,(W8TZG]IM,U?M>Z5>T,1N1>F'%*X%'4LB[9OQ48 %"-/FA
M'2E4T>2A0QPD5&]4NJWLKW8X_:=1:37;NWK4N^RON<E'=;8V*&G)RXSFG@Y4
MDKD"?V3D"FQILM+<RUI["L<EQRP=ZMXS1R;-*.:M=QM?^0[#K/9OH<?0 >12
MZDC"P20+&H67B=2B 7/8V I2TXU.O=3F@O;#Z@E@"!!8/_R6:S(EC8'H8Y%(
M^@L_LEYPS;5<]$>'@>N])0R*HBE;39P7KU?;C<RLK8^[;.=WF"B4BT&.F)T^
M!XD:J?+:)8S*A0@C< (Q5"(%-3ZM9"#$#AKR[>:8?CIQQBURQNI>L$;L=:JW
M:]EU8"?6N'/66-T);VR=>..:=LYJK1]/][___<=@+@'%>U0G]<%CF)T,I/P1
M8^RQ$YGYPA=,!?V>._GX:6O:P>G^XO<?PXPPRCY"9-0UAU%00@8[A"F_$D:>
MAD^L9,@OI:32B?6<T5<7MAQ=PV:2I<?6#S8Z_S?SW"P-M'W&"V5KGTLR@.*(
M$6-;]OG*>*(JI9U2(4H9U-(3"RR5R;X<EB]AE&-^G5ZM-?3N6D;YB1^6UBC/
M1Y4TXVM5SR[:E>[:TVH/A>L=@\%VSX!A.%05&K!)_HBHDZ-VUR&L6Q=3*="F
M'MALQ7XH+>QU6]6;)Q=L&;G]VLP^&T4R&#WU]&V68BQY&1C]B=%MU,)/:;<;
MXF]SS?M6?6-6VXG!E5:=70E)5,[7*!66E('Y'8?#UQW^>;YX@M/)R;%C/V\6
M?6?WN5^EI58+DQ!JAEY;/^!\<GFL;2(MIP7G&$E+^3YR!NI@"QBX022Z@ 4\
MI*;&&=("AZE6FNG9(._K&BN#E-AU\/P4?%]\8@]YO52&'AM9P<FY\Y[.G:7$
M'7QPR<]&GEUAD8;-]QN&WCFY=,IH\6Q.F&6A2H;$HE8\K9-GY\3EWB=P^5YL
M#D=(U!JZ<6)S961SLXZ=K?.Y=I4ZPYSRAH_(B4.3#$\>FY)Y;.A4>B/LT4 ]
MJ(IR]K8!E%ROZJV33Z8$,G_K:FP:73*8.X4G.]V3V^7$X<J5>+<VLZOG34([
M)=N53HG=!'-;/C+9WEQD\E"8WS'X;"^?3><)FX-K+Z8M&J>9V!S+5*:QGEP9
M)5%V^6G=.%_8F.%P6KB@Y_LL\'^3A]>39U=8-#2I=T2CD9F==\I@.3A-N! N
M9<@+FAY<Z>S:'U8&07%BC27(W]LF;VPC;^RVZYFJ\XDWEH0W;M +O"YS[ #"
M5+/B8,?''$\M)0[W_F.PD!YQ.L$NQ?WBCHA[Q-2W82,E&T<5R-EO=S>=C;W<
M6;V#O#\.I-E<(=.E*UN'WT6=PXNXSSK5/4&E,J@$)P9:,DMJ90[:,?8$[4]8
ML_58Q-HLM+8GN%0&%DJ:]\\T6D(=0:0.55ECCLHJ,U%2IC)V?;#, 9C4@<7\
MG'$HG?I>C$/!N68T"X4PGZ9B!6PR=3T<JR@FG#@X-H[FGC[A3%+/\FE,"GHA
MK#%@D1-H< .?22+FD(P$S.C9)D&-DN?M&&Z:B8-1<4PI'V/+;/<51YHD1W<6
MG&.2=_0',?^DU:HTVLW]GP_R3HN:/TGE'09DI"_+$*G90R* L[__A @:O[J)
MZ1C[NO',T1C;]@'Q'4?SU]Y1 -"VOV1PZ@\*F_XXPX%WT4LT5]U1-9Y=-?HL
MMKAWRB>.D"HA]2QG!$3WJ58E'_4NL.T6NX)R)=IYX@/.AJ;GO8$R_6IZ(W\-
M7)OC"EX[!RL?Q+L XM_625A:; SL;F-%7 "M^1Z E-)^)['N*R#=I8IS18.F
MG<;915-O=[N;")JNE5*&)[698,F)0@Z/0MJ[HY#FV45#-XQF9O7L#BCDO56Y
MDDG=I>O7MZ/A;2V+8S_HL*BDB@KU$C2X:H%GIW5VT3(V(JO62MPH**M.>+5Q
M_KYAO,+4L79[$RU_-H%7V[*K9CEX>5"%6F]IA]!Z:S_(;04V+C\344BU65+/
M&8F@I+^Y-ER=#O#Z1ON [)(3\JW,Z]\=^;H@$!K=S([W!Z3REU@@L&%%,]J-
M_<O@WP\:S!$  V8&:0*<I3YS:@6PV7^SD52X@ B_Q*884EQA.[M;I:K76FFT
ML!.V;9OC[Q+;#!IJ4J_I[7)@VY''4I)M6S8:,#FI72L&&?!("F09=C>7&792
MV$N%.86=[VG,68(CUX$CMVN9S=L.2.7>$WY,]319F6\G]WJ9>/2OGNL7UWT:
M9Q==O=JMG33M@T.@HJQZ-01JGEVT]&JC73+E^1"J5[>3'K:3Q1VY"(V*T+5>
MJE7/27@N"<1"C=N*2L_U>TYT6_-$Z3NU$3A)T8UC4E$QN@%,:L^3J>^+20<D
M3DMW_Y$+1<R9CK+T@7RT7DFL2J':B,JGM':SE.JS+[QPFT)5J2:$PR[B/^QL
MJ;)T_3,MNRP^(>^&Y/CJR+NM)B4[0-XM5BV7L6KX@6%TD5MJ[CBSVM?RX>,I
M(^FIA5.X<!P&H<<T9GH.P-G7-6NLF<Z;3@7#@37!BB!,4#8G<+0!/O?UV<*D
M9;@I!/70"TS+J6B]X1".$2ZVQ:T.R,>L%3R;+TP;,(9OMNTW>. 8/M<&;YJ9
MU1.VHF$M=,87FN4,/49Y=GCO=.JY/X \ @;/_-O*;7^JLX25UH=G24WV;NL1
M@ IJR\UJ=5X?5'P807,*&.&.-#RXD5J(K6M8&5IYGW+L7>!T+U%ZSAF0W#9'
M-,R0 H0%Q!II8P:<Q+0)8?T D('0<*:T[0.RMUKU\^W=5_K-^/PQ6>Z&;UP'
MH:J=N2BUL8J.9M4XNZ@9.ACOV=B#8"BX].Y[+;UV=F%T]'JWD>EPT#6/^5/>
M]<-^XTQ 'BZ<V\QYP29\RR?F5&R[R<8CV]PN=<)O5)OP+^.@GIB#;P+:G@*=
M>]C'H58U.H+5OEJV#2SSR7+P"_9C:GG40KM6K3=U[=E]92#^=.+(U# !+A)<
M%5MY4/,'\P=]8U$#E17PPD@V1ZMO$5(-0 ST1!F9";,*J,QQ #QPAAD:;=X3
M@V"F8HF&)N/8@DTB00_"0()5\\/!OP#3$&P= -<,K&P0@0&7/70$*"5)GKV!
MR/2S%U$SL&4&,) 7:\3E$V=4GNN8+Y87^EK/&NG: [,M-M;I.*X X.[$&FI]
M-@P]*WB+V-1E[^&J'S&J'BSTP_U7S3!:YT:]]?& 6?^C7*+Z\ES_Q'NM*B%Q
M_(@I/?R'.9E^_B)JMQ;(DZR-O=?ZBQ)^;3[A9Y:OK*@*83#.R,Z3+R4J+&3/
M#4/11 IA2-%3JL\W#S=Y2BU06.N=;#G& 3)R-<<-!"0.F4$!+P@#2[6Y0#?A
M+9500F2>="R<A>4U(V\FYMN,4(*-F8X3 I-19!&P'A-UI- FM<=]!:GH/UM3
M;4CFB.@,1<:6.P2)XI%NP5XL-_31ZO+H1?05XBK*)[Z>BO8=!*6'<HCWCJIW
M:K2C>J<N^TC=8(\8![D>:!Y.B!QQQ"*!=?-P&8DK$S#5P[Y5M&A:4XB/?W*Q
MU9236G?&]N-- YDXF@4VY(R3%; 0Z<%RN*660!9Q8,T&G.C4]2V\X)/';!,U
MR[CQTT])'[/P553C6\R![]IAD']+JH?.CI#R^MQHS\!'^?D<Q4*FYA,['X %
M_><YZ3"?3/O5?//1;:+L"LS_<Q6$L[O/)]BHN9MZ--+)U#2 1Y63J+G;[ TQ
MC],V(Y0#VCD7*!K1N(O9@=RW$02>!3HE+(,^?,5F;.:+:=DS"GDVS</#?G;Y
MDV2/'[!Y>AGD0?X;T&)1_44., PG(<=E>060:!.5?B!PE\LAI-CX01*C2>8(
M]PW V!W^^>S:0)GP M _T>FC>:YMD[;[[#%VCOJN\$-P>TQ5@Y#?8[FCS4@S
MYS+%AN>&(P+E"#[W )F8<"]E,*Q7*W@6JYTPD]1L6"$P$\F*$IPHP=DJVLTX
MDYO@TN1%"6\!>3C;GP&$RG'[_*CI?,5Q9+)PP:. ^\*I#P-\-!=\0S>T1_#Y
M7R&J *IS AX_A;NDMNAZ0BD0" "O @@ @,$@0(</[.65GD6OH<>-$')^"&]1
M&>(K@Q<A\ %RO%G@ <O;J \H=XM%-EALE^588SI>#/!'[$8K.0(I',LPJLH@
MO&2\5L/'D^%2DX06WD5>!C@_/ IG:*$+%8X2'N&IC1SP 9Z%Y1R<XTFIR-6_
MJU@RXDYXRT62B E,-]J-BO;[LV4S9>7/%I"IAUYNFWN[B+"GL;MW% X#3J^P
MH'@GF8_GU!!!B@QGC&)>AJ(GY#_<@4_6)AS;R$3.%D%*:"#<*>P%BOHC-AF_
MN^!!5;2K%/P!LP'RCE@Z<HGH-0H,!>?XWM<F@*-(-V)M\ 3W!5YA:DV5A2$U
MR5=P"SRU]F@%+L $CGOA"XQFDDEF+!/Q:."Y)IX(\MVA.V6<WO\"!<\:6VRD
MH%-\GX)[Z>,$,^,#5VGP\%U:9_20F(M]K&C7PIW,CR/'FTS0F/VTEG2VPA:1
MQ2.O1TPP[3<?1!,O>T?<B$3?4VB-R%W/FYP(*2"HRI)^&JXBD* <D,PRN:M6
M"BL-]4R!-'QW@H"7P$EDZ;-GFQ1@J35,7#"V"%06ADS\D',<(;R55BV^3IXD
MV,<(%5IA]:#B*M^X:('$/KB\L (I)H:F_RQD@N.^HK00Z.T@>O%E%/0A7,(:
M!IZ5QX"-I1CP <L6ZKA+I0)QH"MT/#9TGQRB<:2C@2C/GFF(FXQ*H(ZVABV_
M($OAN[(FX->R8+RP%=\^NZAU6IECJ*4V0RR%D<6:CJLDO1D^:6 *M%;>\<WM
M]9);?@0.\CLJ23= Q<,@4@Y$>_ $1  KA@B55Q?T-^;$8.B<73AN"@(.DY9N
M/@IP_<RDM]*E+-).\#IT41\XN0CV^;^13=O6\ T1']T5PR$1T)C8%G!L4),)
M<8#UFC:7@KZB^$JF# 9/U*@ZA[)FPWTKAWF7Q[(;L8,[)VH^SWRAI"R'8MU,
M%(M!P\F,=-%<;*MLQV-<6\[-N4MW];L<L3C8>XF@1<[7J)Y=W&:<+Q<CA-$Q
MXB]SUMRF4[X4LI_"23["@%-6;#B"J<"DT]4$+69H39%%(Y6HW>"%32SM[%=F
M Z\"52=X%G1GX0*I9SSHD:.C86#:&.RL!$?R&&A83FQ45/J52 3^*_0L?V0-
M(W7NQ?30J2KDHOHU:(=DKL 5;PA2O(+[B,:J$<^5T=A*&GON!%?#IL)IZKGA
MTS/G@!Z;H+\&K 81; #8.%R3'''=%1=,[@HR2DB+"5$K3R="2"<QV20,/\7[
MT *1(5-IO4U##S1QYA\F/E NWHVC]<(GM.QB8X?._<89VQS #]S QC*8(>F'
M>"5W]B,R_?WFOD]_]8<6#F=(7$4TC<1(](Q>;?.5SAW]A#CA <[;#D=,1[Z!
MGB]R+48D#Y@4>]+A#IO\[Z1LP/E;DW!"YP1O,YH_H3D+F#&D@1#XJ2-L)CA&
MX $^*3?QP\CWIT=H/+1);>6^#(=Y3V_)93CD_0#;!U[N"U8$O]$$>#)IV<0"
MMHR@HB"#$XYA@^12E!N.GT>X%UM-G#.2:\_4<!6>!11GD7XGMS'KP.,Q$*(I
M-YH#@R;3& C#&>(#I!59*1 W*(S0* ZL9KLV&-9;C6K''#>:[>' [!KPKV&T
MNO5QQS3_Q\!1G?%=[]Y3GWC?[=WCE=;5SK6"LU?"@0^F*ISSU0O:OJGI*DW,
M$I%V]*@7B,_P2<F9*_WOO_2O_NO[U>VC=O4;_.RGTC)GP3MW?$Q&A(&_-G&B
M(I/T'(L,/M5;R<Q@<<:)/E+G1F=GU07&EC2^9=[^.0$IHUII(AAX5! ID!C:
MU5\ANLWO;=,1^9XTV0G)T,?F9;[B R(FX?LA]P-Y:NJF(.JQY0'G'6%$<JPQ
M$XS/L84V*TE$Q6U(XE2LH:Y>HY/3R)'&.T-OFI2&(-Q]OK)<99(O.668=G(4
M2FKWD]VCK>=YJ&4A-_SE+;[DWGS#CWHH5F\)4G?C'D 9;S%MNL[G&:8 , (U
ML$H$;E'#WJAA/FFG6LW.GN(;U0%T+Y14BHQ<*SKY.!<N$:=8%33W?$7F$[L;
MWX4!*$P.8B(UU?QF_D!!ES'*JVG4SR[2LX]_^BC-2>[826$H)EV@Y\\V21DB
MJ3@!\<M%HKQ9:HENO!Z)MG!CA+7XMS69L)'%G3Y3T. 979Q 4W( 2I1,K4AQ
MD(JD,7.$ MX/0+"Y7D6[<[1_@$C%,5#<*&[H1;':,!K;.KY<S Z#9]=#8Z8P
M.F,VH%XW6GJC6<M'9_2@OL"M#KE0UT+N+8)G5>QNYF-W$F$5#"6%$_@X5ZD0
MD^:SY3"7O6]>Z=\K25PKG20&'O"-0CL=R0&2?C$,[ 0B3"G2AYX\1IC)!>@E
MO ?#B%K4@?[.>S(=&9+X</EP]Y%"$3S($V<),._%&B;=&*#+4Z(.)C>$4QW-
M!_[L@'1W (#)B8(XGPBLD'^!9QDX<,Q@&/T0C@AR DX1$X$/1N[ :/W)K5+<
M!N,EL.#UTN>:":=[<Y;B<=0D/@B4BKL!8"G!:3E6UHK)N'5V 2>84U0%N&-+
MWPZ/WTIH T@B=BJ+:]3#%E:E&1]KG[(N>LE#YRK67"7(0J_Y7-#,ZD#9?0RE
M&) +HO7TX>G^<AZU]MD%LO TNY\".\*]XDI]'KSW/)+,W.TA <#33A"4/)*!
M^$'(@G8D@$R"SY^"K<BC:SQ^R@-R4\ZS,\\BCA,-70[/Q)LYUG-C7H3BZ>UT
ML>4G[%P%8XOB:VL^OF8?2Y97<QF\[2#>MN?C[59-ZQW==XRI@YW\U,&?!^[H
M#?[W'$SLB_\/4$L#!!0    ( #.!=%B)K@M"<PT  /*(   1    8F5A="TR
M,#(S,3(S,2YX<V3M76MSXC@6_=Z_0LM6[<Y6K<,C2>>QG9YR$Y*AA@ +3O?,
M?ID2M@!5&YN1Y"3,KU])ML'@AVQ"%N\X4U,S8.N>*]US=77U0/GTX\O"!D^(
M4.PZ-[7F2:,&D&.Z%G9F-[5'XTZ[K/WX^<.'3W_1M%^^C'K@UC6]!7(8:!,$
M&;+ ,V9SP.8(?'/)=_P$P="&;.J2A:9]EF)M=[DB>#9GH-5HG87%PK?D&K8F
MTPLX.=-:372EG5U"4[N\:C:UQF1J-EJML\9%X^,_9]=6\_SBRII>:2W4_*B=
M-<\:&KR$#>UB\G$"K8O3J66V).@+O:;F'"T@X$USZ/4+O:G-&5M>U^O/S\\G
MSZ<G+IG56XU&L_[+0V\LB]:"LC9VOF^5?ID0.RQ_6A>O)Y"BL/B$FV"K^!Q!
MPOC3Q8GI+KA,Z[3)_PV+"S"< 8\=RJ!CKN$M1C2V6B+:3!;B[^OBO5#4T!I-
M;L&8J%JRI35.M>U*6IM616MX7O=?U@!DC.")Q] =)_H63:%G<Q'/^=V#-IYB
M9'$OLI'PDZT"D=<,DAEB?;A = E-E,>*GS\ (-C%BZ5+&'!BLE-()[*NE# I
M5@.^)_1<$S+IX*(D#9L5*U]'-J/BFR:^G;Q0JU;/K]6CV@S"92'-41E?>_"D
M2 TB;MV\NKJJOP@_3:Y!HM_)\IKXJ#5;W!4*J$USX/RZ^3<ME#M$'39]M%@=
M0KE7UB&Q3Z;Y@DI2?J>OK<:Z@Q>N1B!9J!K) 2,G%Z& (.&\B$**S).9^U2W
M$,[3_W:+BP\)/0XZCLNDO'@2/%LNL3-U_0?\D?";Z]!Y1F@:AM'84)+00^7_
MKB$QB6LKNG-]2=PE(@PC&AV&),"<H.E-30Q&6A@L?UL2=,)K$A:)*=CN >(U
MUX HC]BRO;U-@T((X00W-<IYL)%OHC*WWT+3HNWG(MC!?XK6VW!2M/5<!-G_
M]PTWH5VTX5S$].Q]O%Z(&_P]P-9-K>WR+'H(9[QZXOGCJ)N1TTC%&XD0-@3>
M>.+GAORG";1-YJT!*0F$Z*?ZKL .E$>1-7 ^R\^['3P0#HID".Z8*+?<=H]*
M% L>AJ;,,+#N69AU'3&UD#7);>>8H-+<K6US2P 00:B0U;] 6V1FXSE"C.8V
M^;:4TMZGW,AC;B$4&#P0![Y\5:T]A(2W9(X8YG7;S_3;$$H>SC)Y #]LP?VC
M0KRLC4+=Z8"/1[(Z^;M#BKB2C_,=/C8XP)V"#5(5F7"G[3ET9HAB9\Q<\_O<
MM2U$:.=W#[-5<6:RX91,?4QC2A 5( /L@"CVWX&/7D7V>$=H0SJ_L]WG_;K1
M1EK)S45F+Q) 0")5B(?!Z%[O=_^C&]U!7^_?#H:=D?P\SLU%.H*2CTN176%J
MVB[U".)?HEB @X$-6H4XN1]T^_?M0;_=&4F+&C]U1H_BFZ%W^T:WDY\;-9*2
MHZM=CB0F"$!]D@0LV,*M$%OCQX<'??3KX&[<O>]W[[IMO6_H[?;@D1NB?S\<
M]+KM(I3EA%/QUFSL\A8 @\$=B$"##38(P:M$GC%H__S3H'?;&8T[_W[L&K_F
M)RHNJB2E&2,E O*WOUZVFA?_ CY8U4CXHH\[M^W!P[#3'\N(7XR(N+B2C%8B
M&9I$ E&H"E$QZO1THW,[U$?&K\9(YP9H%\L&4@&4=)SNTA%  8D%HF 5(H3[
MX4/7>.CTC?P<1&649C_;-7M$ND)V[O9YNSN&_DMN*V\DE#8^W[6Q+PNX<(5,
M/'[\(@9*[EB=KX7\.2:H-/C'>/(30@ ?HU)VSY-1#ET;FQ@5F(,7@\W@[.KJ
M_.SL(IX;Y4Y8P0^AFDHM1>8BP( 3^^"L!J!*3N,I5@%.?2658C0VI2C*7AJ
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MD+.6*8JC12(#A8P3&#*7]E:A55[FU#JG>P#*$[4,?%=,VLSP[?+Z!7W'GZ[
M3 =*&RX\4U X)S+ZP$E.4].<Y\ZP(HL+K1.Z>R V;=4_R:1=&-6:;SX=CH?3
M6;W_9[RZ_X I+%93AY/"U84E.8/748/&B*6H[(-IS?%'(.U2T-R,$W?IWM(7
M#9<H3$D;I;J8[ U^QM%D7EW["LDK+;RW@$D%4#II"$HA&!0E:<N\*:W7:?TE
MH%U*ZMJ2HYT?VD?$&^&>"U$$!7B(RM1L)2)$1EF&<#'6I=/"9>PK)K:3L/==
M5Z0KQ03J>PD-];UDP6DR<#9.4/^STH;6"\\>B?6/1KY^1_E-G7^ODKN1R1MK
MO7[$J_2&@&,$4S3%;Z8C!*DT)",#(J>L-K>>^-M:\M(F>J!'YY5/@"3D07$2
M=@&Y@Y*=*5Y:GV7S69+'HL?S*HQ=X>.#W75-[S7KL-2VR6TLUV.B]2KE:#)8
M;2D:99' 1^E EY*X*2P+WWHY[8-@=DF7["JEVGAR"\0RUFOIL0!&7BNI7I .
M5PZBYPI%L-G[UEI@16*M.5O]<%.=C,$78<#R1)DV#P6\R0DXIT&X\,2IO7U,
M6V_4D;96,FO"D*53VFT\TE 5+?KW+2@W,=;5%M0J;93TP$B<40XB* ?QI-Q8
M"L@T=7QE6G>+57#M4NCMAS'-O;.]Z9^Z/^WGT>3+QK,_WV[4?/+G 8SMYG[J
M SYTD\]#NMOKR]^GF(_'7_7589H-/R]F\% Y834Q(ZO :Y)/]$C&@Y-,9)\L
MTZZYH%D978/$J\,PQ3>X^'T\OMJ7]N9J-?;2_6F#$G.P4BI(6&*5!@9\(5IS
M)M$IE\ABJ7U.M0;2G4K>>R+=DOI]WSYM)_=NSUH49YQ*"#32(BBK,T7+K$$Y
M3+9(88UL+O$>GH-]YD%K.V19WP'MEBJ=A Y?$U'ST>2T,G-NGD',+#DM$]3=
M78NATVM;UQ1RPSS74N?6$_++D>S2NI4ML:*!2UK6!N^$LU5V3@PLERGR8H&%
MHD 9(<%GHK+1S$1=I(ZY]8:6]9#NTIZN9QNAFKNTW0Y0LL>=\QP^DNKOAFF&
M^>J\A]MOW+CR W;#2;[?W#0ZS_.B>SH)XT_XD63OVU(PS0:%L@[+. >M4CTL
MAW[,]T>+(GB6(8O$6D_M;;>%#13#,HK^/!R'<;I-T9)LTJQH0,U(T? <(* H
MH%1(SA94K+1>MK0ZNETJJ>PPQY?HE3[<WU+0KAI!3;&.HV4@M!$407,D?#;6
M=0:&TT#+2O/35M9-+)]7"G__]-S4_7W3\WC\F>QW&Q\7RL6(--!ZE/5H#@9D
M%SNWA;:2LY!;+Q9?'=TN:?+OGYZ;NO\YZ&F=S]Q0./=U.;U*G+J/(/TIG,LL
M1Y:2[:%6L!8]GVX'DL'S,NAOD\-$7.GPP0V7 V>5<]4[)BBR@Y(%7-0.-"5E
MY">AK#*-[; ZNN^A_+8IN>[MC>W'=WWWL64*2B 6HVP"XQ+E^RPS<,H@Z,0I
M^W*!2='Z\,!U!?0:?:R;),0\GXZ?;P!Z?S:?AG][@5T:TE,'"F,2F7R?7#UQ
MR"D/'GT!3IEFHN&9L=*ZROTHJ%U*&WIBTI+-Y@T=U?+X@:^P_AVZ+M1UH0M$
MTP'SD5F1Z^A9>W;@ H*F5,2PK(K./ML>C@MZ&,\NJ?EG8,U&[NF%,,?3Z7D]
M[?9]N7'DU<"[[#*7$A*GIBKK2CTYH4!)M10?HO+-CRMX%-0N*>UGH,[FCNIW
M6O_XEZ/W_WK[V^$?B^Q@^/G; K*:,WS$-"'3C(;S)[VII^R-UIKU7^LY318%
M;-["1FL&EC]_V4J^@2T,4V*4VZ>Z9\10: E.*<BY2!.YL2FTGGQ8'=VF<6P5
M/QS-L];C\?64,UVTF&:N![LMPL=H-/E2>]8@>64D*Q&,8#6A960L8R28&*T-
M5N646F]>:-R$71)E/;'T;HQ\3A(T&Y%7:<3A[&?,=8-879QT3O>[O'7QH*B,
MB=,8DPLEB"I)!J%X =J)G(H02:O6.5(#V+LD"'>(L2V=O566TIM'U,.&\]+C
M?,?:@%/2(S))'B?J,5P$&Z(,'))-L2@O2.3&9R#F?:1/5)C]%HEVB(P;^G2K
M_/ME4@76.5T61U]7UQ9AHRNDDM%Z4LD4PR':DL!3ZB5C9KR(UCNUU\6Z2XLP
M=HB"&[MUJR2<+Q\^'.=W=+?1C7TT \KF?<I*0.:1$$?D$#@WP(LN/G"+J%IO
M =P$[RIDU'\_,C9Q[U8)N5A>F__G?+HX&FX@4&(,QH(MP=0#LATX:R4XP[4F
M\SC6_!#:=7"N0D#S]R/@1N[<;B1<NG[S[47"Z90^<'6BRP?LTOST7FM).SC2
MLKDNE$&E(:9"N9=W/')J&R5?SQ$>G]*(52AK_WZ4[8\(O9_S9)CBJG '4C('
MJJYX<*EBTZ8X#";9YIL!5CKG:8,6KB"NM,[1Q.2!QYIA*F<@EHS I>*(/*B@
M6V=M3X"W2X6N%KQY\.BKQIYJWUEN WS %H^6,S 97^KDEW*VGNL6((IHYR=Z
M&9YRL3WL'6W8@%VJ8FV1CEOP=M^$O2>E,&E+AN) .AY)2A4%OBZ*"5X)HV)1
M"OUVJ+B.&-[6!.@62;:1A_JFSU-F%NKWR*E:I V:N*_J:?>.1 X$U)D5$CF6
MM5['NCGJ7:I';9%T??FU;SX^6)IPVG'/2!_8I!CI>X;@G8O .1E'U*]:,#UL
ME'X*Q%TJ-FV1:4T\UC>MELP 4$)(F6)!2#G&NFM 00P4CTU2JA@K;?LUB2N#
M>V+9J-^)G"UR:4,W]<VB9=G+\KK T:0>]AR\0>V)]E;7HI:DO$9:"=(G9XK,
M4;(>-LYN#GR7*D#/G)LV\NZ65J[=&^Q;+%-[\*9MUZ2MAKW1 K1[#_MG5P]M
MT+Y(EVT]H%AFBC4T6,4<,UB&WGL1O8NM=X L1[)I_+IW5_KCSIDE-_E,H_=5
MOYK^!>%3MDI%YP %NAJ)22%:)LA8W H3I92I=3CKHQV[5'EKP,.[P>W97=]L
M$+[7DGDB/5#))%*6"#;4KU!@OLZ7TTO.G4=TAGZTKF\L1[)+-;-M$.GIYN^/
M"E^%XE'HNLLRZ;Z$+G\3C8%GS^NN!,E)&*C((CB!"4I@F@;GK!)K7?M_(L1=
MJH5M*0JU<EB/ >9Z<WD]PND6T(%R+B$:"3[Y0 "U@^@HHPV.M*8*7+4_4.L)
M\':IR+654-3&41LSJ<KF^^CN#K?A;#@+H^'_85[^)0AUB)T.;*" ZA6"T*J>
MR<,]);JHY]^%S:QT6MS=?GQ?M#?$LTO5K(:4>BZ/]1>T;ISK-/_.X""TQ1"@
MGBH-"DN D!6'D *A=$$7T;JL]0BDYBU>>!^+9:X(!H7Q^AV0JAZJK3P$'3#[
M%&A Z5T'+DG6=BRAV( =CT;AI_NAOUZP9%HC!F&UC13Z?0T/5E-XJ/6:7(1Q
M]7_8_*N?&LU';>VKSK9*EPU=M&(-[>K]^B-2+OO3#_\/4$L#!!0    ( #.!
M=%B8\E41)$4  '#_ @ 5    8F5A="TR,#(S,3(S,5]D968N>&UL[;UI=YLY
MDB;ZO7]%WIJO$Y78ESI=/4<IVSFZ[;0\MK.J:[[P8 G8O$61;I)RVO7K;X"B
M;"VDQ 4O2='NQ2F1%/$@XGF!"""6?_]?GR\&/WW"\:0_&O[U3_S/[$\_X3"-
M<G_X_J]_^OW="W!_^E__\6__]N__#\!__?+FY4_/1NGR H?3GT['&*:8?_JC
M/_WPT_0#_O3WT?B?_4_AI]>#,"VC\07 ?\S^['3T\<NX__[#]"?!A+K^V/6[
MX[\$$8L-48'@Z$&YD,!YSH'%DI@0BEEF_N?[OV2NK<_%@T!N0''%(+C P$83
M0[:RY"1F7SKH#__YE_I/#!/\B:8WG,Q^_>N?/DRG'__R\\]__/''GS_'\>#/
MH_'[GP5C\N?K3_]I_O'/]S[_AYQ]FGOO?YZ]^_6CD_ZB#]+7\I__Z[>7;],'
MO C0'TZF89B^#4##Y^G7/[R)1O]\]29]=-+_RV3V]R]'*4QG"GIT"C\M_43]
M#:X_!O4EX (D__/G2?[3?_S;3S]=22Z,TW@TP#=8?IK_^/N;L_M(^\/IS[E_
M\?/\,S^'P8 0S[YA^N4C_O5/D_[%QP%>O_9AC&4I^NLI5U"ZPOD?]=M^WAK3
M!P(R3I<1@5[%8:5X0XR+OGU[S%^_"S*6<#F8-D1\_[N;XAU=A'Y+ =_[Z@9H
M9U\$%W@1<=P2ZJWOO8'S&N1=A/4K/V 83R.&BS^GT<7/,WRG(UJ*7X?W^#@V
M^L,*0$@NKI[A__'MCV\ ($WWA_VZ>+RD7^??4,?:$ I^GN(PX]6*<3W(8)1N
M?6A0UZO15P$/0L3![-5>QG[O^7#:GWXY&]9-(LR1X=D4+R8]QC476CO0W&10
M.GMPN3C(0<LDA2Q:B/LJFERK?(+IS^]'GWZF47ZNHJD_S&1TI:0'Q[X2VF8S
MNMX4;WSONQ 'V*-M2;+ $@13."AE-/VD.!29$_V?+L:PK>:S;.3;L_E&@I/Q
M];SFC\1:*WL9CRZ:ZW$Z:BS(*XT1_#_]-!IG')-90V_-GMB_I,%H@OFO?YJ.
M+_';BZ/AE'C]?(!U;'K<\'W]85-&7$[@?0@?>V^G9"#5+SH=A,GDO+R=CM(_
M3S[W23SH1!2:0Q".9F-<A&"3 A-TMMS:R)1Z@!8E3.),5?.1KKB!@^GD^I5O
M)'D43$.F/+#?WF9.&S6/NA#W(O)LR8.;>)[--HJ5$/7N& "-B' ?34,&++5>
MONF_L;I&G<AZ-RQ0G!OAM:=ET1=066J(*D5(QL@2>,Q>EB>J_5NVX!Z5OXZ(
MNU#ZZ.)B-)SA.OEM9ASV$BUQ+A1R=Y43H,C)A9BC!651D7\</4%JK?1[*%HJ
M?9%)?5_CV^KFKJJW$^Q]5;-M5?WW,!Z'X70.QA1MO8\.0D@:5 @.?%$!K M!
M$;-=2*:QEF\!>/(*WER<#1_CF[;*._ILKR1MHQ06>'8)E!0!O),,;(J!R<S1
MV]S$GJ^C[4Z''5OS:XNNX>-Y$\?)<'@9!F_PXV@\[:4H.1,\@3,%07'GP-7I
M&>8Q,YV$U:Z)*F^.>C0JW5B4'3V=KW'<'^7GP_R,#(N><E$J:1!$3&1$.$UN
M1**%IR@>HLV)._^0?[6Z;F\->S3*W5R8][4KMM'NZ>5X3'A>]"<I#/Z!87R-
M*0J5,.H"KM _BGOBGF 9= PN>8?)ZH<LY\<5O&SD)Z_C)B*]KV;99(NE'7\R
M$^=\8?'!*V%DI.7$T<*2LX#(601KA4+:2Y1.OLUV>V?D)Z_F)B*]KV:UC9JO
MIOFB/\!7ES.KC@M7.%<2"D^$)7$!7BL/4>:BA-"*86QPVOMMQ">OUJU$>%^=
M>GMUOL'W_<FTFNJOP@7VO!5!"U20BZ!51/,(T9(/7X0H3B>='+<-5'I[U"-1
MZQ:BO*]:L[UJSX9I-*9%8S;)V8G-Z>AR.!U_.1UE[!F#@G$O0%>_3#FR_+S+
M$931J)7T:+9TA58 <22*;R?H^SRPV_/@7?A\EFDOZ9?^51C"?.W)G#PWL@(A
M82##,)-'%WE)8%PP4B+Y["DU8,"2X8]$]RV$>U_K;GNMG^0\QLED_I\Z7=XC
M:]]R$6KX36"@++<0<C*0+:88>>;6MWCF%PQ])-K>5JCW->V[T+3H!6MLK#Z
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M<J8LH+9!EQ2T]JV/S%> =30,::V"AI6C%T"\M[1))C0:,KE2\F0Y!RZA=AZ
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M+3GM^M U>ZS:RR1>W5:QM]<-RFFH)) RI#%RCS+:'KQYD'&E]^)SUY^W:D(
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MD;!,*210C=![F\=1PSJ-MQ>F&Y^\VOVDR#;TXI[AUN\V:3R>/%[><#?I"@N
M5%/F,9O!.-OOF#B#(]U(#I]G5>JE-;K-_Y%1#N=Y/Z2>BD@ F,[/GVDF,CXF
MW#: >X&-_V(I>=\5'<:8*F,=I+ROD-NJ^YPU[OS8F;)&NA8:<N48AQX8 ^;V
M9NO<E/K-F,?+SEG2>F A3>IL*=I;(LAV/N"S4RG!,@\ G_%$JEVPI/IG>]XK
M,]T&V%VZT&9M$S0H,?Q5R9(:<6C6075Y.N0HDOEF(8I]U4<:KS"0-!^="[%'
M)6HS*?BF*G1)'%+;;;)MI;WIQ'$Y6.A9"G:A@-K+ GI/_UYOQHR1YI$2:?\S
M*@N ZVZB-Q0\.>8RMYA@I".ZJ,)5-.=LA_8]PT!&SL74U:;,;V8]9(N]GE^-
MW$ZD)0[\/K8X>'.5V(*%U*0C>>X:L.'<?TPWZ.2H6Q/KSI9GFBVAOI)U=RQ'
M&J+>H+@6_5=1=_![/I)RCKW)ZUZ0^G4WJN10DKF;7*+$8GF12IM3U[LRGY]D
MKE$-@7MS#P1VK$LLDR,?M;E1?1KZNX8_W4\Y76;M3XF[NRUC2F8YM?N3%SR+
M<.Z+D)G%4*#E,T0X8'ZN9W"/-/>'1SWUM:I'[%*"$J[=,7OG^D!K0(#3I7@)
M,Z.ZJ1?F3\U?X**&&D)%E)I!;&'P/9LGU^(CN>($>SJC,5DHJB-Y4$AXI(9N
M2J+^2L]GUF Z)S)_GQM)57Q2\9R2F*.Z_AD1=CB:\J:?4(*ZZX^X$^$#_?D/
MD9KBWO97&<QW)'>;Y<^#>4],V ()CSMYZ$LT B6ED92"5"NKZ!@D&5J9*5=3
MM(VA9"J;X$VYS%&1Q*EC]*U)KVF38W/V9="C$9Z"?(BYT(.FPZE#DK%.@]-\
MCG)/78M CXUS^2Z%EXS>>@4J?!/GD]9UO?)U[A;GCOJB3 0&T.X@I(%>2-M:
MO7(Z1@$9NRS'?Y0*/M_^'A>CYI3Z[+QU?##7I7>:ANL%&R#S,>(<KTGO"0LA
M+G[!5,<)DZ1;@3<,'97?/1A>"MC3FJ9L+HQ9'*B N\DE*75+PZ2Z;@8:&GCF
M^/N(R(N6YQ<;E>Z[O*^+TEK8PM1B),@UAWE!>R:4:P]O[:8N#3H/5V4.-PS?
MM.^,,@.^0X?9F+0]-[)-CPMYX^ 9XG(',QMY?@5(O= !*;* ^(6/"@@ [*;&
MW;4[61F4B/DQVW"TITW7K\142#*6)Y;X6XY^$A%+-UB/X+?/F,@H)#>AGN13
M4.;=/8BY7%0XUYK(^=C$D6?S>03:8>:M6,9]\@FIOM*XA(M"A;JV//=/%&1U
M%@$&"4JYW+K7XZY\>?VQ9?6-PF8Y;SO L?J2)T$O*->*LTW175OMXN^>HDNV
M8X9"2/T'_#<ZQ__JM$O'H[,1C\9Y#O0Q/B&B\4!3/N5(,Y/>[8.4-S6='' I
MK17\*FV"!??R/ZB^5U*5GC^D@"1?-VN6H*,8F*_FUJ8 OJ. .DEYE<?#.( 2
M:U-+KVZQ=;PKZK^GZ=9GW^K)!$8%8CL@2$G"TF[V_Z9#S(J5MD]V37I]$Y>]
MNKQ/TT1>!.K7''PB8$:?B# XR8P'*?'D#XJ,7:$3JG /AFK=UNYA65)[__(!
MG>*LFX]T#<*V?1;(G2X96#NVJ8IO(I=VS/M0<!_YJ1J-_<-GRP+DS\Q5/3JQ
MNZYM;UI_[<N2]^7%,;Y^<COD7=FLKKA2BX(,WWR(D(W2T)BU_3> N&?9GY[G
M+-Z??<:/!30:"K]5?Y?T1R#Y!4-E8J&UK3O;4%J01J8'0^:;%F'H:@A+2S&)
MMNM>VEG0JC(5=6(/S^O?F"8"8^<Q6+ %*M_4@/I 3PUHOU]+ON#GD"=!OW5^
M4#6WV^U93[[ALTD.;@OW<KI1<X1FB*I;FS^!U$LR<"]8NI146/O75D:93[:N
MW]3V]K?>8@^&3P/K-W 7M[95W%&EA 7BIA:^MUJI#R^ ZS =0 'EG_+F-;]%
M5OL;WVBD[9H"/Z 8HG+TX\Q*?8W W+! :M(GQI]].\;D]$5>W%Y,?$.<%*8_
MV](&&JL!*2K>>P'U(,[XD\9=7GCK3%/]E=A?E[H,7/YL^Z*_D8 4YZ>(!W5&
M?V77Z+9ZLP #8@2*>@/%V&E*/Q] 7:;_@<)#<381VE(6YRK+LWY25@[E!PR3
M7H!#([ 04ME$W60$]2R(@7MG'8X\NY[@S#\R>&6P2>"=_'4300"_N'[O][G/
MWX\-W&'H,Y_#7 S;!%T#*:C4O#_SHD#4]S][!J/):[X^(Q>F&XFSAF+_?B__
M<S_V:D]0U2I_QM!>%:?XV4C,]#&$D71A6@?,GU$$P9B5U/P1 3U&'7YE;1=S
M"3^(U\/$DDKM$AG7_VPSR<Z[W%[U'AB\,YT)BZ$I/1H"3M  O0G*H!G 1S+F
MNPR?G]F+I^4=[3C7RP;'91TQ+E>^\//W=V^'N.GU$"N>]7Y$3;UQL!9Z_&E.
M=7K'<BRINF,P:YJ9!J,(&Y%#X%8LBX.%"L_@!\G\60/GJ^#K VNZFZ(%8.-^
MQO')5S%;2SCG(PS>/4_%S^3ELO^U.O-NHW26S,4X/-G\HH%K=5!\@2M=_X?D
ME"0T/4QRM@\)V@IC![Y5B)&Y&0IT2YZ4/:50[&CXDSLOC1KQRVMG\I?7/3E6
MC<8Y<SP:2(+F])3RZ;/E!C=/+(-!)!WI3S[=A,7,98WH+-*X#>1[O&*P@^[W
MSJ\%#-XL7[\UG9P^N\)F3ED^83N%ML*G,RK >B1P1.&YF<5JY:CA"Q2ICYEV
M34Y'FJ=MRH_JI(U$T2+T_(]R_"3.W7ZKJ65@N;Z3#<:3J&>7('6/!9]-/H9I
M#\D="RD+I;Z^A'-HCWG@G9G^\OUA/H+,L82(KT=_D<K10Q7T/\R':!^4L/!V
MA@CM0T;!.^Z9!^.<KRVOQI3:H;VP@RET3V8A8]<M"IB$%ROI\UM\X?FM:+?H
M/I?$ J$3Q*E&^OQ63 JSH]J.P.(:#%&=INKO684.Q2'=<@\_S(O4Y?*9KXP8
MHD;:CF9(;I-)WO;J;N\1R_99S+0%51+F1W)-KEN(F7KY%(>I,:L8J@4^F<9E
M!?>2/,X^$MT+C-,_%VQW60S$]'?,;Z5^'YA1H/?Q_?5!*"G/?HFG<SH.E\E&
M F^GKKT;"!_*%:X%/;%#1A2-!5.*8TH<04+_F$_A;,^TK(UDQO5ZE3%3Z71&
M$CP&4KWS8P_?&\(KPPT;>8MQ^!*M) /=^#K]I+R[QTW/#-")+[V'G4F>VH*R
M/]5=L-5=1X/1=]M]?N8<3^KH1^IDX?%6QBY3F-\%L?7/?6H,MDT+"&,_\%'C
MA6;]+[)7]^/^W;!5&-3)4?>[FO16>!"$^9<WA>%^B?#8M"*H]#25?%<QYLRC
MB@$+OSB*9LI1HDS.$^(0YBZ)MW8OPZ;37U^;QF]2T>>[>.%:O";WY^.E_:0,
MPL@(+.C%3(?5+V%PRW2K!"P'[J&9OZO%K2G/G[XB-@=RW-E<<P0!T,X 15./
MF?BT_SBVT>XZ>>B;UEYZ]X'B]ZL"+Z,=3V(0!#F\M7-LBLB<AOC/[C"S,'3(
M*RBZ"<\=_T'^@E>WDX->=(VL38I<(@N0 HW)[S,8>RLV#S#"N_W"=#;-G"]!
MHLVG]:N*WOT42XT73UGWVW^[DV>52_6*R^V>DUCM7V0A_ &&#E3QPGA"(TYO
M[%&YER:OB(5R=Y!*:%2B\>T;ZN+296P[G"J7SM+?C)F,"O6Q,Z;9(T1_Y)!4
M>X[.SEJ>J&0JL3?_MQ?S_B>'().=HW\[@S2YEF%,8PJG-UZG/\],[?"@]*UK
M#^^_W7GM0?C1=[#=X"<M3!2!&F"WH*@SOX1HM)?VLOIB@Q%(-!SV/?$X=G^P
M:FJ4T*U<X2D60%>EFFR=F\I%A/?%"4>>&+8HQ%DTJ&/K*]:OV-JS&5\- 78_
M6\+,\HYC!#US!#J+PC3&?P>5EY9:[SPD4W=1"B#^-(4%+9D9?@9[\-\RR2U%
M)\<F>L/.RF]SZF6W59N._DOF#M;^Y.B.3X#%3V*>P7^:322A N0Z.]FK%_=>
M>*^5Z:#$5L.]T.<P+N[^[9KT\Z*>/2$AN<+9L#K\#<5AH#>K: 01QFO.GAM-
M2]'<5T/ ET-.M-^P(%+#1WF'.556D:@?GKS&G=^XJ?%KMN+2U-1*ZN60%>*L
M_;ZASLY]]91.GG4JOA-%]2<L?-F4LM1)!EV$17%QERHK'A;NB)]\9*GZB%-6
M]NF44-_R_JT#*CP('J2B7;0[FE%"N#CK[H7D]NKOJ<=.I*S=1ZSNF=W&Y?#L
M4%N>NPSE9U#^F2R+_H6KE0EN2FWRWJ.HUX?9&&_ >GD297(,36^E!6&XT5Z#
M061!7$W(_=01^4<3YN+1J:I58YEPZ40XK4 H$).$X4)@.Y9<+%R/&49=8+[2
M/_:B!DJS_I2Y&99UQ&3YR'(9EU0[ONVYKV'MP_^A%$-+H2D?43L(XQ4,4=2$
M>_'. M%1KPLCROZZJ=N(]61(*V-\U(HA"Z739#T?FX>&>[%_OBUU;]]1-%5E
M4Q$6JH=*%:-!"L'.6:#BB75YZ./4-/UT^6C&[R$T99 0?8]*A'E_:8O'/\^P
MZ_N56B$@4K 7!P>Q,64NX"V]@XT5O9'0KH^!](:.X = ?GD6\#IF8#F!5"4\
MF&Q(+O%H_(E:84<RYBYE3&,%0^I&(:D\O^&#6TLP?PHS#S-J.F\0 G\A"8>7
MJ?[3@EL,X@X":8N9C%!$KS5>: 'MI9B<[2408<(^3,N_5J8"YQYK<_>+NN34
M?N,K@;.8]ZW/B"THZ(!?1G,H.1;/9QD#2Z<T!1+O^M5V[4T]_%R)2C[*9[(M
M5[B/&&-E/\PXTNFW,M3>7.U%;U"^%'7-,%K ;#+5^9YS +588P+RR]W_;'LL
M!?G2K)7-\<IGCL&!W/5(%A!W-)?W30*I:<S3J2FLCZMENF'?L-:77)[F]UJ<
M;^8^U=Y,G?%N!G#H%O30Y+AXZQ@[*!1VH7.AW-&^ZT6 "GOSI2N)J\1?BO1Z
MQ*C.;QVGW^WH+7V4^7A1&\OG$W'XO<.PD\;]CJ>1F[U7T4MOX9JWPJH:)%VD
MXE/LJ54'Z^O15',_J\5N?:/7T$5'+\??O/Z^3XT[-'9+I:P5;/!NY4=@?3N)
MRT#=$Z0FXT<&-C"18=:^N^SW:C_UOR4(?QK,B?X$VDF0XLK\;C?/:]=<>C?N
M_T8E#I7:CE> 1]!40W#0@OZU]QK-+C[H2+?VF\MI(?E<=Y>3FY'"'%\:I@8Q
MJ3Z3_G%"-=2*IIL2?65S\J9EE>8G.*^A'F:N-GPAYX'9V 5A!'8B$%J>@/5*
M'S'HII1!47N:\-T555T)XTL/OWV1MA20K:O;O8"Q1>H:D#*K$5^-:>+'1(-4
MJT^R;48)\G_D^RY;"!1H;D?CY-WWR,EW\JSMFD )SD@?Z"&?IBD\M+NYT#)D
M<Y3I0TVA=R"2#"91"&#Y]Q>A$U5E%BE"4.QO#?K8$8Q:8L[+@]>8JJM92 @-
MI/+0,ZE3SJK0H0F+L^[=Q@+2/+84)B\QCPV6G\I$C/>(Y5T64,S#$(N&>=EH
MYY>:T,75N"PG:G*&[B5Y,\&5\R,Y 3+QA\K24L:)@QJ#^; 0MJ^0\OZO4V"B
M5 H5<U>_BV/L"U;MY3GTQX;SAHS?FWL.MEZ/4;2:G6G+A(3IHXA,?/%MJ J[
M*-+X+JACO"TT?I\?[?*IA#15/QF7XA%$T9Z0T:8;_(T@7>;CYSJNDU26Y'_L
M/M\]B\J7NBLRAX@OGP<_OE7017* A4D^PM"1T$F=^;;7I.842)&0L#KDGRM]
MPZL^NN1S]-&SD;Q?.,K#HBEH2+V5(:8#\RY,A%K&H<HS8A1Z?8.^[/*0Z"MO
ML)@238S^*!0GMY68FX78AFFN+JJX.95#O)LB2#AM(+^?7KB0;^]E($]32(D+
MLS!H]MGC 62X?+9J"B&.$K9!:PUXO1Z[B]2\E9 /"UV3,M'K5CQ>QB<5Z*\*
M)U$?)3V1T!>=?^9\YW^V*_!O.\__[$"L*[,'4Y_"D/I$>[#6#&XW0,'?)/:.
M=*]/9EZR^9EX[TA7ZR3F1U"RW,D64GL/S.?<@^\A43&D;0S]+Z&AZ.WUONS+
M?P[,F>4*+R*J_4)-'J"0YE/&,9S#)BZ\_O(NB3?J[,:42:33T_JHO'=)XUEJ
M:MQ=6)%<U FG_V*#OS/"0VJVUXKMC,>PX6I^K__U-D.1_VJ=]P*'ZH6Y>]_N
M/9(*[>2A;OW@PI]A6DNS3 D3I:HW,_H^!GVS://77(#+F7A$Y :PJ#UC%_.1
MOA:E;?=7F4B/^M]5?2?@BPPUL/YT^2S)NP/2\(@R$#:0^-'89$M?Y%'T'E4V
M2(<3<GB[7;O"5%U?-M=]N&N"Y@-^OU6\4JAUOL_]RJ4M\SZ^!!WC"6"^Q>_4
MP2Y()H)3$C 9[4)>/]P1AZ0"?X/F)@Q#*GZ'Y7#<N.KM.1TT,0TS0IA'BJ#]
M3ZB;<)TM>D-!B6.NXU"XEX2Q0_3G'YO5?*7%X4IL'+&3>7A%L-ZKC! G3A8,
MX]!I:KM7$'J19OPZLNCECK1#@C'RT?=]Z-TDI:W%23W+%J<+XXJQ//5^]H>S
MC3;Q70I><IH<.[Z;L?6D&J)>D 0+*250Z'.'H;2?QJ[^KQW3RF1:?$A$-(1Q
M?3L+"JWX2-V<7 A)=3A5>L9$OW58,R!MX+=3;TEA6$CN-J>78S$\GDOG]_]:
MWPCW^K+<FI!JYP><RL$^#@EZ,_.W<%EHW74;ONB> .1>" V;?;HZUDW29 '^
M*9!\ZWS<YFWHYJ0EU)RK.&+_<7!QX6ZRVWUEJ\#HP4RFT2OTV&$V. PLMV-L
M1]&W#KD$X^Z$>6]YMO=&_W.C'=HO][V3-X/7S'H#[JO*T6T0>,ID ;Y+0Z2)
MG2@>-+9]UQG;L_30-XNY/J$/ZSD.7)Y<(:XHG[I>.7\V[-ZF/=Q(*AU8R*.T
M4$U;PW=IJUXU,*7H!<^8&90!'4-H^@+S"=J7Q&4TB8JL57[?ESXATB9PX<67
M[4OW>6=\YCU_Z(H'G=FVNHN!P7>2J-[X>.J@4Y@E0AP>FK2F#B0\N__%1X#X
MX:#PQ1^%PJ<AX;/(5]\0H[-'4U(-=(LA_DV/&2HNXU3Q_IW5E5=+OHCQVHJD
MA_TQW8KM1EZ[G#X3=:$DZHOQI6:"D#/.HG7CFD1Z]KR:0-?GW)^7KB2GK]LA
MT,]$)AW$?V$!%2&Q!Y(C0>:3"?&OHY?,C#BOC^!\-9R%3S,??JA,F.%U"9^;
M5#%]I<2QCF<6@)1^<-!N\N08+GJ\_--2;/"3>Y6A]ND7;NGNU91>A<1I*#IB
M.U%=8+UT<)6V\)#*DN, 0YF@9Q+UP_%Q>O7V9COLF#5F5M"FN/+Z,<317#?W
M@/6]+$!,7V=B$Q5+JG!.]<M?M^/?U;?VR&_JU%&NK%MR*7F@)Z%T:>$B59&>
M0PVN2*X5Q$4-.+ROL;J8F^KX0.L[[RJ10/+K@/9CYLLW<=!5)]%)V\32RU]$
M3V4$7#F3?8LSN6_K! V*B@U9\$-87Z"Y,G!;ZYC0JPWZQ)=$VL@M1Z?KM\7L
MA9!/W2/0G?:7=<:-]/(=6( >)II,#;1;6-Y4ALH-I.%!>'><S>6D;JUUS5P>
M'MB^''1"O\]GB*'IQLSJE3O2['U)[]Y%<O8_F)SR&(NL=$4'T7.%!X2U-4\L
MF"F8S+9;6V2%WA'?\6'E^$">P81-U#[5'/$'GNSDS+B?><L7P(P?I!P2I()$
M@M8&0O'/;R!G+8]ASCXH)>QK\?#B8*J<>L@UU:=_CMGE(P+V16-3]D".UM#"
MIH>/+Z99C5YS7+)MG]J^C&FKW54SA=Q'$@#FU_]R9? _.5"NLD?7UZ8WRZX[
M0NSQ[,=PY14K+O?X'YJ[EX=)'8UT,RA8,6'KW.#"C=;F'>MQQKW8);MDCE,<
M^Y@^3&Y5*(@9I19D08!TUR;RVA\5JHL=U18[6:?SN-E.20C7#( !0>=%(S,=
M_ND,5=':K5_99\$:PYW^ZB+]O.K^0DU)%J6WE:8&_A0@D=H*<<B,VMUP$_XX
MF@\6FDW%$1Q+ W=1'IV0.#59P;?*/.OC8%Q;_M+9LX)S/>3Z%X[);F,5,!O,
M)#'$+\#;1&ERE-;F; _Z$^A$X)&:W+DU#3!<\M37_IK'U_P%-N,H2ARK-70D
MM8O.Q2LR+'J#F$:3BHTS04O"Y"]_G$8LJZ+$Y!3XHE/"!NCBU-()\ Y> X<Z
M2YN^H^%:5=*GUOU+I)"7;[*6E[A\AIF&I#4LH)QG09PJU#,1-[\ZSI\$-GXX
M-;1^_XO(EU^-C:]-@Z^>^'Y=-9O&4[\TC*:H%XM53:"%?."=GTJO=(VV^1U_
MT3*6\"6F?HV;I-,4\.X8OZW/CNBPC)NW6RW67Q$HH#]2!1I_W]51PM ^DQ7O
MLIIQ3OVE7>G;JM$+7DK?11)^5=N=O[F,[O5MEN'Q"5SJ?G'H,\\96!L.1DP=
M37E/HEJ!$?=?/7F.6YQV*+T[Y>CS67M7ZZOU0"7I^I9C=C-VC2F0;B#]9>>(
M1S.* PII.I0<^R6_YR7ZO,,X*+]KQJ62!1QXG5%^/GK9#A/# N0FESN>3>\=
M5U",2-][RG:T="IMW<;:G 6,M-\B#.M?*Z#0[%37'T Z2 Q59TC2;M9(I](R
MQG].WRG*NT[R+>_ESI/@&!N8IQY%+<82A\ ["($L8) X&<5!90$30JD!.AQ?
M,@,X<PET^6%R7C@W/[JM&*Q[ES6_ @:6HB4G4GB@CKCR]I+J^RG+QBKW64#=
M;%5SV! ]TQ^E&KAT%F]Y+MVVP[I'6ZDI,[PIL"#P\>A1]-W]1;N79T ^NBA:
MYZ'#3<]'"5YDQM%<L=D$3KT$%_>.T^'_(7V0"^^YG'%/VZP,)?3#N^=]TK[X
M*<49+:=@_!6PWHD%>-HQLTA7.NZBMA<I['!J?NG$?/I@Y]*.IU>8GAP0$4&7
MDS,AI/(!AKB',S3R]G7FR.D^K'IJJYR*A08F #,K+/ZUUF%',XCD;U0OC_E-
M?>>=-)T%P<)G6G.E/_=$3ID5Y80.T+]&"^U. "K.#.8?WH@) 04!D$!D2*4@
MY2GVS@-7^*H=!\IZ%^@'%I\1]MM49!@D0>A!V[W@R$[BQ!(L5-4S7LY\A><?
M\^%Q*ZLN+)P>V6%')V[*8H;GP%++**+OW8-'4KUE.9ZJM.2"*L#&Z<S=TEQR
M_D='SMH,CP;E\OI00V'^>(]Q04P]1F"%M&=VP.$A3[.M_SUOV'F(FUDX9/MY
MUV8C)@FDVA+$&2>ICYY0E^%=+."N6IE8%4VP+/ )162].'OH8IN Z&]#U%L6
M(#"9H!&W<>#FV_,*Q15\^:_9N+E"0D6/%;??P&^[-46-?:+0%B]_I%CLRJ%'
M2+K@% SLC#S)'';XCPCVRG?J_9S7BA6;LR*MC6+7*#RL-<Y<:D3?<[#1^Y"*
M?Z80>\WN,^?!S;KDYY]2P,RZ%?:GLJH-5ZY&H!.)(QZPH [$,Y%];G,".Y]5
M] /"6%M/F[I?=$9KBZ/WDS7\S=KQ-I .S&>,(-'67N,)[_=A!Z#6_(H$?=3S
MTT>T*:E#1?&M"-26!6)F]_SD^GXH@8*786A04<UH06<<NG78[<.;?'(#?=E(
MD]LV^40L)ZH(P,N!]08D"@E3$K+PQ,5CG+C=&2F"GEL]6\B3>?5'5Q):%/9F
M_NA>;==P*DDYW_W*\2YF\:/'=6U& CQ&IGI[S ]--O<:J.*_2O0M1859"#^Y
M^6@N=H)7P3+[(A"D_)D%>).D:L6W?C,#4@H1JS(A;&^EQDT^2E5,TI?$[L,E
M=9?=4#FR?2%]\G[$D6E_3PZF[(L 0M'IWY\",,DD*I)_0 ?(\Q6;UR'5L[7E
MO<\Z&49!855ELS]/VEK2+3GABYML4E-V.WBO'.MJL4E>8:,0RA3GVZ@>= +5
M$>*?=(_#%LVV5\9D:M\H;.1,C$Z SR )%0$ZG$&1_G03UF$^U#\1/EZS^H,%
MN*7:VAP(2,H+^^BZB_F\[>BEQ&\G(PS\^B R(F\A1-[-89S,^,.!+V?E<5G-
M)=P'9_N[U4]<#MYL\@A9\^18EX"XD('QR, TA%T%O*(7F0UY5JC1.]RY!LOB
M>/5[ZPT*ZQ?31VZ>$R,9P_N009?0/EA(-:Y)AYF!=L'QQ'U4QLU7YY3D9;J5
M7]UU??NK[B'%I9N%I#@TU1(SW 'SE[\UI47#?#P%9\>QW)];0H\+M8RE]@4\
M9,X>BC+T13T@J=9*S:'*+!F2Z9NW\V,7%A7Z:B6@J-65(>=K!PL?=>FEAV77
M'>G)*6-C1H/UAT *0BT 7G&O@C+"Y6L5:?1W.LYS&5_?77QR[V#BWI+$M3%,
M90)TXU/*:6K'T/(D,1H!&.*=:IWF%&!4H3VVP/\!>_)N5<TH.[D>[<4 "DF*
M"[CT7T;V?_-S"Y4C?B^*S*V/L@ /6B[W>E+_J\^SF87'YX)^&@/JDE6YW%(S
M[B-GR<N^S8 Y4M]Q.[_[GNF[&,?C"JJP %T,I-!Z%UN&6,;1-OM;\NX/%EF
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M1"*#E'-_MEY"=6D=N)'KP 9[%3;QZSQBF A)[L+RPZ.8W#%DG>]-'II:1U@
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MZ\C%K)D&RVZ_B7!9'-SCND4H <R!99)@HRA:=X0I;S43'Z ?/.A>N)J=X1K
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MWVS%=,!!>6!5G&ZX+.L$IE!V>C?J)D>[-9\6,7\[U3_&DQUP!/Q>0S K-I7
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M$;=C>)N]*$TQ)HW]97)ODVV?3*N"II!]Z(8^#8?A*RU/UGI0UPECBU#C-&,
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M,HJ89YKH+A!J:*%L2.]RB)S$X]K5%ZV2 8?4)X.C;[Y[9+_C"<K2OH-N](-
MDWR]*#5J]OA[CII22F.&,CGUZ^#WD<YR1:FL<*5_?3X5?S^1'=.!Y4.ZH2(;
M^5NU'*\\ZLPP:K_[BI%XRI(S%QU&M\3TXT60Y,\&VJ #G9U),/G;*$U93\]W
ML-+@ZBF2KS^FZ_PF8-^\?P9LEH7]TT@5;@EX;X!%29XQM4+)VP$K$E-3\_ZP
MBT8*/DU&C_DB420L)+S!Y#DW@P45[%>Q )6OUT_U.>Z-\L,54\F%X ?F6ISR
M%Z-0S=C5, HPT[%ZF[74/0,8:8^_!G9)Y+=U\S6UU0_81( 3 1WN\[$T55#1
MKVVO#ZZ)M7!^+PE1 *]<*)J=_"4LC_[0LU?FT#'?4Z=U72/;8.$D5H0L9?9/
MRS/>[\(\<2\1@I"'6KAA:VU<5>$YQ0>M,&0MVS[\5[\)+.T;!;%J3-<)C9HC
M)OC>NC3H\R8[VF[\?NKSZY?7 UKM*0.L5U5<_HCF950RY2"=83_1U1VIOR.]
M>A]/OBZ;?/9"9UE4<QY!>2 *">7/AD!"(7.-!71Q3*^6Q2?0M?FOE6RW.U^\
M]NB,\AD1&Z,?]UR'*F! $(IR91<VD3%!^PORPML5R;$_?H[5BO4%1XLOIJ!R
M?D!.0--[K)1O!?:9C"8H6J3F-,4V8O$4ZOK<=- HW )P5U92H%]GNY.=:CMZ
MH.!78A7>99@-DF=9YUPM"5L(B5">9#G.+M_1-Q1BW[;_LU=0W=0OVH+Z"K04
M:?#7/?PVN0LKWT!U8"'I,?1.^IH'Q:N%#'VYCT!LW-1AIC**,6T2 1X *[R<
MDI5$-YQ40SK":/!8DDBC#'28HK_8JAHK4=$8G_-KX(U;;?6M3[$Y<LE>8#OC
M*\LN**3]Z!/4E5![FC_%VT"Q]*GT7Z+-V4L=<K=4NQX'X[*1Y+6-1,1A/0ZZ
M@B.D2VFNE\"4')-\\5KPFYRK;-YE@!-%L4"-<<X0UW#T2V-H%1 W9Z[*Z9'R
MZEYMPZM+8NOM/^[O/]#Q*1N^M-&&I#RR6G,.*;B,?,:4"L4,<B T C0(U=3)
MKUNXCW@W!*@WU(J1IV86)]+/0P:E7X<6DZS7'_Z2XAK^HW-G%3BY0VK!4KQP
MD( I6IKO;$QKO-GZ?53&NK3+=R.GT6V=-D *3[%G&6]5D^HH[YR<P6$003W8
MTB'AT[ZP;R0HPPDM(V(4MY\P<Q[13X"D9NB7H2.,7#U=RN/9O\W\]_F=3*N'
MXZ)-G,[M+SEP,V[?F:AQ?.@NS-5OO(,6"R;1ST&:H!)=-=2YN#Q_8#;1FLK1
M]<]<E>)SV.57[^7F-]D/*D$M6_"7K+FR?K^$A >M1/GGC*/.4XV^O3L=;4VX
MT"*Q]S)0'AG]4%J!)@R&:Z5Z",GXIK!K-?U]>V=G(>(,X(H#%52?X._##X%1
MLX@706_QHB"V3?OWLKV]]D2PH=QF>>Y1KL_["KSYYF?Q5VQ_5+O\$'3Z>ZU7
M_^C8-X58V-WOQ=6WL8Y0_IZT-7,(+P&X8<71^H,8H<L?+3QF]>UX]8WT[9QK
MHHUN35_]+:C<\1[WXY?!#&ZQF\FKGHO6'<8H02*[L*<;%L2-W,16D7C/'2V]
MC\!IBSSO=NC1IN)>R5<M1@MH4F8!H?& G^AK5/MOM%W8>%E[(3'#NW2TR]2Z
M6\S9ECI:K4G9TWLD3ZF.:K=V53(%?J M9GY]6+Y5GQ $?,H2W85UF."F>P_O
M\TA;9KLJ>Y.=F+WB).,(/,38SL^>EJJM"_@2\]*O*!EXA+S4B;XY=R7OG2+Y
MS"-*OG3.FKQB[IB1?7Q]D>NV,%C!<O<>,+JO_3'I"?+P;,.;L%BB?<7F7[KX
M'3GVC5+\<?1>S;8K:T*20@46UGP-))T]M49JD.Y?:RJK385";!W0+5B+&AIN
MR\1=O$DN]L:(K<Y]*=H6CEWTF\,]MT>>5[<>8;09<"(8\BND(^QAF'IR;BQJ
M:U,D>>OA)%*(\%NR!+Q-]\+T9AU);$LSD*2F/PF2U'M=*V*?II*#)Y2$ZM,E
MZ-WD?$C4B\D#IUP<V%)VL_M*?<@;4;)">_SQI?0#BH: ('/;DTG/K8C^R1=B
M_3&K]7ZC,",'3WZS"RMQ6[/UE\FA^C4%KV$R5;VE5XOA= *W<PMCE9C.S'5]
M\/*M<KL&_5PNB-HT^,T\GOBL.M8L1O+!Y$G#[;EN&_,!2_5DEU31'B;:0!QH
MZD,(GIIS;SR-5A_2%%'XF6Y4GT9@GU(0%6=1K#9,)/HX*_'$ W<2)4D=^6BC
M(4W2@76$9EMO=7W5M5V8;[LI<E,ZP$"-]9 7TC731O<NQ2I.SR'7<O(#03^W
MYP26ANE),/ZQ\OOW+"<DJ4T_[W'<'KQ'%34D'N)KKQH9NG'NL73>C/&"IVYU
M%>_]P4_X-2+SRNI#@X3)"SWO=5EYK*H(7O?F^L>BQ?P"AEHH.Y/G#)T;;>T/
MC\*<! ,\;LS<R?JC? ]Y"=OM-]B(&T1;SR /.[W,Y+2M:'A1 _<[:Y)/M?&"
M-B OUH*'_+O@!V7]/Z-5AE7Z0X9^/MG:A9'4S-9V[/MD9_S6<NCGO/R]?&9P
MXJ#"5<-_%KR4I@RNT 6>6_ FJ&\];+_%0B??<K;SMY.N+14TZWX(F&E4?$H_
M_LN6/J7;3@)YMY!#G5<59]\J!L1TKZ"^(9M5054$)'1F1B1=Y-GC+[\P)Z(G
M?EH7W]AXQ=;..U'/Y[_<BGU$)\S8[VU'&/0-AF*T()TA36[J/_<&%-)Z Y<Z
MS]W$L/(I#TT-"DL=KCKW&L$:@1(V8Q%UR1?9I*NG>?;&\Z*:DW+C&YZQ".PT
M<(UE(A\:>4,[9E5?-!Y>,CA2D=[J K^!M2N]/R9?'Z@8%%C'EL)WNLMD/YE,
MG-.&A)!,WK<4'.U>0_I,S.H/ED/P(CO:K617)6Z%S45.)&;.<:@=/*UMORE(
M3:<5@F^I*-I3:L@:?]Z4^<R4>=N0F>^QH9]W>7V.]Q^=5'.X^"$JZ^-]_.==
M&"@';[("Y8=193O, 2Q<0([JG(E_,YM.5-V?;F?OT!-'CXT4/.2HS<YAJ:/+
MGA,#?HZ^9Y/+^7$HF+GEE^,2/(5FZ"6*-2;6Y.\G?WU3*/DE^MV1S_I3)R>_
M9)SV<$KJ@I)W854NE0%@%=D-$F"G_<-:V'3(9A#I10)/:%6I).7UGO1\!5I^
MXZ*5\EV6_#K5#E..[O/::0.=*#$S?YNP7*.@ZLS(VX.9^:.MQQ)T.FXO6YKB
MVO'/ 8J_-B3(.X/!*SQ-C#]:KU4:QE$XD*4I&]7U1 =7A[R' $^HKH;0W2+]
M*)+M=HY%*R?NE__>=P76!P2;^$ZG_HGY7?-W\\.:U/54*=,2F-[PZ_]Y\&%K
MO%_]:%E=A=/GC2K,7K45A&:->@5]QNH%B6*A^KSV.*]>\!U;]F+;&#/H,LN=
M+C;*5I907-M=V$.<1ZP]>K*#8.(Q?W"_-F@T2CTK^B3K^<T4M%_NRSPV1^D%
M)/$4-XN1[&E]\.U'(W@*1^H7K<>'E2)8.9^YCO:_OY/^5'65T^#N?OOM'J#I
M+(XTXP9)F<\A^ 7+UC G1F*0:^;JS IFTN_F%*=ZJ[X+K.=^HX7!(*\9!'C6
MS7[PCUCF;,,/U8U9#K-=&.[@W*>UV@ADOW]J#/7.E][CTV? D6=7&V(=4KC'
M(XXZP"D9[[0N?/_E\-7WVY\BKD3K\P([<T4J83E%"I86L!.+^4)+3$I>W'!2
M/O7J_F'K_X<+P[P80Z@^ )+:)F-!<SPYS>540^SI38]D>4+7:5B<8 ;SY92V
M_;PQ)*K:I#R7"!ZW:E-2?%T295*-A;F=.]3/V0Q0O!;CD3.*C"?M&7?Y:/9<
M7)QROIR0TLX]L0YI)7!R[RQ++T2FB )O=X'S\=ZP\)P(_$Y:^ -]H2/B_\;"
MTO8T]E_-20T.W?!E3>DA/'F%_J<13"$['SR3%O[8<MM8CKDQB,<11A5,PN&T
MBY3CK\G1+Z\\/Q0J&\L\!9 7BIR8 LB)Q&\R^ZINW0R-,I_3^WU((;$=7PL?
M:[G"; -E9XK4_.='+^)S88_C_W\Z&#;:4QILD"\+%Q)=Q*AN;<AH PGP&EF)
MNT(?=:TF0<=G[56G[)GD \(!7EM^3"Z6$^\/IQ A03_R6E_9[ E\N=[MV</P
M\9])L!LV_/,<8M\[ [.\_E3-(E>[*8NS5:W*2K.J+\F/WV9*CY@_/&<6?=%$
MYZ35"NK2R?#,2Z;?ULXCOE5!,N'W'G\.Q9)_1/]3=&K3N##B$[?N+LQPJ<%K
M"\GD+V$9L@70HH;FJF!\PB@Y]C6>H&K&]@HW##M)<.5=3K(<$>?OT\4-L)P'
M#@E$6>_IMF.&2 >A\%D?"V^],^2WCZFG3RJ9:E19>%]'MY+O"$XT8 9'W3-0
MT6AUF:B<UF.5Y96'VB3(L,_5[.SC$<CO!";/3#%D. 20/Y,.;6U$*YU9'L_#
M%XQ=2EMRL1.8?'A55[<-\"!1#%G(2IJPZD$77-F%B1@H&9\&)]K3Y->/9"DG
M^HG,-@4G8=^>_$$5764QC/TX(M)] U1&)@ >B2\JM=,PDI3IDL_+(M&/T9>#
MU.JOQ_DF!:?>O7\[T8PYI'<[K[F1HV%PS75,K%(](N>KF-15SFT1#U)E>BSR
MCM_X[SG+-^1,S0U-X)#7V88X.<'7@MW'[BJ**V0PBY'DIP#%J([ A=Y'A:]Y
M4=N54JE^"6CD)]['3O_0Q PFI;Y$M,B]_K8"V6[+T_=.%([K6=/]6#]=,,?
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M5!PDTM*4Q1FQ_5;O0CY%5_;0B5^H)2?*<N=#$H='&A?RAY,1DCJ 6K2G.Y2
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M"_YFPW\I-"/+2/]NOG86&\X2QNVZ=F$S0$OF0=L,WG-U8;<R*)-!O M/OU]
MZ '2  L)EY!6K2DA-#70WI5"G E/5G(RVE]UBBW-SCKQ'^*  3==)9-<=^WI
M,]F7!D_P?"0F#RDO=([)D[X+XW,B.]Q)OS+H?=]KY75ZL,*4&,]Y:>/>Z0AD
M=G62FK%CZE55F0J'>V,U7B(M;8X'\C_U?KSA?%GY1R5Z-#7Z3U/3][5>V,/J
M3Q)J)3,GVTY;U9U'=-A#4L F<P#%3B*V2Z VA1G^H8*)^SPN!5>\W.9A&K,6
M:9Z/A6LOH_E9 V\Q9U[$%R/9=V'?7^3NPHB%J.]7.>]@'UXK$%V/_8]$D6)>
MG8_X^Q! &*9U9)__X$?6GS;]$IR0,]=6>DB_%U693[S _7NWZAW]O0OSW7B>
M$BS">G/N/GSCQKB(-;P)>^B[I;K;OX])LQZ[8NN+]\8]K^K281*8@?\J;-N?
M[Z[$]X8P>:-\QQ4@*=X/J/"I30_EE%W8S1S<5F8200?WVX_UKY&OQUD X2&D
M'CCT8# 2DDV(0 X06F[[:CB=>ZJGIV@\KY1;?.Y;<GDC?) T,BZ[_:FX_?]P
MB?!_4^];J&"%//?IXZ7A2JUV22@GD[ $6SZD+(H7[<L".;<P'5@9'U]9JM]3
M;]D,_^@TQ4/:F[C^947V;0MPKQ$S']/IHEY=/8R&S_H8M@S5G'JYG\O6"2>6
MY+6P)]X_936A2K:@C"#O$UZ*VF@@EN>J4[/W/UR3#<:M'8N%,0TT>:U '4':
M]4$1DL77F/;@-&A?>K+)?-"2$/%,[K\MKN1\)-?-"U026:OLV/E C<I^\V/[
M_W1:#^)+'0)ZA(J-B^Y/_7+TF?Y9\^+F8]8;G0SV"B@(^++4OCJ_#VB? 55(
M[N>3*T1_;ZZIW[V8+$B5]5E3K$<TF">?Q9B V%RG2?5OL6%:E8#J(X8 E;/)
M*EI&L2*9X#10M"[[SZ&F]$_Z7K]5:2Q,\.0(I@5?_OIR12*\)9=0Y?=FOX,^
MHZ,(ADD/99]+;TZ,#3Z\C(<'3?@X<DNR93]H8454WM:T'.O^]=6=L!(=J TX
M@A=$D@?P3XCV:X5H63 5^/#]P/S3L?C(IN_;3^>V[1"1>/)+),4..6:S'82,
M0(H4_3$I(G0*MPY=,I%BBVR,0)YF36J2#:X9 :H2GD/:(?_,#9\JSNDX;TEE
M:C+CGA_45@92+'.HQK1.1B*27&C7>)8:_+SQ"'7U"C4\85_/_5/=KS[F!;X+
MQOUB1<2]@GF\NU],*>"&#@7AL^:ZUZ'!CH.'7''3E[/AJR$]*$=M=%T)J@_Y
M;1<&ZLK25,&X.S$=@">E</7\7?S)?Q2(PCN/_VV^\J#S0V;W8IJQAS4\\OQ?
M1<]<Z&3Q@8WQG)"'7\=-_<?8D*G^!I)@"ADN[J2\&%WQUGST>]_2?;N5+4W5
M!$VOQW .S]H,M8=/QDVYKV5%:; Q'^++HK3;D*!NG<L/^]/&KK,^3EG97!F7
M<%NO*B65![B68+C?*7O-DAYNLXF0J.NL:$*2>8=($>[FOK"9XM&# ,L,C,52
M4Q],N>\S^W^X6?O0*UU-=K4[B,&L@KZ-P6A[A3VQ[43F07.$V][F!:3^[N_>
MK9V5R_A^6?+#.N9AT'MGE(49LXD4%KWGE$0K4:UB ?)7%,?#<R:QNS"?7VE:
MM$WMBZS?JK\3OMY&35>UX'FKGNEQ? QUO,\WHE5RR:I:JI_S 3:LL?SGKZN%
M3@:HF8+T]SLL3,\*C$T74[H9-9A3!;NP]_DVC/LL,&>(&BVUTJ;I@_9*07[<
M2QV_RQ/P!#<FSSGA0F158MNG5?R/1$'4'/55R@YQAY/95-892#^$/I))Z)GF
M[^\#UOI.0O@G&CTE7XB[,#.WOU6#!8$/M'D)7<AX,<3WOY",SC\4^^::#EVB
M"3MS-(/Y#T!^%;\ -.EC))'%;S@1% [<PDLF'!'CUK+QK-25Z0KMPDC1N%^N
M3*[U2WB*)2&Z$%@2%V5&5.Q$0@*8="D*IW 7^+>=-5/.Y/AKLZJ).-FA\G"1
M<?.Z[C=6W4+J\3WMM743W?IG!\T9%R]'BUVOJWMW\M.RJ;X2>'NO08 U"79;
M&Q.JUH@R4A/=01D2GFFP,_TX+'/5\HL>VP?CZRXB;.EWN]717PY]O%//0N%Z
M.6FWIQQ6M"D==;LP^6&&:S.<YXS,V;Z<B!8%*3V)H,^_/!^$K/_XJ:0IA"LN
M<M#Z'XR]>3B4[_LW/@@A)MG*-A6A;"V6K*-Z1PAM&DM,LB<D61MS*TG6":$H
MHQ E3;)E';M*LF5?9E AAAGKS<S<?O>\C^]S_+[/<7R?S_/\,0?''+-=YW5>
MY_EZ7==YG2\<#!UX+W/*#CJ9.)Q__%7Z.'$]Y*'AR4,5/5-!W&'IIW4[-7/U
M+D;_$+^7ZGP6]H,=STK!U#S6,09 <\=EB_;4^A>VL@FR7X3[6ZSMS;ZUWE9$
M'4_Z>VH)^YY"/]T%*BF1&9AV:8"6P7@TX8@2FA5[KB5C+\9_J?H"YL<,46G/
MG3QD]JE!P5/L6LZ-*Y8) QE=K\1"T6=B<,K(QRGSUQYWJ;V(2#D>4(6_/ L<
MV;06_\K8FW#F1PEMY1NKR"^=G%]F65%'F$7GZ<;:&UNFMC<MBA6@BGHOVA8P
M[-_\FBLJ]NSTOI(9\L=/W]@GM'6))=/%1,RC^7R-)742I8OK/A-H17[9@7*M
MRV$;:Z0.(@P=Z%[*"\QWQ:T;3<"^B;F-X]RNB<7)%U ?MJ!OMX[[_DQ.DHJK
M9AU0Q>826V(V?X*YD+ TNU!K27*H,Q]\0[G2^^KYOG1[4UK.LLZO+<S?)9:4
M(S4XBZD)-.Y5@W;/#3!.;^&)0;X''O.*_#8-#_]#_B!L=NECKYKS-N)BFN^K
MQY*>P0B$GIX2.;H+U+>$! /H/%/(1@KH[O](M^/#W_N*/EGQII@XI2?W2QY#
M^Z6TN.@3<!3@U8U?5X!->-R;S /)75,%F]O3+PV]RTU6%+5D5OAG/+D][, *
M!S>9W'\I0F273I[U,O"E(J$8'+5+5[G8-G4@T=7@4]BO$E(O"M19@@04IK C
MS=/K!*89SN-^7Y/SGDR#V8.9!Z_^M5MF%"K>+SN>L((M0]%#G-/R0/2Z%QB1
M-ULQ)>1CL)D04#B-.-"*" MI)(UT4/U9>^#@N/,EE2(::MT[HBD-#MK45D<_
M%CKQ/>N*[/T7W*:JFSR@/WUI*B.&?)/(';J-F'I9V^T4^FZ1<CFFZXOWP>=?
MD5TW?%91D, @TPCG!8^Q 1=!UWQ8'BI/:<)S/VJW#-G9)3WZW-ET%L&_(Q7K
M"30VTD,=J2B61$C#WU]G\F>EG9X@;DN>S,?K=_.O<0H=ZSC"8K/8C[H+!KP5
MB;<+6HTU]LQMX78.X=3"0J:)3S\!%%N6'KSZA/#[P5$8WCTH:)XFR:H514P)
MW<LJ.+['4D Q,?;K7SU2,=K31@C':9H*YZV\]7J5_NGTCD9(&%OY_<>NY-?G
M_QI^-.T6>DQ@KSA5MFKR>Q-+ 9942E]3/>J47%+J=?4IU-V=T\MM7CS,[YQ5
MB!^"=G(N>GE@17%>C*"1,^II)3HE8H]2/*A<8"9D2*:.($>9;:@R398X9DJG
M>)I9D++4%A[!_MNV^%W2G)3S)+KKC16N%!ZC*SN'!<!_.3)%S\R8DBR9/9:3
M-*FKJ>?#IHQON8V>4$PZ?;\-,U!;0 UI&->%!,PXUY*ZC<6\4L]M'25GV<1Y
MBWT;E]%/.WFHA@M&HWTSWVT<7.L7^25FPML)N!.3FHA*@J'9/8FZAY)3WDJ>
M7-P?NQR@@W!RSD?1@VT'FTB/M]J;@.$S9E:63!U,A:^%_173W\?WONEW;80A
M-AS5J=-4&*6B>8(3MA&M+F^0W9BU1BJP*;KZN2;>COR$Q,AG<UY%PI:3:<!T
MA'([48ST*W/Z-)EPH53H@(ML\NT:/$RP%[H6PN#TXX[O)PMH"QLT4V2U>J:,
M)%'CI6'#:1A^WA"SI,\PZYB;J0KLR^=SWR4V0-8'J"_0] N4*#+](C$R'&C3
M?*2KDJ'A'K?<.N[@$W8P^-I)YZRG[A&9Y']T:CH^)ZEP?_OH8EW(*I\>R<OA
MH\]SU'.]K]=YBX48O%V]P-\%E-L.P@33<TE\3*S2]R$<RAJL "$4W4L]A[B>
M ":_34YWTC=$O>]G5T/C^IESZ$] 8CG_2=&Y7EE(@N4 -+X<@&T@7J_X]^2<
MBW_46EHA#W/3STX/]1+(HK!DW?=R[I@-AIK2P+%J;^796.S<CF_!*0:8S6;8
M1[]^XRC?I=$O5S+,"@*W$0@+#J+6?'1' (^:357NK/\!8_LDP57!%<)#[/)Y
M+?FCQHW\4*1JS^S_<S?4TUS4WIZS"+/?FM<RL>J<;J@\AN6K><OMQ>9G$< +
M-$M">L F&D5W0L?@-0(^7O.YN&MUSM 6BIZ0[\,93&L*#/UU2'R!$0K8#3SC
M>3%(/PS/E^9<)Y7"Z0.%W->D(]G?X1;09.GGPZQF/ULCT+81D?@] RO$LKF>
M<S8_+_#9P&'9#3O<WAZ\Y#]%W.E=&;^_.2Q]EO(=\\N&!@^/;P[?1)1]^:&,
M;8P2/M_ZS-S=JXJW/J&<S?/3&&/DQ0-^8&PC6-+Q4ZB=?\WLV5F0YE^=$[^F
M]&QI_6;7!<]3OGTT/,O<P:$69%?L(X=Q2G3] 0<PH[E"\G+86^," [WH"TD7
M<UWZ)L@5=4F.?U;_U',P=/3?Y5E424R+T:6#9X0/3IY"T0Z(<T%>*+H9>?3,
M>@([#>VU)('SHVO>7S3$A@2LM_WD+13I^#/&]^17U!-4'$2J%8 -<2;T8,L'
M(J-HDA"KM0]$JIY!/47BIS<Q#9Q,A$^6F(DSM'\_OC\XO6E)$?:2CEYIB,HR
MIX=,$A*FVV-7#53[C=[<5X2N=_/_1C;"H%AS09@!V"3^8ASN5?8KF3AP"?FJ
MS6<)RPN-83\-$A(\F^I/]"W64CY+GO=<(:%!C@[9=W9<O8J#N>^4?\R(@A:Q
MK>+H(NL;YK=-JR:H8[ NRYAX%504>F/Z(OU[G]Q7]HNIL0.PLWL<,T'UB#R?
MMA&:/R9PEV:Z+QF:,^6K5GQF\2JYL2L VSX!KUZ^?A8.]"W4><O4804.K%;M
MWWSE6'=Z5J7=)/C8VR#T S+]=M<"D*]HS,>H*R#<<N$[:U\YKB=G ;$N\*\+
M5,4+OM@=CJ$S0F /7X,M_A[?M1790_8"HJ2D8X;/>>>55R8=_8)4E-C"#*+Y
MT=0YXD/YP^0H:["*SK2EOT@Z7?,C/\WFM/78:@YRWCB.108YC2QQ[$?UZL.Q
MJTO2#@Y?@-\O)I]L(Z8;,,/&HNQ\8UZ0UA1JT[(N]3Y\Q_/ 3L2]NG]&*P/.
M/YH2R-W3,/ES@__@^PL['+%5!;=F@KW7L-]3<X7+N#0F-K4Z/X7WG?^\>?+'
MD7]NL0J*$1H#T,:<S;\KZ/5RW2RW0WRGO,<W&_5*D5 )V;CY#=@K[\%Y@U!K
M-FF%A@0KF<=M@-L*/OP5F;]CZ&V#,7YA<C\'UYEONOQ#"DX%WFR<#NWOCSF]
MDSJX.<\17L*[9[#$L9.2.0]A$NH^FI TZO<'/4"N10V_@2(P5.3#I46WX^9*
M60(>1F .,O3-VQ\WRRP6LV)91YHTQE:RO7A8W7#&DDQT98:Q'"I=".!;TBC1
M[,E'MC  D.DV660:<LB22OL1#NK^LV\;$=Q[@*T*WN%TM#;EX(PTG&4[XYH]
MBO7T$;FR"U16_WD):J#P>^[@Q?)[?3.G?1HX"J3A71N[?W4RNNL[MQ%SGALQ
MO3?( SC=R6N65^\DZL[A#)T(OT,@I$J?4OPDJNGE6<8GF]T2J(?"V%X,:P]?
MFR425$8W;2.T?%>T0MT06Q*H2>R/+I:\8X"_\@*;'B=^W2XT+2OI]JX]UZ&T
METP[V"KG_8WW (WH>C%\&Z4T_:-O4!9AUU#E8Q+M6M[ 1RV5KWX)B&8+&8U3
MO%=<P<_,VE'MW(S)_-CB3\-!_J^Q R/$K_)RH<!S1GJ(F6*'1+ZZNQ)1_:1F
MW)UEQT/]Y1)%1KJ0$ 'V'X=R,#ZL"&I%<;E3\KP'G<T>E[OY@^#G2M?Z@0.$
M*AG"A#'>0\9D1,#_"4"%J1']/$H4/T@15X.T6=:ER\;2H7=FOF=THI;%J^,7
M&_=.;]P<.DX^+QR58@$B67MF((&OTZC1P6DUH7>GM$G-[#W71Q9?/SR@(),^
MH?#SJS+BB?%9 \))?K9@K025(L@RH"=E46UXAIK?S&X9E04'!W_4&)I\)"'X
M."<8P84E_GKNA%N17+G6#'HS2V9I?2Q54L@*^I/AI>FQHJ8/<H28,>F^-FO=
MXJO0JFS*I=3R;<0];7H1M*CCLY!UN]D[?]C,TR->_*+*N>F+D0A9!'\^7A1H
MM#44I9+W0CUD7DW6F0]6;R8:WYM\/"5Y+BW=]);.WMN!V&K=U+>IJ9&J= +L
MV?0\D#D=TR03;R<>)EU[W"8@S?Q @MYO\T96T=H)%H0.IE;%'CB+763_W1Q=
MSV 70<+0-Z(("=J/P_2_+JG\%)UG-P0MFSK'Y58IY^-XF=>!1@? DS"LW%P*
MRC2// BM;!=5"T[7MTK65!M$EE\XMH]GR6T%FX'E JBIE#)EVB@#ZEOG *R$
M,:WJNXL9F?Z/=GWWG;SF+C%U*.-^0D)0#O*9\4EH$%T!\VC+=@P* ;@9:6PT
MD7>I.[G4#_BY'0W[#JX<^_U6C?LCM83DQGX%4"=("^CAY@;BI\&FG=?)G\G]
MKX@M#F/)MU+=5O[YM)+N(22=^I4TKSS9WNS/@SM$+R='X>6]@T>LLWRA#T)>
MZ5H[UDY>X T_<OZ]GFP<@@X,%U!U'P(>75&94DTH_J9D1V_)Y 8+C>[O[WAD
MD=<PR_":YW=@J3$P;=L(;MP)T(4:[UE%_EEN[G+6UI#OF(;-QT[@.NMHE\.4
MH3F]JU%>O;]8FR(Z1W<>MY,\:JYU<_'AM('YCJ27A3S+2]#.2CCH+_>AJ=FH
MDC?Q]+X+<0*&9_ TX.WYV ?N3WA'L\U'),FQ-J"^ZB0QEE,Y#--0<@Q^=^6]
MEV<N]>54QDK5&/XXAIW[63&Y^^"J\P/RX2 B>"BCV9_3=-=$@5U=ZW/\IG1T
M6F6RYZWIVXEI\:HN]_==\N+AAW:NP-^\2(>3L=C@NC=V1TNR,>EMF,T]+>^R
MJH<ZX^V*+_RU6>+PIWQG@#%-6/IE1[9-D_^ANO$Q+MO7A^P>[3SWA;1FF?3S
MGRR%*7*F#0%%/P>O>Q\D>*0&W[V-D+@UX"\PI\-U(+'[:+K'\ \1,QFT V*9
M!.K J\H_A*D+=64"M ,,"\5MQ,/<MJM?<0_.*ME-5=L^W6.CI_>GE@ )P4!A
MAR^[ / !XL+-:(>81^-=W\WVO4]Z]3W014%!-1)X+ @UJMU2UQI565"[>..!
MN.CK_0VV/ C$D>Z*KHD<Y'()^_TVXA825 MI0 ]3+K"S *]$W<O&<E6'1:NK
MTL:0:K((BXVM02IV(9]>U$B6A=#>QCO 5^_;7\UE)K9I^'MT[-AE&OKE#WDD
M=?T]^QE+B'D5MZ>_7B3T[_BALI^7!;^_>HZ2E3\+I)FQ)'2AG4%,"ZB)N'=-
M=-+IR+03??Q[9X!GF%=TFNL=.[ZEM#D3U'!! PD\X,G:$W(&Q/J[^!=Z3^PW
M+^8N9Z7/I8_I!3P7F%_"?K5A2=V#!,:9LE!;]J'2?L"#+-7XSCQBO]C<U[T)
MC7TGFS^R?>@C*ZV4,K/(,H9[8$21=S=R?&'%/='LENMMB3D*C#G=4"/QZVV,
M]9>3A!U>6X^*=?(/7+Q]1A_!=2@>E8\ KJ#I'C$)02IH+QOIT#-N!&\C0N9>
M5++=;OUPNBI;?GZ3(S?#P6!RP.0PL(."98Q_#W'69JAX^Y]W_?WH($715<%0
MA;=N?DOAWPZ1W'$WBD3>$$UXC[(98-]?J1_T8V W?R.*?D7XXEWB$'9*8E[6
MM\^9G+*- $\46;K]-%:X&:'K,/P!3SI ^BL$":D7 >Y HQYT")N<6!T Y[C[
M@A"<X*A=ONK7Z1A"^04^9W6C.Q$CKB:HT4KUIVND%9@[1CUMYXALQ=-/&>7V
MQ4#Z:1 A1>=R$/!"DR5;!#MWHRM.A/3EF'?[-D*. \3/H!_> 5I+NKE%JB,J
MH7B'U>X[)YQ=Z2^3C:5F40MS Y0M=9\^!>:#2-3_*#(S^)]%2R%>-)56K#5+
MEL:+@,52/L*FM$H1LJIC=CD[#F@TT(YA(!=LZ=-V'AJ>/3DW C,A2X#*<#QY
MHQ>_YZ\7]Y?,Q"6%PB]1+-4M/&S[LW\I(VBZ-3FZ],OH,R_Z6^4A:01;]?5K
M,]>E2]T\^P;E K"<]7UZ58>AO.#*X+=PMIR3$MX\3"KQ##+3/- @U(D+8?KC
M3M.!&+([/'P-TEM'QQJOC3-N*2I=BUVP&=LW6-)2[]G$-F=U^C0J4U6F9!N1
M>DZ5V8,1!C%T&1@N)LUM2 '2.)_B'+3G/8/>NJ>IP0\Q&Y3=!G@_#H12>1UY
MQ)(<(MSE8GWY\#712@F/.$1GRDZ-GN+%W><*'ETZJ3T)'6,_0WL2'U_HX$]D
M2>7^?7#AC'K_BTL\V>0PJPC>\\M]O9%H)4@9'H@$FOH2*R'^)I_>]T^I.BLX
M^*))\^P5'JQB:!0D7,&.&=BG4;_OIO%!>MJ&77Y?T.$<6[_VFR<EV"*1_!8.
M",@+'N.#*T"C-5[ NR*=4MI.DPMY.SK\L;6BON^;(&'RY IO&-"R-'(&$NI@
M'ATI_U$T&:'<%AQPN]>N,?U68-LO.9^M#X4H@WKKN@ 35&MT!DNV@VF'.U*K
M;T/CHO,['5^E^.ZVG2898L:QW+!;_ND:-I@RHM4_9\C\TX\[8'#_C] 0:+J4
M6DW.J\.>[:X]X[]N=.>'S%#IAE+".;027_TUQM*"*%,2=]X</6D$VDZJ7S+7
M\]:XZV-^+76Q1\Q$EA0) T!BB7^+06A!MV%$/H\^WY7T2=&J=?4EK&6HSS30
MA)8R5:93'JMIGI@XW$-.)K5K)J+H_OXLL:XI]SP8UR2 J//T_K$$)^6^@Y*W
M'LXL/CL]32=U+7&DF"J-#>@^,I3AOJEMQ&.<;AFKQ'$^,\'"Z.,G5PX8O]IU
MM<_?;$MV3IE9G-F]:Z\;AC&>"S3JH*F?T:6T%2?6"7"RT">XYU>>;L:*4SI/
M#MIK CESC9P(4'/(,-$<OK2@V:HIU#5U3_6&Y-7*LK(GG]ON[+LBC8!^O,V^
ML37(R*)V@?JNK<:29&FS=NS#\-_QRAV'&BH.G.+)%D]:V[K/*<1L0G_<:#?P
MVD94ENO2^SOTKL9MZ9S."4\11N W!<17M<+BY[%'0]'K[>QGAH"G,"6Z-C#7
M20":*AYS(4QF;A@@I4)=,;%N?=HJ&ER;48IQE&^1Z/M(T,"9KX1=AA?YV_Q@
MX$B5K*SZ]YBMP0T>IIQ31.FZ$_WL !Y*$U!>(4W%0");D0 ,<4'U#ZTKI#1%
MQQBFF-@@@[0PORY0;4D96FJ0LI\L*]R$8Y,T8FO3Z=QJYY'JRG&C(]$MR4VZ
M%J<+?Z4;"D+WT)PB"?IMLX5Q.'FM9Z/X9Q-1<89F=S_@XLTPN^\G2.JU8V&/
M#2=3*X_ I(SW"!A=-J/4#*?A?^+(Q>CA>RU6DUV@@FZ,H87Q91?Z[_P=0)_J
M585-S"81WT>A7VUAYQH;A$9-8V+OAOVI&M38\<,R25S%]B+A+$*07<_.)%-G
M43$.G@NN ',?SIS^/OWB-J))%QU3-CH[)D[HC'Z-R>(WE/RZ']/PVU[GA!"A
M_<9-L_',#(W*NO&!+.(@M#\TJ]E^&['S]INS#UN<ZZ5#@^Q/?CMR1.OGH26M
MU[T1ET<O+QNL]X U#,LI3". ##5HGSA [B\C(V_J$(?7-U++>D;S;IR]8M(R
M>;J$R^Q4PQ39=!MQ?6DHMQVH)+=_J1<.U5A6UU I=B/_U!9X6NTXTF)K/D(.
M>_[2UM3LV@PW60GM_9SF 3I)3'U[(Q;F][>Q_JIL<M02MM>3):K0#%2B']8;
M>:.DR)[D73<=,AZ4A[9^*#=(YLL*\4Y.^61AJYBB]%O0+^C7[7VERWMO7FIU
M^:C%.'(Y[D6?!2U_<6Z"DC($)7>=$#1$9P=XG%!X>P;Y.%M*^-*>K(<'CA!&
M[XTP/U@=\DM)JRH+05<@A^>IF&;"L">U(IJN.>E>.;SZDF_H]$/J5ZT8=<7>
MW7QN:1T&LG?,:<XU?]#%[G.5?1.Q'S1<EX//87:%1X8:OXAC/>=<M8$1LK$P
MO@DEHD$TKR(X,Z([V.D=YTM=M";N>?(^E3^6M,:TU0\HX+46_.J5X09DG!SS
MQ7D<?*,IH:M?FOHT;WPL7SEX].]HB.><9NLV(A&["\\#GIYI(XL'W8M0^C'D
M&=02%UU%U9@R\N&HFSQ(@2AH"8Y2%K;"[-$VPK-K^ H6Q%KT^@W\D M1EPT\
M>D=(M36]07T+,\*)92[8T7N0T(EI(>0(S_HD@^]5 <[HDF<IO;]EV;%1B;6@
MM#.X;33"#O-W&]&V-"S33"[=:$5'$84!ST1=$_K$_=PR[JEQ==I4NH>]8^"#
MCO3 ^8U*VQ<%.7#8T453X]%\Z!L^/IIRX(B!OV0HZ[ERU<"'Y(*LKJ<5]HH9
M,WN%R^YA:'>?E)UY,55^0PTS4[B(\IJ*/*Y2@)[0&D&$?Z-ZUMFM/%A[5W:!
MK]JJ)K/$SOMP4IGKDP>!)I)_8SU^7%XIBAM]^Y-+/!3UN-/RK#C7Y26__8OM
M-[O(?>_++8,__MQO/X7?)\M=0->N/._RB )#L#9EEEP:_=ZDYP.R*QO54K^'
MOD@L<+8J&O7/GI@X^>LZ]L5'Q."\#4MF-'?V(]"H7<O_;LB^F;>EHC<L*4Z"
MN-$;I%",#P$:)TK\V-%:]W(^+Z_YN!*97JJK9R#A ;(E"3P$1PB1.__L 6:'
M57@VK/0NVN1=VNOVWV3L+AHL7\TO= (24.$(%F<3'9Q7?P7;2[->\7P")NC9
MM23T8\RT/YR?7QD5-/CO_?NYZ4>FU]9,E_;6/9AZ*-R<,8??9!\Z%^+ZXY_S
M0$,T1\*6+\N[:73=9, OF-HAG]5%$H-=!0'8J<3\.:L-W0;H=V2R2*#:3-1^
MUP8K P(HB-DRR1D9?3R/_4.#/U,4/8JF5AJ+E<^7>;NBZ#MRD*N6H)/@63KE
MU/G5DDH42"6==187I-;+G;Y!5R*(&JF]@I_[L/5_.-'O_K] )6W8/^>!8=(T
M@29$I<1<)?.QT$'%EBX188H4C\2\$=DS92]SMJ19X: <\S;0&$;VT(S6UVPB
M\H9>I=U-%.%],*'3%_6DJ.'KL3_DWI=321=7"M$.-J6.0)<V*QH!O(1#\ ,F
M;-$ W-[38-1D?W]7QB"D^&MUR\QA-_QT!XJ.F?9SL8F6.LM$+5S=1DP'08_N
MS%7?W4;,7X^%"H4Q4&-WI3]3?-_:\B!+A8>UK(FF?H##.E9S)&4,]&PT%OAY
M=^_,OA-F;V3N\%OO;5_"$K#T2X0H@'X9&[6QA7R,]M&4!Q_9L3P_>91'6 ='
M2][:\\:HT42F) &S]>NLC\_.87&+W&X5"587T-BUC2AM08D!+H[$V& =<Z.E
MZ'SSAS6F8-^=7S.D<,16#;23T[5C"W1A2D%?\9*#M=)3&Q<82@3?L("[S1H4
M']L7"433F^S21#D8,K>$#_Y"L7:3IVGM[5V@LE1S\8TE_^=OYJX.[+NZZUR%
MC>8+H ;[\2>BBSB20%BZ/)NS<UUWX^W%X+@(<<3%\V.4<?9-2?MG8C5S<8C2
ML__$#8^UY>=P9WZ1*>;T-^ZI]#V\;V^>QZAM)@W]*%+)KCTPT_6@KZ&GT9&:
M<7E*ONV]6#MX:597 #&K^2L2;AZ&ML*=?4HID7K^DBQC,&RZYDP!V'6VI#_'
MK\2I4;:'6'C[+"Z0H0 )1'/$W\ W<BP,G=#TZ?RT\!%OR:^'X97TW@2>GOZ-
M($TM+A8+=YZCV(F^3A:_F7HSF[>\BO[P.SIXY,JRPPZ%ZL??8, CWP.[5B1>
MDVX%5H'N3!-PVCK1^NJ)(B?]77=E'$ZC+:#GP9KY&I*1Z,Y42$2;G8+V)@W7
MF--%2AF6[1O.!GV^']Y(7G)^TM?2[JUW0U>TO1A_G]/4FTS]@*;;RA"CPJ6B
MC%$X=4!\5E_N]>MK9SQ?M E VFU6$2[P,@K^6F"'_S+!6Y,YH/N\O.W@I7=8
MP:+DU!]ZI%$TJ+"8/]G%<3_C>KEY8]F2BE)DP<(3QY9DOKL>.U(BW0MY-BLY
M!T_P*UK(99AHLB=6C*7.D&IV<FPP5B.7I0S(K.SX^/CYT\1OOS\>#1?%-BLW
M(!_B==@59&_A$Y/?M[+,WX4^^'V0:?6K)LDI\O=8]A_R4"XDJ,P4"46M_V)G
MU%ZFV]CUW4K*?3?\52+MUY-7Z0+TX(]WCA^-$ :2431;IAS4MXWXB&P+[F6=
M<7D[&Q+L=ZB<7$G9:6#^6_&TWE[^*!/4$'\3!3S1UQ "[:ZL!A.G[1_E'U\\
MR.>!;8CDQ7,H"1:V_\/L _! /&8EB;M]M<$@(\G-EZY7GX91-- /$[++ISE=
M8JDH\+!R VD'Z8$6419+:=SW37OKT/=W1CS?$]I72%W($4<8Z;T#;FF*FD^A
M$IU5^M<FTUTDOB]VFPIT=:!VDB-SD'(]]0I@^O3I2KIXI<A6X-C9PXE5U]Z8
MT%[@VLB#[9  UU17#)'_W[X=2-99TMBPE\,U'<'><[^O)QQ#I';O2LW<1LB^
M/&+P>>WDV>J,M&NXW)2 OCAV):.+%LL,P)F#-E3@(5I<*Q'?-]D>X\)MH'KR
M=V5EU;5=4L=N:38HIYZ->YHU3ASBIW%:$;_@M-WP(1&JB0N<WA.K)<G%5BWI
M8J%)XP(F/2GOYS2_YP0T"S+)D !LXAT*L&OJA;9#L,%HASD-\!7:!U64?.I\
M$S<?35V2&]\U^G&8*AK',F1'DZE3_D.IZV?!P-<LQ>[Z/:/@9:;.A*KWXO6R
MPX;+_]QW,'=K?[;0XG<H5H\TZT]%L60%_FWQ _;L0(TXJY9USSR_DE8-:.Y8
M-RA49'^-ZQ6R#*JLO"A[,4'E5!DR1P(4_O? NCD#6P'/7M# 79^ZT[_=(ML#
M=@;*8LE [97[FX-_!Q^@?;N&T5.&%C@Y!L]9\E@5MVJ:.FM^I6]]^',_SHEI
MCU,?,)2:MK24TT$?SBLW=]U&F,O[W.TR'KO 3WMAIO?F_'/6S;UO3)D)(DL6
M']VLR$8(MW,U,N(C/;Z),%-'YI_^VYRZV<VK?W@A*XQFM9'#_=#3064J4J-=
MB>)0GR3_L>_7W-9 <:4%HOS?#&J\6+^F?BS+)Q!FD*DVH,$'CF*938>Y_D*_
M^AW\ISCF94BX,NL'[(584)7_:=*I;42R&RF%3*4-X>"H*)X2-/S6'L5*>E"?
M!4<4+T]O@/H,+SZSF,$#0>8FJ.X4>I76W[/7FP^F__^9#4X !@_G:%>/2&[>
MN0*)<[$F88/U;+WM(U,SY!5C0DY<^X?\_(,8).S6<^,3.VI@\Y'TE)Q>Z3:"
M*ST7_I(/Y;RPA1]X448D&S,N/';]*QP^R)(Q?_6!<^I#HZ\-;UIUOHQ/7H5S
M.<R<8MS:T8E 5@A+ZA>[%!*JFBSRJS%]>FP;<:N7W(M=5';81FA30/6R;<0H
MBG[;.='+>E(V\P+ZX<5N_BV#T.,HU:;,N\!8Q6-@^G7U&O/UQS*MMN2;L=W_
MY*Y*U/T?Y./_0Y_9P^\GP_L*<W9N'*.9,BJWKCR]L$/>)SM7G$8C/+_IH,(M
M$0(=PW+VBRX8[R7$DS_&M  \R>E5O>X!;6&/_:"TC=\!P.XR%4-;JB^V.41%
M3K/X4/3]13G.)00*)"S/SBF/Q1W^ /UP>/^]9TYGXX1I@C6UX\X[4X/;/LR@
M).O;M%72"N?P7#TT>WK=&OYG-I1"5216E]7UK]49G^RR>C"9=^WN0CF4='C%
M=.\N_U_=?(_6UO(FLNM\EI4A02+LXE@P +9S#?U-]!16WJO2@3JH+*H6G'OH
MRN)F[/3]BBK*L#(D!#"1^ %IH[2!U"F5NP;,UJ^E9-^DXA1!(EZ%9]U'U63_
MLFHB?2:1)3<UJEU+_Y/O&R8>I>+R5,>,ZE,<&VL=0#,1^U_W$Z[8',\WRO*?
MM@]$/QO60FPJ+?:G+VFJ/,B[2[ETT/.W ^+^0=]ACZYRF[6B8Z=J$FRC*[],
MYR,\?;5HA+C^W7F>P0&VXZ^B#>?.7=!/78Y#O"L1X6(?\5?9NKOQP7FP'8_\
MJ1TX.2]\=<3Q]SXOUV1[NCY=E;0Y%M"TU;W#7(BG\2WK07C<)^+=&\\Z8W*0
MOYB0R&^Z*QB_+DB'2A&'RHJ=QI)'PPM S!B6[E>9])H1PA)3;4Q>'#^4:L,3
MF&U;RO:I@<V\C-N'3:30;33%P8@#*\KE!^\*&A0J;V%^8UG2/HPD=<]UFWZ\
MV-_C/$&Y\R$![]V6Q3IBR2\1@+,RP,5GA5MCY*YCV"\ K\0#94!BO6!/K14/
M=RYM(.#\UYJH\F]+J"A,M]K?YX&1N<5XCA:2+1RL88_F!:@OC'E6M"JB6NHU
MZR8JPN_(48\Z"RWLGS8,RD$^!/QLP(-$EBA =8X/8'A.A<04:^T<.G'H/:9R
M=\SH@^"<K JSF]#A^D-@AQ6[RM#?G:F#;R8+P.!.T.L1M2$C.+A3>^Q5$D^'
MX1LS69'../9YT)X)0XU&<S1UBIQ036S;1B1(][='X\1\#IX5_B3F[Y?\W2YY
MS^YA]/X.G7N8#==_]:U/;"/<L4.8R44BE?(0DOHD5=%CFO(W)2=]T=.$;WDI
M1>!?U=;[FJ-1T$Z]20JH!"SX3'8E.>O_I-@SDDI)=G8TY6,F).&6E.O<NN[)
M^G$0' A=" _0?+4A3 F6?D9;MFA/^>F10\_]R^W.:!I;K+MI;TIPCAY>FS'W
MA)H4[&4D9J#7:4'8*B+=^JHY^H;_HQG9;<0-F+W/YN>(G)G"LO940@(TAD=O
M*,Z>#C31U*;_I,OIJX9\_1ORC_@,@]3NSSD1NVG&$IN?.C\HE;U3"MJ3?=73
MM*3ZQ3O)54Q:!L\<]F<Q'.G4P Y(6!Q&T@*9TU1D6^>=/N)3\]L]U\/=SVEO
M8I@6L#E4 &H1L:2KG2#@58UNL<*T2GW:D65=K7O):2<B^2/RF9V(J0_;V'$Q
MDZ7%KGT_4\NNKI>R1,5Y]%[<3X .S>[.VT;4^]E].K9.Y93-FK$D^2&A/N;^
MF_S-]>AN0GQQ6<7RV-A<,L0 *'&*?E YC=.0.:H:AF^"G;(H:3SRC%_)-N+#
MT;-:;ML(RGD?)ODG3ICZ,D#V[XA1XN#SC8?KLYM;OZ3II+WX5N 30$AKCZ^7
M"\4S.U&ZSSTBB5\$$9 /I[W_*+J4T.+X^>Z2-'AIYLSS%ZI:":<3IK-]UI>H
M@RR)FO4#8*L+[V]BHM;HOC?MBS.?$;_66\.ZVFPXV_IBRM-R6>V%+(V^N\-#
M$BOOW3Y7*"3EG#TX^ O9B@6USJQ;,]071HA-9+G0C*9E:ME%Q_&PY*(UU/P9
MXD D^AUJ%RX0/#;M1*;'@ADV]2O&2ZGZ%8""<[)<:V*3A\ E*\K=!]+D**(8
MT/@!54ENCDZ]P"9">C>Y[>ZX2.EVHJQ?'(F;A-T\$D4/0"_L"V2_*@AMLI&T
M;[ISXZ!J^?[P):OQ.B\>)I0;!RD:R\!SU@#S%9OHC:+))0)E9_': 5&9Q4L#
M=GD*53**/*ND7DU!^#7MVPANQ5[:HK%BJ*Y]KX8 M[OC'=N(<X;=_*LOR*%7
MWQM<(@NO(D'-+I98GV.UHRYCU[IFY+F:^Z_GL3=Q1IR")WPK<0]-<KH9;]!W
M[2._2ZKWS.#!2&.F1EVG"IQ@:VN:R5+07K!BPJ!+Q*="-^#<\7PE+(-D4D[^
M]%FF^$]B.U,-N9PC?.3!F4=O_^X[T5R, -2Q].!;IC:@4MV<(>VGFCEZG2%W
M+X8E(W/' _Y"-S#(\4G*.7XV*Z46QOAUE9IPX/_1;[/A?\L&.M_NU,Z2WK@W
M P]->_6Q?MB=S]N(+RD7^%>?_>]U]AR9PAK^\960N:M'E+81=FC80<[#^('M
M8 D,':18";=4O]]/ (4PL_XL&<;K9CC%-YYD[1$-SNCS1?YZ1%9#4Y>,SIUB
M'O3:"EX(JWZAC*+SD88)X$'YE&HL2XS<L)OKP98M";IO@OJ0U%FV2%J!>>B#
MU[HL12(](#\_E]4A1TM!@KM\L',73XX+C';<('>BURNR(#$4J'=]A#W)][$$
MQ73;"3WE@IX. -6?'L@W(MBJUD5MDEH[^7GR[?[K8.9_?R#_4P=*5W;?^=.Z
MQ/"[Q. <E+,7]_C_@@=F&H:ER<2;80=,K4Q_?(AQR4&NW&-7K_YA)Y&IDQ$R
M4Q69]4[UI*ESXU\G \,D'==N;B-,;03_!LP;RY?VBR4;JE ) 9G07@[I1STL
M <6FD%%H[T0)G6NC/M7W3A0V'CBX:/:9-!\""70P$HWUH#9C;O#9KWW:ZL=U
MG_"\V&W!:0"S2AI16#_+SB;?[.1&B[#"Z/V5C]6IVX@KRAKU6&?3-JP#Y ;<
MM &U.JC(A#4KLW9TJ6:B-IGWYB>4SDCOOC2:ZQ/$,6:#(S]J@K0@3K:J_?/Z
M1@R)'\://RQ;T9]0G.Y2 H>*MA%-7\![4WJU/J^\U2P:?\<_#=UR:9]H[QR*
MV[*DDEARQ4PSEG:FIC!^B+)STBQV_6M 07. OU)O^,NE@ZNK$NSIF]*F:>]'
MZ[*+?21^JF^DV+4\QN<D^?P"XN$\2A@B3^?=0<8"(F4^&\D6&;O#K+ZTV\5U
M\\^0%F 'XN>'&H'R0WF\0<]8FB%JKS5+_QZG76^76R<5XZM ]/I#\/#TZX*F
M;*4^4LBNPKB[>EW3V!\9-.5M!%\)OH4BM1861(BN?E-"-;? E<QE"/TN6E?X
M;J;'\EFYUP+0;Z%H7^GIO]?0PT7KC\F1S=\#L'+? S;,9%1XF*_C;3]6(QRZ
M9&O(GQNV$0H8Z;N/I]^2)E6MV2_1U&G_(;\V0-8;O[\4C/;TRAH9C\GLK/QX
M-MEN1F(0QY$>*S36#>6_ZL^+'P,$E'H7:2_:%;?NBC4-.XM<\@"ZN_G7P4&K
MKT9_ZX"CX2$L.3A#[=C,G/\VX*L=<1+HLSL.6*S>\P?U-B !8A#/M\SBE9.S
MQ3Q(=GHD.O<BYD:\]V8KH#FA G]/,9I*K)>[I/8^2 ;ZW.@^!^/A1!R!@820
M2NSLNU&'2,V4Z,SLXOV3\I;C<39]7V#Z)Y^#I/'NZ]_)@\ <F$(_=MY-]WU.
M9I@6^+AR1\QDVE[#>Y C_??!JW< 3;^ )$@AJ5W#E$FEM(*OX19GU)*=K(Z_
MH@;.')E1!(3M.55"._HXJEU H_53D#*-:?F*$WWE!*V.M'&O47FY8E%T!1-4
M'Y'&*?L<9<<"KHZ'7_T,>H8S*VP[KK8Z%Z5G',,5#1Q%R9&IORF@BA3M54@@
MW6=='?3A2_0M1@]3R9(K8\YYOFUWNGZ+F&VHKOFLPU _ZA+9$QVC7TQ.0'M1
M)'WDT?U<%"U,H$IEL&&V! \7<;UH2Q,T8(KAOVTC$ O%-&/Q4*ESO<*?=I@K
M5 KOYV$7C'GQ;'+$%[6!1@V FD\1V49XJQNLU[+?U]X+.)1 M^[S5OOZW+A'
M+'K7Y\W@4IX&.54F$N-%C]-#%9]+9[P^8OKJRBX$WS&++QTK(<ZK7#>?1(9J
M2V7]13M<UC"XP$_ X4# G7%B4J2..KHZ45F1\E;^]TX2E0?::<,( FXL@4<J
M$] >R'W6%9G!K]Y5'_CLKZ9Z/II+;WJ?$'8"14,SK[+DV6F0K#/+!'Q;:,9;
M7.O+?-G\/15!YU<FY@,I@RSQZ?7\_OJ3^*$M,NTR'6E21[=Z].J@4-CD':>)
M@X'[?7-37]S-02XT0T*P/_*C'%CR5?V !WJHR#JFQ5FSFN(1Q"NL?[J%QA[Y
MP'/TAVF(.HY309\-VT20=9U=A/-!TF+@.9/MURS?$3>);\T=TVD\<$DNT^3H
MZ54>"<XEB!VA[ (T-0U=2HY_;WP0WU,=7#Q%DK&>5\S0+XKUI6947=F]*V%E
MY1AI*81JQI*P7!<'J][DD^_77O9T3^#R:_A':D50A6>1^ @0,I;'[:>W5CZH
ME^$T''A^\VBR8^%%2*GNL*ANYK(3<CJF"2O:HMAC>,KU=L%BVDOD&NETQ:"6
M3U2U4.%+F]-[4?,FJ(Y!EERX!'!#<R<5^#[MOHW(&]1FQL*_<ER/_;A>%AC:
MT[6-.*N.EP$:!T64V(\-#[IRE4[+:&PC5FF!V,\ W7H?,+T3DO7]]2'&D\A<
M+>/:T);8C;O-NK09;R("U&#ASZJ@Q&L;*:_/@-XY(Z$Z70YQ4\/[R@\GU/N6
MK#QS.?VE:.G+3?;[E3OO39CEX&'F/:S7;J#Q'[SDJ;#BFSI25I[R'8Z^V>=S
MN_P<[]Z*^.QB@JH[ACK&O]<AHP-K<2L4I73$@:.8EGMCZW)A#M\"UB)7A^AJ
MZ*Y!33IK]/P,<J ,3E<Z Y D[L1 HW3%_8*NFK<^;LHKK:$Q<6A7\C"A=0N7
MZ5%*+3Y^SFW'T66IN@CSN]^Q/K;Z"-8U-AQ,J5' 1PQ-ZDUY>5<,Q:1FK.7:
MW*=:JR^K:IA54ALAED+W"KGO.^-K2<6TDL6] \^U/'-/%Y-.:I![SO9A&F!3
M%QD8VLLO:!AN$#/BT-1Q,JB&:M0\<0&48\19,N_YW4BRO_#-9':G BH_S(I,
MX^+LH@.-Z!FFYV,U=X93><&BQ35[M<* 'X'R S3L;#=3[#>^OCRF,-2U.?R;
MH4,]T?=NXN"/6#?^%1A@"X::02)-G-T_D ]8Z$JB[%@M$*4["SE^R>MZ^WT!
M;<',F$2SY(68AO/J(EF,>Y,#;U^/B\;*']Z9(*_/9^H_0'Y+D<)_)9;J$JX0
M)$.19^N$!R->W 2T$8,-%!2:FDRA6SIN(T0F0.(4LKD891DW<4*MM&U)M.F!
M#6-Z&R&7@YR!^6\EO +"V 2R'Q94%GD[B7VX]1$:JL[^<>53,CF4^YJIC8S9
M=2M\/$>VEBP)[0,O0P)K^;/R!QB21)\(Q<6SM:E'SO%MZC_P 4?!+*8F2Y9=
M!T<;!O2%7'*5H'-_LJH\5EUX\%G??=Y/8JJ)8]>?WCA)FKUW$0YPEO5'01[+
M&&C?RO2'TKQOXD?C;M1?JL3ML%TS*N1A/NACN4PF7A+5?I3K>WS]V+>"K4$S
M\:\:<CNOA^\.Q#9@X/DA8.G.J.&75I1F= )IRO(</N@"@AH8534_/8Z%1(1A
MTY;B&X ]8E1TFYRRZ6#Y/;ZS7B27YWD!^[^MB,__E$9L(RS)NDDOMBZ=R-54
MEF#QAJ(@Y#YP^K65-,L35'=C)/CIXS)TOD?8+#E?Q.9P1&67-(>%IN2^AX<D
MX23>@GX8W_SLF1_.8XR=:SG(^9X08'<!YD]& Q%4U5VP82Q95U33*^-]J9G4
MZ-UC<C'*[ 7,6+5FZ]*C[(/MZTJ5[G>0IU,/0&5<<Q)B,*PIOW*C_Y;&3M$.
MF:CN(IZKN[)D K#Y"$ 2YFNAPDS2PL;D_!E"UL7(;<0T =M-8(EN=?H"5"):
MI.G#B;Q18):;_-(&-#R0!8EG/ H1)C..PL'-)!Q*!JA//S7Z,!&XD[\4@6'X
MXXY-@Y*1:%,-):91+4'YY&7LG_S 6Q,&\)1DEE_>^R6^9;"'L8TX_[Q]E;2Z
ME_T*?1,=A>(VY"\$4]NW:,6O'?\QOWPDP_\ZEQ*Y"P,)O)SR55C/@=\<J;T4
M7[^/8OP\<,K*X<_$>5DMZ^4T16J0.!?T[+ZC07A_M PF,TK"Q7@VA_]_5#WZ
M#_WM7!_Y\5O<- 7B\O_;A;G(4"W*O^7P_"L43D,)J*.3>0IHU#.T+_::E;E,
M;XB__%"6^Q\U75?T0@D)"?]$>[P^EF7#CD1/BO8ONJ;,- T>=HO]+"7(<^S;
MK^PU9A?S1JA\^Y3F0MTT>2?V58I!YYZUG7+FHL<D6$Y 8SY*K*R+#^<'UC%/
MSI^:(B>="?/;][G%3S3#S\ O![DD0[,.+U8>41S_(U\NW;(TDMVMAPCOY@XC
MS9^?:'_[-F4L>[/(W$._*F?72,(_I)5/=V<#'%4]]Q!OEOPNR$=<%[^4=2U@
MSEEWFC)<2M5LO>M5KQAJ=K[_#/M/)N]XU^=&4DYM(;G&XG&<L0."5<3H8HG"
MQD^>WG3/PH*V!6J?@D(]/B= *:[PRB9E:A-!'28D8%]\^![ YVR?NHTP)%T#
M# >7X-E@,;V)=%\;UIZ!3EP'41!K,RN_F<3IS7$J5 K:>0;.)V5@Q,$Q;[)0
M\8=?-M6#NKHB@!DWV64V!YF)EX>^4DJQ37EV.!YJHK+UE0N1[7[O&\U./=>5
MWA+YUC;0:)BE<FEO.[WME0FKR/J_MA*3_HJ_^'F'UB7GTXS7PW>C8)+IJ;EC
M(I0YU5;BFS<W\+8V*U9"Z)[&U'$OGJ%%C>+WN??BJW9<+.PP^"B(6#0G-:#
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M]07OIXBN? ,BRUEO[R$N]\MR#$D9'.,:X,AY'#$8AMJWAW#9X(7&4)RAHLL
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M"SM[",>L:$ML.2_4TRH7XG:3%O'CCXU36E+KC[6U(7ZJYG(6T=.$RA]-& O
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M,:0%9D.5L-#RDW'F2).2Z+1.>"=_?8E'&L^15Z+1PD(PDAVI4BE4<HH>WT,
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M2P^LD29R9D/P B-(:NI7S" :E%5-!&^CHO+W$*9! $V@G&%725]JDZ_\G]Y
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M:&=&3_/Q<@,; CI?3\=R6#31'#GFUW8CZQ"\)CF3DAIV*8'3RS-7*+>N7:F
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MS5Z(&:QJ<;L<Q&%1$@C>SG#C'_5?RYY[7"9J98,%FJ.3@UJJ>=.:?7/[3:J
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M]6M;G$E-N0>/0_^M(OLQ/AQ8E.:PK3>4.&$0) D[,46G-&&:$9V7-Q$4ZNU
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MZF'Y(K+TA[29V9B_Y0?S^ R@+!9#MMUZ&[+LO*@*W<(0MOA'DE^\-0S=KP6
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MR9SWR;" GG";3[CN(:R+JYB;W)'(F&>*E4S0UXF*&2+(3PW@^C#8;Y# XN4
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M,I-CM;7Y>R'.=[@R%)\I_Q_YXC8Y'/I2@U]"$_YJ.BJ=G?H-')+^&*!PE:,
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M>0_=8#-MR\-J_!/O]2(]KD#G.DCLPG"XWKII@O5I:J=H<\6W//[H(<'+,2Q
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M0<=F#0(*-_;+&PYE57(62B.U.7P4]K%VN4V*8EFQY))/PJ4@!_3KNY O>/4
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MZ7($M-[(TNK?R.J"[J[@TX^,'<U,;?U.4C\^GL89!7W^/;NDZ7Y!2J3>'VI
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M$* 5!!AWMWR^%[JQT6CM/B]3RI-745EE75V;(/QAN^[B]A5!MX:=V/?7=J<
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M[$$QNG;DJ=#+;<@H(_1>__4>5R.W@566$5+QIRW=N"E(I0T]?\GB%7EL/25
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M$WKT$"H:< XM'1,='1/T&,LQZ/^Y4%H!=D8J%> S#=4I@)J=BH:=BM(!P "
MBH[J=P'^+E34H(WT#(Q,S"S@@.KC #45#0TU+<V1U6!O,-@/T++3<9R4TZ8_
M87J+X90G5#XL^16CR,6*3YQF@UNB"K>]PIF8N;AY>/G$3HM+2$HI*IU75E%5
MT[FDJZ=O8'C9W,+RFM5U:QODG;OW')V<[WO[^/KY!SQ$13R*C(I^'!.;DIJ6
MGO'TV?/,O/R"PM=%Q25O/E165=?4UM4WM+5W='9ANC_W# V/C(YAQ[_BYN87
MOBTN+:^LKN%__MK>V=TC[!./_*(":*C^4_Y7O]A!OZAI:6EH&8[\HJ+V/QK
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M@1H^'>997/U-UEV@E@+4&7DDG-:I.6?$)9<T55-;YFU_CB""K^RRJ0E/L0]
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M<>T9[T#<?<M'T) )CZR'3U/358H_NN;.3^ V"@(MRSK\,][;3;0\=U=T.?-
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M(+&=E^ <:F9*'!H"\O>'0A2K@!!%TP%3+8:QC)2,4&9).2,MNJ-/"D)5S!)
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MJZ2#U:-H>X57^B96)/)"%8M!3RE?_P=02P,$%     @ ,X%T6, 1S-AB$@$
MHFD! !0   !B96%T+3(P,C,Q,C,Q7V<T+FIP9^R["3C4_]L_^I%D-\F^3D6(
MD&S),J1(DB*$F$KVAF1GS-BW+$GX1B&R+U-9DXQ=*ME-R#*CLDYF+..#6<[T
M/;_?LUS_YUS7<\[U//]SKNL\'_.^KN%S?][O^W4OK_N^!XQOC'G@\&43,Q.
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MV>1NOUUR^8^"G:J5#ZRWZLDJCUPKOUV6>]N:Y!YO-)P5;T0M9[V<3-+7I4R
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M:$7@\I16O)WM*99[YT75V/7(AM*CI&!*$1A*GK-J>T,*>ANHE'=:W'4RA;4
M[>)<_T%IG@& \FTQ)%4S<GH2'&^+"2]?X4E6R5XVY,)JJ<4;;&_+]PY.271
MZ^CQN64IFB'51XP3"S]NRAIT,;//HJA-?@0]7XT]U*!\R\&25N+">MKF??X)
M_N?Y[V;@CJ!E7RXT34^-/3% WT3*_'(N3$WEV/UHM5Q@R0/S(@ ]/8@7KD$3
M=*TQ-7D>BL0@G"B N/V*+U1'<U$+3;+!Q&@[*UB<^#6F7!C,T31ZH>BX6:__
M^[-,/Q"Y[CWAR'K1;".1/F0#A:Q2I!6&B9I.*K]T/W.73]QT3_GI=.GC\9H9
MHM8H.TRN=V:K3X/E!XJ35D67H)X'X_SF:P0<M9V/Q3US_E9Z^L:1T,&&<"[<
MXN+:-'X],@C>D%WCC^=UVUOMD[._TKBIP!\_%>SR:VO0:\^=L$CT8Z;$?$%J
M/98[))]&#+2X4!YG*(&Z[Z+')-&&8;@,]0]CY2*AH'>UUG-?E8:*XNE?!OE1
MPV?4^V7MZI&<M"*JR/Z%$+]M-/N*>;"D1:.'Q(%+Z9*GH0[ UJ;S";(+I1MT
M(EEWSWTS.(5+*ZB(G;W# 9$,W\<U)O]= 2J6GH0\HC35C=XA.%8%7MPC.@"T
M<-"<G--9(-&J-;4>&WBLPO/SL:172\8 '\=@<_5@*K3>,JH-</2L T=MZ5\L
M+GQ4CA\R7YM\GY*6?Y<>N+O#K#BAY)[!>*K% CI^*D.M5=;)5" ?V6DH [U8
M*T/G2H\()Q=3GC.!1]:_>Y2J^-6,*^9QJ9'P0OJ^NR'T%0-@9P!>@PE0J6W=
M#[H=4\-C/L3CZI_BM/ L0'X;H6YK?5H)[U9%EFKE1F!RR$>?3]/R/D.1/!G/
M<8N^5/ZIOGWM!?9TA$1.T^BOV(+  /9=N[^0VJQTZ3M^?=3>7PQ@.(!EO[#A
M,_(RF%5(E2.5S"52S8,I4G)C;O9OGJ.$QNT^%9"L8;L::%$T3A&H8S;T)T (
M S!V1,\Q^:?'SH^TPS2J&?G<AI*%0*\M)/ADI^/@&9.U"$ .J\;TYHN"UPP@
M"NVYGG!NMH&0Y//D]U=:S<(&1.+\RVWHK*8QA4I+W$)/JEH.Z]G,USS\?;8T
MY[.'$^52:D;T*\F=0LC4#S\YL:LW4J+/\5MB<M%WYE*MJ(:T[ "H0$C:XL?P
ML^*Z>15?66[<?9FTIU KT@O],Y3DBXV7OFF(,';8N*?6.J&F)"^U<=//$.J>
M6Q-1[K@<],3)Z;LI B'Z^;,2FXWTJUPR)!+6F- %G]+:0\"ZQ%\Z69V8G= ^
M:W_IM^%!7 >4=&-P:D3?MSO7-QHICW&:*LW?#_0XALC+"S+\J+/DP;KM<IUL
MDE<"!D4$>;\Z=^-T/=%/[/M[0#9C=:1U9WZ=:$S:6>A]&>$Z/W-OQ4[84.-S
MG<^0?]KB$"X5]15;[]Z%29VKHZW'WQZ3RPI '$Z]\?A,HA&/J1X.R@P=RA#J
MD*>T"MD8>7(<$RA!N;#O,*/ 8CJ0<B?] Q Q8^ZL3UZE5)+8UWZZ\+2ICF=S
M/V, 8Y,78]33KRE]1$FB.RS;^*B&..)60LO[H=\JLOR=>\F*,@*CCRT=@#UZ
M\H*!+-5NR$ (/++8,S4S,2/,QC-J&O/8Q B:%=);P2PO/""LA&I01_;V1BC7
M+)R9GC)A>4&Z),NS%S/+G*LK=X(??YON]_,_TW'P=EV_S)T;?*]R=Q_-IU,%
M[?"F?1"!'CS18&/A\GCIB3L)UVR,C_4^.&V!Q##WO4VKDKF$,) &[6ZUO!FK
MF<$V'(]J]+$R&6Z69/:SM/.CVQ((JW&5^[]E6IK0[T_=%[,<&F_9%:!PT,I:
MQ<C:^%])\P-R>XZI://7D* G01W \\6QY!EPF+DU-VC)S'"1<[STEUI5U8[/
M+;S+%()2/_ Q)]ZR<DRF@2 #Z#!'':9>)[.5)C;EG),K#B"<S;2Z:/CE*C"?
MW[ =\+!ZN#H1GQ'I>F>(B?+$_X;/2 Z45A*E<T*6>NSO/!2[RJ%KJ6'E#=W@
M:&, M<Q4*\Q5./!3\+HAVY]U0EFSG)6T2+#.8M+5,Q,?$ Y>.M[+ "QUDVGM
M]4>GC-+R'18V,)_2047V-3P!QDFU&C70"-'JM%](Z=UQF^$6O9<276NX=M7,
M8'QYCH.9H!@H'QQ/JT>I1S-W(0L]5Q+H\?6Y9V9OHIZO]OP:^Y+D7D-JS<BT
M13B"]S-/]9G+E3_"#_C# :85[QBH>!GP@I8O0]ROM#X96LU4>U9T=C:I2:G@
MO'B;Y9B!*O(R[1W6FYO7N'W$*\P@Z^";7JQKUOBQ)KM3YAEIEV3]X7>8NUR#
MN4?X$MC7]E\Z>QXVJUYI$[O^*XNM).2CQ/0[O1. !ZH3]L:TJT9UWB"K.N21
M81WY4%U-SZ*E7\#[Y IY "6*24%[#![JV>>G3X4)K4>[A4NI;(34LE5**IIL
M"-[K*U7?Q0TQ@#=PJN"C=M1A4-<;#T\4$5@6[XU/Y2(F/,@RT@OJD.2Q&\R7
MFPB$,V<-8D;)BK34R"*<9WFT5V_'."Y>6S7[['S^12 03K(;N!\2TXWE"_1^
MZ"(29!(R_5(B^XS2VEPL]@VV2Y.6>Q_A0]5T#T>7+ROY&;P\EYWU8C3(GY@+
M+M"YA<HZBL N/"T6D!6>2!57+2HW5-I:Q8<.ML/Y"O:BC!E T44 =0O=<7+A
M'0E+-%J 03IT]L\V>30O=VGQP10W&4#*5'[=OA9]2EJ.;)F&E)U5&?51^94M
MV)J:@N!^I]3P]I AAKE-]'U=##%CH3&6_>G%8Q?UN5U?*XVW'4=-YVKV]56M
M,^=#*92TO0/XD/V)X(?F*%=4L^FM\EU+YWJ6'@;0.4][@O72G>%3Y5^JH\+&
M[_AM.D8E&,3&R8AAS)E;YU"-&D'3?450MV.6?ZPTSWP\;VW8J3HJY7$YG\$=
MW$L,,RP1-3(41,OPUFIZS(:E?+*//!>">/7.-_]O#_C\G ?(511?,O81;/Y%
M&UO.C?K\33AI:=_!,4ON1ERDTZO >1\-EM3]$]0+M&PD.\EV^BJYYI5#3N+Z
M6-ZR"N)$T*WT%HY;?IFWRM:4R&?ZVF&-XU_3YU<K!J,#5^.C%2;%KL4?2SC(
MXR):VT2Y0"MD .Z\L/FU,'@WEFNY<59^Y$9QOV;T)1S P_KD''D/5TWOF1/7
MTR&/+ISH-A #-5\M.Z@\4]((HYX^KF$H>9*@MGG8/V6(_2NZX5>%=A\#F-Z;
M[F@I&7OBD1W<?Z]Q=_<\:S/]=@;<ASX.?3W798]U?W$'J8O?1T!LAJH="!-[
M8XC'?PT]%UB/R@7+* NDMIK]<_2I"?01N=$?F>=;/YB/O;A!U,/G&#0+;<T1
MA9C<)4MB3S%@]6)6FOQ56[)6T^TA6MPQG<ASA]>^#<X,E@ A#(#*GR\7TXT^
M7.R?<VGRYGZD^BW+M5$&</+L!'9-QH\91*E!#(!D CNST%UP6*\CR5F]&;HN
M]0XCD]X[1/_,O'7=PMN9'%%/F?):L:J[=/B)2X"B9%A*P4@DS!@[7QY#5U-U
M9@"8O] 4+W!]'M[]:#T>3KJ"%5D1OS_@&^&GZWA1,= J^#D]ZQNZXSS3V;Y<
M5"]0W1\/38A>O67W1#=O]6=L(G$XM$-&1M9]HUIUL@QOL=X+!>7F4C0LM&3\
MRJMK-%N]SMAW^+#/6P"A.6L0,NL\>R15K<8+*W34PK0;E\.3V*0U<KE*6/"'
MD/,[Y=DW")1\B'D[K$DK@6 9:VV&P"/.;XC^BC_K=)A3,O11-+LDSFB?DWH3
M5"7MF..04')!EY;?2A!.658[9\)<)@W8^(KO/6VYX#Q(*J/$D=A[+*?.0#FH
MNJ!R\4JNI)VB]4W'&R9)QOXGN]TE'^H40F3^-(+,/.)D)^K,;]FI/?JL0'>=
MC^R!];9MMM >M0E-T@=R<BVIQRF^#ULN9.91K-P\+[C&9*X^5L)C0<4CU;"&
MIN@AA8N79)R*"SN<E;:];\+(K@T0RS4S]);Y-?:?6.H1WQX19W:R7?<^3#^_
MMW>X[.2T6G7"V5I?BC))N&#_)FHR7VF<>A\[+3P!T9]O:CZ11;G,?R/]BO@2
MD["SQ&^$[?1"DEH"FM5FIONY(T3/UBK-8]-J8;?1T^K.EJ+?OCMX-&T,<'^1
M@:TX&^)Q.%9!EIV$/P%V<)RDVHNP-AE#&KP&57[W=&2;LRFZ7A]]\T-\=YTY
M#A&D+/&0=@; @E1OF/"I)01,^OG)(#=/&0'?'^A;+CK,-<"H0FSKFKY\'O #
MOZ^65%J>WOR9/QW6^/L 2WXH/="4SG625-R'%<2ZH5E#%IQ&]>8$/=^$YC[7
MRECX?$118"/MKRE_0TGL&@,@*U&ND;#MNI:0D/Q/$C5AOV?:IOTTGU?3[\B+
M'O/KN<VL#"IM1[7C8)[KAT,L33_DPSE7HNA?TJH/$S\? M(@ $IHF/X57>^^
MUN]..C.IA\!;:,&$EQ_\]3/9\6!0\^VK'++^4Q_0%#;P0PG5C]SV,J(8"1VA
MJM\IJPIU(%8K/),_JG",72^-ML3Z$S9]!M<-/XA&. Y*@,5=OH14+E,!QY+N
M^R2]\+<B,I&&?6%;G%@/U4E+RE^C 36J/721O';QV(<QE#P;]GR3,T+-OSZ8
M4R)IC2])V+XZTCYAIVO5E'0[*\/W]VT!X93&@XE<>_X=F!?,=%&"3SI>(XEA
M07?9"L+RK5!A2@C_0\BLS?)7!=;MLGE8?*L:'AK7(IPWOTH9:]41!.R_:T3U
M7_V>O$QUQ4"8O8W=!,?W4XA[S3(XKTR:TB]F8JG&M5['HR?19H^ZZ5YB/]7M
MC<\\'FZ_ 9R.Z,!4($V+30G*[-=&F*V^=2AK.S7H3C) O47+I+)!B,7[M[WW
MRM+=$%:=7SU]+.H3E(Y71]EP;'5 LR+"F73$04NA2\/:G2R[VZ2&:C1X78PO
M/M&I$:S("&:II[NU&8!W_GPFS/ESW]F;ES!S!KW&O5N2\C7CN:A35_Q5G?9V
M#)KV#CU?A#H$QI"B%SI@D-("^W'-@8R/O9(<N ='^=[)IKC,1AZC1=\;17M"
M)N6[Z0+DF;=@]%Q77$FCB+TN"^]K5F)CJPB=$TO2[4 +8ST&Q3U0)X?OC =\
MYO!QGN6,MQ%SM[$&6>&NZ X].NLJ]! #<(4?GEVEI+I4>#\P]_O1W)5(>?),
MJMEKMXO.J3)'SIKCAZU.K3. R[:1L%L!4GR#76'ZI3EEG8T4V_+C\2>6*G7M
M!@I(5IA=#0RS4\1"-[SVDKQ_#H(G[:BYELGHN?1=32#$CLIO1[^TF,H UI0@
M]&1-B@CQVL3J/@P<FT%LH.M^?*4_Z^A;A3]!OX83R86H?CH;;DO?\4+SV*\Q
MWR,_[R5]Y!+B6GA9NTAYSN2:;"]X?5^T(WXG$JD6B- J7Y7\77TO W<T$KC^
M_1H;')2M?5<!>JT2?#"'\*7VGJ7!6]\KCL%_>/>CW0L2YR -<U/IW<ZJX+BZ
MU[DP<[W7LL.ME2.<@.'YF/9;=)L]^7V WJ_- )BMGGN$5U_WZ4<1X3V'7^?+
MB:KUWEBS7H_7W*61PNG\!9.^E&K<EF\*2BQMW:@EVR,+HQS[2-23]52RJ/\&
M S@'C-.:#8Y1)<CLB50E C9&B997/?G]9(NYN>=QMAL_M)5PFML88M1"$OTX
M,W>UMYS"EK_DV%V?K/_:'@WWE:5K_H(+P[P*HJ;0Z1HP"%()M"X.&5ZWMW*A
MB([]3!*])>,N*4YA *#"B;]>TV*+TO?%H1"U<%N$UN$#[=T/8X" Y=$&X";3
M7NX>0;,G:$FCYA]>$!$J*</F&O>%,JZD/^%<=K;!KT(GE2A69.GW0C20W%87
M>$SZQG!#U\7!&:M'Z?"O]3!7$=P??K\+9K5J_T+?YW9,E_GT=6VW9E1Z$E/
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MEH&KHCO4KZ+OH7E<Z&',"?XM;NQ< C7D.Y/MY>@FD3 I!G!G</=24Q)LE;#
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M*5JS3ZXX.)6-'9+[T)L,1'O?K%6>XKQK=M1U:OAM]*LPEY%6F!4M$<6S,JM
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M*E)DS'5QF,;.:44LF'C*4*+>>:P^I@[8G*<(X3,B<4S>ZRHZL=,#I#E(DZL
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MKF?#NS^ZKFPU//W]*5TY.)IP,KPYPEXH7:@//%P^)W_V8=;=35.@8T+ LV/
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MAYA9S2V2MQ(_14W'%"&BVG>B8]**4&XNCE<M9+J<NL^$/7Q*6^G?Y]SOBQ
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MHM'VU-O/#:(?AUAKO%5;<W9Y?0"TZ1Q*_&D^T_C1CLYBWWM1\TDW,YBUH&M
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M36Q7"82T9W9]+M_+VBLM[I>Y-B:8BN\^KM;*9@")#DV\4- (%_:H[,YC+@*
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MLDD/NN&8Q@62#>'P32'E$BLJRZ[Z?MB;P=+-*A8.Z)>'2-$DL0)0Z)4!$&X
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M,3'9DF/JD=?LH_T+B.!K8'#>[%(]&\X]?\HI/'EF>M7);2J8<_7Y!X$;_4V
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M\( J.*1:/1A&5JL>%\\4^OU]V'M(XI6AF#3;Q65XP5#$<3"+@.5H]">SPFY
M1053VQC+^O_4WDHG1*5]F(OAION*5 3Q)%]^6C#U+CK@T:0>'L]IVTK^OHB]
MN-!LNF!F6(K8:&\1"?"&NG!/P.V=RUO6!-7N&7J\LD6;F5Y/#*X0(OH^I 7/
M_>F?U3E14U>*W\_P+2Q*L2V[)CLGBSI'(^3 KBTU&A*GN4@+G?(L8'\[A[/=
MRK8*ZW9OL=A%B!33_"TPA[T<D.I&"8(+<V-=.';PT:Z# NUB8\;J6.6:1OF=
MVT<NPJ;GM]><\-&CQ20U)2SGLNBIE/XVA:X$>*!F6NOOC>073!LES5K>E\C;
MA:5(M9P)O]<$OAWDSZN6&B?O<S2]#;7AV54 W_T<77$"=4A["J0?6KPW>*+7
MNBHO.#F(6@6+'C>[LL]-MX*B=[5%7@PX,S)K4PU/#PMZ\BT/0\]L.@;+#C4V
M&]@4T=#&[T)?N#)&-_M_F^SF\-_D>?7?LTDC1"-B$G*R>CT:Q5X-X5ZN>>=L
MNU3?Z=]SXIK \V.SD:Q(K3_A 1 TI;XC7&=]C4@U:<37&=K#[WHDG#J5IG%'
MX -#A-(.S^ZUY1S6P4:9O#YRN1+>^.2RP1L.+@-Z[WN<)<?%RL^C*9"YA3A%
MT#=@_9A'[85KK]IL?P,[B?,1BG24EGC8W&LLNZ;;7#:L592?TEU^;RS#[++0
MC*256C>I*ZY?:<>5"-64R6/?>8 ^ '3+0V:*=V5IYX?ED 64H"S/4S>7%,V)
M:>@K;/#A56^+[NZ9B?-B,4I)$9$W4>> G/](#/>L4(&<I#3]A^;S<!2O7& 6
M7)[.(]-X)#%N=W+MBN?)[JD YOS0,8%"FAKXBR0NYD)=2XX34@Y:NI!?*(K5
MO-W\9%)O0!NBYA1!@).T442IPRF,57I"\-=[%_XR'!;47M_/'-&#946>(3F$
MLU;\4)V6V.I,_2'6+/(_R'OON*:VK5UX(0@;$:("THD*B(J(4@1IP4(3D28@
M($1$:B@B("TD($H5(BB@( 2D2XE($P0B745ZDTZ"2H>$$A80DB_N<^YYMWN?
M<\]YV[WO_NX?Z_=CD:PQQWS&F,]\QLI<<T7@;+/3]UK#Z@-8GP*EW?+;MV!1
M4M=,-D.L]H1< TZS:>Q6C@(N'__]\R%_NZ,4II$>?R%O3C>=K5O?@OG4M?LJ
M^VVDR!R41]6DB8BEFG/I?G)FY*.X [&VHC<.I6%5 ,BD$_/PJD7R1I0\CF-8
M8: (S?FP^M'SHZY[OJ(@\S8J@V6!!3@1)TJUR(@N#8-PKX_ [+SD?]3?"46*
MD'!-\^_8J7HY.;F4H](\=Y^4"=NERS-%3TX,*];#]]4@9,)JU/)$C.?$3ZTV
MY'[BGY,-'#2?6H1:#2+/^-H3%DVVA4P2/$66FKV@;UGVF]? "")"#14-$SJ]
M;@N'F9ELKY@5#P.;&XUTH&0I'GG>#>?WKBFY-=KG^G6='.*],(F;=W^Y=+,V
MJ&!&XM&)A\),[W.-&&5FXM^Y]7*\R+;*NO32$YF-VX:-Z[G:!RZ$B&G&L&D:
MA1B\#-YS04Y/$S#%ZI56!ZT.GY>C P$Z_9BYXVVVKB6%M\8/"[YXY<K/]L7T
MAQUIVV>AXKJ';5*>"AM_=(_/:=7TILT?.Y+U,IC_=:$++\^1V*A,P.QH"4'(
MVN1:95]"\C"-]Y@D)M\D#8(SL>HS9#LYSO'VE@&EO^LC;:9HF^/HFW(=2X?4
M))HES,0L+_T7P9:QG -E^\LRLQZR+G>D4IP>A!E(7WIPLZ[[+4U!FH<)^CAE
M8\$:?._JM=DCY)1\_G#,WM!,7@'JG.65+E99T*R]YOQ.B=*V)K'XP_,69,D$
M=+K<U2U[3-^"-^3$>=%6>6"Q[%'&&\@ABD((0P6S]IK2.I*,(D]5NIY S7A<
M&&,J6CZ]^Z.81[%?.JMTH5&&9@POQ-04@#9@WC1^\]<2/X/V<AK9-)/ 8LJD
M=DRVU2<,H_0*%_>HST,UQMAS7=*4N]:LS[OB%'[)J%+Z-'WX[AU%T8D8P-U?
MK]2ABYM_)/;,;)2K&;GAG9UF3!"O!C3;$5%WHJ=&+C>;DAW$693YYN6GA=--
M:\R#"ME[9SWWWFT9R8R[*,4U^2A4@RT^.Y37>"K3+CE637U8(-EI,O*H1^V1
M%F9H?@&/(0O4MG*5NGP$ID(+<!7"*R-F*3U7)!!^ED;=PZ>M5@OD#9GO]2S^
M^*4N$_&_4$OX@=JQ73*EER1D-YV_3PE18KZLM;.[\=R5RW)Z-.&?H"$Y;]RM
ML5^A1O]07*;68^^[F6+DEWI^N>\3Y9\(QWSB.F%YC"GFP(=LZXOY<X6RQW3B
M%?9$Y66^S'N?R[@J*$VMN>+4]\G4S*///7)'+)96I(FAOG#I7=/S426:@'EL
MR[B H,YDU#FA9>5TEAW]([.4 L47%5V%^-4N+464CP-CE/_A?O&?8R^PO0;<
MEC.59I3Y8HG2]V]"^:N!8BH4[CK8#"\;7,20&BFHOFP/5I?OJ\USXQ8]90,0
ME];N_JM,5#6I(;0[["'M!%A/2AQL1.U+UK,VFS8\3XGX>GLE";&K*=;3)FA;
MD0[4*U!WDWP=RHEWD7#B/::OU?BV(XHV3$JPB'3(B\-TX'XRU9;,,VR=T-DX
M6X90V7Z6H1S=<.%$J=VA1=&Z\JTDPDAX#8GV7#5<5@_!7;)QC+T0T;G;#]Z4
M;%1&^]QK7\X"&7W_S%CMM%*S=^)KB:(RPY8SPD[[?VP?&"SQ,NIV?.%EBR$C
M;3.[$ W(RXRP%:'LS[*MQ]:U6+/;@;\SH?QQ5>7A?S(G/W5/W_VRH#-H]ZO$
M9#^BH:S>:YX1SLLCURJYAZ\F[8O7B)>+JZ]/YY!/*?B DD'>)AN$*A0$01OJ
MF/N0)H&R;'(MZ58YNE Y=[;*;&>J1!]-?%[6>@R<OM+K'>W;.K3HFNWK,[]1
MR;0X'JS&8=@O+9]B_K;F;>S &&JM]+0I-!*G "V;;LROL7 CM,GLJW\U5WG
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MS)9V[BT0LQ<Q?!RPU<7&X'W2&U49AN:;AVYO':,##^,(F"VN'^!]VFR<]%A
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M0[#9>F1N2EE/G>",^KY^'[5=VQ_)"A_*RB-.<\4_Z7Z[9<@61 ?V2!+HP-\
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MQ1"9(O?<QV+6-L?8=VVXL]-,Y\T,5<W.:,HMWWEV3ZTS -@,I5@/N-,.(;W
M*J+T!3NY(9OBYTY%G4_C:J(\U_FI^76B8 P9TH(N,V^" <4E;O8YLXD%$H7S
M[AP9M[76IY<%*[=5_&PV"+ZMG5&"$M1 :9^4AWT+XK"57B^=#K9>J<W>.B&0
MN[E:<=&"S-R\,;R7-&-9]$83X8FI,16S\5\WT>"'<=2XD;6)?.&H0S-)R3OE
MB;D$H:&B)\:QH]Q>;Q0\$SI%@O1=_(2F6J-K[+;%P? 65JM #YZ9AB76E#9.
MX1A [)[:AP(X2XT(D0YPND#YW14\N&X,QP30B'/O;T+/6$IH**]_4/B,/ /"
MI]"<M$\V2J2$Y?!3W/ ^1WP@XJ8Z*47%P!+H(=.!EF419Q@;30",OEQ=0>L:
M\+A546,AQA_TZ>MCK]:Q@N3*IDXAJLI.MBJ44&1P/?Q:5XT)QU+HAR\#2R7O
MD+F2,.\ <Y4I2+BH2E\=._5,MS15QNMH0>;<F1LVFK'[>6^(THC5,H^@$%4K
MHL<PE(".DE]D)0:):6IMWWXF<*&[>HLB;LBZ7(^)JCM*3FJ!18ER]Q5G(D3V
MM9S,NM9X:E42#J^6^KR^'"DJ!29L'Z/JU=3V)[<9]2SEW%=),3WV.?JXH9)Z
ML+DYH7.7WRK!8Q$ZI69WM0M6X2W#*WZR\I/.P<)W'SGI0-#V6B$,H$+(V\@]
M8"9!!*Y__].&656R%=M>=&#UA2G5P"XV-[YF#OP#/!.25^7S<%AVP:99Q;>D
MC)/,4!1[_K*J$5FJ$<:O*L.%]?#"@=K7+,3Z/E=\#OLXV/9+?=7D,MJ@Z@8Z
MLFZOWRIQ<&$D8];<3)> $?"[I[-T\HB#A(W.D!5;:",3IN4=_+Z-+-@^I5<0
M*"/BIP79<_$67V=-S)>4%H'M]%BL3.4X#U,GJLMRE:JZDT,[X$)Y4W:\Z*IW
M=%X?^4B)XT=1_"%<OFGES=@IA56^EF4N?;(<)06TRQENZ+7T\^DH\#\-/6FO
M:Y@[&MX>I(P_Q7:3(0*-;QO%:7!H'M44^+&;Z_^8$V<GX&5\J>OZMM#BY>\-
M[/U+B^3O6LK%_K0RIEQ-!POP?L.V656O[5OSF@J!Q#/]_D4GNWXH*&U+X,0Y
M<1T[Q[C[1QXEV@6?B*W"6?C=:UWT[8FX.<KGN:XF]9$F#3=@C L!/X]ZTEB;
M?8X+.R4E\J7*E0BNLZ'+<19]22=J8VM.0><5S@F]Z:_\6JYVJ[$IV2Q?Y:)S
MWLB-3[7&QYGW@WL4(/N= ZX5B"QE>"#$O"VR]AA,VYPA2Q%P8:H*Z?Y;1POE
M.>_VN5<^+^9?MAT*N^JUEH<Z2%4A;425>>;Y8<RLT3;OA'*E[GPJ>4(]P22B
MGH I3U*4*%<SR+/=P0SX?VLKK_)97[0;)R2?F[(0\XD_^U7V1:CQ8!C("E+/
MD#MJ"6U%FM-=MM&+=VH;#YZ&)$EA#9)KM1MIJETU1G+-.2YGK'5J$DPZI)P,
M4F^LGKF.+FC75,EY8O QE9,G):^(ZXQ3UH=,>0;:W+_J3V.'X(-15Z)DC^W*
M^4E9/[DNMOUOSQJ6_?AM D.$''16Y]N&4;(7[J%0RS*?E<8J!5J_PY2_%,(/
M^*EHD9TJ!>M2/?(X@L;A6'ZW=R4O' >=J*_L P/?I1A1D/,C\*0V+TG:P=8'
M=&!&$<$8?-UT@,.N ;TF5$X'ZN8.DSSJT6NG?BPB?,BHS."@"8I1L&7<:Z11
M94 S>.V*F@RHOPQ[_^0?FX#]=(T1P\I?3*)_M0@+_ HEI8RC0R2ITAAV.M#E
M/DC;SORMM3XT*8?*QZCJ%L-W0/B/6P(3]QF?6;^F W@.&@]JXP.,H%A#!W89
M@%:BW'0@?0RWLZ']&VMY=("@#\K0'HY MDEX1I5['+^;\=$[6SJ 8A38.\N/
MK:3_T@7\G[<+Z 8/?QH+EE2A*DD'SK^#;R]A?F.+X7)#"@F^PU$!W2"@&77Z
M3_W9GCC$D KCJU3V'^M$#6BA]_ ;8]#?F,JD P\5)_%;?*ZPY0;&W]"?N[-1
M=YZAH6NGP0/HAB\D[ [K(GJY^C>F-'\'&/P/S5=8_6_A@_\>ONE?X2OY&WS2
MB1O82;W?QFR&X68) ;;%.<Q(71_H[P#[?7]J5R#_+(UE?G+:^'> CF^R48\R
M?-#];_7A/Y:'^'^4AUF,9L_]UH6ZO[J0]%_A OI?&0I9_PB%?]D%8_1? P'[
M*1#_>C(<A_TTM):1H33NP$Z2Q&^O\?Y-8F-^-WK1__6)P&'_CP>3]N\A_YWW
M]X?^YQ+!/_/]+\B+_TF1_Z_W?A;]CTGT[\<=_V_!FON)2*[]1Z:@GP;1*YE_
M;>C+_.LT_GL7_AF-\_V+%/J_(8___D[\%4<X \<#?\7QIZ"^^J<4>K#M#WGT
M(ZY'T=___2[\I";0?Q$3^']%#OU/P?#ORJ%_UH-?U1"K8H2JT:1^P%;/EOZM
M<:GMB\_<[>X(!-P.XMKMKDV&-T1%<56YZ@C'[SAC__L3\R_$PF#?O_&!P;^'
MEG\52/]Y0'_;IJYDL\<>V=/6=X>N/]H%S9;[E^C)?L;F%.GL0[7VSP'M94E)
MTM56X3<M:G>[_K9CT?_]-/V?5TI_9XS].[AZ]YO_ER?)_Y?1_S/+J_^D[_^D
M2/O_?8WK6OE?<Y?A3WRCY(\1""%;-3SZA!\Q&[(+6>W3GORI29GZ"=8"*9EP
M5]_C'W8:UJEY#!/X7WU@QE6FGCJB:^=&?CM:J/)CUP,=A1@V(CZB(RZK(N_&
M45(AZT1"D'Y@=OD;RX:X2QEBY\NO[074I)Z0Z$"HNS=&"&'Y.;[@8@#/$:[,
M/6QK18//O[Z#7VS( A/R08]F&XFZQ ]?YC:BXL3U5UTWPPQX,_B:8CP:%,VJ
M0Q%\RJ-<VL-%MT/ZCBU=>ZPV_X[,5^^,U"1R>AC%?[-#I!:Y?/D8$^J8%O1*
M25W(#V=551IJ75>F?W;T_CQBGUF*:)9@$;M<F4"-/?G">%! FP7M8XD9S+X"
M3FR%*GZ[;@[?5V-3![DY2%2SVC8<>LZ7S@\G%[^1":N3(=54WD,)]F=$Z[R]
MU7#NB?3!@*GD GN2MFEEEVUI\HYDJ@^THJ90G=2PO6THBVE&<\T/P#D7ZT:*
MRD?K LJR8K/28"?FOH)>7L6@BKZS#V?UPL&IA:UD3/(AK3NP/3/J8G[JTRVB
M_-9GQTVCSA]1_S[;[!W@5F Q.S"PX"MO=()[/GCWI?CX4H5L8V^'7+97ZE9/
M&O40^3<:JO<&!#^DM!?XW??99;9N5'45ML>)]*6ZSVU2'1KV\6C0X[EQ:*I!
M?!/INKL=IK$\T+%Y.=S3KU$S\;O4X;RY>[.T&(1\BJT=K:N>-1.\2)I5E<BL
M]U=[W.NC2S3R0K \?W 6]@!@,T9T4M1W,&]H YA^M>R=^>&)8CJ07<VO?I)T
M G0D%.-\_6&4L!*)NH\>*<L?JOC92,PKQ=SU6U%?P-9&\Z0 *Z>S^1PR:;6G
MN(2*I29J@@@C&![PZO:5"A_=7/U7[5V"JP70![3C PX];C6:>2,523FIW<V[
M.#\'=2"ZHXS,M%OZ"Y1[IE/>G=N!$W-RB?J!)@>KIYP2[\7S$RX]'/WT/BY>
M0STAH'7*H<2?P%,9NV]XK1)V.\K,^-701TAG3X6[.C^")M*/FVALL_6T\_NN
MGQ27[_3L*\E@("=ILGEL\,$ NTR_3Q-V\<SH$8+1YJ17;W+1WBMP;MTI.@ ,
M?1EO+VK-N^CE*7@U6^?,TDTEZIRN#T80+&U-SL%DNT3;VB,$\<_.2TJJHA+L
M;I#8,#6VG#%U!6B$2'EAWC=;9MG%FW?]*<6M#76_U'11K0I=GN@4<1*/O,09
M/:(#,8?3/++ T-:Z$[T^*A'E2H6#6@XQSQE3A<[-P%6;<M)R4SR(:[BG_&CN
M@#_W1K!WNQT(>Z^8!NWVV3Z7K16XF:SSB<*FAE8>!'T)*1AVT')$O\K'_V6'
M18#AKCGH_IISV3:Z"-\"JT9/@4:M]OLG\+^AC'P%V,.Z@P,RXC4U70M+IVZ?
M\Q=_J ?-;S;_'9O>W,'IB9:A2S?-55)IE_Y%"G_RXT;?%N-_:C?1BPQ>>2@S
MOLG[EQEPOPN65U7J5))?9)&5G/PI8*QO4?Y:0&X]'6"[F&/](0U:8G[=.F2?
M#)LSY64R)=757B8O*-;C_7+>RZ@OJ[L>4[)SR@&D%]F*DD*N2R(_,2$MQ?ED
M.1DY7[DO)&+[7.C:Z*NK#;S5CB+:ERET@!_5+2H$NF7-Y#;+<;C!#6-N?!E!
M+F2^0U>?]J?@1, =DB+1 %.N[ZAWOU.;S!7^BG=;>GT+6N;\C%E%QS;M;H!H
M.2P"[P@7\;NZVCB,"SMULGS[BS=\P:JO[UIEVRJ-["\<PQ@+0* IOI71@7&_
MT$L]TAZT7L]"B[8@E^Z5(F&7PHE8?G/%5ZA!&Z#'53ZPJOC[[?[<^/%N4R9G
M$9&XX.E^@V\VE^G FXE858C_9"J\4?&@95AN[O#8B$WK7:YF129FV14EZYPB
M$$*Q)E^->864K>KG+*0#7Q0K%17?"J-6G(7=IKN;@8"QUD6#214/7@LG2)#D
M\-+I0H+LXZJ9V$!1[+.".%I/'<L3(A,IHO\I?'GE0>N.49+22CV-XM?LCT2S
MH<1![9;Q(R6D-4NUUK#RG2MSLA/CERP1=R[<#]VK(ID;0)#'?UEN'H =J&OS
ME%=,XZ:-T$;Y8E%W: X[P8[GJ&<TH/"9M+,E@ZJ:!4XD;=G1V<("*66"U=TP
M(0,4I__T(IP,A3,FMN1I,U);LVCQX#ZKAM6]KYY+7/HX20<"WBU#*BJJ*?F<
MBZDU@M>L#G8XT:BA3A_=@[QN2"Z:DD9N@-FD5U,ZI)G(<M.J^T2)E*62V&M(
M4>T-)^9/5"'R"!'2@(?ZH1NQ!]V]Y\?DX.7QWT>N_W_MW'M4$E@>!W#4*4M+
MQK&TU,)>9CYG-!\I2*V9SEA9/O(M66FBIOD:45DPR[=&2.J*)F:96@J3"BAB
M9/BHK*CPB9H"E24JD"]&7NN</6>WV?]W]YP]_7'_N_=\?O>?^_O^<<^/O'=#
M@&IQHUU]WPNHZ3(I!]JJ=_612;0?_DP!^F-H4.D3]Y\^UCN85]T!^['2IF>'
MQ7K+U^CD,IY9P"?=P-!;MK5%367FX4EJ+_8G7M:X&J@$M)!FV3SA.LG"R0'9
MR=<%(5H3<S'O"XO8JMPK#M!7&1 HW[[G1/1C)4#GT8[(M)32&')_>QAM_!#G
MH>XV_H!?G%B'1[DJ8D@-!0FM, [U#7QYS"W@PMG[4)O0 *DGTDY,S0>?F$+_
M@#!].[2Z<H16?)%*<_#;O!UV6A \V<W*@6Y%'90 W6B#K1/0G\5V68UC,V>&
M[J>X6O<8SQK^)+CR+@,2N[*<+0JMN,@+>O#2/="E^I<;(:V5R-F*0;\!;( =
M@^R9:4G7AN:5\KB7;N/ZTR,P.NOYA4GS3L-Y,Z!F*@;LQP5M.W$_>#1(DBWU
MI0XV[2H$[?T;=_1A=EJB@$.A^XKJ^/N+D/91*Q=_85?,?1<,MX-37^;6GRXU
M/Y:(DYQ2?SVYR=D4D<Y;R68'BS[P)D:%D97H+;%T:VJ;[:NHR=:R*TFP'599
ML;:^BM?C>XI=E0 _'>R-PO0?S&[*;SAK1$/5Z* FN./C7,B[!LBL!]#5+>'P
M3*HJ'1<BOR&[0/C!]F9S>[;PR>I0#?X:^SD*<;G-;!A: DC78Q(XQ4R>>A]!
M%VE?X-&6>6GC$6D0L#04U6E6(RF2NDOLN7%YEY)"$F;<B1%CG8,H]R.?_'%L
MF=E-2;PHKANE(J^AA_ R+(A("&FL>@'0C76LNI5VV2F%9"=?BY<1K-S)K?0P
MGG'F#&?%I9.:%W,>AVEQS![W-"I.@)H"EC191?I,%/L=2!1RQV5_CNV.S4L6
M2D#WRX]&7@Z?LTF)CSH\# P*&K3V9-MA'^5;HTN0"Q=%;MT4J %X#_^[+X%L
M=Q%CV0>+ZS^Y"25W=@E]PR4/V9(V_AZZCY(]?*HMCU]EXOQITP8^CI/A'/L&
M98V\(&E*1O-8:O! N*B*4/_S.7PR^S>\Z)@TH'<+O\YPA=C!1+=F$7&I_ >L
MK3-8)KR:KAD?K5_(L>EN]*E,?$:T/RJQ$5=PTZ.<@:+0!V%Z67%+!ZQJ!O=Y
M3X\V8LJ.+&P2%\9S6I+C1MUZ[?&P'J<46N8\O[M,M[G+:0EMN<7/@I5P+P."
M"Y W@C5K$+%]_FUM;5^$%=\'-::6#$NGT"G;9461;E(/A#'?.WU;'#[ V\.Q
MW92>JF*/6^JYK 3H*H"(7JOM"'2/0H/*%EK-+HKOO0Q#$#HTLPT>/_T$6R3:
M]$ZVD+HKFA* VB,>M>,SJ]>SC+'UW?5G3%*.?6^M.M&<C@<(DF"<"+0N$O$Z
MZ9:I^UC7\*KA:AZVCT4[5 *!O$S&6\V%3<5IPP3XY*SQHOMP2G-(4V.^6O#N
M WOKP)B;"M_W#* 2$,XR0'CVZ*^_:V4Q5<ID4@/C*AE,,*XQ_S#KN%H >C,C
M'&KH+_-^*#[S:)EW].TTFU@;K%LR>D'U)-"S$N6C,K#V-#,+>.2Z:[8&QI=4
M;"V\//:3VX^49]*(*M/#2R1/W/(]"1IT'9/5VT#[#'L670V]W(R^3"7!GM,]
MGC":UW+ ;%E7J=ZSB-(JT% =S<:EJU@/NP&2QH6#EL,D&>?I(LNY@Q)G@5?Z
M0N,Z*-PW(N) Y5)_<N^/)FI#0FA,7,Z94.,*EXI36,MJAN)5^;(,VY_5ZWE[
M7)T?RC4L,(^:23';E.DT_/22]( D#[F?/W?(M258L',7=>!2^%G[5!,1#E?5
M5O3@,W##,UYD<H7 PNOM.PO]=R:EKQ LUJZNB0Y"711 C.&8\7)Z@#FKY"'2
MW:[:$83'+Z[8JKFQEXSSF(EZ3NK[Q3WSPSMX0LZ=/NV9P-*.6O^ ( 2,>6E3
M&IG,U#Z8->$S-[6H!3S]EJA8>R=0YA(!WPYSWQ_^J^-T9M*MYB.UXPZ:>\>1
ML_:%?'.H_M6^R18T!NQ"C!YR3%E&.N\4)_TV/G/OL,>8M6.+:1CM^XPD2*0J
M$*@8"C45V^<U(KW#-Q<@#]$&<4?=J2#PT[<Q"XY)PB&:E0YJD(I##53I2E*K
M77;T9CGJU,.2?Y?NEO)_]S.[HWBJ,'N=[ #>#K? (\$YOB%AEC=!D&!G^2VT
MULU>>6[RI(8L1A27UPK:"O.L@2=Z),9O93:<??%BS.]*WT$5 4&/$=E/T)#M
M&P1[<M' =P*]WP[>N+L/H-U<OV^,0%.1F[&(T,BXG9(R[B2S#7QH1R:"VHU/
MC++I3W"_OO?HL;,_UJV%Z9.#,\-GUIIPK0C=HQ\^7Z%5WC"QET)YOE[MP/'U
MX%7\EP+,Z'3?(SV1.K. H&6PG>[+[;1M%>1:JOSTE)C;Z/;",69)>-BPDS27
MRB?E498#+V89L1<[S_6^XBUXX<6YUSUWQQW .D \(>O2,4^@G'-,'O0:'9*V
MFOQD!E]5-8PZKDG[L;_#="/D)&N(;A4JOR[SKI-8'6$O2BWL?1[U=-'+N_SR
M[I7<=7#*]HGM/307*A Y<5&=(C\7$?5J4U-3[**!$SAD$BOMLO3GIGY>23^E
MODM$X@N[0;F!F&Z)>K;7D-35G]'<.I;I2T@ISY1\OO6 ;8OE0@LG]6X/T;VY
M!@\V6W7O/$!IT2N=BYK[$/1P+/?"+C<CZ.W/(9DR*W'?M25&@;XPIZA]T/;3
M[A 3QE'LT<JJ=-W +XPLAB;*7@+DL@J2QOX*.D$6QS;H],MIK_1_KHN8(A"J
MO=RF3-2((E O,#_P#H+]!%>TQTMLF9_/]\H:FQ5_R @_IW>_L*ID!-4/U;=E
MY:U:=@#S4+W#@9#%TO.G*4C71')^L;5Z75W:@A*0"=-0F*]9Q+I:R_)[<&>C
MI[>$(T+'PJQL)< &.'',R4L&E:_%2=2):'\QI<$Y*[DAI*"$G;3]NWC7[/V5
M\\\.35<-J*#[8&1*YUU96H=H/>;>)_$H)S5L:;-7ZGEK&U.*3J21?%Y1LF31
M6+2/'C,R_GPC)\'Q5U(IR@JI*9XN)!N0-H]P/GU!1$C^0N!\.3890_'QW;X_
MQ3Q^Q(_-@6"60\OA%^G/WA]]. \1F:@N_<_'O?[WUTY/,;_')I)"L[CF=<(P
M97B=L9T2(-"X4JG1+HJ:'PH*.:D9).W F 8;!(VGWDA O/)<F N":M,U%#;D
MA\6<>'C]2/]TT NFD>'9JQ(?D)9,+9[K5.1Q:L"R5.@]8'CPY;9=ZVTR5%;9
M:DV#2L![8/H_)XH_4 *>[ESYQS>?N^LX?\R$S>9]MJ ( [3FJX*/*P&K&QQJ
M\@$Y4B_0?+ 2,&7.D)T <6XH 0G32H!*N!+ BZS) ,ZYH]L3E8",M;X@/HB.
M<I'W$V3KRI2 O+6C4/(NQ0>60K5_+5R\D3< 5RS1(EV8PCC?!* 8R)&6026:
M5FL!U&WY+G2\70EX'("6X$VJU;Z!_VD0G<#_EZ=R_["#]CA0FOP'<>?KG5M.
MJ7Q%8/Y4U^G#ZE\;?ZK+%?!OE_JZ--<M@*_O] W\!GX#OX'?P&_@_R_H.VB[
MX2/;DN].+.?H^9Z.MMK;P)]_X[I%13GZ=U!+ P04    "  S@718A%]C2):P
M   5%P< %0   &)E870M,C R,S$R,S%?;&%B+GAM;-R]?7/C.)(W^/]^"MS,
MQ5Q/A#$-DB )S.SN$VZ7:]:QU>5Z7.Z9G>BX4.#5I1M9\HIT=7D__0$D]69)
M%$""E.N)F'&[9!*9^8,RD0DD,O_U?WU[G(&O:EE,%_-_^UWT)_0[H.9B(:?S
MAW_[W2_W[R'YW?_Z]W_YEW_]OR#\KY_N/H!W"_'\J.8EN%HJ5BH)?IN67T#Y
M18&_+Y;_G'YEX-.,E7JQ?(3PWZO7KA9/+\OIPY<2Q"C&J\=6?UW^F<5<YXQC
M&$>*0DR8@(1&$41<"Q3'&.4HNWCXLXS2G$I-8:RB#.(((\@(0S#G&6<R3[04
M<37H;#K_YY_M#\X*!8QX\Z+ZY[_][DM9/OWYQQ]_^^VW/WWCR]F?%LN''V.$
MDA]73_^N>?S;WO._)=73$:7TQ^JOZT>+Z:$'S;#1C__U\X?/XHMZ9' Z+THV
M%Y9 ,?US47WX82%86:%^DB]P] G[+[AZ#-J/8!3#)/K3MT+^[M__!8 :CN5B
MINZ4!O:_O]S='"5)?[1/_#A7#W9N/ZGE="$_EVQ9?F!<S0SWU6CERY/ZM]\5
MT\>GF5I]]F6I].%A9\OESJB62VJYC#++Y>^/$?NQ!_N!^"WW>0W 7"7NQU \
MMF'Z,1B[]\9"J.$9WB+3F^7Z"W4]EV-]=]>D>K,^/,>AOA:+DLU&^%ILR&RQ
M/+,??#"_-63L0"W&M*+3F.XM5M6W4LVEJJWESM!@*O_M=^:WB533R?6\G)8O
M?UO,GN?&1+V\G\[,5W62QS+E@J909=RL77F*(4UC"@E7E%&1))+A2;G^4D_4
M'/[R>46_(G*"PN\\9"N/Z.A2%8OGI:A7-T/5KNPU(_]>TP1KHJ"F^J\_;ACL
M LML>&%G@\JY$#LCS^Q2O5B^EF4A3LNR^>X71IA*D$*)/STLOOYHWC4"Q8G]
M!=I?JJ_\\1%_W)N*R^6*3[84)U!KGOA1+(P?\E3"'0#U<O'H*%"Y<)S%&CI#
M]G=@L91J:;S+ R*LOTW%LIS<F3E3/ZM'KI:31-*$Y'D,-<UBB!.>0B8$-DY?
MGK!8,1E'L8MJO1IW8(4R_DLY+<JI8#/PLV+%\U)5WO*O[Q:/;#K_?]TTZS46
M[?K40T(_+>HLG+,Z'1'E@!)I5O!*&/-*K45J5A;V7QM5>CW:* IT1(25VAS[
MLY^R/!?P@;&GR9TJE'GIR^5<OE-?U6SQ9"?D^MN3FA=JDFN*!"=F->68F<B*
M8,BQ"9Y8A&*=$HP8XBXJY$1M8,5:T09L+H'<4'=3*#>\VM4L. I^RK<#P!9A
MT%#NKWQ> K:I9#/0EEHVGVQ4TXW6* KK)?9*C?U>ZJ;<-W.Q-%96O5/U?V_F
MMT]J:4SP_.&*/4V-2WS)BW+)1#E!64818PKJ-,809Y)"SF(-<:R3&!.>"Z1\
M--V=],!J?_7%VLH"3.=@L>( L*)095$IPFS*^'0V+:>J^+.?*?! U\TN#(.9
MGY%8\0!^6''Q1PO=FA'0< )^7?$28-'N#D @(^)!>%2+X@_(:_/2882NCL2L
MVLA@R_+E?LGFA1ERNIB;Z%K=E.JQF*A,YHRPQ,2WQJ' *F/&':<YC&B",R;2
M."+(SY=H)SBX.U&1!Q5]L,4 ^-6R "H>'+UU9PQ=_8MPR/BZ&+U Z>!HN$D:
MS-<X06YD=\--^'V/P_$]/T/ %2LG5S.SM-[JO[.E&;B\7=[98YO+AX=EM0UW
M,R^7TWDQ%7]CLV=U^US:,PU[4#31*4*QT RJ..<0(RZ,F9#*Q!WF\UPASF7J
M8ASZ,#&PP=BBY&85>@':;BG&@LG/>E0,@5L-&I; [1)43%V -5M@S1>H&+L
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M':;JQVO2 Z_D#E4_+JI"'U6S^M798ZCB%7LX=SU;#(%>H!/$3;&*"[!B9VW
M!@,N5-6//@ .5O7#!\B 53^.8=&]ZL?>B&^DZL<Q2=VK?AP=X2W49__KTE;X
MS)F,$YY0B#.60\PB9-S2B$,D)4:YB!A&['PUV"L>1TIW;-HVG:_I[J'I&?B\
M+ SHHQ^+M=1 KYA_ X=?IY$]]QE7"X??QU'6:8B'+4>^2VKX!, []<BF=C?C
MPU2K=0TCQ)),8H(AS>WA%4\X)(G*8$2XPEJG610Y-<$,QM'8J7_+%1-@9K@
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M2HX3B!FC]E:)A"C%)!8"Y2)V.DQTHC;P F+H>'=9;\/&S8X'D]C/Z&[(UC?
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M-G_2 UN;O][:T._J]N/5]=W'RFVYO?^/ZSOPB_W@_O+&A(:^96D\8'4T.(.
MY6EN]EKML$.M=@;Q8/SE#V5IW F/:V>\ =FS,OXC=-A=>J>T6BZ5O&??+HM"
ME<7J@R;;^XH]34LVL_M9JZ0!XV6]V^3HU/=^\YBH',<,)@(AB).$0I)*#9'.
MXISKV(143LY.0)Z&]H&4^!.(<NRQK1((:X<MJO$1]#-5*W:JI*2:PPNP_G!]
M566+S77*4A6F;7%ZXN[V8+/@L?$U_FQTVQ0;;U;\MM'"XM>ZQ1:(U'C;;V&Q
MV=F:"SQT^!2SI^G2YDG).,7*A-@(85$?_!-JXNQ4IID6,I&"2(]\66?"XZ3&
M-L2&R9:J 7183X+A,6"F5,5$:&S"94EY8S1DCE0[5D$SI';D[I,?50_T9K*C
M=N3RR8W:?;'CMH#XHN2SW86X- &"G,Z>;>JO<4F?E]-RJ@P5,7N62KXW(ME;
MFL^KJHC7;&F/JHM/:EEM66SB7!2GD<SS!&J>,(@QHI!*^UN2LQA329'PNF84
MGL6A'?J&8;M!M\TRV/ ,5DP#^UT!6VS;EU:,VYSZ>HO/<U,B_*0Z;EZ<=:H\
M-SG"SU)3U&V8HYWAL VU@1*>P7$W6@8#>&]#9CA*G:O+'O"Z&^^\J:.:\$@H
MQ3%,ZQJS$8%<DABJ+.-9GAM;+[SJGCO0'-A.W_V!/3[]Y9UWL=F34+D9R\
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M!P""W9USISSR'3IO2/;OTOD/T<W _%*H6WU=E--'0]">Q%.<,9E 6:7)YU)
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M7>_"PV- Z+8@A/TV^1G\%6VP(@Y^V :FH7\\OZ5#84!788,5"CQ)<.3"@:X
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M(')L<:J.N;+97='46XAE<QYJ?OBU4ZIS=&[NS!ET.T<6$THW%W:&HCE _NF
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MM]H/$(O[UHX#SWT'V\_NGGO9G@,%XA(R@S<7>5:KS1]F\[5@2!5Z.<F!(IP
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M@2BB?]R9F2(&C;NDBAA^/% AMQY\MUODE N2Y@QDLD@!*DD!=,Q2F4,O4WQ
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MOIJRC(!"RK3*!$=*66U\/.5']M*=-LD/G3X_FA:FIRK]'RVACU??8E_4K5.
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MCZ9@ZUXU9Y@'YJ'FQXLBS7%18@)@(4RU=*D ID0"6K"<\JQDM+3*)D34,7)
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MVS1O4(.7T#K/!B++!GI60_ERYK^7GY;FHM9Z_XY^D0LD5965(@4"<V[N$E<
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MI9[:90[=SH3LQ$:>WA_KQED-N6Q3><E/='!LE6"'H]U,#X^._UE);^%$JT'
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MM.8L9K']3%!6S9JP\YW\H_[-;D$D(205QJ.9[MXI90!GIL%+F>&RD-3T#0S
MHWDN-?:6F*ZD6:A?;;Y\T0%_$^'_!_WR]2_)'TV-[.XF6<N]>4;)MN?+4FM6
M?]OY9N<:SMA!;1?:! ?0<5M;@]7(3QH%#MWP_MJ02&LMF@<"QCU.5L>EO'PB
M\R607/;#8$EK>>7#GJ51_WA<[K_?,D/?QVW+\LX_%+'2II:3_-Y)"GBJVV]"
MJ$*8\\'G+6_I->RB:*7_*8]8N_>NPL_F[X8%X] 3>X&JLBHQQ !*4@+$B0(T
MA1P4%$%S/U%FR"I7XB(T\K)4"TR$J?Q2IL5\S<D_B0[""5&+@#P"3FXSN+E3
M='^\4W3?WBFZ21KTC!Z)462$^]X?)H= /0)<?@%[,-C<(GA'^P<C>=NQYHOH
M':T[B^Q=/^NW&/^R67_2?NB+:5IN^NPT]RMS+'/%4D!*@0 260F(@ )@A:F$
M>2D+ZI1D[A,2V5$:D<#(3(Q0NQY"]@#9Q2Q3S7;S>[7%']TL=HYAADP*%,GT
MBI@UGADR\FE4,_BL!]NC=MRB;KMFFO=1+&2EE Y;9$8!@ID$& F]NTX%+BM6
M2B2M6J5>C!S[A+"3Y=C/\-SZX4DVR2;'HSX[<]R8'_M4]^-^/!MI/O;'/@/.
M^!]['PAZ)?#59KU?KA_U-K4]R]^L=\>2^+-R^,-V4Y5%SA&K@*0T!2C/"6!E
M2D'.\K)@>2I19L6G'%ZUR)/2_@[)[9?-XWIOLP>._;+LUMGG>05N/F3HEM]-
M$N/=A+HB. '&N+<*?11["1<1)P!J>7=QB@0_!ZW'?;650HLV=?1JLS5L<,UW
M=9&J4A4%@D 6"@)49GHC(3@%$E8DS5%IZ*)</.Z K,@NU,Q*7HMN[@NTLMW<
MXQ!4=OXN$ !N#LS8WDA-3L5V'BF<&[*P+I!?&9(TJZ.P,/GIS+?YB"?M$MV9
MPG;S'W-D^XVN3&W$;2-(NY3FB"LKTR(K.0("FGJ&*E6 *4% Q5F:E:7*,^AT
MY<]*:N3I;837>3QN_B*/:CCR,%D!:#?5@\/B>);:(5+_Y42#FX2V?L D]P+W
M$'4R.A1ODY7,>3F<7&"XX'-R^K#WHM^D!]N[K8@JKFA!05' '"!<:)^ ,--;
MJRPG)>,I%$X^X<GX,RSN+4N]WYW?IW!8+^:^1KHOX+;V^2S:?5:$6ZC/1I][
M<>XSK6=![GW,]\!#?X/E;O] E^*=W"\HAFG!<0H@A1E !26 ((2 N5FO!&)5
M0:Q. J^,'WEJ==*2KUJ<ZV'".1"V)P+>YKENZUO+C"3#6\97CZ:WL5X;OR[W
M=+7\IQ1)]]#-2=GOK=GN+_?+D 4P5ZP.M@L_'WWFK72O:9?[X?['?*Z1Z17S
M7M7U,'_=K!Z_/&4RKQG,]8QO"L3JJP,MR8K^Y0*:&V15*@'&I0 H8P7 !5:@
M5!C+*J.R*JVXRJ:K$GEJ=W5R-<OAC:D^:.6:'YI[]%T'"TY7_'%5]S+[5AN1
M_/&TR473V^)0P)#\0'<)[89TNELVZ=T-NYAYWXB;-ZI?QKUJJA5ODD:URP82
MM78F%CA4-QH%#R1!^I'9L':Y0#87YIY7QZ)C[WAU+ 1<PY?&)DF8\;I8""3.
M+XH%&3%H27;3>+SY^=O-]H/<?M,Z[!:0891B) %%*@6(IQA0(00H4,H$(15%
M;H>O;N)C+SYUH?&R*316&[UN-'+K@KAZ#;&]DNR)KETT&@\SQ^5AH"Z[4>:F
M^ZT!LU,H>H7V"!!Q2[6O"7\)-=LCP%@6;X^-$H_@\M5G<WWV;OW:-$3=2F&H
MK78[N=^9TZ<F_;1:;?XP5R86**UT<,PED(Q"@(@J *%5 50%*U;D>G_+8&C>
M2P?]8A\]UYHDVFU]ZT0GM),=GAS3Y<78^;AGA-O-"=JGVH_OI%.XH<>K54X.
M.B<'I9^)9M,#UAG9-UVT>W&DG![0^G!U^HCQ\]I/ M7N*O3KY>JQ8W7?W3_N
M=WNZ-L=8"\)S6@DE@,CR$B!,"<!%F8*JHA!G,!5($A>O["@_LM>]:+/)FSU9
M$SH:*L!.D9M$-"KZAY:NT-OYW8B NOG5BYWND>R@T2*Y/X6S53"<I_0$(I G
M=)4^JZ?SA.:I)_,=9EH&I'&;;7W3N\WZ0!MBL@$YI1)54((T%SIHI)("HK#0
M06,A2"X109EC2XAQH7/E2I:U#G[9DD'0W%(HH:#PS*NT0=H/K0(_U@SG!QW,
M1>* T9:+S8&S*H,BGR758@/"M?R+U6<]S[]\>]-V_NI6B*7Y"%TU+JLE6_ZG
M%(NJ$C"GIJ\,S01 "&> 0<%!P:0DE%.FD)JE,_FXKI&]T''QI@<5NK"('I2H
MCXD.I ?^AVX17ZGE"=W+>%&.QWG3.XX?7_/1@"Y<.YKP EJ,V^/\W&W%+33]
MUV@E;@]YL/;A#B+]%H]6V.[CYI;_XW&YE0];LS3MOS_HF;6_70M3*U>3.2\X
M+E*4PQQ )/1:(#,%*#1[X+S*D5X)A%XC%FOYR62T/]HO"?8:6#D.TCB."SVL
MG<B#_OEG_1YJ4OQ6E;KB4W9ZN/ER!X3M7'-@P+P\;:>#:130:I%T:MPDM2(W
M-6AO1D%S=IGN]@?R@ Z"9W5H[H \]4\>(W@4$/UJ#I66_.]M)5C'R_7++Z]:
M.C<E2)4AE .:R@*@+$6 R12"2A:JR'*I@U'[3AMCTB+'BYWXKN[M0/1VDV@5
M',I)1E$;]AK!L7!S%,,P^' "CN+A4$$3$A>_(AG/KXE;Y8NMF8/%+:.#S%>_
M8FO/68F*]8?\ JECA&9*+>_6K9CV.YE"62(."2CS2@)$,PE()AB0C*-,T*I@
MV(KLU$I:9,]VLC$RPH'>Y+;B'1LX#R)F%PL%P\'-JUV'8-RCN7=JMK$Q5(/F
M05GS]F6V,?NB';/5A]Q92%ZWSOUVO7ZDJ_?RZV:[7T!4I*ID>AM4"0X0SPG
M-*> <\P+F5>L@-9D)'T"(L_C3F32R$P:H?;<)+V8#$_;$):ZS51'(YT82X8L
M\2(NZ1UP-OZ2(7-.:4P&GYMVK^#59KU;BO:"_GO)Y?*;%/?KCUNZWE%N?OCS
M=K/;+0J(*<P)!P6NA,ERI0"S@H*,J#3+B<*9LDK">\J//#%K&0D_U279MLHD
M^N_[HSI^9>FV,%OL+.*"YWC\>UYP?J9/TBF4W*^3$Y4,EY]6*BZ.?C7]$? ,
M4L@?!%?OTGU'5&SK]6V'?98B?4>;KU7FNP[CN1&JZ[06)"LAD7D.*"<90"6N
M ,L@!(041):05:Q$B_U&!V>6.YYZ6"?/>QC<^IO^T7RDK6=TW,PT5EON6IQM
M<=R>#!O@O@,YTS?45J,9=-X]Q9DA%YN'\]^Z[Q)>;;[)K255U\7S\;X.M9B@
M!%E7E?<*>\]'FBW>[37@--#M?\"S2..1[>0_'O7:^^9;?=(N_]S_I#7Y^T+@
M/(6*EJ#,"P(0@3E@9<& *',DJ-Y?,N54L7554N2H]<-O/WUX\S]_>_/N8_+F
MK_K/#XXE#U<!LO.I0<QVC#</(I-&9O*[D9K48@,> (V:%BK#?U7.O/GY,7,O
MLNNC'_ ]TOW?C[M]EQCK/UFJT_'L:6;_O<D5FT[J[=6BYMJ1*7'_M*Y':1B/
M:$FYA$P 2)B.D?*L "RO&* LU9%3FG/J=L,GML*Q/4A]&Z_6S=2='\MW9%,V
MYWJ\'/GMV9Y0OYQWXAA%/MR]NNFOE3IM 'JWYEMIZB5,Z=NKS6Z?G*@8\A1\
M'AR#':1'5G?FL_AYP+\\SI])[D2ZKYH"O^ L16G& :ED"I#$IEDVUGZ=0T@0
M24LDG9I^G8T>V?6>4F%YM 0X!\+.,7J;Y^;%["WSI_B*P/E_/O;ST'L-L?SW
M/Q20*O<=_2);VK@J%[F"%3;9<KU#0J8L*"]* ,M<,@(E1M*I"'U$W@Q3K9<V
MUFC@3[0WB*#UC R%B_L<G0!)&$+=2T-CDNJ>2'M^8MU+TZW(=7L^-O,-EJ:#
MVMUZM]_6>8W=_?ZSW'[\3-=-=_+=7^5N+W6LT/BJ)_?U>OI4:6]"<EI 4"_D
M",H*8,HH((:76Y T4PS/<M\EM&6QMV[-#8EOM5*3NJ^]..1B7YAYSC?M>-XU
M_7I-VTSRQ-JD-C?9:WN3UN";I#'9$$UT;#P7EZDCM6![L:_SN6_Q!+?K7^/.
M3ZS7&>R&4#0%_?,<2[&DV^\GB>=?EFMYMY=?=@N"!.1%68$BS7* =&0/,&<,
MJ (*DF<LS7,G0NQA<;$7O8/PFZ1C_6S.,'\W*B2U#HZ1_ A^]KF0,*BX)T0F
M .*5&!FW,V!V9$#8["F2<</[\B06G_*;^ <BY_:.^VX!B[3@YI9@5IIM.X0"
ML"S'(,^)(38K",U2EPJ0"PFS%(,<+NIW60C'PI!+7.SF\"1KW:;MD8/[S9B)
MSE/TJAF!9N7E^+-.Q*OF/9U[UQ_T[TGSI)7%>[W0;Y=<+^YMJXOS'YP\V80"
M7>+FM6S^J__=4+6_^9/7]%N&EJLAZUH4.$5"$5.DP J .!. %)FAW!<L$RG-
M2L5=YO*\ZD=V%.]DS4W39,%^$*T^/YKM"^_:Q6P/QM0_<^^?,^/+MG-0+_<5
MNGD_H]E-3SN?H^Y)\XAYC4]^>/Z)-LUP2(C^T-GU8YTE;?L@=+8U%(N-=6$[
M!<W_5@*V')I1^=E[%\W_8OJ:(#V#%GYKG/:K1H.'[>;;4DCQT_??=F8C^W:Y
MIFNN!1X[AAQJ+E.>%QE3"""J(TT$]=:2F7;1.,.5PH(K!KG+_M)=A<A[SMKK
MO%UM_M@E;_5W+#EH8M,_)13*=@M$7.S<G+Q9HFOH.FW,.>4/1B&]2O_8BV*4
MCK+^F 1RL1X*S.HF_0%ZZNHFC.3)_UV?Q)GCN\U:N\NN!5Q>L:J2)>!E82)G
MG@)""PXRQ"F2G"E9.)7W]DJ)['3:4_N#4,\L=3] =LYDLMEN_L+=8G<BZR&+
M0M%1]\J8EU1ZR,P+:NC!AWW;@^AX1(<UO^@WLOJ_'[?+G5C6EYTZTIFT9$25
M"J2PQ.86=P88K7*0ZD BIYDD,'<JPAV1%[V&UNPJS%:EEI^<*N#:^&,8-\NC
MZ'!H.)Y%#P 1@:3!TLY@G3N&I<W<JL/*],O>''8?\SP?VZSK-?V1KN[9:OFI
MN7I;XA+#HH2@K$@.4)%3P$BN%V-"2U@1(JAP*M'LE1)YAC<MK0WQ&I-U^TCS
MUU?ZLTM>\QOLI ;K<W*__437RW]2]XG?#YWEH=!40!S/;H[BDJ.\@*<I0^:$
M.O3HE3'OV<20F1='"(,/^\W6BS8/O?5FN^[+O5"5GLB\*(%25040E@00IH-J
MG)<Y0YA6/*<N\]A1?N09?IC#9O42\IM<;6KNO837*CGN[UVQM9OH$1%S<P$]
MG6ANDBL%I<VI;JU0.!_AB40@[^$J?5:_X@G-4X_C.XR;+]IM]TU,8J;:!R[7
M=+O<U/<9<)H*)?46/B\1 DCOZ $N4@Y21 7.:)G!7-IXFZL28N\)6E%.5SNN
MPS'L(((8Z1CJ6]IG/;5';1B:O/K#)Q-7_^LX::^/.\NT'#6KFWCC#P9:Y@]9
M\5\VN]W99%XH4I0(PA)@I:-T5%1F=<<,I!)F>848+I#32;Z#[,C3T9Q%'ZM*
M5C77TZGXB<O[ *:>2WL8I (LZ\="%:/)^=(><4$?MS_68CX@^7D7\G%(1A=Q
MBR&"=G2[:,?T$]TM^4+  I>E1*!$N 0(B@I0P5-0Y40I2E5:I4[G\T[2(WL:
MEVYNS.@3O)?;%=#M'%$T*-U<D6,?MUJ;Z%W<AD&(V\/MBNR7T,%M&!;+_FTC
M@[CS0KU9[TU:XU'[O_6^(<S4HYH(ZW&WD 7.*\PA*(7)/T!35<<(!["0G,HJ
MSTH[!S0F*':.L!:=M+*3@_"DD6Y/*SL(UK#C" F!8[[0TWHGQBT;T[P(N 8'
MGHV/R\:\4WHNJ^<G%K,W;=M,A+)(124R7$ =&:00(-/]E9"2@!Q*O16A>94B
MZ57.?I3A-$7=ZU3KH-E@WFT_-FO?8O837.S6\HG6NLW&XSZA:Y9HY%V/:/RK
MVB^M"5W7?B+A>2K;+TV\6MO>\^B$G+TY?/CE</.)EP51I4! %86.T\N< 9IA
M ;*4I%E.*\C=S@,N1<R1F:^/\2?<#KO$Q6[Z3;/6\3C.S5"_5'NO+2&SZ^<"
MYD^H]QK8FT/O?])WXFWXW^]VNT<I7C]N]91N:G[KFZ&O-FL=)^_TJG&OFK_O
MEVPE/TBNGS1U= M>E5)D%)G:&0H032E@2$F0"L@*2@H,A=5!>1!MHD]G<Z_Q
MKFOU^?BUYJF36[YL6L?]0<W=7==DW33\;7W!3*BZNHT.4+W5;A0[W/ZO=:N9
MQUOM#,(G^B5'!4/ZF0 X!7-)4W29V7L%@.W2T848U+-%YK5>> ^;U9)_/Q+5
MJ@*+B@D.*"_,#03. &/:!_),*IP7LI"Y$WF,K>#(GN[A_?W#F_<?_RNY??<Z
M>?,_?[M[^/7-NX\WR;LW'QT[8=H":>?'8L#CYK*>=+P\;WBI?UCKD?S>_C<*
M-[ K"*%:8=J*G;<1IB,8%VTP73_O46'09E-_6^^^2KY42^W0FCKX#!6"I@@!
M#',%$$PE(-+D)3*2XJJ0,$NMO,>@E-DJ#9PN" P#,^P-@IGK&*U86^I6=3!F
MR93*@ZMCSU=],&;>607"Z,,SL\VUA#I''MK7RQU?;7:/VY.[<0669<I8"2JF
M,H!DD0&2E0(HE?,,X2(GL)B%0<Y&V\CNX,#G18_]$L51BYD(X:Q>F^76Z:6\
M#$=G-9VX[? J3UI?GM@0Y;+D+&@_-Z^:E:[_&EQI+K 'XS]S$NK1G?"7N[_^
M>O^^O?.4I2E$I9#:N8M4QV@$ VS:$&JG#FF58R$RJT/HBY$C.^)&E$.3NS.K
MAWWC)%O<_%@CQ:=I^)D]#NWX?.WR:[0W\IK<>N;UJ3[8#>_L _/UN>O3\ZR#
M7>\#04,_XT=,%SS^6=ZO9?<M42DK4X) RHD *"\H(# 70$):%K L*E0YM>QV
MD!U[ES;6TJ/5)]$*!8G1>O&=%'%-1<T_?AH#+,;=4G<,XD8UO9)?0HPR!(EE
MQ#$X1,#^!O55"E4B0DJE0*&R"J LK0 NRPJD),,E44P)Z934OBHILD>Y<M_*
MMY?(%;3L/$80#-S\@Z?Y8?H6Q&D^<D7.\_<J&&E*,O*!:Q/X]!W]HO_VW_];
M]Q/]AVDN]-__V_\'4$L#!!0    ( #.!=%CZM<,I<&X  "D0!0 5    8F5A
M="TR,#(S,3(S,5]P<F4N>&ULY+UIEYNYCB;XO7]%SIVO@TKN2YVNZA/I)=NG
MG;;'=MY;U5]TN("VYD9(;DGA3/>O;U"Q[UKXQDOEU*GK#$>$11!X" (@EO_Z
MW_X\.?[I.RZ6T_GLW_[&_X7][2><I7F>SK[\V]]^__P:W-_^V[__E__R7_\O
M@/_XY>/;GU[.T^D)SE8_O5A@6&'^Z8_IZNM/JZ_XTS_FBW].OX>?/AR'59DO
M3@#^??W/7LR__5A,OWQ=_2284!>_=O'3Q;\&$8L-48'@Z$&YD,!YSH'%DI@0
MBEEF_I\O_YJYMCX7#P*Y <45@^ " QM-#-G*DI-8?^CQ=/;/?ZU_Q+#$GVA[
ML^7ZK__VMZ^KU;=__?GG/_[XXU_^C(OC?YDOOOPL&),_7_SVW\Y__<\[O_^'
M7/\V]][_O/[IY:\NI_?](GTL__D_?GO[*7W%DP#3V7(59JDNL)S^ZW+]S;?S
M%%9KKC])UT\/_D;]&US\&M1O 1<@^;_\N<Q_^_?_\M-/9^Q8S(_Q(Y:?ZG]_
M__CFQI)?,2Q6$</)OZ3YR<_U-WY^,2=$? A?*KWK?[_Z\0W_[6_+Z<FWX\OO
M?5U@^;>_T3]<T;I"<G&VZO]]]8]_OB+@VP*7A)KUAM_2-\X_HZZV(S'XYPIG
M&<]V>;',\3S=^*7CRN/YXN)?'H>(Q^OO3C).)^M//HK+U2*DU21@\ Q5 2TL
M 4P7"<&D"%&F@#X'%JR]N?=*]Y((7XMDB>E?OLR__TP?_'/E1_UBS9@U4^XL
M=\:<W>B^.(-O9O6<K7GZ.<1CG- ID"RP1(07#DH935\I#D7F1/^OBS%LKRT\
MM/+-W5P7]M$B_31?9%R0<KE8.BS2'<'?A/7Y;_S\+2SH@R!]G1[GBW]=%O.3
M%C)<S1MS]$QT1/K??B(.%%PL,+\]D]R#&UWO<D7J%]>_N2LJ3I?P)81ODT_$
M=*P;>7$<ELOWY=-JGOYY].=T.6'H1!2:0Q".-F)<A&"3 A-TMMS:R)1Z!!HE
M+..:ZO.5SO"!QZOEQ7>N@/(D,>.AI8V<YT,PO0/T7*?_Y?PD3&<3Q;D17GO(
MP1=066J(B@Y4,D:6P&/VLC2&S5TJQL%+8_'.F_*Z![3,3T[FL_4^CG[#DXB+
M2:)3Y$(A4TXY 8H,.(@Y6E 6%=E^T=,66J/E#A7CHF5?N=Z&R7Y,[@ F_PB+
M19BMSHDWA:QX'QV$D#2H$!SXH@)8%X*B4T36OVF,D!L$; 0.<2#@V)VU.^."
MC*TXWQ,9]2)^-5M-5S^N7</D%. ;TK.D5;GF0FL'FIM,-ESVX')QQ" MDQ2R
M:"'V,F(?7GL<=#0W3!HR>$0%<ITMG^EW)R5I&Z6PP+-+H*0(X)UD8%,,3&:.
MWN:]@'%]M?%LU%:2N\>]V9J-G8C_:#8[#<<?\=M\L9JD*#D3/($S!4%QY\!5
M=ACF,3.=A-6N"0RNKSJ>9A@0#CNSM1-8?,#%=)Y?S?)+LM GRD6II$$0,9&F
M=)HT9:*;M"@>HLV)._^8A[LY+FXLNQ$PY($!8W?&CHR,%Z>+RK;7TV4*Q_^)
M87&QARA4PJ@+N$)_*.X)YX)ET#&XY!TFJQ_S8S<([CVP\D;X4 >"CR;L[41Y
M?";3>3FM?#E7@#YX)8R,I/8<*<"<!43.(E@K%-)]J73R;<R+6RMO!!%](!!I
MPMZ1(7+&EM?38WQWNG:MN'"%<R6A\$2T)R[ :^4ARER4$%HQC U<DJL5-X*$
M.1!([,7.+J#P$;],ZPO#;/4NG.#$6Q&T0 6Y"-)VFD>(UM&%*$1Q.NGD^'XO
M1?>MNA$D[$%!8@^V=@&+-[,T7Y!R6S-E'29^,3^=K18_7LPS3HQ!P;@7H&M0
M1CFRJKW+$<B%1ZVD1[.GN[H!$1N!QAT4:-HQO0L,?0Y_OLG$RVF9GJ4#G.O(
MS,D;)PL;$@8RNC-YZ9&7!,8%(R6:HE-J@)X'EM\(-_Z@<-."T5T@YBAGDL?R
M_#^5/7Q"7ICE(M2\F,! 66XAY&0@6TPQ\LRM;Z%K[EEZLS@9.RBH[,OA3F$B
M)L$:&ZMS)HK"FFK%(&@= ;T7*7#A$[90*O<LO1E,#B6>VH;#/<'D!7WY?O%Y
M_L=LPEE260D%G$M!6Z#+-"3:D34\ILB<T#*T \G5PIM!Y%!BK"VXVQ- UI;6
M^\6'Q?S[=)9P$@I94\89<,G0M2FR!2=E@HCH=8@^"K5?JMECJV\&E4.)NC;C
M<T]X^3!?KL+Q_YQ^6YOE%E$EY@J0C457J',,7&$:2B:%J$U0-NIV:+FQ]F98
M.90(;",>CQVFKWM88%C3[424NKY')B.(%3$7 C<1[VV,A6A+,NR'C>NK;8:&
M0PFV[LS'D>5?4]^//WR=SRXB@E&PY!BY7H%+3=BU"4BS!4 1K _H9-;[1=1N
MK[@9#@XEPKH7/T?&PB=,IPMB"!?Q\W1UC!.M1,P,#7@, 921A&/C)006'?GC
MTJH]G93;*VZ&A4,)K>[%SY&Q\'D1:N'1IQ\G<7X\R=8*DS4'8301CEE!\"F0
M_2.")H\;D]_/Q+RQW&8H.)18Z>Z<[$0=O/HS?0VS+[A^&5 A<=2. TJI0!6O
MP$5&/I0C/>89ZI2QB4JXONIF@#B4(.C>?.W"N?@''A__CQGYT9\P+.FZRV^6
MRU.Z[SPGXR82MAUGY%4;0U_ED$!JNNNB35QYOA= 'EU^L^2PPXJ!MN!T%Y#Y
M^_SXE*2Q6#] +X@MS$?IG" WR3I0*D@@+YH!(C/>8>3)M'B\O;7L9A YK/CG
M/ISM AKGZ4QG"2KUMB2)G"XG69"A9 +Q(B8&*I$W5<F'((M KI7U_K$:A4T1
M<O_JFP'EL**@#?C<!5[>S.C30EI-O^/+L KGVYI@,KF40C95"81[49/?9-*0
M24]R,K"8-_M9)X^MOAE>#BL4VH#/7>!EK1=?A!5^F2]^3%*P$6U-BO2.?')3
M,C@5;4V9],S*P(UO 9,;BVZ&CL,*?N[.U2Y \>DD'!__<KHD;BR7$\.D]C7G
M*:7ZMFR$)LI)&Q:IE10V1!9:/-S?6'0S4!Q*#'1?KG8!BE<GN/A"-^.OB_D?
MJZ\OYB??PNS'1%ON1#$1)$.Z($G#@6/$%Y.%([0;*7,+4_7>Q3<#R:$$2%MQ
MN0^P_'F57'U6J3$Q10BN)=V%1#^H7*M #7%(*%:,8BFHO%]YPT,K;P:30XF=
M-N'OR!AYD\KBZ#1/Z3>.5BM<GDGC]7'X,M'1VN!4AIBU!>6Q)N,7#<&78H*+
M/)K]+IN'U]X,)X<276W$XTXJ85Y/9Y]6)ZM7B\5\\6).1*3+W5BE.%8&L2*)
M0=Z28:5$ 3+ 94X&L]_39GV:ALV0<RAAV,8\[^(^^O05CX\O;E-9:@Q(&4BY
M)O&S9,''FH]-N\K!8DGIL18@&QNTU];<K 3SL,*O._.T"T1\.(W'T_3Z>!Y6
MDZ1*"%H7DF(F6UP(!&<Q02S6&7+<?9(M '%MR<WP<%BQUETYV@4<SIK8K+N>
M?/I*/%R^/UW5?HCUA7(2F4*K.1G=6M<F2I[ G;D#SWA4S&7,JD5JV&,T; :8
M XNYMN)Y'P@B-B["\9M9QC__!_Z8!"ZME$P!B\:#BIY!9'1;"AXQ.<\-BRW\
MG5O+;H:3PXJU[L/9;NS7BW+TU_2=Y42X[,A?T\"+E>30.T*WEK29E(D=2?J<
M][MQ'EAX,W@<2K"U!7>[ LB9*W^Q"6M$J ^413AB2G!07Z_!^.QM<=)XM]\3
MWX-+;P:20PF^MN'PR# YHAWD]2[6#KRVBCSX"")98D6P :**"0I*P:2.0>W9
M!OC&<IO!X5#"K+MSLA--L;RJ+L;\RX^/E1*<)?R,?ZY^H5_^YP1]BJG6=L4L
MQ%F20[!. /..D!V+$[)-B^4G2=D,.H<2>AU& LU@]5]_OL-EVO,_=^ZPOHX>
M7F/@38(W:[1^YS/:]%M_G+0]VZ[774QNKW#9OEO%6)((9%M$GVIR600?<X2,
M3&AR4)@K^BFN/+K"7M?$6<#W]71Q\B9/8O#(?+9@L;9+*Z3AR/*)@#4Y0;"2
M5-@O,GICN7&Z$;83UHU+8F<^CFTGG!&^SIQE%CTJSD$64_M,D)L4F"@01!*(
M*DM242W$OW$B<O/HQ*#"WYJ'?8C^[?G(CHEC=,EE1]NWW-4>S *\YQ(DX^0A
M"Q]EV*]&Y=:"XW09'!0"._&RV_O\EW!<Y[M\^HJX6NYRF=_\@#8W^2-$[7F-
MW^F-_[Z\GLYHL2EY@?.SI_-+H)C@4\E!0+2Z#OA)D5Q!@HQDUL;LO)6N=5?X
M3>C:M['YT7));+W<99(FHI4%3,!:2T$6J7/%0#!2F1R3$H]F@>ZRRYL4=#(E
MH142;C<[WX/='73!/Z/^/)/U<A-,8DZ5ZL2(%2J$!.04*^#91,Y(W-$\UNI\
M=\S<(F1<Z.PCV7M!L@^;.\#*B[#\>C3+]3^O_M?I]'LXKG[QT>I%6"Q^3&=?
M_AZ.3W'"3<F^-N\NTE<WN&9#9Y& ?.^4#6=&/]J 8Z=9&YL0U@.6]@+ [0D<
MS:71 <0^+/!;F.97?W[#V1)I>^]77W%Q@WD3@Z8$^E^U[U3MZ1LA%E=C.C7^
MSVW@CQ9=[@*P#<@:=X!'>WBUED0'X+I)?/8A\IQJ?[UD027IP2=64^,8J786
M%<K6$U^V!TQSUVDXP.S.W=VA,5^%XT9Z9_X-%ZL?'\@Q61'8JT;]5JW&=T@.
M)9&?@F)@N22N(&+M,\^A^!*YCJ:D1S-!=E,X#]/3@Z9I8A0U8WH'NN6:=GPW
MGZ6+4^"24RD[L*SZ%4@LBJYPR%+0#C#$'%O;0O<2TH.N:0*9_=G< 5;.Z)_4
M$02%0 [:Y4!.9ZX5ZX;XP'E2:)1FCW;KWOT"&F?TPV!>U5:,[."N>3L-<7H\
M74UQ24IOG0GW=7Y,3%]6!;CZ<74;1^O1!P,^D,6NO U0I\B"#5)K+WC2S0&R
M*6WCWD&#QW0&$5$'FN?:OFZ;?@%CM$8Y$ X-Z5!EZ;YEM!V7=78HE BMKZJ'
MJ1G75Q]&^@]#;!]1= "JHY1JH_OEA_"C3@8DEM%W%J=$QYTM3G@2KB3D(%6M
MBO;,@8\% 5.1B%EYKA^K]-KISMN<O&Y@MQ<B;E^2 XFG ^1=V\'$>[1)&P8L
MUNF!66F(LA;=>RTX_5_4L77(^MKRX]Z'SZVPMF)V!Q97K3F8KM997#5B.I_5
M9B](9@-M)447C*UY'K*H6I)/!D-)F4Z:Y)*.@D+^6%?Q74=#/T#.N([:L^"H
ME3 ZT#^/<"B%8DLV$;2WG-R:P,#74876VJ0"&:"F^7SZ/:WUP1R^9T%5(U%T
M *H/%^NNMW3VBH-5W=8AE\5E"4I9XI$B<R#9'!2/BM1M:R5U#QEC/^2WD?#=
M=XZ]V-T!8JZ5U)W13[<R"R+6^<F8B7ZG(-2.VS8GC$5[8U+S)]A;-(P=(!@$
M*WLQN@.@'.6\CI&$XP]AFM_,7H1O4[*Q)D8ZE6S$:O'76'LL$+C*@"X[EP6I
MWOQ8E]*=O++[21G7_AD(-BW8W@%Z/N(J3&>87X7%C$RV);F1IR>GQ[4>XB66
M:9H2EQQMHJ "*6T=X1XSQ%3(DPQTM2MMZXRJQD!ZFJIQK9^!,-58&!W ZRZC
M)J80T=X+,+K6ZM5<W."M!H_.JV*8"*QU /PN%>-,01X8/GLRNP.?_BFO8N*5
METS2+FJZ=DU.4>#LVI(KN6CE2]*J,7B>HFE<*#UWE&A_L32#V:!9]1_6W/^*
MJVDB ^8&Z3NDV-_\M 'R[1\A]SF3[TG:02G-(.M02-VP ,XI17^UA5GRL?*C
M#49[3;Z_7.-S#;9/8O46/3.0:W]@I9VKSY&U%:S1AI42(F\=E;Y)P=@^>V,D
MW+W'=F9W!R;/1UP;;'0B5S_6K1W#NMO:LI877_WDZ,_I<A(EQR 30B)^T&4O
M/#B4Y'C6">2>1QVT;VY9;TI=)R#; 0-WK.I!!-(9U%[.3\AWF-A@>59!D&M@
MZ8\8:QN$5-O-%F6S8+(\VD-Q7TB=43$N=(:2]R.PVH'YG<'G-UR/<E/<,N:2
MA"0UDE/)) 1>JZ2UD=X9$VQN'9.^2T4_\-E%KH_ 9 <F=P"32U7\]K+O1F Y
M.JDC>0]L/>++U<&/"3BS)1FI4);6;MA=*L:.1C>[H/9D< <0V=@+=1B=3=(
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M7(D<0A1%DI.I)0[0/'TCVL;M9CD0V@813 > ^TC2(0+J27J)W_%XOM[4^1#
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M4-*%ZUT&60PQ0G@7=?,GJ=M$C!O]:P^1_;C< TSNNZ#?7N:4)$VP#KQ 82J
M<KHV%ZVSIG/B7#LL63Q+[_6W6XU(&2P#[#G?,G<30J^0>G^Z6I+-GZ>S+Q,F
MK B>>6 BE=J+0()W08(6RB:;@U.V>4N2)VCJ\$%K1_EO JU=A3&ZPWW?9GZM
M7[\D,_&RL51MB:Q=R )XKC$)SFKG;TN*&%/4TDMBVJV4I&UJK.\NV.&;UG[H
M&8S;':BG+<?\A*!8PD0;"TZ $IF!UTF1[5<\C[Y8GYJW.VP_C^EY \YM5->
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MT>[?U:E]RQ6>?WL2LHW9!(1D4JS]0#PX6=N#2)>,2EKYL-D0A6'HZ_S9;1C
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MDS'ZU99]H;*]MO@K;9FMFBGGLW9*4_W)JRF<OUTN;H)45_> CX<.O$R,1RG
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M._WRQ_K>W J422BRRKUGU5+/X#DYQUD(GI+':$MKP#Y+4.=77(/C93Z4\#I
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M3!Q"U@680L.Y,UFRUVV>]I<F]9JT<1^X'?M0B<V9\V)FS%U!:V%2D-D!MS:
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MZ6ZR*=^_MK$6^QBJ!Y9]!V@_.5_]#FGNHTM?.X(3U#4V9CV@K^W1;6$06"G
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M5%O7H*PJ$!Q$^BXHX;CZM7#\B;/J^?=L!!%];!!IS>".]IA;%IUB=6!IW_Q
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M7BZD#2;*.CL,.43F$7CT@F?A=6&MHPU;D-=)#<>>B/EULQI*/AV<J ^6=N,
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MB-? %3(IG$SYUU8QS:V+-2GC7H T/SU:,+Q/W%SK$RT$LT6PUM1J$AD@$K=
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M(T#Y"Y40$\M9@2>K,/493_'*,E,@RWH3Y=8$2IE*Y[B=D4C![R7Z7;+I\$[
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MOL6A(,(DGE5Z(>*%?O,<SQ]]L(I4X!]8&&Z@6$N5#7L#C4Z$J'".KE@)?8"
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M!(]A?E1FW61C$BO?]7NY??<^\&]02P,$%     @ ,X%T6&WG#F=]%P  )J@
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M5L(3G"!R<W'BFC\9GWO*<PV_9\ ,5T%(P69P5GB*\-SD%3H@IA@ZM/RQ%+>
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M"( 5:2=G6D+BH;*KF67I/ID'K:]X8YJ/J^C-71UM*PNN66I=8@$UF;." S-
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M_P-02P$"% ,4    "  S@718?0>ZH;@? @#&,Q0 $0              @ $
M    8F5A="TR,#(S,3(S,2YH=&U02P$"% ,4    "  S@718B:X+0G,-  #R
MB   $0              @ 'G'P( 8F5A="TR,#(S,3(S,2YX<V102P$"% ,4
M    "  S@7187R- J'\0  "XE0  %0              @ &)+0( 8F5A="TR
M,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ ,X%T6)CR51$D10  </\" !4
M             ( !.SX" &)E870M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( #.!=%@V&\'6,0D!  (H 0 4              "  9*# @!B96%T+3(P
M,C,Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( #.!=%@J[C(>M8H  -"K   4
M          "  ?6, P!B96%T+3(P,C,Q,C,Q7V<R+FIP9U!+ 0(4 Q0    (
M #.!=%A)<.E-H1X  +P@   4              "  =P7! !B96%T+3(P,C,Q
M,C,Q7V<S+FIP9U!+ 0(4 Q0    ( #.!=%C $<S88A(! *)I 0 4
M      "  :\V! !B96%T+3(P,C,Q,C,Q7V<T+FIP9U!+ 0(4 Q0    ( #.!
M=%B$7V-(EK   !47!P 5              "  4-)!0!B96%T+3(P,C,Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    "  S@718^K7#*7!N   I$ 4 %0
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HI'@& &5X:&EB:70Y-S$N:'1M4$L%!@     .  X E ,  $V0!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>beat-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:beat="http://www.heartbeam.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="beat-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:AGPAllianceGlobalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:AGPAllianceGlobalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2022-11-14</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:OpenSkyOpportunitiesFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-20</startDate>
            <endDate>2023-04-20</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:MaverickCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:CertainInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">beat:PennyWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">beat:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beat:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">beat:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2015EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">beat:ExecutivesAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:LIVMORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:TripleRingTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:TripleRingTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">beat:TaxPeriodsPriorTo2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">beat:TaxPeriodsAfter2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">beat:A2022EquityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:ClinicalResearchOrganizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001779372</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">beat:ClinicalResearchOrganizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>beat:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="site">
        <measure>beat:site</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-38">0001779372</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-39">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-40">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-41">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-41060</dei:EntityFileNumber>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">001-41060</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-8">HEARTBEAM, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-10">47-4881450</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">2118 Walsh Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-12">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">Santa Clara</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-15">95050</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-16">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-17">899-4443</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">BEAT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">BEATW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-24">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-25">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-26">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-27">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-28">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-29">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-31">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-32">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-33">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-34">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-4" decimals="0" id="f-35" unitRef="usd">21352087</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-36" unitRef="shares">26329032</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-42">688</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-43">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-44">East Hanover, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-45" unitRef="usd">16189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-46" unitRef="usd">3594000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-47" unitRef="usd">636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-48" unitRef="usd">445000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-49" unitRef="usd">16825000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-50" unitRef="usd">4039000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-51" unitRef="usd">256000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-52" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-53" unitRef="usd">50000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-55" unitRef="usd">17131000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-56" unitRef="usd">4039000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-57" unitRef="usd">2000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-58" unitRef="usd">2000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-59" unitRef="usd">1194000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-60" unitRef="usd">1665000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-61" unitRef="usd">1194000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-62" unitRef="usd">1665000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-63" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-65"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-67" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-68" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-69" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-75" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-76" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-77" unitRef="shares">26329032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-78" unitRef="shares">26329032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-79" unitRef="shares">8009743</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-80" unitRef="shares">8009743</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">52759000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">24559000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">-36825000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">-22186000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">15937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">2374000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">17131000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-90" unitRef="usd">4039000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">8516000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-92" unitRef="usd">7354000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">6798000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-3" id="f-94" unitRef="usd">5677000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">15314000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-10" decimals="-3" id="f-96" unitRef="usd">13031000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">-15314000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-98" unitRef="usd">-13031000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">675000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-10" decimals="-3" id="f-100" unitRef="usd">66000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-102" unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">675000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-104" unitRef="usd">69000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">-14639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-106" unitRef="usd">-12962000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-14639000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-110" unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-115" unitRef="shares">20333280</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-116" unitRef="shares">20333280</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-117" unitRef="shares">8168516</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-118" unitRef="shares">8168516</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-119"
      unitRef="shares">7809912</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-120" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-121" unitRef="usd">22633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-122" unitRef="usd">-9224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-123" unitRef="usd">13410000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-124" unitRef="usd">1120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="-3" id="f-125" unitRef="usd">1120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-16"
      decimals="INF"
      id="f-126"
      unitRef="shares">38806</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-127" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-10" decimals="-3" id="f-128" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-16"
      decimals="INF"
      id="f-129"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-16"
      decimals="INF"
      id="f-130"
      unitRef="shares">136025</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-131" unitRef="usd">804000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-10" decimals="-3" id="f-132" unitRef="usd">804000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-133" unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-134" unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-135"
      unitRef="shares">8009743</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-136" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-137" unitRef="usd">24559000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-138" unitRef="usd">-22186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">2374000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-3" id="f-140" unitRef="usd">3208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">3208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-22"
      decimals="INF"
      id="f-142"
      unitRef="shares">17872955</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-143" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-144" unitRef="usd">24762000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">24764000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-22"
      decimals="INF"
      id="f-146"
      unitRef="shares">180072</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-21" decimals="-3" id="f-147" unitRef="usd">214000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">214000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-22"
      decimals="INF"
      id="f-149"
      unitRef="shares">258970</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-22"
      decimals="INF"
      id="f-150"
      unitRef="shares">7292</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-21" decimals="-3" id="f-151" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-153" unitRef="usd">-14639000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-14639000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-155"
      unitRef="shares">26329032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-156" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-157" unitRef="usd">52759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-158" unitRef="usd">-36825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">15937000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-14639000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-161" unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">3208000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-10" decimals="-3" id="f-163" unitRef="usd">1120000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">191000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-10" decimals="-3" id="f-165" unitRef="usd">-361000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-471000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-10" decimals="-3" id="f-167" unitRef="usd">1533000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-12093000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-10" decimals="-3" id="f-169" unitRef="usd">-9948000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">256000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-256000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-10" decimals="-3" id="f-173" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">24764000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-10" decimals="-3" id="f-175" unitRef="usd">348000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">214000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-10" decimals="-3" id="f-177" unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">16000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-10" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">24994000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-10" decimals="-3" id="f-181" unitRef="usd">350000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">12645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-10" decimals="-3" id="f-183" unitRef="usd">-9598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-184" unitRef="usd">3594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-185" unitRef="usd">13192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-186" unitRef="usd">16239000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-187" unitRef="usd">3594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-10" decimals="-3" id="f-189" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-10" decimals="-3" id="f-191" unitRef="usd">0</us-gaap:InterestPaidNet>
    <beat:StockAndClassOfWarrantOrRightIssued contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">0</beat:StockAndClassOfWarrantOrRightIssued>
    <beat:StockAndClassOfWarrantOrRightIssued contextRef="c-10" decimals="-3" id="f-193" unitRef="usd">456000</beat:StockAndClassOfWarrantOrRightIssued>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-194" unitRef="usd">16189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-195" unitRef="usd">3594000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-6" decimals="-3" id="f-196" unitRef="usd">50000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-7" decimals="-3" id="f-197" unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-198" unitRef="usd">16239000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">3594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-200">ORGANIZATION AND OPERATIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;HeartBeam, Inc. (&#x201c;HeartBeam&#x201d; or the &#x201c;Company&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (&#x201c;ECG&#x201d;) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company&#x2019;s ability to develop higher resolution ECG solutions is achieved through the development of the Company&#x2019;s proprietary and patented Vector Electrocardiography (&#x201c;VECG&#x201d;) technology platform. HeartBeam&#x2019;s VECG is capable of developing three-dimensional (3D) images of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver equal or superior diagnostic capability than traditional hospital-based ECG systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has validated this novel technology and is seeking U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) clearance of its initial telehealth products during 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in 2015 as a Delaware corporation. The Company&#x2019;s operations are based in Santa Clara, California and operates as one segment&lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-201"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-202">GOING CONCERN AND OTHER UNCERTAINTIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to those of early stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of December&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of&#160;approximately $36.8 million and $22.2 million, respectively. As of December&#160;31, 2023 the Company had approximately $16.2&#160;million cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2023, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;) pursuant to which the Company may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $13.0&#160;million in at-the-market offerings (&#x201c;ATM&#x201d;) sales. At the same time, the Company filed a prospectus supplement under a shelf registration relating to the Sales Agreement. AGP will act as sales agent and will be paid a 3% commission on each sale under the Sales Agreement. The Company&#x2019;s common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary. As &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;of December 31, 2023 there was approximately $11.0&#160;million available for issuance under the ATM.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#x201c;SPA&#x201d;, NPA&#x201d; or together &#x201c;Agreements&#x201d;) with Maverick Capital Partners, LLC (&#x201c;Maverick&#x201d; or &#x201c;Investor&#x201d;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $4,000,000 of the Company&#x2019;s common stock at 75% of the average calculated Volume Weighted Average Price (&#x201c;VWAP&#x201d;) per share during a Drawdown Pricing Period as defined in the Agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2023, the Company issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023 the Convertible Note was settled upon the execution of a SPA and related issuance of 0.2&#160;million shares of common stock pursuant to the SPA drawdown notice dated March 7, 2023. These shares of common stock were registered under the Company&#x2019;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships and revenue. Management can provide no assurance that such &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.&lt;/span&gt;&lt;/div&gt;The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-5" id="f-203" unitRef="usd">-36800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-5" id="f-204" unitRef="usd">-22200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-205" unitRef="usd">16200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <beat:SaleOfStockMaximumAmountAuthorized contextRef="c-27" decimals="INF" id="f-206" unitRef="usd">13000000</beat:SaleOfStockMaximumAmountAuthorized>
    <beat:SaleOfStockAgentCommissionPercentage
      contextRef="c-27"
      decimals="INF"
      id="f-207"
      unitRef="number">0.03</beat:SaleOfStockAgentCommissionPercentage>
    <beat:SaleOfStockRemainingAmountAuthorizedForIssuance contextRef="c-28" decimals="-5" id="f-208" unitRef="usd">11000000</beat:SaleOfStockRemainingAmountAuthorizedForIssuance>
    <beat:SaleOfStockMaximumAmountAuthorized contextRef="c-29" decimals="INF" id="f-209" unitRef="usd">4000000</beat:SaleOfStockMaximumAmountAuthorized>
    <beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage contextRef="c-29" decimals="2" id="f-210" unitRef="number">0.75</beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-30" decimals="INF" id="f-211" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-31" decimals="-5" id="f-212" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-213">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BASIS&#160;OF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PRESENTATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of financial statements in conformity with US GAAP,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. On an ongoing basis, management evaluates its estimate related to probability and timing related to vesting of the stock-based compensation related to probability and timing related to vesting of milestone options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2023 the Company has $15.9&#160;million held as cash equivalents and as of December 31, 2022 there were $2.6&#160;million held as cash equivalents. The Company maintains cash balances in accounts which exceed the federally insured limits during the year ended December 31, 2023 and 2022. The Company has made a deposit to the bank for their credit cards in the amount of $50,000 and is classified as restricted cash included in other non-current assets as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company&#x2019;s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. As of December 31, 2023, property and equipment, net represents construction-in-progress of $256,000 related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;RESEARCH AND DEVELOPMENT EXPENSE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional services costs associated with the development of cardiovascular technologies and products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist primarily of cash, accounts payable and accrued liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or is derived from such prices. The Company uses the market approach &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valuation technique to value its investments.&#160;The market approach uses prices and other pertinent information generated from market transactions involving identical or comparable assets or liabilities.&#160;The types of factors that the Company may consider in fair value pricing the investments include available current market data, including relevant and applicable market quotes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.&#160;In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ACCOUNTING FOR WARRANTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company accounts for its currently issued warrant instruments in conjunction with the Company&#x2019;s common stock in permanent equity. These warrants are indexed to the Company&#x2019;s stock and meet the requirements of equity classification as prescribed under ASC 815. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;STOCK-BASED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically issues stock options and restricted stock awards (&#x201c;RSUs&#x201d;) to employees and non-employees for services. The Company accounts for such grants issued and vesting to employees and non-employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of stock options on the date of grant is calculated using the Black-Scholes option pricing model, based on key assumptions such as the fair value of common stock, expected volatility and expected term. These estimates require the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. These assumptions are primarily based on historical data, peer company data and the judgment of management regarding future trends and other factors. The Company has estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by the actual awards forfeited. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation cost for RSUs issued to employees and non-employees is measured using the grant date fair value of the award, and expense is recognized over the service period, adjusted to reflect actual forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;INCOME TAXES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition and measurement are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LOSS PER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COMMON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SHARE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the years ended December&#160;31, 2023&#160;and&#160;2022&#160;as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December 31, 2022, the penny warrants issued during 2019 have been excluded from the net loss per common share calculation following treatment of contingently issuable shares as there are circumstances under which these shares would not be issued and therefore not exercisable. These warrants expired as unissued in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of December 31, 2023, and 2022, 176,674 and 175,958 penny options have been included in the calculation of weighted average basic and diluted earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of awards outstanding as of&#160;December&#160;31, 2023&#160;and&#160;2022, which are not included in the computation of basic and diluted weighted average shares: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options (excluding exercisable penny stock options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,286,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,183,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RECENTLY ISSUED ACCOUNTING STANDARDS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Not Yet Adopted as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We do not expect that the updated standard will have a rather significant impact on our financial statement disclosures&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued&#160;ASU 2016-13&#160;&#x201c;Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments&#x201d;. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the FASB issued ASU 2019-05 &#x201c;Financial Instruments-Credit Losses (Topic 326)&#x201d; which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on an instrument by instrument basis. The guidance is effective for the fiscal year beginning January 1,&#160;2023, including interim periods within that year. The Company has adopted this guidance and it had an immaterial impact on Company&#x2019;s accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-214">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BASIS&#160;OF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PRESENTATION&lt;/span&gt;&lt;/div&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-215">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of financial statements in conformity with US GAAP,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. On an ongoing basis, management evaluates its estimate related to probability and timing related to vesting of the stock-based compensation related to probability and timing related to vesting of milestone options&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-216">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2023 the Company has $15.9&#160;million held as cash equivalents and as of December 31, 2022 there were $2.6&#160;million held as cash equivalents. The Company maintains cash balances in accounts which exceed the federally insured limits during the year ended December 31, 2023 and 2022. The Company has made a deposit to the bank for their credit cards in the amount of $50,000 and is classified as restricted cash included in other non-current assets as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-217" unitRef="usd">15900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-7" decimals="-5" id="f-218" unitRef="usd">2600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">50000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-220">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company&#x2019;s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ConstructionInProgressGross contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">256000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-222">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;RESEARCH AND DEVELOPMENT EXPENSE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional services costs associated with the development of cardiovascular technologies and products.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-223">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist primarily of cash, accounts payable and accrued liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or is derived from such prices. The Company uses the market approach &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valuation technique to value its investments.&#160;The market approach uses prices and other pertinent information generated from market transactions involving identical or comparable assets or liabilities.&#160;The types of factors that the Company may consider in fair value pricing the investments include available current market data, including relevant and applicable market quotes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy.&#160;In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <beat:AccountingForWarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-224">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ACCOUNTING FOR WARRANTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company accounts for its currently issued warrant instruments in conjunction with the Company&#x2019;s common stock in permanent equity. These warrants are indexed to the Company&#x2019;s stock and meet the requirements of equity classification as prescribed under ASC 815. Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as the warrants continue to be classified as equity.&lt;/span&gt;&lt;/div&gt;</beat:AccountingForWarrantsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-225">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;STOCK-BASED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically issues stock options and restricted stock awards (&#x201c;RSUs&#x201d;) to employees and non-employees for services. The Company accounts for such grants issued and vesting to employees and non-employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of stock options on the date of grant is calculated using the Black-Scholes option pricing model, based on key assumptions such as the fair value of common stock, expected volatility and expected term. These estimates require the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. These assumptions are primarily based on historical data, peer company data and the judgment of management regarding future trends and other factors. The Company has estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by the actual awards forfeited. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation cost for RSUs issued to employees and non-employees is measured using the grant date fair value of the award, and expense is recognized over the service period, adjusted to reflect actual forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-226">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;INCOME TAXES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition and measurement are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-227">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LOSS PER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COMMON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SHARE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements contextRef="c-1" decimals="INF" id="f-228" unitRef="shares">176674</us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements
      contextRef="c-10"
      decimals="INF"
      id="f-229"
      unitRef="shares">175958</us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-230">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of awards outstanding as of&#160;December&#160;31, 2023&#160;and&#160;2022, which are not included in the computation of basic and diluted weighted average shares: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options (excluding exercisable penny stock options)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,286,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,183,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-32" decimals="0" id="f-231" unitRef="shares">5915851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-33" decimals="0" id="f-232" unitRef="shares">2020819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-34" decimals="0" id="f-233" unitRef="shares">217881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-35" decimals="0" id="f-234" unitRef="shares">253970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-36" decimals="0" id="f-235" unitRef="shares">5152397</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-37" decimals="0" id="f-236" unitRef="shares">3908276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-237" unitRef="shares">11286129</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-10" decimals="0" id="f-238" unitRef="shares">6183065</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-239">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RECENTLY ISSUED ACCOUNTING STANDARDS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Not Yet Adopted as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We do not expect that the updated standard will have a rather significant impact on our financial statement disclosures&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued&#160;ASU 2016-13&#160;&#x201c;Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments&#x201d;. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the FASB issued ASU 2019-05 &#x201c;Financial Instruments-Credit Losses (Topic 326)&#x201d; which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on an instrument by instrument basis. The guidance is effective for the fiscal year beginning January 1,&#160;2023, including interim periods within that year. The Company has adopted this guidance and it had an immaterial impact on Company&#x2019;s accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-240">STOCKHOLDERS&#x2019; EQUITY&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 14, 2022 the Company held a Special Meeting of Stockholders (&#x201c;Special Meeting&#x201d;), wherein the stockholders of the Company approved an amendment to the Company&#x2019;s Certificate of Incorporation (&#x201c;Certificate of Incorporation&#x201d;) to increase the number of authorized shares of the Company&#x2019;s common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;) to 100,000,000, and to authorize 10,000,000 shares of the Company&#x2019;s preferred stock. The amendment to the Certificate of Incorporation became effective upon filing with, and acceptance for record by, the Secretary of State of Delaware on November 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COMMON STOCK&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2022, the Company issued 78,025 shares of Common Stock to a consulting firm for services provided that were related to the IPO. The Company calculated the value of the common stock using closing stock price on November 11, 2022, resulting in a fair value of approximately $365,000. Additionally, the Company was required to issue 72,727 warrants based on performance metrics achieved in 2021, the warrants have an exercise price of $5.50 with an expiration of five years from the date of issuance. The Company calculated the fair value of $1.25 each for these warrants using the Black-Scholes option pricing model on the date the consulting firm achieved the milestone, using the following assumptions: (a) fair value of $2.28 per share, (b) expected volatility of 90.81%, (c) dividend yield of 0%, (d) risk-free interest rate of 0.87%, and (e) expected life of 5 years, resulting in the fair value of approximately $91,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 18, 2022, the Company entered into a stock purchase agreement (&#x201c;Stock Purchase Agreement&#x201d;) pursuant to which the Company agreed to issue and sell (&#x201c;Private Placement&#x201d;) to OpenSky Opportunities Fund Ltd. 58,000 shares of common stock par value $0.0001 and 58,000 warrants to purchase one share of common stock at a combined price of $6.00 per share. The common stock and the warrants were immediately separable and issued separately but were purchased together in the Private Placement. These securities issued pursuant to the Stock Purchase Agreement. The Company received $348,000 in proceeds from the Private Placement. The Warrants will expire five years from the date of issuance. The Company paid no underwriting discounts or commissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 2, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor, for the purchase and sale in a registered direct offering of 1,000,000 shares of the Company&#x2019;s common stock at a price of $1.50 per share, generating net proceeds from the offering of approximately $1.1&#160;million after deducting financial advisory and legal fees as well as other estimated offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 20, 2023, the Company entered into a Placement Agency Agreement with Public Ventures, LLC to consummate an offering of 16,666,666 shares of Common Stock at an offering price of $1.50 per share, which closed in accordance with the subscription agreement dated May 2, 2023. The Company received $23.2&#160;million in net proceeds from the offering after deducting placement agent discounts and commission and other estimated offering expenses payable by the Company. In&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;addition, the subscription agreement grants placement agent warrants as part of this transaction. See Warrants section below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 2, 2023, the Company entered into a securities purchase agreement and a note purchase agreement (&#x201c;SPA&#x201d;, NPA&#x201d; or together &#x201c;Agreements&#x201d;) with Maverick Capital Partners, LLC (&#x201c;Investor&#x201d;). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $4,000,000 of the Company&#x2019;s common stock at 75% of the average calculated Volume Weighted Average Price per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 28, 2023, the Company issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023, the Convertible Note was settled upon the execution of the SPA and related issuance of 200,105 shares of common stock pursuant to the SPA draw down notice dated March 9, 2023. These shares of common stock were registered under the Company&#x2019;s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023, whereby, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the Company received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;total proceeds of $500,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. These were the only transactions consummated under the SPA and NPA and the respective agreements expired on May 31 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 1, 2023, the Company entered into an At-the-Market Sales Agreement (&#x201c;ATM&#x201d; or &#x201c;Sales Agreement&#x201d;) with A.G.P./ Alliance Global Partners as placement agent, to issue and sell shares of the Company&#x2019;s common stock. The issuance and sale of shares of Common Stock to or through the placement agent are effected pursuant to the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Registration Statement dated February 2, 2023. The Company shall pay to the sales agent in cash, upon each sale of placement shares through the placement agent pursuant to the Sales Agreement, an amount equal to 3.00% of the aggregate gross proceeds from each sale of placement shares. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection to the Sales Agreement, on February 17, 2023 and February 22, 2023, the Company sold 6,184 shares at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$3.76 per&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; share for gross proceeds of approxi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;mately $23,000. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;of December 31, 2023 there was approximately $11.0&#160;million available for issuance under the ATM.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total stock issuance costs, which consist primarily of legal, accounting and underwriting fees in connection with the above stated transactions related to the offerings and SPA was approximately $174,000, which as of December 31 2023, was recorded in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022 the Company issued 439,042 and 63,806 shares of common stock upon exercise of vested stock options and vesting of restricted stock units. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WARRANTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, milestone warrants were issued to certain executives totaling 407,272 warrants (&#x201c;Penny Warrants&#x201d;). These warrants were valued on the date of grant at $0.0003 to vest upon meeting certain milestones. These warrants expired unissued in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2022, the Company issued 72,727 warrants based on performance metrics achieved in 2021 to purchase 72,727 shares of common stock at an exercise price of $5.50 per share, with an expiration of five years from the date of issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2022, the Company issued 58,000 warrants to purchase 58,000 shares of common stock at an exercise price of $6.00 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 2, 2023 the Company issued 1,666,666 placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise price of $1.875 per share and are exercisable for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;five years&lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the year ended December 31, 2023, 11,638 warrants were exercised, of which 5,817 were exercised in the form of a cashless exercise utilizing 4,346 warrants which resulted in the net issuance of 1,471 common shares. The remaining 5,821 warrants were exercised for cash for approximately $16,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the outstanding warrants as of December&#160;31, 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable -  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,777,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-38"
      decimals="INF"
      id="f-241"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-38"
      decimals="INF"
      id="f-242"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-38"
      decimals="INF"
      id="f-243"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-39"
      decimals="INF"
      id="f-244"
      unitRef="shares">78025</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-40" decimals="-3" id="f-245" unitRef="usd">365000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-41"
      decimals="INF"
      id="f-246"
      unitRef="shares">72727</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-42"
      decimals="INF"
      id="f-247"
      unitRef="usdPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <beat:ClassOfWarrantOrRightExpirationPeriod contextRef="c-43" id="f-248">P5Y</beat:ClassOfWarrantOrRightExpirationPeriod>
    <beat:ClassOfWarrantOrRightFairValuePerWarrant
      contextRef="c-44"
      decimals="2"
      id="f-249"
      unitRef="usdPerShare">1.25</beat:ClassOfWarrantOrRightFairValuePerWarrant>
    <beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare
      contextRef="c-39"
      decimals="2"
      id="f-250"
      unitRef="usdPerShare">2.28</beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-39" decimals="4" id="f-251" unitRef="number">0.9081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-39"
      decimals="INF"
      id="f-252"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-39" decimals="4" id="f-253" unitRef="number">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-39" id="f-254">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <beat:ClassOfWarrantOrRightFairValueIssuedForService contextRef="c-39" decimals="-3" id="f-255" unitRef="usd">91000</beat:ClassOfWarrantOrRightFairValueIssuedForService>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-45"
      decimals="INF"
      id="f-256"
      unitRef="shares">58000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-257"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-45"
      decimals="INF"
      id="f-258"
      unitRef="shares">58000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <beat:SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit
      contextRef="c-47"
      decimals="INF"
      id="f-259"
      unitRef="shares">1</beat:SaleOfStockNumberOfSharesIssuedInTransactionPerEachUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-48"
      decimals="2"
      id="f-260"
      unitRef="usdPerShare">6.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-45" decimals="-3" id="f-261" unitRef="usd">348000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <beat:ClassOfWarrantOrRightTerminationPeriod contextRef="c-47" id="f-262">P5Y</beat:ClassOfWarrantOrRightTerminationPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-49"
      decimals="INF"
      id="f-263"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-50"
      decimals="2"
      id="f-264"
      unitRef="usdPerShare">1.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-49" decimals="-5" id="f-265" unitRef="usd">1100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-51"
      decimals="INF"
      id="f-266"
      unitRef="shares">16666666</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-52"
      decimals="2"
      id="f-267"
      unitRef="usdPerShare">1.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-51" decimals="-5" id="f-268" unitRef="usd">23200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <beat:SaleOfStockMaximumAmountAuthorized contextRef="c-53" decimals="INF" id="f-269" unitRef="usd">4000000</beat:SaleOfStockMaximumAmountAuthorized>
    <beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage contextRef="c-53" decimals="2" id="f-270" unitRef="number">0.75</beat:SaleOfStockVolumeWeightedAveragePricePerCommonSharePercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-30" decimals="INF" id="f-271" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-31" decimals="0" id="f-272" unitRef="shares">200105</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-31" decimals="-3" id="f-273" unitRef="usd">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <beat:SaleOfStockPlacementFeePercentage
      contextRef="c-54"
      decimals="INF"
      id="f-274"
      unitRef="number">0.0300</beat:SaleOfStockPlacementFeePercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-55"
      decimals="INF"
      id="f-275"
      unitRef="shares">6184</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-56"
      decimals="INF"
      id="f-276"
      unitRef="usdPerShare">3.76</us-gaap:SaleOfStockPricePerShare>
    <beat:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-55" decimals="-3" id="f-277" unitRef="usd">23000</beat:SaleOfStockConsiderationReceivedOnTransactionGross>
    <beat:SaleOfStockRemainingAmountAuthorizedForIssuance contextRef="c-28" decimals="-5" id="f-278" unitRef="usd">11000000</beat:SaleOfStockRemainingAmountAuthorizedForIssuance>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-55" decimals="-3" id="f-279" unitRef="usd">174000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-1" decimals="INF" id="f-280" unitRef="shares">439042</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-10"
      decimals="INF"
      id="f-281"
      unitRef="shares">63806</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-282"
      unitRef="shares">407272</us-gaap:ClassOfWarrantOrRightOutstanding>
    <beat:ClassOfWarrantOrRightGrantDateFairValue
      contextRef="c-58"
      decimals="4"
      id="f-283"
      unitRef="usdPerShare">0.0003</beat:ClassOfWarrantOrRightGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-59"
      decimals="INF"
      id="f-284"
      unitRef="shares">72727</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants
      contextRef="c-39"
      decimals="INF"
      id="f-285"
      unitRef="shares">72727</beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-44"
      decimals="INF"
      id="f-286"
      unitRef="usdPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <beat:ClassOfWarrantOrRightExpirationPeriod contextRef="c-39" id="f-287">P5Y</beat:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-60"
      decimals="INF"
      id="f-288"
      unitRef="shares">58000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants
      contextRef="c-61"
      decimals="INF"
      id="f-289"
      unitRef="shares">58000</beat:StockIssuedDuringPeriodSharesNewIssuesPurchasedWithWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-290"
      unitRef="usdPerShare">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-291"
      unitRef="shares">1666666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-63"
      decimals="3"
      id="f-292"
      unitRef="usdPerShare">1.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-63" id="f-293">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <beat:ClassOfWarrantOrRightWarrantsExercised contextRef="c-1" decimals="INF" id="f-294" unitRef="shares">11638</beat:ClassOfWarrantOrRightWarrantsExercised>
    <beat:ClassOfWarrantOrRightWarrantsCashlessExercise contextRef="c-1" decimals="INF" id="f-295" unitRef="shares">5817</beat:ClassOfWarrantOrRightWarrantsCashlessExercise>
    <beat:ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized contextRef="c-1" decimals="INF" id="f-296" unitRef="shares">4346</beat:ClassOfWarrantOrRightWarrantsCashlessExerciseWarrantsUtilized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-1" decimals="INF" id="f-297" unitRef="shares">1471</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <beat:ClassOfWarrantOrRightWarrantsExercisedForCash contextRef="c-1" decimals="INF" id="f-298" unitRef="shares">5821</beat:ClassOfWarrantOrRightWarrantsExercisedForCash>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">16000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-300">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the outstanding warrants as of December&#160;31, 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable -  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,777,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-301"
      unitRef="shares">3777549</us-gaap:ClassOfWarrantOrRightOutstanding>
    <beat:ClassOfWarrantOrRightExercisable
      contextRef="c-14"
      decimals="INF"
      id="f-302"
      unitRef="shares">3777549</beat:ClassOfWarrantOrRightExercisable>
    <beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="c-14"
      decimals="2"
      id="f-303"
      unitRef="usdPerShare">5.42</beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-14"
      decimals="2"
      id="f-304"
      unitRef="usdPerShare">5.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="c-64" id="f-305">P4Y5M12D</beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <beat:ClassOfWarrantOrRightWeightedAverageRemainingLife contextRef="c-64" id="f-306">P4Y5M12D</beat:ClassOfWarrantOrRightWeightedAverageRemainingLife>
    <beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding contextRef="c-14" decimals="-3" id="f-307" unitRef="usd">1259000</beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding contextRef="c-14" decimals="-3" id="f-308" unitRef="usd">1259000</beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding>
    <beat:ClassOfWarrantOrRightWarrantsExercised
      contextRef="c-10"
      decimals="INF"
      id="f-309"
      unitRef="shares">0</beat:ClassOfWarrantOrRightWarrantsExercised>
    <beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="c-10"
      decimals="2"
      id="f-310"
      unitRef="usdPerShare">0</beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <beat:ClassOfWarrantOrRightWarrantsIssued
      contextRef="c-10"
      decimals="INF"
      id="f-311"
      unitRef="shares">130727</beat:ClassOfWarrantOrRightWarrantsIssued>
    <beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
      contextRef="c-10"
      decimals="2"
      id="f-312"
      unitRef="usdPerShare">5.72</beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-7" decimals="INF" id="f-313" unitRef="shares">3908276</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-7"
      decimals="2"
      id="f-314"
      unitRef="usdPerShare">5.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <beat:ClassOfWarrantOrRightWeightedAverageRemainingLife contextRef="c-10" id="f-315">P3Y5M19D</beat:ClassOfWarrantOrRightWeightedAverageRemainingLife>
    <beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">2020000</beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <beat:ClassOfWarrantOrRightWarrantsIssued contextRef="c-1" decimals="INF" id="f-317" unitRef="shares">1666666</beat:ClassOfWarrantOrRightWarrantsIssued>
    <beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
      contextRef="c-1"
      decimals="2"
      id="f-318"
      unitRef="usdPerShare">1.88</beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued>
    <beat:ClassOfWarrantOrRightWarrantsExercised contextRef="c-1" decimals="INF" id="f-319" unitRef="shares">11638</beat:ClassOfWarrantOrRightWarrantsExercised>
    <beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="c-1"
      decimals="2"
      id="f-320"
      unitRef="usdPerShare">2.75</beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <beat:ClassOfWarrantOrRightWarrantsExpired contextRef="c-1" decimals="INF" id="f-321" unitRef="shares">410907</beat:ClassOfWarrantOrRightWarrantsExpired>
    <beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
      contextRef="c-1"
      decimals="2"
      id="f-322"
      unitRef="usdPerShare">0</beat:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-6" decimals="INF" id="f-323" unitRef="shares">5152397</us-gaap:ClassOfWarrantOrRightOutstanding>
    <beat:ClassOfWarrantOrRightExercisable contextRef="c-6" decimals="INF" id="f-324" unitRef="shares">5152397</beat:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-6"
      decimals="2"
      id="f-325"
      unitRef="usdPerShare">4.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="c-6"
      decimals="2"
      id="f-326"
      unitRef="usdPerShare">4.71</beat:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="c-1" id="f-327">P3Y4M6D</beat:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <beat:ClassOfWarrantOrRightWeightedAverageRemainingLife contextRef="c-1" id="f-328">P3Y4M6D</beat:ClassOfWarrantOrRightWeightedAverageRemainingLife>
    <beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding contextRef="c-6" decimals="-3" id="f-329" unitRef="usd">792000</beat:ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding>
    <beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding contextRef="c-6" decimals="-3" id="f-330" unitRef="usd">792000</beat:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-331">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Company&#x2019;s Board of Directors approved the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company&#x2019;s business. The 2015 Plan provides for the grant of stock options and RSU&#x2019;s to purchase common stock of which 1,636,362 were authorized by the board of which 970,704 are outstanding as of December&#160;31, 2023. The 2015 Plan was terminated upon shareholder approval of the 2022 Equity Incentive Plan (&#x201c;2022 Equity Plan&#x201d;) whereby no new awards can be issued under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s shareholders approved the 2022 Equity Plan at the annual meeting of stockholders held on June 15, 2022, pursuant to which 1,900,000 shares of common stock were authorized for issuance. Under the 2022 Equity Plan, the number of shares available for issuance will be increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2023 400,487 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan. Also see Note 9- Subsequent event section below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;At the July 7, 2023, Annual Shareholders&#x2019; Meeting, the proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from 1,900,000 shares to 5,900,000 shares was approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Equity Plan includes a provision to add-back any cancelled options from the 2015 Plan up to 1,372,816 shares. As of December&#160;31, 2023, there are 252,856 shares from the 2015 Plan that are included in the 849,171 shares available for issuance under the 2022 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company granted 2,208,000 options to various executives and employees. Sixty percent (60%) of these options vest based on FDA Clearance for marketing of HeartBeam&#x2019;s synthesized 12L product  and the remaining forty percent (40%) vest monthly over a period of 48 months. The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and it is expensed based on management&#x2019;s probability assessment of FDA clearance. The 60% milestone options are issued and outstanding as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received proceeds of $0.2&#160;million from the exercise of stock options during the year ended December&#160;31, 2023 and a de minimis amount during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;STOCK OPTIONS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity during the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;options&lt;br/&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;br/&gt;remaining&lt;br/&gt;contractual life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic value&lt;br/&gt;(in thousands)&lt;br/&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,092,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable &#x2013; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*) Intrinsic value is based on &lt;/span&gt;&lt;span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair market value of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the years ended December&#160;31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average Black-Scholes option pricing model assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.23% - 117.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.25% - 111.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85 - 6.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62 -  5.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54% - 4.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47% - 3.17%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.75 - 3.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.08 - 3.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RESTRICTED STOCK UNITS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSUs award activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;STOCK BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total general and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $8.1&#160;million and $0.4&#160;million, respectively, which is expected to be recognized over a weighted-average period of 2.66 years and 1.2 years, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-65"
      decimals="INF"
      id="f-332"
      unitRef="shares">1636362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber
      contextRef="c-66"
      decimals="INF"
      id="f-333"
      unitRef="shares">970704</beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-67"
      decimals="INF"
      id="f-334"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-68"
      decimals="INF"
      id="f-335"
      unitRef="shares">3800000</beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-68"
      decimals="INF"
      id="f-336"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-69"
      decimals="INF"
      id="f-337"
      unitRef="shares">400487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-68"
      decimals="INF"
      id="f-338"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-70"
      decimals="INF"
      id="f-339"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-71"
      decimals="INF"
      id="f-340"
      unitRef="shares">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-72"
      decimals="INF"
      id="f-341"
      unitRef="shares">1372816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-73"
      decimals="INF"
      id="f-342"
      unitRef="shares">252856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-74"
      decimals="INF"
      id="f-343"
      unitRef="shares">849171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-75"
      decimals="INF"
      id="f-344"
      unitRef="shares">2208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-76"
      decimals="INF"
      id="f-345"
      unitRef="number">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-77"
      decimals="INF"
      id="f-346"
      unitRef="number">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-77" id="f-347">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-76"
      decimals="INF"
      id="f-348"
      unitRef="number">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-5" id="f-349" unitRef="usd">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-350">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity during the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;options&lt;br/&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;br/&gt;remaining&lt;br/&gt;contractual life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic value&lt;br/&gt;(in thousands)&lt;br/&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding &#x2013; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,092,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable &#x2013; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*) Intrinsic value is based on &lt;/span&gt;&lt;span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair market value of the Company's common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-14"
      decimals="INF"
      id="f-351"
      unitRef="shares">1105938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-14"
      decimals="2"
      id="f-352"
      unitRef="usdPerShare">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-64" id="f-353">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-14" decimals="-3" id="f-354" unitRef="usd">1535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-10"
      decimals="INF"
      id="f-355"
      unitRef="shares">1251000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-356"
      unitRef="usdPerShare">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-10"
      decimals="INF"
      id="f-357"
      unitRef="shares">121334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-358"
      unitRef="usdPerShare">2.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-10"
      decimals="INF"
      id="f-359"
      unitRef="shares">38806</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-360"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-361" unitRef="shares">2196798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-362"
      unitRef="usdPerShare">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-10" id="f-363">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-7" decimals="-3" id="f-364" unitRef="usd">6770000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-365" unitRef="shares">4363800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-366"
      unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-367" unitRef="shares">288001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-368"
      unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-369" unitRef="shares">180072</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-371" unitRef="shares">6092525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-372"
      unitRef="usdPerShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-373">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-374">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-375" unitRef="usd">2945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-6" decimals="INF" id="f-376" unitRef="shares">1212312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-377"
      unitRef="usdPerShare">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-378">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-379" unitRef="usd">1203000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-380">For the years ended December&#160;31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average Black-Scholes option pricing model assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.23% - 117.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.25% - 111.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85 - 6.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62 -  5.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54% - 4.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47% - 3.17%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.75 - 3.38&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.08 - 3.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-78" decimals="4" id="f-381" unitRef="number">1.1023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-79" decimals="4" id="f-382" unitRef="number">1.1762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-80" decimals="4" id="f-383" unitRef="number">1.0725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-81" decimals="4" id="f-384" unitRef="number">1.1106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-78" id="f-385">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-79" id="f-386">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-80" id="f-387">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-81" id="f-388">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-78" decimals="4" id="f-389" unitRef="number">0.0354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-79" decimals="4" id="f-390" unitRef="number">0.0477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-80" decimals="4" id="f-391" unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-81" decimals="4" id="f-392" unitRef="number">0.0317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-82" decimals="0" id="f-393" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-83" decimals="0" id="f-394" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-78"
      decimals="2"
      id="f-395"
      unitRef="usdPerShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-79"
      decimals="2"
      id="f-396"
      unitRef="usdPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-80"
      decimals="2"
      id="f-397"
      unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-81"
      decimals="2"
      id="f-398"
      unitRef="usdPerShare">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-399">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSUs award activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-84"
      decimals="INF"
      id="f-400"
      unitRef="shares">253970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-401"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-85"
      decimals="INF"
      id="f-402"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-403"
      unitRef="usdPerShare">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-86"
      decimals="INF"
      id="f-404"
      unitRef="shares">222881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-405"
      unitRef="usdPerShare">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-87"
      decimals="INF"
      id="f-406"
      unitRef="shares">248970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-10"
      decimals="2"
      id="f-407"
      unitRef="usdPerShare">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-86"
      decimals="INF"
      id="f-408"
      unitRef="shares">258970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-86"
      decimals="2"
      id="f-409"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-87"
      decimals="INF"
      id="f-410"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-87"
      decimals="2"
      id="f-411"
      unitRef="usdPerShare">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-88"
      decimals="INF"
      id="f-412"
      unitRef="shares">217881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-88"
      decimals="2"
      id="f-413"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-84"
      decimals="INF"
      id="f-414"
      unitRef="shares">253970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-415"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-416">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total general and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="0" id="f-417" unitRef="usd">2069556</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-90" decimals="0" id="f-418" unitRef="usd">657368</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-91" decimals="0" id="f-419" unitRef="usd">488971</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-92" decimals="0" id="f-420" unitRef="usd">235035</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="0" id="f-421" unitRef="usd">2558527</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-94" decimals="0" id="f-422" unitRef="usd">892403</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="0" id="f-423" unitRef="usd">629092</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="0" id="f-424" unitRef="usd">213813</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="0" id="f-425" unitRef="usd">20457</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="0" id="f-426" unitRef="usd">13601</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-99" decimals="0" id="f-427" unitRef="usd">649549</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-100" decimals="0" id="f-428" unitRef="usd">227414</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-429" unitRef="usd">3208076</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="0" id="f-430" unitRef="usd">1119817</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-6" decimals="-5" id="f-431" unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-6" decimals="-5" id="f-432" unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-82" id="f-433">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-86" id="f-434">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-435">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which the Company&#x2019;s former Chief Financial Officer has significant influence&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company incurred accounting fees from these firms of approximately $20,000 and $21,000 during the years ended December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the Company had balances due to these firms amounting to approximately $2,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-1" decimals="-3" id="f-436" unitRef="usd">20000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-10" decimals="-3" id="f-437" unitRef="usd">21000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-438" unitRef="usd">2000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-439" unitRef="usd">2000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-440">COMMITMENTS &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company entered into a month to month lease agreement for our headquarters. The agreement is for an undefined term and can be cancelled at any time, given one month&#x2019;s notice by either party. The Company&#x2019;s monthly rent expense associated with this agreement is approximately $1,440. The Company&#x2019;s month to month headquarters lease is in the name of the Company&#x2019;s Chief Executive Officer, and the cost is reimbursed monthly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023 and 2022, rent expense was approximately $17,000, for each year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnership Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a partnership agreement with LIVMOR Inc. (&#x201c;LIVMOR&#x201d;) to build a Company-branded version of the LIVMOR&#x2019;s Halo+ FDA cleared turnkey solution for RPM to connect physicians and patients. As included in the agreement, the Company and LIVMOR have the right to enter into additional agreements as needed in order to further the Company&#x2019;s development of its products. The agreement with LIVMOR included a commitment in 2022 of $1.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into a supplemental agreement with LIVMOR. The supplemental agreement stated the Company would pay an additional $0.2&#160;million for the source code access under the partnership agreement. Payments totaling $0.2&#160;million have been made by the Company and LIVMOR has delivered to the Company copies of source materials and codes. All licenses granted by LIVMOR will automatically be converted into a non-exclusive and perpetual license and become licenses granted on a royalty-free and fully paid-up basis, in which LIVMOR hereby expressly waives and relinquishes all HeartBeam payment obligations under the initial partnership agreement. Based on management&#x2019;s review of Topic ASC 805 and 730, it was determined that only the source code and perpetual license were purchased and it was determined there was no alternative future uses, therefore management recorded the expense as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company expensed a total of $1.2&#160;million associated with the LIVMOR agreements, which &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;has been recognized as R&amp;amp;D expense. In February 2023, the Company acquired LIVMOR&#x2019;s Halo+&#x2122; Atrial Fibrillation Detection System, the world&#x2019;s first FDA-cleared (K201208) prescription wearable for continuous cardiac rhythm monitoring, comprising of intellectual property, including 3 issued United States patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Professional Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (&#x201c;TRT&#x201d;), a co-development company, to assist in the design and development of the Company&#x2019;s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with Triple Ring includes a commitment totaling $1.7&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 the Company has a remaining commitment of $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <beat:LesseeOperatingLeasePriorNoticeForCancellation contextRef="c-101" id="f-441">P1M</beat:LesseeOperatingLeasePriorNoticeForCancellation>
    <beat:LesseeOperatingLeaseMonthlyRentExpense contextRef="c-1" decimals="-1" id="f-442" unitRef="usd">1440</beat:LesseeOperatingLeaseMonthlyRentExpense>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">17000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-10" decimals="-3" id="f-444" unitRef="usd">17000</us-gaap:OperatingLeaseCost>
    <us-gaap:PurchaseObligation contextRef="c-102" decimals="-5" id="f-445" unitRef="usd">1000000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation contextRef="c-103" decimals="-5" id="f-446" unitRef="usd">200000</us-gaap:PurchaseObligation>
    <beat:PaymentsForPurchaseObligations contextRef="c-104" decimals="-5" id="f-447" unitRef="usd">200000</beat:PaymentsForPurchaseObligations>
    <us-gaap:PurchaseObligation contextRef="c-105" decimals="-5" id="f-448" unitRef="usd">1200000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation contextRef="c-106" decimals="-5" id="f-449" unitRef="usd">1700000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="c-107" decimals="-5" id="f-450" unitRef="usd">400000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-451">INCOME TAX &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computed &#x201c;expected&#x201d; tax benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,074,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,722,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (reduction) in income taxes resulting from):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5,799,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4,115,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;619,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;377,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;647,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sec. 174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,027,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,032,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;172,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,092,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;6,047,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Valuation Allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(9,092,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(6,047,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,044,500 for the period ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of approximately $21,496,500 and $18,394,200, respectively. The federal NOL carryforwards consist of $2,405,400 generated prior to 2018 which will begin to expire in 2035, however, are able to offset 100% of taxable income and $19,091,000 generated after December 31, 2017 that will carryforward indefinitely but will be subject to 80% taxable income limitation beginning tax years after December 31, 2021 as provided by the Coronavirus Aid, Relief, and Economic Security (&#x201c;CARES&#x201d;) Act (PL 116-136).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company has federal R&amp;amp;D credit carryforwards of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $617,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which will begin to expire in 2041 and state R&amp;amp;D credit carryforwards of approximately $338,400 which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code (&#x201c;IRC&#x201d;) a corporation that undergoes an ownership change may be subject to limitations on its &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company&#x2019;s ability to use its NOLs or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (&#x201c;R&amp;amp;E&#x201d;) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the years ended December 31, 2023 and December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits as of December&#160;31, 2023 is approximately $286,600, which relates to federal and state R&amp;amp;D credits. If recognized none of the unrecognized tax benefits would affect the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's policy is to account for interest and penalties as income tax expense. As of the December&#160;31, 2023 the Company had no interest related to unrecognized tax benefits.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No amounts of penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within twelve months of this reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, with varying statutes of limitations. The tax years from inception through 2023 remain open to examination due to the carryover of unused net operating losses that are being carried forward for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, the U.S. Inflation Reduction Act of 2022 and the CHIPS and Science Act of 2022 were signed into law. These acts include, among other provisions, a corporate alternative minimum tax of 15%, an excise tax on the repurchase of corporate stock, various climate and energy provisions, and incentives for investment in semiconductor manufacturing. These provisions are not expected to have a material impact on the Company&#x2019;s results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-452">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computed &#x201c;expected&#x201d; tax benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,074,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,722,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (reduction) in income taxes resulting from):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-2" id="f-453" unitRef="usd">-3074000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="4" id="f-454" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-10" decimals="-2" id="f-455" unitRef="usd">-2722000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-10" decimals="4" id="f-456" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-2" id="f-457" unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="4" id="f-458" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-10" decimals="-2" id="f-459" unitRef="usd">-1024900</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-10" decimals="4" id="f-460" unitRef="number">0.0795</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-2" id="f-461" unitRef="usd">-80500</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="4" id="f-462" unitRef="number">0.0055</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-10" decimals="-2" id="f-463" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-10" decimals="4" id="f-464" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-2" id="f-465" unitRef="usd">221200</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="4" id="f-466" unitRef="number">-0.0151</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-2" id="f-467" unitRef="usd">241800</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="4" id="f-468" unitRef="number">-0.0165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-10" decimals="-2" id="f-469" unitRef="usd">224100</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-10" decimals="4" id="f-470" unitRef="number">-0.0170</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-2" id="f-471" unitRef="usd">130600</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="4" id="f-472" unitRef="number">-0.0089</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-10" decimals="-2" id="f-473" unitRef="usd">-2000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-10" decimals="4" id="f-474" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-2" id="f-475" unitRef="usd">3044500</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="4" id="f-476" unitRef="number">-0.2080</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-2" id="f-477" unitRef="usd">3973000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="4" id="f-478" unitRef="number">-0.3065</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-2" id="f-479" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="4" id="f-480" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-2" id="f-481" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-10" decimals="4" id="f-482" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-483">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5,799,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4,115,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;619,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;377,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;647,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sec. 174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,027,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,032,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;172,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,092,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;6,047,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Valuation Allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(9,092,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(6,047,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:20pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-2" id="f-484" unitRef="usd">5799000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-2" id="f-485" unitRef="usd">4115800</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-2" id="f-486" unitRef="usd">619000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-2" id="f-487" unitRef="usd">377200</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-2" id="f-488" unitRef="usd">647000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-2" id="f-489" unitRef="usd">349900</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-6" decimals="-2" id="f-490" unitRef="usd">2027200</beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-7" decimals="-2" id="f-491" unitRef="usd">1032700</beat:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-2" id="f-492" unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-2" id="f-493" unitRef="usd">172100</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-2" id="f-494" unitRef="usd">9092200</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-2" id="f-495" unitRef="usd">6047700</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-2" id="f-496" unitRef="usd">9092200</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-2" id="f-497" unitRef="usd">6047700</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-2" id="f-498" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-2" id="f-499" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="0" id="f-500" unitRef="usd">3044500</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-108" decimals="0" id="f-501" unitRef="usd">21496500</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-109" decimals="0" id="f-502" unitRef="usd">18394200</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-110" decimals="0" id="f-503" unitRef="usd">2405400</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-111" decimals="-3" id="f-504" unitRef="usd">19091000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-112" decimals="-3" id="f-505" unitRef="usd">617000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-113" decimals="-2" id="f-506" unitRef="usd">338400</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-2" id="f-507" unitRef="usd">286600</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="INF" id="f-508" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense contextRef="c-1" decimals="INF" id="f-509" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense contextRef="c-1" decimals="INF" id="f-510" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-511">SUBSEQUENT EVENTS&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;Under the 2022 Equity Plan, the number of shares available for issuance are increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2024, 1,316,452 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $0.5&#160;million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of five planned sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-68"
      decimals="INF"
      id="f-512"
      unitRef="shares">3800000</beat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-68"
      decimals="INF"
      id="f-513"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-114"
      decimals="INF"
      id="f-514"
      unitRef="shares">1316452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-114"
      decimals="INF"
      id="f-515"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ContractualObligation contextRef="c-115" decimals="-5" id="f-516" unitRef="usd">500000</us-gaap:ContractualObligation>
    <beat:ResearchAndDevelopmentNumberOfClinicalStudySites contextRef="c-115" decimals="INF" id="f-517" unitRef="site">5</beat:ResearchAndDevelopmentNumberOfClinicalStudySites>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-116" decimals="-5" id="f-518" unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
